<SEC-DOCUMENT>0001628280-19-010781.txt : 20190814
<SEC-HEADER>0001628280-19-010781.hdr.sgml : 20190814
<ACCEPTANCE-DATETIME>20190814172820
ACCESSION NUMBER:		0001628280-19-010781
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		56
CONFORMED PERIOD OF REPORT:	20190630
FILED AS OF DATE:		20190814
DATE AS OF CHANGE:		20190814

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33637
		FILM NUMBER:		191027744

	BUSINESS ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>cpix-20190630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2017 Workiva--><!--r:fe2e4db3-48f2-4e84-a542-8dc9a0c345cd,g:b764091f-bd8f-4ce0-9900-bde14803e897,d:f70b0c533f98489a8ce3150e2417b757--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt="http://fasb.org/srt/2018-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:cpix="http://www.cumberlandpharma.com/20190630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31"><head><meta http-equiv="Content-Type" content="text/html"></meta>


<title>Document</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180L2ZyYWc6NjQ3OWYzNGVkM2M5NDQ5NzkxNmI2NzY2OWY1YTViMDMvdGFibGU6MDJhYWUyODQ5YWEwNGM4ZTgyNDNmYzc0NzI3YTQzZmEvdGFibGVyYW5nZTowMmFhZTI4NDlhYTA0YzhlODI0M2ZjNzQ3MjdhNDNmYV83LTEtMS0xLTA_c47fa85f-932b-4cda-ac0a-0c43a6930ca9">2019</ix:nonNumeric><ix:nonNumeric contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180L2ZyYWc6NjQ3OWYzNGVkM2M5NDQ5NzkxNmI2NzY2OWY1YTViMDMvdGFibGU6MDJhYWUyODQ5YWEwNGM4ZTgyNDNmYzc0NzI3YTQzZmEvdGFibGVyYW5nZTowMmFhZTI4NDlhYTA0YzhlODI0M2ZjNzQ3MjdhNDNmYV84LTEtMS0xLTA_8c0bac0f-0677-41ed-81c6-72a216716055">Q2</ix:nonNumeric><ix:nonNumeric contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180L2ZyYWc6NjQ3OWYzNGVkM2M5NDQ5NzkxNmI2NzY2OWY1YTViMDMvdGFibGU6MDJhYWUyODQ5YWEwNGM4ZTgyNDNmYzc0NzI3YTQzZmEvdGFibGVyYW5nZTowMmFhZTI4NDlhYTA0YzhlODI0M2ZjNzQ3MjdhNDNmYV85LTEtMS0xLTA_41b3d616-32dd-4477-93ae-81685cef6136">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180L2ZyYWc6NjQ3OWYzNGVkM2M5NDQ5NzkxNmI2NzY2OWY1YTViMDMvdGV4dHJlZ2lvbjo2NDc5ZjM0ZWQzYzk0NDk3OTE2YjY3NjY5ZjVhNWIwM183OQ_a528c88a-7ec2-462e-8cbb-50577953b2d0">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180L2ZyYWc6NjQ3OWYzNGVkM2M5NDQ5NzkxNmI2NzY2OWY1YTViMDMvdGV4dHJlZ2lvbjo2NDc5ZjM0ZWQzYzk0NDk3OTE2YjY3NjY5ZjVhNWIwM184MA_14dbb1b9-a72a-4bc9-af79-436d92ea867a">0001087294</ix:nonNumeric><ix:nonNumeric contextRef="i3a0c4a5e2fe642ca846722954640695b_D20190101-20190630" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181OC9mcmFnOmViNzI5MWIzYzY3NTRhM2ZiYmE0OWRkY2JmNzA3OGY0L3RleHRyZWdpb246ZWI3MjkxYjNjNjc1NGEzZmJiYTQ5ZGRjYmY3MDc4ZjRfMTg2MQ_7b6a6f88-b9bb-43f7-bebc-cb00283f1265">P1Y</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="cpix-20190630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ie9d09c8c58d4466aa24ccf16fbf3dfe5_I20190809"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-08-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="if478ab72402a4dbca17cebf84905f137_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d8f4802d39d424297c0f861bec1a0b2_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6eecb6cf82d946f791b1e9b3d617a3ba_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5d60a75c7914cbf8204350654c33543_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e1c5e9c7cbe4efc93a736d76e33fe31_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf52e3a90b564e61a9df4d3dd81a200b_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ec531ec35eb439399c9436b7345e202_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d3bd3dbf1ee431ca1035d16d2daf32b_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4acfcd09578f42f994a9b89541ecf28c_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12bdf0ab8f4c49578c9eb30f38190373_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i389b9f06784a4fa895bf9d85d0373d0a_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieeeb240a56f744c5976744da0dbe5ad7_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2aef2419d2a434d882a0412b764c40a_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i525c05bfba8a496bb3f3ad3dd759b4b6_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia885021b86044725a1fb10e4cc611b1f_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if02d00db9a714fb7b9ff2e6a67ac03d2_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad96f105789947c999f7d544dd4620db_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77e056bccd4543089353688903d60102_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa6a17eccce2451499b89a8ee27e36af_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ebb41ca72a9412d830adbbcce277c27_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefb8318507a84b1eab45ae17e36b7a7e_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86ad84a3cb90495fa0d9574cd4dfc3e8_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6695ed74ccf34594a009b751a9867ab5_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0658642e8184a7e8bcf52ddf1229693_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idaa440b71edc463180ffe7cc20dc52c5_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b03a84c29d54b778087726fae7de356_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73c240c1815a42e2ab3c71622ab5a7f7_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a0b25c5749f4e71aca5511d2c6057b6_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac307e50d1064fb993f7c13e652bf744_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id01be75c70fd4c0390e4cb8f8a56f1f8_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58d3402c22484d6bb6b255a3e69c04eb_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d6b70bf87e540e287238c2db49676b4_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69067cc85b7d439ab6017dfcbfd70f2a_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5b7d8e3ae1349cea30af6ae38abd9fa_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i274cc8eea0aa47a382670b52aaf0929c_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide4bf4cd636d4c2db7c36e6913c5b859_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic39d78c819df43acb7f94d5a5d3f0944_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f374a018db6442e9076cb34a527615d_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>cpix:Segment</xbrli:measure></xbrli:unit><xbrli:context id="ic019dd81917f4783874bd24e8143629b_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cpix:UsTreasuryNotesAndBondsSecuritiesMemberMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5397d60c4bf94ba38de2eefaf434ab55_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cpix:UsTreasuryNotesAndBondsSecuritiesMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd24a3ddd9ed4cff93e5196a8a035c10_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cpix:UsTreasuryNotesAndBondsSecuritiesMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7816c3023a04362a69740727a0dd6e9_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cpix:UsTreasuryNotesAndBondsSecuritiesMemberMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i028152dc8c66421282a458a7c0e3da06_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cpix:UsTreasuryNotesAndBondsSecuritiesMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8259efcffe104ccab3daeae3ae558f18_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cpix:UsTreasuryNotesAndBondsSecuritiesMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6339bfa7be7414c90203e8b3decb32f_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74755af90b0c4281990f79ae0cb80fab_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i766a4625499e44acb284ded61ea081ad_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47855873ec2141deb6a6cffeea9a5bb5_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic748d7f98c564aa2ba93b74292ce51c0_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1ab8d666f804ee78d5b108e427da078_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83a70ec3a6574e21aa0d9467d12afc51_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43b135623a96479ea579b1956e4c6a0b_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1494544e74bc4c1a9fcca142b7cf104f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77a66b694d774bcf85ff772a27ee7736_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07ba47fdb1fd4a0aa68832470d83b72c_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie26e2ca1b03b4f848952f34a6f12fe2d_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i666181952a8f4f1f9d14d2034e887833_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bd2419e0e6145b5b2690fdf708d4661_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d842da52c554dfe889a17eb09da349c_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf1ce67d14544c34852c969eba3ab613_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6dd35f38e91e4cad82cac63ffaf3bc06_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44c95989d56940448855dceadabf3ab2_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ac200ae04284253b7355e519011ebb7_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9fe1490366c4bb1a705a3377e185ae5_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf31cf850409470eb07e4575e50d16c6_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i509cfd55792547fd9065aab962dd801a_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4235e45b96d4113803c1249687d3d50_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77326b611af749e2afb25a76a3b386d1_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4751466a08f94bcb8c0ebfec0b01ecfd_D20180101-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i491e5531cbfa47b496005caa8455badb_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c520713e19c495f82ed1f2dd92ef634_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8396c0f613f441f58ba22039a93eb1c8_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia32476d410f440b48f0c3b631a90632f_D20180101-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i781c10013fee46d6b029f560be240be7_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd51eac788ff4878870c597b6d74c24e_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14a5b5dcc523443dab0df6907169ca3b_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcb718271f734482856f23f2d01609d5_D20180101-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73375a6aee6f45c8b2af7cc1cfecddb0_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ad6dbad74074d38ac2d08ebcc3d3518_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53374edc460d4ca6aba30ff2b618e21f_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i838404f0559b43babedeea791e195f2f_D20180101-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30dca836f3804983b44dbc23d365d55e_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70367091d6b44d47b966554d9af79237_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i588715008b8b450f8b15c09e4bcd9681_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc7ca2c1d2ac45b99b06dd4e5cff07df_D20180101-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ae15c900cfd4ad6a4de1687287609b2_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:EthyolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic29f620b439f49eeaefd0f5c28509e1c_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:EthyolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie85bd361954b4f98bced4efeca36ce9f_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:EthyolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i231a37bb2fbf47f5b7eceed5c5e05224_D20180101-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:EthyolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i868db2e678dd4291af1d258118e04a77_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:TotectMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibccd184195764941825e341a41aa4fa5_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:TotectMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f03cf3962ed4acf8caf27c28f2427d9_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:TotectMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb51e348437d4dec85fd92befc0b9624_D20180101-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:TotectMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic06c5fb3bfd44b16ab85550780690d5f_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7367fd73f204d1e8f84cd61df343493_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9ea66098fd04256848a2d79539e4156_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77b145b291264578bbd035e0bf21476c_D20180101-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if954c9a78bb24172936c43e0061fedae_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if66b9371f94f461f93cfcc16bb63966b_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7677c5f4087746ed8da807d078e316b6_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8da9ab9ca7a9436c81b40d1a21447d49_D20180101-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40852bb795f343e3a355c9a4dac17887_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b6f56b360f242dba5580399c147efc2_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueRightsGrantedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i994113efc2f24ab7bbf0e24b5c88051c_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueRightsGrantedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i674a647fde3f44be85e9cae6e936a816_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5332b0b2238e4d09b5c7a0b66e8b457a_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24c5c7f1311c41b0adf7f2ad2954b3dc_I20190101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i3c6be34147e74633b283a3faf26291a6_I20100513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2010-05-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie34c3c9c4b6c4086a134e19d8fa48fdd_I20160131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2016-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbb1a7efb54a4443b860e667b9d9f4ff_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fee3684442c4d5f9e424da6bdc3b780_D20180101-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide11bc6060924df19448d4e6a244010d_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i959855896ce142fbac309e421bbe56a9_D20171101-20171130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89a377e795d5407db1aaac39ada6ab01_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia72329a5bc7744a280d614667782cdc8_D20180101-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a0c4a5e2fe642ca846722954640695b_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94c12e61b0d14ff5a5b7a3c975510ecc_I20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:HongKongWinHealthPharmaGroupCoLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib97eaa219e974f16a39fa98e445d047a_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11a9395935dd46a587ef0b6c9587b057_I20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id03a7800662a48cd8cf59f4d3cdb9811_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:GloriaPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf561525052b4733845421e5e0fffabf_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i265ae74e8bfa4726841ed00db8f8e437_I20181017"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:SecondAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie283482fcb0a418f903f4565757a59f1_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i389446a0e5ad467cb0b7d185b5851168_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c66d110828e4d3290867f75611b26b4_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5709e5c0528d4106ba0350257862d329_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icca6e0f80b33475a8371b8499f5d8919_D20181101-20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b571fa0594646398781261aceb478b2_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d064a4268974d2eaa1aee9282ceb970_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8e3a8763ebf4e4299a795047276e3dd_I20181112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62c36aedf5f84b7d8160f6870615925e_D20181113-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-13</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i385e5bd994794f80a9f4101d706edbbb_D20181112-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-12</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfc029c334714ab1b6a1fa6f662c915e_I20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55ab197a5f614ea393244079e62f621c_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89124f6164c440dea6f61c2e5b7f5ef8_D20191001-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i_0_1"></div><div style="height:45pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div style="text-align:center;margin-top:3pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:18pt;font-weight:700;line-height:120%;">UNITED STATES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:18pt;font-weight:700;line-height:120%;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:700;line-height:120%;">WASHINGTON, DC 20549</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:18pt;font-weight:700;line-height:120%;">FORM <ix:nonNumeric contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xL2ZyYWc6ODg5OTZmNjBiZGFmNDAyYWFlNjcyYzM4MmY4NDkwNjcvdGV4dHJlZ2lvbjo4ODk5NmY2MGJkYWY0MDJhYWU2NzJjMzgyZjg0OTA2N18xOTQ1_5bef0efc-8a0c-4186-aad9-af06b51de814">10-Q</ix:nonNumeric> </span></div><div style="margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(Mark One)</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:3.865103%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.134897%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:12pt;font-weight:400;font-family:'Wingdings';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" format="ixt:booleantrue" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xL2ZyYWc6ODg5OTZmNjBiZGFmNDAyYWFlNjcyYzM4MmY4NDkwNjcvdGFibGU6ODhkNjBiZjA0ODRkNDYxMGIxOTVlN2MwNjJmYTQ4MzYvdGFibGVyYW5nZTo4OGQ2MGJmMDQ4NGQ0NjEwYjE5NWU3YzA2MmZhNDgzNl8wLTAtMS0xLTQwNTg_544fd539-b6dd-47fd-ab86-ac88d8489a5c">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:11pt;font-weight:700;line-height:100%;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="text-align:center;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">For the quarterly period ended <ix:nonNumeric contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xL2ZyYWc6ODg5OTZmNjBiZGFmNDAyYWFlNjcyYzM4MmY4NDkwNjcvdGV4dHJlZ2lvbjo4ODk5NmY2MGJkYWY0MDJhYWU2NzJjMzgyZjg0OTA2N185ODk1NjA0NjUyMDg2_2eecc618-50cc-428e-9622-94e35156892c">June 30, 2019</ix:nonNumeric></span></div><div style="text-align:center;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">OR</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:3.865103%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.134897%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:12pt;font-weight:400;font-family:'Wingdings';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" format="ixt:booleanfalse" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xL2ZyYWc6ODg5OTZmNjBiZGFmNDAyYWFlNjcyYzM4MmY4NDkwNjcvdGFibGU6YWQxZDVmYzI4NTBhNGUwYWJlNWZmZDRkNjZkYWYxYWUvdGFibGVyYW5nZTphZDFkNWZjMjg1MGE0ZTBhYmU1ZmZkNGQ2NmRhZjFhZV8wLTAtMS0xLTQwNjA_82f478b3-783c-4195-867f-351b89051dde">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:11pt;font-weight:700;line-height:100%;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="text-align:center;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.</span></div><div style="text-align:center;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Commission file number: <ix:nonNumeric contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xL2ZyYWc6ODg5OTZmNjBiZGFmNDAyYWFlNjcyYzM4MmY4NDkwNjcvdGV4dHJlZ2lvbjo4ODk5NmY2MGJkYWY0MDJhYWU2NzJjMzgyZjg0OTA2N182MDQ3MzEzOTU0Nzk2_10aea164-1a8c-4c60-89d7-6ecd72e0df5c">001-33637</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:20pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xL2ZyYWc6ODg5OTZmNjBiZGFmNDAyYWFlNjcyYzM4MmY4NDkwNjcvdGV4dHJlZ2lvbjo4ODk5NmY2MGJkYWY0MDJhYWU2NzJjMzgyZjg0OTA2N18xOTQ2_cb198088-9e54-498d-a4e2-487ba7de3e67">Cumberland Pharmaceuticals Inc.</ix:nonNumeric> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(Exact Name of Registrant as Specified In Its Charter)</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"></td><td style="width:47.632893%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.443172%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:45.723935%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"><ix:nonNumeric contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xL2ZyYWc6ODg5OTZmNjBiZGFmNDAyYWFlNjcyYzM4MmY4NDkwNjcvdGFibGU6OGUxOGU3OWJmZTQ1NGIzZjg5MjExYWFlNWNkZDYwOTAvdGFibGVyYW5nZTo4ZTE4ZTc5YmZlNDU0YjNmODkyMTFhYWU1Y2RkNjA5MF8wLTAtMS0xLTQwNDk_5d26c198-4d00-4375-8fd2-351ba0038f9b">Tennessee</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"><ix:nonNumeric contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xL2ZyYWc6ODg5OTZmNjBiZGFmNDAyYWFlNjcyYzM4MmY4NDkwNjcvdGFibGU6OGUxOGU3OWJmZTQ1NGIzZjg5MjExYWFlNWNkZDYwOTAvdGFibGVyYW5nZTo4ZTE4ZTc5YmZlNDU0YjNmODkyMTFhYWU1Y2RkNjA5MF8wLTItMS0xLTQwNTE_7bf2ef00-1bdc-4ca9-a841-5ebf2360e1eb">62-1765329</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">(State or Other Jurisdiction of</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">Incorporation or Organization)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">(I.R.S. Employer</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">Identification No.)</span></div></td></tr><tr><td colspan="3" style="height:4pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="height:4pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"><ix:nonNumeric contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xL2ZyYWc6ODg5OTZmNjBiZGFmNDAyYWFlNjcyYzM4MmY4NDkwNjcvdGFibGU6OGUxOGU3OWJmZTQ1NGIzZjg5MjExYWFlNWNkZDYwOTAvdGFibGVyYW5nZTo4ZTE4ZTc5YmZlNDU0YjNmODkyMTFhYWU1Y2RkNjA5MF8zLTAtMS0xLTQxMjUvdGV4dHJlZ2lvbjo2ZDhjMTIwYTNiZDc0N2FjODVmOTQxYjA4M2E5ZTAwNF84Nzk2MDkzMDIyMjg2_c6c2a4a1-70f2-4697-89fc-bbbccdd8aab8">2525 West End Avenue</ix:nonNumeric>, <ix:nonNumeric contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xL2ZyYWc6ODg5OTZmNjBiZGFmNDAyYWFlNjcyYzM4MmY4NDkwNjcvdGFibGU6OGUxOGU3OWJmZTQ1NGIzZjg5MjExYWFlNWNkZDYwOTAvdGFibGVyYW5nZTo4ZTE4ZTc5YmZlNDU0YjNmODkyMTFhYWU1Y2RkNjA5MF8zLTAtMS0xLTQxMjUvdGV4dHJlZ2lvbjo2ZDhjMTIwYTNiZDc0N2FjODVmOTQxYjA4M2E5ZTAwNF84Nzk2MDkzMDIyMzY5_80fe2264-35dd-4b19-ba75-26d6583a03b7">Suite 950</ix:nonNumeric>,</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"><ix:nonNumeric contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xL2ZyYWc6ODg5OTZmNjBiZGFmNDAyYWFlNjcyYzM4MmY4NDkwNjcvdGFibGU6OGUxOGU3OWJmZTQ1NGIzZjg5MjExYWFlNWNkZDYwOTAvdGFibGVyYW5nZTo4ZTE4ZTc5YmZlNDU0YjNmODkyMTFhYWU1Y2RkNjA5MF8zLTAtMS0xLTQxMjUvdGV4dHJlZ2lvbjo2ZDhjMTIwYTNiZDc0N2FjODVmOTQxYjA4M2E5ZTAwNF84Nzk2MDkzMDIyMzgw_ab6dca6e-6df1-4266-a0ae-ed264134ae10">Nashville</ix:nonNumeric>, <ix:nonNumeric contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xL2ZyYWc6ODg5OTZmNjBiZGFmNDAyYWFlNjcyYzM4MmY4NDkwNjcvdGFibGU6OGUxOGU3OWJmZTQ1NGIzZjg5MjExYWFlNWNkZDYwOTAvdGFibGVyYW5nZTo4ZTE4ZTc5YmZlNDU0YjNmODkyMTFhYWU1Y2RkNjA5MF8zLTAtMS0xLTQxMjUvdGV4dHJlZ2lvbjo2ZDhjMTIwYTNiZDc0N2FjODVmOTQxYjA4M2E5ZTAwNF84Nzk2MDkzMDIyMzkx_bf0bf2c6-2a8d-493f-afef-e8bc873c76c1">Tennessee</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xL2ZyYWc6ODg5OTZmNjBiZGFmNDAyYWFlNjcyYzM4MmY4NDkwNjcvdGFibGU6OGUxOGU3OWJmZTQ1NGIzZjg5MjExYWFlNWNkZDYwOTAvdGFibGVyYW5nZTo4ZTE4ZTc5YmZlNDU0YjNmODkyMTFhYWU1Y2RkNjA5MF8zLTItMS0xLTQwNTM_a542a111-2245-481a-b713-5374d2b328eb">37203</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">(Address of Principal Executive Offices)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">(Zip Code)</span></div></td></tr></table></div><div style="text-align:center;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(<ix:nonNumeric contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xL2ZyYWc6ODg5OTZmNjBiZGFmNDAyYWFlNjcyYzM4MmY4NDkwNjcvdGV4dHJlZ2lvbjo4ODk5NmY2MGJkYWY0MDJhYWU2NzJjMzgyZjg0OTA2N182MDQ3MzEzOTU0Nzk0_89891fbe-96df-40e7-b9b9-e67cb33185ef">615</ix:nonNumeric>) <ix:nonNumeric contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xL2ZyYWc6ODg5OTZmNjBiZGFmNDAyYWFlNjcyYzM4MmY4NDkwNjcvdGV4dHJlZ2lvbjo4ODk5NmY2MGJkYWY0MDJhYWU2NzJjMzgyZjg0OTA2N182MDQ3MzEzOTU0Nzk1_be0b2698-cee8-4a6b-9923-c48602df1cc9">255-0068</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:120%;">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="text-align:justify;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9.5pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xL2ZyYWc6ODg5OTZmNjBiZGFmNDAyYWFlNjcyYzM4MmY4NDkwNjcvdGV4dHJlZ2lvbjo4ODk5NmY2MGJkYWY0MDJhYWU2NzJjMzgyZjg0OTA2N182MDQ3MzEzOTU0Nzky_3e6fea56-d65d-46a2-a3e5-56cb6daf3f19">Yes</ix:nonNumeric>&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings';font-size:9.5pt;font-weight:400;line-height:120%;">&#9746;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9.5pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings';font-size:9.5pt;font-weight:400;line-height:120%;">&#9744;</span></div><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files.)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9.5pt;font-weight:400;line-height:120%;"> <ix:nonNumeric contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xL2ZyYWc6ODg5OTZmNjBiZGFmNDAyYWFlNjcyYzM4MmY4NDkwNjcvdGV4dHJlZ2lvbjo4ODk5NmY2MGJkYWY0MDJhYWU2NzJjMzgyZjg0OTA2N182MDQ3MzEzOTU0Nzkz_5de71190-c0a7-44d9-a53f-c8085c363ceb">Yes</ix:nonNumeric>&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings';font-size:9.5pt;font-weight:400;line-height:120%;">&#9746;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9.5pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings';font-size:9.5pt;font-weight:400;line-height:120%;">&#9744;</span></div><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9.5pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. (Check one):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"><tr><td style="width:1.0%;"></td><td style="width:21.529412%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.300000%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:41.088235%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.447059%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:20.941176%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.447059%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:2.447059%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9.5pt;font-weight:400;line-height:100%;">Large&#160;accelerated&#160;filer</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Wingdings';color:#000000;background-color:rgb(255,255,255, 0.0);">&#9744;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9.5pt;font-weight:400;line-height:100%;">Accelerated&#160;filer</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Wingdings';color:#000000;background-color:rgb(255,255,255, 0.0);">&#9744;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9.5pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xL2ZyYWc6ODg5OTZmNjBiZGFmNDAyYWFlNjcyYzM4MmY4NDkwNjcvdGFibGU6ZjNkYTc2NzJjYzg0NGFmY2FjZmU4MWZjZDQ1NTdkMGQvdGFibGVyYW5nZTpmM2RhNzY3MmNjODQ0YWZjYWNmZTgxZmNkNDU1N2QwZF8xLTAtMS0xLTM5MjI_724a6440-8191-457b-85b0-472c04b8850a">Non-accelerated filer</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Wingdings';color:#000000;background-color:rgb(255,255,255, 0.0);">&#9746;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9.5pt;font-weight:400;line-height:100%;">Smaller&#160;reporting&#160;company</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Wingdings';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" format="ixt:booleanfalse" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xL2ZyYWc6ODg5OTZmNjBiZGFmNDAyYWFlNjcyYzM4MmY4NDkwNjcvdGFibGU6ZjNkYTc2NzJjYzg0NGFmY2FjZmU4MWZjZDQ1NTdkMGQvdGFibGVyYW5nZTpmM2RhNzY3MmNjODQ0YWZjYWNmZTgxZmNkNDU1N2QwZF8xLTYtMS0xLTQwMjU_fdd45b0c-d7c9-4722-b739-94d5036bb454">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9.5pt;font-weight:400;line-height:100%;">Emerging growth company</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Wingdings';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xL2ZyYWc6ODg5OTZmNjBiZGFmNDAyYWFlNjcyYzM4MmY4NDkwNjcvdGFibGU6ZjNkYTc2NzJjYzg0NGFmY2FjZmU4MWZjZDQ1NTdkMGQvdGFibGVyYW5nZTpmM2RhNzY3MmNjODQ0YWZjYWNmZTgxZmNkNDU1N2QwZF8yLTItMS0xLTQwNzM_862fb73e-531e-4905-aa18-042979db26eb">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9.5pt;font-weight:400;line-height:120%;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to&#160;Section 13(a) of the Exchange Act. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings';font-size:9.5pt;font-weight:400;line-height:120%;">&#9744;</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9.5pt;font-weight:400;line-height:120%;">Indicate by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings';font-size:9.5pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" format="ixt:booleanfalse" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xL2ZyYWc6ODg5OTZmNjBiZGFmNDAyYWFlNjcyYzM4MmY4NDkwNjcvdGV4dHJlZ2lvbjo4ODk5NmY2MGJkYWY0MDJhYWU2NzJjMzgyZjg0OTA2N182MDQ3MzEzOTU0Nzkx_cb864746-103a-4960-8ecb-64e64aaf5706">&#9744;</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9.5pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings';font-size:9.5pt;font-weight:400;line-height:120%;">&#9746;</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9.5pt;font-weight:400;line-height:120%;">Indicate the number of shares outstanding of each of the issuer&#8217;s classes of common stock, as of the latest practicable date.</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9.5pt;font-weight:400;line-height:120%;">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:9pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269006%;"><tr><td style="width:1.0%;"></td><td style="width:22.594993%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.389102%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.727541%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.389102%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:32.315169%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.389102%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:22.594993%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Class</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Trading Symbol</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Name of exchanged on which registered</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding&#160;at August 9, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xL2ZyYWc6ODg5OTZmNjBiZGFmNDAyYWFlNjcyYzM4MmY4NDkwNjcvdGFibGU6OGQ0ZDc0ZmI5MzZiNDg2Y2JkOTY0Yjk0MDcwMWM1YWIvdGFibGVyYW5nZTo4ZDRkNzRmYjkzNmI0ODZjYmQ5NjRiOTQwNzAxYzVhYl8xLTAtMS0xLTQwMzA_68faa833-afe8-4034-b7d8-883353a838ca">Common stock, no par value</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xL2ZyYWc6ODg5OTZmNjBiZGFmNDAyYWFlNjcyYzM4MmY4NDkwNjcvdGFibGU6OGQ0ZDc0ZmI5MzZiNDg2Y2JkOTY0Yjk0MDcwMWM1YWIvdGFibGVyYW5nZTo4ZDRkNzRmYjkzNmI0ODZjYmQ5NjRiOTQwNzAxYzVhYl8xLTItMS0xLTQwMzI_3711180e-0e74-41e4-bf37-4396d74446d1">CPIX</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xL2ZyYWc6ODg5OTZmNjBiZGFmNDAyYWFlNjcyYzM4MmY4NDkwNjcvdGFibGU6OGQ0ZDc0ZmI5MzZiNDg2Y2JkOTY0Yjk0MDcwMWM1YWIvdGFibGVyYW5nZTo4ZDRkNzRmYjkzNmI0ODZjYmQ5NjRiOTQwNzAxYzVhYl8xLTQtMS0xLTQwMzQ_51e5451e-84af-4769-873f-35a85a5c361c">NASDAQ Global Select Market</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ie9d09c8c58d4466aa24ccf16fbf3dfe5_I20190809" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xL2ZyYWc6ODg5OTZmNjBiZGFmNDAyYWFlNjcyYzM4MmY4NDkwNjcvdGFibGU6OGQ0ZDc0ZmI5MzZiNDg2Y2JkOTY0Yjk0MDcwMWM1YWIvdGFibGVyYW5nZTo4ZDRkNzRmYjkzNmI0ODZjYmQ5NjRiOTQwNzAxYzVhYl8xLTYtMS0xLTA_c38cd8a9-d0b7-42da-8772-d6b11f85897f">15,373,815</ix:nonFraction>&#160;</span></td></tr></table></div><div style="margin-top:9pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div id="i_0_7"></div><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">CUMBERLAND PHARMACEUTICALS INC.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">INDEX</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:81.431085%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.568915%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_10">PART I &#8211; FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_10">1</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;padding-right:-18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_13">Item&#160;1. Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_13">1</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_16">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_16">1</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_22">Condensed Consolidated Statements of Operations and Comprehensive Income (loss)</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_22">2</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_25">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_25">3</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_28">Condensed Consolidated Statements of Equity</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_28">4</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:25pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_31">Notes to the Unaudited Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_31">5</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_73">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_73">15</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_94">Item&#160;3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_94">25</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_97">Item&#160;4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_97">25</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_100">PART II &#8211; OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_100">26</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_103">Item&#160;1. Legal Proceedings</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_103">26</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_106">Item&#160;1A. Risk Factors</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_106">26</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_109">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_109">26</a></span></div></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:19pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_115">Item&#160;6. Exhibits</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_115">26</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_118">SIGNATURES</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_118">28</a></span></div></td></tr></table></div><div><span><br/></span></div><div id="i_0_10"></div><div style="text-align:center;-sec-extract:summary;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">PART I &#8211; FINANCIAL INFORMATION</span></div><div id="i_0_13"></div><div style="margin-top:14pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Item&#160;1. Financial Statements (Unaudited)</span></div><div id="i_0_16"></div><div style="text-align:center;margin-top:18pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.122807%;"><tr><td style="width:1.0%;"></td><td style="width:58.029499%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.616519%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537463%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.616519%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Current assets:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:19pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMy0xLTEtMS0w_64ff01de-e5f8-4fa5-9571-16b3a82c0e0d">20,951,180</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMy0zLTEtMS0w_3f380190-3e9d-488d-8370-28ae35f07b93">27,938,960</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:19pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:MarketableSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfNC0xLTEtMS0w_f1cf7ab0-7168-4a2d-8bfc-23568647b904">9,479,686</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:MarketableSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfNC0zLTEtMS0w_24f67d87-015d-43ca-a74f-0dcc8b2ae582">8,290,679</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:19pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable, net</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfNS0xLTEtMS0w_22b6386a-895b-4e09-a598-9400607c6200">8,427,278</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfNS0zLTEtMS0w_e119ce68-0c82-402b-8610-ed8cb342a875">7,844,249</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:19pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Inventories, net</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfNi0xLTEtMS0w_e8539f3c-5df8-46aa-a5e9-48d8e7be1cc1">10,648,859</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfNi0zLTEtMS0w_4e2061d1-326e-4d99-95d8-0e8fbf9121d3">12,078,343</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:19pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid and other current assets</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfNy0xLTEtMS0w_aa74f281-962e-4aae-ada0-38b167f08989">2,425,354</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfNy0zLTEtMS0w_2a2a3dbf-9285-4e43-a2bd-7ab942a8e445">2,963,806</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:37pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total current assets</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfOC0xLTEtMS0w_cbb14478-868f-47f5-ac53-01b396d3c99b">51,932,357</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfOC0zLTEtMS0w_f428eb97-89c2-4142-82e2-080162a4de1a">59,116,037</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Non-current inventories</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfOS0xLTEtMS0w_029256be-cb24-43ab-b7bb-bbe737095e3e">15,840,962</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfOS0zLTEtMS0w_e36b531d-7a14-49a3-8007-ac7979b1fcf0">15,749,000</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, net</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMTAtMS0xLTEtMA_d9d1c431-cfc8-45f3-8060-46c378db4263">737,238</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMTAtMy0xLTEtMA_d2b16b0b-c69b-453c-a7e9-356b64e67773">771,213</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Intangible assets, net</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMTEtMS0xLTEtMA_543744be-0803-4635-8440-11ab7d1cd7c3">32,044,234</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMTEtMy0xLTEtMA_7b05308c-2b29-4ae3-b514-e268caa3c286">33,655,099</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMTItMS0xLTEtMA_89a23f38-0883-460a-a19c-7ac8d60fbfbe">882,000</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMTItMy0xLTEtMA_e33c4781-3d3a-4997-8831-1dd794ba337c">784,000</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax assets, net</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMTMtMS0xLTEtMA_3acb910d-90c7-4199-8390-9f0171849cca">43,605</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMTMtMy0xLTEtMA_430e8f10-6dfc-4ea3-b1ff-afbf53e6c5a4">87,210</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other assets</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMTQtMS0xLTEtMA_5397b848-5bcb-4fa2-ba41-a015ff5b26c4">6,065,828</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMTQtMy0xLTEtMA_9177ba58-1468-4dc3-8e95-c0caa6100e40">2,531,309</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:37pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMTUtMS0xLTEtMA_fc96f856-abf3-4fc2-b339-2783a1a25005">107,546,224</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMTUtMy0xLTEtMA_148f6695-4ef5-4a65-8541-d80ca1dbed21">112,693,868</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">LIABILITIES AND EQUITY</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:19pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMTgtMS0xLTEtMA_578d2940-c285-4dc4-b912-db0afbda6208">9,539,981</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMTgtMy0xLTEtMA_65568ab8-27b6-4cbe-91b8-bfd2be169c41">11,093,297</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:19pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other current liabilities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMTktMS0xLTEtMA_0daf15a6-13b0-4a36-ac39-225cec7791fa">12,777,148</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMTktMy0xLTEtMA_15d030c5-7e5a-4a7c-ab66-33128ad0bd3b">16,710,927</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:37pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total current liabilities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMjAtMS0xLTEtMA_4401a172-5c53-4dfe-a2e5-7c21522858e4">22,317,129</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMjAtMy0xLTEtMA_9d089725-b547-481c-b39c-06ac991d6ae2">27,804,224</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Revolving line of credit</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermLineOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMjEtMS0xLTEtMA_e654cda4-04f1-4a43-8fe9-5fd8c7d40fd3">20,000,000</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermLineOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMjEtMy0xLTEtMA_7a900cf8-bb98-4c3b-971b-eafc19b081c8">20,000,000</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other long-term liabilities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" decimals="0" format="ixt:numdotdecimal" name="cpix:OtherLongTermObligationsExcludingCurrentPortion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMjItMS0xLTEtMA_9bb9ce35-a710-401f-af42-928bcf0d6938">11,540,378</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231" decimals="0" format="ixt:numdotdecimal" name="cpix:OtherLongTermObligationsExcludingCurrentPortion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMjItMy0xLTEtMA_b8a50c7b-0a09-4375-94c1-6fccb5c9d864">9,319,143</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:37pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMjMtMS0xLTEtMA_ebcad7a0-7347-4ae7-b0b9-0c47ce4757c9">53,857,507</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMjMtMy0xLTEtMA_54ebadc5-8eaa-44b0-848c-0e947ca3d74d">57,123,367</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><ix:nonFraction unitRef="usd" contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMjQtMS0xLTEtMA_7560ea79-9214-41fb-82d5-ae1fa8f4206a"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><ix:nonFraction unitRef="usd" contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMjQtMy0xLTEtMA_6712adc9-dcfd-4c14-bfd1-9a63e563ad3d"></ix:nonFraction></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Equity:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Shareholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:19pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Common stock&#8212;<ix:nonFraction unitRef="usdPerShare" contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CommonStockNoParValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjViNDcyODZjODM0YjQzZmRiZGEzYTBkNGZkMDk4OWE0XzU0OTc1NTgxNDA2Mw_64672c3a-9461-4333-8f52-857fa2304eab"><ix:nonFraction unitRef="usdPerShare" contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CommonStockNoParValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjViNDcyODZjODM0YjQzZmRiZGEzYTBkNGZkMDk4OWE0XzU0OTc1NTgxNDA2Mw_8e90b6a6-09ca-42e1-aae8-36fb98997510">no</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjViNDcyODZjODM0YjQzZmRiZGEzYTBkNGZkMDk4OWE0XzU0OTc1NTgxNDA3Ng_13e34e6b-d976-45bc-9aaf-5878f33fa292"><ix:nonFraction unitRef="shares" contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjViNDcyODZjODM0YjQzZmRiZGEzYTBkNGZkMDk4OWE0XzU0OTc1NTgxNDA3Ng_270d4349-e74a-4909-8787-d041031d29f5">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjViNDcyODZjODM0YjQzZmRiZGEzYTBkNGZkMDk4OWE0XzU0OTc1NTgxNDA4OA_1315214b-cca7-45b5-bf5d-7fe1b94c1b5e"><ix:nonFraction unitRef="shares" contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjViNDcyODZjODM0YjQzZmRiZGEzYTBkNGZkMDk4OWE0XzU0OTc1NTgxNDA4OA_e963529f-b523-4320-8bdc-01b97dac63c2">15,471,070</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjViNDcyODZjODM0YjQzZmRiZGEzYTBkNGZkMDk4OWE0XzU0OTc1NTgxNDEwMA_02eb04d2-8252-4c90-8bde-a119168e77be"><ix:nonFraction unitRef="shares" contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjViNDcyODZjODM0YjQzZmRiZGEzYTBkNGZkMDk4OWE0XzU0OTc1NTgxNDEwMA_0d138625-da82-45ab-a263-910ce179efea">15,481,497</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of June 30, 2019 and December 31, 2018, respectively</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMjctMS0xLTEtMA_c385ceed-0a8a-45b2-acf8-80bcea08d208">49,938,254</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMjctMy0xLTEtMA_84129ef0-f4d2-4815-8364-8ca781d22e58">51,098,613</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:19pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Retained earnings</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMjgtMS0xLTEtMA_145c63b7-8354-412c-a071-120a5cbd8834">4,122,769</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMjgtMy0xLTEtMA_f8a35567-2ff4-4ece-9bc9-5dcf1023c5aa">4,746,154</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:37pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total shareholders&#8217; equity</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMjktMS0xLTEtMA_ad08b794-9edc-4dfa-b174-fc165937cdf6">54,061,023</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMjktMy0xLTEtMA_a7b589b2-224d-4819-b6a4-ceb2e915ce72">55,844,767</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Noncontrolling interests</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:MinorityInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMzAtMS0xLTEtMA_111601e3-e765-4b65-b6c2-a815a7d7008d">372,306</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:MinorityInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMzAtMy0xLTEtMA_f13c04ee-2ab6-46db-8366-ce55d2765223">274,266</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:37pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total equity</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMzEtMS0xLTEtMA_1480bb0c-8fde-496a-b382-8225b41312b4">53,688,717</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMzEtMy0xLTEtMA_1d25acf8-7e37-4f56-a405-86eb1842a59a">55,570,501</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:37pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities and equity</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMzItMS0xLTEtMA_ae3c9cce-45de-43f7-b262-0cf99e713e49">107,546,224</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMzItMy0xLTEtMA_510444a1-33c6-4548-94c1-744897b9954c">112,693,868</ix:nonFraction>&#160;</span></td></tr></table></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">See accompanying Notes to Unaudited Condensed Consolidated Financial Statements. </span></div><div id="i_0_22"></div><div style="text-align:center;-sec-extract:summary;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">1</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Condensed Consolidated Statements of Operations and Comprehensive Income (loss)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="text-align:center;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:46.099415%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.426901%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.426901%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.426901%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.426901%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net revenues</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMi0xLTEtMS0w_417c1621-036c-4f87-a446-68aa8cbf763e">11,580,600</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMi0zLTEtMS0w_9933222d-11ae-4edb-96ef-8fd6ab98d68a">10,163,724</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMi01LTEtMS0w_a5715e70-dcb2-4add-9a76-fc4d36389f09">23,483,347</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMi03LTEtMS0w_a5c78df2-7196-4d42-b9a1-2c9c67a1b707">18,751,329</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Costs and expenses:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:19pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of products sold</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfNC0xLTEtMS0w_ea6d77cf-9316-45a6-8501-e858b4314579">2,012,196</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfNC0zLTEtMS0w_b03ae125-2dab-40ef-9761-0e6934794e87">1,523,319</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfNC01LTEtMS0w_5be4cac1-7301-4c8f-b2a1-fd0c7b74a85c">4,011,932</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfNC03LTEtMS0w_0370455d-e316-42b7-9e86-fb08c174a230">3,051,280</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:19pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Selling and marketing</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfNS0xLTEtMS0w_db68069f-da67-4cf7-ae1d-b0715c8f05a0">5,153,129</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfNS0zLTEtMS0w_626e9b29-77c2-464a-b177-f6e53b415bee">5,076,250</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfNS01LTEtMS0w_57e30738-929a-4157-a85d-5e4c0f3d9427">10,273,634</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfNS03LTEtMS0w_53c624aa-24f1-4ec7-8fc7-e968e2b13bb4">9,746,761</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:19pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfNi0xLTEtMS0w_1a54158d-d322-4a3c-a666-fd21ea69498a">1,458,366</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfNi0zLTEtMS0w_8cbdf6a6-0c5c-429d-9238-8e93c4b9dc46">1,450,390</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfNi01LTEtMS0w_fc491f8c-0880-435d-9b3c-32f15184c6a9">2,725,967</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfNi03LTEtMS0w_7aecc0b7-154b-40c4-bc41-e1aa942ec321">3,325,329</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:19pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfNy0xLTEtMS0w_16d63399-0750-4784-b2bc-66dd89c3e685">2,528,916</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfNy0zLTEtMS0w_a3b25942-4a6a-41d3-8db6-88cae504f2c3">2,334,223</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfNy01LTEtMS0w_03fb1b71-1193-433d-9d8b-f3b473e2f664">5,198,972</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfNy03LTEtMS0w_dbb55a08-dd57-4120-a239-57edc65198c0">4,664,504</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:19pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfOC0xLTEtMS0w_aea76217-78e2-46ac-8df0-21a7386a7b15">1,029,708</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfOC0zLTEtMS0w_917fa066-f763-416a-8f76-9aa3e9a7a6c7">648,520</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfOC01LTEtMS0w_baef68e8-fa8b-4f65-9f4e-d48d44945bc8">2,051,353</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfOC03LTEtMS0w_fdf3a310-e89e-4995-b7fd-b301d7c34e1a">1,284,655</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total costs and expenses</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfOS0xLTEtMS0w_656fdada-0e77-4b21-a7b9-c1e0655fb50d">12,182,315</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfOS0zLTEtMS0w_2f23ba6f-ab5e-4ea6-bade-c0f7530a36f7">11,032,702</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfOS01LTEtMS0w_9bc3d1bf-a329-423e-9d3b-49dc00130619">24,261,858</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfOS03LTEtMS0w_a5a1f5c2-610b-4289-9feb-d18573551d79">22,072,529</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Operating income (loss)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTAtMS0xLTEtMA_3e4ffe88-0aeb-4e58-8a4e-0b29693afd0f">601,715</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTAtMy0xLTEtMA_3b56503d-8cdf-4cf9-870b-0eaf8f98f738">868,978</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTAtNS0xLTEtMA_b0b88711-cc78-49c7-9f9e-60aa773f6e60">778,511</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTAtNy0xLTEtMA_f6cf5b0f-c899-4e7a-87a0-fa655c87b2be">3,321,200</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Interest income</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTEtMS0xLTEtMA_290fb0b2-e67b-4def-a06d-dda76726a755">130,565</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTEtMy0xLTEtMA_dc81906a-1404-4613-8e69-b02490530b5f">149,706</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTEtNS0xLTEtMA_76577062-8395-4461-a381-3319980bb007">246,426</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTEtNy0xLTEtMA_262204e7-876c-4095-823d-f876332ab489">232,200</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTItMS0xLTEtMA_4936d22c-029b-4619-9ecc-9c77c9b9e4bd">91,200</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTItMy0xLTEtMA_b96b2188-0893-486a-a33d-039b7582bfa5">22,019</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTItNS0xLTEtMA_534923b4-3eea-4e01-ac8a-4fd138b5c81c">152,111</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTItNy0xLTEtMA_4ca50792-e191-42aa-ae62-030260b85bb4">40,321</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:19pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Income (loss) before income taxes</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTMtMS0xLTEtMA_d7403299-e777-4209-8ad7-7a34a99c2171">562,350</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTMtMy0xLTEtMA_dc8e2363-da02-4641-b2bd-61f07d3307c1">741,291</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTMtNS0xLTEtMA_04d71cd5-66f9-40d9-994a-eb0802210fa4">684,196</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTMtNy0xLTEtMA_5672a11e-71c3-4580-897f-e3afb3c68a52">3,129,321</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax (expense) benefit</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTQtMS0xLTEtMA_e0899da0-c324-4303-9695-7b32f539cfa7">4,462</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTQtMy0xLTEtMA_7cee680c-f819-43c4-af9e-17605867200e">4,159</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTQtNS0xLTEtMA_e30df282-f6a5-479e-91ff-936bc8e5b24f">76,966</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTQtNy0xLTEtMA_c390db93-557d-40be-ac22-5bb8cffa73d7">8,318</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:19pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTUtMS0xLTEtMA_dec0831c-0e8f-4580-8dec-06302abed295">566,812</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTUtMy0xLTEtMA_06c947f1-0391-4c13-bbc8-6cad42d71f23">745,450</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTUtNS0xLTEtMA_05f039b4-c04b-4f6b-b9ae-a7afd2891e6d">607,230</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTUtNy0xLTEtMA_7cb21d88-5d9a-4824-b086-4dc7015a5371">3,137,639</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net (income) loss at subsidiary attributable to noncontrolling interests</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTYtMS0xLTEtMA_0e7b7819-d604-4aed-b5a2-7fb7538b216b">17,305</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTYtMy0xLTEtMA_07fb3a9f-c106-4e47-a650-79b631936885">24,762</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTYtNS0xLTEtMA_132dc34e-de1e-43fa-8270-cf95b3c9466e">16,155</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTYtNy0xLTEtMA_f0782fc4-9feb-4650-abd3-e046b3b73f38">37,712</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:19pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) attributable to common shareholders</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTctMS0xLTEtMA_add4c9d4-19fe-42c3-b3e0-8fb5897199ec">549,507</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTctMy0xLTEtMA_c8e813db-72ab-4215-9b40-2d664e7a66df">720,688</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTctNS0xLTEtMA_4a97237f-ebc4-49d9-9f6b-2181df84041a">623,385</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTctNy0xLTEtMA_ec10c811-3464-4156-bfca-a0c11e6df31d">3,099,927</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Earnings (loss) per share attributable to common shareholders</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:19pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">- basic</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTktMS0xLTEtMA_49b74102-cc2e-4dbe-8ed3-c9d0e715916b">0.04</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTktMy0xLTEtMA_c9b19402-78d8-4c45-922c-4679216c3bf0">0.05</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTktNS0xLTEtMA_b57f2e8c-80a4-4662-a394-be75c22d2908">0.04</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTktNy0xLTEtMA_28d5449c-2057-40d9-a244-e95963c74013">0.20</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:19pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">- diluted</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMjAtMS0xLTEtMA_d6b8ca60-0e85-492b-b292-2055e16407da">0.04</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMjAtMy0xLTEtMA_2986163c-1d90-45bf-8a80-55c7b932cddf">0.05</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMjAtNS0xLTEtMA_4934856b-6024-44f8-9488-9b03575d86ea">0.04</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMjAtNy0xLTEtMA_8a8cd478-c482-4298-849e-30837eea9c92">0.20</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:19pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">- basic</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMjItMS0xLTEtMA_d9b5111c-2bc0-4cbc-83fe-7896ce172251">15,523,628</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMjItMy0xLTEtMA_0fa9d9a4-68ad-4f79-8778-76e667214916">15,674,954</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMjItNS0xLTEtMA_9c8e3451-9ed6-4d22-9dc5-099938b01a48">15,497,989</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMjItNy0xLTEtMA_635a4480-003e-466b-bc7e-9be7fbb0e4e8">15,682,348</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:19pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">- diluted</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMjMtMS0xLTEtMA_9b5d89ae-79ec-4590-be3a-bd33239874e7">15,523,628</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMjMtMy0xLTEtMA_d639cf17-4b62-4725-aacf-50b09be64284">15,674,954</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMjMtNS0xLTEtMA_5ab68aa6-f8a6-46df-8d37-a1e03abe2fab">15,497,989</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMjMtNy0xLTEtMA_6d7d3c2a-232d-4e3e-be5e-8a7fb56213dc">15,682,348</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Comprehensive income (loss) attributable to common shareholders</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMjUtMS0xLTEtMA_ffa47055-3dfa-48dc-851a-4810d97bb193">549,507</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMjUtMy0xLTEtMA_316e5b12-b2d4-48c1-81ac-12a72e4dad05">720,688</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMjUtNS0xLTEtMA_8e7802b4-add6-4d20-b518-b34a118af340">623,385</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMjUtNy0xLTEtMA_fa5e2cb5-ed40-4c22-bb88-13ea284effb5">3,099,927</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:19pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net (income) loss at subsidiary attributable to noncontrolling interests</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMjYtMS0xLTEtMA_bb5ae260-e121-492f-b6e3-809f6afed0ce">17,305</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMjYtMy0xLTEtMA_ddf5272a-9bdd-4c42-874a-0aea68e127b8">24,762</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMjYtNS0xLTEtMA_205e05c7-306c-488c-8187-072fba1861bc">16,155</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMjYtNy0xLTEtMA_551329da-3241-441f-b8f9-9bac5ee3b7ba">37,712</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total comprehensive income (loss)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMjctMS0xLTEtMA_4d8a651c-6621-439d-9e45-dc55928977ef">566,812</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMjctMy0xLTEtMA_aa615923-c674-4495-96dd-80ab85248b29">745,450</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMjctNS0xLTEtMA_8a916fd1-940f-494a-bc9d-f2f88d6370ea">607,230</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMjctNy0xLTEtMA_8322a3e6-4f62-431d-a1da-58302255f109">3,137,639</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.</span></div><div style="margin-top:17pt;margin-bottom:17pt;"><span><br/></span></div><div id="i_0_25"></div><div style="text-align:center;-sec-extract:summary;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">2</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.122807%;"><tr><td style="width:1.0%;"></td><td style="width:58.029499%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.616519%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537463%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.616519%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:19pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMy0xLTEtMS0w_46bbc6e4-ffab-4b6e-b48e-a13a99bdfd8c">607,230</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMy0zLTEtMS0w_3f5fb8cb-2c96-4557-bf3b-182db3fcaa2e">3,137,639</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:19pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments to reconcile net income (loss) to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:37pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization expense</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfNS0xLTEtMS0w_6b8f7a28-009f-4e58-8831-c0471e69e661">2,174,397</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfNS0zLTEtMS0w_5e9f428b-6d4f-45e7-8341-4b0e5885dbce">1,394,728</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:37pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax expense</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfNi0xLTEtMS0w_39c22164-6529-42ea-999c-6f4d77b94445">43,605</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="0" format="ixt:zerodash" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfNi0zLTEtMS0w_43dc85e9-d482-4f3f-a541-b1a3ef9fac85">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:37pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfNy0xLTEtMS0w_27b537f7-638f-4afa-8c26-35d4aac2af4a">760,982</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfNy0zLTEtMS0w_fe250a23-628c-4b88-9352-cc9491664192">665,309</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:37pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(Decrease) increase in non-cash contingent consideration</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfOC0xLTEtMS0w_4e280f49-0aeb-43a5-8d81-c851b1780477">321,894</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="0" format="ixt:zerodash" name="us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfOC0zLTEtMS0w_f7ac5b25-4de7-43f5-b428-fd83f43e4b62">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:37pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Noncash interest expense</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfOS0xLTEtMS0w_52c26fae-7df4-4149-b2cf-03400448fc1e">28,111</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfOS0zLTEtMS0w_f72e17fc-942b-41cc-9072-5be3d6f94620">33,730</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:37pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Noncash investment gains</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMTAtMS0xLTEtMA_a7673d44-95fa-457b-a9a5-74fc807589dd">125,804</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMTAtMy0xLTEtMA_4a25a528-e955-4b9c-847c-acb278c54de2">118,188</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:37pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net changes in assets and liabilities affecting operating activities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:55pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMTItMS0xLTEtMA_0fc0b18c-8dc2-4fd3-984d-983c3e26721d">583,029</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMTItMy0xLTEtMA_30b5ea76-f1de-448a-90c3-663a40c40e65">2,589,017</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:55pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Inventories</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMTMtMS0xLTEtMA_cf124a29-4d7a-48c7-9ce7-18a90c211339">1,429,484</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMTMtMy0xLTEtMA_c5b638b9-48b9-4cc0-aaa5-ed34f7362c32">607,653</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:55pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other current assets and other assets</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMTQtMS0xLTEtMA_7e4839b2-ae42-4fcd-8c0e-7d4df9e6d23d">141,577</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMTQtMy0xLTEtMA_553b1164-d9ec-4d22-ac24-c521ecfc4a42">804,729</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:55pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable and other current liabilities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="cpix:IncreaseDecreaseInCurrentOperatingLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMTUtMS0xLTEtMA_7678d56c-7d6a-4be9-bcbd-36cf86deaa09">1,132,333</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="0" sign="-" format="ixt:numdotdecimal" name="cpix:IncreaseDecreaseInCurrentOperatingLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMTUtMy0xLTEtMA_1524061f-a7fa-4463-aac9-33d2f1c22b4a">730,760</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:55pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other long-term liabilities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMTYtMS0xLTEtMA_6d7946fc-bf1f-476a-953c-f762219460f6">342,940</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMTYtMy0xLTEtMA_91ae49bd-e81c-49a7-9382-cecfe94435fe">136,402</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:37pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by operating activities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMTctMS0xLTEtMA_b1bc1906-1722-46a4-a3e8-80597af356eb">1,464,926</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMTctMy0xLTEtMA_6bad1374-480d-4387-974a-8912237c536e">1,029,675</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:37pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Additions to property and equipment</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMTktMS0xLTEtMA_6b08ad9b-8500-4e9c-943c-a9032a540120">89,070</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMTktMy0xLTEtMA_42bd5cd5-328e-4b78-ace2-710f17ed716d">131,684</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:37pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Purchases of marketable securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMjAtMS0xLTEtMA_92c51b50-faa0-4e17-a1f6-3e3eb3c58529">9,627,191</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMjAtMy0xLTEtMA_8d551c8b-6ae8-452b-9d44-4b231d94ae8c">16,916,890</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:37pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from sale of marketable securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMjEtMS0xLTEtMA_31e3e1c7-099f-4b5e-a823-57a0b9f628b7">8,563,988</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMjEtMy0xLTEtMA_03ee653b-ac9b-4be2-979e-87f77bbf6ca4">6,904,205</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid for acquisitions</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMjItMS0xLTEtMA_318a10b5-7df2-47c8-9f4f-062efce3f55b">5,000,000</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="0" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMjItMy0xLTEtMA_e4a4b8cd-2f8f-4a7e-9329-1fe754ebd645">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:37pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Additions to intangible assets</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMjMtMS0xLTEtMA_27885b2c-0147-4657-8fa2-860a9296440f">395,005</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMjMtMy0xLTEtMA_b5bfd384-d107-4c93-ba04-c5df61ce8518">593,121</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:37pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in investing activities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMjQtMS0xLTEtMA_3588df48-23ef-475c-a377-d904df9b0cdd">6,547,278</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMjQtMy0xLTEtMA_0f97100e-9d35-4c96-b7e5-aca591e46ac9">10,737,490</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:37pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Borrowings on line of credit</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRepaymentsOfLinesOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMjctMS0xLTEtMA_ebc4905e-3210-4d7c-a371-efb714b023a7">36,000,000</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRepaymentsOfLinesOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMjctMy0xLTEtMA_3f3dfac1-4f57-47e5-a38f-81aa06890957">24,000,000</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:37pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Repayments on line of credit</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfNotesPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMjgtMS0xLTEtMA_b62baa4f-ec20-4c01-9486-322dfa2e421a">36,000,000</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfNotesPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMjgtMy0xLTEtMA_9741e0b0-a85c-4b9a-bc6b-a1897bd08448">21,800,000</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:37pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from sales of common stock, net of offering costs</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="0" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMjktMS0xLTEtMA_979d9b0c-dd77-4177-bfed-4267979d2d63">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMjktMy0xLTEtMA_6ee77c58-24f6-49d2-bec9-bb06566b920c">200,909</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:37pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Payments of deferred offering costs</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="0" format="ixt:zerodash" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMzAtMS0xLTEtMA_8e0e65fc-dfc5-4126-a843-949d4cb4d634">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMzAtMy0xLTEtMA_acf8116a-fb37-4ab7-b5a3-3bccb4fbbaee">248,108</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:37pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash payment of contingent consideration</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMzEtMS0xLTEtMA_22148dcc-4120-43bf-8de6-f72dbbc2fd2b">684,738</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="0" format="ixt:zerodash" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMzEtMy0xLTEtMA_f8d33617-6832-40b1-8219-70343f97973a">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:37pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Repurchase of common shares</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMzUtMS0xLTEtMA_0d1f4493-b9a4-49f8-a536-434d4f48162f">1,220,690</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMzUtMy0xLTEtMA_cbb3067c-e019-4aea-931b-1a712759ae87">1,951,199</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:37pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash (used in) provided by financing activities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMzYtMS0xLTEtMA_85bed606-f0b7-47d3-9291-eae94be3355a">1,905,428</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMzYtMy0xLTEtMA_89692202-2bf3-479c-bc60-c470d6356386">201,602</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:37pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMzctMS0xLTEtMA_252adae6-dca0-48b6-9acf-f132703d856d">6,987,780</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMzctMy0xLTEtMA_4248ac45-42c2-459e-bdbe-809ae1d9dba1">9,506,213</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents at beginning of period</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMzgtMS0xLTEtMA_d71900bd-dda8-40fa-a5a9-513eabf1e510">27,938,960</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6eecb6cf82d946f791b1e9b3d617a3ba_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMzgtMy0xLTEtMA_36b634e6-e508-4fc8-8879-9ba9fad65537">45,412,868</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents at end of period</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMzktMS0xLTEtMA_1b48b58e-5f8a-4559-ad2e-3245bce26694">20,951,180</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id5d60a75c7914cbf8204350654c33543_I20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMzktMy0xLTEtMA_34b8a221-9b53-45a4-bc01-ccdc8555bec4">35,906,655</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Supplemental non-cash operating, investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:13pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Recognition of operating lease assets and liabilities through adoption of ASC 842</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfNDItMS0xLTEtMA_963d3767-69ea-4a4d-b56b-18440e2ae746">3,629,320</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="0" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfNDItMy0xLTEtMA_0da2f928-68c0-44f3-8d92-c361be99f848">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:13pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Repurchase of subsidiary shares from noncontrolling interests</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfNDQtMS0xLTEtMzY3OQ_b55b8e39-cc87-4312-bc23-bc9aca417346">800,000</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="0" format="ixt:zerodash" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfNDQtMy0xLTEtMzY4MQ_2b08f633-dc84-4fc5-a691-95357029332b">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Additions to intangible assets from final purchase price allocation</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfNDUtMS0xLTEtMzY4Mw_62eeffdb-d2a4-42c9-aa92-acec8fdadba7">148,000</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="0" format="ixt:zerodash" name="us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfNDUtMy0xLTEtMzY4NQ_7517b55c-f120-483d-9f2d-4d00e4dab118">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.</span></div><div id="i_0_28"></div><div style="text-align:center;-sec-extract:summary;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">3</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Condensed Consolidated Statements of Equity</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="text-align:center;margin-bottom:3pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.684211%;"><tr><td style="width:1.0%;"></td><td style="width:30.592593%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.888889%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.392593%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.888889%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.392593%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.888889%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.392593%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.777778%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.392593%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.592593%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Retained earnings</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Noncontrolling interests</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total equity</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2017</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i0e1c5e9c7cbe4efc93a736d76e33fe31_I20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjIzYzg4ZTU5ZTNmMDQ0Zjk4MDEwMWZiZjRmNzBjZjE2L3RhYmxlcmFuZ2U6MjNjODhlNTllM2YwNDRmOTgwMTAxZmJmNGY3MGNmMTZfMi0xLTEtMS0zNzEx_d37d03bb-843c-405b-b7b3-4b4041b32a90">15,723,075</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e1c5e9c7cbe4efc93a736d76e33fe31_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjIzYzg4ZTU5ZTNmMDQ0Zjk4MDEwMWZiZjRmNzBjZjE2L3RhYmxlcmFuZ2U6MjNjODhlNTllM2YwNDRmOTgwMTAxZmJmNGY3MGNmMTZfMi0zLTEtMS0zNzEz_dcf1be5f-0022-4765-af5a-d30ab34d6b36">52,410,941</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icf52e3a90b564e61a9df4d3dd81a200b_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjIzYzg4ZTU5ZTNmMDQ0Zjk4MDEwMWZiZjRmNzBjZjE2L3RhYmxlcmFuZ2U6MjNjODhlNTllM2YwNDRmOTgwMTAxZmJmNGY3MGNmMTZfMi01LTEtMS0zNzE1_22f7b1b4-6f88-4f90-b972-b245f28b10ea">11,709,222</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9ec531ec35eb439399c9436b7345e202_I20171231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjIzYzg4ZTU5ZTNmMDQ0Zjk4MDEwMWZiZjRmNzBjZjE2L3RhYmxlcmFuZ2U6MjNjODhlNTllM2YwNDRmOTgwMTAxZmJmNGY3MGNmMTZfMi03LTEtMS0zNzE3_73fc10a8-1d9f-4101-b7b9-3fbcde6ebb43">198,562</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6eecb6cf82d946f791b1e9b3d617a3ba_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjIzYzg4ZTU5ZTNmMDQ0Zjk4MDEwMWZiZjRmNzBjZjE2L3RhYmxlcmFuZ2U6MjNjODhlNTllM2YwNDRmOTgwMTAxZmJmNGY3MGNmMTZfMi05LTEtMS0zNzE5_59cd7bce-f53b-4f50-bd48-16a307fa0edd">63,921,601</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from sales of common stock, net of offering costs</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i8d3bd3dbf1ee431ca1035d16d2daf32b_D20180101-20180331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjIzYzg4ZTU5ZTNmMDQ0Zjk4MDEwMWZiZjRmNzBjZjE2L3RhYmxlcmFuZ2U6MjNjODhlNTllM2YwNDRmOTgwMTAxZmJmNGY3MGNmMTZfMy0xLTEtMS0zNzQ3_2cfc4fac-b5dd-44ee-8643-d135a220f1a3">30,704</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8d3bd3dbf1ee431ca1035d16d2daf32b_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjIzYzg4ZTU5ZTNmMDQ0Zjk4MDEwMWZiZjRmNzBjZjE2L3RhYmxlcmFuZ2U6MjNjODhlNTllM2YwNDRmOTgwMTAxZmJmNGY3MGNmMTZfMy0zLTEtMS0zNzQ1_6dfa8e44-981d-4d15-b42c-85abe07ff688">200,909</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4acfcd09578f42f994a9b89541ecf28c_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjIzYzg4ZTU5ZTNmMDQ0Zjk4MDEwMWZiZjRmNzBjZjE2L3RhYmxlcmFuZ2U6MjNjODhlNTllM2YwNDRmOTgwMTAxZmJmNGY3MGNmMTZfMy05LTEtMS0zNzIx_175c6d7a-b47c-430e-bd24-fee0a1aebb57">200,909</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i8d3bd3dbf1ee431ca1035d16d2daf32b_D20180101-20180331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjIzYzg4ZTU5ZTNmMDQ0Zjk4MDEwMWZiZjRmNzBjZjE2L3RhYmxlcmFuZ2U6MjNjODhlNTllM2YwNDRmOTgwMTAxZmJmNGY3MGNmMTZfNC0xLTEtMS0zNzQ5_b2863dbd-5662-4337-962a-de1a4f704cb1">145,550</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8d3bd3dbf1ee431ca1035d16d2daf32b_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjIzYzg4ZTU5ZTNmMDQ0Zjk4MDEwMWZiZjRmNzBjZjE2L3RhYmxlcmFuZ2U6MjNjODhlNTllM2YwNDRmOTgwMTAxZmJmNGY3MGNmMTZfNC0zLTEtMS0zNzQz_96a9608b-4dad-427b-8a97-164f637a2a59">339,209</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4acfcd09578f42f994a9b89541ecf28c_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjIzYzg4ZTU5ZTNmMDQ0Zjk4MDEwMWZiZjRmNzBjZjE2L3RhYmxlcmFuZ2U6MjNjODhlNTllM2YwNDRmOTgwMTAxZmJmNGY3MGNmMTZfNC05LTEtMS0zNzIz_fcc77199-f759-40c3-a4c5-bec413dc7207">339,209</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Repurchase of common shares</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i8d3bd3dbf1ee431ca1035d16d2daf32b_D20180101-20180331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjIzYzg4ZTU5ZTNmMDQ0Zjk4MDEwMWZiZjRmNzBjZjE2L3RhYmxlcmFuZ2U6MjNjODhlNTllM2YwNDRmOTgwMTAxZmJmNGY3MGNmMTZfNS0xLTEtMS0zNzUx_44260695-082d-4d4b-b2f5-729846b40060">172,079</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8d3bd3dbf1ee431ca1035d16d2daf32b_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjIzYzg4ZTU5ZTNmMDQ0Zjk4MDEwMWZiZjRmNzBjZjE2L3RhYmxlcmFuZ2U6MjNjODhlNTllM2YwNDRmOTgwMTAxZmJmNGY3MGNmMTZfNS0zLTEtMS0zNzQx_0140f06b-7c26-49d3-af15-8395683edb3f">1,195,225</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4acfcd09578f42f994a9b89541ecf28c_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjIzYzg4ZTU5ZTNmMDQ0Zjk4MDEwMWZiZjRmNzBjZjE2L3RhYmxlcmFuZ2U6MjNjODhlNTllM2YwNDRmOTgwMTAxZmJmNGY3MGNmMTZfNS05LTEtMS0zNzI1_59fa61a9-dbd8-4f3f-b58a-9fa92b41484b">1,195,225</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i12bdf0ab8f4c49578c9eb30f38190373_D20180101-20180331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjIzYzg4ZTU5ZTNmMDQ0Zjk4MDEwMWZiZjRmNzBjZjE2L3RhYmxlcmFuZ2U6MjNjODhlNTllM2YwNDRmOTgwMTAxZmJmNGY3MGNmMTZfNi01LTEtMS0zNzM1_cdb83a72-c7eb-4a17-ba8b-0a81104b3ebe">2,379,239</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i389b9f06784a4fa895bf9d85d0373d0a_D20180101-20180331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjIzYzg4ZTU5ZTNmMDQ0Zjk4MDEwMWZiZjRmNzBjZjE2L3RhYmxlcmFuZ2U6MjNjODhlNTllM2YwNDRmOTgwMTAxZmJmNGY3MGNmMTZfNi03LTEtMS0zNzMz_4a8dd21c-2edb-40f5-8a75-dd99a1f5cb4f">12,950</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4acfcd09578f42f994a9b89541ecf28c_D20180101-20180331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjIzYzg4ZTU5ZTNmMDQ0Zjk4MDEwMWZiZjRmNzBjZjE2L3RhYmxlcmFuZ2U6MjNjODhlNTllM2YwNDRmOTgwMTAxZmJmNGY3MGNmMTZfNi05LTEtMS0zNzI3_73913fcf-8316-477a-b66c-c51a2d5f53b9">2,392,189</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, March 31, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ieeeb240a56f744c5976744da0dbe5ad7_I20180331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjIzYzg4ZTU5ZTNmMDQ0Zjk4MDEwMWZiZjRmNzBjZjE2L3RhYmxlcmFuZ2U6MjNjODhlNTllM2YwNDRmOTgwMTAxZmJmNGY3MGNmMTZfNy0xLTEtMS0zNzUz_29bd2abe-dd45-4469-b2d1-f342e8f0a84b">15,727,250</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieeeb240a56f744c5976744da0dbe5ad7_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjIzYzg4ZTU5ZTNmMDQ0Zjk4MDEwMWZiZjRmNzBjZjE2L3RhYmxlcmFuZ2U6MjNjODhlNTllM2YwNDRmOTgwMTAxZmJmNGY3MGNmMTZfNy0zLTEtMS0zNzM5_0ca0cd52-7a4d-499e-98f1-929924572ce4">51,755,834</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie2aef2419d2a434d882a0412b764c40a_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjIzYzg4ZTU5ZTNmMDQ0Zjk4MDEwMWZiZjRmNzBjZjE2L3RhYmxlcmFuZ2U6MjNjODhlNTllM2YwNDRmOTgwMTAxZmJmNGY3MGNmMTZfNy01LTEtMS0zNzM3_86c12e7f-cd47-4e5a-a733-d1c81de346b5">9,329,983</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i525c05bfba8a496bb3f3ad3dd759b4b6_I20180331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjIzYzg4ZTU5ZTNmMDQ0Zjk4MDEwMWZiZjRmNzBjZjE2L3RhYmxlcmFuZ2U6MjNjODhlNTllM2YwNDRmOTgwMTAxZmJmNGY3MGNmMTZfNy03LTEtMS0zNzMx_50ecc596-ecfe-4c3b-b677-a45aa493eb70">211,512</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia885021b86044725a1fb10e4cc611b1f_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjIzYzg4ZTU5ZTNmMDQ0Zjk4MDEwMWZiZjRmNzBjZjE2L3RhYmxlcmFuZ2U6MjNjODhlNTllM2YwNDRmOTgwMTAxZmJmNGY3MGNmMTZfNy05LTEtMS0zNzI5_735188a7-d38a-40c5-8c61-e6ee7a060b70">60,874,305</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;margin-bottom:3pt;"><span><br/></span></div><div style="margin-bottom:21pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.976608%;"><tr><td style="width:1.0%;"></td><td style="width:30.496307%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.850812%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390842%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.850812%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390842%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.850812%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390842%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.737075%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390842%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.850812%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, March 31, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ieeeb240a56f744c5976744da0dbe5ad7_I20180331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjMyY2IyMjdjMzJjMjRmM2E4ZDY3OWFhNjgwYzc2NjIyL3RhYmxlcmFuZ2U6MzJjYjIyN2MzMmMyNGYzYThkNjc5YWE2ODBjNzY2MjJfMi0xLTEtMS0w_7ff7bde5-d294-4b6c-bf74-5aba6bdce258">15,727,250</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieeeb240a56f744c5976744da0dbe5ad7_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjMyY2IyMjdjMzJjMjRmM2E4ZDY3OWFhNjgwYzc2NjIyL3RhYmxlcmFuZ2U6MzJjYjIyN2MzMmMyNGYzYThkNjc5YWE2ODBjNzY2MjJfMi0zLTEtMS0w_b43b50ba-f3b7-4045-87bd-234be4bffed8">51,755,834</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie2aef2419d2a434d882a0412b764c40a_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjMyY2IyMjdjMzJjMjRmM2E4ZDY3OWFhNjgwYzc2NjIyL3RhYmxlcmFuZ2U6MzJjYjIyN2MzMmMyNGYzYThkNjc5YWE2ODBjNzY2MjJfMi01LTEtMS0w_a63ba878-d1b0-4a16-9b8c-fdd67f1a845d">9,329,983</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i525c05bfba8a496bb3f3ad3dd759b4b6_I20180331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjMyY2IyMjdjMzJjMjRmM2E4ZDY3OWFhNjgwYzc2NjIyL3RhYmxlcmFuZ2U6MzJjYjIyN2MzMmMyNGYzYThkNjc5YWE2ODBjNzY2MjJfMi03LTEtMS0w_c15ff446-b606-4635-8240-9ea0089e5eaf">211,512</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia885021b86044725a1fb10e4cc611b1f_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjMyY2IyMjdjMzJjMjRmM2E4ZDY3OWFhNjgwYzc2NjIyL3RhYmxlcmFuZ2U6MzJjYjIyN2MzMmMyNGYzYThkNjc5YWE2ODBjNzY2MjJfMi05LTEtMS0w_2f1a8fef-5970-4890-9f5d-f2b1cde4c9e8">60,874,305</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from sales of common stock, net of offering costs</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if02d00db9a714fb7b9ff2e6a67ac03d2_D20180401-20180630" decimals="INF" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjMyY2IyMjdjMzJjMjRmM2E4ZDY3OWFhNjgwYzc2NjIyL3RhYmxlcmFuZ2U6MzJjYjIyN2MzMmMyNGYzYThkNjc5YWE2ODBjNzY2MjJfMy0xLTEtMS0w_3c223fc0-87a9-40f9-bb6b-38d66f570a0e">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if02d00db9a714fb7b9ff2e6a67ac03d2_D20180401-20180630" decimals="0" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjMyY2IyMjdjMzJjMjRmM2E4ZDY3OWFhNjgwYzc2NjIyL3RhYmxlcmFuZ2U6MzJjYjIyN2MzMmMyNGYzYThkNjc5YWE2ODBjNzY2MjJfMy0zLTEtMS0w_5bd3ac35-59a0-48a5-a3f2-ac60cfcfc4b7">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjMyY2IyMjdjMzJjMjRmM2E4ZDY3OWFhNjgwYzc2NjIyL3RhYmxlcmFuZ2U6MzJjYjIyN2MzMmMyNGYzYThkNjc5YWE2ODBjNzY2MjJfMy05LTEtMS0w_6e559078-99dd-4508-bfea-8f528d9ac56e">0</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if02d00db9a714fb7b9ff2e6a67ac03d2_D20180401-20180630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjMyY2IyMjdjMzJjMjRmM2E4ZDY3OWFhNjgwYzc2NjIyL3RhYmxlcmFuZ2U6MzJjYjIyN2MzMmMyNGYzYThkNjc5YWE2ODBjNzY2MjJfNC0xLTEtMS0w_c0d28fca-d100-4f45-8da8-6fe9c68aed8a">4,750</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if02d00db9a714fb7b9ff2e6a67ac03d2_D20180401-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjMyY2IyMjdjMzJjMjRmM2E4ZDY3OWFhNjgwYzc2NjIyL3RhYmxlcmFuZ2U6MzJjYjIyN2MzMmMyNGYzYThkNjc5YWE2ODBjNzY2MjJfNC0zLTEtMS0w_6ad5a682-e00e-4948-93ea-b0d3e63bdda8">326,100</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjMyY2IyMjdjMzJjMjRmM2E4ZDY3OWFhNjgwYzc2NjIyL3RhYmxlcmFuZ2U6MzJjYjIyN2MzMmMyNGYzYThkNjc5YWE2ODBjNzY2MjJfNC05LTEtMS0w_e47012ca-67d3-4bbd-a65d-094c8822f9a4">326,100</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Repurchase of common shares</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="if02d00db9a714fb7b9ff2e6a67ac03d2_D20180401-20180630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjMyY2IyMjdjMzJjMjRmM2E4ZDY3OWFhNjgwYzc2NjIyL3RhYmxlcmFuZ2U6MzJjYjIyN2MzMmMyNGYzYThkNjc5YWE2ODBjNzY2MjJfNS0xLTEtMS0w_073dfcb4-114b-4cfd-a418-78ed4a71cf83">127,291</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if02d00db9a714fb7b9ff2e6a67ac03d2_D20180401-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjMyY2IyMjdjMzJjMjRmM2E4ZDY3OWFhNjgwYzc2NjIyL3RhYmxlcmFuZ2U6MzJjYjIyN2MzMmMyNGYzYThkNjc5YWE2ODBjNzY2MjJfNS0zLTEtMS0w_85853ba4-9294-45c0-a157-b09e1f7a371e">784,505</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjMyY2IyMjdjMzJjMjRmM2E4ZDY3OWFhNjgwYzc2NjIyL3RhYmxlcmFuZ2U6MzJjYjIyN2MzMmMyNGYzYThkNjc5YWE2ODBjNzY2MjJfNS05LTEtMS0w_a15cd438-208e-41d8-aef4-fa4ac842eeee">784,505</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iad96f105789947c999f7d544dd4620db_D20180401-20180630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjMyY2IyMjdjMzJjMjRmM2E4ZDY3OWFhNjgwYzc2NjIyL3RhYmxlcmFuZ2U6MzJjYjIyN2MzMmMyNGYzYThkNjc5YWE2ODBjNzY2MjJfNi01LTEtMS0w_791cbc43-978b-4eba-8b12-bd0a7bfac6e5">720,688</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i77e056bccd4543089353688903d60102_D20180401-20180630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjMyY2IyMjdjMzJjMjRmM2E4ZDY3OWFhNjgwYzc2NjIyL3RhYmxlcmFuZ2U6MzJjYjIyN2MzMmMyNGYzYThkNjc5YWE2ODBjNzY2MjJfNi03LTEtMS0w_f5bbb9e1-e026-4e2e-9224-3e0fd32a003c">24,762</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjMyY2IyMjdjMzJjMjRmM2E4ZDY3OWFhNjgwYzc2NjIyL3RhYmxlcmFuZ2U6MzJjYjIyN2MzMmMyNGYzYThkNjc5YWE2ODBjNzY2MjJfNi05LTEtMS0w_47fd0524-b404-4c01-bd6a-bef97cd514a9">745,450</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, June 30, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ifa6a17eccce2451499b89a8ee27e36af_I20180630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjMyY2IyMjdjMzJjMjRmM2E4ZDY3OWFhNjgwYzc2NjIyL3RhYmxlcmFuZ2U6MzJjYjIyN2MzMmMyNGYzYThkNjc5YWE2ODBjNzY2MjJfNy0xLTEtMS0w_4f7db7b3-bd6f-4ee6-9072-63677fe6d46f">15,604,709</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa6a17eccce2451499b89a8ee27e36af_I20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjMyY2IyMjdjMzJjMjRmM2E4ZDY3OWFhNjgwYzc2NjIyL3RhYmxlcmFuZ2U6MzJjYjIyN2MzMmMyNGYzYThkNjc5YWE2ODBjNzY2MjJfNy0zLTEtMS0w_c5199d73-953c-470a-a966-764be11e65a4">51,297,429</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7ebb41ca72a9412d830adbbcce277c27_I20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjMyY2IyMjdjMzJjMjRmM2E4ZDY3OWFhNjgwYzc2NjIyL3RhYmxlcmFuZ2U6MzJjYjIyN2MzMmMyNGYzYThkNjc5YWE2ODBjNzY2MjJfNy01LTEtMS0w_08d97631-d5c5-4608-98b8-6fe0f345e2ac">8,609,295</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iefb8318507a84b1eab45ae17e36b7a7e_I20180630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjMyY2IyMjdjMzJjMjRmM2E4ZDY3OWFhNjgwYzc2NjIyL3RhYmxlcmFuZ2U6MzJjYjIyN2MzMmMyNGYzYThkNjc5YWE2ODBjNzY2MjJfNy03LTEtMS0w_6e725005-a0c4-4e20-a6ed-9bf6fe0ad8a0">236,274</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id5d60a75c7914cbf8204350654c33543_I20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjMyY2IyMjdjMzJjMjRmM2E4ZDY3OWFhNjgwYzc2NjIyL3RhYmxlcmFuZ2U6MzJjYjIyN2MzMmMyNGYzYThkNjc5YWE2ODBjNzY2MjJfNy05LTEtMS0w_0d7559a1-a5af-4124-80cd-7dcafcd27721">59,670,450</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.976608%;"><tr><td style="width:1.0%;"></td><td style="width:30.496307%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.850812%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390842%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.850812%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390842%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.850812%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390842%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.737075%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390842%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.850812%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Retained earnings</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Noncontrolling interests</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total equity</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i86ad84a3cb90495fa0d9574cd4dfc3e8_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjNjA2N2VkNTgwZjRmMDVhNWY5MmY1YTY2YjhiNDRkL3RhYmxlcmFuZ2U6MmM2MDY3ZWQ1ODBmNGYwNWE1ZjkyZjVhNjZiOGI0NGRfMi0xLTEtMS0zODIz_257d4b8e-3c66-4914-9d30-ad6afb5d3e57">15,481,497</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i86ad84a3cb90495fa0d9574cd4dfc3e8_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjNjA2N2VkNTgwZjRmMDVhNWY5MmY1YTY2YjhiNDRkL3RhYmxlcmFuZ2U6MmM2MDY3ZWQ1ODBmNGYwNWE1ZjkyZjVhNjZiOGI0NGRfMi0zLTEtMS0zODI1_b2d6ff87-4e13-4559-ad9c-d4b7f8509dd1">51,098,613</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6695ed74ccf34594a009b751a9867ab5_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjNjA2N2VkNTgwZjRmMDVhNWY5MmY1YTY2YjhiNDRkL3RhYmxlcmFuZ2U6MmM2MDY3ZWQ1ODBmNGYwNWE1ZjkyZjVhNjZiOGI0NGRfMi01LTEtMS0zODI3_ccab0403-988a-4752-969c-dc7073c8005d">4,746,154</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib0658642e8184a7e8bcf52ddf1229693_I20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjNjA2N2VkNTgwZjRmMDVhNWY5MmY1YTY2YjhiNDRkL3RhYmxlcmFuZ2U6MmM2MDY3ZWQ1ODBmNGYwNWE1ZjkyZjVhNjZiOGI0NGRfMi03LTEtMS0zODI5_10e8327b-f5ad-46c8-b52e-39e0e4d4dc08">274,266</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjNjA2N2VkNTgwZjRmMDVhNWY5MmY1YTY2YjhiNDRkL3RhYmxlcmFuZ2U6MmM2MDY3ZWQ1ODBmNGYwNWE1ZjkyZjVhNjZiOGI0NGRfMi05LTEtMS0zODM0_aaaf6ce4-badd-47b6-af0e-bd5b4a9fde72">55,570,501</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="idaa440b71edc463180ffe7cc20dc52c5_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjNjA2N2VkNTgwZjRmMDVhNWY5MmY1YTY2YjhiNDRkL3RhYmxlcmFuZ2U6MmM2MDY3ZWQ1ODBmNGYwNWE1ZjkyZjVhNjZiOGI0NGRfMy0xLTEtMS0zODQx_a9c6d755-cc7e-4c2f-b9f4-0b0ba855cc49">187,486</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idaa440b71edc463180ffe7cc20dc52c5_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjNjA2N2VkNTgwZjRmMDVhNWY5MmY1YTY2YjhiNDRkL3RhYmxlcmFuZ2U6MmM2MDY3ZWQ1ODBmNGYwNWE1ZjkyZjVhNjZiOGI0NGRfMy0zLTEtMS0zODM4_09db7e5b-c792-4c9a-8753-0289dfb011a7">364,434</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4b03a84c29d54b778087726fae7de356_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjNjA2N2VkNTgwZjRmMDVhNWY5MmY1YTY2YjhiNDRkL3RhYmxlcmFuZ2U6MmM2MDY3ZWQ1ODBmNGYwNWE1ZjkyZjVhNjZiOGI0NGRfMy05LTEtMS0zODM2_b1d70942-7b99-4d6e-b750-dc9f71b4533b">364,434</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Repurchase of common shares</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="idaa440b71edc463180ffe7cc20dc52c5_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjNjA2N2VkNTgwZjRmMDVhNWY5MmY1YTY2YjhiNDRkL3RhYmxlcmFuZ2U6MmM2MDY3ZWQ1ODBmNGYwNWE1ZjkyZjVhNjZiOGI0NGRfNC0xLTEtMS0zODQz_5a7b5605-8bd0-4562-967a-d6a6e4046d31">121,466</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idaa440b71edc463180ffe7cc20dc52c5_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjNjA2N2VkNTgwZjRmMDVhNWY5MmY1YTY2YjhiNDRkL3RhYmxlcmFuZ2U6MmM2MDY3ZWQ1ODBmNGYwNWE1ZjkyZjVhNjZiOGI0NGRfNC0zLTEtMS0zODQ1_d86d81f6-8a38-463f-bff4-968960bddb6b">703,790</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4b03a84c29d54b778087726fae7de356_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjNjA2N2VkNTgwZjRmMDVhNWY5MmY1YTY2YjhiNDRkL3RhYmxlcmFuZ2U6MmM2MDY3ZWQ1ODBmNGYwNWE1ZjkyZjVhNjZiOGI0NGRfNC05LTEtMS0zODQ3_9d1672a3-6dc9-4734-85e5-82644920152a">703,790</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i73c240c1815a42e2ab3c71622ab5a7f7_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjNjA2N2VkNTgwZjRmMDVhNWY5MmY1YTY2YjhiNDRkL3RhYmxlcmFuZ2U6MmM2MDY3ZWQ1ODBmNGYwNWE1ZjkyZjVhNjZiOGI0NGRfNS01LTEtMS0zODUz_38f90e01-4034-420d-be70-295794de26f6">73,878</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9a0b25c5749f4e71aca5511d2c6057b6_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjNjA2N2VkNTgwZjRmMDVhNWY5MmY1YTY2YjhiNDRkL3RhYmxlcmFuZ2U6MmM2MDY3ZWQ1ODBmNGYwNWE1ZjkyZjVhNjZiOGI0NGRfNS03LTEtMS0zODUw_6bf8fbe0-ba44-484d-b296-3d928068db6b">33,460</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4b03a84c29d54b778087726fae7de356_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjNjA2N2VkNTgwZjRmMDVhNWY5MmY1YTY2YjhiNDRkL3RhYmxlcmFuZ2U6MmM2MDY3ZWQ1ODBmNGYwNWE1ZjkyZjVhNjZiOGI0NGRfNS05LTEtMS0zODQ5_ee2aead6-efdb-4fc8-9557-07e9e5bea3ba">40,418</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, March 31, 2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iac307e50d1064fb993f7c13e652bf744_I20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjNjA2N2VkNTgwZjRmMDVhNWY5MmY1YTY2YjhiNDRkL3RhYmxlcmFuZ2U6MmM2MDY3ZWQ1ODBmNGYwNWE1ZjkyZjVhNjZiOGI0NGRfNi0xLTEtMS0zODU1_66a293c5-65b0-4bf5-a5f0-e74546cbb3cd">15,547,517</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iac307e50d1064fb993f7c13e652bf744_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjNjA2N2VkNTgwZjRmMDVhNWY5MmY1YTY2YjhiNDRkL3RhYmxlcmFuZ2U6MmM2MDY3ZWQ1ODBmNGYwNWE1ZjkyZjVhNjZiOGI0NGRfNi0zLTEtMS0zODU3_4ea2dfc8-a4ce-438f-9558-73dd6103588f">50,759,257</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id01be75c70fd4c0390e4cb8f8a56f1f8_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjNjA2N2VkNTgwZjRmMDVhNWY5MmY1YTY2YjhiNDRkL3RhYmxlcmFuZ2U6MmM2MDY3ZWQ1ODBmNGYwNWE1ZjkyZjVhNjZiOGI0NGRfNi01LTEtMS0zODU5_0487dff2-5db2-40f1-8d86-6a7ceb948954">4,672,276</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i58d3402c22484d6bb6b255a3e69c04eb_I20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjNjA2N2VkNTgwZjRmMDVhNWY5MmY1YTY2YjhiNDRkL3RhYmxlcmFuZ2U6MmM2MDY3ZWQ1ODBmNGYwNWE1ZjkyZjVhNjZiOGI0NGRfNi03LTEtMS0zODYx_655445bb-e4b9-4aec-bac0-57b1d78cf839">240,806</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4d6b70bf87e540e287238c2db49676b4_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjNjA2N2VkNTgwZjRmMDVhNWY5MmY1YTY2YjhiNDRkL3RhYmxlcmFuZ2U6MmM2MDY3ZWQ1ODBmNGYwNWE1ZjkyZjVhNjZiOGI0NGRfNi05LTEtMS0zODYz_4b399ed4-941b-4bf6-926c-03bc2fa334fb">55,190,727</ix:nonFraction>&#160;</span></td></tr></table></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.122807%;"><tr><td style="width:1.0%;"></td><td style="width:30.448378%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.946903%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.389971%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.831858%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.389971%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.831858%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.389971%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.749263%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.389971%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.831858%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, March 31, 2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iac307e50d1064fb993f7c13e652bf744_I20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjZDRiNGFhNjQ1MTQxMTI5OTIwNGRkYWE4ZTlhNzYxL3RhYmxlcmFuZ2U6MmNkNGI0YWE2NDUxNDExMjk5MjA0ZGRhYThlOWE3NjFfMy0xLTEtMS0w_95bf0d13-09cc-4f46-9c6b-c13e2590e845">15,547,517</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iac307e50d1064fb993f7c13e652bf744_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjZDRiNGFhNjQ1MTQxMTI5OTIwNGRkYWE4ZTlhNzYxL3RhYmxlcmFuZ2U6MmNkNGI0YWE2NDUxNDExMjk5MjA0ZGRhYThlOWE3NjFfMy0zLTEtMS0w_84d15c4f-0c4e-4c2b-8c4f-8ca4e1af4aee">50,759,257</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id01be75c70fd4c0390e4cb8f8a56f1f8_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjZDRiNGFhNjQ1MTQxMTI5OTIwNGRkYWE4ZTlhNzYxL3RhYmxlcmFuZ2U6MmNkNGI0YWE2NDUxNDExMjk5MjA0ZGRhYThlOWE3NjFfMy01LTEtMS0w_17bc52e1-d833-458a-b80a-88930c9779e1">4,672,276</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i58d3402c22484d6bb6b255a3e69c04eb_I20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjZDRiNGFhNjQ1MTQxMTI5OTIwNGRkYWE4ZTlhNzYxL3RhYmxlcmFuZ2U6MmNkNGI0YWE2NDUxNDExMjk5MjA0ZGRhYThlOWE3NjFfMy03LTEtMS0w_0859a064-aaad-47b2-ae46-5157eb19de27">240,806</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4d6b70bf87e540e287238c2db49676b4_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjZDRiNGFhNjQ1MTQxMTI5OTIwNGRkYWE4ZTlhNzYxL3RhYmxlcmFuZ2U6MmNkNGI0YWE2NDUxNDExMjk5MjA0ZGRhYThlOWE3NjFfMy05LTEtMS0w_a53d7a5e-5c75-40d0-8667-8bce29ac3d9e">55,190,727</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i69067cc85b7d439ab6017dfcbfd70f2a_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjZDRiNGFhNjQ1MTQxMTI5OTIwNGRkYWE4ZTlhNzYxL3RhYmxlcmFuZ2U6MmNkNGI0YWE2NDUxNDExMjk5MjA0ZGRhYThlOWE3NjFfNi0xLTEtMS0w_d2752fae-534a-4505-8e61-7e1a6a522276">8,000</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i69067cc85b7d439ab6017dfcbfd70f2a_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjZDRiNGFhNjQ1MTQxMTI5OTIwNGRkYWE4ZTlhNzYxL3RhYmxlcmFuZ2U6MmNkNGI0YWE2NDUxNDExMjk5MjA0ZGRhYThlOWE3NjFfNi0zLTEtMS0w_ef84a84a-1c98-4a41-bb19-41f694648633">396,548</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjZDRiNGFhNjQ1MTQxMTI5OTIwNGRkYWE4ZTlhNzYxL3RhYmxlcmFuZ2U6MmNkNGI0YWE2NDUxNDExMjk5MjA0ZGRhYThlOWE3NjFfNi05LTEtMS0w_9d1e2e7e-7612-4e45-b701-09639cbd3951">396,548</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Repurchase of subsidiary shares from noncontrolling interest</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i69067cc85b7d439ab6017dfcbfd70f2a_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjZDRiNGFhNjQ1MTQxMTI5OTIwNGRkYWE4ZTlhNzYxL3RhYmxlcmFuZ2U6MmNkNGI0YWE2NDUxNDExMjk5MjA0ZGRhYThlOWE3NjFfNi0zLTEtMS0xNTYx_3ea8f8bd-5928-4b85-a0b4-be9ea976b13d">685,805</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if5b7d8e3ae1349cea30af6ae38abd9fa_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjZDRiNGFhNjQ1MTQxMTI5OTIwNGRkYWE4ZTlhNzYxL3RhYmxlcmFuZ2U6MmNkNGI0YWE2NDUxNDExMjk5MjA0ZGRhYThlOWE3NjFfMy03LTEtMS0zODgy_4afd3067-d3f2-4991-89d2-ee74a077b911">114,195</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjZDRiNGFhNjQ1MTQxMTI5OTIwNGRkYWE4ZTlhNzYxL3RhYmxlcmFuZ2U6MmNkNGI0YWE2NDUxNDExMjk5MjA0ZGRhYThlOWE3NjFfNi05LTEtMS0xNTY4_b436ee7e-7997-4c72-b18f-8b4cde5b69c9">800,000</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Repurchase of common shares</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i69067cc85b7d439ab6017dfcbfd70f2a_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjZDRiNGFhNjQ1MTQxMTI5OTIwNGRkYWE4ZTlhNzYxL3RhYmxlcmFuZ2U6MmNkNGI0YWE2NDUxNDExMjk5MjA0ZGRhYThlOWE3NjFfOS0xLTEtMS0w_5fcd391c-68d4-4475-a015-0d95814f6158">84,447</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i69067cc85b7d439ab6017dfcbfd70f2a_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjZDRiNGFhNjQ1MTQxMTI5OTIwNGRkYWE4ZTlhNzYxL3RhYmxlcmFuZ2U6MmNkNGI0YWE2NDUxNDExMjk5MjA0ZGRhYThlOWE3NjFfOS0zLTEtMS0w_a79a32c2-6e05-4b04-93b4-3d340ea6ea8e">531,746</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjZDRiNGFhNjQ1MTQxMTI5OTIwNGRkYWE4ZTlhNzYxL3RhYmxlcmFuZ2U6MmNkNGI0YWE2NDUxNDExMjk5MjA0ZGRhYThlOWE3NjFfOS05LTEtMS0w_6ca82cca-71bd-413f-ae8a-f6ae3cdb8f5c">531,746</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i274cc8eea0aa47a382670b52aaf0929c_D20190401-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjZDRiNGFhNjQ1MTQxMTI5OTIwNGRkYWE4ZTlhNzYxL3RhYmxlcmFuZ2U6MmNkNGI0YWE2NDUxNDExMjk5MjA0ZGRhYThlOWE3NjFfMTAtNS0xLTEtMA_d19acb10-2c82-43c5-a51f-1dc24c9e1c7b">549,507</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if5b7d8e3ae1349cea30af6ae38abd9fa_D20190401-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjZDRiNGFhNjQ1MTQxMTI5OTIwNGRkYWE4ZTlhNzYxL3RhYmxlcmFuZ2U6MmNkNGI0YWE2NDUxNDExMjk5MjA0ZGRhYThlOWE3NjFfMTAtNy0xLTEtMA_ad387e97-2185-49e4-baa1-3cd8f88c028d">17,305</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjZDRiNGFhNjQ1MTQxMTI5OTIwNGRkYWE4ZTlhNzYxL3RhYmxlcmFuZ2U6MmNkNGI0YWE2NDUxNDExMjk5MjA0ZGRhYThlOWE3NjFfMTAtOS0xLTEtMA_4a712ff5-b7d3-422e-a3e5-8e6662bc6bfa">566,812</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, June 30, 2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ide4bf4cd636d4c2db7c36e6913c5b859_I20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjZDRiNGFhNjQ1MTQxMTI5OTIwNGRkYWE4ZTlhNzYxL3RhYmxlcmFuZ2U6MmNkNGI0YWE2NDUxNDExMjk5MjA0ZGRhYThlOWE3NjFfMTEtMS0xLTEtMA_0e14e1e0-fdd8-487f-895f-dc2fe859ce7b">15,471,070</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ide4bf4cd636d4c2db7c36e6913c5b859_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjZDRiNGFhNjQ1MTQxMTI5OTIwNGRkYWE4ZTlhNzYxL3RhYmxlcmFuZ2U6MmNkNGI0YWE2NDUxNDExMjk5MjA0ZGRhYThlOWE3NjFfMTEtMy0xLTEtMA_c7e073ff-e6e4-4906-b67d-939b6ef0916c">49,938,254</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic39d78c819df43acb7f94d5a5d3f0944_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjZDRiNGFhNjQ1MTQxMTI5OTIwNGRkYWE4ZTlhNzYxL3RhYmxlcmFuZ2U6MmNkNGI0YWE2NDUxNDExMjk5MjA0ZGRhYThlOWE3NjFfMTEtNS0xLTEtMA_11528a9e-e416-4ff9-8fff-35260a9416e7">4,122,769</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8f374a018db6442e9076cb34a527615d_I20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjZDRiNGFhNjQ1MTQxMTI5OTIwNGRkYWE4ZTlhNzYxL3RhYmxlcmFuZ2U6MmNkNGI0YWE2NDUxNDExMjk5MjA0ZGRhYThlOWE3NjFfMTEtNy0xLTEtMA_ae3333b3-9394-4d48-a5af-53b72575729e">372,306</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjZDRiNGFhNjQ1MTQxMTI5OTIwNGRkYWE4ZTlhNzYxL3RhYmxlcmFuZ2U6MmNkNGI0YWE2NDUxNDExMjk5MjA0ZGRhYThlOWE3NjFfMTEtOS0xLTEtMA_2624d009-ba43-4ade-8734-6a16496388fc">53,688,717</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="30" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="margin-top:6pt;"><span><br/></span></div><div id="i_0_31"></div><div style="text-align:center;-sec-extract:summary;"></div><div style="position:relative;width:100%;height:27pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">4</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div id="i_0_34"></div><div style="margin-top:6pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(1) <ix:nonNumeric contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNC9mcmFnOjEwNzJiODA1MTI3ZjQzMzdiZmMzYmM2NjFiOTVjN2M4L3RleHRyZWdpb246MTA3MmI4MDUxMjdmNDMzN2JmYzNiYzY2MWI5NWM3YzhfODMzNw_637df4a1-6a92-4c50-8683-d13ad09ad584" continuedAt="ibd9b450325e948f2bc7e6545ff3d6dbb" escape="true">ORGANIZATION AND BASIS OF PRESENTATION</ix:nonNumeric></span></div><ix:continuation id="ibd9b450325e948f2bc7e6545ff3d6dbb" continuedAt="if505b6a1f6644fa2a02ac56b3c4859ac"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Cumberland Pharmaceuticals Inc. (&#8220;Cumberland,&#8221; the &#8220;Company,&#8221; or as used in the context of &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products.  The Company's primary target markets are hospital acute care, gastroenterology, and oncology supportive care. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company&#8217;s products are manufactured by third parties, which are overseen by Cumberland&#8217;s quality control and manufacturing professionals. The Company works closely with its third-party distribution partners to make its products available in the United States.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In the opinion of management, the accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a basis consistent with the December 31, 2018 audited consolidated financial statements, with the exception of the impacts of adopting accounting pronouncements during 2019, and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly present the information set forth herein. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements have been prepared in accordance with the regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;), and certain information and disclosures have been condensed or omitted as permitted by the SEC for interim period presentation. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2018 (the &#8220;2018 Annual Report on Form 10-K&#8221;). The results of operations for the three and six months ended June 30, 2019 are not necessarily indicative of the results to be expected for the entire fiscal year or any future period.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Total comprehensive income (loss) consisted solely of net income (loss) for the three and six months ended June 30, 2019 and 2018.</span></div><ix:nonNumeric contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNC9mcmFnOjEwNzJiODA1MTI3ZjQzMzdiZmMzYmM2NjFiOTVjN2M4L3RleHRyZWdpb246MTA3MmI4MDUxMjdmNDMzN2JmYzNiYzY2MWI5NWM3YzhfODM0MA_156e0cbe-cbe1-41de-a91d-c6b50f76d9a4" continuedAt="i61df06c1fe25460888fa92f44e3a08ec" escape="true"><div style="margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Guidance</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Recent Adopted Accounting Pronouncement</span></div><div style="text-align:justify;margin-top:7pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In February 2016, the Financial Accounting Standards Board ("FASB") issued guidance in the form of a FASB Accounting Standards Update ("ASU") No. 2016-02, &#8220;Leases.&#8221; The new standard establishes a right-of-use (&#8220;ROU&#8221;) model that requires a lessee to record an ROU asset and a lease liability on the balance sheet for all leases with terms longer than twelve months. Leases will be classified as either finance (formerly "capital leases") or operating, with classification affecting the pattern of expense recognition in the income statement. The standard provides for a modified retrospective transition approach for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain optional practical expedients.  In July 2018, the FASB issued ASU 2018-11, "Leases: Targeted Improvements", allowing for an alternative transition method (the effective date approach). It allows an entity to initially apply the new lease guidance at the adoption date (rather than at the beginning of the earliest period presented). Cumberland adopted the lease guidance effective January 1, 2019 using the package of transition practical expedients.  This allowed the Company to retain the lease classification for any leases existing prior to adoption, in addition to other benefits. See additional discussion of the impact of adopting the lease accounting guidance in Note 6.</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Recent Accounting Pronouncements - Not Yet Adopted </span></div><div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the FASB issued ASU No. 2016-13, &#8220;Financial Instruments-Credit Losses,&#8221; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#8220;expected loss&#8221; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose significantly more information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#8217;s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is adopted. This standard is effective for the Company on January 1, 2020 with early adoption permitted. The Company is in the initial stage of evaluating the impact of this new standard on its trade and other receivables.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">5</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><ix:continuation id="if505b6a1f6644fa2a02ac56b3c4859ac" continuedAt="i76aa3f5092c5483bbd05d36793cbc45a"><ix:continuation id="i61df06c1fe25460888fa92f44e3a08ec"><div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In November 2018, the FASB issued ASU No. 2018-18, &#8220;Collaboration Arrangements: Clarifying the Interaction between Topic 808 and Topic 606&#8221; (ASU 2018-18). The issuance of ASU 2014-09 raised questions about the interaction between the guidance on collaborative arrangements and revenue recognition. ASU 2018-18 addresses this uncertainty by (1) clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASU 2014-09 when the collaboration arrangement participant is a customer, (2) adding unit of account guidance to assess whether the collaboration arrangement or a part of the arrangement is with a customer and (3) precluding a company from presenting transactions with collaboration arrangement participants that are not directly related to sales to third parties together with revenue from contracts with customers. The new standard will be effective for the Company on January 1, 2020 with early adoption permitted. The Company is in the initial stage of evaluating the impact of this new standard on its condensed consolidated financial statements and related disclosures.</span></div><div style="text-align:justify;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">In May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably elect the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met, the election must be applied on an instrument-by-instrument basis, and the election is not available for either available-for-sale or held-to-maturity debt securities. As Cumberland has not yet adopted ASU 2016-13, the effective dates are the same as those in ASU 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">January 1, 2020. The Company is in the initial stage of evaluating the impact of this new standard on its condensed consolidated financial statements and related disclosures.</span></div><div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In January 2017, the FASB issued ASU No. 2017-04, &#8220;Simplifying the Test for Goodwill Impairment&#8221; (ASU 2017-04). The guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation.  As a result of the revised guidance, a goodwill impairment will be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The new standard will be effective for the Company on January 1, 2020 and will be applied prospectively. The Company is in the initial stage of evaluating the impact of this new standard on its condensed consolidated financial statements and related disclosures.</span></div></ix:continuation><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accounting Policies:</span></div><ix:nonNumeric contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNC9mcmFnOjEwNzJiODA1MTI3ZjQzMzdiZmMzYmM2NjFiOTVjN2M4L3RleHRyZWdpb246MTA3MmI4MDUxMjdmNDMzN2JmYzNiYzY2MWI5NWM3YzhfODMzMw_04d5100b-e5cb-40ef-9641-32df150a1c95" escape="true"><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Use of Estimates</span></div><div style="text-align:justify;margin-top:7pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns (2) the allowances for obsolescent or unmarketable inventory (3) assumptions used in estimating acquisition date fair value of assets acquired in business combinations and (4) valuation of contingent consideration liability associated with business combinations.</span></div></ix:nonNumeric><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"><ix:nonNumeric contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNC9mcmFnOjEwNzJiODA1MTI3ZjQzMzdiZmMzYmM2NjFiOTVjN2M4L3RleHRyZWdpb246MTA3MmI4MDUxMjdmNDMzN2JmYzNiYzY2MWI5NWM3YzhfODMzNQ_19082bea-29a2-4b20-adf1-d642e2041013" continuedAt="if57d893ce1ea41a0ba14a2eede4aeb42" escape="true">Operating Segments</ix:nonNumeric></span></div></ix:continuation><div style="text-align:justify;margin-top:8pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i76aa3f5092c5483bbd05d36793cbc45a"><ix:continuation id="if57d893ce1ea41a0ba14a2eede4aeb42">The Company has <ix:nonFraction unitRef="segment" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNC9mcmFnOjEwNzJiODA1MTI3ZjQzMzdiZmMzYmM2NjFiOTVjN2M4L3RleHRyZWdpb246MTA3MmI4MDUxMjdmNDMzN2JmYzNiYzY2MWI5NWM3YzhfNzUzMA_0d9804b3-9c19-43e9-b805-319738051748">one</ix:nonFraction> operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#8217;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.</ix:continuation></ix:continuation> </span></div><div id="i_0_37"></div><div style="margin-top:6pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(2) <ix:nonNumeric contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RleHRyZWdpb246Mzk5Mjk5Mjc5NDYyNGU3YzlhNDFiNmJhN2Q5NWRiNjFfMzM4Nw_a0e5e37d-7f86-4ce4-8cef-ce1748818a68" continuedAt="i5cf81926d2274a52a6bfeb12f0fa2c5e" escape="true">MARKETABLE SECURITIES</ix:nonNumeric></span></div><ix:continuation id="i5cf81926d2274a52a6bfeb12f0fa2c5e" continuedAt="ia859eb02fc9a4618a3366ed9c15aff3c"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company invests in marketable debt securities in order to maximize its return on cash. Marketable securities consist of short-term cash investments, U.S. Treasury notes and bonds,  corporate bonds and commercial paper.  At the time of purchase, the Company classifies marketable securities as either trading securities or available-for-sale securities, depending on the intent at that time.  As of June 30, 2019 and December&#160;31, 2018, marketable securities were comprised solely of trading securities.  Trading securities are carried at fair value with unrealized gains and losses recognized as a component of interest income in the consolidated statements of operations.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company's fair value measurements follow the appropriate rules as well as the fair value hierarchy that prioritizes the information used to develop the measurements.  It applies whenever other guidance requires (or permits) assets or liabilities to be measured at fair value and gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). </span></div></ix:continuation><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">6</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><ix:continuation id="ia859eb02fc9a4618a3366ed9c15aff3c"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">A summary of the fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels is described below:</span></div><div style="text-indent:-45pt;padding-left:81pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Level 1 -   Quoted prices for identical instruments in active markets.</span></div><div style="text-indent:-45pt;padding-left:81pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Level 2 -   Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.</span></div><div style="text-indent:-45pt;padding-left:81pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Level 3 -   Significant inputs to the valuation model are unobservable.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company's fair values of marketable securities are determined based on valuations provided by a third-party pricing service, as derived from such service's pricing models, and are considered either Level 1 or Level 2 measurements, depending on the nature of the investment.  The Company has no marketable securities in which the fair value is determined based on Level 3 measurements.  The level of management judgment required in evaluating fair value for Level 1 investments is minimal.  Similarly, there is little subjectivity or judgment required for Level 2 investments valued using valuation models that are standard across the industry and whose parameter inputs are quoted in active markets.  Inputs to the models may include, but are not limited to, reported trades, executable bid and ask prices, broker/dealer quotations, prices or yields of securities with similar characteristics, benchmark curves or information pertaining to the issuer, as well as industry and economic events. Based on the information available, the Company believes that the valuations provided by the third-party pricing service, as derived from such service's pricing models, are representative of prices that would be received to sell the assets at the measurement date (exit prices).  There were no transfers of assets between levels within the fair value hierarchy.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:11pt;font-weight:400;line-height:120%;"> </span></div><ix:nonNumeric contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" name="us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RleHRyZWdpb246Mzk5Mjk5Mjc5NDYyNGU3YzlhNDFiNmJhN2Q5NWRiNjFfMzM4NQ_2a792503-6eb2-477e-96bf-c07090d87eaa" escape="true"><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the fair value of our marketable securities, by level within the fair value hierarchy, as of each period end:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"></td><td style="width:27.368576%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.160059%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.160059%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.160059%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.160059%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.160059%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.160059%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasury notes and bonds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic019dd81917f4783874bd24e8143629b_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfMi0xLTEtMS0w_260d9c5a-9c4b-4c37-b5cf-502f73d07683">5,155,696</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5397d60c4bf94ba38de2eefaf434ab55_I20190630" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfMi0zLTEtMS0w_bd88111b-5edc-4437-bd2c-b60fa3eeab3f">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idd24a3ddd9ed4cff93e5196a8a035c10_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfMi01LTEtMS0w_b624775d-a78d-4fdf-aa4a-5ea372da186b">5,155,696</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic7816c3023a04362a69740727a0dd6e9_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfMi03LTEtMS0w_c56f31fd-5d68-4418-ae72-79cf809253a6">5,034,955</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i028152dc8c66421282a458a7c0e3da06_I20181231" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfMi05LTEtMS0w_1fc60e1e-6f41-4a99-bb07-a0be34f3145e">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8259efcffe104ccab3daeae3ae558f18_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfMi0xMS0xLTEtMA_b89c2348-77b4-434b-86ea-c3e9553fd3a5">5,034,955</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate bonds</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id6339bfa7be7414c90203e8b3decb32f_I20190630" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfMy0xLTEtMS0w_63354b1d-479e-4558-9614-9c68143ac640">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74755af90b0c4281990f79ae0cb80fab_I20190630" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfMy0zLTEtMS0w_3d5a2a6c-431a-42de-af6f-38f289ae1f09">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i766a4625499e44acb284ded61ea081ad_I20190630" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfMy01LTEtMS0w_1110b0cf-775b-4ab1-811e-57614f531f0c">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i47855873ec2141deb6a6cffeea9a5bb5_I20181231" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfMy03LTEtMS0w_ccf2c687-6db9-4236-8f0d-42b8713c0718">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic748d7f98c564aa2ba93b74292ce51c0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfMy05LTEtMS0w_87fbd62c-dda3-4ae4-bee6-67c2d59e24b0">2,504,551</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie1ab8d666f804ee78d5b108e427da078_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfMy0xMS0xLTEtMA_b72ee745-2201-41ec-863c-f6856b94f09f">2,504,551</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i83a70ec3a6574e21aa0d9467d12afc51_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfNC0zLTEtMS0w_c5935278-ea91-4979-9786-eaf71573cb26">2,265,824</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i43b135623a96479ea579b1956e4c6a0b_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfNC01LTEtMS0w_8747ffc1-1b14-4525-92cf-ba52d5a03184">2,265,824</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1494544e74bc4c1a9fcca142b7cf104f_I20181231" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfNC03LTEtMS0w_4da7f795-10b9-4be7-bd3b-25900721a1ee">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i77a66b694d774bcf85ff772a27ee7736_I20181231" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfNC05LTEtMS0w_4414f542-3e4e-48d7-9b6b-6b6e0ea66928">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i07ba47fdb1fd4a0aa68832470d83b72c_I20181231" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfNC0xMS0xLTEtMA_7cd259ac-cff5-4735-bb57-99425d14268f">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term cash investments</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie26e2ca1b03b4f848952f34a6f12fe2d_I20190630" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfNS0xLTEtMS0w_abe1412e-64bc-4214-b2de-537db28219c3">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i666181952a8f4f1f9d14d2034e887833_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfNS0zLTEtMS0w_9a44295e-967d-4b21-8a02-bab11d2f3e15">2,058,166</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8bd2419e0e6145b5b2690fdf708d4661_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfNS01LTEtMS0w_4d7ab56b-725c-457f-9a69-a1a7d100ef92">2,058,166</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3d842da52c554dfe889a17eb09da349c_I20181231" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfNS03LTEtMS0w_7d8bced4-7b98-4682-93fb-f6ce7f9808bb">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibf1ce67d14544c34852c969eba3ab613_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfNS05LTEtMS0w_2b635e76-dd65-4500-b365-fc408da3acb5">751,173</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6dd35f38e91e4cad82cac63ffaf3bc06_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfNS0xMS0xLTEtMA_7752e5c8-ddd3-4d24-baae-485ba79676b8">751,173</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total fair value of marketable  securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44c95989d56940448855dceadabf3ab2_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfNi0xLTEtMS0w_0872d7c2-2e24-4cbf-9d21-f3e6b7356561">5,155,696</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2ac200ae04284253b7355e519011ebb7_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfNi0zLTEtMS0w_2ff84cb4-fc2f-4a5f-9f00-e6b130f9a2b5">4,323,990</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfNi01LTEtMS0w_46b65590-1b76-4462-9cab-e58009762283">9,479,686</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if9fe1490366c4bb1a705a3377e185ae5_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfNi03LTEtMS0w_85d8d416-d140-4a8e-b686-842774fb0557">5,034,955</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icf31cf850409470eb07e4575e50d16c6_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfNi05LTEtMS0w_fc7de41b-c9ab-4531-beec-17342798011e">3,255,724</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfNi0xMS0xLTEtMA_e8f17900-037a-4644-9661-4aff1978268d">8,290,679</ix:nonFraction>&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div id="i_0_40"></div><div style="margin-top:6pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(3) <ix:nonNumeric contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180MC9mcmFnOjRjYjg3MTk1ZTMwODQ3MDE4MzliNGM0MGY1YmQyYTQ2L3RleHRyZWdpb246NGNiODcxOTVlMzA4NDcwMTgzOWI0YzQwZjViZDJhNDZfNDI3_295b4d52-0fc9-4d29-9f74-1bb359cc537e" continuedAt="if76173013525479dbee476e776d82abb" escape="true">EARNINGS (LOSS) PER SHARE</ix:nonNumeric></span></div><ix:continuation id="if76173013525479dbee476e776d82abb" continuedAt="icd6a7fc8a7074030a3cfc7612a460c31"><ix:nonNumeric contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180MC9mcmFnOjRjYjg3MTk1ZTMwODQ3MDE4MzliNGM0MGY1YmQyYTQ2L3RleHRyZWdpb246NGNiODcxOTVlMzA4NDcwMTgzOWI0YzQwZjViZDJhNDZfNjA0NzMxMzk1MzIxMg_5a2f6bf0-b05b-48b8-920d-27877de5448c" continuedAt="i5a2e3c1d42e44babbbc6edf225403487" escape="true"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three and six months ended June 30, 2019 and 2018:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.122807%;"><tr><td style="width:1.0%;"></td><td style="width:58.029499%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.616519%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537463%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.616519%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) attributable to common shareholders</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180MC9mcmFnOjRjYjg3MTk1ZTMwODQ3MDE4MzliNGM0MGY1YmQyYTQ2L3RhYmxlOmRiNGIyNTZkOWE0NjQyYTJhZTA4MGRkM2E0YzE3MjY5L3RhYmxlcmFuZ2U6ZGI0YjI1NmQ5YTQ2NDJhMmFlMDgwZGQzYTRjMTcyNjlfMy0xLTEtMS0w_add4c9d4-19fe-42c3-b3e0-8fb5897199ec">549,507</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180MC9mcmFnOjRjYjg3MTk1ZTMwODQ3MDE4MzliNGM0MGY1YmQyYTQ2L3RhYmxlOmRiNGIyNTZkOWE0NjQyYTJhZTA4MGRkM2E0YzE3MjY5L3RhYmxlcmFuZ2U6ZGI0YjI1NmQ5YTQ2NDJhMmFlMDgwZGQzYTRjMTcyNjlfMy0zLTEtMS0w_c8e813db-72ab-4215-9b40-2d664e7a66df">720,688</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180MC9mcmFnOjRjYjg3MTk1ZTMwODQ3MDE4MzliNGM0MGY1YmQyYTQ2L3RhYmxlOmRiNGIyNTZkOWE0NjQyYTJhZTA4MGRkM2E0YzE3MjY5L3RhYmxlcmFuZ2U6ZGI0YjI1NmQ5YTQ2NDJhMmFlMDgwZGQzYTRjMTcyNjlfNS0xLTEtMS0w_d9b5111c-2bc0-4cbc-83fe-7896ce172251">15,523,628</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180MC9mcmFnOjRjYjg3MTk1ZTMwODQ3MDE4MzliNGM0MGY1YmQyYTQ2L3RhYmxlOmRiNGIyNTZkOWE0NjQyYTJhZTA4MGRkM2E0YzE3MjY5L3RhYmxlcmFuZ2U6ZGI0YjI1NmQ5YTQ2NDJhMmFlMDgwZGQzYTRjMTcyNjlfNS0zLTEtMS0w_0fa9d9a4-68ad-4f79-8778-76e667214916">15,674,954</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Dilutive effect of other securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630" decimals="0" format="ixt:zerodash" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180MC9mcmFnOjRjYjg3MTk1ZTMwODQ3MDE4MzliNGM0MGY1YmQyYTQ2L3RhYmxlOmRiNGIyNTZkOWE0NjQyYTJhZTA4MGRkM2E0YzE3MjY5L3RhYmxlcmFuZ2U6ZGI0YjI1NmQ5YTQ2NDJhMmFlMDgwZGQzYTRjMTcyNjlfNi0xLTEtMS0w_f9ffb428-f991-4927-b231-6349a668236f">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630" decimals="0" format="ixt:zerodash" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180MC9mcmFnOjRjYjg3MTk1ZTMwODQ3MDE4MzliNGM0MGY1YmQyYTQ2L3RhYmxlOmRiNGIyNTZkOWE0NjQyYTJhZTA4MGRkM2E0YzE3MjY5L3RhYmxlcmFuZ2U6ZGI0YjI1NmQ5YTQ2NDJhMmFlMDgwZGQzYTRjMTcyNjlfNi0zLTEtMS0w_1561ba71-2573-4c80-b652-cdea4430555b">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180MC9mcmFnOjRjYjg3MTk1ZTMwODQ3MDE4MzliNGM0MGY1YmQyYTQ2L3RhYmxlOmRiNGIyNTZkOWE0NjQyYTJhZTA4MGRkM2E0YzE3MjY5L3RhYmxlcmFuZ2U6ZGI0YjI1NmQ5YTQ2NDJhMmFlMDgwZGQzYTRjMTcyNjlfNy0xLTEtMS0w_9b5d89ae-79ec-4590-be3a-bd33239874e7">15,523,628</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180MC9mcmFnOjRjYjg3MTk1ZTMwODQ3MDE4MzliNGM0MGY1YmQyYTQ2L3RhYmxlOmRiNGIyNTZkOWE0NjQyYTJhZTA4MGRkM2E0YzE3MjY5L3RhYmxlcmFuZ2U6ZGI0YjI1NmQ5YTQ2NDJhMmFlMDgwZGQzYTRjMTcyNjlfNy0zLTEtMS0w_d639cf17-4b62-4725-aacf-50b09be64284">15,674,954</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify;margin-top:11pt;margin-bottom:6pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">7</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><ix:continuation id="icd6a7fc8a7074030a3cfc7612a460c31"><div style="text-align:justify;margin-top:11pt;margin-bottom:6pt;"><ix:continuation id="i5a2e3c1d42e44babbbc6edf225403487"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:57.210526%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.883041%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.823392%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.883041%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) attributable to common shareholders</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180MC9mcmFnOjRjYjg3MTk1ZTMwODQ3MDE4MzliNGM0MGY1YmQyYTQ2L3RhYmxlOjYxOThhZGMzZDdkNjQzYzJhMWNjNGQzOTFjZTg0N2NiL3RhYmxlcmFuZ2U6NjE5OGFkYzNkN2Q2NDNjMmExY2M0ZDM5MWNlODQ3Y2JfMy0xLTEtMS0xNzY5_4a97237f-ebc4-49d9-9f6b-2181df84041a">623,385</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180MC9mcmFnOjRjYjg3MTk1ZTMwODQ3MDE4MzliNGM0MGY1YmQyYTQ2L3RhYmxlOjYxOThhZGMzZDdkNjQzYzJhMWNjNGQzOTFjZTg0N2NiL3RhYmxlcmFuZ2U6NjE5OGFkYzNkN2Q2NDNjMmExY2M0ZDM5MWNlODQ3Y2JfMy0zLTEtMS0xNzcx_ec10c811-3464-4156-bfca-a0c11e6df31d">3,099,927</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180MC9mcmFnOjRjYjg3MTk1ZTMwODQ3MDE4MzliNGM0MGY1YmQyYTQ2L3RhYmxlOjYxOThhZGMzZDdkNjQzYzJhMWNjNGQzOTFjZTg0N2NiL3RhYmxlcmFuZ2U6NjE5OGFkYzNkN2Q2NDNjMmExY2M0ZDM5MWNlODQ3Y2JfNS0xLTEtMS0xODcx_9c8e3451-9ed6-4d22-9dc5-099938b01a48">15,497,989</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180MC9mcmFnOjRjYjg3MTk1ZTMwODQ3MDE4MzliNGM0MGY1YmQyYTQ2L3RhYmxlOjYxOThhZGMzZDdkNjQzYzJhMWNjNGQzOTFjZTg0N2NiL3RhYmxlcmFuZ2U6NjE5OGFkYzNkN2Q2NDNjMmExY2M0ZDM5MWNlODQ3Y2JfNS0zLTEtMS0xODc1_635a4480-003e-466b-bc7e-9be7fbb0e4e8">15,682,348</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Dilutive effect of other securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180MC9mcmFnOjRjYjg3MTk1ZTMwODQ3MDE4MzliNGM0MGY1YmQyYTQ2L3RhYmxlOjYxOThhZGMzZDdkNjQzYzJhMWNjNGQzOTFjZTg0N2NiL3RhYmxlcmFuZ2U6NjE5OGFkYzNkN2Q2NDNjMmExY2M0ZDM5MWNlODQ3Y2JfNy0xLTEtMS0xODcz_5ab68aa6-f8a6-46df-8d37-a1e03abe2fab">15,497,989</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180MC9mcmFnOjRjYjg3MTk1ZTMwODQ3MDE4MzliNGM0MGY1YmQyYTQ2L3RhYmxlOjYxOThhZGMzZDdkNjQzYzJhMWNjNGQzOTFjZTg0N2NiL3RhYmxlcmFuZ2U6NjE5OGFkYzNkN2Q2NDNjMmExY2M0ZDM5MWNlODQ3Y2JfNy0zLTEtMS0xODc3_6d7d3c2a-232d-4e3e-be5e-8a7fb56213dc">15,682,348</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></ix:continuation></div><div style="text-align:justify;margin-top:11pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">As of June 30, 2019 and 2018, restricted stock awards and options to purchase <ix:nonFraction unitRef="shares" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180MC9mcmFnOjRjYjg3MTk1ZTMwODQ3MDE4MzliNGM0MGY1YmQyYTQ2L3RleHRyZWdpb246NGNiODcxOTVlMzA4NDcwMTgzOWI0YzQwZjViZDJhNDZfMjUw_f736066e-ecb3-4817-8ce5-2e0ef64bbd86">13,500</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180MC9mcmFnOjRjYjg3MTk1ZTMwODQ3MDE4MzliNGM0MGY1YmQyYTQ2L3RleHRyZWdpb246NGNiODcxOTVlMzA4NDcwMTgzOWI0YzQwZjViZDJhNDZfMjU3_1709cf7f-b8c6-42b0-86ae-a30143205615">231,905</ix:nonFraction> shares of common stock, respectively, were outstanding but were not included in the computation of diluted earnings per share because the effect would be antidilutive.</span></div></ix:continuation><div id="i_0_43"></div><div style="margin-top:6pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(4) <ix:nonNumeric contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RleHRyZWdpb246ZGMwOGNjMmI1YzM5NGU1N2FhMGIwM2VkNTlhMzY2OGFfMTY5NQ_78dc5c2c-c2e0-4a1f-a66e-f5975618c76c" continuedAt="iffe9f486282046ecade21e0ef56e36f6" escape="true">REVENUES</ix:nonNumeric></span></div><ix:continuation id="iffe9f486282046ecade21e0ef56e36f6" continuedAt="i5277652cffee4acfbaae4abb1c1cbfa1"><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Product Revenues</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for revenues from contracts with customers under ASC 606, which became effective January 1, 2018. As part of the adoption of ASC 606, the Company applied the new standard on a modified retrospective basis analyzing open contracts as of January 1, 2018. Results for reporting periods beginning after January 1, 2018 are presented under ASC 606. As discussed in Note 10, during November 2018 Cumberland entered into an agreement to acquire the global responsibility for Vibativ.  The product began contributing to Cumberland's net revenue during 2018.</span></div><ix:nonNumeric contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RleHRyZWdpb246ZGMwOGNjMmI1YzM5NGU1N2FhMGIwM2VkNTlhMzY2OGFfMTY5Nw_67b4181c-a337-4dfd-bb7a-75dfbd95a8bc" escape="true"><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s net revenues consisted of the following for the three and six months ended June 30, 2019 and 2018:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:27.824561%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.444444%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.823392%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.298246%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.058480%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.888889%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Products:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Acetadote</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i509cfd55792547fd9065aab962dd801a_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfMy0xLTEtMS0w_a408ac8d-f023-4305-ae54-8ad8a56bc374">983,473</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id4235e45b96d4113803c1249687d3d50_D20180401-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfMy0zLTEtMS0w_eb2cd48f-20ff-43f7-9697-c48041f86f20">841,431</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i77326b611af749e2afb25a76a3b386d1_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfMy01LTEtMS0w_7139bade-0cc9-4e0d-a28b-0afa169907ea">1,832,976</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4751466a08f94bcb8c0ebfec0b01ecfd_D20180101-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfMy03LTEtMS0w_bc94b556-a674-4211-a998-5b1c2fee785b">2,115,741</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Omeclamox-Pak</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i491e5531cbfa47b496005caa8455badb_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfNC0xLTEtMS0w_b5fbbddb-fa23-4ccd-b5c0-83365e932cd3">478,604</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2c520713e19c495f82ed1f2dd92ef634_D20180401-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfNC0zLTEtMS0w_aa68a909-b0ce-4f69-8259-7553a02e9621">89,952</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8396c0f613f441f58ba22039a93eb1c8_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfNC01LTEtMS0w_d3322c21-6139-4282-9022-0b1e1bb70cab">678,141</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia32476d410f440b48f0c3b631a90632f_D20180101-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfNC03LTEtMS0w_b564c1ab-907f-40a7-be44-2f64425c235e">231,344</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Kristalose</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i781c10013fee46d6b029f560be240be7_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfNS0xLTEtMS0w_2bfa6e3c-b12c-433c-81e4-be1508e91d6b">3,476,807</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idd51eac788ff4878870c597b6d74c24e_D20180401-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfNS0zLTEtMS0w_50693c57-20ae-424a-bd12-d4ae7ccbcab2">3,203,743</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i14a5b5dcc523443dab0df6907169ca3b_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfNS01LTEtMS0w_22d13cc4-291c-482a-bbe3-9dea55dddc6d">6,785,050</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcb718271f734482856f23f2d01609d5_D20180101-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfNS03LTEtMS0w_93857472-6e0f-410d-a3b0-aab79c0769cc">6,473,097</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Vaprisol</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i73375a6aee6f45c8b2af7cc1cfecddb0_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfNi0xLTEtMS0w_31502195-b3f6-4fe6-970f-abef0dbff244">212,526</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7ad6dbad74074d38ac2d08ebcc3d3518_D20180401-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfNi0zLTEtMS0w_3352e62b-0568-4b95-84b2-eeef9b42c4a7">1,685,900</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i53374edc460d4ca6aba30ff2b618e21f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfNi01LTEtMS0w_024566b7-7def-4d4b-8bfc-21ef3ee2fb49">499,202</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i838404f0559b43babedeea791e195f2f_D20180101-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfNi03LTEtMS0w_a9553978-4f76-40f7-9eca-8ad43131bf9b">1,779,790</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Caldolor</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i30dca836f3804983b44dbc23d365d55e_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfNy0xLTEtMS0w_3384b760-9cb2-437d-8ce9-f83f995445bc">1,054,718</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i70367091d6b44d47b966554d9af79237_D20180401-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfNy0zLTEtMS0w_4f4219c4-b95f-4d86-9740-075166022f47">1,101,023</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i588715008b8b450f8b15c09e4bcd9681_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfNy01LTEtMS0w_d93416dd-84f2-4f05-9f13-b2d8d5dd1f14">2,372,599</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc7ca2c1d2ac45b99b06dd4e5cff07df_D20180101-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfNy03LTEtMS0w_16fd7e42-cfbe-41da-ac70-8d15f56cdb34">2,140,771</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Ethyol</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2ae15c900cfd4ad6a4de1687287609b2_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfOC0xLTEtMS0w_c6fb3d9c-4bd6-4afe-a194-529a906fff11">2,008,247</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic29f620b439f49eeaefd0f5c28509e1c_D20180401-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfOC0zLTEtMS0w_3327a096-90ea-4028-91fa-be2d0b74b311">2,809,691</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie85bd361954b4f98bced4efeca36ce9f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfOC01LTEtMS0w_2d61d66b-d10e-4cc9-b83c-2a86ebec8344">5,099,429</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i231a37bb2fbf47f5b7eceed5c5e05224_D20180101-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfOC03LTEtMS0w_e35510f6-24b0-4a9c-81c8-d3ffd24c0754">5,065,764</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Totect</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i868db2e678dd4291af1d258118e04a77_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfOS0xLTEtMS0w_654a8730-3de2-4dba-bee3-11ef2615461d">154,910</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibccd184195764941825e341a41aa4fa5_D20180401-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfOS0zLTEtMS0w_2da864c5-523f-48c0-8a6b-a6f61f895ea5">269,190</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2f03cf3962ed4acf8caf27c28f2427d9_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfOS01LTEtMS0w_3c23d1fe-28e1-43ec-b378-b99046f24c15">235,805</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibb51e348437d4dec85fd92befc0b9624_D20180101-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfOS03LTEtMS0w_c919cc94-7686-4c1b-b87d-5067e2a8443d">681,964</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Vibativ</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic06c5fb3bfd44b16ab85550780690d5f_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfMTAtMS0xLTEtMA_54a6e9f3-24ab-4462-992a-5c60b37fd317">2,599,280</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7367fd73f204d1e8f84cd61df343493_D20180401-20180630" decimals="0" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfMTAtMy0xLTEtMA_e7b6d017-9450-4acb-a823-e0ae81bbba8a">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia9ea66098fd04256848a2d79539e4156_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfMTAtNS0xLTEtOTc3_2aceb591-f936-4558-9de6-f1c822ba4e64">4,659,471</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i77b145b291264578bbd035e0bf21476c_D20180101-20180630" decimals="0" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfMTAtNy0xLTEtMzkxNg_430d72c6-8cb4-478c-8634-dc63d45a03c2">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if954c9a78bb24172936c43e0061fedae_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfMTEtMS0xLTEtMA_9a79dbd8-c897-439e-9848-04a262cef3af">612,035</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if66b9371f94f461f93cfcc16bb63966b_D20180401-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfMTEtMy0xLTEtMA_86e621a1-c3bc-4e8c-8d9c-d07a0d964656">162,794</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7677c5f4087746ed8da807d078e316b6_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfMTEtNS0xLTEtMA_8dd6a9cf-92c6-42be-9202-568cb7722573">1,320,674</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8da9ab9ca7a9436c81b40d1a21447d49_D20180101-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfMTEtNy0xLTEtMA_a6d5672f-eb2c-4f22-9d76-a053f632a726">262,858</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total net revenues</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfMTItMS0xLTEtMA_0e0bc066-ae8e-4f49-abbc-a6ece491154f">11,580,600</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfMTItMy0xLTEtMA_94199575-2475-439c-9951-75ae6d6dacae">10,163,724</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfMTItNS0xLTEtMA_f5a3fff4-ccc4-4fd1-81d0-dbe695f64d49">23,483,347</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfMTItNy0xLTEtMA_77d29cc4-9750-4453-bab8-f9910fc0d2ef">18,751,329</ix:nonFraction>&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Other Revenues</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">During the three months ended June 30, 2019, Cumberland executed a License and Distribution agreement with HongKong WinHealth Pharma Group Co. Limited (&#8220;WinHealth&#8221;) for our Caldolor and Acetadote</span><sup style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"> </sup><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">brands in China and Hong Kong.  In conjunction with these new arrangements, the Company terminated a previous License and Distribution agreement with Gloria Pharmaceuticals Co ("Gloria Pharmaceuticals") for the two brands.  In addition, we also signed a new License and Distribution agreement with DB Pharm Korea Co., Ltd. (&#8220;DB Pharm&#8221;) for Vibativ in South Korea. As a result of these agreements, Cumberland recognized approximately $<ix:nonFraction unitRef="usd" contextRef="i40852bb795f343e3a355c9a4dac17887_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RleHRyZWdpb246ZGMwOGNjMmI1YzM5NGU1N2FhMGIwM2VkNTlhMzY2OGFfNzY5NjU4MTQwMDg4Nw_d57e80b4-026a-4f0d-bbd5-b1bfde2b015b">0.3</ix:nonFraction>&#160;million of non-refundable up-front payments as other revenue in the consolidated statement of operations during the three months ended June 30, 2019.  Cumberland's performance obligation was satisfied upon entering into the agreements to license each of the products intellectual property. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">CET grant revenue for the three and six months ended June 30, 2019 included in other revenue was $<ix:nonFraction unitRef="usd" contextRef="i3b6f56b360f242dba5580399c147efc2_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RleHRyZWdpb246ZGMwOGNjMmI1YzM5NGU1N2FhMGIwM2VkNTlhMzY2OGFfNzY5NjU4MTQwMDkwMQ_20fc04b4-16fc-46c5-8b96-6cc67ea2e113">0.2</ix:nonFraction>&#160;million  and $<ix:nonFraction unitRef="usd" contextRef="i994113efc2f24ab7bbf0e24b5c88051c_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RleHRyZWdpb246ZGMwOGNjMmI1YzM5NGU1N2FhMGIwM2VkNTlhMzY2OGFfNzY5NjU4MTQwMDkxNQ_3cc7ea37-580b-43fc-95a1-bd668ca70fa1">0.8</ix:nonFraction>&#160;million, respectively. </span></div></ix:continuation><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">8</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i5277652cffee4acfbaae4abb1c1cbfa1">The Company has agreements with international partners for commercialization of the Company's products. The international agreements provide that each of the partners are responsible for seeking regulatory approvals for the products, and following approvals, each partner will handle ongoing distribution and sales in the respective international territories. The Company maintains responsibility for the intellectual property and product formulations. Under the international agreements, the Company is typically entitled to receive a non-refundable, up-front payment at the time each agreement is entered into as a result of providing the distinct intellectual property rights for the respective international territory. These agreements also provide for additional payments upon the partners' achievement of defined regulatory approvals, sales milestones or both. The Company may also be entitled to receive royalties on future sales of the products under the agreements and a transfer price on supplies.  The contractual payments associated with the partners achievement of regulatory approvals, sales milestones and royalties on future sales are recognized as revenue upon occurrence, or at such time that the Company has a high degree of confidence that the revenue would not be reversed in a subsequent period.</ix:continuation></span></div><div id="i_0_46"></div><div style="margin-top:6pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(5) <ix:nonNumeric contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180Ni9mcmFnOmJhZGI2MmVmYTE1YjQ4MWE4ZmY0YWVlY2E4NzRhODhiL3RleHRyZWdpb246YmFkYjYyZWZhMTViNDgxYThmZjRhZWVjYTg3NGE4OGJfMTg5NA_397f0f57-2b6c-4b6b-af3f-74310a47a121" continuedAt="i1085083495a845a8b9dc2d21ccee1097" escape="true">INVENTORIES</ix:nonNumeric></span></div><ix:continuation id="i1085083495a845a8b9dc2d21ccee1097"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company works closely with third parties to manufacture and package finished goods for sale.  Based on the relationship with the manufacturer or packager, the Company will either take title to the finished goods at the time of shipment or at the time of arrival from the manufacturer.  The Company then warehouses such goods until distribution and sale. Inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company continually evaluates inventory for potential losses due to excess, obsolete or slow-moving inventory by comparing sales history and sales projections to the inventory on hand. When evidence indicates that the carrying value may not be recoverable, a charge is taken to reduce the inventory to its current net realizable value.  At June 30, 2019 and December 31, 2018, the Company has recognized and maintained cumulative charges for potential obsolescence and discontinuance losses of approximately $<ix:nonFraction unitRef="usd" contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryValuationReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180Ni9mcmFnOmJhZGI2MmVmYTE1YjQ4MWE4ZmY0YWVlY2E4NzRhODhiL3RleHRyZWdpb246YmFkYjYyZWZhMTViNDgxYThmZjRhZWVjYTg3NGE4OGJfOTky_a6bf1991-bc51-4e32-84a4-c898806c2294">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryValuationReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180Ni9mcmFnOmJhZGI2MmVmYTE1YjQ4MWE4ZmY0YWVlY2E4NzRhODhiL3RleHRyZWdpb246YmFkYjYyZWZhMTViNDgxYThmZjRhZWVjYTg3NGE4OGJfMTAwMA_c1381d16-fcfa-4376-b16d-a7292a196162">0.3</ix:nonFraction> million, respectively. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In connection with the acquisition of certain product rights related to the Kristalose brand, the Company is responsible for the purchase of the active pharmaceutical ingredient (&#8220;API&#8221;) for Kristalose and maintains the inventory at the third-party manufacturer. As the API is consumed in production, the value of the API is transferred from raw materials to finished goods. API for the Company's Vaprisol brand is also included in the raw materials inventory total.  Consigned inventory represents Authorized Generic inventory stored until shipment.  </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">As part of the Vibativ acquisition, Cumberland acquired API and work in process inventories of $<ix:nonFraction unitRef="usd" contextRef="i674a647fde3f44be85e9cae6e936a816_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180Ni9mcmFnOmJhZGI2MmVmYTE1YjQ4MWE4ZmY0YWVlY2E4NzRhODhiL3RleHRyZWdpb246YmFkYjYyZWZhMTViNDgxYThmZjRhZWVjYTg3NGE4OGJfMTY2Ng_0e75540c-42d9-4054-834a-52ceb81f4b04"><ix:nonFraction unitRef="usd" contextRef="i5332b0b2238e4d09b5c7a0b66e8b457a_I20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180Ni9mcmFnOmJhZGI2MmVmYTE1YjQ4MWE4ZmY0YWVlY2E4NzRhODhiL3RleHRyZWdpb246YmFkYjYyZWZhMTViNDgxYThmZjRhZWVjYTg3NGE4OGJfMTY2Ng_b1dcccf4-3a9f-4216-b1c2-e1c9ec9d5e0d">14.9</ix:nonFraction></ix:nonFraction> million that are classified as non-current inventories at June 30, 2019 and December 31, 2018. Non-current inventories also include $<ix:nonFraction unitRef="usd" contextRef="i5332b0b2238e4d09b5c7a0b66e8b457a_I20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180Ni9mcmFnOmJhZGI2MmVmYTE1YjQ4MWE4ZmY0YWVlY2E4NzRhODhiL3RleHRyZWdpb246YmFkYjYyZWZhMTViNDgxYThmZjRhZWVjYTg3NGE4OGJfMTc2Nw_3c89045d-ec42-4fa9-ae0d-e3d439d8a6ea">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i674a647fde3f44be85e9cae6e936a816_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180Ni9mcmFnOmJhZGI2MmVmYTE1YjQ4MWE4ZmY0YWVlY2E4NzRhODhiL3RleHRyZWdpb246YmFkYjYyZWZhMTViNDgxYThmZjRhZWVjYTg3NGE4OGJfMTc3NA_3a763226-c581-4bdb-813e-b7fc0b7b1f3e">0.8</ix:nonFraction> million in Vibativ finished goods at June 30, 2019 and December&#160;31, 2018, respectively.  During 2019, Cumberland also obtained $<ix:nonFraction unitRef="usd" contextRef="i5332b0b2238e4d09b5c7a0b66e8b457a_I20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180Ni9mcmFnOmJhZGI2MmVmYTE1YjQ4MWE4ZmY0YWVlY2E4NzRhODhiL3RleHRyZWdpb246YmFkYjYyZWZhMTViNDgxYThmZjRhZWVjYTg3NGE4OGJfODI0NjMzNzIxMDQ3OA_6f9bfa2c-cb32-49d2-aa04-d5546c62bc10">0.3</ix:nonFraction>&#160;million in non-current inventory for API related to its ifetroban clinical initiatives.</span></div><ix:nonNumeric contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180Ni9mcmFnOmJhZGI2MmVmYTE1YjQ4MWE4ZmY0YWVlY2E4NzRhODhiL3RleHRyZWdpb246YmFkYjYyZWZhMTViNDgxYThmZjRhZWVjYTg3NGE4OGJfMTg5Mw_967f9516-dd5d-43e0-a5cc-635cdf28ce8d" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company's net inventories consisted of the following:</span></div><div style="text-align:center;margin-top:7pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"></td><td style="width:56.737151%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.121586%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.530103%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.681057%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.530103%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials and work in process</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180Ni9mcmFnOmJhZGI2MmVmYTE1YjQ4MWE4ZmY0YWVlY2E4NzRhODhiL3RhYmxlOjc2MWUyNGZlMzA2YjQ3ZjFhODg0YzhkM2Q2OTJhNmRlL3RhYmxlcmFuZ2U6NzYxZTI0ZmUzMDZiNDdmMWE4ODRjOGQzZDY5MmE2ZGVfMi0yLTEtMS0w_970fbddb-d0dc-4977-b0d9-f0033e859a9f">19,076,378</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180Ni9mcmFnOmJhZGI2MmVmYTE1YjQ4MWE4ZmY0YWVlY2E4NzRhODhiL3RhYmxlOjc2MWUyNGZlMzA2YjQ3ZjFhODg0YzhkM2Q2OTJhNmRlL3RhYmxlcmFuZ2U6NzYxZTI0ZmUzMDZiNDdmMWE4ODRjOGQzZDY5MmE2ZGVfMi00LTEtMS0w_73b4066b-db9e-447d-8ad2-e2bc1473dc7a">18,378,450</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Consigned inventory</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180Ni9mcmFnOmJhZGI2MmVmYTE1YjQ4MWE4ZmY0YWVlY2E4NzRhODhiL3RhYmxlOjc2MWUyNGZlMzA2YjQ3ZjFhODg0YzhkM2Q2OTJhNmRlL3RhYmxlcmFuZ2U6NzYxZTI0ZmUzMDZiNDdmMWE4ODRjOGQzZDY5MmE2ZGVfMy0yLTEtMS0w_47d4b109-b85d-4b67-9d9e-6a787e4f791c">774,225</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180Ni9mcmFnOmJhZGI2MmVmYTE1YjQ4MWE4ZmY0YWVlY2E4NzRhODhiL3RhYmxlOjc2MWUyNGZlMzA2YjQ3ZjFhODg0YzhkM2Q2OTJhNmRlL3RhYmxlcmFuZ2U6NzYxZTI0ZmUzMDZiNDdmMWE4ODRjOGQzZDY5MmE2ZGVfMy00LTEtMS0w_0e9a0672-5e2b-4e78-a3c3-198ebb09b241">937,006</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods, net of reserves</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180Ni9mcmFnOmJhZGI2MmVmYTE1YjQ4MWE4ZmY0YWVlY2E4NzRhODhiL3RhYmxlOjc2MWUyNGZlMzA2YjQ3ZjFhODg0YzhkM2Q2OTJhNmRlL3RhYmxlcmFuZ2U6NzYxZTI0ZmUzMDZiNDdmMWE4ODRjOGQzZDY5MmE2ZGVfNC0yLTEtMS0w_9ec1ed49-1a26-41f7-a7fe-fd7932678ccd">6,639,218</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180Ni9mcmFnOmJhZGI2MmVmYTE1YjQ4MWE4ZmY0YWVlY2E4NzRhODhiL3RhYmxlOjc2MWUyNGZlMzA2YjQ3ZjFhODg0YzhkM2Q2OTJhNmRlL3RhYmxlcmFuZ2U6NzYxZTI0ZmUzMDZiNDdmMWE4ODRjOGQzZDY5MmE2ZGVfNC00LTEtMS0w_d15f52e3-ccd9-4578-a94b-538717d92983">8,511,887</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:13pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180Ni9mcmFnOmJhZGI2MmVmYTE1YjQ4MWE4ZmY0YWVlY2E4NzRhODhiL3RhYmxlOjc2MWUyNGZlMzA2YjQ3ZjFhODg0YzhkM2Q2OTJhNmRlL3RhYmxlcmFuZ2U6NzYxZTI0ZmUzMDZiNDdmMWE4ODRjOGQzZDY5MmE2ZGVfNS0yLTEtMS0w_c705a2a1-ca55-4f21-ba38-bb1f36668dc9">26,489,821</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180Ni9mcmFnOmJhZGI2MmVmYTE1YjQ4MWE4ZmY0YWVlY2E4NzRhODhiL3RhYmxlOjc2MWUyNGZlMzA2YjQ3ZjFhODg0YzhkM2Q2OTJhNmRlL3RhYmxlcmFuZ2U6NzYxZTI0ZmUzMDZiNDdmMWE4ODRjOGQzZDY5MmE2ZGVfNS00LTEtMS0w_56b0af4a-75ba-4a35-874c-93436fb6c6b6">27,827,343</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:13pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">less non-current inventories</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180Ni9mcmFnOmJhZGI2MmVmYTE1YjQ4MWE4ZmY0YWVlY2E4NzRhODhiL3RhYmxlOjc2MWUyNGZlMzA2YjQ3ZjFhODg0YzhkM2Q2OTJhNmRlL3RhYmxlcmFuZ2U6NzYxZTI0ZmUzMDZiNDdmMWE4ODRjOGQzZDY5MmE2ZGVfNi0yLTEtMS0w_1f0f421d-6475-4c70-b463-69ef32df6b23">15,840,962</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180Ni9mcmFnOmJhZGI2MmVmYTE1YjQ4MWE4ZmY0YWVlY2E4NzRhODhiL3RhYmxlOjc2MWUyNGZlMzA2YjQ3ZjFhODg0YzhkM2Q2OTJhNmRlL3RhYmxlcmFuZ2U6NzYxZTI0ZmUzMDZiNDdmMWE4ODRjOGQzZDY5MmE2ZGVfNi00LTEtMS0w_22e59bd1-bc11-470f-96a3-f4f71768b36c">15,749,000</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventories classified as current</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180Ni9mcmFnOmJhZGI2MmVmYTE1YjQ4MWE4ZmY0YWVlY2E4NzRhODhiL3RhYmxlOjc2MWUyNGZlMzA2YjQ3ZjFhODg0YzhkM2Q2OTJhNmRlL3RhYmxlcmFuZ2U6NzYxZTI0ZmUzMDZiNDdmMWE4ODRjOGQzZDY5MmE2ZGVfNy0yLTEtMS0w_7d377025-9bf9-426a-b2c6-1fa26ed6c625">10,648,859</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180Ni9mcmFnOmJhZGI2MmVmYTE1YjQ4MWE4ZmY0YWVlY2E4NzRhODhiL3RhYmxlOjc2MWUyNGZlMzA2YjQ3ZjFhODg0YzhkM2Q2OTJhNmRlL3RhYmxlcmFuZ2U6NzYxZTI0ZmUzMDZiNDdmMWE4ODRjOGQzZDY5MmE2ZGVfNy00LTEtMS0w_41814051-7890-4e85-83cf-4bdf8d33a9b4">12,078,343</ix:nonFraction>&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div id="i_0_52"></div><div style="margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(6) <ix:nonNumeric contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181Mi9mcmFnOmQ0NDRlYTE0ZTk3OTRlNTI5NDIzZTZjNDBkNmExNDQ1L3RleHRyZWdpb246ZDQ0NGVhMTRlOTc5NGU1Mjk0MjNlNmM0MGQ2YTE0NDVfMzA5NA_ce4f1edc-7417-4df6-9d1d-5f24f896f432" continuedAt="i84d0999e19c34f52814d074886359d17" escape="true">LEASES</ix:nonNumeric></span></div><div style="text-align:justify;margin-top:7pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i84d0999e19c34f52814d074886359d17" continuedAt="i6f9240661d024e5bbd0d102e40a0da7e">In March 2016, the FASB issued ASU 2016-02. ASU 2016-02&#8217;s core principle is to increase transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information. The Company adopted ASU 2016-02 under the alternative transition method (the effective date approach). It allowed the Company to initially apply the new lease guidance at the adoption date (rather than at the beginning of the earliest period presented). Prior periods have not been adjusted.   </ix:continuation></span></div><div style="text-align:justify;margin-top:7pt;"><span><br/></span></div><div style="text-align:justify;margin-top:7pt;"><span><br/></span></div><div style="text-align:justify;margin-top:7pt;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">9</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><ix:continuation id="i6f9240661d024e5bbd0d102e40a0da7e"><div style="text-align:justify;margin-top:7pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The primary effect of adopting ASU 2016-02 to the Company was to record right-of-use assets and obligations for the leases currently classified as operating leases.  The Company&#8217;s significant operating leases include the lease of approximately 25,500 square feet of office space in Nashville, Tennessee for its corporate headquarters.  This lease currently expires in October 2022.  The operating leases also include the lease of approximately 14,200 square feet of wet laboratory and office space in Nashville, Tennessee by Cumberland Emerging Technologies (&#8220;CET&#8221;), our majority-owned subsidiary, where it operates the CET Life Sciences Center.  This lease currently expires in April 2023. The Company did not have any leases classified as finance leases at January 1, 2019 or June 30, 2019.  The new lease accounting standard did not have a significant impact on the Company's Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) for any period presented. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company elected the package of practical expedients offered in the transition guidance which allows management not to reassess lease identification, lease classification and initial direct costs at the adoption date. </span></div><div style="text-align:justify;margin-top:7pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">These operating leases resulted in initial ROU assets of $<ix:nonFraction unitRef="usd" contextRef="i24c5c7f1311c41b0adf7f2ad2954b3dc_I20190101" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181Mi9mcmFnOmQ0NDRlYTE0ZTk3OTRlNTI5NDIzZTZjNDBkNmExNDQ1L3RleHRyZWdpb246ZDQ0NGVhMTRlOTc5NGU1Mjk0MjNlNmM0MGQ2YTE0NDVfMTgxMw_22760e33-7604-4112-88d9-e1cc08f16397">3.6</ix:nonFraction> million and lease liabilities of $<ix:nonFraction unitRef="usd" contextRef="i24c5c7f1311c41b0adf7f2ad2954b3dc_I20190101" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181Mi9mcmFnOmQ0NDRlYTE0ZTk3OTRlNTI5NDIzZTZjNDBkNmExNDQ1L3RleHRyZWdpb246ZDQ0NGVhMTRlOTc5NGU1Mjk0MjNlNmM0MGQ2YTE0NDVfMTg0OQ_b7e1cbf9-6437-49b1-acbc-69691305a07b">3.8</ix:nonFraction> million as of January 1, 2019 for non-cancelable operating leases with original lease terms in excess of one year.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Operating lease liabilities were recorded as the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for lease incentives and initial direct costs. As the Company&#8217;s leases do not contain implicit borrowing rates, the incremental borrowing rates were calculated based on information available at January 1, 2019. Incremental borrowing rates reflect the Company&#8217;s estimated interest rates for collateralized borrowings over similar lease terms. The weighted-average remaining lease term is <ix:nonNumeric contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181Mi9mcmFnOmQ0NDRlYTE0ZTk3OTRlNTI5NDIzZTZjNDBkNmExNDQ1L3RleHRyZWdpb246ZDQ0NGVhMTRlOTc5NGU1Mjk0MjNlNmM0MGQ2YTE0NDVfMjYzNg_ab04f4bf-94e0-41c2-b456-97559a2b4c17">3.5</ix:nonNumeric> years and the weighted-average incremental borrowing rate used to discount the present value of the remaining lease payments is <ix:nonFraction unitRef="number" contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" decimals="INF" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181Mi9mcmFnOmQ0NDRlYTE0ZTk3OTRlNTI5NDIzZTZjNDBkNmExNDQ1L3RleHRyZWdpb246ZDQ0NGVhMTRlOTc5NGU1Mjk0MjNlNmM0MGQ2YTE0NDVfMjc2Nw_126d9e1c-1942-40e8-a1b9-7030fd3cab90">7.42</ix:nonFraction>%.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Lease Position</span></div><ix:nonNumeric contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" name="cpix:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181Mi9mcmFnOmQ0NDRlYTE0ZTk3OTRlNTI5NDIzZTZjNDBkNmExNDQ1L3RleHRyZWdpb246ZDQ0NGVhMTRlOTc5NGU1Mjk0MjNlNmM0MGQ2YTE0NDVfMzA5NQ_8ea1b418-ab89-4f8e-b118-759448a26702" escape="true"><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">At June 30, 2019, the Company recorded the following on the Condensed Consolidated Balance Sheet: </span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.368421%;"><tr><td style="width:1.0%;"></td><td style="width:34.036036%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.751952%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:38.090090%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.751952%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.969970%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Right-of-Use Assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance Sheet Classification</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other non-current assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181Mi9mcmFnOmQ0NDRlYTE0ZTk3OTRlNTI5NDIzZTZjNDBkNmExNDQ1L3RhYmxlOjYxZDU4NzIyYzI2MzRmMDJhMzcwYzlhNWJjZjlmMmNhL3RhYmxlcmFuZ2U6NjFkNTg3MjJjMjYzNGYwMmEzNzBjOWE1YmNmOWYyY2FfMS00LTEtMS0w_2ff43882-a1d9-4c5a-b66d-44b4049fe444">3,260,767</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:7pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" decimals="0" format="ixt:numdotdecimal" name="cpix:LeaseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181Mi9mcmFnOmQ0NDRlYTE0ZTk3OTRlNTI5NDIzZTZjNDBkNmExNDQ1L3RhYmxlOjYxZDU4NzIyYzI2MzRmMDJhMzcwYzlhNWJjZjlmMmNhL3RhYmxlcmFuZ2U6NjFkNTg3MjJjMjYzNGYwMmEzNzBjOWE1YmNmOWYyY2FfMi00LTEtMS0w_55eb81c8-9ae1-45ca-93ea-41719aae9cb7">3,260,767</ix:nonFraction>&#160;</span></td></tr></table></div><div style="margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.368421%;"><tr><td style="width:1.0%;"></td><td style="width:34.036036%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.751952%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:38.090090%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.751952%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.969970%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Lease Liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance Sheet Classification</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Current:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:7pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other current liabilities&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181Mi9mcmFnOmQ0NDRlYTE0ZTk3OTRlNTI5NDIzZTZjNDBkNmExNDQ1L3RhYmxlOmI4MmQzMTM5MGI2ZTQ2ZWJiMzNkZDMxYzdiNzFiMDMyL3RhYmxlcmFuZ2U6YjgyZDMxMzkwYjZlNDZlYmIzM2RkMzFjN2I3MWIwMzJfMi00LTEtMS0w_5a8a475b-c45c-4925-8879-ce0f8037c947">899,262</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Noncurrent:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:7pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other long-term liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181Mi9mcmFnOmQ0NDRlYTE0ZTk3OTRlNTI5NDIzZTZjNDBkNmExNDQ1L3RhYmxlOmI4MmQzMTM5MGI2ZTQ2ZWJiMzNkZDMxYzdiNzFiMDMyL3RhYmxlcmFuZ2U6YjgyZDMxMzkwYjZlNDZlYmIzM2RkMzFjN2I3MWIwMzJfNC00LTEtMS0w_589de204-4864-4e68-87e7-3b37c518ee83">2,502,850</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" decimals="0" format="ixt:numdotdecimal" name="cpix:LeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181Mi9mcmFnOmQ0NDRlYTE0ZTk3OTRlNTI5NDIzZTZjNDBkNmExNDQ1L3RhYmxlOmI4MmQzMTM5MGI2ZTQ2ZWJiMzNkZDMxYzdiNzFiMDMyL3RhYmxlcmFuZ2U6YjgyZDMxMzkwYjZlNDZlYmIzM2RkMzFjN2I3MWIwMzJfNS00LTEtMS0w_b87bef02-2940-4e0c-902a-53d5cb19f558">3,402,112</ix:nonFraction>&#160;</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span><br/></span></div><div><ix:nonNumeric contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181Mi9mcmFnOmQ0NDRlYTE0ZTk3OTRlNTI5NDIzZTZjNDBkNmExNDQ1L3RleHRyZWdpb246ZDQ0NGVhMTRlOTc5NGU1Mjk0MjNlNmM0MGQ2YTE0NDVfMzA5Ng_614fbd22-73c7-4384-8c50-c91b35d3625a" escape="true"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.368421%;"><tr><td style="width:1.0%;"></td><td style="width:76.078078%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.751952%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.969970%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Maturity of Leases Liabilities at June 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Operating Leases</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181Mi9mcmFnOmQ0NDRlYTE0ZTk3OTRlNTI5NDIzZTZjNDBkNmExNDQ1L3RhYmxlOmI0NmI3OGFhZTVmNDRhN2Q4MmRmZmJhNTg0NGVkOGU0L3RhYmxlcmFuZ2U6YjQ2Yjc4YWFlNWY0NGE3ZDgyZGZmYmE1ODQ0ZWQ4ZTRfMS0yLTEtMS0w_24ba8293-65b6-4a62-a076-df09b00df923">532,465</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181Mi9mcmFnOmQ0NDRlYTE0ZTk3OTRlNTI5NDIzZTZjNDBkNmExNDQ1L3RhYmxlOmI0NmI3OGFhZTVmNDRhN2Q4MmRmZmJhNTg0NGVkOGU0L3RhYmxlcmFuZ2U6YjQ2Yjc4YWFlNWY0NGE3ZDgyZGZmYmE1ODQ0ZWQ4ZTRfMi0yLTEtMS0w_579dd10d-eedd-4e2a-905c-db6951d41f09">1,120,066</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181Mi9mcmFnOmQ0NDRlYTE0ZTk3OTRlNTI5NDIzZTZjNDBkNmExNDQ1L3RhYmxlOmI0NmI3OGFhZTVmNDRhN2Q4MmRmZmJhNTg0NGVkOGU0L3RhYmxlcmFuZ2U6YjQ2Yjc4YWFlNWY0NGE3ZDgyZGZmYmE1ODQ0ZWQ4ZTRfMy0yLTEtMS0w_ba9a73fb-2dbb-443f-8201-9aa2d048fdd3">1,144,889</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181Mi9mcmFnOmQ0NDRlYTE0ZTk3OTRlNTI5NDIzZTZjNDBkNmExNDQ1L3RhYmxlOmI0NmI3OGFhZTVmNDRhN2Q4MmRmZmJhNTg0NGVkOGU0L3RhYmxlcmFuZ2U6YjQ2Yjc4YWFlNWY0NGE3ZDgyZGZmYmE1ODQ0ZWQ4ZTRfNC0yLTEtMS0w_8970ce79-445b-4153-802a-48c32c7d3316">1,019,313</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181Mi9mcmFnOmQ0NDRlYTE0ZTk3OTRlNTI5NDIzZTZjNDBkNmExNDQ1L3RhYmxlOmI0NmI3OGFhZTVmNDRhN2Q4MmRmZmJhNTg0NGVkOGU0L3RhYmxlcmFuZ2U6YjQ2Yjc4YWFlNWY0NGE3ZDgyZGZmYmE1ODQ0ZWQ4ZTRfNS0yLTEtMS0w_84dd757a-2563-43a0-85f3-8491962391ea">92,477</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">After 2023</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181Mi9mcmFnOmQ0NDRlYTE0ZTk3OTRlNTI5NDIzZTZjNDBkNmExNDQ1L3RhYmxlOmI0NmI3OGFhZTVmNDRhN2Q4MmRmZmJhNTg0NGVkOGU0L3RhYmxlcmFuZ2U6YjQ2Yjc4YWFlNWY0NGE3ZDgyZGZmYmE1ODQ0ZWQ4ZTRfNi0yLTEtMS0w_90b60545-3b25-44af-9ae5-1ada26d48f80">0</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181Mi9mcmFnOmQ0NDRlYTE0ZTk3OTRlNTI5NDIzZTZjNDBkNmExNDQ1L3RhYmxlOmI0NmI3OGFhZTVmNDRhN2Q4MmRmZmJhNTg0NGVkOGU0L3RhYmxlcmFuZ2U6YjQ2Yjc4YWFlNWY0NGE3ZDgyZGZmYmE1ODQ0ZWQ4ZTRfNy0yLTEtMS0w_d5c68c01-84a5-4fa3-a9bb-08944711796d">3,909,210</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Interest</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181Mi9mcmFnOmQ0NDRlYTE0ZTk3OTRlNTI5NDIzZTZjNDBkNmExNDQ1L3RhYmxlOmI0NmI3OGFhZTVmNDRhN2Q4MmRmZmJhNTg0NGVkOGU0L3RhYmxlcmFuZ2U6YjQ2Yjc4YWFlNWY0NGE3ZDgyZGZmYmE1ODQ0ZWQ4ZTRfOC0yLTEtMS0w_207e4108-eb00-4660-aee3-9770d7cb6c2c">507,098</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if478ab72402a4dbca17cebf84905f137_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181Mi9mcmFnOmQ0NDRlYTE0ZTk3OTRlNTI5NDIzZTZjNDBkNmExNDQ1L3RhYmxlOmI0NmI3OGFhZTVmNDRhN2Q4MmRmZmJhNTg0NGVkOGU0L3RhYmxlcmFuZ2U6YjQ2Yjc4YWFlNWY0NGE3ZDgyZGZmYmE1ODQ0ZWQ4ZTRfOS0yLTEtMS0w_1a34a410-08b9-415c-a2ed-b64b87d5c90a">3,402,112</ix:nonFraction>&#160;</span></td></tr></table></ix:nonNumeric></div></ix:continuation><div><span><br/></span></div><div id="i_0_58"></div><div style="margin-bottom:6pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><span><br/></span></div><div style="margin-bottom:6pt;-sec-extract:summary;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">10</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(7) <ix:nonNumeric contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181OC9mcmFnOmViNzI5MWIzYzY3NTRhM2ZiYmE0OWRkY2JmNzA3OGY0L3RleHRyZWdpb246ZWI3MjkxYjNjNjc1NGEzZmJiYTQ5ZGRjYmY3MDc4ZjRfNDYxMw_639bd782-c880-4a8f-b923-e29f693bcf53" continuedAt="ic80a3c15da134d83a6675223d234fb78" escape="true">SHAREHOLDERS&#8217; EQUITY AND DEBT</ix:nonNumeric></span></div><ix:continuation id="ic80a3c15da134d83a6675223d234fb78" continuedAt="i1589d3e554b94cdcb8b7495226f3c11f"><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Share repurchases</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company currently has a share repurchase program to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="i3c6be34147e74633b283a3faf26291a6_I20100513" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181OC9mcmFnOmViNzI5MWIzYzY3NTRhM2ZiYmE0OWRkY2JmNzA3OGY0L3RleHRyZWdpb246ZWI3MjkxYjNjNjc1NGEzZmJiYTQ5ZGRjYmY3MDc4ZjRfMTMw_e266faa1-5b9a-4da0-b63b-8ab1c913fd05">10</ix:nonFraction> million of its common stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. In January 2019, the Company's Board of Directors established the current $<ix:nonFraction unitRef="usd" contextRef="ie34c3c9c4b6c4086a134e19d8fa48fdd_I20160131" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181OC9mcmFnOmViNzI5MWIzYzY3NTRhM2ZiYmE0OWRkY2JmNzA3OGY0L3RleHRyZWdpb246ZWI3MjkxYjNjNjc1NGEzZmJiYTQ5ZGRjYmY3MDc4ZjRfMjkx_3d79d3ee-2558-49a1-b87a-4abea9794bbd">10</ix:nonFraction> million repurchase program to replace the prior authorizations.  During the six months ended June 30, 2019 and June 30, 2018, the Company repurchased <ix:nonFraction unitRef="shares" contextRef="idbb1a7efb54a4443b860e667b9d9f4ff_D20190101-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181OC9mcmFnOmViNzI5MWIzYzY3NTRhM2ZiYmE0OWRkY2JmNzA3OGY0L3RleHRyZWdpb246ZWI3MjkxYjNjNjc1NGEzZmJiYTQ5ZGRjYmY3MDc4ZjRfMzk3_cdda5d58-5861-42d9-a2ba-ecdb3c28eb23">205,913</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="i1fee3684442c4d5f9e424da6bdc3b780_D20180101-20180630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181OC9mcmFnOmViNzI5MWIzYzY3NTRhM2ZiYmE0OWRkY2JmNzA3OGY0L3RleHRyZWdpb246ZWI3MjkxYjNjNjc1NGEzZmJiYTQ5ZGRjYmY3MDc4ZjRfNDEx_f30a6891-55e8-4448-a1a2-81fd57656b95">299,370</ix:nonFraction> shares, respectively, of common stock for approximately $<ix:nonFraction unitRef="usd" contextRef="idbb1a7efb54a4443b860e667b9d9f4ff_D20190101-20190630" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181OC9mcmFnOmViNzI5MWIzYzY3NTRhM2ZiYmE0OWRkY2JmNzA3OGY0L3RleHRyZWdpb246ZWI3MjkxYjNjNjc1NGEzZmJiYTQ5ZGRjYmY3MDc4ZjRfNDcw_32c745ee-7058-4929-af75-1a6febb147c2">1.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1fee3684442c4d5f9e424da6bdc3b780_D20180101-20180630" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181OC9mcmFnOmViNzI5MWIzYzY3NTRhM2ZiYmE0OWRkY2JmNzA3OGY0L3RleHRyZWdpb246ZWI3MjkxYjNjNjc1NGEzZmJiYTQ5ZGRjYmY3MDc4ZjRfNDg1_15648305-dc20-4b8e-b8b8-8edb0a7c7d92">2.0</ix:nonFraction> million, respectively. </span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Share purchases and sales</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">During the Company's March 2019 trading window, several members of Cumberland's Board of Directors entered into share purchase agreements of the Company's stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. These purchases are designed to increase ownership in the Company by the members of the Board.  During the March 2019 trading window, one member of the Board of Directors entered into a share sale agreement, as required by a policy change by his employer, which prohibits his ownership in a pharmaceutical company.  The policy change did not impact his ability to serve on the Company's Board of Directors.  This Board member sold <ix:nonFraction unitRef="shares" contextRef="ide11bc6060924df19448d4e6a244010d_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="cpix:SaleOfStockNumberOfSharesSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181OC9mcmFnOmViNzI5MWIzYzY3NTRhM2ZiYmE0OWRkY2JmNzA3OGY0L3RleHRyZWdpb246ZWI3MjkxYjNjNjc1NGEzZmJiYTQ5ZGRjYmY3MDc4ZjRfMTA5OTUxMTYzMjY1Ng_3583b5d4-493e-426a-8428-bc9b9e6b45f7">47,969</ix:nonFraction> Cumberland shares during the second quarter 2019.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Share Sale</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In November 2017, the Company filed a Shelf Registration on Form S-3 with the SEC associated with the sale of up to $<ix:nonFraction unitRef="usd" contextRef="i959855896ce142fbac309e421bbe56a9_D20171101-20171130" decimals="-6" format="ixt:numdotdecimal" name="cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181OC9mcmFnOmViNzI5MWIzYzY3NTRhM2ZiYmE0OWRkY2JmNzA3OGY0L3RleHRyZWdpb246ZWI3MjkxYjNjNjc1NGEzZmJiYTQ5ZGRjYmY3MDc4ZjRfMTI1NA_b8d49751-5140-42a6-bc44-b0816abe7dad">100</ix:nonFraction> million in corporate securities. The Shelf Registration was declared effective in January 2018. During the six months ended June 30, 2018, the Company issued <ix:nonFraction unitRef="shares" contextRef="i1fee3684442c4d5f9e424da6bdc3b780_D20180101-20180630" decimals="INF" format="ixt:numdotdecimal" name="cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181OC9mcmFnOmViNzI5MWIzYzY3NTRhM2ZiYmE0OWRkY2JmNzA3OGY0L3RleHRyZWdpb246ZWI3MjkxYjNjNjc1NGEzZmJiYTQ5ZGRjYmY3MDc4ZjRfMTM3OQ_5d93bdd1-1016-4c43-9e39-39d77e8881b6">30,704</ix:nonFraction> shares of common stock for gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181OC9mcmFnOmViNzI5MWIzYzY3NTRhM2ZiYmE0OWRkY2JmNzA3OGY0L3RleHRyZWdpb246ZWI3MjkxYjNjNjc1NGEzZmJiYTQ5ZGRjYmY3MDc4ZjRfMTQyNw_8f6722e4-433a-47dd-88ab-b3804891c170">0.2</ix:nonFraction> million as part of its At-The-Market (&#8220;ATM&#8221;) sales agreement with B. Riley FBR. The Company did not issue any shares under the ATM during the six months ended June 30, 2019.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Restricted Share Grants </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">During the six months ended June 30, 2019, and June 30, 2018, the Company issued <ix:nonFraction unitRef="shares" contextRef="i89a377e795d5407db1aaac39ada6ab01_D20190101-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181OC9mcmFnOmViNzI5MWIzYzY3NTRhM2ZiYmE0OWRkY2JmNzA3OGY0L3RleHRyZWdpb246ZWI3MjkxYjNjNjc1NGEzZmJiYTQ5ZGRjYmY3MDc4ZjRfMTY0NA_2e327579-d059-497a-8e3b-36c13a87fb4f">222,469</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="ia72329a5bc7744a280d614667782cdc8_D20180101-20180630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181OC9mcmFnOmViNzI5MWIzYzY3NTRhM2ZiYmE0OWRkY2JmNzA3OGY0L3RleHRyZWdpb246ZWI3MjkxYjNjNjc1NGEzZmJiYTQ5ZGRjYmY3MDc4ZjRfMTY1OA_3cc501c6-712c-4aa3-afd4-ff3e0503b18f">233,330</ix:nonFraction> shares of restricted stock to employees and directors, respectively. Restricted stock issued to employees generally cliff-vests on the fourth anniversary of the date of grant and for directors on the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181OC9mcmFnOmViNzI5MWIzYzY3NTRhM2ZiYmE0OWRkY2JmNzA3OGY0L3RleHRyZWdpb246ZWI3MjkxYjNjNjc1NGEzZmJiYTQ5ZGRjYmY3MDc4ZjRfMTg2MQ_7b6a6f88-b9bb-43f7-bebc-cb00283f1265">one</span>-year anniversary of the date of grant.  Stock compensation expense is presented as a component of general and administrative expense in the condensed consolidated statements of operations and comprehensive income (loss).</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Cumberland Emerging Technologies</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In April 2019, Cumberland Emerging Technologies ("CET"), our majority-owned subsidiary, entered into </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">an agreement with WinHealth whereby WinHealth will make a $<ix:nonFraction unitRef="usd" contextRef="i94c12e61b0d14ff5a5b7a3c975510ecc_I20190430" decimals="-6" format="ixt:numdotdecimal" name="cpix:SubsidiaryInvestmentPurchaseOfShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181OC9mcmFnOmViNzI5MWIzYzY3NTRhM2ZiYmE0OWRkY2JmNzA3OGY0L3RleHRyZWdpb246ZWI3MjkxYjNjNjc1NGEzZmJiYTQ5ZGRjYmY3MDc4ZjRfODI0NjMzNzIxODQ0OA_33ccfd92-61e9-4602-a263-0e2e42cb9a58">1</ix:nonFraction>&#160;million investment through the purchase of shares of CET stock. As part of the agreement, WinHealth obtained a Board position at CET and the first opportunity to license CET products for the Chinese market. In connection with WinHealth's investment in CET, Cumberland also made an additional $<ix:nonFraction unitRef="usd" contextRef="i94c12e61b0d14ff5a5b7a3c975510ecc_I20190430" decimals="-6" format="ixt:numdotdecimal" name="cpix:SubsidiaryInvestmentPurchaseOfShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181OC9mcmFnOmViNzI5MWIzYzY3NTRhM2ZiYmE0OWRkY2JmNzA3OGY0L3RleHRyZWdpb246ZWI3MjkxYjNjNjc1NGEzZmJiYTQ5ZGRjYmY3MDc4ZjRfODI0NjMzNzIxODQ2MA_e941bab7-b14e-4d22-85b8-c2a9e1e12427">1</ix:nonFraction>&#160;million investment in CET.  Cumberland purchased additional CET shares through contribution of $<ix:nonFraction unitRef="usd" contextRef="ib97eaa219e974f16a39fa98e445d047a_D20190401-20190430" decimals="-5" format="ixt:numdotdecimal" name="cpix:SubsidiaryInvestmentCashContribution" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181OC9mcmFnOmViNzI5MWIzYzY3NTRhM2ZiYmE0OWRkY2JmNzA3OGY0L3RleHRyZWdpb246ZWI3MjkxYjNjNjc1NGEzZmJiYTQ5ZGRjYmY3MDc4ZjRfODI0NjMzNzIxODQ3NA_59f58b5d-09c1-4d73-8faf-216978b249e8">0.3</ix:nonFraction>&#160;million in cash and a conversion of $<ix:nonFraction unitRef="usd" contextRef="i11a9395935dd46a587ef0b6c9587b057_I20190430" decimals="-5" format="ixt:numdotdecimal" name="cpix:SubsidiaryInvestmentConversionOfIntercompanyLoansPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181OC9mcmFnOmViNzI5MWIzYzY3NTRhM2ZiYmE0OWRkY2JmNzA3OGY0L3RleHRyZWdpb246ZWI3MjkxYjNjNjc1NGEzZmJiYTQ5ZGRjYmY3MDc4ZjRfODI0NjMzNzIxODUxNg_ec706ac3-7b94-44b9-a5e2-3173d6beb05a">0.7</ix:nonFraction>&#160;million in intercompany loans payable.  Upon completion of the additional investment by WinHealth and Cumberland, Gloria Pharmaceuticals agreed to return it's shares in CET in exchange for a payment of $<ix:nonFraction unitRef="usd" contextRef="id03a7800662a48cd8cf59f4d3cdb9811_D20190401-20190430" decimals="-5" format="ixt:numdotdecimal" name="cpix:SubsidiaryInvestmentPaymentsForReturnOfCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181OC9mcmFnOmViNzI5MWIzYzY3NTRhM2ZiYmE0OWRkY2JmNzA3OGY0L3RleHRyZWdpb246ZWI3MjkxYjNjNjc1NGEzZmJiYTQ5ZGRjYmY3MDc4ZjRfODI0NjMzNzIxODUzMA_5d9b83a9-8803-4e85-bb94-e9e3ec12e701">0.8</ix:nonFraction>&#160;million.  </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Debt Agreement</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On May 10, 2019, the Company entered into a third amendment ("Third Amendment") to the Revolving Credit Loan Agreement, dated July 28, 2017, with Pinnacle Bank (&#8220;Pinnacle Agreement&#8221;). The Third Amendment extended the term of the Pinnacle Agreement through July 31, 2021 as well as modified certain definitions and terms of the existing financial covenants.  The initial revolving line of credit under the Pinnacle Agreement was for up to an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="idf561525052b4733845421e5e0fffabf_I20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181OC9mcmFnOmViNzI5MWIzYzY3NTRhM2ZiYmE0OWRkY2JmNzA3OGY0L3RleHRyZWdpb246ZWI3MjkxYjNjNjc1NGEzZmJiYTQ5ZGRjYmY3MDc4ZjRfMjkxNw_51826786-335a-42bf-b69f-fb7191aa56b2">12.0</ix:nonFraction> million with the ability to increase the principal amount available for borrowing up to $<ix:nonFraction unitRef="usd" contextRef="idf561525052b4733845421e5e0fffabf_I20190630" decimals="INF" format="ixt:numdotdecimal" name="cpix:LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181OC9mcmFnOmViNzI5MWIzYzY3NTRhM2ZiYmE0OWRkY2JmNzA3OGY0L3RleHRyZWdpb246ZWI3MjkxYjNjNjc1NGEzZmJiYTQ5ZGRjYmY3MDc4ZjRfMzAwMA_de04b950-8291-427b-9e85-09b2f5ecad48">20.0</ix:nonFraction> million, upon the satisfaction of certain conditions.   On October 17, 2018, the Company entered into a second amendment (&#8220;Second Amendment&#8221;) which increased the maximum aggregate principal available for borrowing under the Pinnacle Agreement to $<ix:nonFraction unitRef="usd" contextRef="i265ae74e8bfa4726841ed00db8f8e437_I20181017" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181OC9mcmFnOmViNzI5MWIzYzY3NTRhM2ZiYmE0OWRkY2JmNzA3OGY0L3RleHRyZWdpb246ZWI3MjkxYjNjNjc1NGEzZmJiYTQ5ZGRjYmY3MDc4ZjRfMTA5OTUxMTYzNjg1Ng_7cd30365-40c9-4026-a68d-902988354d4c">20.0</ix:nonFraction> million.  Cumberland increased the maximum aggregate principal available for borrowing to support potential future acquisitions and general corporate purposes.  </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. There is no LIBOR minimum and the LIBOR pricing provides for an interest rate spread of <ix:nonFraction unitRef="number" contextRef="ie283482fcb0a418f903f4565757a59f1_I20190630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181OC9mcmFnOmViNzI5MWIzYzY3NTRhM2ZiYmE0OWRkY2JmNzA3OGY0L3RleHRyZWdpb246ZWI3MjkxYjNjNjc1NGEzZmJiYTQ5ZGRjYmY3MDc4ZjRfMzU1Mw_fa6637da-bcf6-4a0a-adf7-2dfde501a5ac">1.75</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i389446a0e5ad467cb0b7d185b5851168_I20190630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181OC9mcmFnOmViNzI5MWIzYzY3NTRhM2ZiYmE0OWRkY2JmNzA3OGY0L3RleHRyZWdpb246ZWI3MjkxYjNjNjc1NGEzZmJiYTQ5ZGRjYmY3MDc4ZjRfMzU1OQ_eab5ed07-a7d0-49ea-81b5-ce1018683905">2.75</ix:nonFraction>% (representing an interest rate of <ix:nonFraction unitRef="number" contextRef="idf561525052b4733845421e5e0fffabf_I20190630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181OC9mcmFnOmViNzI5MWIzYzY3NTRhM2ZiYmE0OWRkY2JmNzA3OGY0L3RleHRyZWdpb246ZWI3MjkxYjNjNjc1NGEzZmJiYTQ5ZGRjYmY3MDc4ZjRfMzU5Ng_30013126-f88d-4692-9ed8-bb6dca5a5372">5.15</ix:nonFraction>% at June 30, 2019).  In addition, a fee of <ix:nonFraction unitRef="number" contextRef="i4c66d110828e4d3290867f75611b26b4_D20190101-20190630" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181OC9mcmFnOmViNzI5MWIzYzY3NTRhM2ZiYmE0OWRkY2JmNzA3OGY0L3RleHRyZWdpb246ZWI3MjkxYjNjNjc1NGEzZmJiYTQ5ZGRjYmY3MDc4ZjRfMzYzMA_94be63da-f599-44a6-9a7b-8bb5a45e98a2">0.25</ix:nonFraction>% per year is charged on the unused line of credit.  Interest and the unused line fee are payable quarterly.  Borrowings under the line of credit are collateralized by substantially all of our assets. </span></div></ix:continuation><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">11</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i1589d3e554b94cdcb8b7495226f3c11f">Under the Pinnacle Agreement, Cumberland was initially subject to one financial covenant, the maintenance of a Funded Debt Ratio, as such term is defined in the agreement and determined on a quarterly basis.  On August 14, 2018, the Company amended the Pinnacle Agreement ("First Amendment") to replace the single financial covenant with the maintenance of either the Funded Debt Ratio or a Tangible Capital Ratio, as defined in the First Amendment.  The Third Amendment modified the definition of the Funded Debt Ratio and the compliance target of the Tangible Capital Ratio. Both Third Amendment modifications were related to the Vibativ transaction.  The Company was in compliance with the Tangible Capital Ratio financial covenant as of June 30, 2019.</ix:continuation></span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div id="i_0_64"></div><div style="margin-top:6pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(8) <ix:nonNumeric contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N182NC9mcmFnOmEwOTE0MzFmNWEyYjQyN2NiYTM0ZGFlMjcwOGFlNGNhL3RleHRyZWdpb246YTA5MTQzMWY1YTJiNDI3Y2JhMzRkYWUyNzA4YWU0Y2FfMTU0NA_ff3ef8c7-0db7-42b6-b9ef-e3595da7621f" continuedAt="i449884321c974af9b6b64c1addc8d938" escape="true">INCOME TAXES</ix:nonNumeric></span></div><ix:continuation id="i449884321c974af9b6b64c1addc8d938"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (&#8220;the Tax Act&#8221;).  The Tax Act makes broad and complex changes to the U.S. tax code, including, but not limited to, (1) reducing the U.S. federal corporate tax rate to 21%; (2) eliminating the corporate alternative minimum tax (&#8220;AMT&#8221;) and changing how AMT credits can be realized; (3) capital expensing; and (4) creating new limitations on deductible interest expense and executive compensation.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The SEC staff issued Staff Accounting Bulletin (&#8220;SAB&#8221;) 118, providing guidance on applying the Tax Act.  SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740.  In accordance with SAB 118, a company reflects the income tax effects of the Tax Act for which the accounting under ASC 740 is complete.  To the extent that a company&#8217;s accounting for certain income tax effects of the Tax Act is incomplete but a reasonable estimate is available, it must record the estimate in the financial statements.  If a company cannot determine an estimate, it should continue to apply ASC 740 on the basis of the tax laws that were in effect immediately prior to enactment of the Tax Act.  The Company expects it will continue to pay minimal taxes in future periods through the continued utilization of net operating loss carryforwards, as it is able to achieve taxable income through its operations.</span></div></ix:continuation><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div id="i_0_67"></div><div style="margin-top:6pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(9) <ix:nonNumeric contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N182Ny9mcmFnOjZhYWI5ZGM5NWVkMDRmOTU4ZjE3MDFiZGM2NGFhYTk1L3RleHRyZWdpb246NmFhYjlkYzk1ZWQwNGY5NThmMTcwMWJkYzY0YWFhOTVfOTgw_a9974540-8075-410b-9ee4-861102f4cfd9" continuedAt="ica2f5480d5e04f3b8710dad63d737c8e" escape="true">COLLABORATIVE AGREEMENTS</ix:nonNumeric></span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><ix:continuation id="ica2f5480d5e04f3b8710dad63d737c8e"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Cumberland is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The Company has determined that these collaborative agreements do not meet the criteria for accounting under ASC Topic 808, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaborative Agreements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">. The agreements do not specifically designate each party&#8217;s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from grants are recorded as net revenues in the condensed consolidated statements of operations and comprehensive income (loss).</span></ix:continuation></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div id="i_0_70"></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(10) <ix:nonNumeric contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RleHRyZWdpb246ZDQ4OWI1YThlY2E3NDBiOTkxNDMyY2E5ZTFkYjgwZjFfNjA0NzMxMzk1ODI5Ng_c6d89799-0ec5-4c70-8f46-8f095cc0f4d6" continuedAt="i2680257382dc4a508c5f4ec55b278d53" escape="true">RECENT ADDITIONS AND EXPECTED RETURN OF PRODUCT RIGHTS</ix:nonNumeric></span></div><ix:continuation id="i2680257382dc4a508c5f4ec55b278d53" continuedAt="iccacd1bc5f0946ec9ee3dd233322fbb8"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Omeclamox-Pak</span></div><div style="text-align:justify;margin-top:7pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In December 2018, Cumberland completed an agreement with Gasto-enterlogics Inc. ("GEL") to acquire the remaining product rights associated with Omeclamox-Pak, including the product&#8217;s FDA-approved New Drug Application and the domestic and international trademarks. As part of the transaction, which was accounted for as an asset acquisition, Cumberland paid $<ix:nonFraction unitRef="usd" contextRef="i5709e5c0528d4106ba0350257862d329_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="cpix:PaymentsForAssetAcquisitions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RleHRyZWdpb246ZDQ4OWI1YThlY2E3NDBiOTkxNDMyY2E5ZTFkYjgwZjFfNDA2_0ecc3f34-e666-4044-8018-3d8b80c2abe1">2.3</ix:nonFraction> million during 2018 and ended Cumberland&#8217;s payments of royalties and manufacturing fees to GEL.  The Company has now assumed responsibility for the maintenance of the product&#8217;s FDA approval and for the oversight of the product&#8217;s manufacturing and packaging.</span></div><div style="text-align:justify;margin-top:7pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Vibativ</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">During November 2018, the Company closed on an agreement with Theravance Biopharma ("Theravance") to acquire the global responsibility for Vibativ including the marketing, distribution, manufacturing and regulatory activities associated with the brand.  Vibativ is a patented, FDA approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.  Cumberland acquired Vibativ to further add to its product offerings, increase its net revenue and positively contribute to the Company's operating results.  While Cumberland is still evaluating the tax deductibility of the goodwill acquired in the acquisition, it expects those amounts to be deductible for tax purposes.    </span></div></ix:continuation><div style="text-align:justify;margin-top:8pt;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">12</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><ix:continuation id="iccacd1bc5f0946ec9ee3dd233322fbb8" continuedAt="ib95eb3f356aa41d6aacc0bbd757d2587"><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="icca6e0f80b33475a8371b8499f5d8919_D20181101-20181130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RleHRyZWdpb246ZDQ4OWI1YThlY2E3NDBiOTkxNDMyY2E5ZTFkYjgwZjFfMTg2OQ_0fea43eb-a727-4a38-99c9-32be260841af">20.0</ix:nonFraction> million at the closing of the transaction and a $<ix:nonFraction unitRef="usd" contextRef="i1b571fa0594646398781261aceb478b2_D20190401-20190430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherPaymentsToAcquireBusinesses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RleHRyZWdpb246ZDQ4OWI1YThlY2E3NDBiOTkxNDMyY2E5ZTFkYjgwZjFfMTg3OQ_ce49fd95-2244-47f6-b0b8-415b770bb5e0">5.0</ix:nonFraction> million milestone payment in early April 2019. In addition, Cumberland has agreed to pay a royalty of up to <ix:nonFraction unitRef="number" contextRef="icca6e0f80b33475a8371b8499f5d8919_D20181101-20181130" decimals="2" name="cpix:TieredRoyaltyPaymentsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RleHRyZWdpb246ZDQ4OWI1YThlY2E3NDBiOTkxNDMyY2E5ZTFkYjgwZjFfMTk5NQ_4a4b0536-6314-4df8-8cda-3fa726ffa6ae">20</ix:nonFraction>% on future net sales of the product.  The future royalty payments are required to be recognized at their acquisition-date fair value as part of the contingent consideration transferred in the business combination. </span></div><ix:nonNumeric contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RleHRyZWdpb246ZDQ4OWI1YThlY2E3NDBiOTkxNDMyY2E5ZTFkYjgwZjFfMzU4Mw_abe831c2-77bc-49ac-b63f-4ba7ec24c344" escape="true"><div style="margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the initial payments and consideration for the business combination:</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:75.631579%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:20.368421%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Consideration:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid at closing</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9d064a4268974d2eaa1aee9282ceb970_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RhYmxlOjNjMDNhODg0YThhZDRlMjViNjE4NWE2YzQ3NzNhZWU1L3RhYmxlcmFuZ2U6M2MwM2E4ODRhOGFkNGUyNWI2MTg1YTZjNDc3M2FlZTVfMi0xLTEtMS0w_040b9ef1-574f-4416-9f5d-88d603e31a78">20,000,000</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash payment during early 2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9d064a4268974d2eaa1aee9282ceb970_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherPaymentsToAcquireBusinesses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RhYmxlOjNjMDNhODg0YThhZDRlMjViNjE4NWE2YzQ3NzNhZWU1L3RhYmxlcmFuZ2U6M2MwM2E4ODRhOGFkNGUyNWI2MTg1YTZjNDc3M2FlZTVfMy0xLTEtMS0w_19c97551-0081-4636-a5ef-fd78afaeaf9e">5,000,000</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of contingent consideration - net sales royalty</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9d064a4268974d2eaa1aee9282ceb970_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="cpix:PaymentsForContingentConsideration" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RhYmxlOjNjMDNhODg0YThhZDRlMjViNjE4NWE2YzQ3NzNhZWU1L3RhYmxlcmFuZ2U6M2MwM2E4ODRhOGFkNGUyNWI2MTg1YTZjNDc3M2FlZTVfNC0xLTEtMS0w_7f8654cd-3a1c-42c3-8441-31c680bb45ac">9,182,000</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total consideration </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9d064a4268974d2eaa1aee9282ceb970_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RhYmxlOjNjMDNhODg0YThhZDRlMjViNjE4NWE2YzQ3NzNhZWU1L3RhYmxlcmFuZ2U6M2MwM2E4ODRhOGFkNGUyNWI2MTg1YTZjNDc3M2FlZTVfNS0xLTEtMS0w_5d6c97fb-68c9-4706-94c9-43bce4f8d769">34,182,000</ix:nonFraction>&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;margin-top:6pt;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The contingent consideration liability represents the future net sales royalty payments discussed above.  Cumberland prepared the valuations of the contingent consideration liability and the intangible assets utilizing significant unobservable inputs.  As a result, the valuations are classified as Level 3 fair value measurements.  The Company will continue to evaluate the assets acquired and liabilities assumed during the measurement period. </span></div><ix:nonNumeric contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RleHRyZWdpb246ZDQ4OWI1YThlY2E3NDBiOTkxNDMyY2E5ZTFkYjgwZjFfMzU4NA_ebaed603-fae9-4057-a4b6-823fb561fb97" escape="true"><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table presents the changes in the Company's Level 3 contingent consideration liability that is measured at fair value on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to the seller quarterly.</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:75.923977%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:20.076023%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration liability</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at November 12, 2018</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic8e3a8763ebf4e4299a795047276e3dd_I20181112" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RhYmxlOjc1ZDBlODQ3MTFhYjQ3MGU4OWE0NTc5MjhiNTRjMDg3L3RhYmxlcmFuZ2U6NzVkMGU4NDcxMWFiNDcwZTg5YTQ1NzkyOGI1NGMwODdfMS0xLTEtMS0w_3e8d7973-3879-4b14-b368-bb7e45f92300">9,034,000</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i62c36aedf5f84b7d8160f6870615925e_D20181113-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RhYmxlOjc1ZDBlODQ3MTFhYjQ3MGU4OWE0NTc5MjhiNTRjMDg3L3RhYmxlcmFuZ2U6NzVkMGU4NDcxMWFiNDcwZTg5YTQ1NzkyOGI1NGMwODdfMi0xLTEtMS0w_eb91546d-81c5-476c-ac5f-c89e7f40ca25">40,000</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i385e5bd994794f80a9f4101d706edbbb_D20181112-20181231" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RhYmxlOjc1ZDBlODQ3MTFhYjQ3MGU4OWE0NTc5MjhiNTRjMDg3L3RhYmxlcmFuZ2U6NzVkMGU4NDcxMWFiNDcwZTg5YTQ1NzkyOGI1NGMwODdfMy0xLTEtMS0w_da5d481b-e92a-4cde-bd45-718f997a9c9f">508,000</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i674a647fde3f44be85e9cae6e936a816_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RhYmxlOjc1ZDBlODQ3MTFhYjQ3MGU4OWE0NTc5MjhiNTRjMDg3L3RhYmxlcmFuZ2U6NzVkMGU4NDcxMWFiNDcwZTg5YTQ1NzkyOGI1NGMwODdfNC0xLTEtMS0w_d45676dc-511d-4f0d-b3a1-3eb73840503c">9,502,000</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustment to initial fair value of the contingent consideration liability</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9d064a4268974d2eaa1aee9282ceb970_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RhYmxlOjc1ZDBlODQ3MTFhYjQ3MGU4OWE0NTc5MjhiNTRjMDg3L3RhYmxlcmFuZ2U6NzVkMGU4NDcxMWFiNDcwZTg5YTQ1NzkyOGI1NGMwODdfNS0xLTEtMS0w_1be39357-a608-42ae-b16b-371de25be7da">148,000</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash payment of royalty during the period</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9d064a4268974d2eaa1aee9282ceb970_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRoyalties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RhYmxlOjc1ZDBlODQ3MTFhYjQ3MGU4OWE0NTc5MjhiNTRjMDg3L3RhYmxlcmFuZ2U6NzVkMGU4NDcxMWFiNDcwZTg5YTQ1NzkyOGI1NGMwODdfNi0xLTEtMS0w_d84f8453-1737-4bba-8301-186dc1db75a9">684,738</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9d064a4268974d2eaa1aee9282ceb970_D20190101-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RhYmxlOjc1ZDBlODQ3MTFhYjQ3MGU4OWE0NTc5MjhiNTRjMDg3L3RhYmxlcmFuZ2U6NzVkMGU4NDcxMWFiNDcwZTg5YTQ1NzkyOGI1NGMwODdfNy0xLTEtMS0w_bd23186a-07ad-4425-b1b3-d340fd391412">321,894</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9d064a4268974d2eaa1aee9282ceb970_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RhYmxlOjc1ZDBlODQ3MTFhYjQ3MGU4OWE0NTc5MjhiNTRjMDg3L3RhYmxlcmFuZ2U6NzVkMGU4NDcxMWFiNDcwZTg5YTQ1NzkyOGI1NGMwODdfOC0xLTEtMS0w_f1861305-a9b9-4afe-82ad-64f514170fac">423,041</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at June 30, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5332b0b2238e4d09b5c7a0b66e8b457a_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RhYmxlOjc1ZDBlODQ3MTFhYjQ3MGU4OWE0NTc5MjhiNTRjMDg3L3RhYmxlcmFuZ2U6NzVkMGU4NDcxMWFiNDcwZTg5YTQ1NzkyOGI1NGMwODdfOS0xLTEtMS0w_1d72aa37-7525-4a5b-a5b4-108baa5c4d22">9,066,409</ix:nonFraction>&#160;</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:8pt;"><span><br/></span></div><ix:nonNumeric contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RleHRyZWdpb246ZDQ4OWI1YThlY2E3NDBiOTkxNDMyY2E5ZTFkYjgwZjFfMzU4NQ_913428ec-9663-49b6-9593-e6ff3dce85d0" escape="true"><div style="margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the final allocation of the fair values of the assets acquired as part of the acquisition of Vibativ:</span></div><div style="text-align:justify;margin-top:8pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:75.923977%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:20.076023%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods inventory</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfc029c334714ab1b6a1fa6f662c915e_I20181130" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RhYmxlOmMxODMzZTViMTQ4YjQ5ZmRiMmViNGQ2Mjk3ZGQxYmM1L3RhYmxlcmFuZ2U6YzE4MzNlNWIxNDhiNDlmZGIyZWI0ZDYyOTdkZDFiYzVfMC0xLTEtMS0w_7afa74f9-03d5-4364-a317-ac06057fa489">6,624,000</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Work in process - unlabeled vials</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfc029c334714ab1b6a1fa6f662c915e_I20181130" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RhYmxlOmMxODMzZTViMTQ4YjQ5ZmRiMmViNGQ2Mjk3ZGQxYmM1L3RhYmxlcmFuZ2U6YzE4MzNlNWIxNDhiNDlmZGIyZWI0ZDYyOTdkZDFiYzVfMS0xLTEtMS0w_cfb437b2-988d-4e51-be8a-3f8e2b7a6e36">3,970,000</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Work in process - validation vials</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfc029c334714ab1b6a1fa6f662c915e_I20181130" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RhYmxlOmMxODMzZTViMTQ4YjQ5ZmRiMmViNGQ2Mjk3ZGQxYmM1L3RhYmxlcmFuZ2U6YzE4MzNlNWIxNDhiNDlmZGIyZWI0ZDYyOTdkZDFiYzVfMi0xLTEtMS0w_a73500ac-8475-4dff-9cfe-ebff3233d5bf">1,827,000</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfc029c334714ab1b6a1fa6f662c915e_I20181130" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RhYmxlOmMxODMzZTViMTQ4YjQ5ZmRiMmViNGQ2Mjk3ZGQxYmM1L3RhYmxlcmFuZ2U6YzE4MzNlNWIxNDhiNDlmZGIyZWI0ZDYyOTdkZDFiYzVfMy0xLTEtMS0w_15722482-ab44-4a3f-adcc-01d618edafa4">9,129,000</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:13pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventory</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfc029c334714ab1b6a1fa6f662c915e_I20181130" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RhYmxlOmMxODMzZTViMTQ4YjQ5ZmRiMmViNGQ2Mjk3ZGQxYmM1L3RhYmxlcmFuZ2U6YzE4MzNlNWIxNDhiNDlmZGIyZWI0ZDYyOTdkZDFiYzVfNC0xLTEtMS0w_6c7f7f86-ca05-4960-bd87-dad5ee15f13a">21,550,000</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Intellectual property amortizable intangible assets</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfc029c334714ab1b6a1fa6f662c915e_I20181130" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RhYmxlOmMxODMzZTViMTQ4YjQ5ZmRiMmViNGQ2Mjk3ZGQxYmM1L3RhYmxlcmFuZ2U6YzE4MzNlNWIxNDhiNDlmZGIyZWI0ZDYyOTdkZDFiYzVfNi0xLTEtMS0w_9d32e30b-5a9c-45f4-bbb6-592795b7920f">11,750,000</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfc029c334714ab1b6a1fa6f662c915e_I20181130" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RhYmxlOmMxODMzZTViMTQ4YjQ5ZmRiMmViNGQ2Mjk3ZGQxYmM1L3RhYmxlcmFuZ2U6YzE4MzNlNWIxNDhiNDlmZGIyZWI0ZDYyOTdkZDFiYzVfNy0xLTEtMS0w_d8d230c0-1ad5-49aa-a6e0-02d1df365ebf">882,000</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:13pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total intangibles and goodwill</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfc029c334714ab1b6a1fa6f662c915e_I20181130" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RhYmxlOmMxODMzZTViMTQ4YjQ5ZmRiMmViNGQ2Mjk3ZGQxYmM1L3RhYmxlcmFuZ2U6YzE4MzNlNWIxNDhiNDlmZGIyZWI0ZDYyOTdkZDFiYzVfOC0xLTEtMS0w_98bb5af0-06c5-4bd2-9e79-24fcb27b379d">12,632,000</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets acquired</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfc029c334714ab1b6a1fa6f662c915e_I20181130" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RhYmxlOmMxODMzZTViMTQ4YjQ5ZmRiMmViNGQ2Mjk3ZGQxYmM1L3RhYmxlcmFuZ2U6YzE4MzNlNWIxNDhiNDlmZGIyZWI0ZDYyOTdkZDFiYzVfOS0xLTEtMS0w_56998aa3-58ac-46b2-9110-8fd7fbb53a94">34,182,000</ix:nonFraction>&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify;margin-top:8pt;"><span><br/></span></div><div style="text-align:justify;margin-top:8pt;"><span><br/></span></div><div style="text-align:justify;margin-top:8pt;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">13</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><ix:continuation id="ib95eb3f356aa41d6aacc0bbd757d2587"><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company's contingent consideration liability is a Level 3 fair value measurement that is updated on a recurring basis at each reporting period using a valuation model.  Consistent with Level 3 fair value measurements, there are significant inputs to the valuation model that are unobservable. The current portion of the contingent consideration liability is $<ix:nonFraction unitRef="usd" contextRef="i55ab197a5f614ea393244079e62f621c_I20190630" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RleHRyZWdpb246ZDQ4OWI1YThlY2E3NDBiOTkxNDMyY2E5ZTFkYjgwZjFfMzUyNg_f857078f-fded-48da-ad0e-6e5977e57004">2.1</ix:nonFraction> million and the non-current portion is $<ix:nonFraction unitRef="usd" contextRef="i55ab197a5f614ea393244079e62f621c_I20190630" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RleHRyZWdpb246ZDQ4OWI1YThlY2E3NDBiOTkxNDMyY2E5ZTFkYjgwZjFfMzU2OA_49bbf964-f68f-479b-8f56-3a353125ef39">7.0</ix:nonFraction> million. </span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Ethyol and Totect </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">During May 2019, Cumberland entered into a Dissolution Agreement with Clinigen Healthcare Limited ("Agreement") in which the Company will return the exclusive rights to commercialize Ethyol and Totect in the United States to Clinigen. The Agreement results in a transition from the Company's current arrangement with Clinigen effective September 30, 2019.  Under the terms of the agreement, Cumberland will no longer be involved directly or indirectly with the distribution, marketing and promotion of either Ethyol or Totect or any competing products.  In exchange for the return of these product license rights and not competing with either product, Cumberland will receive $<ix:nonFraction unitRef="usd" contextRef="i89124f6164c440dea6f61c2e5b7f5ef8_D20191001-20210930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RleHRyZWdpb246ZDQ4OWI1YThlY2E3NDBiOTkxNDMyY2E5ZTFkYjgwZjFfNjA0NzMxMzk1ODMwOA_7673d6d7-42e3-404b-b163-8f0276fc477c">5</ix:nonFraction>&#160;million in financial consideration paid over the two-years following September 30, 2019.</span></div></ix:continuation><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div id="i_0_73"></div><div style="margin-top:6pt;margin-bottom:6pt;-sec-extract:summary;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">14</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Disclosure regarding forward-looking statements</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following discussion contains certain forward-looking statements which reflect management&#8217;s current views of future events and operations. These statements involve certain risks and uncertainties, and actual results may differ materially from them. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We caution you that our actual results may differ significantly from the results we discuss in these forward-looking statements. Some important factors which may cause results to differ from expectations include: availability of additional debt and equity capital required to finance the business model; market conditions at the time additional capital is required; our ability to continue to acquire branded products; product sales; and management of our growth and integration of our acquisitions. While forward-looking statements reflect our beliefs and best judgment based upon current information, they are not guarantees of future performance. Other important factors that may cause actual results to differ materially from forward-looking statements are discussed in the sections entitled &#8220;Risk Factors&#8221; and &#8220;Special Note Regarding Forward-Looking Statements&#8221; of our Annual Report on Form 10-K for the year ended December&#160;31, 2018 (&#8220;2018 Annual Report on Form 10-K&#8221;).  We do not undertake to publicly update or revise any of our forward-looking statements, even in the event that experience or future changes indicate that the anticipated results will not be realized. The following presentation of management&#8217;s discussion and analysis of financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes included in this report on Form 10-Q.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">15</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div id="i_0_76"></div><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">OVERVIEW</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Our Business</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Cumberland Pharmaceuticals Inc. (&#8220;Cumberland,&#8221; the &#8220;Company,&#8221; or as used in the context of &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;), is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription products. Our primary target markets are hospital acute care and gastroenterology. These medical specialties are characterized by relatively concentrated prescriber bases that we believe can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve the quality of care for patients and address unmet or poorly met medical needs.  We promote our approved products through our hospital and field sales forces in the United States and are establishing a network of international partners to bring our medicines to patients in their countries.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Our portfolio of FDA approved brands includes:</span></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;">Acetadote</span><sup style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-weight:700;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">acetylcysteine</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">) Injection, for the treatment of acetaminophen poisoning; </span></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;">Caldolor</span><sup style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-weight:700;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">ibuprofen</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">) Injection, for the treatment of pain and fever;</span></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;">Kristalose</span><sup style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-weight:700;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">lactulose</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">) for Oral Solution, a prescription laxative, for the treatment of chronic and acute constipation;</span></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;">Omeclamox</span><sup style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-weight:700;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">-Pak</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">, (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">omeprazole, clarithromycin, and amoxicillin</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">) for the treatment of Helicobacter pylori (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">H. pylori</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">) infection and related duodenal ulcer disease;</span></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;">Vaprisol</span><sup style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-weight:700;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">conivaptan</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">) Injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia;</span></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;">Ethyol</span><sup style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-weight:700;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> (amifostine) </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Injection, for the reduction of xerostomia (dry mouth) in patients undergoing post-operative radiation treatment for head and neck cancer and the renal toxicity associated with the administration of cisplatin in patients with advanced ovarian cancer;</span></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;">Totect</span><sup style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-weight:700;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">(dexrazoxane hydrochloride) </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Injection, for emergency oncology intervention, to treat the toxic effects of anthracycline chemotherapy in case of extravasation (drug leakage from the bloodstream into the tissues); and</span></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;">Vibativ</span><sup style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-weight:700;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">telavancin</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">) Injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.</span></div><div style="padding-left:36pt;margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Our pipeline of product candidates includes:</span></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;">Hepatoren</span><sup style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-weight:700;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">ifetroban</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">) Injection, a Phase II candidate for the treatment of critically ill patients suffering from liver and kidney failure associated with hepatorenal syndrome ("HRS"); </span></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;">Boxaban</span><sup style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-weight:700;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">(ifetroban) </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Oral Capsules, a Phase II candidate for the treatment of asthma patients with aspirin-exacerbated respiratory disease ("AERD");</span></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;">Vasculan</span><sup style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-weight:700;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">(ifetroban) </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Oral Capsules, a Phase II candidate for the treatment of patients with the systemic sclerosis ("SSc") form of autoimmune disease;</span></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;">Portaban</span><sup style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-weight:700;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">(ifetroban) </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Injection and Oral Capsules, a Phase II candidate for the treatment of patients with portal hypertension associated with liver disease; and</span></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;">RediTrex</span><sup style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#8482;</sup><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">methotrexate</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">) Injection, an approval submission candidate for the treatment of active rheumatoid, juvenile idiopathic and severe psoriatic arthritis, as well as severe disabling psoriasis.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We have both product development and commercial capabilities and believe we can leverage our existing infrastructure to support our expected growth. Our management team consists of pharmaceutical industry veterans experienced in business development, product development, regulatory, manufacturing, sales, marketing, and finance. Our business development team identifies, evaluates, and negotiates product acquisition, licensing, and co-promotion opportunities. Our product development team creates proprietary product formulations, manages our clinical studies, prepares all regulatory submissions, and manages our medical call center. Our quality and manufacturing professionals oversee the manufacture, release, and shipment of our products. Our marketing and sales professionals are responsible for our commercial activities, and we work closely with our distribution partners to ensure availability and delivery of our products.</span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">16</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div style="text-align:justify;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Growth Strategy</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Our growth strategy involves maximizing the potential of our existing brands, while continuing to build a portfolio of differentiated products. We currently market eight FDA approved products for sale in the United States. Through our international partners, we are working to bring our products to patients in their countries. We also look for opportunities to expand our products into additional patient populations through clinical trials, new indications, and select investigator-initiated studies. We actively pursue opportunities to acquire additional marketed products, as well as late-stage development product candidates in our target medical specialties. Our clinical team is developing a pipeline of new product candidates to address poorly met medical needs. Further, we are supplementing these activities with the early stage drug development activities at Cumberland Emerging Technologies ("CET"), our majority-owned subsidiary. Specifically, we are seeking long term sustainable growth by executing the following plans:        </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Support and expand the use of our marketed products.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> We continue to evaluate our products following their FDA approval to determine if additional clinical data could expand their market and use.  We will continue to explore opportunities for label expansion to bring our products to new patient populations.  We have secured pediatric approval, expanding the labeling for both our Acetadote and Caldolor brands. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Selectively add complementary brands.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> In addition to our product development activities, we are also seeking to acquire products or late-stage development product candidates to continue to build a portfolio of complementary brands. We focus on under-promoted, FDA approved drugs, as well as late-stage development products that address poorly met medical needs. We will continue to target product acquisition candidates that are competitively differentiated, have valuable intellectual property or other protective features, and allow us to leverage our existing infrastructure. Our acquisition of Vibativ represents our largest product acquisition.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Progress clinical pipeline and incubate future product opportunities at CET.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> We believe it is important to build a pipeline of innovative new product opportunities. Our ifetroban Phase II development programs represent the implementation of this strategy. At CET, we are supplementing our acquisition and late-stage development activities with the early-stage drug development activities. CET partners with universities and other research organizations to develop promising, early-stage product candidates, which Cumberland has the opportunity to further develop and commercialize. We expanded our network of university collaborations with the addition of Louisiana State University and the Medical University of South Carolina.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Leverage our infrastructure through co-promotion partnerships.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> We believe that our commercial infrastructure can help drive prescription volume and product sales. We look for strategic co-promotion partners that can complement our capabilities and enhance the opportunity for our brands. Our co-promotion arrangements with Poly Pharmaceuticals, Inc. and Foxland Pharmaceuticals, Inc allow us to expand current promotional support for Kristalose across the United States.     </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Build an international contribution to our business.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> We have established our own commercial capabilities, including two sales divisions to address the U.S. market for our products. We are also building a network of select international partners to register our products and make them available to patients in their countries. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We will continue to develop and expand our network of international partners while supporting our partners&#8217; registration and commercialization efforts in their respective territories. The acquisition of Vibativ resulted in several new international partners and market opportunities.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Manage our operations with financial discipline.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> We continually work to manage our expenses in line with our revenues in order to deliver positive cash flow from operations. We remain in a strong financial position, with favorable gross margins, and a strong balance sheet. We continue to use cash flow from operations for our ongoing share repurchase program. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We were incorporated in 1999 and have been headquartered in Nashville, Tennessee since inception. During 2009, we completed an initial public offering of our common shares and listing on the Nasdaq stock exchange. Our website address is www.cumberlandpharma.com. We make available through our website our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and all material press releases and other reports as soon as reasonably practicable after their filing with the U.S. Securities and Exchange Commission, (&#8220;SEC&#8221;). These filings are also available to the public at </span><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">www.sec.gov</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">17</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">RECENT DEVELOPMENTS</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Strategic Review Update</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Earlier this year, we announced a strategic review of our brands, capabilities, and international partners. This review followed our accelerated business development initiative, which resulted in a series of transactions. Because of that progress, we felt that it was prudent to take a fresh look at our product portfolio, partners, and organization to ensure we have the proper focus and capabilities. As a result: </span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">We executed a License and Distribution agreement with HongKong WinHealth Pharma Group Co. Limited (&#8220;WinHealth&#8221;) for our Caldolor and Acetadote</span><sup style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"> </sup><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">brands in China and Hong Kong.  We anticipate WinHealth will provide $2 million in milestone payments and up to an estimated $290 million in revenue contribution over a ten - year period for supplies of the products following their registration  in China.  In conjunction with these new arrangements, we terminated a previous License and Distribution agreement with Gloria Pharmaceuticals Co for the two brands.  </span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">We also entered into a Strategic Alliance agreement with WinHealth to explore future business opportunities that will further the mission and goals of each organization.  Founded in Hangzhou, China and currently headquartered in Hong Kong, WinHealth has developed a wide breadth of capabilities including drug licensing, product development and registration, and has established a strong network of distribution and sales promotional capabilities for the Chinese market. Further, WinHealth has established partnerships with international companies that include Boehringer-Ingelheim, Janssen, Novartis, Pfizer, and Roche, generating approximately $330 million in annual sales in 2018.</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">In addition, WinHealth entered into an agreement with CET to make a $1 million investment through the purchase of shares of CET stock. As part of that agreement, WinHealth obtained a Board position at CET and the first opportunity to license CET products for the Chinese market. Subsequently, the Investment agreement CET had with Gloria Pharmaceuticals Co. was terminated. </span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">We completed the assignment and amendment of a Commercialization Agreement with Hikma Pharmaceuticals LLC (&#8220;Hikma&#8221;) to register and distribute Vibativ in a number of countries throughout the Middle East. Hikma is a multinational pharmaceutical company currently headquartered in London, United Kingdom. Originally founded in Amman, Jordan the company now has market representation throughout the world, with a particular focus in the Middle East and North African regions. Hikma develops, manufactures, and markets a broad range of branded and non-branded generic medicines, generating over $2 billion in gross sales during 2018.</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">We also completed the assignment and amendment of a Commercialization Agreement with R-Pharma JSC (&#8220;R Pharma&#8221;) associated with ongoing distribution of Vibativ in Russia and a number of adjacent countries in Eastern Europe. R-Pharma is one of the leading multinational pharmaceutical organizations based in Russia. Headquartered in Moscow and focusing in a wide breadth of therapeutic areas in the specialty and hospital care markets, R-Pharma generated over $1.6 billion in revenues in 2018. </span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Cumberland also completed the assignment and amendment of a Commercialization Agreement with Dr. Reddy&#8217;s Laboratories Limited (&#8220;Dr. Reddy&#8217;s&#8221;) for the registration and distribution of Vibativ in India. Dr. Reddy's is a multinational pharmaceutical company based in Hyderabad, India. The company currently markets over 190 medications through their commercial operations in over 35 countries. Combined with their extensive network of manufacturing capabilities, Dr. Reddy&#8217;s generated over $2.2 billion in sales during their 2018 &#8211; 2019 fiscal year. </span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">In addition, we also signed a new License and Distribution agreement with DB Pharm Korea Co., Ltd. (&#8220;DB Pharm&#8221;) for Vibativ in South Korea. DB Pharm is also currently distributing our Caldolor product in that market.</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Meanwhile, we reached an agreement with Clinigen Healthcare Limited to return the U.S rights to their Ethyol and Totect brands at the end of the third quarter 2019, in exchange for $5 million in financial consideration paid over a two-year period.</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">As a result, our hospital product efforts will now be focused on our three key acute care products &#8211; Caldolor, Vibativ, and Vaprisol. In order to support this acute care business, we have completed the expansion of our hospital sales division, as well as our field-based medical science team.</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Lastly, we also concluded the License and Distribution agreement with Teligent Inc. for Caldolor in Canada.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">18</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Methotrexate</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In January 2019, the Company received notification from the U.S Food and Drug Administration (&#8220;FDA&#8221;) that the new drug application (&#8220;NDA&#8221;) for our new line of methotrexate products is complete and acceptable for filing. Furthermore, the FDA has set September 2019 as the Prescription Drug User Fee (&#8220;PDUFA&#8221;) action date for an approval decision.  </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In November 2018, we submitted the NDA for approval from the FDA. In conjunction with this submission, we remitted payment of $1.3 million to the FDA for the PDUFA Application Fee associated with this methotrexate product line application.  These products are designed to treat adult and pediatric patients with rheumatoid arthritis, as well as adults with psoriasis.  </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">During 2019, we provided additional data to the FDA to address a number of requests arising from their review of our NDA.  There is no assurance that the information provided in our response will be sufficient for the product line's approval. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Caldolor</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In February 2018, Cumberland completed and filed with the FDA an application for approval. The product features a new, patented formulation in a more convenient to use package. In April 2018, the FDA determined that the application was complete and notified us of their acceptance for review. In August 2018, we received a complete response from the FDA outlining additional quality and nonclinical data needed for the application&#8217;s approval. In September 2018, the Company submitted an amendment to our application containing additional quality and nonclinical data. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In January 2019, the FDA approved the application, and in April 2019, the Company began initial shipments of the product to select customers. A full launch of this next generation product is planned for late 2019.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In addition, we completed a submission to the FDA an application in support of an update to our Caldolor approval that included new geriatric, shortened infusion, pediatric, and safety data.  Aiming to further expand the product&#8217;s label, we provided important data generated from our clinical studies regarding an optimal infusion time, additional safety information, as well as geriatric and pediatric administration. The revised label will also include class label update on the use of NSAIDs with aspirin. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Meanwhile, we completed enrollment in our study of Caldolor in newborns with ages ranging from birth to six months of age. Once the data gathering and evaluation is complete, we will provide top line results from this trial. We also submitted a label update to the FDA for Caldolor. </span></div><div style="margin-top:6pt;margin-bottom:8pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Ifetroban</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:8pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We have been evaluating our ifetroban product candidate in a series of clinical studies. We have completed three pilot Phase II studies involving 1) patients suffering from hepatorenal syndrome, a life threatening condition involving liver and kidney failure, 2) patients with portal hypertension associated with chronic liver disease and 3) patients suffering from aspirin-exacerbated respiratory disease, a severe form of asthma. A follow-up Phase II study is currently underway for this asthma indication. In addition, we are currently evaluating ifetroban in pilot Phase II study of patients with  systemic sclerosis or scleroderma, a debilitating autoimmune disorder characterized by diffuse fibrosis of the skin and internal organs. Additional pilot studies of ifetroban are underway including several investigator initiated trials. We are awaiting further study results before deciding on the best path for approval for ifetroban, our first new chemical entity.</span></div><div id="i_0_79"></div><div style="margin-top:8pt;margin-bottom:6pt;"><span><br/></span></div><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">CRITICAL ACCOUNTING POLICIES AND SIGNIFICANT JUDGMENTS AND ESTIMATES</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Please see a discussion of our critical accounting policies and significant judgments and estimates in Note 1 to the Company's Condensed Consolidated Financial Statements accompanying this report and the section entitled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our 2018 Annual Report on Form 10-K.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Accounting Estimates and Judgments</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The preparation of condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. We base our estimates on past experience and on other factors we deem reasonable given the circumstances. Past results help form the basis of our judgments about the carrying value of assets and liabilities that cannot be determined from other sources. Actual results could differ from these estimates. These estimates, judgments and assumptions are most critical with respect to our accounting for revenue recognition, fair value of marketable securities, inventories, provision for income taxes, share-based compensation, research and development expenses and intangible assets.</span></div><div id="i_0_82"></div><div style="margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">19</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div style="margin-top:6pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Three months ended June 30, 2019 compared to the three months ended June 30, 2018 </span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table presents the unaudited interim statements of operations for the three months ended June 30, 2019 and 2018:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:47.707602%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.643275%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.228070%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.228070%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="18" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net revenues</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11,580,600&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">10,163,724&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,416,876&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Costs and expenses:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of products sold</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,012,196&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,523,319&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">488,877&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Selling and marketing</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,153,129&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,076,250&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">76,879&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,458,366&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,450,390&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">7,976&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,528,916&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,334,223&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">194,693&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,029,708&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">648,520&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">381,188&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total costs and expenses</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">12,182,315&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11,032,702&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,149,613&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Operating income (loss)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(601,715)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(868,978)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">267,263&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Interest income</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">130,565&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">149,706&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(19,141)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(91,200)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(22,019)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(69,181)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Income (loss) before income taxes</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(562,350)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(741,291)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">178,941&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax (expense) benefit</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(4,462)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(4,159)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(303)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(566,812)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(745,450)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">178,638&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes net revenues by product for the periods presented: </span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"><tr><td style="width:1.0%;"></td><td style="width:47.780381%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.251830%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532064%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.251830%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532064%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.251830%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Products:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:13pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Acetadote</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">983,473&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">841,431&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">142,042&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:13pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Omeclamox-Pak</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">478,604&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">89,952&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">388,652&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:13pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Kristalose</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,476,807&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,203,743&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">273,064&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:13pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Vaprisol</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">212,526&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,685,900&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,473,374)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:13pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Caldolor</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,054,718&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,101,023&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(46,305)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:13pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Ethyol</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,008,247&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,809,691&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(801,444)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:13pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Totect</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">154,910&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">269,190&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(114,280)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:13pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Vibativ</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,599,280&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,599,280&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:13pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">612,035&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">162,794&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">449,241&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total net revenues</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11,580,600&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">10,163,724&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,416,876&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Net revenues.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> Net revenues for the three months ended June 30, 2019 were $11.6 million, an increase of 14% over the $10.2 million for the three months ended June 30, 2018.  The increase was due primarily to our newest product, Vibativ, which delivered $2.6 million in net revenue.  As detailed in the table above, net revenue increased for three of our marketed products: Acetadote, Omeclamox-Pak and Kristalose during the quarter. These increases were partially offset by the decreases in Ethyol and Vaprisol net revenue.   </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Kristalose revenue increased by $0.3 million or 9% during the second quarter of 2019 when compared to the prior year period.  The product's net revenue was positively impacted by an improvement in sales volumes and net pricing. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Omeclamox-Pak revenue increased $0.4 million or 432% for the second quarter of 2019 compared to the second quarter of 2018 primarily due to an increase in sales volumes and improved net pricing during the period.  This improvement in net pricing included a decrease in expired product returns in the current period.   </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">20</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Acetadote revenue includes net sales of our Acetadote brand and our share of net sales from our Authorized Generic. During the quarter, there was a 17% increase in the product's revenue when compared to the prior year period as a result of improved sales volumes. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Caldolor revenue was $1.1&#160;million for both the second quarter of 2019 and the second quarter of 2018.  While there were higher domestic shipments of the product and improved net pricing, these changes were offset by a reduction in international shipments of Caldolor when compared to the prior year period.  </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Vaprisol revenue decreased $1.5 million during the second quarter of 2019 when compared to the prior year period due to lower sales volumes.  The prior year period sales were higher as a result of the arrival of a new lot of the product during April 2018 resolving temporary supply issues associated with product.  </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Ethyol revenue decreased by $0.8 million for the three months ended June 30, 2019 compared to three months ended June 30, 2018 primarily as a result of lower sales volume, partially offset by improved net pricing.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Other revenue during the three months ended June 30, 2019 includes $0.3 million in revenue related to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">non-refundable up-front payments associated with two new agreements with International partners.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Cost of products sold</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Co</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">st of products sold for the second quarter of 2019 increased $0.5 million compared to the prior year period as a result of increased sales. Cost of products sold, as a percentage of net revenues, were 17.4% during the three months ended June 30, 2019 compared to 15.0% during the three months ended June 30, 2018.  This change in costs of products sold as a percentage of revenue was attributable to a change in the product sales mix, including the sales of Vibativ.  </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Selling and marketing</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">. Selling and marketing expense for the second quarter of 2019 increased $0.1 million compared to the prior year period.  This increase is primarily attributable to higher royalties related to the increased product sales during the second quarter of 2019. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Research and development</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">. Research and development costs were $1.5 million for the second quarter of 2019 and for the same period last year.  A portion of our research and development costs is variable based on the number of trials, study sites, cost of the per patient study protocol and patients involved in the development of our new product candidates. We continue to fund our ongoing clinical initiatives associated with our pipeline products.  </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">General and administrative</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">.  General and administrative expense for the second quarter of 2019 increased to $2.5 million from  $2.3 million during the second quarter of 2018 as a result of increases in advisory, legal and professional fees during the period.  A portion of these increased costs were related to our acquisition of Vibativ. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Amortization.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> Amortization expense is the ratable use of our capitalized intangible assets including product and license rights, patents, trademarks and patent defense costs.  Amortization for the three months ended June 30, 2019 and the three months ended June 30, 2018  totaled approximately $1.0 million and $0.6 million, respectively.  This increase was driven primarily by the amortization of the intangible assets acquired in the Vibativ transaction.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Income taxes</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">. Income tax expense for the three months ended June 30, 2019 as a percentage of income (loss) before income taxes was 0.8% for the three months ended June 30, 2019 compared to 0.6% for the three months ended June 30, 2018.  </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">As of June 30, 2019, we had approximately $44 million of net operating loss carryforwards resulting from the exercise of nonqualified stock options that have historically been used to significantly offset income tax obligations.  We expect to continue to pay minimal income taxes during 2019 and beyond, through the continued utilization of these net operating loss carryforwards, on any taxable income generated from our operations. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">21</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div id="i_0_85"></div><div style="margin-top:6pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Six months ended June 30, 2019 compared to the six months ended June 30, 2018 </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table presents the unaudited interim statements of operations for the six months ended June 30, 2019 and 2018:</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.122807%;"><tr><td style="width:1.0%;"></td><td style="width:47.557522%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.634218%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537463%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.076696%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537463%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.519174%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537463%;"></td><td style="width:0.1%;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="18" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net revenues</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">23,483,347&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">18,751,329&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4,732,018&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Costs and expenses:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of products sold</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4,011,932&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,051,280&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">960,652&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Selling and marketing</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">10,273,634&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">9,746,761&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">526,873&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,725,967&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,325,329&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(599,362)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,198,972&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4,664,504&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">534,468&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,051,353&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,284,655&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">766,698&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total costs and expenses</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">24,261,858&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">22,072,529&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,189,329&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Operating income (loss)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(778,511)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(3,321,200)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,542,689&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Interest income</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">246,426&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">232,200&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">14,226&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(152,111)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(40,321)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(111,790)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Income (loss) before income taxes</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(684,196)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(3,129,321)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,445,125&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax (expense) benefit</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">76,966&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(8,318)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">85,284&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(607,230)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(3,137,639)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,530,409&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes net revenues by product for the periods presented: </span></div><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:95.906433%;"><tr><td style="width:1.0%;"></td><td style="width:48.000000%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.158537%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.562195%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.158537%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.562195%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.158537%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Products:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Acetadote</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,832,976&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,115,741&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(282,765)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Omeclamox-Pak</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">678,141&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">231,344&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">446,797&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Kristalose</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6,785,050&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6,473,097&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">311,953&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Vaprisol</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">499,202&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,779,790&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,280,588)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Caldolor</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,372,599&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,140,771&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">231,828&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Ethyol</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,099,429&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,065,764&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">33,665&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Totect</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">235,805&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">681,964&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(446,159)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Vibativ</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4,659,471&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4,659,471&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,320,674&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">262,858&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,057,816&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total net revenues</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">23,483,347&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">18,751,329&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4,732,018&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Net revenues.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> Net revenues for the six months ended June 30, 2019 were $23.5 million, an increase of $4.7 million, or 25% compared to $18.7 million for the six months ended June 30, 2018.  The increase was due primarily to our newest product, Vibativ, which delivered $4.7&#160;million in net revenue.  As detailed in the table above, net revenue increased for four of our marketed products: Caldolor, Ethyol, Omeclamox-Pak and Kristalose during the six months ended June 30, 2019.  These increases were partially offset by the decreases to Totect, Acetadote and Vaprisol net revenue.  </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Kristalose revenue increased by 5% or $0.3 million during the six months ended June 30, 2019. The product's net revenue was positively impacted by an improvement in sales volumes and net pricing.   </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Caldolor revenue experienced an increase of $0.2 million during the six months ended June 30, 2019 compared to the same period last year.  This 11% increase in revenue in the six months ended June 30, 2019 compared to the prior year period was the result of higher domestic shipments of the product and improved net pricing, these changes were offset by a reduction in international shipments of Caldolor when compared to the prior year period. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">22</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Omeclamox-Pak revenue increased $0.4 million during the six months ended June 30, 2019 compared to the prior year, primarily due to an increase in sales volumes and improved net pricing during the period.  This improvement in net pricing included a decrease in expired product returns in the current period.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Ethyol revenue was $5.1 million for the six months ended June 30, 2019 and the six months ended June 30, 2018. The product experienced a decrease in sales volumes but an improvement in net pricing. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Acetadote revenue includes net sales of our Acetadote brand and our share of net sales from our Authorized Generic. During the six months ended June 30, 2019 the Acetadote net revenue decreased $0.3 million as a result of lower sales volumes and a decrease in net pricing.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Vaprisol revenue decreased $1.3 million during the six months ended June 30, 2019 compared to the prior year period primarily due to decreased sales volume. The prior year period sales were higher as a result of the arrival of a new lot of the product during April 2018 resolving temporary supply issues associated with the product.    </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Totect revenue decreased to $0.2&#160;million during the six months ended June 30, 2019. We began shipments of Totect during a national shortage of dexrazoxane, resulting in strong initial demand for the product.  Following our launch, supplies of dexrazoxane became available from competing suppliers, all with labeling for the cardiac indication. Totect is the only dexrazoxane available in the U.S. FDA approved for the extravasation indication.  </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Other revenue during the six months ended June 30, 2019 includes $0.3 million in revenue related to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">non-refundable up-front payments associated with two new agreements with International partners as well as $0.8 million in CET grant revenue.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Cost of products sold</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">.  Cost of products sold for the six months ended June 30, 2019 and six months ended June 30, 2018 were $4.0 million and $3.1 million, respectively.  Cost of products sold, as a percentage of net revenues were 17.1% compared to 16.3% during the prior year.  This change in costs of products sold as a percentage of revenue was attributable to a change in the product sales mix, including the sales of Vibativ.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Selling and marketing</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">.  Selling and marketing expenses for the six months ended June 30, 2019 were $10.3 million, compared to $9.7 million for the prior year period, representing an increase of approximately $0.5 million or 5%  This increase was primarily attributable to increased royalties related to product sales.  There were also increases in sales and promotional spending during the six months ended June 30, 2019 to promote Vibativ, our newest brand.    </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Research and development</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">.  Research and development costs for the six months ended June 30, 2019 were $2.7 million, compared to $3.3 million for the same period last year, representing a decrease of approximately $0.6 million. A portion of our research and development costs is variable based on the number of trials, study sites and patients involved in the development of our product candidates. The decrease was primarily the result of lower expenditures in our ongoing clinical initiatives associated with our pipeline products as well as decreases in our FDA fees.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">General and administrative</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">.  General and administrative expenses were $5.2 million for the six months ended June 30, 2019, compared to $4.7 million during the same period last year.  The $0.5 million increase from the prior year was primarily driven by an increase in compensation and benefits, including non-cash stock based compensation.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Amortization.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">  Amortization expense is the ratable use of our capitalized intangible assets including product and license rights, patents, trademarks and patent defense costs.  Amortization for the six months ended June 30, 2019 totaled approximately $2.1 million, which was an increase of $0.8 million over the prior year. The increase in expense was attributable to the amortization of additional product rights and capitalized patents, including those assets associated with the Vibativ acquisition.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Income taxes</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">.  Income tax benefit for the six months ended June 30, 2019 as a percentage of income (loss) before income taxes was 11.2%.  This is compared to income tax expense as a percentage of loss before income taxes of 0.3% for the six months ended June 30, 2018. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">23</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div id="i_0_88"></div><div style="margin-top:6pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Working Capital</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Our primary sources of liquidity are cash flows provided by our operations, the amounts borrowed and available under our line of credit and the cash proceeds from our initial public offering of common stock that was completed in August 2009. We believe that our internally generated cash flows, existing working capital and our line of credit, including its recent expansion to $20 million, will be adequate to finance internal growth, finance business development initiatives, and fund capital expenditures for the foreseeable future. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We invest a portion of our cash reserves in marketable securities including short-term cash investments, U.S. Treasury notes and bonds, corporate bonds and commercial paper.  At June 30, 2019 and December 31, 2018, we had approximately $9.5 million and $8.3 million, respectively, invested in marketable securities.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes our liquidity and working capital as of June 30, 2019 and December 31, 2018:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"><tr><td style="width:1.0%;"></td><td style="width:57.852941%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.558824%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.829412%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.558824%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td></tr><tr><td colspan="3" style="height:7pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:7pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:7pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:7pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">20,951,180&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">27,938,960&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">9,479,686&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">8,290,679&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash, cash equivalents and marketable securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">30,430,866&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">36,229,639&#160;</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Working capital (current assets less current liabilities)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">29,615,228&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">31,311,813&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Current ratio (multiple of current assets to current liabilities)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2.3&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2.1&#160;</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Revolving line of credit availability</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr></table></div><div style="margin-top:11pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes our net changes in cash and cash equivalents for the six months ended June 30, 2019 and June 30, 2018:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"><tr><td style="width:1.0%;"></td><td style="width:57.852941%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.558824%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.829412%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.558824%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Operating activities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,464,926&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,029,675&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Investing activities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(6,547,278)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(10,737,490)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Financing activities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(1,905,428)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">201,602&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net increase (decrease) in cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(6,987,780)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(9,506,213)</span></td></tr></table></div><div style="text-align:justify;margin-top:11pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The net $7.0 million decrease in cash and cash equivalents for the six months ended June 30, 2019 was attributable to cash used in investing and financing activities, partially offset by the $1.5&#160;million in cash provided by operating activities.  Cash provided by operating activities of $1.5 million was positively impacted by the decrease in inventory of $1.4&#160;million as well as the add back of non-cash expenses of depreciation, amortization and share-based compensation expense totaling $2.9 million.  Cash used in investing activities included the $5.0&#160;million payment to Theravance as part of the acquisition of Vibativ. Cash used in investing activities also included net cash invested in marketable securities of $1.1 million and additions to intangibles of $0.4 million.  Our financing activities reflected the $1.2 million in cash used to repurchase shares of our common stock. </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The net $9.5 million decrease in cash and cash equivalents for the six months ended June&#160;30, 2018 was attributable to cash used in investing activities partially offset by cash provided by financing and operating activities.  Cash provided by operating activities of $1.0 million was primarily impacted by changes in our working capital which provided net cash of $2.2 million, including net collections of accounts receivable of $2.6 million and non-cash expenses of depreciation and amortization and share-based compensation expense totaling $2.1 million. The generation of operating cash was offset by a net loss for the period of $3.1 million. Cash used in investing activities included net cash invested in marketable securities of $10.0 million and additions to intangibles of $0.6 million.  Our financing activities included $2.2 million in net cash provided by borrowings under our line of credit offset by $2.0 million in cash used to repurchase shares of our common stock. </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">24</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Debt Agreement</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On May 10, 2019, we entered into a third amendment ("Third Amendment") to the Revolving Credit Loan Agreement, dated July 28, 2017, with Pinnacle Bank (&#8220;Pinnacle Agreement&#8221;). The Third Amendment extended the term of the Pinnacle Agreement through July 31, 2021 as well as modified certain definitions and terms of the existing financial covenants.  On October 17, 2018, we entered into a second amendment (&#8220;Second Amendment&#8221;) which increased the maximum aggregate principal available for borrowing under the Pinnacle Agreement to $20.0 million.  For a summary of the material terms of the Pinnacle Agreement, as amended, see Note 7 to the accompanying unaudited condensed consolidated financial statements</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Under the Pinnacle Agreement, we were initially subject to one financial covenant, the maintenance of a Funded Debt Ratio. On August 14, 2018 we amended the Pinnacle Agreement ("First Amendment") to replace the single financial covenant with the maintenance of either the Funded Debt Ratio or a Tangible Capital Ratio, as defined in the First Amendment.  The Third Amendment modified the definition of the Funded Debt Ratio and the compliance target of the Tangible Capital Ratio. Both Third Amendment modifications were related to the Vibativ transaction.  We were in compliance with the Tangible Capital Ratio financial covenant as of June 30, 2019 and expect to maintain compliance with this covenant in future periods. </span></div><div id="i_0_91"></div><div style="margin-top:12pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">OFF-BALANCE SHEET ARRANGEMENTS</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">During the six months ended June 30, 2019 and 2018, we did not engage in any off-balance sheet arrangements.</span></div><div id="i_0_94"></div><div style="margin-top:6pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Item&#160;3. Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Interest Rate Risk</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We are exposed to market risk related to changes in interest rates on our cash on deposit in highly-liquid money market accounts and our revolving credit facility. We do not utilize derivative financial instruments or other market risk-sensitive instruments to manage exposure to interest rate changes. The main objective of our cash investment activities is to preserve principal while maximizing interest income through low-risk investments. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We believe that our interest rate risk related to our cash and cash equivalents is not material. The risk related to interest rates for these accounts would produce less income than expected if market interest rates fall. Based on current interest rates, we do not believe we are exposed to significant downside risk related to a change in interest on our money market accounts. Based on the $9.5 million in marketable securities outstanding at June 30, 2019, a 1% decrease in the fair value of the securities would result in a reduction in pretax net income (loss) of $0.1 million.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Based on current interest rates, we do not believe we are exposed to significant downside risk related to change in interest on our investment accounts.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The interest rate risk related to borrowings under our line of credit is based on LIBOR plus an interest rate spread.  There is no LIBOR minimum and the LIBOR pricing provides for an interest rate spread of 1.75% to 2.75% (representing an interest rate of 5.15% at June 30, 2019). As of June 30, 2019, we had $20 million in borrowings outstanding under our revolving credit facility. </span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Exchange Rate Risk</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">While we operate primarily in the United States, we are exposed to foreign currency risk.  Currently, we do not utilize financial instruments to hedge exposure to foreign currency fluctuations.  We believe our exposure to foreign currency fluctuation is minimal as our purchases in foreign currency have a maximum exposure of 90 days based on invoice terms with a portion of the exposure being limited to 30 days based on the due date of the invoice.  Foreign currency exchange gains and losses were immaterial for the six months ended June 30, 2019 and 2018.  Neither a five percent increase nor decrease from current exchange rates would have a material effect on our operating results or financial condition.</span></div><div id="i_0_97"></div><div style="margin-top:6pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Item&#160;4. Controls and Procedures</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15-15(e) of the Exchange Act, as of June 30, 2019. Based on that evaluation, our CEO and CFO concluded that, as of June 30, 2019, our disclosure controls and procedures are considered effective to ensure that the information required to be disclosed by the Company in reports filed under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and that such information is accumulated and communicated to the Company's management, including the Company's CEO and CFO, as appropriate, to allow for timely decisions regarding required disclosure.  </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">During the three months ended June 30, 2019, there has not been any change in our internal control over financial reporting that has materially affected, or is likely to materially affect, our internal control over financial reporting. </span></div><div id="i_0_100"></div><div style="text-align:center;-sec-extract:summary;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">25</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">PART II &#8211; OTHER INFORMATION</span></div><div id="i_0_103"></div><div style="margin-top:14pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Item&#160;1. Legal Proceedings</span></div><div style="text-align:justify;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div id="i_0_106"></div><div style="margin-top:12pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Item&#160;1A. Risk Factors</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">There have been no material changes to the information regarding risk factors that appears in the 2018 Annual Report on Form 10-K under the section titled "Risk Factors." </span></div><div id="i_0_109"></div><div style="margin-top:12pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Purchases of Equity Securities</span></div><div style="text-align:justify;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We currently have a share repurchase program to purchase up to $10 million of our common stock pursuant to Rule 10b-18 of the Exchange Act. In January 2019, our Board of Directors established the current $10 million repurchase program to replace the prior authorizations for repurchases of our outstanding common stock.  </span></div><div style="margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the activity, by month, during the three months ended June 30, 2019:</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:17.444444%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.444444%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.654971%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:15.105263%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.444444%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.444444%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Period</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">Total</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">Number&#160;of</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">Shares (or</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">Units)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">Purchased (1)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">Price&#160;Paid</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">per&#160;Share</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">(or Unit)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">Total&#160;Number&#160;of</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">Shares (or Units)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">Purchased&#160;as&#160;Part</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">of Publicly</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">Announced Plans</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">or Programs</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">Maximum&#160;Number</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">(or Approximate</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">Dollar Value) of</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">Shares&#160;(or&#160;Units)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">that May Yet Be</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">Purchased&#160;Under</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">the Plans or</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:8pt;font-weight:700;line-height:100%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Programs </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;">(1)</sup></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">April</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">7,129&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6.10&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">7,129&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">9,378,593&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">May</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">26,303&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6.42&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">26,303&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">9,209,770&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">June</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">50,792&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6.29&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">50,792&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">8,890,319&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">84,224&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">84,224&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-indent:-18pt;padding-left:18pt;margin-top:6pt;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">(1) Of this amount, 3,125 shares were repurchased directly through private purchases at the then-current fair market value of common stock.</span></div><div id="i_0_115"></div><div style="margin-top:12pt;"><span><br/></span></div><div style="margin-top:12pt;"><span><br/></span></div><div style="margin-top:12pt;"><span><br/></span></div><div style="margin-top:12pt;"><span><br/></span></div><div style="margin-top:12pt;"><span><br/></span></div><div style="margin-top:12pt;"><span><br/></span></div><div style="margin-top:12pt;"><span><br/></span></div><div style="margin-top:12pt;"><span><br/></span></div><div style="margin-top:12pt;"><span><br/></span></div><div style="margin-top:12pt;"><span><br/></span></div><div style="margin-top:12pt;"><span><br/></span></div><div style="margin-top:12pt;"><span><br/></span></div><div style="margin-top:12pt;"><span><br/></span></div><div style="margin-top:12pt;-sec-extract:summary;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">26</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Item&#160;6. Exhibits</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"><tr><td style="width:1.0%;"></td><td style="width:8.000000%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.970588%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:84.029412%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">No.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Description</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">10.1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1087294/000162828018012707/revolveragreementexpansion.htm">First Amendment to Revolving Credit Note and Second Amendment to Revolving Credit Loan Agreement, dated as of October 17, 2018, by and between Cumberland Pharmaceuticals Inc. and Pinnacle Bank, incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K (File No. 001-33637) as filed with the SEC on October 19, 2018.</a></span></div></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">10.2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1087294/000162828019006841/cpixq12019-exhibit102.htm">Second Amendment to Revolving Credit Note and Third Amendment to Revolving Credit Loan Agreement, dated as of May 10, 2019 by and between Cumberland Pharmaceuticals Inc. and Pinnacle </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1087294/000162828019006841/cpixq12019-exhibit102.htm">Bank, incorporated herein by refer</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1087294/000162828019006841/cpixq12019-exhibit102.htm">ence to Exhibit 10</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1087294/000162828019006841/cpixq12019-exhibit102.htm">.2 to the Company's Current R</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1087294/000162828019006841/cpixq12019-exhibit102.htm">eport on F</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1087294/000162828019006841/cpixq12019-exhibit102.htm">orm </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1087294/000162828019006841/cpixq12019-exhibit102.htm">10-Q</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1087294/000162828019006841/cpixq12019-exhibit102.htm"> (File</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1087294/000162828019006841/cpixq12019-exhibit102.htm"> No. 001-33637) as filed with the SEC on May 1</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1087294/000162828019006841/cpixq12019-exhibit102.htm">5</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1087294/000162828019006841/cpixq12019-exhibit102.htm">, 2019.</a></span></div></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">31.1*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="a2019q2-exhibit311.htm">Certification of Chief Executive Officer Pursuant to Rule 13-14(a) of the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">31.2*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="a2019q2-exhibit312.htm">Certification of Chief Financial Officer Pursuant to Rule 13-14(a) of the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">32.1**</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="a2019q2-exhibit321.htm">Certification of Chief Executive and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">101.INS*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL INSTANCE DOCUMENT - THE INSTANCE DOCUMENT DOES NOT APPEAR IN THE INTERACTIVE DATA FILE BECAUSE ITS XBRL TAGS ARE EMBEDDED WITHIN THE INLINE XBRL DOCUMENT.</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">101.SCH*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">101.CAL*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">101.DEF*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">101.LAB*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">101.PRE*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Filed herewith.</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">**</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Furnished herewith.</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;"><span><br/></span></div><div id="i_0_118"></div><div style="text-align:center;-sec-extract:summary;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">27</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">SIGNATURES</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.099415%;"><tr><td style="width:1.0%;"></td><td style="width:7.388972%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:24.080477%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.184501%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:2.769001%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.307004%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.172876%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:2.184501%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:34.512668%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cumberland Pharmaceuticals Inc.</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="6" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="6" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Date:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">August 14, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">By:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Michael Bonner</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Michael Bonner</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Financial Officer</span></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">28</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>a2019q2-exhibit311.htm
<DESCRIPTION>EXHIBIT-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2019 Workiva -->
<title>Document</title></head><body><div id="i_0_1"></div><div style="height:45pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Exhibit 31.1</font></div><div style="text-align:center;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">PURSUANT TO SECTION&#160;302 OF</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">I, A.J. Kazimi, certify that&#58;</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:3.865103%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.134897%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">I have reviewed this Form 10-Q of Cumberland Pharmaceuticals Inc.&#59;</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:3.865103%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.134897%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:3.865103%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.134897%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:3.865103%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.134897%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div></td></tr></table></div><div style="text-indent:-18pt;padding-left:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-18pt;padding-left:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:-18pt;padding-left:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">c.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:-18pt;padding-left:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">d.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:3.865103%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.134897%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div></td></tr></table></div><div style="text-indent:-18pt;padding-left:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:-18pt;padding-left:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="padding-left:30pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"></td><td style="width:49.395007%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.698972%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:2.443172%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:39.262849%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">August 14, 2019</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; A.J. Kazimi</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">A.J. Kazimi</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Executive Officer</font></td></tr></table></div><div><font><br></font></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>a2019q2-exhibit312.htm
<DESCRIPTION>EXHIBIT-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2019 Workiva -->
<title>Document</title></head><body><div id="i_0_1"></div><div style="height:45pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Exhibit 31.2</font></div><div style="text-align:center;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">PURSUANT TO SECTION&#160;302 OF</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">I, Michael Bonner, certify that&#58;</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:3.865103%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.134897%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">I have reviewed this Form 10-Q of Cumberland Pharmaceuticals Inc.&#59;</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:3.865103%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.134897%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:3.865103%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.134897%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:3.865103%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.134897%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div></td></tr></table></div><div style="text-indent:-18pt;padding-left:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-18pt;padding-left:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:-18pt;padding-left:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">c.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:-18pt;padding-left:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">d.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:3.865103%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.134897%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div></td></tr></table></div><div style="text-indent:-18pt;padding-left:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:-18pt;padding-left:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="padding-left:30pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"></td><td style="width:49.835536%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.258443%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:2.443172%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:39.262849%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">August 14, 2019</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Michael Bonner</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Michael Bonner</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>a2019q2-exhibit321.htm
<DESCRIPTION>EXHIBIT-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2019 Workiva -->
<title>Document</title></head><body><div id="i_0_1"></div><div style="height:45pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Exhibit 32.1</font></div><div style="text-align:center;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION OF CHIEF EXECUTIVE AND</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">PURSUANT TO 18 U.S.C. SECTION&#160;1350,</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">AS ADOPTED PURSUANT TO SECTION&#160;906</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In connection with the Quarterly Report on Form&#160;10-Q for the fiscal quarter ended June 30, 2019 of Cumberland Pharmaceuticals Inc. (the &#8220;Company&#8221;), as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, A.J. Kazimi, Chief Executive Officer and Michael Bonner, Chief Financial Officer of the Company, certify, pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. section 1350), that&#58;</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:3.865103%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.134897%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934&#59; and</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:3.865103%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.134897%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></td></tr></table></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:right;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:38.888889%;"><tr><td style="width:1.0%;"></td><td style="width:98.000000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; A. J. Kazimi</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">A.J. Kazimi</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">August 14, 2019</font></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Michael Bonner</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Michael Bonner</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">August 14, 2019</font></td></tr></table></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:right;"><font><br></font></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>cpix-20190630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2017 Workiva-->
<!--r:fe2e4db3-48f2-4e84-a542-8dc9a0c345cd,g:b764091f-bd8f-4ce0-9900-bde14803e897-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:cpix="http://www.cumberlandpharma.com/20190630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:link="http://www.xbrl.org/2003/linkbase" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.cumberlandpharma.com/20190630">
  <xs:import namespace="http://fasb.org/srt/2018-01-31" schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xs:element id="cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital" abstract="false" name="SubsidiaryInvestmentPaymentsForReturnOfCapital" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_LeaseAsset" abstract="false" name="LeaseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_SubsidiaryInvestmentCashContribution" abstract="false" name="SubsidiaryInvestmentCashContribution" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_OtherProductsMember" abstract="true" name="OtherProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_KristaloseMember" abstract="true" name="KristaloseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" abstract="false" name="LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable" abstract="false" name="SubsidiaryInvestmentConversionOfIntercompanyLoansPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_IncreaseDecreaseInCurrentOperatingLiabilities" abstract="false" name="IncreaseDecreaseInCurrentOperatingLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_SecondAmendmentMember" abstract="true" name="SecondAmendmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_OmeclamoxPakMember" abstract="true" name="OmeclamoxPakMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_GloriaPharmaceuticalsMember" abstract="true" name="GloriaPharmaceuticalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_TieredRoyaltyPaymentsPercentage" abstract="false" name="TieredRoyaltyPaymentsPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="cpix_EquityAndDebtAbstract" abstract="true" name="EquityAndDebtAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_PaymentsForAssetAcquisitions" abstract="false" name="PaymentsForAssetAcquisitions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_VaprisolMember" abstract="true" name="VaprisolMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_ProductsAbstract" abstract="true" name="ProductsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_PinnacleBankMember" abstract="true" name="PinnacleBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_VIBATIVMember" abstract="true" name="VIBATIVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_CaldolorMember" abstract="true" name="CaldolorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_NumeratorAbstract" abstract="true" name="NumeratorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_AcetadoteMember" abstract="true" name="AcetadoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cpix_UsTreasuryNotesAndBondsSecuritiesMemberMember" abstract="true" name="UsTreasuryNotesAndBondsSecuritiesMemberMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment" abstract="false" name="BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="cpix_ShareholdersEquityTextualAbstract" abstract="true" name="ShareholdersEquityTextualAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_SaleOfStockNumberOfSharesSold" abstract="false" name="SaleOfStockNumberOfSharesSold" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_ClinigenHealthcareLimitedMember" abstract="true" name="ClinigenHealthcareLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_PaymentsForContingentConsideration" abstract="false" name="PaymentsForContingentConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_HongKongWinHealthPharmaGroupCoLimitedMember" abstract="true" name="HongKongWinHealthPharmaGroupCoLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_EthyolMember" abstract="true" name="EthyolMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_OtherLongTermObligationsExcludingCurrentPortion" abstract="false" name="OtherLongTermObligationsExcludingCurrentPortion" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_SubsidiaryInvestmentPurchaseOfShares" abstract="false" name="SubsidiaryInvestmentPurchaseOfShares" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_DenominatorAbstract" abstract="true" name="DenominatorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" abstract="false" name="StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_TotectMember" abstract="true" name="TotectMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember" abstract="true" name="HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" abstract="false" name="BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_LeaseLiability" abstract="false" name="LeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20190630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20190630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20190630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20190630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.cumberlandpharma.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementofEquity" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity">
        <link:definition>1005006 - Statement - Condensed Consolidated Statement of Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentation" roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation">
        <link:definition>2101101 - Disclosure - Organization and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentationPolicies" roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies">
        <link:definition>2202201 - Disclosure - Organization and Basis of Presentation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentationOrganizationDetails" roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails">
        <link:definition>2403401 - Disclosure - Organization and Basis of Presentation Organization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecurities" roleURI="http://www.cumberlandpharma.com/role/MarketableSecurities">
        <link:definition>2104102 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesTables" roleURI="http://www.cumberlandpharma.com/role/MarketableSecuritiesTables">
        <link:definition>2305301 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesDetails" roleURI="http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails">
        <link:definition>2406402 - Disclosure - Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShare" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShare">
        <link:definition>2107103 - Disclosure - Earnings (Loss) Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShareTables" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables">
        <link:definition>2308302 - Disclosure - Earnings (Loss) Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShareDetails" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails">
        <link:definition>2409403 - Disclosure - Earnings (Loss) Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShareDetailsTextual" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual">
        <link:definition>2410404 - Disclosure - Earnings (Loss) Per Share (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.cumberlandpharma.com/role/Revenues">
        <link:definition>2111104 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.cumberlandpharma.com/role/RevenuesTables">
        <link:definition>2312303 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesDetails" roleURI="http://www.cumberlandpharma.com/role/RevenuesDetails">
        <link:definition>2413405 - Disclosure - Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.cumberlandpharma.com/role/Inventories">
        <link:definition>2114105 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.cumberlandpharma.com/role/InventoriesTables">
        <link:definition>2315304 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails">
        <link:definition>2416406 - Disclosure - Inventories (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesScheduleofInventoriesDetails" roleURI="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails">
        <link:definition>2417407 - Disclosure - Inventories (Schedule of Inventories) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.cumberlandpharma.com/role/Leases">
        <link:definition>2118106 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.cumberlandpharma.com/role/LeasesTables">
        <link:definition>2319305 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails">
        <link:definition>2420408 - Disclosure - Leases (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeasePositionDetails" roleURI="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails">
        <link:definition>2421409 - Disclosure - Leases (Lease Position) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails">
        <link:definition>2422410 - Disclosure - Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1" roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1">
        <link:definition>2422410 - Disclosure - Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityandDebt" roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt">
        <link:definition>2123107 - Disclosure - Shareholders' Equity and Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityandDebtShareholdersEquityDetails" roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails">
        <link:definition>2424411 - Disclosure - Shareholders' Equity and Debt (Shareholders' Equity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityandDebtDebtDetails" roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails">
        <link:definition>2425412 - Disclosure - Shareholders' Equity and Debt (Debt) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.cumberlandpharma.com/role/IncomeTaxes">
        <link:definition>2126108 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetailsTextual" roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual">
        <link:definition>2427413 - Disclosure - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAgreements" roleURI="http://www.cumberlandpharma.com/role/CollaborativeAgreements">
        <link:definition>2128109 - Disclosure - Collaborative Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentAdditionsandExpectedReturnofProductRights" roleURI="http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRights">
        <link:definition>2129110 - Disclosure - Recent Additions and Expected Return of Product Rights</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentAdditionsandExpectedReturnofProductRightsTables" roleURI="http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsTables">
        <link:definition>2330306 - Disclosure - Recent Additions and Expected Return of Product Rights (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentAdditionsandExpectedReturnofProductRightsNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsNarrativeDetails">
        <link:definition>2431414 - Disclosure - Recent Additions and Expected Return of Product Rights - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentAdditionsandExpectedReturnofProductRightsScheduleofInitialPaymentsandConsiderationDetails" roleURI="http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsScheduleofInitialPaymentsandConsiderationDetails">
        <link:definition>2432415 - Disclosure - Recent Additions and Expected Return of Product Rights - Schedule of Initial Payments and Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentAdditionsandExpectedReturnofProductRightsChangeinConsiderationDetails" roleURI="http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsChangeinConsiderationDetails">
        <link:definition>2433416 - Disclosure - Recent Additions and Expected Return of Product Rights - Change in Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentAdditionsandExpectedReturnofProductRightsScheduleofPreliminaryPurchaseAllocationDetails" roleURI="http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsScheduleofPreliminaryPurchaseAllocationDetails">
        <link:definition>2434417 - Disclosure - Recent Additions and Expected Return of Product Rights - Schedule of Preliminary Purchase Allocation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>cpix-20190630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2017 Workiva-->
<!--r:fe2e4db3-48f2-4e84-a542-8dc9a0c345cd,g:b764091f-bd8f-4ce0-9900-bde14803e897-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="simple" xlink:href="cpix-20190630.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cpix-20190630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ca93a043-7aa7-4075-b8f7-b4a3a2602e29" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_72c67c30-4539-4dd4-9e5a-974f8d040e5e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ca93a043-7aa7-4075-b8f7-b4a3a2602e29" xlink:to="loc_us-gaap_CommonStockValue_72c67c30-4539-4dd4-9e5a-974f8d040e5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_20a8d740-f6a2-42f6-838d-0964490c2378" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ca93a043-7aa7-4075-b8f7-b4a3a2602e29" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_20a8d740-f6a2-42f6-838d-0964490c2378" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_463c48c8-34b4-40f3-8da3-2513b322d870" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4abb49c6-4607-4be4-b9a6-0e5b53ec6e15" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_463c48c8-34b4-40f3-8da3-2513b322d870" xlink:to="loc_us-gaap_AssetsCurrent_4abb49c6-4607-4be4-b9a6-0e5b53ec6e15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0aef6e1b-22e3-4839-98d3-49740c3b0a04" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_463c48c8-34b4-40f3-8da3-2513b322d870" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_0aef6e1b-22e3-4839-98d3-49740c3b0a04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_dd40140b-b522-42bf-9df1-b9325e378540" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_463c48c8-34b4-40f3-8da3-2513b322d870" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_dd40140b-b522-42bf-9df1-b9325e378540" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_777c9c23-7412-4a7d-b33f-e55baef29ad5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_463c48c8-34b4-40f3-8da3-2513b322d870" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_777c9c23-7412-4a7d-b33f-e55baef29ad5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_4e794eb3-3109-4380-8c4a-c44d8d8bbaa0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_463c48c8-34b4-40f3-8da3-2513b322d870" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_4e794eb3-3109-4380-8c4a-c44d8d8bbaa0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_53ec1327-4dd9-4b68-9f36-0117957d3276" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_463c48c8-34b4-40f3-8da3-2513b322d870" xlink:to="loc_us-gaap_InventoryNoncurrent_53ec1327-4dd9-4b68-9f36-0117957d3276" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_680550fc-aa8b-4d7f-8b71-703ccd123aba" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_463c48c8-34b4-40f3-8da3-2513b322d870" xlink:to="loc_us-gaap_Goodwill_680550fc-aa8b-4d7f-8b71-703ccd123aba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_8e941868-4bc8-4e74-82a9-e585cdd53d4f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a08f82aa-cb43-4e78-a90a-32e0754d3155" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8e941868-4bc8-4e74-82a9-e585cdd53d4f" xlink:to="loc_us-gaap_Liabilities_a08f82aa-cb43-4e78-a90a-32e0754d3155" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f9e30944-78b9-49a8-a248-0c5954ed5dd0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8e941868-4bc8-4e74-82a9-e585cdd53d4f" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f9e30944-78b9-49a8-a248-0c5954ed5dd0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_8695d55b-613d-4fd0-b62f-75af90bb7ddf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8e941868-4bc8-4e74-82a9-e585cdd53d4f" xlink:to="loc_us-gaap_CommitmentsAndContingencies_8695d55b-613d-4fd0-b62f-75af90bb7ddf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_54324ca2-8343-4a81-9e4c-1111c8afb80d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_4f6c8fdb-32e7-4a1d-9109-fea2313cfd53" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_54324ca2-8343-4a81-9e4c-1111c8afb80d" xlink:to="loc_us-gaap_AccountsPayableCurrent_4f6c8fdb-32e7-4a1d-9109-fea2313cfd53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_fb9f5836-e5eb-43ea-aa4f-8e44880f46a2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_54324ca2-8343-4a81-9e4c-1111c8afb80d" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_fb9f5836-e5eb-43ea-aa4f-8e44880f46a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_8b8d7770-c599-43fc-b650-123b5f41a94a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6bde9331-fc65-4804-a4d2-208b9cb913c6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8b8d7770-c599-43fc-b650-123b5f41a94a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6bde9331-fc65-4804-a4d2-208b9cb913c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_b92dc954-2647-4f55-81d3-09646b7e0469" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MarketableSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8b8d7770-c599-43fc-b650-123b5f41a94a" xlink:to="loc_us-gaap_MarketableSecurities_b92dc954-2647-4f55-81d3-09646b7e0469" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_98b69af5-e021-4a3f-a902-7dca3bec6573" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8b8d7770-c599-43fc-b650-123b5f41a94a" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_98b69af5-e021-4a3f-a902-7dca3bec6573" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_6c0f46fb-f4a1-4259-bd06-531469f0b359" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8b8d7770-c599-43fc-b650-123b5f41a94a" xlink:to="loc_us-gaap_InventoryNet_6c0f46fb-f4a1-4259-bd06-531469f0b359" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_621b8aa0-5237-4431-9ffd-30b3d8dfb5c4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8b8d7770-c599-43fc-b650-123b5f41a94a" xlink:to="loc_us-gaap_OtherAssetsCurrent_621b8aa0-5237-4431-9ffd-30b3d8dfb5c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_46215ce4-d526-4300-b7c5-221af1fc44bb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_666e92a1-4668-415c-9dcf-896ca2c12ede" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_46215ce4-d526-4300-b7c5-221af1fc44bb" xlink:to="loc_us-gaap_LiabilitiesCurrent_666e92a1-4668-415c-9dcf-896ca2c12ede" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_17fe77d6-f58d-4ccc-a195-eb0160f3673b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_46215ce4-d526-4300-b7c5-221af1fc44bb" xlink:to="loc_us-gaap_LongTermLineOfCredit_17fe77d6-f58d-4ccc-a195-eb0160f3673b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion_078a8533-efaa-4136-81e9-6a318ae84f01" xlink:href="cpix-20190630.xsd#cpix_OtherLongTermObligationsExcludingCurrentPortion"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_46215ce4-d526-4300-b7c5-221af1fc44bb" xlink:to="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion_078a8533-efaa-4136-81e9-6a318ae84f01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7e3cb65f-2da6-4752-8328-1bb0c81d1119" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3fc7d4c6-e114-42c5-9863-b893af19aa09" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7e3cb65f-2da6-4752-8328-1bb0c81d1119" xlink:to="loc_us-gaap_StockholdersEquity_3fc7d4c6-e114-42c5-9863-b893af19aa09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_6af32de1-6873-4bd3-9198-1fd6ebd10a4d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7e3cb65f-2da6-4752-8328-1bb0c81d1119" xlink:to="loc_us-gaap_MinorityInterest_6af32de1-6873-4bd3-9198-1fd6ebd10a4d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cpix-20190630.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss" xlink:type="simple" xlink:href="cpix-20190630.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_571c2d92-edd8-4aad-8520-d2bac0848949" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_ff73e530-99f9-4b55-b18b-596398c01897" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_571c2d92-edd8-4aad-8520-d2bac0848949" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_ff73e530-99f9-4b55-b18b-596398c01897" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b109f79b-ae17-47cc-8ca5-b29a73beebf8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_571c2d92-edd8-4aad-8520-d2bac0848949" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b109f79b-ae17-47cc-8ca5-b29a73beebf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_ef82ecdc-9062-432e-b1a6-9d92ab1ff55c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_8feaf343-2334-459e-b619-103e709cd99a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_ef82ecdc-9062-432e-b1a6-9d92ab1ff55c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_8feaf343-2334-459e-b619-103e709cd99a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_01c61737-9979-42cb-937a-b3efbf9d2d6b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_ef82ecdc-9062-432e-b1a6-9d92ab1ff55c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_01c61737-9979-42cb-937a-b3efbf9d2d6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_aa603637-bcfd-40c4-9123-199d721b24e5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d6421550-5db9-4fe0-91a9-779838e1c2e2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_aa603637-bcfd-40c4-9123-199d721b24e5" xlink:to="loc_us-gaap_ProfitLoss_d6421550-5db9-4fe0-91a9-779838e1c2e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_fef91534-c752-469f-9896-c0adbd307c03" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_aa603637-bcfd-40c4-9123-199d721b24e5" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_fef91534-c752-469f-9896-c0adbd307c03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8abb7dc6-753f-469f-aae4-0402047b9cd9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_85efe7db-a50d-4cea-b944-d36c8284ba6a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8abb7dc6-753f-469f-aae4-0402047b9cd9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_85efe7db-a50d-4cea-b944-d36c8284ba6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_dd95e41d-15b9-4687-a156-c7256e8eef98" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8abb7dc6-753f-469f-aae4-0402047b9cd9" xlink:to="loc_us-gaap_CostsAndExpenses_dd95e41d-15b9-4687-a156-c7256e8eef98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_fe8eb2e8-2a21-46e8-9334-0021853498a7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_3118bdd8-18ec-4f67-894c-9e65a8844530" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_fe8eb2e8-2a21-46e8-9334-0021853498a7" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_3118bdd8-18ec-4f67-894c-9e65a8844530" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_1f1451a6-ec9a-4228-913a-fef5dad8fe7e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_fe8eb2e8-2a21-46e8-9334-0021853498a7" xlink:to="loc_us-gaap_SellingAndMarketingExpense_1f1451a6-ec9a-4228-913a-fef5dad8fe7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4bb0858a-e9a4-4dcb-9a5f-40de6c1eed46" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_fe8eb2e8-2a21-46e8-9334-0021853498a7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4bb0858a-e9a4-4dcb-9a5f-40de6c1eed46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_7ac67485-d17d-4ce9-b340-23f54e81a76a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_fe8eb2e8-2a21-46e8-9334-0021853498a7" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_7ac67485-d17d-4ce9-b340-23f54e81a76a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_c4d43129-3890-4f39-b90b-5efc3732c6c7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_fe8eb2e8-2a21-46e8-9334-0021853498a7" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_c4d43129-3890-4f39-b90b-5efc3732c6c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_b0a6b2fd-ee68-4127-9fb9-15ac93a92a5f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_cbbc991f-9d2e-4e65-9c68-bf4cf7c9e1df" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_b0a6b2fd-ee68-4127-9fb9-15ac93a92a5f" xlink:to="loc_us-gaap_OperatingIncomeLoss_cbbc991f-9d2e-4e65-9c68-bf4cf7c9e1df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_4c311e09-fd02-4dda-9c9f-a5940d06dce0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_b0a6b2fd-ee68-4127-9fb9-15ac93a92a5f" xlink:to="loc_us-gaap_InvestmentIncomeInterest_4c311e09-fd02-4dda-9c9f-a5940d06dce0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_426b5810-2933-4348-ac8f-6bdd243a8a89" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_b0a6b2fd-ee68-4127-9fb9-15ac93a92a5f" xlink:to="loc_us-gaap_InterestExpense_426b5810-2933-4348-ac8f-6bdd243a8a89" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cpix-20190630.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_4ff19ed6-844c-4dab-9846-a0bd0aeb2e59" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_43e74974-1e65-4b3f-97a0-3f21abc4e915" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_4ff19ed6-844c-4dab-9846-a0bd0aeb2e59" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_43e74974-1e65-4b3f-97a0-3f21abc4e915" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fac4f2d7-4cc0-4094-a224-9505aafc3b2b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_4ff19ed6-844c-4dab-9846-a0bd0aeb2e59" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fac4f2d7-4cc0-4094-a224-9505aafc3b2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_14e5be8c-2ce8-4b38-b23e-b4284b4a47d4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_4ff19ed6-844c-4dab-9846-a0bd0aeb2e59" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_14e5be8c-2ce8-4b38-b23e-b4284b4a47d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f6f493-67ef-4fe5-9d3e-0c3667b54b6d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f647f3a7-698c-4965-92c9-130b1a88a2a1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f6f493-67ef-4fe5-9d3e-0c3667b54b6d" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f647f3a7-698c-4965-92c9-130b1a88a2a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_6750749c-ee1b-4882-96d7-f94de6688979" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f6f493-67ef-4fe5-9d3e-0c3667b54b6d" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_6750749c-ee1b-4882-96d7-f94de6688979" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_4ef38e7a-8ff3-40c0-b4ef-e7b8cb20ff1d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f6f493-67ef-4fe5-9d3e-0c3667b54b6d" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_4ef38e7a-8ff3-40c0-b4ef-e7b8cb20ff1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_dec506f2-4c6a-48a7-b8f5-6c3a14c52d6b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f6f493-67ef-4fe5-9d3e-0c3667b54b6d" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_dec506f2-4c6a-48a7-b8f5-6c3a14c52d6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_0de51aeb-c1e8-494a-8fc3-f5d099462338" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f6f493-67ef-4fe5-9d3e-0c3667b54b6d" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_0de51aeb-c1e8-494a-8fc3-f5d099462338" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_37a89d87-0224-49f1-b588-d7bcf5908b46" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_0a3bed2a-a3e8-4572-bb39-20a03407e0b5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_37a89d87-0224-49f1-b588-d7bcf5908b46" xlink:to="loc_us-gaap_ProfitLoss_0a3bed2a-a3e8-4572-bb39-20a03407e0b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_60840d45-9e46-4d4c-a804-67236facd672" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_37a89d87-0224-49f1-b588-d7bcf5908b46" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_60840d45-9e46-4d4c-a804-67236facd672" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_adc2f5c6-4f45-4fb8-93a0-17e40b071e26" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_37a89d87-0224-49f1-b588-d7bcf5908b46" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_adc2f5c6-4f45-4fb8-93a0-17e40b071e26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_79b35f88-1b01-45ef-ac77-3800ef7ce7d5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_37a89d87-0224-49f1-b588-d7bcf5908b46" xlink:to="loc_us-gaap_ShareBasedCompensation_79b35f88-1b01-45ef-ac77-3800ef7ce7d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_d9d640e3-cdb8-4b6d-a561-d907b94e5f63" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_37a89d87-0224-49f1-b588-d7bcf5908b46" xlink:to="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_d9d640e3-cdb8-4b6d-a561-d907b94e5f63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_33c63381-e4e8-4557-85ea-7453ce34568d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_37a89d87-0224-49f1-b588-d7bcf5908b46" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_33c63381-e4e8-4557-85ea-7453ce34568d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_29e20dd5-2644-4588-952a-04054f1692e6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_37a89d87-0224-49f1-b588-d7bcf5908b46" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_29e20dd5-2644-4588-952a-04054f1692e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_d4de500b-faee-42dc-9bc2-b5b60262f43a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_37a89d87-0224-49f1-b588-d7bcf5908b46" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_d4de500b-faee-42dc-9bc2-b5b60262f43a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_eaae71a9-cf2c-4182-a226-49453346ca7c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_37a89d87-0224-49f1-b588-d7bcf5908b46" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_eaae71a9-cf2c-4182-a226-49453346ca7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_0498f2b1-5aa6-4d8f-8305-c26528a335dc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_37a89d87-0224-49f1-b588-d7bcf5908b46" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_0498f2b1-5aa6-4d8f-8305-c26528a335dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_f762bf09-6bbb-4d65-8709-b6eadd613b13" xlink:href="cpix-20190630.xsd#cpix_IncreaseDecreaseInCurrentOperatingLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_37a89d87-0224-49f1-b588-d7bcf5908b46" xlink:to="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_f762bf09-6bbb-4d65-8709-b6eadd613b13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_c9605d2e-f44a-4ef7-936f-3e96e2be0d9f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_37a89d87-0224-49f1-b588-d7bcf5908b46" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_c9605d2e-f44a-4ef7-936f-3e96e2be0d9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_580e6cf6-1dc2-4b9d-b5d9-941ea4750245" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_e49154c6-2d79-4921-b5f2-ef31563aa6fe" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_580e6cf6-1dc2-4b9d-b5d9-941ea4750245" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_e49154c6-2d79-4921-b5f2-ef31563aa6fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_03b9fd45-acf1-4aaa-8a1c-1fa3a3324906" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_580e6cf6-1dc2-4b9d-b5d9-941ea4750245" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_03b9fd45-acf1-4aaa-8a1c-1fa3a3324906" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0f515cf9-771b-4178-a2a8-e7b1027e4c77" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_580e6cf6-1dc2-4b9d-b5d9-941ea4750245" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0f515cf9-771b-4178-a2a8-e7b1027e4c77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_cce826c0-7877-4668-9e74-d63bf8c4d8df" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_580e6cf6-1dc2-4b9d-b5d9-941ea4750245" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_cce826c0-7877-4668-9e74-d63bf8c4d8df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_41c00e6b-d3c2-41e3-a7a6-9dedc826eb63" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_580e6cf6-1dc2-4b9d-b5d9-941ea4750245" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_41c00e6b-d3c2-41e3-a7a6-9dedc826eb63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_3f109cad-50cb-44a6-89ac-29fbd52a30ee" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_580e6cf6-1dc2-4b9d-b5d9-941ea4750245" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_3f109cad-50cb-44a6-89ac-29fbd52a30ee" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="simple" xlink:href="cpix-20190630.xsd#CondensedConsolidatedStatementofEquity"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="cpix-20190630.xsd#OrganizationandBasisofPresentation"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="simple" xlink:href="cpix-20190630.xsd#OrganizationandBasisofPresentationPolicies"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" xlink:type="simple" xlink:href="cpix-20190630.xsd#OrganizationandBasisofPresentationOrganizationDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/MarketableSecurities" xlink:type="simple" xlink:href="cpix-20190630.xsd#MarketableSecurities"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/MarketableSecurities" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="cpix-20190630.xsd#MarketableSecuritiesTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/MarketableSecuritiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="cpix-20190630.xsd#MarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="simple" xlink:href="cpix-20190630.xsd#EarningsLossPerShare"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="simple" xlink:href="cpix-20190630.xsd#EarningsLossPerShareTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="simple" xlink:href="cpix-20190630.xsd#EarningsLossPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d47f2817-a2e2-40da-8dea-84f6f15c87fb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0727cf5d-c84a-4c4d-b1ef-cbdb208b07ad" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d47f2817-a2e2-40da-8dea-84f6f15c87fb" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0727cf5d-c84a-4c4d-b1ef-cbdb208b07ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_0b0e902b-39c4-40c6-812f-5799038e958e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d47f2817-a2e2-40da-8dea-84f6f15c87fb" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_0b0e902b-39c4-40c6-812f-5799038e958e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" xlink:type="simple" xlink:href="cpix-20190630.xsd#EarningsLossPerShareDetailsTextual"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Revenues" xlink:type="simple" xlink:href="cpix-20190630.xsd#Revenues"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/Revenues" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="simple" xlink:href="cpix-20190630.xsd#RevenuesTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:type="simple" xlink:href="cpix-20190630.xsd#RevenuesDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Inventories" xlink:type="simple" xlink:href="cpix-20190630.xsd#Inventories"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/Inventories" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="simple" xlink:href="cpix-20190630.xsd#InventoriesTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20190630.xsd#InventoriesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="cpix-20190630.xsd#InventoriesScheduleofInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_686c29a0-afda-497b-8328-9d142fd2d95f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_648deba1-af8d-44e7-82db-a079e9826f7e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_686c29a0-afda-497b-8328-9d142fd2d95f" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_648deba1-af8d-44e7-82db-a079e9826f7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_c3ae60dc-a6c9-49ad-8d56-259413116b87" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_686c29a0-afda-497b-8328-9d142fd2d95f" xlink:to="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_c3ae60dc-a6c9-49ad-8d56-259413116b87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_891a2d6b-0d2b-49bb-a511-8b7c12b44ba9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_686c29a0-afda-497b-8328-9d142fd2d95f" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_891a2d6b-0d2b-49bb-a511-8b7c12b44ba9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_1f9266fc-d0cf-4be9-b6ff-6ad60b344901" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_cfdf4dae-640c-430c-84e6-5688b656d838" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_1f9266fc-d0cf-4be9-b6ff-6ad60b344901" xlink:to="loc_us-gaap_InventoryNoncurrent_cfdf4dae-640c-430c-84e6-5688b656d838" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_6d4be445-3fd2-418f-bb2e-0d7fd809b934" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_1f9266fc-d0cf-4be9-b6ff-6ad60b344901" xlink:to="loc_us-gaap_InventoryGross_6d4be445-3fd2-418f-bb2e-0d7fd809b934" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Leases" xlink:type="simple" xlink:href="cpix-20190630.xsd#Leases"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/Leases" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="simple" xlink:href="cpix-20190630.xsd#LeasesTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20190630.xsd#LeasesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="simple" xlink:href="cpix-20190630.xsd#LeasesLeasePositionDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="simple" xlink:href="cpix-20190630.xsd#LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_348ab5ae-471f-4999-b7f8-7f3bdffea8c5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_f134d4a8-1fa7-44eb-bb0f-c327d97166c1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_348ab5ae-471f-4999-b7f8-7f3bdffea8c5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_f134d4a8-1fa7-44eb-bb0f-c327d97166c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_fb1fbaf8-e90e-4c90-bf4e-dcb51fe2a0d6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_348ab5ae-471f-4999-b7f8-7f3bdffea8c5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_fb1fbaf8-e90e-4c90-bf4e-dcb51fe2a0d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a27ba899-d5cc-4b67-9d0a-705cf26ab8b1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_348ab5ae-471f-4999-b7f8-7f3bdffea8c5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a27ba899-d5cc-4b67-9d0a-705cf26ab8b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0485411c-6c51-4276-8909-66ff20e85e59" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_348ab5ae-471f-4999-b7f8-7f3bdffea8c5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0485411c-6c51-4276-8909-66ff20e85e59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_6497a6a1-0a4f-4a4c-80fa-8ba8689867e8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_348ab5ae-471f-4999-b7f8-7f3bdffea8c5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_6497a6a1-0a4f-4a4c-80fa-8ba8689867e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_f5f5f30a-519a-47de-b7df-117762997868" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_348ab5ae-471f-4999-b7f8-7f3bdffea8c5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_f5f5f30a-519a-47de-b7df-117762997868" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1" xlink:type="simple" xlink:href="cpix-20190630.xsd#LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2fdcbc26-3763-47f3-98d0-34c70e7ecb4d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_288c797b-3212-4c86-88b2-4930614d603a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2fdcbc26-3763-47f3-98d0-34c70e7ecb4d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_288c797b-3212-4c86-88b2-4930614d603a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_89b21e15-8b90-4d6a-9cdc-cc375ba40b72" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2fdcbc26-3763-47f3-98d0-34c70e7ecb4d" xlink:to="loc_us-gaap_OperatingLeaseLiability_89b21e15-8b90-4d6a-9cdc-cc375ba40b72" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt" xlink:type="simple" xlink:href="cpix-20190630.xsd#ShareholdersEquityandDebt"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="simple" xlink:href="cpix-20190630.xsd#ShareholdersEquityandDebtShareholdersEquityDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="simple" xlink:href="cpix-20190630.xsd#ShareholdersEquityandDebtDebtDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cpix-20190630.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="simple" xlink:href="cpix-20190630.xsd#IncomeTaxesDetailsTextual"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="simple" xlink:href="cpix-20190630.xsd#CollaborativeAgreements"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRights" xlink:type="simple" xlink:href="cpix-20190630.xsd#RecentAdditionsandExpectedReturnofProductRights"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRights" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsTables" xlink:type="simple" xlink:href="cpix-20190630.xsd#RecentAdditionsandExpectedReturnofProductRightsTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20190630.xsd#RecentAdditionsandExpectedReturnofProductRightsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsScheduleofInitialPaymentsandConsiderationDetails" xlink:type="simple" xlink:href="cpix-20190630.xsd#RecentAdditionsandExpectedReturnofProductRightsScheduleofInitialPaymentsandConsiderationDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsScheduleofInitialPaymentsandConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_a0ca27c6-95c2-413d-8914-de1c82123229" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_22bea613-f2c2-4ee7-8dfd-ee884e92ce68" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_a0ca27c6-95c2-413d-8914-de1c82123229" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_22bea613-f2c2-4ee7-8dfd-ee884e92ce68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_fcddba4b-9ad3-43f1-8594-fce55273006a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_a0ca27c6-95c2-413d-8914-de1c82123229" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_fcddba4b-9ad3-43f1-8594-fce55273006a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsForContingentConsideration_1b17aa14-a698-4410-ab89-7d9109ba440b" xlink:href="cpix-20190630.xsd#cpix_PaymentsForContingentConsideration"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_a0ca27c6-95c2-413d-8914-de1c82123229" xlink:to="loc_cpix_PaymentsForContingentConsideration_1b17aa14-a698-4410-ab89-7d9109ba440b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsChangeinConsiderationDetails" xlink:type="simple" xlink:href="cpix-20190630.xsd#RecentAdditionsandExpectedReturnofProductRightsChangeinConsiderationDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsChangeinConsiderationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsScheduleofPreliminaryPurchaseAllocationDetails" xlink:type="simple" xlink:href="cpix-20190630.xsd#RecentAdditionsandExpectedReturnofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsScheduleofPreliminaryPurchaseAllocationDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>cpix-20190630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2017 Workiva-->
<!--r:fe2e4db3-48f2-4e84-a542-8dc9a0c345cd,g:b764091f-bd8f-4ce0-9900-bde14803e897-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="simple" xlink:href="cpix-20190630.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="extended" id="i734437feab404e28b12ab0e35a6a4b95_cb4585d4-b924-4ee7-8ccc-93df846a3fd8"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cpix-20190630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" id="i5f5649b566a24ca8b92a35096e999d45_2e9ea7be-9fd5-4cc1-b3c3-15c40c3010f2"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cpix-20190630.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="i5629773f6e8e41eab2df7fc26b61073e_1a99dea6-a356-400f-a334-0de24939c4f1"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss" xlink:type="simple" xlink:href="cpix-20190630.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss" xlink:type="extended" id="i788e0b6a2a1f4c5580229dc7f094aa63_9f078b65-52b8-4fae-bf21-10eb088602d8"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cpix-20190630.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended" id="i14b980079861404f9f3696d490bd5251_5b9491d2-42be-4471-8927-19e01e700fac"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="simple" xlink:href="cpix-20190630.xsd#CondensedConsolidatedStatementofEquity"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="extended" id="i0b277013efad41efbb21e70efd14ab5a_6c6990cf-5715-4bcb-9d59-75460b8d2798">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e7112159-493d-4db8-9730-8c27ce51fa94" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ae76d731-2008-48d3-9057-dbc7de59253d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e7112159-493d-4db8-9730-8c27ce51fa94" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ae76d731-2008-48d3-9057-dbc7de59253d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c04f18d1-c9a3-413f-85b5-56b0e6a91112" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ae76d731-2008-48d3-9057-dbc7de59253d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c04f18d1-c9a3-413f-85b5-56b0e6a91112" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8b6745d7-cd12-4ba3-822b-2b0cba7eabda" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ae76d731-2008-48d3-9057-dbc7de59253d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8b6745d7-cd12-4ba3-822b-2b0cba7eabda" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8423ba89-d394-4c6a-a06e-7a38b952cfe8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ae76d731-2008-48d3-9057-dbc7de59253d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8423ba89-d394-4c6a-a06e-7a38b952cfe8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6a3605e9-c331-4ee7-afa8-5a79380c46e0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ae76d731-2008-48d3-9057-dbc7de59253d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6a3605e9-c331-4ee7-afa8-5a79380c46e0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_dc47b7da-d154-45d7-890a-ffcf11008126" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ae76d731-2008-48d3-9057-dbc7de59253d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_dc47b7da-d154-45d7-890a-ffcf11008126" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_12925cb7-8a3a-4769-ac15-c076dba197cb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ae76d731-2008-48d3-9057-dbc7de59253d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_12925cb7-8a3a-4769-ac15-c076dba197cb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_3cbdeec3-b7f2-43ab-88ee-14e39bd94532" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ae76d731-2008-48d3-9057-dbc7de59253d" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_3cbdeec3-b7f2-43ab-88ee-14e39bd94532" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_abf61ec2-3926-4ab5-b7bb-0235343b96e9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ae76d731-2008-48d3-9057-dbc7de59253d" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_abf61ec2-3926-4ab5-b7bb-0235343b96e9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_f4ad6bdf-8d81-415b-bc90-a526be9e353c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ae76d731-2008-48d3-9057-dbc7de59253d" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_f4ad6bdf-8d81-415b-bc90-a526be9e353c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4b7230b4-7c35-438a-9872-15367f7cdec8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ae76d731-2008-48d3-9057-dbc7de59253d" xlink:to="loc_us-gaap_ProfitLoss_4b7230b4-7c35-438a-9872-15367f7cdec8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a8b763c5-b547-40ae-ad4e-dc5f40a75983" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1d34bb20-a64d-40e1-b429-748c861cd97b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_90331584-6311-45f3-bd1b-cb8c225c72d2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_e7112159-493d-4db8-9730-8c27ce51fa94" xlink:to="loc_us-gaap_StatementTable_90331584-6311-45f3-bd1b-cb8c225c72d2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_726762a0-0e05-4e52-8f7f-46d49309834d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_90331584-6311-45f3-bd1b-cb8c225c72d2" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_726762a0-0e05-4e52-8f7f-46d49309834d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_726762a0-0e05-4e52-8f7f-46d49309834d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_726762a0-0e05-4e52-8f7f-46d49309834d" xlink:to="loc_us-gaap_EquityComponentDomain_726762a0-0e05-4e52-8f7f-46d49309834d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7e0914fb-237c-45f9-b129-96f3843b3676" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_726762a0-0e05-4e52-8f7f-46d49309834d" xlink:to="loc_us-gaap_EquityComponentDomain_7e0914fb-237c-45f9-b129-96f3843b3676" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4ba4322e-3939-42b4-bb4d-93e79dacfdf3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7e0914fb-237c-45f9-b129-96f3843b3676" xlink:to="loc_us-gaap_CommonStockMember_4ba4322e-3939-42b4-bb4d-93e79dacfdf3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_54b58365-b8c9-4b05-b3ff-fd8d37d4da83" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7e0914fb-237c-45f9-b129-96f3843b3676" xlink:to="loc_us-gaap_RetainedEarningsMember_54b58365-b8c9-4b05-b3ff-fd8d37d4da83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_98a80ee5-3f5e-465a-b2a6-6ccbaa6f8b3e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7e0914fb-237c-45f9-b129-96f3843b3676" xlink:to="loc_us-gaap_NoncontrollingInterestMember_98a80ee5-3f5e-465a-b2a6-6ccbaa6f8b3e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="cpix-20190630.xsd#OrganizationandBasisofPresentation"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation" xlink:type="extended" id="ibd2aba789915483eb89f3d7ecd91c668_d1bdb7e1-592d-48a5-bd97-6a924d7ea9f6"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="simple" xlink:href="cpix-20190630.xsd#OrganizationandBasisofPresentationPolicies"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="extended" id="ib203b7c40a254f458d8f162f24b776ee_d3672a1f-3c06-48e6-91d2-ecc60d7805f7"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" xlink:type="simple" xlink:href="cpix-20190630.xsd#OrganizationandBasisofPresentationOrganizationDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" xlink:type="extended" id="ia395ba42938d4517aacb776aa74372ca_37cf76f9-7828-4d48-bd38-94a4ae3a559c"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/MarketableSecurities" xlink:type="simple" xlink:href="cpix-20190630.xsd#MarketableSecurities"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/MarketableSecurities" xlink:type="extended" id="ia4776c35bd5c4ea2a3915eb5d1c7c212_c38429df-acab-4568-96ca-6e0605d066a3"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="cpix-20190630.xsd#MarketableSecuritiesTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/MarketableSecuritiesTables" xlink:type="extended" id="i66035553a6b74d7b905fd65abb9255e6_be54aab9-bd5d-4ee3-8064-c4198b643da0"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="cpix-20190630.xsd#MarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails" xlink:type="extended" id="i381090d0fdd64e0eaf91a8f172365dab_799a48ec-5aab-4f92-be0b-81079aa35bb0">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a87797cf-4361-4be3-8be2-a9f0c6e5ab94" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities_3d52aa46-caa3-4a08-8e8d-1b94bc954e87" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TradingSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a87797cf-4361-4be3-8be2-a9f0c6e5ab94" xlink:to="loc_us-gaap_TradingSecurities_3d52aa46-caa3-4a08-8e8d-1b94bc954e87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_5abd5c03-89ed-457e-827c-898384739e3c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a87797cf-4361-4be3-8be2-a9f0c6e5ab94" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_5abd5c03-89ed-457e-827c-898384739e3c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ca8dc7aa-d938-46c1-a631-7523413f4f76" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_5abd5c03-89ed-457e-827c-898384739e3c" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ca8dc7aa-d938-46c1-a631-7523413f4f76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ca8dc7aa-d938-46c1-a631-7523413f4f76_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ca8dc7aa-d938-46c1-a631-7523413f4f76" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ca8dc7aa-d938-46c1-a631-7523413f4f76_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_18cae46d-ed04-40e8-af23-1ef605e0770b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ca8dc7aa-d938-46c1-a631-7523413f4f76" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_18cae46d-ed04-40e8-af23-1ef605e0770b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_95b64082-f8a1-4299-8e48-bfd236da20ef" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_18cae46d-ed04-40e8-af23-1ef605e0770b" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_95b64082-f8a1-4299-8e48-bfd236da20ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_169abc3c-1887-4fc0-819c-c2f4dba6ffb6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_18cae46d-ed04-40e8-af23-1ef605e0770b" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_169abc3c-1887-4fc0-819c-c2f4dba6ffb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6623cd24-a5de-4ace-91dc-c7d67dcfab2c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_5abd5c03-89ed-457e-827c-898384739e3c" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6623cd24-a5de-4ace-91dc-c7d67dcfab2c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6623cd24-a5de-4ace-91dc-c7d67dcfab2c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6623cd24-a5de-4ace-91dc-c7d67dcfab2c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6623cd24-a5de-4ace-91dc-c7d67dcfab2c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ac69a334-867f-43b2-840f-87d4f6d73e37" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6623cd24-a5de-4ace-91dc-c7d67dcfab2c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ac69a334-867f-43b2-840f-87d4f6d73e37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_UsTreasuryNotesAndBondsSecuritiesMemberMember_d3356255-bb97-48e1-b4cc-e12ea81a8722" xlink:href="cpix-20190630.xsd#cpix_UsTreasuryNotesAndBondsSecuritiesMemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ac69a334-867f-43b2-840f-87d4f6d73e37" xlink:to="loc_cpix_UsTreasuryNotesAndBondsSecuritiesMemberMember_d3356255-bb97-48e1-b4cc-e12ea81a8722" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_797b92c2-73ad-4dd8-bca1-f7c4a7070a86" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ac69a334-867f-43b2-840f-87d4f6d73e37" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_797b92c2-73ad-4dd8-bca1-f7c4a7070a86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_039328f2-2f31-40f5-83b0-d0720ed5292b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ac69a334-867f-43b2-840f-87d4f6d73e37" xlink:to="loc_us-gaap_CommercialPaperMember_039328f2-2f31-40f5-83b0-d0720ed5292b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_2c6a6055-3c11-4571-85e2-4d20f7fe729a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ac69a334-867f-43b2-840f-87d4f6d73e37" xlink:to="loc_us-gaap_MunicipalBondsMember_2c6a6055-3c11-4571-85e2-4d20f7fe729a" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="simple" xlink:href="cpix-20190630.xsd#EarningsLossPerShare"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="extended" id="ib588e58e902a4d9fb4ccd16b7c44d99a_16d69222-4ca2-40a2-b2fb-533359e67d02"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="simple" xlink:href="cpix-20190630.xsd#EarningsLossPerShareTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="extended" id="i031f8486df924389b411558c8043e70b_67b93ced-7330-4023-8d4e-537a8a8e2722"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="simple" xlink:href="cpix-20190630.xsd#EarningsLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="extended" id="ifa56cac3db4a4766a580d6d9488265df_c8ce4f78-cb4b-4316-bea7-5e3dba977f44"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" xlink:type="simple" xlink:href="cpix-20190630.xsd#EarningsLossPerShareDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" xlink:type="extended" id="i4ce724acc39f457caf14045ef4ed06ce_ab755dd6-fcfe-4145-9da0-c4e85c8d6679"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Revenues" xlink:type="simple" xlink:href="cpix-20190630.xsd#Revenues"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/Revenues" xlink:type="extended" id="i0f1e11cec71448de9749791b995b1f77_ddfca47a-ac5f-4484-a9c1-9e74a0dd65a3"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="simple" xlink:href="cpix-20190630.xsd#RevenuesTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="extended" id="ifaac1b43af4246b99835202d76ea53ae_9dacefe4-ead8-4582-a3aa-4b9a335ffa0b"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:type="simple" xlink:href="cpix-20190630.xsd#RevenuesDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:type="extended" id="ib435ca2e3e4841319100cef39c2f8dbf_bcc978dd-aedb-486a-9cd3-bc3ddcc7e29e">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_4c583caf-3a86-4d6e-8295-06e0e41823cc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_09c2a230-db47-4247-b6a4-0082b56cb6fd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_4c583caf-3a86-4d6e-8295-06e0e41823cc" xlink:to="loc_us-gaap_RevenuesAbstract_09c2a230-db47-4247-b6a4-0082b56cb6fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductsAbstract_a439716d-656c-48a9-8b69-e38d722948d5" xlink:href="cpix-20190630.xsd#cpix_ProductsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_09c2a230-db47-4247-b6a4-0082b56cb6fd" xlink:to="loc_cpix_ProductsAbstract_a439716d-656c-48a9-8b69-e38d722948d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b75b553c-8533-4c46-a33a-91100f030955" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ProductsAbstract_a439716d-656c-48a9-8b69-e38d722948d5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b75b553c-8533-4c46-a33a-91100f030955" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_151b1a3f-f5b0-4790-a0a5-cb5911255ece" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_4c583caf-3a86-4d6e-8295-06e0e41823cc" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_151b1a3f-f5b0-4790-a0a5-cb5911255ece" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_966797c6-9edf-4bcf-b42b-f623710de99b" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_151b1a3f-f5b0-4790-a0a5-cb5911255ece" xlink:to="loc_srt_ProductOrServiceAxis_966797c6-9edf-4bcf-b42b-f623710de99b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_966797c6-9edf-4bcf-b42b-f623710de99b_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_966797c6-9edf-4bcf-b42b-f623710de99b" xlink:to="loc_srt_ProductsAndServicesDomain_966797c6-9edf-4bcf-b42b-f623710de99b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f42ca1de-9a67-4bd0-8067-799c1d73fa4c" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_966797c6-9edf-4bcf-b42b-f623710de99b" xlink:to="loc_srt_ProductsAndServicesDomain_f42ca1de-9a67-4bd0-8067-799c1d73fa4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AcetadoteMember_5e5d36f8-78cf-4b8d-8ec2-00a7c9e05ae7" xlink:href="cpix-20190630.xsd#cpix_AcetadoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f42ca1de-9a67-4bd0-8067-799c1d73fa4c" xlink:to="loc_cpix_AcetadoteMember_5e5d36f8-78cf-4b8d-8ec2-00a7c9e05ae7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OmeclamoxPakMember_dab5a768-416b-4aa9-b8bf-09021e95fc2b" xlink:href="cpix-20190630.xsd#cpix_OmeclamoxPakMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f42ca1de-9a67-4bd0-8067-799c1d73fa4c" xlink:to="loc_cpix_OmeclamoxPakMember_dab5a768-416b-4aa9-b8bf-09021e95fc2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KristaloseMember_63ce9d1b-5a3c-4105-b749-6f3d156a52ef" xlink:href="cpix-20190630.xsd#cpix_KristaloseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f42ca1de-9a67-4bd0-8067-799c1d73fa4c" xlink:to="loc_cpix_KristaloseMember_63ce9d1b-5a3c-4105-b749-6f3d156a52ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VaprisolMember_59df7da8-d4e8-49fd-a453-cf20eb4aeee8" xlink:href="cpix-20190630.xsd#cpix_VaprisolMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f42ca1de-9a67-4bd0-8067-799c1d73fa4c" xlink:to="loc_cpix_VaprisolMember_59df7da8-d4e8-49fd-a453-cf20eb4aeee8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CaldolorMember_b21727b4-3af9-4b6f-a255-208ee6bd9f6a" xlink:href="cpix-20190630.xsd#cpix_CaldolorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f42ca1de-9a67-4bd0-8067-799c1d73fa4c" xlink:to="loc_cpix_CaldolorMember_b21727b4-3af9-4b6f-a255-208ee6bd9f6a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EthyolMember_f761ba0a-7048-4352-8ef3-7f42c34c508e" xlink:href="cpix-20190630.xsd#cpix_EthyolMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f42ca1de-9a67-4bd0-8067-799c1d73fa4c" xlink:to="loc_cpix_EthyolMember_f761ba0a-7048-4352-8ef3-7f42c34c508e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TotectMember_282639c0-8815-44eb-b171-30e2ea0d53d3" xlink:href="cpix-20190630.xsd#cpix_TotectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f42ca1de-9a67-4bd0-8067-799c1d73fa4c" xlink:to="loc_cpix_TotectMember_282639c0-8815-44eb-b171-30e2ea0d53d3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_75b654bd-2a7c-4b80-891e-e9f282174aaa" xlink:href="cpix-20190630.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f42ca1de-9a67-4bd0-8067-799c1d73fa4c" xlink:to="loc_cpix_VIBATIVMember_75b654bd-2a7c-4b80-891e-e9f282174aaa" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherProductsMember_d89eca6a-70e8-47e5-bbb5-89bf189695ca" xlink:href="cpix-20190630.xsd#cpix_OtherProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f42ca1de-9a67-4bd0-8067-799c1d73fa4c" xlink:to="loc_cpix_OtherProductsMember_d89eca6a-70e8-47e5-bbb5-89bf189695ca" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f4a3f1d3-7373-45a5-8a1a-09ed7b6e549d" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_151b1a3f-f5b0-4790-a0a5-cb5911255ece" xlink:to="loc_srt_CounterpartyNameAxis_f4a3f1d3-7373-45a5-8a1a-09ed7b6e549d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f4a3f1d3-7373-45a5-8a1a-09ed7b6e549d_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_f4a3f1d3-7373-45a5-8a1a-09ed7b6e549d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f4a3f1d3-7373-45a5-8a1a-09ed7b6e549d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_98c5aab5-87b7-400c-9587-4c4f9e9a7b43" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_f4a3f1d3-7373-45a5-8a1a-09ed7b6e549d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_98c5aab5-87b7-400c-9587-4c4f9e9a7b43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember_c145b525-3003-4d06-b2f7-475fb36f9045" xlink:href="cpix-20190630.xsd#cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_98c5aab5-87b7-400c-9587-4c4f9e9a7b43" xlink:to="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember_c145b525-3003-4d06-b2f7-475fb36f9045" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_501ad854-14e8-48ba-a854-7ab1ab24daee" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_151b1a3f-f5b0-4790-a0a5-cb5911255ece" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_501ad854-14e8-48ba-a854-7ab1ab24daee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_501ad854-14e8-48ba-a854-7ab1ab24daee_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_501ad854-14e8-48ba-a854-7ab1ab24daee" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_501ad854-14e8-48ba-a854-7ab1ab24daee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6044437d-08f9-4593-a362-ebdbbb35cd48" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_501ad854-14e8-48ba-a854-7ab1ab24daee" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6044437d-08f9-4593-a362-ebdbbb35cd48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRightsGrantedMember_df915955-25de-4061-9e27-3aeb7c672302" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRightsGrantedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6044437d-08f9-4593-a362-ebdbbb35cd48" xlink:to="loc_us-gaap_RevenueRightsGrantedMember_df915955-25de-4061-9e27-3aeb7c672302" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Inventories" xlink:type="simple" xlink:href="cpix-20190630.xsd#Inventories"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/Inventories" xlink:type="extended" id="i4c0149f617d44ca78ae429c4612616f3_60050e1a-e00e-4bb6-ae3b-199179d1e0c9"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="simple" xlink:href="cpix-20190630.xsd#InventoriesTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="extended" id="i70bbae9f65b347c9ae5cdef7fc079b70_543fbdf3-198b-4256-926d-623afc3ced28"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20190630.xsd#InventoriesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="extended" id="ie4c5f31f41f749038e58779705f90237_ce6cdbd7-8a2d-4223-b7f6-5b13371feeb0">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_ae201dba-0e08-4735-bfde-5ea9a45298f4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_327b27c2-2801-4bb7-b68a-8895829c5f1c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_ae201dba-0e08-4735-bfde-5ea9a45298f4" xlink:to="loc_us-gaap_InventoryValuationReserves_327b27c2-2801-4bb7-b68a-8895829c5f1c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_d2d0086b-ba85-4cbc-925c-648579f38ccf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_ae201dba-0e08-4735-bfde-5ea9a45298f4" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_d2d0086b-ba85-4cbc-925c-648579f38ccf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_0d473331-1022-4fe0-81c2-f7a60af66a8e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_ae201dba-0e08-4735-bfde-5ea9a45298f4" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_0d473331-1022-4fe0-81c2-f7a60af66a8e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_0be86020-759f-47ac-9363-c157236f440f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_ae201dba-0e08-4735-bfde-5ea9a45298f4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_0be86020-759f-47ac-9363-c157236f440f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_2b117b24-8928-44ce-8fcf-775fa15cadaa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_ae201dba-0e08-4735-bfde-5ea9a45298f4" xlink:to="loc_us-gaap_InventoryCurrentTable_2b117b24-8928-44ce-8fcf-775fa15cadaa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3f68b765-a430-4f80-9358-5f69f5dce4a1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_2b117b24-8928-44ce-8fcf-775fa15cadaa" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3f68b765-a430-4f80-9358-5f69f5dce4a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3f68b765-a430-4f80-9358-5f69f5dce4a1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3f68b765-a430-4f80-9358-5f69f5dce4a1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3f68b765-a430-4f80-9358-5f69f5dce4a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f7a4719e-be35-4bd4-bafe-29a3509a48ad" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3f68b765-a430-4f80-9358-5f69f5dce4a1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f7a4719e-be35-4bd4-bafe-29a3509a48ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_ea4b83f1-c676-43eb-964e-13afd88874ee" xlink:href="cpix-20190630.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f7a4719e-be35-4bd4-bafe-29a3509a48ad" xlink:to="loc_cpix_VIBATIVMember_ea4b83f1-c676-43eb-964e-13afd88874ee" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="cpix-20190630.xsd#InventoriesScheduleofInventoriesDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="extended" id="i54d3226201f84e4d9ff8f939074faafb_e43f74d5-7723-4ef9-9bca-9fa60a24a37c"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Leases" xlink:type="simple" xlink:href="cpix-20190630.xsd#Leases"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/Leases" xlink:type="extended" id="i4b2029a9bac84bb58d8cae3df7b5cba5_955dc773-7714-4b1c-b8bb-99dec8621462"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="simple" xlink:href="cpix-20190630.xsd#LeasesTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="extended" id="i156c04af550a43d7b7374779ff7333e8_7f4ec0e5-e300-4b2f-b979-26e9fab4a20a"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20190630.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="extended" id="i08ba2cc63d274e4e8cee4104727017b9_1ec85939-2de9-4fae-bb67-5e2e03d034dc"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="simple" xlink:href="cpix-20190630.xsd#LeasesLeasePositionDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="extended" id="i51ec455347b14dcb8de04b1d80c6cf93_2677f17e-5fef-4f2d-8d7d-ffbb0605c2dc"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="simple" xlink:href="cpix-20190630.xsd#LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="extended" id="i26f1ae1196c54957917520b49552ef2b_513b3a8b-92ed-4e42-b511-2794de2c115a"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt" xlink:type="simple" xlink:href="cpix-20190630.xsd#ShareholdersEquityandDebt"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt" xlink:type="extended" id="i57dfc885df9d440f85114b1e40df685b_127049ea-2a4b-471e-98b2-9dc04f63aeba"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="simple" xlink:href="cpix-20190630.xsd#ShareholdersEquityandDebtShareholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="extended" id="ie7b88217af1641a9a94de0ca155fa85d_d428bde6-5155-46d0-a895-ff8e7d839c09">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1811f97a-85a9-4021-807d-6fd6e5a224fa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareholdersEquityTextualAbstract_1852c3a7-355b-4427-ac9a-76118dbb8a61" xlink:href="cpix-20190630.xsd#cpix_ShareholdersEquityTextualAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1811f97a-85a9-4021-807d-6fd6e5a224fa" xlink:to="loc_cpix_ShareholdersEquityTextualAbstract_1852c3a7-355b-4427-ac9a-76118dbb8a61" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_be6b37d9-737f-44ad-ab6d-3079d97daf83" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_1852c3a7-355b-4427-ac9a-76118dbb8a61" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_be6b37d9-737f-44ad-ab6d-3079d97daf83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_29f51757-53d4-4880-83f6-d3d542644a35" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_1852c3a7-355b-4427-ac9a-76118dbb8a61" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_29f51757-53d4-4880-83f6-d3d542644a35" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_f38ace9b-c35a-4d87-9b52-e5b2ae1c9e81" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_1852c3a7-355b-4427-ac9a-76118dbb8a61" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_f38ace9b-c35a-4d87-9b52-e5b2ae1c9e81" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SaleOfStockNumberOfSharesSold_58d7e57f-07dd-4c7e-aadf-43b60c976f04" xlink:href="cpix-20190630.xsd#cpix_SaleOfStockNumberOfSharesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_1852c3a7-355b-4427-ac9a-76118dbb8a61" xlink:to="loc_cpix_SaleOfStockNumberOfSharesSold_58d7e57f-07dd-4c7e-aadf-43b60c976f04" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_0c551249-16a9-42ee-be32-b3884b019c17" xlink:href="cpix-20190630.xsd#cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_1852c3a7-355b-4427-ac9a-76118dbb8a61" xlink:to="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_0c551249-16a9-42ee-be32-b3884b019c17" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding_1b7754d8-847f-4110-9b6c-e3cecbc6796f" xlink:href="cpix-20190630.xsd#cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_1852c3a7-355b-4427-ac9a-76118dbb8a61" xlink:to="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding_1b7754d8-847f-4110-9b6c-e3cecbc6796f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e14d852a-d8a6-457b-bb2d-0a9ecc3dd58c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_1852c3a7-355b-4427-ac9a-76118dbb8a61" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e14d852a-d8a6-457b-bb2d-0a9ecc3dd58c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_96c0317e-32dd-46f9-b5a7-8daa8bbd0bb0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_1852c3a7-355b-4427-ac9a-76118dbb8a61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_96c0317e-32dd-46f9-b5a7-8daa8bbd0bb0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d0200492-33b9-43fa-bc05-ed2873389200" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_1852c3a7-355b-4427-ac9a-76118dbb8a61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d0200492-33b9-43fa-bc05-ed2873389200" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentPurchaseOfShares_6817b74f-920b-4856-9f1b-baa8da27b1f8" xlink:href="cpix-20190630.xsd#cpix_SubsidiaryInvestmentPurchaseOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_1852c3a7-355b-4427-ac9a-76118dbb8a61" xlink:to="loc_cpix_SubsidiaryInvestmentPurchaseOfShares_6817b74f-920b-4856-9f1b-baa8da27b1f8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentCashContribution_46976612-475b-4ffc-b93f-bd28546f6b1e" xlink:href="cpix-20190630.xsd#cpix_SubsidiaryInvestmentCashContribution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_1852c3a7-355b-4427-ac9a-76118dbb8a61" xlink:to="loc_cpix_SubsidiaryInvestmentCashContribution_46976612-475b-4ffc-b93f-bd28546f6b1e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable_78e916fa-1a93-49aa-99b2-31c9c2932c17" xlink:href="cpix-20190630.xsd#cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_1852c3a7-355b-4427-ac9a-76118dbb8a61" xlink:to="loc_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable_78e916fa-1a93-49aa-99b2-31c9c2932c17" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_94af428a-9134-467e-8b6f-6bd9c06fd2d3" xlink:href="cpix-20190630.xsd#cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_1852c3a7-355b-4427-ac9a-76118dbb8a61" xlink:to="loc_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_94af428a-9134-467e-8b6f-6bd9c06fd2d3" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e49720c2-68e3-49a4-ae7a-325f2a80e009" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_1852c3a7-355b-4427-ac9a-76118dbb8a61" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e49720c2-68e3-49a4-ae7a-325f2a80e009" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_800ea043-8ac1-4ab0-b904-49deffe5613a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1811f97a-85a9-4021-807d-6fd6e5a224fa" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_800ea043-8ac1-4ab0-b904-49deffe5613a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1a773038-2e08-43c8-8df5-a495445d93af" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_800ea043-8ac1-4ab0-b904-49deffe5613a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1a773038-2e08-43c8-8df5-a495445d93af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1a773038-2e08-43c8-8df5-a495445d93af_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1a773038-2e08-43c8-8df5-a495445d93af" xlink:to="loc_us-gaap_EquityComponentDomain_1a773038-2e08-43c8-8df5-a495445d93af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1b64fcef-42b0-4974-bdca-f64d17e362dc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1a773038-2e08-43c8-8df5-a495445d93af" xlink:to="loc_us-gaap_EquityComponentDomain_1b64fcef-42b0-4974-bdca-f64d17e362dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_125b167e-55c4-4b58-bd54-bda46a109dec" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1b64fcef-42b0-4974-bdca-f64d17e362dc" xlink:to="loc_us-gaap_CommonStockMember_125b167e-55c4-4b58-bd54-bda46a109dec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualAxis_a6daa225-d340-4ce9-907b-a2c84419c321" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_800ea043-8ac1-4ab0-b904-49deffe5613a" xlink:to="loc_us-gaap_TitleOfIndividualAxis_a6daa225-d340-4ce9-907b-a2c84419c321" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_a6daa225-d340-4ce9-907b-a2c84419c321_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_a6daa225-d340-4ce9-907b-a2c84419c321" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_a6daa225-d340-4ce9-907b-a2c84419c321_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_926e59bb-05f9-455f-91e1-0dd756c469e1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_a6daa225-d340-4ce9-907b-a2c84419c321" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_926e59bb-05f9-455f-91e1-0dd756c469e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DirectorMember_ef17297f-14ee-409e-88c1-ee6b3fdccf65" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_926e59bb-05f9-455f-91e1-0dd756c469e1" xlink:to="loc_us-gaap_DirectorMember_ef17297f-14ee-409e-88c1-ee6b3fdccf65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ba88e009-0c20-4ea3-9e2e-c85ddcf68443" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_800ea043-8ac1-4ab0-b904-49deffe5613a" xlink:to="loc_us-gaap_AwardTypeAxis_ba88e009-0c20-4ea3-9e2e-c85ddcf68443" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ba88e009-0c20-4ea3-9e2e-c85ddcf68443_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ba88e009-0c20-4ea3-9e2e-c85ddcf68443" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ba88e009-0c20-4ea3-9e2e-c85ddcf68443_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0ac62c9c-2739-40e6-aaa3-4e23ece2cf14" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ba88e009-0c20-4ea3-9e2e-c85ddcf68443" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0ac62c9c-2739-40e6-aaa3-4e23ece2cf14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_af0450ea-220a-475c-95da-82ffbed1a112" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0ac62c9c-2739-40e6-aaa3-4e23ece2cf14" xlink:to="loc_us-gaap_RestrictedStockMember_af0450ea-220a-475c-95da-82ffbed1a112" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_74b27ff2-275c-485d-a526-ca8903bdd35e" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_800ea043-8ac1-4ab0-b904-49deffe5613a" xlink:to="loc_srt_CounterpartyNameAxis_74b27ff2-275c-485d-a526-ca8903bdd35e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_74b27ff2-275c-485d-a526-ca8903bdd35e_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_74b27ff2-275c-485d-a526-ca8903bdd35e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_74b27ff2-275c-485d-a526-ca8903bdd35e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e7a8c40b-b31d-4e34-a603-31248755320d" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_74b27ff2-275c-485d-a526-ca8903bdd35e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e7a8c40b-b31d-4e34-a603-31248755320d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_1675d667-32e8-4316-93c2-7bc2d021a380" xlink:href="cpix-20190630.xsd#cpix_HongKongWinHealthPharmaGroupCoLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e7a8c40b-b31d-4e34-a603-31248755320d" xlink:to="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_1675d667-32e8-4316-93c2-7bc2d021a380" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_GloriaPharmaceuticalsMember_2985d14e-ceef-4bb8-8a47-8b039611a12c" xlink:href="cpix-20190630.xsd#cpix_GloriaPharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e7a8c40b-b31d-4e34-a603-31248755320d" xlink:to="loc_cpix_GloriaPharmaceuticalsMember_2985d14e-ceef-4bb8-8a47-8b039611a12c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="simple" xlink:href="cpix-20190630.xsd#ShareholdersEquityandDebtDebtDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="extended" id="i3ba5f6529eb9477da94a86549bcc1b7a_395fce15-5e58-462c-b8fa-c11af11d726e">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_d5b94176-a98e-451f-a5fb-5418521d7495" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_4234fe0f-98d4-45e8-a52b-eb1a21bd5c42" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_d5b94176-a98e-451f-a5fb-5418521d7495" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_4234fe0f-98d4-45e8-a52b-eb1a21bd5c42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_d6ff1c3f-ebb8-454c-8362-971063d71223" xlink:href="cpix-20190630.xsd#cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_d5b94176-a98e-451f-a5fb-5418521d7495" xlink:to="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_d6ff1c3f-ebb8-454c-8362-971063d71223" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_2fb01d18-de70-428a-a03e-bf1589164995" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_d5b94176-a98e-451f-a5fb-5418521d7495" xlink:to="loc_us-gaap_LongTermLineOfCredit_2fb01d18-de70-428a-a03e-bf1589164995" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_02b7cbf8-255a-4c60-bb96-6a59afe392dc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_d5b94176-a98e-451f-a5fb-5418521d7495" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_02b7cbf8-255a-4c60-bb96-6a59afe392dc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_bd14d6f4-9ce1-4dc3-942f-da6eea0c600f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_d5b94176-a98e-451f-a5fb-5418521d7495" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_bd14d6f4-9ce1-4dc3-942f-da6eea0c600f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_abe78ffe-0a0b-4533-bb18-c2b9bd0b550e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_d5b94176-a98e-451f-a5fb-5418521d7495" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_abe78ffe-0a0b-4533-bb18-c2b9bd0b550e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_a1c77180-f3f8-416d-9ac9-2580eaf6f7fe" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_abe78ffe-0a0b-4533-bb18-c2b9bd0b550e" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_a1c77180-f3f8-416d-9ac9-2580eaf6f7fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_a1c77180-f3f8-416d-9ac9-2580eaf6f7fe_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_a1c77180-f3f8-416d-9ac9-2580eaf6f7fe" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_a1c77180-f3f8-416d-9ac9-2580eaf6f7fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_636e1078-1924-4762-bd03-0f1c03483dd0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_a1c77180-f3f8-416d-9ac9-2580eaf6f7fe" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_636e1078-1924-4762-bd03-0f1c03483dd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember_69f47bc8-2be8-4be3-9e27-dab5749cbb63" xlink:href="cpix-20190630.xsd#cpix_PinnacleBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_636e1078-1924-4762-bd03-0f1c03483dd0" xlink:to="loc_cpix_PinnacleBankMember_69f47bc8-2be8-4be3-9e27-dab5749cbb63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_62fddef8-51be-4214-a118-27f14e4a0bf9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_abe78ffe-0a0b-4533-bb18-c2b9bd0b550e" xlink:to="loc_us-gaap_DebtInstrumentAxis_62fddef8-51be-4214-a118-27f14e4a0bf9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_62fddef8-51be-4214-a118-27f14e4a0bf9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_62fddef8-51be-4214-a118-27f14e4a0bf9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_62fddef8-51be-4214-a118-27f14e4a0bf9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_52412943-dd1b-4ac5-a82b-be1c17475260" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_62fddef8-51be-4214-a118-27f14e4a0bf9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_52412943-dd1b-4ac5-a82b-be1c17475260" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SecondAmendmentMember_8150ea41-efa8-4420-a0c4-340ee65fd849" xlink:href="cpix-20190630.xsd#cpix_SecondAmendmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52412943-dd1b-4ac5-a82b-be1c17475260" xlink:to="loc_cpix_SecondAmendmentMember_8150ea41-efa8-4420-a0c4-340ee65fd849" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_a9794b73-cd58-4a97-91d2-494c8a695c17" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52412943-dd1b-4ac5-a82b-be1c17475260" xlink:to="loc_us-gaap_LineOfCreditMember_a9794b73-cd58-4a97-91d2-494c8a695c17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_4140b677-ee91-48d6-b6c7-e0f9f541a88c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_abe78ffe-0a0b-4533-bb18-c2b9bd0b550e" xlink:to="loc_us-gaap_CreditFacilityAxis_4140b677-ee91-48d6-b6c7-e0f9f541a88c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_4140b677-ee91-48d6-b6c7-e0f9f541a88c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_4140b677-ee91-48d6-b6c7-e0f9f541a88c" xlink:to="loc_us-gaap_CreditFacilityDomain_4140b677-ee91-48d6-b6c7-e0f9f541a88c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_b06a9684-1571-4898-a386-ba5689d3f259" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_4140b677-ee91-48d6-b6c7-e0f9f541a88c" xlink:to="loc_us-gaap_CreditFacilityDomain_b06a9684-1571-4898-a386-ba5689d3f259" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_aed51f27-6e1f-45ab-a6b6-3e9a2b41ed70" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_b06a9684-1571-4898-a386-ba5689d3f259" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_aed51f27-6e1f-45ab-a6b6-3e9a2b41ed70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bab75a4c-b8e1-40a7-b67a-85988fb56885" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_abe78ffe-0a0b-4533-bb18-c2b9bd0b550e" xlink:to="loc_srt_RangeAxis_bab75a4c-b8e1-40a7-b67a-85988fb56885" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bab75a4c-b8e1-40a7-b67a-85988fb56885_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_bab75a4c-b8e1-40a7-b67a-85988fb56885" xlink:to="loc_srt_RangeMember_bab75a4c-b8e1-40a7-b67a-85988fb56885_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_acf390e8-7b35-4b68-a16d-2870c5659921" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_bab75a4c-b8e1-40a7-b67a-85988fb56885" xlink:to="loc_srt_RangeMember_acf390e8-7b35-4b68-a16d-2870c5659921" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c3f4e541-9222-4de4-a619-dc2ede06f33b" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_acf390e8-7b35-4b68-a16d-2870c5659921" xlink:to="loc_srt_MinimumMember_c3f4e541-9222-4de4-a619-dc2ede06f33b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2a134e32-7657-4c1a-84bb-fd22f79e7754" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_acf390e8-7b35-4b68-a16d-2870c5659921" xlink:to="loc_srt_MaximumMember_2a134e32-7657-4c1a-84bb-fd22f79e7754" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cpix-20190630.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="extended" id="idbd9ca17989e47f1a4fe5b4d6fd5ca8b_ee8d0e55-74fc-4b7f-9f8b-e09aace8eb71"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="simple" xlink:href="cpix-20190630.xsd#IncomeTaxesDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="extended" id="i9b9cad9af4204b859ba860cec29123f0_8a19ba9e-ae3d-4cc9-9d49-2f26894bf3c1"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="simple" xlink:href="cpix-20190630.xsd#CollaborativeAgreements"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="extended" id="i0fe05807aef242238472dd7e7f90ca4a_784c4487-2a4d-419b-af94-0a7c7750ca7f"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRights" xlink:type="simple" xlink:href="cpix-20190630.xsd#RecentAdditionsandExpectedReturnofProductRights"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRights" xlink:type="extended" id="i4913e21094bc4adb9d994e9f14b401d2_65879c85-c687-4dc4-8208-cabf1a891cb0"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsTables" xlink:type="simple" xlink:href="cpix-20190630.xsd#RecentAdditionsandExpectedReturnofProductRightsTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsTables" xlink:type="extended" id="id4af9bdef8ae4f649fbc34f6895e2a9d_06bb97bc-5b3e-4c90-98fc-5d1d79ce0bc6"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20190630.xsd#RecentAdditionsandExpectedReturnofProductRightsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsNarrativeDetails" xlink:type="extended" id="i152aa31e92044d42af3f609c455902d1_7eb53c7c-5c8e-4931-b6f2-f52a7a19fe04">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1cbfda4e-4b75-4ffc-92de-785df9f39154" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsForAssetAcquisitions_c030b2a8-a4d9-49cd-bf6f-9a2d5908b758" xlink:href="cpix-20190630.xsd#cpix_PaymentsForAssetAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1cbfda4e-4b75-4ffc-92de-785df9f39154" xlink:to="loc_cpix_PaymentsForAssetAcquisitions_c030b2a8-a4d9-49cd-bf6f-9a2d5908b758" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_8fff1405-5b48-4e21-8db3-0bd3e2aab5fe" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1cbfda4e-4b75-4ffc-92de-785df9f39154" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_8fff1405-5b48-4e21-8db3-0bd3e2aab5fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_c75dcd0b-b939-4667-b703-a111940512a3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1cbfda4e-4b75-4ffc-92de-785df9f39154" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_c75dcd0b-b939-4667-b703-a111940512a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TieredRoyaltyPaymentsPercentage_a00b07e8-523f-4511-8e60-f64b13dd2a1c" xlink:href="cpix-20190630.xsd#cpix_TieredRoyaltyPaymentsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1cbfda4e-4b75-4ffc-92de-785df9f39154" xlink:to="loc_cpix_TieredRoyaltyPaymentsPercentage_a00b07e8-523f-4511-8e60-f64b13dd2a1c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_bb2f7ffd-6c34-4341-bb86-5d0ccb616968" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1cbfda4e-4b75-4ffc-92de-785df9f39154" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_bb2f7ffd-6c34-4341-bb86-5d0ccb616968" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_fe9bba12-3f1c-4910-8d90-ad9bc4c05586" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1cbfda4e-4b75-4ffc-92de-785df9f39154" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_fe9bba12-3f1c-4910-8d90-ad9bc4c05586" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_f75485fe-9db2-459f-ab4a-032f1fc906d4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1cbfda4e-4b75-4ffc-92de-785df9f39154" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_f75485fe-9db2-459f-ab4a-032f1fc906d4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_94233ec3-7a6f-4d83-823e-dabed88afe47" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1cbfda4e-4b75-4ffc-92de-785df9f39154" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_94233ec3-7a6f-4d83-823e-dabed88afe47" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_93d9b421-9559-438b-8a93-4610edaca72d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_94233ec3-7a6f-4d83-823e-dabed88afe47" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_93d9b421-9559-438b-8a93-4610edaca72d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_93d9b421-9559-438b-8a93-4610edaca72d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_93d9b421-9559-438b-8a93-4610edaca72d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_93d9b421-9559-438b-8a93-4610edaca72d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cd65c33b-3871-4167-9b24-2b7f8c542ebb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_93d9b421-9559-438b-8a93-4610edaca72d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cd65c33b-3871-4167-9b24-2b7f8c542ebb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_9567190f-1cc4-4141-8ab1-801b9d9391d3" xlink:href="cpix-20190630.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cd65c33b-3871-4167-9b24-2b7f8c542ebb" xlink:to="loc_cpix_VIBATIVMember_9567190f-1cc4-4141-8ab1-801b9d9391d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a9bdcc2d-26f1-4867-a36f-6a61ef11fbd9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_94233ec3-7a6f-4d83-823e-dabed88afe47" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a9bdcc2d-26f1-4867-a36f-6a61ef11fbd9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a9bdcc2d-26f1-4867-a36f-6a61ef11fbd9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a9bdcc2d-26f1-4867-a36f-6a61ef11fbd9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a9bdcc2d-26f1-4867-a36f-6a61ef11fbd9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54eb9f45-54e1-4f14-87c3-9348c8b21c75" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a9bdcc2d-26f1-4867-a36f-6a61ef11fbd9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54eb9f45-54e1-4f14-87c3-9348c8b21c75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_525d097c-9f44-4bd5-9e73-1e614c7a906c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54eb9f45-54e1-4f14-87c3-9348c8b21c75" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_525d097c-9f44-4bd5-9e73-1e614c7a906c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_31fa1b1c-c6ed-4f9d-b7b8-b44e8e62f71f" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_94233ec3-7a6f-4d83-823e-dabed88afe47" xlink:to="loc_srt_CounterpartyNameAxis_31fa1b1c-c6ed-4f9d-b7b8-b44e8e62f71f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_31fa1b1c-c6ed-4f9d-b7b8-b44e8e62f71f_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_31fa1b1c-c6ed-4f9d-b7b8-b44e8e62f71f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_31fa1b1c-c6ed-4f9d-b7b8-b44e8e62f71f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_94219b5a-b655-47d2-9918-950fc8738312" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_31fa1b1c-c6ed-4f9d-b7b8-b44e8e62f71f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_94219b5a-b655-47d2-9918-950fc8738312" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ClinigenHealthcareLimitedMember_749ceedb-3225-4fa4-bff5-d517bcda51a6" xlink:href="cpix-20190630.xsd#cpix_ClinigenHealthcareLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_94219b5a-b655-47d2-9918-950fc8738312" xlink:to="loc_cpix_ClinigenHealthcareLimitedMember_749ceedb-3225-4fa4-bff5-d517bcda51a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementScenarioAxis_61025222-3df7-4558-8cab-ac659b3924bd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_94233ec3-7a6f-4d83-823e-dabed88afe47" xlink:to="loc_us-gaap_StatementScenarioAxis_61025222-3df7-4558-8cab-ac659b3924bd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_61025222-3df7-4558-8cab-ac659b3924bd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_61025222-3df7-4558-8cab-ac659b3924bd" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_61025222-3df7-4558-8cab-ac659b3924bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_a3aad95d-00e7-4074-ade8-b9cd8198323a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_61025222-3df7-4558-8cab-ac659b3924bd" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_a3aad95d-00e7-4074-ade8-b9cd8198323a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScenarioForecastMember_52f04fee-c6e9-418d-a748-317f0bdd75ff" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_a3aad95d-00e7-4074-ade8-b9cd8198323a" xlink:to="loc_us-gaap_ScenarioForecastMember_52f04fee-c6e9-418d-a748-317f0bdd75ff" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsScheduleofInitialPaymentsandConsiderationDetails" xlink:type="simple" xlink:href="cpix-20190630.xsd#RecentAdditionsandExpectedReturnofProductRightsScheduleofInitialPaymentsandConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsScheduleofInitialPaymentsandConsiderationDetails" xlink:type="extended" id="ic2844f3479f84d1a9de5a9ce1bf28efe_92804ef6-2de9-4a9a-9799-2370db8b2d56">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_42aefef6-ff15-4587-a903-a3079cc7281d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_6c21dd75-c113-4e08-8c11-0954a597d49d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_42aefef6-ff15-4587-a903-a3079cc7281d" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_6c21dd75-c113-4e08-8c11-0954a597d49d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_08231939-6832-4a53-a589-b4ea79f50304" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_42aefef6-ff15-4587-a903-a3079cc7281d" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_08231939-6832-4a53-a589-b4ea79f50304" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsForContingentConsideration_a94d20e7-b130-4415-a916-55fecdc3de66" xlink:href="cpix-20190630.xsd#cpix_PaymentsForContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_42aefef6-ff15-4587-a903-a3079cc7281d" xlink:to="loc_cpix_PaymentsForContingentConsideration_a94d20e7-b130-4415-a916-55fecdc3de66" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_b25a1a89-7781-443e-86a6-0eb82485b1f4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_42aefef6-ff15-4587-a903-a3079cc7281d" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_b25a1a89-7781-443e-86a6-0eb82485b1f4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_79f914c5-c106-4fc0-9188-436632dc36d1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_42aefef6-ff15-4587-a903-a3079cc7281d" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_79f914c5-c106-4fc0-9188-436632dc36d1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_003d3c67-cc5d-4d49-bdf6-296324901431" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_79f914c5-c106-4fc0-9188-436632dc36d1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_003d3c67-cc5d-4d49-bdf6-296324901431" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_003d3c67-cc5d-4d49-bdf6-296324901431_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_003d3c67-cc5d-4d49-bdf6-296324901431" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_003d3c67-cc5d-4d49-bdf6-296324901431_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_060aab48-cedc-46eb-9619-fab6a98a3762" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_003d3c67-cc5d-4d49-bdf6-296324901431" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_060aab48-cedc-46eb-9619-fab6a98a3762" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_0a7f2206-eb2c-4483-a96a-f0b7fb4ac4bd" xlink:href="cpix-20190630.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_060aab48-cedc-46eb-9619-fab6a98a3762" xlink:to="loc_cpix_VIBATIVMember_0a7f2206-eb2c-4483-a96a-f0b7fb4ac4bd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsChangeinConsiderationDetails" xlink:type="simple" xlink:href="cpix-20190630.xsd#RecentAdditionsandExpectedReturnofProductRightsChangeinConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsChangeinConsiderationDetails" xlink:type="extended" id="i9f4060912ae34fcf943f4dca74a7f402_7b49a21f-619e-48be-9161-79851b101c42">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_f91c8e8b-c27b-460e-82b6-bc8b1d424bbe" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualRollForward_d01692f8-d5c0-4870-860e-049fd8fd8457" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyAccrualRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f91c8e8b-c27b-460e-82b6-bc8b1d424bbe" xlink:to="loc_us-gaap_LossContingencyAccrualRollForward_d01692f8-d5c0-4870-860e-049fd8fd8457" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1957d00c-d55d-4aac-8eb1-3ce17e1588cb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_d01692f8-d5c0-4870-860e-049fd8fd8457" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1957d00c-d55d-4aac-8eb1-3ce17e1588cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment_8dd46388-1052-4c97-8cdf-c5537ad73e96" xlink:href="cpix-20190630.xsd#cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_d01692f8-d5c0-4870-860e-049fd8fd8457" xlink:to="loc_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment_8dd46388-1052-4c97-8cdf-c5537ad73e96" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_bf1f7fa8-e854-4d0d-8a96-1100bb623c93" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_d01692f8-d5c0-4870-860e-049fd8fd8457" xlink:to="loc_us-gaap_PaymentsForRoyalties_bf1f7fa8-e854-4d0d-8a96-1100bb623c93" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_b6ef7026-fa77-43e0-ab47-714c67f0dd0b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_d01692f8-d5c0-4870-860e-049fd8fd8457" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_b6ef7026-fa77-43e0-ab47-714c67f0dd0b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_ee125c8f-bbb0-4b81-8c62-89443b1db863" xlink:href="cpix-20190630.xsd#cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_d01692f8-d5c0-4870-860e-049fd8fd8457" xlink:to="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_ee125c8f-bbb0-4b81-8c62-89443b1db863" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e8397a1f-f0fe-45c0-afd6-14acb01a4f1a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1af8a990-3380-4314-b6d2-49919f99aeba" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f91c8e8b-c27b-460e-82b6-bc8b1d424bbe" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1af8a990-3380-4314-b6d2-49919f99aeba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1c2b73fa-841c-416d-882e-994fe1bb7ef6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1af8a990-3380-4314-b6d2-49919f99aeba" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1c2b73fa-841c-416d-882e-994fe1bb7ef6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1c2b73fa-841c-416d-882e-994fe1bb7ef6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1c2b73fa-841c-416d-882e-994fe1bb7ef6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1c2b73fa-841c-416d-882e-994fe1bb7ef6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0d935164-e4cc-4b25-849d-e3c83c4b20e7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1c2b73fa-841c-416d-882e-994fe1bb7ef6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0d935164-e4cc-4b25-849d-e3c83c4b20e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_19ecfc76-33fd-427c-ac63-50e4451f0162" xlink:href="cpix-20190630.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0d935164-e4cc-4b25-849d-e3c83c4b20e7" xlink:to="loc_cpix_VIBATIVMember_19ecfc76-33fd-427c-ac63-50e4451f0162" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsScheduleofPreliminaryPurchaseAllocationDetails" xlink:type="simple" xlink:href="cpix-20190630.xsd#RecentAdditionsandExpectedReturnofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsScheduleofPreliminaryPurchaseAllocationDetails" xlink:type="extended" id="ia45218f4f43c43dd8fac288b8221636a_00ebb21d-8c93-41cc-8897-17bf06b42fa2">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_836f9c30-34cf-492d-b822-2d59c13d3685" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_1632fd96-61ad-48a1-88a8-33d06d819492" xlink:href="cpix-20190630.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_836f9c30-34cf-492d-b822-2d59c13d3685" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_1632fd96-61ad-48a1-88a8-33d06d819492" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_ccf02570-2c75-4cf6-9c53-ed6b7ac4f81c" xlink:href="cpix-20190630.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_836f9c30-34cf-492d-b822-2d59c13d3685" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_ccf02570-2c75-4cf6-9c53-ed6b7ac4f81c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_6d8ca5fc-4187-4190-ba23-ed551b0f8e3a" xlink:href="cpix-20190630.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_836f9c30-34cf-492d-b822-2d59c13d3685" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_6d8ca5fc-4187-4190-ba23-ed551b0f8e3a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_4e52bd86-ba96-4286-a941-f978435bc2b0" xlink:href="cpix-20190630.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_836f9c30-34cf-492d-b822-2d59c13d3685" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_4e52bd86-ba96-4286-a941-f978435bc2b0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_78d9b06a-8269-4487-8de8-6269fdd4c2a9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_836f9c30-34cf-492d-b822-2d59c13d3685" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_78d9b06a-8269-4487-8de8-6269fdd4c2a9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_2638f475-6a22-4a79-8f80-efa418491f3d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_836f9c30-34cf-492d-b822-2d59c13d3685" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_2638f475-6a22-4a79-8f80-efa418491f3d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_aa64886e-bedb-47aa-9235-b39284379271" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_836f9c30-34cf-492d-b822-2d59c13d3685" xlink:to="loc_us-gaap_Goodwill_aa64886e-bedb-47aa-9235-b39284379271" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_088abda2-a87e-4f28-8051-4ebdc16f100b" xlink:href="cpix-20190630.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_836f9c30-34cf-492d-b822-2d59c13d3685" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_088abda2-a87e-4f28-8051-4ebdc16f100b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_246c58e3-9ec4-46f0-b5cb-5779eb5aa7fb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_836f9c30-34cf-492d-b822-2d59c13d3685" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_246c58e3-9ec4-46f0-b5cb-5779eb5aa7fb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c91212f9-33fc-4358-ab90-87e644083132" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_836f9c30-34cf-492d-b822-2d59c13d3685" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c91212f9-33fc-4358-ab90-87e644083132" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8c1553c3-a310-40d9-b3c2-0e89a371f68b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c91212f9-33fc-4358-ab90-87e644083132" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8c1553c3-a310-40d9-b3c2-0e89a371f68b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8c1553c3-a310-40d9-b3c2-0e89a371f68b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8c1553c3-a310-40d9-b3c2-0e89a371f68b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8c1553c3-a310-40d9-b3c2-0e89a371f68b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6dc3bf30-4782-480e-a062-7438bf8da7b4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8c1553c3-a310-40d9-b3c2-0e89a371f68b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6dc3bf30-4782-480e-a062-7438bf8da7b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_a1c0268f-34cb-4460-b276-00e171b3f376" xlink:href="cpix-20190630.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6dc3bf30-4782-480e-a062-7438bf8da7b4" xlink:to="loc_cpix_VIBATIVMember_a1c0268f-34cb-4460-b276-00e171b3f376" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>cpix-20190630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2017 Workiva-->
<!--r:fe2e4db3-48f2-4e84-a542-8dc9a0c345cd,g:b764091f-bd8f-4ce0-9900-bde14803e897-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c040a9e6-2f09-41ae-84c3-24adb7b47d4a_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition of operating lease assets and liabilities through adoption of ASC 842</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_57162ccc-619f-486c-868e-385c2eb462c6_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_4a270ebf-ac60-49f8-83b8-a1b5a56ed3ea_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to intangible assets from final purchase price allocation</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_afa6695e-5e65-4e69-a591-84c3fa54318f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate spread</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_19396394-baa3-4211-af96-4c1d4062f361_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_858a1705-9c07-4973-8b28-e99e3001ea41_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intangibles and goodwill</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_label_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles and Goodwill</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles and Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" xlink:href="cpix-20190630.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" xlink:to="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_164f2136-630d-4d5c-b6ed-1dea98ddf6b7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_44970ee9-a8d6-4e8e-9e4e-5840b096fd22_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_5fc65c41-1534-4b37-be82-2afbd4cf8c28_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payment of contingent consideration</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_cab080cb-1deb-4264-961a-aa48bd89a723_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_label_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Raw Materials Inventory</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Raw Materials Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" xlink:href="cpix-20190630.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" xlink:to="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_fe297830-f6ea-43d1-96a1-9cfcd0a4b90e_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_efeae02f-ce2f-4cea-87ad-e067ebb37af7_terseLabel_en-US" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:label id="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1050ac7e-61ac-4557-9322-794714aa7963_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity of Leases Liabilities at June 30, 2019</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liabilities, Payments Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_c2934f93-bdea-45e3-836b-033632210d90_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of the contingent consideration liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_fc9ebedc-70f4-49e2-8134-499ce69b81cb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8402fd07-549b-4da3-8f2f-13f029d0873d_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecurities_64a4dff1-49de-401d-bdfa-56fab0537dca_verboseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecurities_label_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecurities" xlink:to="lab_us-gaap_MarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_065ab412-1eac-495d-9490-0545492ed36a_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_a03382f0-ccdc-477b-9aed-308248256dbf_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_05408b8b-2fdd-4c27-ad57-b6ac1b8e5afd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e331e50d-32e5-46e5-8ea8-8f7133ba846c_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_cc9a3905-41ce-4ecd-b2a6-ce6e4b4f4500_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent portion of the contingent consideration liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_bf755850-1377-42a4-93a7-91e9c28d1207_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of marketable securities, by type</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_819e4f4e-0119-4562-b26b-d81510a92c62_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash investment gains</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CaldolorMember_5c79b51b-8f2a-4116-aa47-1c238ae3e872_terseLabel_en-US" xlink:label="lab_cpix_CaldolorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caldolor</link:label>
    <link:label id="lab_cpix_CaldolorMember_label_en-US" xlink:label="lab_cpix_CaldolorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caldolor [Member]</link:label>
    <link:label id="lab_cpix_CaldolorMember_documentation_en-US" xlink:label="lab_cpix_CaldolorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caldolor</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CaldolorMember" xlink:href="cpix-20190630.xsd#cpix_CaldolorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CaldolorMember" xlink:to="lab_cpix_CaldolorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_781cabe1-3d06-4e22-9fdd-19b4e7a7ba1e_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods, net of reserves</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_dda48541-8800-49fb-b847-46069bc455db_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_e3ae01be-2a98-42f1-a378-e780efbc97c5_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_ce972d2e-69c2-4a7a-93f5-8f9d30263908_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, Beginning of Period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_198a008c-4ad6-463b-a694-b4e67bc10c6e_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, End of Period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion_13c324b6-5ec0-43e3-aa77-cdeb766e5ae6_verboseLabel_en-US" xlink:label="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion_label_en-US" xlink:label="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long Term Obligations, Excluding Current Portion</link:label>
    <link:label id="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion_documentation_en-US" xlink:label="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long Term Obligations, Excluding Current Portion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:href="cpix-20190630.xsd#cpix_OtherLongTermObligationsExcludingCurrentPortion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:to="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_f3b4594f-2c57-4ca9-85b5-6d07da3aa334_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_PaymentsForAssetAcquisitions_35088425-05f2-4bec-93ef-73ddbef19cb8_terseLabel_en-US" xlink:label="lab_cpix_PaymentsForAssetAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for asset acquisitions</link:label>
    <link:label id="lab_cpix_PaymentsForAssetAcquisitions_label_en-US" xlink:label="lab_cpix_PaymentsForAssetAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Asset Acquisitions</link:label>
    <link:label id="lab_cpix_PaymentsForAssetAcquisitions_documentation_en-US" xlink:label="lab_cpix_PaymentsForAssetAcquisitions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Asset Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsForAssetAcquisitions" xlink:href="cpix-20190630.xsd#cpix_PaymentsForAssetAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_PaymentsForAssetAcquisitions" xlink:to="lab_cpix_PaymentsForAssetAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_3175de4c-2262-461f-b964-0e3f78ca8162_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_9bb604c2-054e-4484-9297-f607720a88b6_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common shares</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_6bb504c2-4fc8-457f-abae-f71c3798edd0_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net, Items Net of Reserve Alternative [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:to="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember_4f5026ed-4d39-4b36-8561-75a1383ed4e6_terseLabel_en-US" xlink:label="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WinHealth and DB Pharm</link:label>
    <link:label id="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember_label_en-US" xlink:label="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HongKong WinHealth Pharma Group Co. Limited And DB Pharm Korea Co., Ltd. [Member]</link:label>
    <link:label id="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember_documentation_en-US" xlink:label="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HongKong WinHealth Pharma Group Co. Limited And DB Pharm Korea Co., Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember" xlink:href="cpix-20190630.xsd#cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember" xlink:to="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_4e6d4783-55c4-43be-acfd-8362f46c6e24_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_9a751c32-dfd6-46a2-9449-31ad3309aec9_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_bfa540e3-5587-48b9-8073-5bf8e819dc26_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_e74b0938-4e33-4830-b3d8-d00289d4bd54_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_e914a202-c444-4cd5-9b37-4e034009be44_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_64f47a85-ada8-41e2-a148-d752de22e092_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_bd3606cd-5c65-4329-8457-c798ef574525_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_83cf643c-6ddd-4bc6-aeb0-4a503903f404_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0d93c50e-cd89-41f9-803a-6489e8f02b41_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment_16ecfe25-fdc9-40cb-b1dc-6d20d2e049eb_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to initial fair value of the contingent consideration liability</link:label>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment_label_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Contingent Consideration, Liability, Initial Fair Value Adjustment</link:label>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Contingent Consideration, Liability, Initial Fair Value Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment" xlink:href="cpix-20190630.xsd#cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment" xlink:to="lab_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_18af6540-85b6-4198-a5c3-62faefc24abf_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After 2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SecondAmendmentMember_12fa4579-3c37-4648-9d40-6edff32ae6f3_terseLabel_en-US" xlink:label="lab_cpix_SecondAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Amendment</link:label>
    <link:label id="lab_cpix_SecondAmendmentMember_label_en-US" xlink:label="lab_cpix_SecondAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Amendment [Member]</link:label>
    <link:label id="lab_cpix_SecondAmendmentMember_documentation_en-US" xlink:label="lab_cpix_SecondAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Amendment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SecondAmendmentMember" xlink:href="cpix-20190630.xsd#cpix_SecondAmendmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SecondAmendmentMember" xlink:to="lab_cpix_SecondAmendmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_1211eeb6-c746-4f15-8e6f-57eb3cca3c0e_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and Marketing Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpense" xlink:to="lab_us-gaap_SellingAndMarketingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LeaseLiability_4ce89464-6868-4dc3-824e-514abe157cf5_terseLabel_en-US" xlink:label="lab_cpix_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_cpix_LeaseLiability_label_en-US" xlink:label="lab_cpix_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability</link:label>
    <link:label id="lab_cpix_LeaseLiability_documentation_en-US" xlink:label="lab_cpix_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LeaseLiability" xlink:href="cpix-20190630.xsd#cpix_LeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LeaseLiability" xlink:to="lab_cpix_LeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_744196f9-2fbb-4c3b-9494-93035460cdc6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SaleOfStockNumberOfSharesSold_962302f6-b083-4a49-809e-56905cb5403b_terseLabel_en-US" xlink:label="lab_cpix_SaleOfStockNumberOfSharesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares sold (in shares)</link:label>
    <link:label id="lab_cpix_SaleOfStockNumberOfSharesSold_label_en-US" xlink:label="lab_cpix_SaleOfStockNumberOfSharesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Number Of Shares Sold</link:label>
    <link:label id="lab_cpix_SaleOfStockNumberOfSharesSold_documentation_en-US" xlink:label="lab_cpix_SaleOfStockNumberOfSharesSold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Number Of Shares Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SaleOfStockNumberOfSharesSold" xlink:href="cpix-20190630.xsd#cpix_SaleOfStockNumberOfSharesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SaleOfStockNumberOfSharesSold" xlink:to="lab_cpix_SaleOfStockNumberOfSharesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_8390d7fb-2305-453f-b917-3930e04b9e16_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income (loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_426e0fcc-bedd-45a8-a444-4953f9737589_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_0cdd694d-9be0-494c-9677-0972776c409d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_eb88ab59-8ee0-4e77-9248-693815ed2690_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial consideration received in exchange for product license rights</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_be3ca775-a266-437b-ba5d-ae094c5891df_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c248b47f-30a2-4893-9589-06664d1b618d_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net changes in assets and liabilities affecting operating activities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_bdae453f-f558-496c-9799-74b2bd9e64ac_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7fe6d801-e009-4ebf-89e2-06935fc4a068_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_ff2c342f-0803-431a-b78c-a2b928cd7533_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ClinigenHealthcareLimitedMember_f60bffb7-5b9e-4203-b38e-031fdb424140_terseLabel_en-US" xlink:label="lab_cpix_ClinigenHealthcareLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement</link:label>
    <link:label id="lab_cpix_ClinigenHealthcareLimitedMember_label_en-US" xlink:label="lab_cpix_ClinigenHealthcareLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinigen Healthcare Limited [Member]</link:label>
    <link:label id="lab_cpix_ClinigenHealthcareLimitedMember_documentation_en-US" xlink:label="lab_cpix_ClinigenHealthcareLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinigen Healthcare Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ClinigenHealthcareLimitedMember" xlink:href="cpix-20190630.xsd#cpix_ClinigenHealthcareLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ClinigenHealthcareLimitedMember" xlink:to="lab_cpix_ClinigenHealthcareLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LeaseAsset_061ef566-f093-4562-ad30-abfae7947607_terseLabel_en-US" xlink:label="lab_cpix_LeaseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_cpix_LeaseAsset_label_en-US" xlink:label="lab_cpix_LeaseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Asset</link:label>
    <link:label id="lab_cpix_LeaseAsset_documentation_en-US" xlink:label="lab_cpix_LeaseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LeaseAsset" xlink:href="cpix-20190630.xsd#cpix_LeaseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LeaseAsset" xlink:to="lab_cpix_LeaseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_63273e17-6a52-42c7-9fee-eae00d873930_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of remaining lease payments, percent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_9d7d0253-a3f9-4552-a928-eca1ee44a2a4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consigned inventory</link:label>
    <link:label id="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_label_en-US" xlink:label="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Inventory, Materials, Supplies and Merchandise under Consignment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:to="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_f32b9238-f989-48d3-9d3c-0232df9bf087_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of common stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_4483bd0d-5afb-4b4c-be5a-30882ecc4fb1_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_0fbafa8c-4651-4233-9d2d-6f3dd53f136d_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_db87f85d-2aaa-430e-9cef-6b895d2b2b2b_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_4b2a48ca-cf9c-4821-9b23-61fb8e1882fe_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings on line of credit</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Repayments of) Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_fc9aca69-0f63-40f1-a6ad-19a31ea8e188_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_cef3ef2a-ef86-40a9-8310-f86966fac999_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross, Total</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_82c79f05-0d80-4154-abf1-75a8c49ea5cd_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process - validation vials</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_label_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Validation Vials</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Validation Vials</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" xlink:href="cpix-20190630.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" xlink:to="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ShareholdersEquityTextualAbstract_f044e757-3167-49e8-9f9c-f295ace19c88_verboseLabel_en-US" xlink:label="lab_cpix_ShareholdersEquityTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity (Textual) [Abstract]</link:label>
    <link:label id="lab_cpix_ShareholdersEquityTextualAbstract_label_en-US" xlink:label="lab_cpix_ShareholdersEquityTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders Equity (Textual) [Abstract]</link:label>
    <link:label id="lab_cpix_ShareholdersEquityTextualAbstract_documentation_en-US" xlink:label="lab_cpix_ShareholdersEquityTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders Equity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareholdersEquityTextualAbstract" xlink:href="cpix-20190630.xsd#cpix_ShareholdersEquityTextualAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract" xlink:to="lab_cpix_ShareholdersEquityTextualAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_d6154621-3950-4ec6-ad79-126928f10da6_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_1a4811ca-3496-4a3d-a7af-15292adcee71_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RECENT ADDITIONS AND EXPECTED RETURN OF PRODUCT RIGHTS</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b0c54a9a-3d1a-4a65-9a6e-f2e2458ffdc4_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_a94e1882-5098-4be3-9bc1-54a66ce6ca0e_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental non-cash operating, investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_3e40730b-cccd-45ce-8191-9a2392c30be4_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_e99953ec-e65e-4842-8a0a-99fa7fc354de_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">- basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_eaa5628a-1754-4f32-8cd0-a6649fc8214f_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">- basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_abf91c68-bfb3-4369-a585-825218c2aa40_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding &#8211; basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_5f57794b-4541-4ef7-a8a1-f7c78d94fea3_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (income) loss at subsidiary attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_db201d64-1aa4-492c-abc9-59ec4abe7b6a_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_081333de-3330-4580-93da-d29476cc9044_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ProductsAbstract_3211e263-59a2-4374-9037-acbc2b796a6d_verboseLabel_en-US" xlink:label="lab_cpix_ProductsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products:</link:label>
    <link:label id="lab_cpix_ProductsAbstract_label_en-US" xlink:label="lab_cpix_ProductsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products [Abstract]</link:label>
    <link:label id="lab_cpix_ProductsAbstract_documentation_en-US" xlink:label="lab_cpix_ProductsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductsAbstract" xlink:href="cpix-20190630.xsd#cpix_ProductsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ProductsAbstract" xlink:to="lab_cpix_ProductsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_ac3cd2f4-4d41-43d5-887a-02c08d9cde62_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_a2954ef1-6ec6-4a8c-a2d3-4ee8dee720ae_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_141452a5-201b-4427-8e21-e13eb070ec44_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DenominatorAbstract_a5f7e556-4e0b-4040-9ed1-91fcf766935e_verboseLabel_en-US" xlink:label="lab_cpix_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_cpix_DenominatorAbstract_label_en-US" xlink:label="lab_cpix_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator [Abstract]</link:label>
    <link:label id="lab_cpix_DenominatorAbstract_documentation_en-US" xlink:label="lab_cpix_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DenominatorAbstract" xlink:href="cpix-20190630.xsd#cpix_DenominatorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DenominatorAbstract" xlink:to="lab_cpix_DenominatorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bea4462d-e4cd-4587-a415-0719b89c6f2c_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_bfd06997-77af-409a-b791-c6a0ff73c7d5_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash interest expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_c67c04a8-495c-40f3-820e-5ce82a6aec21_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_VaprisolMember_f9818617-ea06-4968-8d26-36c51f8b4e8c_terseLabel_en-US" xlink:label="lab_cpix_VaprisolMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaprisol</link:label>
    <link:label id="lab_cpix_VaprisolMember_label_en-US" xlink:label="lab_cpix_VaprisolMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaprisol [Member]</link:label>
    <link:label id="lab_cpix_VaprisolMember_documentation_en-US" xlink:label="lab_cpix_VaprisolMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaprisol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VaprisolMember" xlink:href="cpix-20190630.xsd#cpix_VaprisolMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_VaprisolMember" xlink:to="lab_cpix_VaprisolMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_AcetadoteMember_f2d0dc81-26b4-4973-83b7-205e6a91c8fa_terseLabel_en-US" xlink:label="lab_cpix_AcetadoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acetadote</link:label>
    <link:label id="lab_cpix_AcetadoteMember_label_en-US" xlink:label="lab_cpix_AcetadoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acetadote [Member]</link:label>
    <link:label id="lab_cpix_AcetadoteMember_documentation_en-US" xlink:label="lab_cpix_AcetadoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acetadote</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AcetadoteMember" xlink:href="cpix-20190630.xsd#cpix_AcetadoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_AcetadoteMember" xlink:to="lab_cpix_AcetadoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3f27778a-f076-418e-a631-2fe3645014e9_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPaymentsToAcquireBusinesses_a6dff511-a4db-4203-9cba-d14bfb6db9ba_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payment during early 2019</link:label>
    <link:label id="lab_us-gaap_OtherPaymentsToAcquireBusinesses_label_en-US" xlink:label="lab_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Payments to Acquire Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:to="lab_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_59c90441-044b-4262-a0d0-52c7649acf77_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_OtherProductsMember_14709f2b-9f84-4019-99f6-2febfb52e976_terseLabel_en-US" xlink:label="lab_cpix_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_cpix_OtherProductsMember_label_en-US" xlink:label="lab_cpix_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products [Member]</link:label>
    <link:label id="lab_cpix_OtherProductsMember_documentation_en-US" xlink:label="lab_cpix_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherProductsMember" xlink:href="cpix-20190630.xsd#cpix_OtherProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_OtherProductsMember" xlink:to="lab_cpix_OtherProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4e887377-f7cb-4972-b58e-13ea08ab99cc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_1dd7537c-aa8f-4437-a6c4-bda870ae95f1_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock&#8212;no par value; 100,000,000 shares authorized; 15,555,865 and 15,723,075 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_2a11ac3c-8489-4307-a84a-0ba0ca716ab4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_3ea6be38-c96f-4c07-a604-667a2d88abd6_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_fe360acc-6c56-44d9-b855-c4fb3751617b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intellectual property amortizable intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_152aacaf-182c-4c93-9108-1aab08f1a539_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_5c21f46d-ea44-4e6f-99e9-550bb5e2f8a4_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_88fb1185-ab6b-446e-ad37-9992c9effe30_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_33db3f61-fc02-4892-8282-87de249d1c85_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_52463912-2d57-4363-8648-c0795afe9c55_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_0fd0c8c3-b368-4d92-9978-1d6d571ca0a6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScenarioUnspecifiedDomain_ec179686-4f4e-4984-b94f-22654b6f7dc9_terseLabel_en-US" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:label id="lab_us-gaap_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain" xlink:to="lab_us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_03f79ad3-18d7-4599-9ebf-6911868ecc8b_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DirectorMember_38583022-d197-4e08-bf77-40dbf5c6ca0f_terseLabel_en-US" xlink:label="lab_us-gaap_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director</link:label>
    <link:label id="lab_us-gaap_DirectorMember_label_en-US" xlink:label="lab_us-gaap_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DirectorMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DirectorMember" xlink:to="lab_us-gaap_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_e32ea514-dc9f-47ff-bcdb-d660ec96920d_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_e284a553-1697-4175-bc49-a32910704aa4_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SHAREHOLDERS' EQUITY AND DEBT</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_ca592bdc-d8a0-463f-96cd-948b0fd9ab9f_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Revenues</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_46a533a0-a2a1-410c-a9c3-e0cafaa51bcb_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_5e67fffe-ef98-4a02-a7f7-8e39ae7721c6_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_70d05cf9-d28f-4a15-aa74-f4c7676cc1c6_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_3cb5c736-a7f2-4831-8426-e13d10a9cdc2_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_88e8a5ab-803a-4c0e-b32f-34ddb93ebedd_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TitleOfIndividualAxis_75d802d9-8c9b-4248-bce6-04b1ff67f3a6_terseLabel_en-US" xlink:label="lab_us-gaap_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_us-gaap_TitleOfIndividualAxis_label_en-US" xlink:label="lab_us-gaap_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualAxis" xlink:to="lab_us-gaap_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementScenarioAxis_9c7df43a-deb6-4baa-816f-875d3562b4ae_terseLabel_en-US" xlink:label="lab_us-gaap_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementScenarioAxis_label_en-US" xlink:label="lab_us-gaap_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementScenarioAxis" xlink:to="lab_us-gaap_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_94f04673-ad53-493b-8a19-3b753cfb4bd2_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_44bdb5be-d35a-49d7-a3bb-b125de476ef0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax expense</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_8b82af26-3293-40b0-96da-7a6f7494bd1e_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_5b44baea-4f5c-44c3-b32a-de3a46e09872_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_4aaef1d3-bb31-4739-8e21-4d120b826ddd_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_c1ed99a6-27d3-49f8-8919-d4e2ac6c3a7a_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_d140e2cf-dffb-47ae-b156-412029ba5595_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_ede1d90f-905d-4f7f-887c-4acb59f8f3cf_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryCurrentTable_775a4d30-66e7-45b6-8d05-1a23bd72d0fb_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable" xlink:to="lab_us-gaap_InventoryCurrentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_051f0a3a-badf-45b6-8413-425ad36132a2_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_e324b6b0-80fe-4511-9565-8b3f7da660e9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_865950d6-8a75-4d9a-9e67-a16de8afc2df_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_297f39bd-33d0-4a9c-9e47-ee253db8c7d2_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_18614205-a8ad-407d-8368-a3e4f18886a3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d7b76ca7-c4b2-4c86-bef0-b8af47630554_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the sale of common stock, net of offering costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_cc89f95a-6cb8-4909-b096-396ed18f2b84_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">- diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_cb9868fa-1e5d-4531-aab3-7041aa934eef_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_4ce1d788-a5a7-4cba-8eb3-a6486d5333b5_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_4bdcd74b-b765-4d86-a0f7-b083511402be_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_b16a1c33-e070-495a-9bff-67122714f7a9_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_c98b8d7b-275e-4807-9b1a-30940e89ffc7_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit, unused capacity, commitment fee percentage</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Unused Capacity, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_eb256662-2194-4bf7-9220-17a36e93304d_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_57d19dac-81c7-4aff-921e-b0b6f1ae5a6c_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_c893f2b0-0656-4ebc-b839-47ff6e0e1fd3_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax (expense) benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_2a221348-b08e-48d9-a45c-aae5ff1e2bdd_terseLabel_en-US" xlink:label="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit, maximum borrowing capacity upon satisfaction of certain conditions</link:label>
    <link:label id="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_label_en-US" xlink:label="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Maximum Borrowing Capacity Upon Satisfaction Of Certain Conditions</link:label>
    <link:label id="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_documentation_en-US" xlink:label="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Maximum Borrowing Capacity Upon Satisfaction Of Certain Conditions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" xlink:href="cpix-20190630.xsd#cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" xlink:to="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_6595635b-a676-4337-8e7b-bd26195412fb_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_013f73da-01d7-4868-aa81-0b5bd62761de_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REVENUES</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_813e2f43-6ee7-45bf-9f6d-7decbabc55c5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_6d832586-a680-4d63-98ac-24a83a6d248c_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_72942fb4-5d5d-427d-915a-011783124cef_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories classified as current</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_55b23927-6086-4955-a31d-bcd7357b3533_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_06307b33-5ad4-468d-b22f-88c36ec58c8a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturity of Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_fa66b91c-5559-45bc-bf7c-6be7ab18d627_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_c54ed432-65ca-4c20-babf-ed2635814ca1_negatedLabel_en-US" xlink:label="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Decrease) increase in non-cash contingent consideration</link:label>
    <link:label id="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_label_en-US" xlink:label="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess Tax Benefit from Share-based Compensation, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:to="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_83e7321e-0b6f-4be0-aa3d-3c1e570ae29d_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock available for purchase through restricted stock awards and options (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermLineOfCredit_6b24d2ac-f844-49dc-b62f-4e37ad237a23_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermLineOfCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving line of credit</link:label>
    <link:label id="lab_us-gaap_LongTermLineOfCredit_label_en-US" xlink:label="lab_us-gaap_LongTermLineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Line of Credit, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermLineOfCredit" xlink:to="lab_us-gaap_LongTermLineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_3bf1344e-ff9a-4ab2-8e3e-7317e32cd008_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MARKETABLE SECURITIES</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_dd7b8f61-5ec1-449f-aa1a-a20c52fb7100_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_1c3f5886-2364-41e3-b6d1-899c5f89b124_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_c4c1c967-29fd-4f76-a3a4-73697c13601c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_253f5469-aae2-4244-8337-6735492e445b_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_2a4cdd82-61b0-4eb2-b190-2111139d3cff_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_80849093-9653-48da-baf9-f0f0610265a5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_12877d78-325e-43aa-afd2-1af964c24ea5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of numerator and denominator</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_eb8daaea-9caf-45e6-b720-64b9707d23f7_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_ceecad11-4eb0-4d67-8a6e-08eb879f2632_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualRollForward_ad05e847-a26f-4433-baa0-b501b99424b8_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualRollForward_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyAccrualRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward" xlink:to="lab_us-gaap_LossContingencyAccrualRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_b1861477-c44b-464a-aa94-e29bf76ecee5_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8de3b355-3e12-4e51-8482-0cb426eb5118_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_c243b2d7-5d2a-4cd4-ace2-b6d7f900f93b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fed1abd2-5b52-47f0-8a1f-d2cb0ccbff88_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_04bbfdfb-ce26-4e92-aedd-657fbeab1a9f_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, Beginning of Period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1898bfea-8694-40e1-a4c8-757f7f21bb9f_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, End of Period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_a9f44054-1e40-4657-8862-66cd5ebdc0d1_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c82df13e-5969-491e-b920-7d7370629eee_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss) attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_8ef4146c-d282-46ff-b6c3-b8486cb69af6_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_0366ef10-df5e-450a-af4c-b0065eb9b176_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_c643d1e0-1f25-4aa4-b787-6cc81fb79569_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_adb5deac-4081-4465-a7f7-18a7807281ad_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_ed12361e-d141-46ec-a9c9-14497f58d313_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2f024abe-a31c-4f2b-8e53-cd7855ac3d45_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock granted in period, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_5fc5ca21-1a2f-4b3a-80c6-8899d5552eb1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_OmeclamoxPakMember_b88a7771-33fa-47be-b382-f2ee4946a192_terseLabel_en-US" xlink:label="lab_cpix_OmeclamoxPakMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omeclamox-Pak</link:label>
    <link:label id="lab_cpix_OmeclamoxPakMember_label_en-US" xlink:label="lab_cpix_OmeclamoxPakMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omeclamox-Pak [Member]</link:label>
    <link:label id="lab_cpix_OmeclamoxPakMember_documentation_en-US" xlink:label="lab_cpix_OmeclamoxPakMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omeclamox-Pak</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OmeclamoxPakMember" xlink:href="cpix-20190630.xsd#cpix_OmeclamoxPakMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_OmeclamoxPakMember" xlink:to="lab_cpix_OmeclamoxPakMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_66775900-a084-416f-82ae-ed7b26daa0f3_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_d58568f1-1cd4-40c4-899d-05781985b3c9_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_44bf6a16-fe7f-4b73-8a89-dd019a1e0156_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of common stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_19a4c743-94ce-42e8-9d00-89639aded716_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6b7cf6a6-d792-4f3e-9b12-5d1b210db0c4_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Guidance</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_dbf12193-449d-40ac-99db-cf387e3ae3a3_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">- diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3c6769b8-2282-4f72-a418-03640d8f170e_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding &#8211; diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_2cdbdc83-ebcf-4ebf-9a9b-19800fd9f6f1_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MunicipalBondsMember_e53fab24-eb5b-4944-b890-12c3785b79a8_terseLabel_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term cash investments</link:label>
    <link:label id="lab_us-gaap_MunicipalBondsMember_label_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MunicipalBondsMember" xlink:to="lab_us-gaap_MunicipalBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_811292b7-e85f-4003-acc8-380677441b92_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ORGANIZATION AND BASIS OF PRESENTATION</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_7bae71c9-d900-4a1c-9dfb-d85c4f4c3792_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_14e4c27e-2f00-4992-ac63-048dcce34652_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_PaymentsForContingentConsideration_664bcdfb-81f7-43c7-b8b4-deb1c7693885_terseLabel_en-US" xlink:label="lab_cpix_PaymentsForContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of contingent consideration - net sales royalty</link:label>
    <link:label id="lab_cpix_PaymentsForContingentConsideration_label_en-US" xlink:label="lab_cpix_PaymentsForContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Contingent Consideration</link:label>
    <link:label id="lab_cpix_PaymentsForContingentConsideration_documentation_en-US" xlink:label="lab_cpix_PaymentsForContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsForContingentConsideration" xlink:href="cpix-20190630.xsd#cpix_PaymentsForContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_PaymentsForContingentConsideration" xlink:to="lab_cpix_PaymentsForContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_012286d6-9a7a-4ef1-bf9d-bd2b0d5005b5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_4faf5de1-2df1-44ca-81b6-50e190070bd4_verboseLabel_en-US" xlink:label="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other current liabilities</link:label>
    <link:label id="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_label_en-US" xlink:label="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IncreaseDecreaseInCurrentOperatingLiabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:href="cpix-20190630.xsd#cpix_IncreaseDecreaseInCurrentOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:to="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserves_4deea850-57ad-44c8-8409-0aa808378824_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for potential obsolescence of products</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves" xlink:to="lab_us-gaap_InventoryValuationReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable_18bb0110-6700-4e98-a6d5-0b60ae7f597d_terseLabel_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of intercompany loans payable</link:label>
    <link:label id="lab_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable_label_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary Investment, Conversion Of Intercompany Loans Payable</link:label>
    <link:label id="lab_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable_documentation_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary Investment, Conversion Of Intercompany Loans Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable" xlink:href="cpix-20190630.xsd#cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable" xlink:to="lab_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_10c87e33-a400-4525-83c6-30f0648a3063_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of net revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_PinnacleBankMember_e395f18a-7672-4458-85d1-8a6d2c1eeda0_terseLabel_en-US" xlink:label="lab_cpix_PinnacleBankMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Bank</link:label>
    <link:label id="lab_cpix_PinnacleBankMember_label_en-US" xlink:label="lab_cpix_PinnacleBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Bank [Member]</link:label>
    <link:label id="lab_cpix_PinnacleBankMember_documentation_en-US" xlink:label="lab_cpix_PinnacleBankMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Bank</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember" xlink:href="cpix-20190630.xsd#cpix_PinnacleBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_PinnacleBankMember" xlink:to="lab_cpix_PinnacleBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_f676fb13-530a-427d-93df-66b336c0b5e2_terseLabel_en-US" xlink:label="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Position</link:label>
    <link:label id="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="cpix-20190630.xsd#cpix_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_ffa05ff5-f015-441a-a3c6-af28c6506380_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_ed6f0720-685a-42ca-930f-0bf8429f375e_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for acquisitions</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_1948bea2-eff9-4ecf-8baa-b964403c249c_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment to acquire business upon closing</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_5a8135ee-f119-4324-8c63-ee7d0f192f6b_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment to acquire business upon closing</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNoParValue_e60c0a35-43ac-419e-b6e8-0febc04af34d_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNoParValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockNoParValue_label_en-US" xlink:label="lab_us-gaap_CommonStockNoParValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, No Par Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNoParValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockNoParValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNoParValue" xlink:to="lab_us-gaap_CommonStockNoParValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_529ce49b-7410-48a8-83f1-e44432ac4bed_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_51f49750-2e02-4571-a930-bc678dab6248_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_e0480d91-3a66-4bba-a0b9-1d46a22c506b_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive effect of other securities (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_5694b0b1-758b-4085-81a9-e308eb2ab2bb_terseLabel_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payments for return of shares</link:label>
    <link:label id="lab_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_label_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary Investment, Payments For Return Of Capital</link:label>
    <link:label id="lab_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_documentation_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary Investment, Payments For Return Of Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital" xlink:href="cpix-20190630.xsd#cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital" xlink:to="lab_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_18262ba7-1287-469e-b549-b89b2a7d8b6d_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration earned and accrued in operating expenses</link:label>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_label_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses</link:label>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:href="cpix-20190630.xsd#cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:to="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_61b7b37f-2a03-4c70-a179-dfe485db5f07_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_ee522040-233b-40ad-a82f-d4fddbdef7cc_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_44fdc3eb-5062-4b88-adf5-ac974824bf99_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (income) loss at subsidiary attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_658e4161-4b60-4827-a5ce-cee94394fcce_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials and work in process</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_745e3556-9ba9-430a-a4ab-26392dcad6bc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments on line of credit</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9e422f1a-95a2-46c4-9d4d-709eb9f78e70_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_EthyolMember_77c4b11b-c904-4a26-90c3-bb1c61ec4f45_terseLabel_en-US" xlink:label="lab_cpix_EthyolMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ethyol</link:label>
    <link:label id="lab_cpix_EthyolMember_label_en-US" xlink:label="lab_cpix_EthyolMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ethyol [Member]</link:label>
    <link:label id="lab_cpix_EthyolMember_documentation_en-US" xlink:label="lab_cpix_EthyolMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ethyol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EthyolMember" xlink:href="cpix-20190630.xsd#cpix_EthyolMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_EthyolMember" xlink:to="lab_cpix_EthyolMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_578c97fb-d6c8-4195-90b2-b16faf42d73c_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_3868165c-bf2a-4a19-85dc-84926a2df762_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_f5b7304a-c0ee-4853-a142-f5a62a1592a9_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_17ab20f7-3ea5-4b10-9728-edc734b9f4c9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_d9d0096b-084d-43cd-b35e-7d35a5717354_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_36dfc0c7-25b0-4f00-80db-ec2b07c6a437_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_47b96aad-b00d-43bf-8556-3ca74e1ce69f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_a228b066-1bb1-4312-8fdf-16827c559239_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScenarioForecastMember_51cf920c-db82-4d4f-93ae-d9c14a6f8c33_terseLabel_en-US" xlink:label="lab_us-gaap_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Forecast</link:label>
    <link:label id="lab_us-gaap_ScenarioForecastMember_label_en-US" xlink:label="lab_us-gaap_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScenarioForecastMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioForecastMember" xlink:to="lab_us-gaap_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_UsTreasuryNotesAndBondsSecuritiesMemberMember_2edb358d-7c20-4766-b299-6aca247a0ca9_terseLabel_en-US" xlink:label="lab_cpix_UsTreasuryNotesAndBondsSecuritiesMemberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury notes and bonds</link:label>
    <link:label id="lab_cpix_UsTreasuryNotesAndBondsSecuritiesMemberMember_label_en-US" xlink:label="lab_cpix_UsTreasuryNotesAndBondsSecuritiesMemberMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Us Treasury Notes And Bonds Securities Member [Member]</link:label>
    <link:label id="lab_cpix_UsTreasuryNotesAndBondsSecuritiesMemberMember_documentation_en-US" xlink:label="lab_cpix_UsTreasuryNotesAndBondsSecuritiesMemberMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Us Treasury Notes And Bonds Securities Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_UsTreasuryNotesAndBondsSecuritiesMemberMember" xlink:href="cpix-20190630.xsd#cpix_UsTreasuryNotesAndBondsSecuritiesMemberMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_UsTreasuryNotesAndBondsSecuritiesMemberMember" xlink:to="lab_cpix_UsTreasuryNotesAndBondsSecuritiesMemberMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_96202735-7d3a-4ec3-bc11-72e390bad713_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_eb37b5fc-e18c-4817-9ed7-a39f0c2602d7_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_37562c85-268a-49cb-9108-1e457b0b1b6f_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_6121e378-5639-499d-8726-b25ad7c70192_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_69215eba-d44e-47ad-927d-97c00e92d2be_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_0b6fcd3d-21fe-45c7-93b2-cf84673d43e5_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_d23172fa-8505-4bb4-b749-7686b91eb208_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process - unlabeled vials</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_label_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Unlabeled Vials</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Unlabeled Vials</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" xlink:href="cpix-20190630.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" xlink:to="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_92dcca23-eea0-49d2-b50b-b252b37eb71e_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_5b7e7263-d5c4-41b4-ae90-9b18abc2fbdc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of shares, value</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_6311a48a-1c8c-49c5-b2fa-5d04b19e9f7c_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_GloriaPharmaceuticalsMember_4381cd5e-319f-445c-98a8-0fc85c061161_terseLabel_en-US" xlink:label="lab_cpix_GloriaPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gloria Pharmaceuticals</link:label>
    <link:label id="lab_cpix_GloriaPharmaceuticalsMember_label_en-US" xlink:label="lab_cpix_GloriaPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gloria Pharmaceuticals [Member]</link:label>
    <link:label id="lab_cpix_GloriaPharmaceuticalsMember_documentation_en-US" xlink:label="lab_cpix_GloriaPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gloria Pharmaceuticals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_GloriaPharmaceuticalsMember" xlink:href="cpix-20190630.xsd#cpix_GloriaPharmaceuticalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_GloriaPharmaceuticalsMember" xlink:to="lab_cpix_GloriaPharmaceuticalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ca7eb0e4-33b3-4856-ba8b-d2487ae51f51_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards, vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_9685a15d-277f-4ff1-a59d-e65e2aa74576_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_565e3094-a964-4bac-be58-924b0ddf1df0_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_cbaea4e6-3661-4b7e-b8a1-bfef54f561a8_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNoncurrent_09e9be87-e3dd-4843-9a4a-e5c94464165b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_397dbfc5-466c-45f6-8781-8ab353b57a7d_negatedLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent" xlink:to="lab_us-gaap_InventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_72146b1a-d800-40dc-9f23-49ce23c9f849_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_6b40cacd-a3c7-4cdb-ad9d-1d77ed406e72_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradingSecurities_468f4fc6-6d89-4597-af9e-85fe4bbb51a8_terseLabel_en-US" xlink:label="lab_us-gaap_TradingSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_TradingSecurities_label_en-US" xlink:label="lab_us-gaap_TradingSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TradingSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradingSecurities" xlink:to="lab_us-gaap_TradingSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_b5b993b3-8fc2-424f-b455-9c22ca231b8e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration included in operating expenses</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_EquityAndDebtAbstract_label_en-US" xlink:label="lab_cpix_EquityAndDebtAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity and Debt [Abstract]</link:label>
    <link:label id="lab_cpix_EquityAndDebtAbstract_documentation_en-US" xlink:label="lab_cpix_EquityAndDebtAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity and Debt [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EquityAndDebtAbstract" xlink:href="cpix-20190630.xsd#cpix_EquityAndDebtAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_EquityAndDebtAbstract" xlink:to="lab_cpix_EquityAndDebtAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_be9b8ed6-8d2e-4546-a7de-d385222840c2_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_c2460551-3419-4682-ae94-f798c76e3455_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_0b0c0d34-0ac2-4d66-be48-4021f0764b75_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_84de788d-b582-4338-8aff-20da796b49ac_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_4aeaec86-9201-4133-94d3-b0f29bc66658_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payment of royalty during the period</link:label>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_label_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRoyalties" xlink:to="lab_us-gaap_PaymentsForRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_806fc707-2052-48c6-88ea-022650364dd8_verboseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase outstanding common shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_KristaloseMember_5e476e18-3314-48ab-b5d5-884ec3cec979_terseLabel_en-US" xlink:label="lab_cpix_KristaloseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kristalose</link:label>
    <link:label id="lab_cpix_KristaloseMember_label_en-US" xlink:label="lab_cpix_KristaloseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kristalose [Member]</link:label>
    <link:label id="lab_cpix_KristaloseMember_documentation_en-US" xlink:label="lab_cpix_KristaloseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kristalose</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KristaloseMember" xlink:href="cpix-20190630.xsd#cpix_KristaloseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_KristaloseMember" xlink:to="lab_cpix_KristaloseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_f1f77731-3bb6-44f1-b358-5de1e937cb3a_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_fa687a41-2468-40c4-b004-6e6edbdaab10_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_f0f8e255-9847-4809-bc25-0f55bd2aecf1_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_14ae08e3-526c-490a-83ea-0209b9cefdb8_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_8a16f40c-8da4-4913-bb17-a1e5e00aebca_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_0f84515b-9e16-45b9-913b-9a9f9bfb4030_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fb54f349-08a2-4570-85e7-8ca52a3ccd8b_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a27064ad-cd7d-4a16-9a64-1bce7546b5f9_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_6089b940-3843-44aa-8ae0-6b9b42a7cb79_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_54782d59-0848-4d4f-b0f1-0196945fec1b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_NumeratorAbstract_11522f4f-b04e-40cf-9014-12e6c8797379_verboseLabel_en-US" xlink:label="lab_cpix_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_cpix_NumeratorAbstract_label_en-US" xlink:label="lab_cpix_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator [Abstract]</link:label>
    <link:label id="lab_cpix_NumeratorAbstract_documentation_en-US" xlink:label="lab_cpix_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NumeratorAbstract" xlink:href="cpix-20190630.xsd#cpix_NumeratorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_NumeratorAbstract" xlink:to="lab_cpix_NumeratorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_d925560a-c785-48ef-88f8-be4764ffdf07_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_0ca7b667-d9df-457f-b69e-02ff4e307a40_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_322d9593-ae6c-4355-ad1f-8e7d1ba19def_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of deferred offering costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3421420d-2147-4a03-8867-0f2a01aab2ae_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_55d367d5-d047-4b60-98a6-f40a087bb7a6_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_917aa4a6-7124-4204-8100-0b24e37b01c3_terseLabel_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration, sale of corporate securities (up to)</link:label>
    <link:label id="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_label_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:href="cpix-20190630.xsd#cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:to="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7149cd21-cb36-44e0-9777-1c0bc8456ab4_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit, maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_49a28e2d-c7d5-4eb0-93ca-fd38d5787e9c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SubsidiaryInvestmentCashContribution_7465d218-1c69-47c2-bd68-05240ea51b8a_terseLabel_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentCashContribution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contribution of cash</link:label>
    <link:label id="lab_cpix_SubsidiaryInvestmentCashContribution_label_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentCashContribution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary Investment, Cash Contribution</link:label>
    <link:label id="lab_cpix_SubsidiaryInvestmentCashContribution_documentation_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentCashContribution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary Investment, Cash Contribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentCashContribution" xlink:href="cpix-20190630.xsd#cpix_SubsidiaryInvestmentCashContribution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SubsidiaryInvestmentCashContribution" xlink:to="lab_cpix_SubsidiaryInvestmentCashContribution" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_f981e9ef-a327-4c88-bec0-745d2e0b3967_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SubsidiaryInvestmentPurchaseOfShares_59044413-a738-4d99-9995-00162b36bdc7_terseLabel_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentPurchaseOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment through purchase of shares of CET Stock</link:label>
    <link:label id="lab_cpix_SubsidiaryInvestmentPurchaseOfShares_label_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentPurchaseOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary Investment, Purchase Of Shares</link:label>
    <link:label id="lab_cpix_SubsidiaryInvestmentPurchaseOfShares_documentation_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentPurchaseOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary Investment, Purchase Of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentPurchaseOfShares" xlink:href="cpix-20190630.xsd#cpix_SubsidiaryInvestmentPurchaseOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SubsidiaryInvestmentPurchaseOfShares" xlink:to="lab_cpix_SubsidiaryInvestmentPurchaseOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_f951239b-8a22-4573-8b99-bad31aec5488_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_5790c3ce-1c96-4904-b1f3-b1ddc1c27f40_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_d728c8ea-f406-4ef3-8d67-9fff04f7df55_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_4e789b39-0754-4d00-ae46-59def0b91af6_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_3ced6958-0102-47fe-8ca1-14d1845d7027_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_b5f7eefc-8e2c-417b-b3cd-bffca197830a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_33c7a721-1617-4d22-ad17-966bdca4af7e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_100a92ef-5a22-47c7-92f7-91aa498d23f4_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of subsidiary shares from noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_feee2db3-68a7-44d2-8c15-8115b18b339c_negatedLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of subsidiary shares from noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRightsGrantedMember_3d1a1e72-8074-42a8-8a9b-74392c5def77_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRightsGrantedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CET Grant Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueRightsGrantedMember_label_en-US" xlink:label="lab_us-gaap_RevenueRightsGrantedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Rights Granted [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRightsGrantedMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRightsGrantedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRightsGrantedMember" xlink:to="lab_us-gaap_RevenueRightsGrantedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_8b1cc682-495e-4a72-ad59-a54083efb211_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_822a496b-0652-4b48-b0f4-a57686f3b80d_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_0306aa8f-ed15-4227-857d-608da0b06a6b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVENTORIES</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_d79245fc-7786-4f32-bca0-852e425b2874_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_98136720-125f-4ceb-8b9e-49daddb9f71a_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_fbdce0db-85d3-47bb-8268-38d98d1060f3_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current inventory</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_5068081e-3433-48be-b13d-bcd67a56f123_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_35fe34c9-c850-40f7-a2ec-04baa002cfa3_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_TieredRoyaltyPaymentsPercentage_3b0a2869-219f-4cf8-80c1-7689c445cbcb_terseLabel_en-US" xlink:label="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of tiered royalty payments (up to)</link:label>
    <link:label id="lab_cpix_TieredRoyaltyPaymentsPercentage_label_en-US" xlink:label="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered Royalty Payments, Percentage</link:label>
    <link:label id="lab_cpix_TieredRoyaltyPaymentsPercentage_documentation_en-US" xlink:label="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered Royalty Payments, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TieredRoyaltyPaymentsPercentage" xlink:href="cpix-20190630.xsd#cpix_TieredRoyaltyPaymentsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_TieredRoyaltyPaymentsPercentage" xlink:to="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_f636a71d-ccf4-4f96-ad6f-8a3f1761c11b_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_5496b91e-c449-4f00-803c-3291628e572c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EARNINGS (LOSS) PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_0378c697-a5ac-4df2-b4d8-af9319efc45a_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COLLABORATIVE AGREEMENTS</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_53dd4694-9ea2-49ca-b934-e181da216d24_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding_c76ab23d-d811-43a7-8e02-f280218816e5_terseLabel_en-US" xlink:label="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued</link:label>
    <link:label id="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding_label_en-US" xlink:label="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Net of Shares for Tax Withholding</link:label>
    <link:label id="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding_documentation_en-US" xlink:label="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Net of Shares for Tax Withholding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding" xlink:href="cpix-20190630.xsd#cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding" xlink:to="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_1c19372b-2a8a-4ada-b3b9-d80e300ac0c5_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods inventory</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_label_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finished Goods Inventory</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finished Goods Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" xlink:href="cpix-20190630.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" xlink:to="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_97381350-dcc0-4607-bd03-c47c71d13946_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_VIBATIVMember_fa270ed7-274f-46f8-8f6d-440290f34048_terseLabel_en-US" xlink:label="lab_cpix_VIBATIVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vibativ</link:label>
    <link:label id="lab_cpix_VIBATIVMember_label_en-US" xlink:label="lab_cpix_VIBATIVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VIBATIV [Member]</link:label>
    <link:label id="lab_cpix_VIBATIVMember_documentation_en-US" xlink:label="lab_cpix_VIBATIVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VIBATIV</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember" xlink:href="cpix-20190630.xsd#cpix_VIBATIVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_VIBATIVMember" xlink:to="lab_cpix_VIBATIVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_2a8818dd-dd41-433e-a7a0-435d6b0af6a6_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_f1836a20-4e2a-42c2-981e-ce8070056401_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_d255a95c-7e24-472a-b2af-05e83a21ac5c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_a50e2531-f7b3-418d-9f8e-ae3ee6840be8_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_TotectMember_e9a4dc72-f1ce-4fa0-9ce7-ce9a2e702c1c_terseLabel_en-US" xlink:label="lab_cpix_TotectMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Totect</link:label>
    <link:label id="lab_cpix_TotectMember_label_en-US" xlink:label="lab_cpix_TotectMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Totect [Member]</link:label>
    <link:label id="lab_cpix_TotectMember_documentation_en-US" xlink:label="lab_cpix_TotectMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Totect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TotectMember" xlink:href="cpix-20190630.xsd#cpix_TotectMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_TotectMember" xlink:to="lab_cpix_TotectMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_89e8a61f-20e9-47a9-95ac-d95362b57f5e_terseLabel_en-US" xlink:label="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WinHealth</link:label>
    <link:label id="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_label_en-US" xlink:label="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HongKong WinHealth Pharma Group Co. Limited [Member]</link:label>
    <link:label id="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_documentation_en-US" xlink:label="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HongKong WinHealth Pharma Group Co. Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember" xlink:href="cpix-20190630.xsd#cpix_HongKongWinHealthPharmaGroupCoLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember" xlink:to="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5e7f7fe4-a996-415d-9397-4799bc7aaea6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_c7cf5a4d-133e-4531-baa7-c0d70081c15a_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>cpix-20190630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2017 Workiva-->
<!--r:fe2e4db3-48f2-4e84-a542-8dc9a0c345cd,g:b764091f-bd8f-4ce0-9900-bde14803e897-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="simple" xlink:href="cpix-20190630.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_a266795a-1c10-4850-bfc4-4300735fc085" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_69ed601a-7671-456c-8f52-6a9f77f9b83b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a266795a-1c10-4850-bfc4-4300735fc085" xlink:to="loc_dei_DocumentType_69ed601a-7671-456c-8f52-6a9f77f9b83b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_99497e54-d159-495a-85ed-a89747e38bb0" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a266795a-1c10-4850-bfc4-4300735fc085" xlink:to="loc_dei_DocumentQuarterlyReport_99497e54-d159-495a-85ed-a89747e38bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_fafb4d2e-572a-4d47-8304-cd8ba674b978" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a266795a-1c10-4850-bfc4-4300735fc085" xlink:to="loc_dei_DocumentTransitionReport_fafb4d2e-572a-4d47-8304-cd8ba674b978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_18e9d511-0add-4352-95c8-be453eb0d2c7" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a266795a-1c10-4850-bfc4-4300735fc085" xlink:to="loc_dei_DocumentPeriodEndDate_18e9d511-0add-4352-95c8-be453eb0d2c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_8e213e28-ac24-429f-8839-68c81072b220" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a266795a-1c10-4850-bfc4-4300735fc085" xlink:to="loc_dei_EntityFileNumber_8e213e28-ac24-429f-8839-68c81072b220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_92858cbe-582f-4957-8cc8-921ef91c1ecb" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a266795a-1c10-4850-bfc4-4300735fc085" xlink:to="loc_dei_EntityRegistrantName_92858cbe-582f-4957-8cc8-921ef91c1ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_bf7826ef-b2af-47be-a38c-a27f6463440f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a266795a-1c10-4850-bfc4-4300735fc085" xlink:to="loc_dei_EntityCentralIndexKey_bf7826ef-b2af-47be-a38c-a27f6463440f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_224f77e0-facb-4924-8e57-b7b9d9f8a9ae" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a266795a-1c10-4850-bfc4-4300735fc085" xlink:to="loc_dei_CurrentFiscalYearEndDate_224f77e0-facb-4924-8e57-b7b9d9f8a9ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_24e4aa8d-cc15-4538-be68-cf1cdb4abd7d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a266795a-1c10-4850-bfc4-4300735fc085" xlink:to="loc_dei_DocumentFiscalYearFocus_24e4aa8d-cc15-4538-be68-cf1cdb4abd7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_c09d55df-5d01-4a2c-8c2e-0ce49fd3e36c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a266795a-1c10-4850-bfc4-4300735fc085" xlink:to="loc_dei_DocumentFiscalPeriodFocus_c09d55df-5d01-4a2c-8c2e-0ce49fd3e36c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_8263c0cd-9796-4249-a62f-c399d68fbb44" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a266795a-1c10-4850-bfc4-4300735fc085" xlink:to="loc_dei_AmendmentFlag_8263c0cd-9796-4249-a62f-c399d68fbb44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_cfd4cc02-015e-4c2d-a2a2-87d376b8fc8c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a266795a-1c10-4850-bfc4-4300735fc085" xlink:to="loc_dei_EntityIncorporationStateCountryCode_cfd4cc02-015e-4c2d-a2a2-87d376b8fc8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_39d23b49-4471-4c0b-a123-677921e00630" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a266795a-1c10-4850-bfc4-4300735fc085" xlink:to="loc_dei_EntityTaxIdentificationNumber_39d23b49-4471-4c0b-a123-677921e00630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_38415bcc-7a37-4eaa-b441-7fca44d8aab3" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a266795a-1c10-4850-bfc4-4300735fc085" xlink:to="loc_dei_EntityAddressAddressLine1_38415bcc-7a37-4eaa-b441-7fca44d8aab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_5f1f285d-1594-4286-afc6-01264f43fecd" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a266795a-1c10-4850-bfc4-4300735fc085" xlink:to="loc_dei_EntityAddressAddressLine2_5f1f285d-1594-4286-afc6-01264f43fecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_550f910b-91b7-4671-bc6b-cfb045578e11" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a266795a-1c10-4850-bfc4-4300735fc085" xlink:to="loc_dei_EntityAddressCityOrTown_550f910b-91b7-4671-bc6b-cfb045578e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_7a937c2e-80d9-400e-8e3b-658cf0acec96" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a266795a-1c10-4850-bfc4-4300735fc085" xlink:to="loc_dei_EntityAddressStateOrProvince_7a937c2e-80d9-400e-8e3b-658cf0acec96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_a03b737a-c656-4034-a0d7-6bf2d1a2f8ee" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a266795a-1c10-4850-bfc4-4300735fc085" xlink:to="loc_dei_EntityAddressPostalZipCode_a03b737a-c656-4034-a0d7-6bf2d1a2f8ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_dd671626-87c0-4811-aa2a-0ced874376a5" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a266795a-1c10-4850-bfc4-4300735fc085" xlink:to="loc_dei_CityAreaCode_dd671626-87c0-4811-aa2a-0ced874376a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_243cf4dd-393c-4372-bd12-150c057dd803" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a266795a-1c10-4850-bfc4-4300735fc085" xlink:to="loc_dei_LocalPhoneNumber_243cf4dd-393c-4372-bd12-150c057dd803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_d33c1b60-aa91-432a-bb08-b7ad792e6a8b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a266795a-1c10-4850-bfc4-4300735fc085" xlink:to="loc_dei_EntityCurrentReportingStatus_d33c1b60-aa91-432a-bb08-b7ad792e6a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_e2fd9d5a-01b3-43df-9146-7cc07a84fd46" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a266795a-1c10-4850-bfc4-4300735fc085" xlink:to="loc_dei_EntityInteractiveDataCurrent_e2fd9d5a-01b3-43df-9146-7cc07a84fd46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_d12b1bf4-2c22-401f-b904-b9745fca7667" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a266795a-1c10-4850-bfc4-4300735fc085" xlink:to="loc_dei_EntityFilerCategory_d12b1bf4-2c22-401f-b904-b9745fca7667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_e127b2cb-83d1-42ee-87cf-4292fdcf03ad" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a266795a-1c10-4850-bfc4-4300735fc085" xlink:to="loc_dei_EntitySmallBusiness_e127b2cb-83d1-42ee-87cf-4292fdcf03ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_befb3cfb-d0f6-4a7c-ab42-34b85b950dcb" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a266795a-1c10-4850-bfc4-4300735fc085" xlink:to="loc_dei_EntityEmergingGrowthCompany_befb3cfb-d0f6-4a7c-ab42-34b85b950dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_6608e4a4-dd82-47a2-93fb-57b055c28a0a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a266795a-1c10-4850-bfc4-4300735fc085" xlink:to="loc_dei_EntityShellCompany_6608e4a4-dd82-47a2-93fb-57b055c28a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_bb78c4f4-d260-480b-8b36-ac8b4bc2fb27" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a266795a-1c10-4850-bfc4-4300735fc085" xlink:to="loc_dei_Security12bTitle_bb78c4f4-d260-480b-8b36-ac8b4bc2fb27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_6ad3d2d0-d023-4259-9fc5-7a2c00acaf0e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a266795a-1c10-4850-bfc4-4300735fc085" xlink:to="loc_dei_TradingSymbol_6ad3d2d0-d023-4259-9fc5-7a2c00acaf0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_ddcc2fff-402d-4809-84e1-5db5687fc41d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a266795a-1c10-4850-bfc4-4300735fc085" xlink:to="loc_dei_SecurityExchangeName_ddcc2fff-402d-4809-84e1-5db5687fc41d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_2aa6342e-c41a-41c7-9ecc-6ad8b77e6180" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a266795a-1c10-4850-bfc4-4300735fc085" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_2aa6342e-c41a-41c7-9ecc-6ad8b77e6180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cpix-20190630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_110b4553-8a2e-4400-80e0-35fa93240d7f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_39507346-2a1a-413f-934e-058831725730" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_110b4553-8a2e-4400-80e0-35fa93240d7f" xlink:to="loc_us-gaap_AssetsAbstract_39507346-2a1a-413f-934e-058831725730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_bda9efba-1dec-47cf-96f8-0e21f93292ef" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_39507346-2a1a-413f-934e-058831725730" xlink:to="loc_us-gaap_AssetsCurrentAbstract_bda9efba-1dec-47cf-96f8-0e21f93292ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0b05e053-2ad4-453b-b422-88c82ab5ece1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bda9efba-1dec-47cf-96f8-0e21f93292ef" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0b05e053-2ad4-453b-b422-88c82ab5ece1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_2adbf368-fe38-4cc4-82a3-19194a88b1c6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bda9efba-1dec-47cf-96f8-0e21f93292ef" xlink:to="loc_us-gaap_MarketableSecurities_2adbf368-fe38-4cc4-82a3-19194a88b1c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_3c2547c7-6b25-484b-ab89-7dc82ab70105" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bda9efba-1dec-47cf-96f8-0e21f93292ef" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_3c2547c7-6b25-484b-ab89-7dc82ab70105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_2750f50b-1958-44fc-8713-54aaa1e66ce5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bda9efba-1dec-47cf-96f8-0e21f93292ef" xlink:to="loc_us-gaap_InventoryNet_2750f50b-1958-44fc-8713-54aaa1e66ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_8a18a6d6-9679-46dd-8c19-1893733b3baf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bda9efba-1dec-47cf-96f8-0e21f93292ef" xlink:to="loc_us-gaap_OtherAssetsCurrent_8a18a6d6-9679-46dd-8c19-1893733b3baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_66f3ffd1-be6a-4008-9a17-ddc8e7696e9f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bda9efba-1dec-47cf-96f8-0e21f93292ef" xlink:to="loc_us-gaap_AssetsCurrent_66f3ffd1-be6a-4008-9a17-ddc8e7696e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_5eae1cb9-57e1-483e-8b8c-8602ea36e9dc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_39507346-2a1a-413f-934e-058831725730" xlink:to="loc_us-gaap_InventoryNoncurrent_5eae1cb9-57e1-483e-8b8c-8602ea36e9dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_eee0be2a-0501-47c8-b9b0-cac71a118d5b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_39507346-2a1a-413f-934e-058831725730" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_eee0be2a-0501-47c8-b9b0-cac71a118d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8ba74211-a9b0-42f2-87b1-a129856e7041" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_39507346-2a1a-413f-934e-058831725730" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8ba74211-a9b0-42f2-87b1-a129856e7041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_4261ee60-9f12-4599-a023-915f14082936" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_39507346-2a1a-413f-934e-058831725730" xlink:to="loc_us-gaap_Goodwill_4261ee60-9f12-4599-a023-915f14082936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_4e686f8a-1efd-4d29-8a96-c765e4760afd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_39507346-2a1a-413f-934e-058831725730" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_4e686f8a-1efd-4d29-8a96-c765e4760afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_837b193a-ba25-46e0-a724-e827f1cbf6f3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_39507346-2a1a-413f-934e-058831725730" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_837b193a-ba25-46e0-a724-e827f1cbf6f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b290ed3b-f6c9-4c40-bc13-fb3d11646a0d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_39507346-2a1a-413f-934e-058831725730" xlink:to="loc_us-gaap_Assets_b290ed3b-f6c9-4c40-bc13-fb3d11646a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_75a039da-5bef-41b0-802b-3335600b33a5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_110b4553-8a2e-4400-80e0-35fa93240d7f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_75a039da-5bef-41b0-802b-3335600b33a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_6f679bb7-dee9-4371-b7c9-d6eadb8f494a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_75a039da-5bef-41b0-802b-3335600b33a5" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_6f679bb7-dee9-4371-b7c9-d6eadb8f494a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_506b93e1-e157-4cbf-b823-5253430c7f24" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6f679bb7-dee9-4371-b7c9-d6eadb8f494a" xlink:to="loc_us-gaap_AccountsPayableCurrent_506b93e1-e157-4cbf-b823-5253430c7f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_2ab5c50f-a79a-4476-b5e7-e9b7192af443" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6f679bb7-dee9-4371-b7c9-d6eadb8f494a" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_2ab5c50f-a79a-4476-b5e7-e9b7192af443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_add0070f-adf1-4ce9-84f8-989fb399ebd5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6f679bb7-dee9-4371-b7c9-d6eadb8f494a" xlink:to="loc_us-gaap_LiabilitiesCurrent_add0070f-adf1-4ce9-84f8-989fb399ebd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_775bd645-939e-48b9-8bab-5f7446254000" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_75a039da-5bef-41b0-802b-3335600b33a5" xlink:to="loc_us-gaap_LongTermLineOfCredit_775bd645-939e-48b9-8bab-5f7446254000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion_341b2fc4-ad5b-4dad-bd63-b3298ba5ba6a" xlink:href="cpix-20190630.xsd#cpix_OtherLongTermObligationsExcludingCurrentPortion"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_75a039da-5bef-41b0-802b-3335600b33a5" xlink:to="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion_341b2fc4-ad5b-4dad-bd63-b3298ba5ba6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_bfefbacc-ea76-4017-a356-5fb99b966ef1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_75a039da-5bef-41b0-802b-3335600b33a5" xlink:to="loc_us-gaap_Liabilities_bfefbacc-ea76-4017-a356-5fb99b966ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_204ec3ac-a86c-4471-a51b-b2608f8b17c3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_75a039da-5bef-41b0-802b-3335600b33a5" xlink:to="loc_us-gaap_CommitmentsAndContingencies_204ec3ac-a86c-4471-a51b-b2608f8b17c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_4bcad03e-e787-4e05-b802-289079d57a58" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_75a039da-5bef-41b0-802b-3335600b33a5" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_4bcad03e-e787-4e05-b802-289079d57a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_97be849d-6d13-496d-a0ac-1bf121a9ea2e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_4bcad03e-e787-4e05-b802-289079d57a58" xlink:to="loc_us-gaap_StockholdersEquityAbstract_97be849d-6d13-496d-a0ac-1bf121a9ea2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_ad2063fa-da3a-47c8-8308-f1b4ef85e64e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_97be849d-6d13-496d-a0ac-1bf121a9ea2e" xlink:to="loc_us-gaap_CommonStockValue_ad2063fa-da3a-47c8-8308-f1b4ef85e64e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c35a56bf-ac22-40b2-b347-d0526974fa8c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_97be849d-6d13-496d-a0ac-1bf121a9ea2e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c35a56bf-ac22-40b2-b347-d0526974fa8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_91680448-f7e8-4e8e-9640-b5aa7ca5d6c9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_97be849d-6d13-496d-a0ac-1bf121a9ea2e" xlink:to="loc_us-gaap_StockholdersEquity_91680448-f7e8-4e8e-9640-b5aa7ca5d6c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_a6627fc6-c5f3-40e6-b46d-856ef709ff44" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_4bcad03e-e787-4e05-b802-289079d57a58" xlink:to="loc_us-gaap_MinorityInterest_a6627fc6-c5f3-40e6-b46d-856ef709ff44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_bdc92fa7-e05d-4468-9136-46e98327d5e2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_4bcad03e-e787-4e05-b802-289079d57a58" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_bdc92fa7-e05d-4468-9136-46e98327d5e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_08c4268e-9e5e-47bf-a30d-60715e65d9f2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_75a039da-5bef-41b0-802b-3335600b33a5" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_08c4268e-9e5e-47bf-a30d-60715e65d9f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cpix-20190630.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_5648b89e-b881-4ffe-af32-8c6aca1db63f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNoParValue_609436d0-3509-4382-8cf2-c6e9cc3f13a9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockNoParValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5648b89e-b881-4ffe-af32-8c6aca1db63f" xlink:to="loc_us-gaap_CommonStockNoParValue_609436d0-3509-4382-8cf2-c6e9cc3f13a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_0459973a-3a3a-47ee-912c-fd76934a29f3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5648b89e-b881-4ffe-af32-8c6aca1db63f" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_0459973a-3a3a-47ee-912c-fd76934a29f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_d9847f8e-e83e-42e0-a904-ea0bbda54855" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5648b89e-b881-4ffe-af32-8c6aca1db63f" xlink:to="loc_us-gaap_CommonStockSharesIssued_d9847f8e-e83e-42e0-a904-ea0bbda54855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_451f0dd2-663a-4521-b7c4-50784067f15b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5648b89e-b881-4ffe-af32-8c6aca1db63f" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_451f0dd2-663a-4521-b7c4-50784067f15b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss" xlink:type="simple" xlink:href="cpix-20190630.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_ebf4ff24-dc42-49d2-abd9-4b03c199f18b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e644d303-dffe-45ba-af90-5967b907dba7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ebf4ff24-dc42-49d2-abd9-4b03c199f18b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e644d303-dffe-45ba-af90-5967b907dba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_25ed83b3-1c5e-4110-ad25-dde50758db7d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ebf4ff24-dc42-49d2-abd9-4b03c199f18b" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_25ed83b3-1c5e-4110-ad25-dde50758db7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_6ebd2cfe-5eca-4a68-8250-74c4a33ec7b6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_25ed83b3-1c5e-4110-ad25-dde50758db7d" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_6ebd2cfe-5eca-4a68-8250-74c4a33ec7b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_adae1fe9-afb5-4cf1-8a10-ef83e62b6282" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_25ed83b3-1c5e-4110-ad25-dde50758db7d" xlink:to="loc_us-gaap_SellingAndMarketingExpense_adae1fe9-afb5-4cf1-8a10-ef83e62b6282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_508db5d4-4dc1-4dfd-b60c-8900ec114722" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_25ed83b3-1c5e-4110-ad25-dde50758db7d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_508db5d4-4dc1-4dfd-b60c-8900ec114722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_519eba0a-44b3-4f44-a643-32eced854871" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_25ed83b3-1c5e-4110-ad25-dde50758db7d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_519eba0a-44b3-4f44-a643-32eced854871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_5c9917b9-0d53-4a7a-9aeb-9c17476912a2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_25ed83b3-1c5e-4110-ad25-dde50758db7d" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_5c9917b9-0d53-4a7a-9aeb-9c17476912a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_5fcb6805-6965-4cca-9473-86ab98eb3050" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_25ed83b3-1c5e-4110-ad25-dde50758db7d" xlink:to="loc_us-gaap_CostsAndExpenses_5fcb6805-6965-4cca-9473-86ab98eb3050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_28e51977-747a-4009-abf0-d39892cbfbb6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_25ed83b3-1c5e-4110-ad25-dde50758db7d" xlink:to="loc_us-gaap_OperatingIncomeLoss_28e51977-747a-4009-abf0-d39892cbfbb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_2ed55a0b-a619-4da0-be80-a28beb519d6b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ebf4ff24-dc42-49d2-abd9-4b03c199f18b" xlink:to="loc_us-gaap_InvestmentIncomeInterest_2ed55a0b-a619-4da0-be80-a28beb519d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_fb4d052b-7f10-401d-bef7-151fadd85907" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ebf4ff24-dc42-49d2-abd9-4b03c199f18b" xlink:to="loc_us-gaap_InterestExpense_fb4d052b-7f10-401d-bef7-151fadd85907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5f86a8fd-3f19-4691-99cf-1f9620551f27" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ebf4ff24-dc42-49d2-abd9-4b03c199f18b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5f86a8fd-3f19-4691-99cf-1f9620551f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_89899674-e33e-4c7f-8c2e-e45d78d81870" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ebf4ff24-dc42-49d2-abd9-4b03c199f18b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_89899674-e33e-4c7f-8c2e-e45d78d81870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c366637f-a994-4f98-ac1d-8a9ccaf9b777" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ebf4ff24-dc42-49d2-abd9-4b03c199f18b" xlink:to="loc_us-gaap_ProfitLoss_c366637f-a994-4f98-ac1d-8a9ccaf9b777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_bd8f7276-2683-457c-80a1-73d8d1a421c1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ebf4ff24-dc42-49d2-abd9-4b03c199f18b" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_bd8f7276-2683-457c-80a1-73d8d1a421c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0d77550e-f7b3-4473-995a-a1d0ba22cabe" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ebf4ff24-dc42-49d2-abd9-4b03c199f18b" xlink:to="loc_us-gaap_NetIncomeLoss_0d77550e-f7b3-4473-995a-a1d0ba22cabe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_fa2bf6d6-549a-4268-801f-bf696beae816" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ebf4ff24-dc42-49d2-abd9-4b03c199f18b" xlink:to="loc_us-gaap_EarningsPerShareAbstract_fa2bf6d6-549a-4268-801f-bf696beae816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_795fa506-27b6-4919-a502-0eec9cfe01d1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fa2bf6d6-549a-4268-801f-bf696beae816" xlink:to="loc_us-gaap_EarningsPerShareBasic_795fa506-27b6-4919-a502-0eec9cfe01d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_a65c8c19-4e91-4645-bb29-f2c8c2d87d50" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fa2bf6d6-549a-4268-801f-bf696beae816" xlink:to="loc_us-gaap_EarningsPerShareDiluted_a65c8c19-4e91-4645-bb29-f2c8c2d87d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_038bedb1-53f0-4231-80f6-406e38bf25fb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ebf4ff24-dc42-49d2-abd9-4b03c199f18b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_038bedb1-53f0-4231-80f6-406e38bf25fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_12d63b04-bfb0-4634-8a32-e8d25f9f22b3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_038bedb1-53f0-4231-80f6-406e38bf25fb" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_12d63b04-bfb0-4634-8a32-e8d25f9f22b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_503bf526-54bf-4f06-a38e-68626f2141dc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_038bedb1-53f0-4231-80f6-406e38bf25fb" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_503bf526-54bf-4f06-a38e-68626f2141dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_17b98521-1827-4f44-8b08-d59f2ac35af4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ebf4ff24-dc42-49d2-abd9-4b03c199f18b" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_17b98521-1827-4f44-8b08-d59f2ac35af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_3355e118-928d-47e5-be2f-3d6c4a70e9e2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ebf4ff24-dc42-49d2-abd9-4b03c199f18b" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_3355e118-928d-47e5-be2f-3d6c4a70e9e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_11962ef6-2bfa-4451-a399-1407e8a5c84d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ebf4ff24-dc42-49d2-abd9-4b03c199f18b" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_11962ef6-2bfa-4451-a399-1407e8a5c84d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cpix-20190630.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_794dc9fb-86da-4319-9278-cec737a7dca7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4b31bf66-bdb3-402c-a11f-3d88cda39e7c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_794dc9fb-86da-4319-9278-cec737a7dca7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4b31bf66-bdb3-402c-a11f-3d88cda39e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_eb0de47d-14bc-45c1-a93f-0e09f0f77041" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4b31bf66-bdb3-402c-a11f-3d88cda39e7c" xlink:to="loc_us-gaap_ProfitLoss_eb0de47d-14bc-45c1-a93f-0e09f0f77041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ed0cbc62-613d-4873-895c-0bdceb321356" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4b31bf66-bdb3-402c-a11f-3d88cda39e7c" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ed0cbc62-613d-4873-895c-0bdceb321356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_20527502-e8fe-47e6-a585-fbfae3dd8d58" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ed0cbc62-613d-4873-895c-0bdceb321356" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_20527502-e8fe-47e6-a585-fbfae3dd8d58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e9ddf080-80ad-47ba-b2b3-b38e499e93e2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ed0cbc62-613d-4873-895c-0bdceb321356" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e9ddf080-80ad-47ba-b2b3-b38e499e93e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_f80de882-a7e9-4739-971a-217712108419" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ed0cbc62-613d-4873-895c-0bdceb321356" xlink:to="loc_us-gaap_ShareBasedCompensation_f80de882-a7e9-4739-971a-217712108419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_c4d9a967-713c-4d92-b0bb-f6f4fed4d580" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ed0cbc62-613d-4873-895c-0bdceb321356" xlink:to="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_c4d9a967-713c-4d92-b0bb-f6f4fed4d580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_1c1ce008-bb51-49b2-8ffc-e6f91b1e05d6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ed0cbc62-613d-4873-895c-0bdceb321356" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_1c1ce008-bb51-49b2-8ffc-e6f91b1e05d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_861dba84-d990-4b8a-a0f6-d5defebd86ba" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ed0cbc62-613d-4873-895c-0bdceb321356" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_861dba84-d990-4b8a-a0f6-d5defebd86ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_00ec88f9-78ee-4bc6-86eb-564690f0a921" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ed0cbc62-613d-4873-895c-0bdceb321356" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_00ec88f9-78ee-4bc6-86eb-564690f0a921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c7d59cf9-b71b-4516-9b36-db574c4bf98a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_00ec88f9-78ee-4bc6-86eb-564690f0a921" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c7d59cf9-b71b-4516-9b36-db574c4bf98a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_779c343b-e66e-48a2-87a2-53a9db6485b0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_00ec88f9-78ee-4bc6-86eb-564690f0a921" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_779c343b-e66e-48a2-87a2-53a9db6485b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_2b1e1a2a-7e97-46f3-88b5-46cc32a7590c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_00ec88f9-78ee-4bc6-86eb-564690f0a921" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_2b1e1a2a-7e97-46f3-88b5-46cc32a7590c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_094a0e1b-bf96-4a2c-970f-472f433d49ce" xlink:href="cpix-20190630.xsd#cpix_IncreaseDecreaseInCurrentOperatingLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_00ec88f9-78ee-4bc6-86eb-564690f0a921" xlink:to="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_094a0e1b-bf96-4a2c-970f-472f433d49ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_624ff798-8f80-4ce7-a650-e0e71dedad87" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_00ec88f9-78ee-4bc6-86eb-564690f0a921" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_624ff798-8f80-4ce7-a650-e0e71dedad87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_12ccb84c-3dc8-47a0-adb7-8d1472b6c35a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4b31bf66-bdb3-402c-a11f-3d88cda39e7c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_12ccb84c-3dc8-47a0-adb7-8d1472b6c35a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e4810e16-c4b3-4c7e-a870-b22401fac4de" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_794dc9fb-86da-4319-9278-cec737a7dca7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e4810e16-c4b3-4c7e-a870-b22401fac4de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_68141e7b-99f3-4c63-9568-49909d82f0fc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e4810e16-c4b3-4c7e-a870-b22401fac4de" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_68141e7b-99f3-4c63-9568-49909d82f0fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_6484683b-0d6f-4de9-bdf3-de222e7d781c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e4810e16-c4b3-4c7e-a870-b22401fac4de" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_6484683b-0d6f-4de9-bdf3-de222e7d781c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_86e6e283-ee6f-44b9-913b-a93266638b45" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e4810e16-c4b3-4c7e-a870-b22401fac4de" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_86e6e283-ee6f-44b9-913b-a93266638b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_0c7e1d60-a6f4-47fd-9877-e436f646304d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e4810e16-c4b3-4c7e-a870-b22401fac4de" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_0c7e1d60-a6f4-47fd-9877-e436f646304d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_753be3ce-23b6-485e-a328-bb92e0258ad1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e4810e16-c4b3-4c7e-a870-b22401fac4de" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_753be3ce-23b6-485e-a328-bb92e0258ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b81e2677-d768-4161-9c86-91e63d021b1c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e4810e16-c4b3-4c7e-a870-b22401fac4de" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b81e2677-d768-4161-9c86-91e63d021b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e22cf801-3192-4dc7-a04c-86f473e95b76" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_794dc9fb-86da-4319-9278-cec737a7dca7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e22cf801-3192-4dc7-a04c-86f473e95b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_1e591b89-7a49-4f6d-9f0a-21308c87e1e6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e22cf801-3192-4dc7-a04c-86f473e95b76" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_1e591b89-7a49-4f6d-9f0a-21308c87e1e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_ba368929-6353-40fe-bfa5-e667fab0bf77" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e22cf801-3192-4dc7-a04c-86f473e95b76" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_ba368929-6353-40fe-bfa5-e667fab0bf77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_65181cbf-c074-44b4-aefb-3f17bef73454" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e22cf801-3192-4dc7-a04c-86f473e95b76" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_65181cbf-c074-44b4-aefb-3f17bef73454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_1087395c-e3b8-46c3-9920-e048d3a84644" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e22cf801-3192-4dc7-a04c-86f473e95b76" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_1087395c-e3b8-46c3-9920-e048d3a84644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_bee1a061-d268-45c0-997a-b8e8b2d92f04" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e22cf801-3192-4dc7-a04c-86f473e95b76" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_bee1a061-d268-45c0-997a-b8e8b2d92f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_74f565e4-6287-43d5-b415-9450cdabb797" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e22cf801-3192-4dc7-a04c-86f473e95b76" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_74f565e4-6287-43d5-b415-9450cdabb797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7cc86e17-c089-4856-8719-4da4d2aaa401" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e22cf801-3192-4dc7-a04c-86f473e95b76" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7cc86e17-c089-4856-8719-4da4d2aaa401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_b7ccc966-57f1-42ee-8908-75b8eaf961aa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e22cf801-3192-4dc7-a04c-86f473e95b76" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_b7ccc966-57f1-42ee-8908-75b8eaf961aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a63146e3-bb3a-444e-9f9f-9bd1450ebd76" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e22cf801-3192-4dc7-a04c-86f473e95b76" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a63146e3-bb3a-444e-9f9f-9bd1450ebd76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_74730538-d69a-4dc7-a3b5-8357580ba8c2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e22cf801-3192-4dc7-a04c-86f473e95b76" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_74730538-d69a-4dc7-a3b5-8357580ba8c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_b8028e2e-455a-46e4-8326-dc32a6da3a3e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_794dc9fb-86da-4319-9278-cec737a7dca7" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_b8028e2e-455a-46e4-8326-dc32a6da3a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_bf539d1f-c641-423e-b24e-4f9d10025e0e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_b8028e2e-455a-46e4-8326-dc32a6da3a3e" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_bf539d1f-c641-423e-b24e-4f9d10025e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_1498d2d7-99c7-4f56-862d-731b61d30da0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_b8028e2e-455a-46e4-8326-dc32a6da3a3e" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_1498d2d7-99c7-4f56-862d-731b61d30da0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_c73e8c51-17be-43ee-b4d4-43751372c243" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_b8028e2e-455a-46e4-8326-dc32a6da3a3e" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_c73e8c51-17be-43ee-b4d4-43751372c243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="simple" xlink:href="cpix-20190630.xsd#CondensedConsolidatedStatementofEquity"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_dbf8c483-e84f-4d5d-85b2-7f8224e62c19" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_90331584-6311-45f3-bd1b-cb8c225c72d2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_dbf8c483-e84f-4d5d-85b2-7f8224e62c19" xlink:to="loc_us-gaap_StatementTable_90331584-6311-45f3-bd1b-cb8c225c72d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_726762a0-0e05-4e52-8f7f-46d49309834d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_90331584-6311-45f3-bd1b-cb8c225c72d2" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_726762a0-0e05-4e52-8f7f-46d49309834d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7e0914fb-237c-45f9-b129-96f3843b3676" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_726762a0-0e05-4e52-8f7f-46d49309834d" xlink:to="loc_us-gaap_EquityComponentDomain_7e0914fb-237c-45f9-b129-96f3843b3676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4ba4322e-3939-42b4-bb4d-93e79dacfdf3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7e0914fb-237c-45f9-b129-96f3843b3676" xlink:to="loc_us-gaap_CommonStockMember_4ba4322e-3939-42b4-bb4d-93e79dacfdf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_54b58365-b8c9-4b05-b3ff-fd8d37d4da83" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7e0914fb-237c-45f9-b129-96f3843b3676" xlink:to="loc_us-gaap_RetainedEarningsMember_54b58365-b8c9-4b05-b3ff-fd8d37d4da83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_98a80ee5-3f5e-465a-b2a6-6ccbaa6f8b3e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7e0914fb-237c-45f9-b129-96f3843b3676" xlink:to="loc_us-gaap_NoncontrollingInterestMember_98a80ee5-3f5e-465a-b2a6-6ccbaa6f8b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e7112159-493d-4db8-9730-8c27ce51fa94" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_90331584-6311-45f3-bd1b-cb8c225c72d2" xlink:to="loc_us-gaap_StatementLineItems_e7112159-493d-4db8-9730-8c27ce51fa94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ae76d731-2008-48d3-9057-dbc7de59253d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e7112159-493d-4db8-9730-8c27ce51fa94" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ae76d731-2008-48d3-9057-dbc7de59253d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c04f18d1-c9a3-413f-85b5-56b0e6a91112" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ae76d731-2008-48d3-9057-dbc7de59253d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c04f18d1-c9a3-413f-85b5-56b0e6a91112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8b6745d7-cd12-4ba3-822b-2b0cba7eabda" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ae76d731-2008-48d3-9057-dbc7de59253d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8b6745d7-cd12-4ba3-822b-2b0cba7eabda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8423ba89-d394-4c6a-a06e-7a38b952cfe8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ae76d731-2008-48d3-9057-dbc7de59253d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8423ba89-d394-4c6a-a06e-7a38b952cfe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6a3605e9-c331-4ee7-afa8-5a79380c46e0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ae76d731-2008-48d3-9057-dbc7de59253d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6a3605e9-c331-4ee7-afa8-5a79380c46e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_dc47b7da-d154-45d7-890a-ffcf11008126" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ae76d731-2008-48d3-9057-dbc7de59253d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_dc47b7da-d154-45d7-890a-ffcf11008126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_12925cb7-8a3a-4769-ac15-c076dba197cb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ae76d731-2008-48d3-9057-dbc7de59253d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_12925cb7-8a3a-4769-ac15-c076dba197cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_3cbdeec3-b7f2-43ab-88ee-14e39bd94532" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ae76d731-2008-48d3-9057-dbc7de59253d" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_3cbdeec3-b7f2-43ab-88ee-14e39bd94532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_abf61ec2-3926-4ab5-b7bb-0235343b96e9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ae76d731-2008-48d3-9057-dbc7de59253d" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_abf61ec2-3926-4ab5-b7bb-0235343b96e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_f4ad6bdf-8d81-415b-bc90-a526be9e353c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ae76d731-2008-48d3-9057-dbc7de59253d" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_f4ad6bdf-8d81-415b-bc90-a526be9e353c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4b7230b4-7c35-438a-9872-15367f7cdec8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ae76d731-2008-48d3-9057-dbc7de59253d" xlink:to="loc_us-gaap_ProfitLoss_4b7230b4-7c35-438a-9872-15367f7cdec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a8b763c5-b547-40ae-ad4e-dc5f40a75983" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ae76d731-2008-48d3-9057-dbc7de59253d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a8b763c5-b547-40ae-ad4e-dc5f40a75983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1d34bb20-a64d-40e1-b429-748c861cd97b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ae76d731-2008-48d3-9057-dbc7de59253d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1d34bb20-a64d-40e1-b429-748c861cd97b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="cpix-20190630.xsd#OrganizationandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a423126c-9fca-4fe1-abe2-4932a2f1d039" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_f9aa9139-cc72-4ee1-9352-6f39c604e0f3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a423126c-9fca-4fe1-abe2-4932a2f1d039" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_f9aa9139-cc72-4ee1-9352-6f39c604e0f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="simple" xlink:href="cpix-20190630.xsd#OrganizationandBasisofPresentationPolicies"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0f573dfc-b859-476d-9bca-529ecd3ecac9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_981d6ee4-3b2a-4bed-bf93-d84d046de355" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0f573dfc-b859-476d-9bca-529ecd3ecac9" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_981d6ee4-3b2a-4bed-bf93-d84d046de355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_0ab749a1-447c-43a1-b32e-2e2c64275b04" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0f573dfc-b859-476d-9bca-529ecd3ecac9" xlink:to="loc_us-gaap_UseOfEstimates_0ab749a1-447c-43a1-b32e-2e2c64275b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_4b2745a0-a529-4c24-b520-ca85dd2e749c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0f573dfc-b859-476d-9bca-529ecd3ecac9" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_4b2745a0-a529-4c24-b520-ca85dd2e749c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" xlink:type="simple" xlink:href="cpix-20190630.xsd#OrganizationandBasisofPresentationOrganizationDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a4ddb50c-87f3-4b15-91b1-6b4b0a91ad61" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_ae8b9cbd-6fee-42bf-8234-184c3cb4709d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a4ddb50c-87f3-4b15-91b1-6b4b0a91ad61" xlink:to="loc_us-gaap_NumberOfOperatingSegments_ae8b9cbd-6fee-42bf-8234-184c3cb4709d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/MarketableSecurities" xlink:type="simple" xlink:href="cpix-20190630.xsd#MarketableSecurities"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/MarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d8e6ee93-e210-4c15-aed8-db3ca7ec072a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_10f4982a-b5da-4d58-ba5b-c1206c8188dd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d8e6ee93-e210-4c15-aed8-db3ca7ec072a" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_10f4982a-b5da-4d58-ba5b-c1206c8188dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="cpix-20190630.xsd#MarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/MarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3a80f599-a400-41b4-aa88-2b4f9cbbb523" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_88e57aad-3eb4-468d-b142-7b409acc3109" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3a80f599-a400-41b4-aa88-2b4f9cbbb523" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_88e57aad-3eb4-468d-b142-7b409acc3109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="cpix-20190630.xsd#MarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9628f2a0-4b90-42df-868c-aeceb2df74b6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_5abd5c03-89ed-457e-827c-898384739e3c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9628f2a0-4b90-42df-868c-aeceb2df74b6" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_5abd5c03-89ed-457e-827c-898384739e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ca8dc7aa-d938-46c1-a631-7523413f4f76" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_5abd5c03-89ed-457e-827c-898384739e3c" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ca8dc7aa-d938-46c1-a631-7523413f4f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_18cae46d-ed04-40e8-af23-1ef605e0770b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ca8dc7aa-d938-46c1-a631-7523413f4f76" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_18cae46d-ed04-40e8-af23-1ef605e0770b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_95b64082-f8a1-4299-8e48-bfd236da20ef" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_18cae46d-ed04-40e8-af23-1ef605e0770b" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_95b64082-f8a1-4299-8e48-bfd236da20ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_169abc3c-1887-4fc0-819c-c2f4dba6ffb6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_18cae46d-ed04-40e8-af23-1ef605e0770b" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_169abc3c-1887-4fc0-819c-c2f4dba6ffb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6623cd24-a5de-4ace-91dc-c7d67dcfab2c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_5abd5c03-89ed-457e-827c-898384739e3c" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6623cd24-a5de-4ace-91dc-c7d67dcfab2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ac69a334-867f-43b2-840f-87d4f6d73e37" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6623cd24-a5de-4ace-91dc-c7d67dcfab2c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ac69a334-867f-43b2-840f-87d4f6d73e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_UsTreasuryNotesAndBondsSecuritiesMemberMember_d3356255-bb97-48e1-b4cc-e12ea81a8722" xlink:href="cpix-20190630.xsd#cpix_UsTreasuryNotesAndBondsSecuritiesMemberMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ac69a334-867f-43b2-840f-87d4f6d73e37" xlink:to="loc_cpix_UsTreasuryNotesAndBondsSecuritiesMemberMember_d3356255-bb97-48e1-b4cc-e12ea81a8722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_797b92c2-73ad-4dd8-bca1-f7c4a7070a86" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ac69a334-867f-43b2-840f-87d4f6d73e37" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_797b92c2-73ad-4dd8-bca1-f7c4a7070a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_039328f2-2f31-40f5-83b0-d0720ed5292b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ac69a334-867f-43b2-840f-87d4f6d73e37" xlink:to="loc_us-gaap_CommercialPaperMember_039328f2-2f31-40f5-83b0-d0720ed5292b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_2c6a6055-3c11-4571-85e2-4d20f7fe729a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ac69a334-867f-43b2-840f-87d4f6d73e37" xlink:to="loc_us-gaap_MunicipalBondsMember_2c6a6055-3c11-4571-85e2-4d20f7fe729a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a87797cf-4361-4be3-8be2-a9f0c6e5ab94" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_5abd5c03-89ed-457e-827c-898384739e3c" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a87797cf-4361-4be3-8be2-a9f0c6e5ab94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities_3d52aa46-caa3-4a08-8e8d-1b94bc954e87" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TradingSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a87797cf-4361-4be3-8be2-a9f0c6e5ab94" xlink:to="loc_us-gaap_TradingSecurities_3d52aa46-caa3-4a08-8e8d-1b94bc954e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="simple" xlink:href="cpix-20190630.xsd#EarningsLossPerShare"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d6914ce6-0e18-472c-b181-f53b581dacf3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_404d01b7-c9f6-4a3b-b831-f608a5e42e65" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d6914ce6-0e18-472c-b181-f53b581dacf3" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_404d01b7-c9f6-4a3b-b831-f608a5e42e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="simple" xlink:href="cpix-20190630.xsd#EarningsLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_caa1e14f-b1d9-4b70-937a-14911c5499f4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_bf85ddc9-6db3-4f86-a58d-5d1dafc32282" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_caa1e14f-b1d9-4b70-937a-14911c5499f4" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_bf85ddc9-6db3-4f86-a58d-5d1dafc32282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="simple" xlink:href="cpix-20190630.xsd#EarningsLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0763bcd5-30a5-4e4d-946d-74bf8c6eb1e6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NumeratorAbstract_3d39bf49-dea0-413b-80d0-97cd3125a7e6" xlink:href="cpix-20190630.xsd#cpix_NumeratorAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0763bcd5-30a5-4e4d-946d-74bf8c6eb1e6" xlink:to="loc_cpix_NumeratorAbstract_3d39bf49-dea0-413b-80d0-97cd3125a7e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d7bf2c99-7a46-4d1b-a97e-b7ee061813c7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_3d39bf49-dea0-413b-80d0-97cd3125a7e6" xlink:to="loc_us-gaap_NetIncomeLoss_d7bf2c99-7a46-4d1b-a97e-b7ee061813c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DenominatorAbstract_38b95de8-b38a-42f4-926a-ce77bb20c5c5" xlink:href="cpix-20190630.xsd#cpix_DenominatorAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0763bcd5-30a5-4e4d-946d-74bf8c6eb1e6" xlink:to="loc_cpix_DenominatorAbstract_38b95de8-b38a-42f4-926a-ce77bb20c5c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fd8aa352-20ad-402a-9a41-611d10cc2d9b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DenominatorAbstract_38b95de8-b38a-42f4-926a-ce77bb20c5c5" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fd8aa352-20ad-402a-9a41-611d10cc2d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_c7191d83-0ce1-40e1-9628-84836ebaffad" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DenominatorAbstract_38b95de8-b38a-42f4-926a-ce77bb20c5c5" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_c7191d83-0ce1-40e1-9628-84836ebaffad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_00a85325-c101-4738-9ee6-a37f3120278d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DenominatorAbstract_38b95de8-b38a-42f4-926a-ce77bb20c5c5" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_00a85325-c101-4738-9ee6-a37f3120278d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" xlink:type="simple" xlink:href="cpix-20190630.xsd#EarningsLossPerShareDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_59e92c6c-2b4b-457f-ab72-e638f0505b23" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_94f49de7-105c-45f4-984a-1e3b5963f104" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_59e92c6c-2b4b-457f-ab72-e638f0505b23" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_94f49de7-105c-45f4-984a-1e3b5963f104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Revenues" xlink:type="simple" xlink:href="cpix-20190630.xsd#Revenues"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_9861f97e-92c6-4d0c-85ce-10adeb14cbab" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_4f62b1bd-4ac6-468f-9251-8152094ffd1b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_9861f97e-92c6-4d0c-85ce-10adeb14cbab" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_4f62b1bd-4ac6-468f-9251-8152094ffd1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="simple" xlink:href="cpix-20190630.xsd#RevenuesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_25bdb8a9-316b-4741-9955-026e9aa86821" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_526431f1-8f4a-41ff-9e77-c3d49902218d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_25bdb8a9-316b-4741-9955-026e9aa86821" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_526431f1-8f4a-41ff-9e77-c3d49902218d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:type="simple" xlink:href="cpix-20190630.xsd#RevenuesDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_42412e21-7242-4e34-8f62-074d795859f2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_151b1a3f-f5b0-4790-a0a5-cb5911255ece" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_42412e21-7242-4e34-8f62-074d795859f2" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_151b1a3f-f5b0-4790-a0a5-cb5911255ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_966797c6-9edf-4bcf-b42b-f623710de99b" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_151b1a3f-f5b0-4790-a0a5-cb5911255ece" xlink:to="loc_srt_ProductOrServiceAxis_966797c6-9edf-4bcf-b42b-f623710de99b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f42ca1de-9a67-4bd0-8067-799c1d73fa4c" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_966797c6-9edf-4bcf-b42b-f623710de99b" xlink:to="loc_srt_ProductsAndServicesDomain_f42ca1de-9a67-4bd0-8067-799c1d73fa4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AcetadoteMember_5e5d36f8-78cf-4b8d-8ec2-00a7c9e05ae7" xlink:href="cpix-20190630.xsd#cpix_AcetadoteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f42ca1de-9a67-4bd0-8067-799c1d73fa4c" xlink:to="loc_cpix_AcetadoteMember_5e5d36f8-78cf-4b8d-8ec2-00a7c9e05ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OmeclamoxPakMember_dab5a768-416b-4aa9-b8bf-09021e95fc2b" xlink:href="cpix-20190630.xsd#cpix_OmeclamoxPakMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f42ca1de-9a67-4bd0-8067-799c1d73fa4c" xlink:to="loc_cpix_OmeclamoxPakMember_dab5a768-416b-4aa9-b8bf-09021e95fc2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KristaloseMember_63ce9d1b-5a3c-4105-b749-6f3d156a52ef" xlink:href="cpix-20190630.xsd#cpix_KristaloseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f42ca1de-9a67-4bd0-8067-799c1d73fa4c" xlink:to="loc_cpix_KristaloseMember_63ce9d1b-5a3c-4105-b749-6f3d156a52ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VaprisolMember_59df7da8-d4e8-49fd-a453-cf20eb4aeee8" xlink:href="cpix-20190630.xsd#cpix_VaprisolMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f42ca1de-9a67-4bd0-8067-799c1d73fa4c" xlink:to="loc_cpix_VaprisolMember_59df7da8-d4e8-49fd-a453-cf20eb4aeee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CaldolorMember_b21727b4-3af9-4b6f-a255-208ee6bd9f6a" xlink:href="cpix-20190630.xsd#cpix_CaldolorMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f42ca1de-9a67-4bd0-8067-799c1d73fa4c" xlink:to="loc_cpix_CaldolorMember_b21727b4-3af9-4b6f-a255-208ee6bd9f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EthyolMember_f761ba0a-7048-4352-8ef3-7f42c34c508e" xlink:href="cpix-20190630.xsd#cpix_EthyolMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f42ca1de-9a67-4bd0-8067-799c1d73fa4c" xlink:to="loc_cpix_EthyolMember_f761ba0a-7048-4352-8ef3-7f42c34c508e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TotectMember_282639c0-8815-44eb-b171-30e2ea0d53d3" xlink:href="cpix-20190630.xsd#cpix_TotectMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f42ca1de-9a67-4bd0-8067-799c1d73fa4c" xlink:to="loc_cpix_TotectMember_282639c0-8815-44eb-b171-30e2ea0d53d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_75b654bd-2a7c-4b80-891e-e9f282174aaa" xlink:href="cpix-20190630.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f42ca1de-9a67-4bd0-8067-799c1d73fa4c" xlink:to="loc_cpix_VIBATIVMember_75b654bd-2a7c-4b80-891e-e9f282174aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherProductsMember_d89eca6a-70e8-47e5-bbb5-89bf189695ca" xlink:href="cpix-20190630.xsd#cpix_OtherProductsMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f42ca1de-9a67-4bd0-8067-799c1d73fa4c" xlink:to="loc_cpix_OtherProductsMember_d89eca6a-70e8-47e5-bbb5-89bf189695ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f4a3f1d3-7373-45a5-8a1a-09ed7b6e549d" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_151b1a3f-f5b0-4790-a0a5-cb5911255ece" xlink:to="loc_srt_CounterpartyNameAxis_f4a3f1d3-7373-45a5-8a1a-09ed7b6e549d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_98c5aab5-87b7-400c-9587-4c4f9e9a7b43" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_f4a3f1d3-7373-45a5-8a1a-09ed7b6e549d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_98c5aab5-87b7-400c-9587-4c4f9e9a7b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember_c145b525-3003-4d06-b2f7-475fb36f9045" xlink:href="cpix-20190630.xsd#cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_98c5aab5-87b7-400c-9587-4c4f9e9a7b43" xlink:to="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember_c145b525-3003-4d06-b2f7-475fb36f9045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_501ad854-14e8-48ba-a854-7ab1ab24daee" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_151b1a3f-f5b0-4790-a0a5-cb5911255ece" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_501ad854-14e8-48ba-a854-7ab1ab24daee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6044437d-08f9-4593-a362-ebdbbb35cd48" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_501ad854-14e8-48ba-a854-7ab1ab24daee" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6044437d-08f9-4593-a362-ebdbbb35cd48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRightsGrantedMember_df915955-25de-4061-9e27-3aeb7c672302" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRightsGrantedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6044437d-08f9-4593-a362-ebdbbb35cd48" xlink:to="loc_us-gaap_RevenueRightsGrantedMember_df915955-25de-4061-9e27-3aeb7c672302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_4c583caf-3a86-4d6e-8295-06e0e41823cc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_151b1a3f-f5b0-4790-a0a5-cb5911255ece" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_4c583caf-3a86-4d6e-8295-06e0e41823cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_09c2a230-db47-4247-b6a4-0082b56cb6fd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_4c583caf-3a86-4d6e-8295-06e0e41823cc" xlink:to="loc_us-gaap_RevenuesAbstract_09c2a230-db47-4247-b6a4-0082b56cb6fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductsAbstract_a439716d-656c-48a9-8b69-e38d722948d5" xlink:href="cpix-20190630.xsd#cpix_ProductsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_09c2a230-db47-4247-b6a4-0082b56cb6fd" xlink:to="loc_cpix_ProductsAbstract_a439716d-656c-48a9-8b69-e38d722948d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b75b553c-8533-4c46-a33a-91100f030955" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ProductsAbstract_a439716d-656c-48a9-8b69-e38d722948d5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b75b553c-8533-4c46-a33a-91100f030955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Inventories" xlink:type="simple" xlink:href="cpix-20190630.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_2d0a76de-92c8-4335-9afe-d6c5249af8d4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_e08efc03-9110-4b7b-9b12-948c3d3f6199" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_2d0a76de-92c8-4335-9afe-d6c5249af8d4" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_e08efc03-9110-4b7b-9b12-948c3d3f6199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="simple" xlink:href="cpix-20190630.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_163e844d-ac89-40db-abe9-b5f9ee1bd57a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_07a5ee75-674f-48db-a59c-fa0119c86c65" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_163e844d-ac89-40db-abe9-b5f9ee1bd57a" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_07a5ee75-674f-48db-a59c-fa0119c86c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20190630.xsd#InventoriesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_87907d8f-975f-4e78-bd81-f98bd136a24e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_2b117b24-8928-44ce-8fcf-775fa15cadaa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_87907d8f-975f-4e78-bd81-f98bd136a24e" xlink:to="loc_us-gaap_InventoryCurrentTable_2b117b24-8928-44ce-8fcf-775fa15cadaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3f68b765-a430-4f80-9358-5f69f5dce4a1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_2b117b24-8928-44ce-8fcf-775fa15cadaa" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3f68b765-a430-4f80-9358-5f69f5dce4a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f7a4719e-be35-4bd4-bafe-29a3509a48ad" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3f68b765-a430-4f80-9358-5f69f5dce4a1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f7a4719e-be35-4bd4-bafe-29a3509a48ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_ea4b83f1-c676-43eb-964e-13afd88874ee" xlink:href="cpix-20190630.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f7a4719e-be35-4bd4-bafe-29a3509a48ad" xlink:to="loc_cpix_VIBATIVMember_ea4b83f1-c676-43eb-964e-13afd88874ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_ae201dba-0e08-4735-bfde-5ea9a45298f4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_2b117b24-8928-44ce-8fcf-775fa15cadaa" xlink:to="loc_us-gaap_InventoryLineItems_ae201dba-0e08-4735-bfde-5ea9a45298f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_327b27c2-2801-4bb7-b68a-8895829c5f1c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_ae201dba-0e08-4735-bfde-5ea9a45298f4" xlink:to="loc_us-gaap_InventoryValuationReserves_327b27c2-2801-4bb7-b68a-8895829c5f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_d2d0086b-ba85-4cbc-925c-648579f38ccf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_ae201dba-0e08-4735-bfde-5ea9a45298f4" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_d2d0086b-ba85-4cbc-925c-648579f38ccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_0d473331-1022-4fe0-81c2-f7a60af66a8e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_ae201dba-0e08-4735-bfde-5ea9a45298f4" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_0d473331-1022-4fe0-81c2-f7a60af66a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_0be86020-759f-47ac-9363-c157236f440f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_ae201dba-0e08-4735-bfde-5ea9a45298f4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_0be86020-759f-47ac-9363-c157236f440f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="cpix-20190630.xsd#InventoriesScheduleofInventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_48aeec5e-b112-4e01-8718-9b6adffb063b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_76550886-9977-4434-84a2-28b6d0dc6d4c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_48aeec5e-b112-4e01-8718-9b6adffb063b" xlink:to="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_76550886-9977-4434-84a2-28b6d0dc6d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_754db10a-acf3-40ca-8ba9-a2131dd0f0ff" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_76550886-9977-4434-84a2-28b6d0dc6d4c" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_754db10a-acf3-40ca-8ba9-a2131dd0f0ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_257a49c6-e3c5-4231-bb7d-31008611f27e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_76550886-9977-4434-84a2-28b6d0dc6d4c" xlink:to="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_257a49c6-e3c5-4231-bb7d-31008611f27e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_421739a0-5bb5-464d-8a6b-7aedd414b920" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_76550886-9977-4434-84a2-28b6d0dc6d4c" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_421739a0-5bb5-464d-8a6b-7aedd414b920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_8dce5320-849d-4495-9939-24af0ac9859d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_76550886-9977-4434-84a2-28b6d0dc6d4c" xlink:to="loc_us-gaap_InventoryGross_8dce5320-849d-4495-9939-24af0ac9859d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_c554c876-4915-4249-a2d8-e49508964688" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_76550886-9977-4434-84a2-28b6d0dc6d4c" xlink:to="loc_us-gaap_InventoryNoncurrent_c554c876-4915-4249-a2d8-e49508964688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_17cf074e-787c-45a2-83f7-35cd2b687e76" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_76550886-9977-4434-84a2-28b6d0dc6d4c" xlink:to="loc_us-gaap_InventoryNet_17cf074e-787c-45a2-83f7-35cd2b687e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Leases" xlink:type="simple" xlink:href="cpix-20190630.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_5f2d2ad8-3e53-4aa6-b232-12781273b67f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_1683ee1f-c6d5-4864-8ec2-ac8bceb0ff4f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5f2d2ad8-3e53-4aa6-b232-12781273b67f" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_1683ee1f-c6d5-4864-8ec2-ac8bceb0ff4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="simple" xlink:href="cpix-20190630.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a554ee7b-deb0-4a13-9f53-53541e58344b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_cc88de04-76c0-40e6-a5f8-1adcae1bdf68" xlink:href="cpix-20190630.xsd#cpix_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a554ee7b-deb0-4a13-9f53-53541e58344b" xlink:to="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_cc88de04-76c0-40e6-a5f8-1adcae1bdf68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_6e1cf120-a124-46f0-9134-3fc45b4835a0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a554ee7b-deb0-4a13-9f53-53541e58344b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_6e1cf120-a124-46f0-9134-3fc45b4835a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20190630.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_cc382f20-e310-448c-90da-d9677d5b29a8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6d53e91e-487e-4ed0-9f8f-402cdcd6bdb9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cc382f20-e310-448c-90da-d9677d5b29a8" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_6d53e91e-487e-4ed0-9f8f-402cdcd6bdb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_a09d50f8-d783-4bae-baef-1798ce70c52a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cc382f20-e310-448c-90da-d9677d5b29a8" xlink:to="loc_us-gaap_OperatingLeaseLiability_a09d50f8-d783-4bae-baef-1798ce70c52a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c7a8550a-463d-4a64-bc70-8c7228ee9a45" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cc382f20-e310-448c-90da-d9677d5b29a8" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c7a8550a-463d-4a64-bc70-8c7228ee9a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_d8f1e190-cfdb-430f-af16-37f4de906e29" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cc382f20-e310-448c-90da-d9677d5b29a8" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_d8f1e190-cfdb-430f-af16-37f4de906e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="simple" xlink:href="cpix-20190630.xsd#LeasesLeasePositionDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_0d003a6e-46cd-4270-9079-33ef61677e55" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_7f841e7d-b75c-473e-a047-9213ea99fab9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0d003a6e-46cd-4270-9079-33ef61677e55" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_7f841e7d-b75c-473e-a047-9213ea99fab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LeaseAsset_f69c8a7e-f24e-4f38-98d8-dbdd638ab202" xlink:href="cpix-20190630.xsd#cpix_LeaseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0d003a6e-46cd-4270-9079-33ef61677e55" xlink:to="loc_cpix_LeaseAsset_f69c8a7e-f24e-4f38-98d8-dbdd638ab202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_5ebb8793-940f-4921-9849-a5ee5a048e2d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0d003a6e-46cd-4270-9079-33ef61677e55" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_5ebb8793-940f-4921-9849-a5ee5a048e2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8666716c-8f06-4701-a4e1-dff3d7a779f1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0d003a6e-46cd-4270-9079-33ef61677e55" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8666716c-8f06-4701-a4e1-dff3d7a779f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LeaseLiability_988bd191-7cb4-47be-b63e-1ed9a3722d92" xlink:href="cpix-20190630.xsd#cpix_LeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0d003a6e-46cd-4270-9079-33ef61677e55" xlink:to="loc_cpix_LeaseLiability_988bd191-7cb4-47be-b63e-1ed9a3722d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="simple" xlink:href="cpix-20190630.xsd#LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_95dde8c9-a3cd-4367-99cc-e0bb97dbb6ad" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7777e076-1da9-44b8-9093-ed3c2eef37a6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_95dde8c9-a3cd-4367-99cc-e0bb97dbb6ad" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7777e076-1da9-44b8-9093-ed3c2eef37a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0dda9987-c7bd-4fb4-9151-4f8b45e4be25" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7777e076-1da9-44b8-9093-ed3c2eef37a6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0dda9987-c7bd-4fb4-9151-4f8b45e4be25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_7d16e748-af61-455b-b0fe-e677d1f3b0d7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7777e076-1da9-44b8-9093-ed3c2eef37a6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_7d16e748-af61-455b-b0fe-e677d1f3b0d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_4578de70-3279-4889-8cc5-5ebf9568e9de" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7777e076-1da9-44b8-9093-ed3c2eef37a6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_4578de70-3279-4889-8cc5-5ebf9568e9de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0597c5fb-a5cc-496a-a927-689cd5353ac8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7777e076-1da9-44b8-9093-ed3c2eef37a6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0597c5fb-a5cc-496a-a927-689cd5353ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_6bef7d94-53ae-4bc1-b294-12cb0d98bb66" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7777e076-1da9-44b8-9093-ed3c2eef37a6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_6bef7d94-53ae-4bc1-b294-12cb0d98bb66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_c74b2139-f664-4488-a940-e57dfa91da9a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7777e076-1da9-44b8-9093-ed3c2eef37a6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_c74b2139-f664-4488-a940-e57dfa91da9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ad344acb-f2e8-4f85-a48e-808517f5ad2f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7777e076-1da9-44b8-9093-ed3c2eef37a6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ad344acb-f2e8-4f85-a48e-808517f5ad2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_24a35baa-01aa-4b72-af21-3005acf9b8c6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7777e076-1da9-44b8-9093-ed3c2eef37a6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_24a35baa-01aa-4b72-af21-3005acf9b8c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_26f8b56c-ea2d-4d41-a481-fb69d103d1c8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7777e076-1da9-44b8-9093-ed3c2eef37a6" xlink:to="loc_us-gaap_OperatingLeaseLiability_26f8b56c-ea2d-4d41-a481-fb69d103d1c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt" xlink:type="simple" xlink:href="cpix-20190630.xsd#ShareholdersEquityandDebt"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EquityAndDebtAbstract_2c284f27-6711-4143-8114-295412757bf7" xlink:href="cpix-20190630.xsd#cpix_EquityAndDebtAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_168c850f-8eac-4e2a-a946-51b2500ce181" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_EquityAndDebtAbstract_2c284f27-6711-4143-8114-295412757bf7" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_168c850f-8eac-4e2a-a946-51b2500ce181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="simple" xlink:href="cpix-20190630.xsd#ShareholdersEquityandDebtShareholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EquityAndDebtAbstract_86c1808a-0f9b-4081-95c2-1997349c1592" xlink:href="cpix-20190630.xsd#cpix_EquityAndDebtAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_800ea043-8ac1-4ab0-b904-49deffe5613a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_EquityAndDebtAbstract_86c1808a-0f9b-4081-95c2-1997349c1592" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_800ea043-8ac1-4ab0-b904-49deffe5613a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1a773038-2e08-43c8-8df5-a495445d93af" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_800ea043-8ac1-4ab0-b904-49deffe5613a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1a773038-2e08-43c8-8df5-a495445d93af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1b64fcef-42b0-4974-bdca-f64d17e362dc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1a773038-2e08-43c8-8df5-a495445d93af" xlink:to="loc_us-gaap_EquityComponentDomain_1b64fcef-42b0-4974-bdca-f64d17e362dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_125b167e-55c4-4b58-bd54-bda46a109dec" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1b64fcef-42b0-4974-bdca-f64d17e362dc" xlink:to="loc_us-gaap_CommonStockMember_125b167e-55c4-4b58-bd54-bda46a109dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualAxis_a6daa225-d340-4ce9-907b-a2c84419c321" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_800ea043-8ac1-4ab0-b904-49deffe5613a" xlink:to="loc_us-gaap_TitleOfIndividualAxis_a6daa225-d340-4ce9-907b-a2c84419c321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_926e59bb-05f9-455f-91e1-0dd756c469e1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_a6daa225-d340-4ce9-907b-a2c84419c321" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_926e59bb-05f9-455f-91e1-0dd756c469e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DirectorMember_ef17297f-14ee-409e-88c1-ee6b3fdccf65" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_926e59bb-05f9-455f-91e1-0dd756c469e1" xlink:to="loc_us-gaap_DirectorMember_ef17297f-14ee-409e-88c1-ee6b3fdccf65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ba88e009-0c20-4ea3-9e2e-c85ddcf68443" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_800ea043-8ac1-4ab0-b904-49deffe5613a" xlink:to="loc_us-gaap_AwardTypeAxis_ba88e009-0c20-4ea3-9e2e-c85ddcf68443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0ac62c9c-2739-40e6-aaa3-4e23ece2cf14" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ba88e009-0c20-4ea3-9e2e-c85ddcf68443" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0ac62c9c-2739-40e6-aaa3-4e23ece2cf14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_af0450ea-220a-475c-95da-82ffbed1a112" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0ac62c9c-2739-40e6-aaa3-4e23ece2cf14" xlink:to="loc_us-gaap_RestrictedStockMember_af0450ea-220a-475c-95da-82ffbed1a112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_74b27ff2-275c-485d-a526-ca8903bdd35e" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_800ea043-8ac1-4ab0-b904-49deffe5613a" xlink:to="loc_srt_CounterpartyNameAxis_74b27ff2-275c-485d-a526-ca8903bdd35e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e7a8c40b-b31d-4e34-a603-31248755320d" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_74b27ff2-275c-485d-a526-ca8903bdd35e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e7a8c40b-b31d-4e34-a603-31248755320d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_1675d667-32e8-4316-93c2-7bc2d021a380" xlink:href="cpix-20190630.xsd#cpix_HongKongWinHealthPharmaGroupCoLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e7a8c40b-b31d-4e34-a603-31248755320d" xlink:to="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_1675d667-32e8-4316-93c2-7bc2d021a380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_GloriaPharmaceuticalsMember_2985d14e-ceef-4bb8-8a47-8b039611a12c" xlink:href="cpix-20190630.xsd#cpix_GloriaPharmaceuticalsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e7a8c40b-b31d-4e34-a603-31248755320d" xlink:to="loc_cpix_GloriaPharmaceuticalsMember_2985d14e-ceef-4bb8-8a47-8b039611a12c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1811f97a-85a9-4021-807d-6fd6e5a224fa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_800ea043-8ac1-4ab0-b904-49deffe5613a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1811f97a-85a9-4021-807d-6fd6e5a224fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareholdersEquityTextualAbstract_1852c3a7-355b-4427-ac9a-76118dbb8a61" xlink:href="cpix-20190630.xsd#cpix_ShareholdersEquityTextualAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1811f97a-85a9-4021-807d-6fd6e5a224fa" xlink:to="loc_cpix_ShareholdersEquityTextualAbstract_1852c3a7-355b-4427-ac9a-76118dbb8a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_be6b37d9-737f-44ad-ab6d-3079d97daf83" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_1852c3a7-355b-4427-ac9a-76118dbb8a61" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_be6b37d9-737f-44ad-ab6d-3079d97daf83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_29f51757-53d4-4880-83f6-d3d542644a35" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_1852c3a7-355b-4427-ac9a-76118dbb8a61" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_29f51757-53d4-4880-83f6-d3d542644a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_f38ace9b-c35a-4d87-9b52-e5b2ae1c9e81" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_1852c3a7-355b-4427-ac9a-76118dbb8a61" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_f38ace9b-c35a-4d87-9b52-e5b2ae1c9e81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SaleOfStockNumberOfSharesSold_58d7e57f-07dd-4c7e-aadf-43b60c976f04" xlink:href="cpix-20190630.xsd#cpix_SaleOfStockNumberOfSharesSold"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_1852c3a7-355b-4427-ac9a-76118dbb8a61" xlink:to="loc_cpix_SaleOfStockNumberOfSharesSold_58d7e57f-07dd-4c7e-aadf-43b60c976f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_0c551249-16a9-42ee-be32-b3884b019c17" xlink:href="cpix-20190630.xsd#cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_1852c3a7-355b-4427-ac9a-76118dbb8a61" xlink:to="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_0c551249-16a9-42ee-be32-b3884b019c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding_1b7754d8-847f-4110-9b6c-e3cecbc6796f" xlink:href="cpix-20190630.xsd#cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_1852c3a7-355b-4427-ac9a-76118dbb8a61" xlink:to="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding_1b7754d8-847f-4110-9b6c-e3cecbc6796f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e14d852a-d8a6-457b-bb2d-0a9ecc3dd58c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_1852c3a7-355b-4427-ac9a-76118dbb8a61" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e14d852a-d8a6-457b-bb2d-0a9ecc3dd58c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_96c0317e-32dd-46f9-b5a7-8daa8bbd0bb0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_1852c3a7-355b-4427-ac9a-76118dbb8a61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_96c0317e-32dd-46f9-b5a7-8daa8bbd0bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d0200492-33b9-43fa-bc05-ed2873389200" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_1852c3a7-355b-4427-ac9a-76118dbb8a61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d0200492-33b9-43fa-bc05-ed2873389200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentPurchaseOfShares_6817b74f-920b-4856-9f1b-baa8da27b1f8" xlink:href="cpix-20190630.xsd#cpix_SubsidiaryInvestmentPurchaseOfShares"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_1852c3a7-355b-4427-ac9a-76118dbb8a61" xlink:to="loc_cpix_SubsidiaryInvestmentPurchaseOfShares_6817b74f-920b-4856-9f1b-baa8da27b1f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentCashContribution_46976612-475b-4ffc-b93f-bd28546f6b1e" xlink:href="cpix-20190630.xsd#cpix_SubsidiaryInvestmentCashContribution"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_1852c3a7-355b-4427-ac9a-76118dbb8a61" xlink:to="loc_cpix_SubsidiaryInvestmentCashContribution_46976612-475b-4ffc-b93f-bd28546f6b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable_78e916fa-1a93-49aa-99b2-31c9c2932c17" xlink:href="cpix-20190630.xsd#cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_1852c3a7-355b-4427-ac9a-76118dbb8a61" xlink:to="loc_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable_78e916fa-1a93-49aa-99b2-31c9c2932c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_94af428a-9134-467e-8b6f-6bd9c06fd2d3" xlink:href="cpix-20190630.xsd#cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_1852c3a7-355b-4427-ac9a-76118dbb8a61" xlink:to="loc_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_94af428a-9134-467e-8b6f-6bd9c06fd2d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e49720c2-68e3-49a4-ae7a-325f2a80e009" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_1852c3a7-355b-4427-ac9a-76118dbb8a61" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e49720c2-68e3-49a4-ae7a-325f2a80e009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="simple" xlink:href="cpix-20190630.xsd#ShareholdersEquityandDebtDebtDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EquityAndDebtAbstract_9f974378-760c-4f78-8050-105d5dd95780" xlink:href="cpix-20190630.xsd#cpix_EquityAndDebtAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_abe78ffe-0a0b-4533-bb18-c2b9bd0b550e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_EquityAndDebtAbstract_9f974378-760c-4f78-8050-105d5dd95780" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_abe78ffe-0a0b-4533-bb18-c2b9bd0b550e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_a1c77180-f3f8-416d-9ac9-2580eaf6f7fe" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_abe78ffe-0a0b-4533-bb18-c2b9bd0b550e" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_a1c77180-f3f8-416d-9ac9-2580eaf6f7fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_636e1078-1924-4762-bd03-0f1c03483dd0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_a1c77180-f3f8-416d-9ac9-2580eaf6f7fe" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_636e1078-1924-4762-bd03-0f1c03483dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember_69f47bc8-2be8-4be3-9e27-dab5749cbb63" xlink:href="cpix-20190630.xsd#cpix_PinnacleBankMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_636e1078-1924-4762-bd03-0f1c03483dd0" xlink:to="loc_cpix_PinnacleBankMember_69f47bc8-2be8-4be3-9e27-dab5749cbb63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_62fddef8-51be-4214-a118-27f14e4a0bf9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_abe78ffe-0a0b-4533-bb18-c2b9bd0b550e" xlink:to="loc_us-gaap_DebtInstrumentAxis_62fddef8-51be-4214-a118-27f14e4a0bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_52412943-dd1b-4ac5-a82b-be1c17475260" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_62fddef8-51be-4214-a118-27f14e4a0bf9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_52412943-dd1b-4ac5-a82b-be1c17475260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SecondAmendmentMember_8150ea41-efa8-4420-a0c4-340ee65fd849" xlink:href="cpix-20190630.xsd#cpix_SecondAmendmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52412943-dd1b-4ac5-a82b-be1c17475260" xlink:to="loc_cpix_SecondAmendmentMember_8150ea41-efa8-4420-a0c4-340ee65fd849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_a9794b73-cd58-4a97-91d2-494c8a695c17" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_52412943-dd1b-4ac5-a82b-be1c17475260" xlink:to="loc_us-gaap_LineOfCreditMember_a9794b73-cd58-4a97-91d2-494c8a695c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_4140b677-ee91-48d6-b6c7-e0f9f541a88c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_abe78ffe-0a0b-4533-bb18-c2b9bd0b550e" xlink:to="loc_us-gaap_CreditFacilityAxis_4140b677-ee91-48d6-b6c7-e0f9f541a88c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_b06a9684-1571-4898-a386-ba5689d3f259" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_4140b677-ee91-48d6-b6c7-e0f9f541a88c" xlink:to="loc_us-gaap_CreditFacilityDomain_b06a9684-1571-4898-a386-ba5689d3f259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_aed51f27-6e1f-45ab-a6b6-3e9a2b41ed70" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_b06a9684-1571-4898-a386-ba5689d3f259" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_aed51f27-6e1f-45ab-a6b6-3e9a2b41ed70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bab75a4c-b8e1-40a7-b67a-85988fb56885" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_abe78ffe-0a0b-4533-bb18-c2b9bd0b550e" xlink:to="loc_srt_RangeAxis_bab75a4c-b8e1-40a7-b67a-85988fb56885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_acf390e8-7b35-4b68-a16d-2870c5659921" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_bab75a4c-b8e1-40a7-b67a-85988fb56885" xlink:to="loc_srt_RangeMember_acf390e8-7b35-4b68-a16d-2870c5659921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c3f4e541-9222-4de4-a619-dc2ede06f33b" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_acf390e8-7b35-4b68-a16d-2870c5659921" xlink:to="loc_srt_MinimumMember_c3f4e541-9222-4de4-a619-dc2ede06f33b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2a134e32-7657-4c1a-84bb-fd22f79e7754" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_acf390e8-7b35-4b68-a16d-2870c5659921" xlink:to="loc_srt_MaximumMember_2a134e32-7657-4c1a-84bb-fd22f79e7754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_d5b94176-a98e-451f-a5fb-5418521d7495" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_abe78ffe-0a0b-4533-bb18-c2b9bd0b550e" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_d5b94176-a98e-451f-a5fb-5418521d7495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_4234fe0f-98d4-45e8-a52b-eb1a21bd5c42" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_d5b94176-a98e-451f-a5fb-5418521d7495" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_4234fe0f-98d4-45e8-a52b-eb1a21bd5c42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_d6ff1c3f-ebb8-454c-8362-971063d71223" xlink:href="cpix-20190630.xsd#cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_d5b94176-a98e-451f-a5fb-5418521d7495" xlink:to="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_d6ff1c3f-ebb8-454c-8362-971063d71223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_2fb01d18-de70-428a-a03e-bf1589164995" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_d5b94176-a98e-451f-a5fb-5418521d7495" xlink:to="loc_us-gaap_LongTermLineOfCredit_2fb01d18-de70-428a-a03e-bf1589164995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_02b7cbf8-255a-4c60-bb96-6a59afe392dc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_d5b94176-a98e-451f-a5fb-5418521d7495" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_02b7cbf8-255a-4c60-bb96-6a59afe392dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_bd14d6f4-9ce1-4dc3-942f-da6eea0c600f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_d5b94176-a98e-451f-a5fb-5418521d7495" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_bd14d6f4-9ce1-4dc3-942f-da6eea0c600f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cpix-20190630.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_095bf3e1-74d5-417a-bf1d-5e3b439e2468" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_76c857f7-8694-4857-a5c8-88cb639d86b1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_095bf3e1-74d5-417a-bf1d-5e3b439e2468" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_76c857f7-8694-4857-a5c8-88cb639d86b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="simple" xlink:href="cpix-20190630.xsd#IncomeTaxesDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3cd2c68f-cc0c-4f5d-9a7e-4f1f532dba7f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_ef23faf3-0812-4734-8353-6acc23f6585f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3cd2c68f-cc0c-4f5d-9a7e-4f1f532dba7f" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_ef23faf3-0812-4734-8353-6acc23f6585f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="simple" xlink:href="cpix-20190630.xsd#CollaborativeAgreements"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_93afd4f5-cacf-401b-89e6-c2d79dfa1cb6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_7d45ea8e-46b8-4d8c-a3b2-92e8fd1c50b9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_93afd4f5-cacf-401b-89e6-c2d79dfa1cb6" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_7d45ea8e-46b8-4d8c-a3b2-92e8fd1c50b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRights" xlink:type="simple" xlink:href="cpix-20190630.xsd#RecentAdditionsandExpectedReturnofProductRights"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRights" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_bbe02bd8-ff51-47ca-88f3-97a5791355b1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_ce1ef55c-bbf2-4054-9e9e-7d7fdfb13057" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_bbe02bd8-ff51-47ca-88f3-97a5791355b1" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_ce1ef55c-bbf2-4054-9e9e-7d7fdfb13057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsTables" xlink:type="simple" xlink:href="cpix-20190630.xsd#RecentAdditionsandExpectedReturnofProductRightsTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_b72e45b8-ec1c-46ab-952e-c8209faaa27d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_4726364a-0118-4f5f-bf0f-5286b3219296" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_b72e45b8-ec1c-46ab-952e-c8209faaa27d" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_4726364a-0118-4f5f-bf0f-5286b3219296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_19513b3f-0bc0-4f6d-9cfe-d2288da54749" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_b72e45b8-ec1c-46ab-952e-c8209faaa27d" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_19513b3f-0bc0-4f6d-9cfe-d2288da54749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_d4c258d9-8872-4089-aa7a-22deb5b8142e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_b72e45b8-ec1c-46ab-952e-c8209faaa27d" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_d4c258d9-8872-4089-aa7a-22deb5b8142e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20190630.xsd#RecentAdditionsandExpectedReturnofProductRightsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_d13cbee0-2ab2-4ad2-bd62-9197c507b8c8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_94233ec3-7a6f-4d83-823e-dabed88afe47" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_d13cbee0-2ab2-4ad2-bd62-9197c507b8c8" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_94233ec3-7a6f-4d83-823e-dabed88afe47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_93d9b421-9559-438b-8a93-4610edaca72d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_94233ec3-7a6f-4d83-823e-dabed88afe47" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_93d9b421-9559-438b-8a93-4610edaca72d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cd65c33b-3871-4167-9b24-2b7f8c542ebb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_93d9b421-9559-438b-8a93-4610edaca72d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cd65c33b-3871-4167-9b24-2b7f8c542ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_9567190f-1cc4-4141-8ab1-801b9d9391d3" xlink:href="cpix-20190630.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cd65c33b-3871-4167-9b24-2b7f8c542ebb" xlink:to="loc_cpix_VIBATIVMember_9567190f-1cc4-4141-8ab1-801b9d9391d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a9bdcc2d-26f1-4867-a36f-6a61ef11fbd9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_94233ec3-7a6f-4d83-823e-dabed88afe47" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a9bdcc2d-26f1-4867-a36f-6a61ef11fbd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54eb9f45-54e1-4f14-87c3-9348c8b21c75" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a9bdcc2d-26f1-4867-a36f-6a61ef11fbd9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54eb9f45-54e1-4f14-87c3-9348c8b21c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_525d097c-9f44-4bd5-9e73-1e614c7a906c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54eb9f45-54e1-4f14-87c3-9348c8b21c75" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_525d097c-9f44-4bd5-9e73-1e614c7a906c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_31fa1b1c-c6ed-4f9d-b7b8-b44e8e62f71f" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_94233ec3-7a6f-4d83-823e-dabed88afe47" xlink:to="loc_srt_CounterpartyNameAxis_31fa1b1c-c6ed-4f9d-b7b8-b44e8e62f71f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_94219b5a-b655-47d2-9918-950fc8738312" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_31fa1b1c-c6ed-4f9d-b7b8-b44e8e62f71f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_94219b5a-b655-47d2-9918-950fc8738312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ClinigenHealthcareLimitedMember_749ceedb-3225-4fa4-bff5-d517bcda51a6" xlink:href="cpix-20190630.xsd#cpix_ClinigenHealthcareLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_94219b5a-b655-47d2-9918-950fc8738312" xlink:to="loc_cpix_ClinigenHealthcareLimitedMember_749ceedb-3225-4fa4-bff5-d517bcda51a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementScenarioAxis_61025222-3df7-4558-8cab-ac659b3924bd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_94233ec3-7a6f-4d83-823e-dabed88afe47" xlink:to="loc_us-gaap_StatementScenarioAxis_61025222-3df7-4558-8cab-ac659b3924bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_a3aad95d-00e7-4074-ade8-b9cd8198323a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_61025222-3df7-4558-8cab-ac659b3924bd" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_a3aad95d-00e7-4074-ade8-b9cd8198323a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScenarioForecastMember_52f04fee-c6e9-418d-a748-317f0bdd75ff" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_a3aad95d-00e7-4074-ade8-b9cd8198323a" xlink:to="loc_us-gaap_ScenarioForecastMember_52f04fee-c6e9-418d-a748-317f0bdd75ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1cbfda4e-4b75-4ffc-92de-785df9f39154" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_94233ec3-7a6f-4d83-823e-dabed88afe47" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_1cbfda4e-4b75-4ffc-92de-785df9f39154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsForAssetAcquisitions_c030b2a8-a4d9-49cd-bf6f-9a2d5908b758" xlink:href="cpix-20190630.xsd#cpix_PaymentsForAssetAcquisitions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1cbfda4e-4b75-4ffc-92de-785df9f39154" xlink:to="loc_cpix_PaymentsForAssetAcquisitions_c030b2a8-a4d9-49cd-bf6f-9a2d5908b758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_8fff1405-5b48-4e21-8db3-0bd3e2aab5fe" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1cbfda4e-4b75-4ffc-92de-785df9f39154" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_8fff1405-5b48-4e21-8db3-0bd3e2aab5fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_c75dcd0b-b939-4667-b703-a111940512a3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1cbfda4e-4b75-4ffc-92de-785df9f39154" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_c75dcd0b-b939-4667-b703-a111940512a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TieredRoyaltyPaymentsPercentage_a00b07e8-523f-4511-8e60-f64b13dd2a1c" xlink:href="cpix-20190630.xsd#cpix_TieredRoyaltyPaymentsPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1cbfda4e-4b75-4ffc-92de-785df9f39154" xlink:to="loc_cpix_TieredRoyaltyPaymentsPercentage_a00b07e8-523f-4511-8e60-f64b13dd2a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_bb2f7ffd-6c34-4341-bb86-5d0ccb616968" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1cbfda4e-4b75-4ffc-92de-785df9f39154" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_bb2f7ffd-6c34-4341-bb86-5d0ccb616968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_fe9bba12-3f1c-4910-8d90-ad9bc4c05586" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1cbfda4e-4b75-4ffc-92de-785df9f39154" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_fe9bba12-3f1c-4910-8d90-ad9bc4c05586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_f75485fe-9db2-459f-ab4a-032f1fc906d4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1cbfda4e-4b75-4ffc-92de-785df9f39154" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_f75485fe-9db2-459f-ab4a-032f1fc906d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsScheduleofInitialPaymentsandConsiderationDetails" xlink:type="simple" xlink:href="cpix-20190630.xsd#RecentAdditionsandExpectedReturnofProductRightsScheduleofInitialPaymentsandConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsScheduleofInitialPaymentsandConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_6c33c4c5-4276-4bb3-b0e9-8f566b01b6a2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_79f914c5-c106-4fc0-9188-436632dc36d1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_6c33c4c5-4276-4bb3-b0e9-8f566b01b6a2" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_79f914c5-c106-4fc0-9188-436632dc36d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_003d3c67-cc5d-4d49-bdf6-296324901431" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_79f914c5-c106-4fc0-9188-436632dc36d1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_003d3c67-cc5d-4d49-bdf6-296324901431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_060aab48-cedc-46eb-9619-fab6a98a3762" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_003d3c67-cc5d-4d49-bdf6-296324901431" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_060aab48-cedc-46eb-9619-fab6a98a3762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_0a7f2206-eb2c-4483-a96a-f0b7fb4ac4bd" xlink:href="cpix-20190630.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_060aab48-cedc-46eb-9619-fab6a98a3762" xlink:to="loc_cpix_VIBATIVMember_0a7f2206-eb2c-4483-a96a-f0b7fb4ac4bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_42aefef6-ff15-4587-a903-a3079cc7281d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_79f914c5-c106-4fc0-9188-436632dc36d1" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_42aefef6-ff15-4587-a903-a3079cc7281d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_6c21dd75-c113-4e08-8c11-0954a597d49d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_42aefef6-ff15-4587-a903-a3079cc7281d" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_6c21dd75-c113-4e08-8c11-0954a597d49d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_08231939-6832-4a53-a589-b4ea79f50304" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_42aefef6-ff15-4587-a903-a3079cc7281d" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_08231939-6832-4a53-a589-b4ea79f50304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsForContingentConsideration_a94d20e7-b130-4415-a916-55fecdc3de66" xlink:href="cpix-20190630.xsd#cpix_PaymentsForContingentConsideration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_42aefef6-ff15-4587-a903-a3079cc7281d" xlink:to="loc_cpix_PaymentsForContingentConsideration_a94d20e7-b130-4415-a916-55fecdc3de66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_b25a1a89-7781-443e-86a6-0eb82485b1f4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_42aefef6-ff15-4587-a903-a3079cc7281d" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_b25a1a89-7781-443e-86a6-0eb82485b1f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsChangeinConsiderationDetails" xlink:type="simple" xlink:href="cpix-20190630.xsd#RecentAdditionsandExpectedReturnofProductRightsChangeinConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsChangeinConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_f4462b36-0ddf-48f2-83f3-dbb6037ea8d0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1af8a990-3380-4314-b6d2-49919f99aeba" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_f4462b36-0ddf-48f2-83f3-dbb6037ea8d0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1af8a990-3380-4314-b6d2-49919f99aeba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1c2b73fa-841c-416d-882e-994fe1bb7ef6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1af8a990-3380-4314-b6d2-49919f99aeba" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1c2b73fa-841c-416d-882e-994fe1bb7ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0d935164-e4cc-4b25-849d-e3c83c4b20e7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1c2b73fa-841c-416d-882e-994fe1bb7ef6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0d935164-e4cc-4b25-849d-e3c83c4b20e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_19ecfc76-33fd-427c-ac63-50e4451f0162" xlink:href="cpix-20190630.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0d935164-e4cc-4b25-849d-e3c83c4b20e7" xlink:to="loc_cpix_VIBATIVMember_19ecfc76-33fd-427c-ac63-50e4451f0162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_f91c8e8b-c27b-460e-82b6-bc8b1d424bbe" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1af8a990-3380-4314-b6d2-49919f99aeba" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_f91c8e8b-c27b-460e-82b6-bc8b1d424bbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualRollForward_d01692f8-d5c0-4870-860e-049fd8fd8457" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyAccrualRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f91c8e8b-c27b-460e-82b6-bc8b1d424bbe" xlink:to="loc_us-gaap_LossContingencyAccrualRollForward_d01692f8-d5c0-4870-860e-049fd8fd8457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1957d00c-d55d-4aac-8eb1-3ce17e1588cb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_d01692f8-d5c0-4870-860e-049fd8fd8457" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1957d00c-d55d-4aac-8eb1-3ce17e1588cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment_8dd46388-1052-4c97-8cdf-c5537ad73e96" xlink:href="cpix-20190630.xsd#cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_d01692f8-d5c0-4870-860e-049fd8fd8457" xlink:to="loc_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment_8dd46388-1052-4c97-8cdf-c5537ad73e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_bf1f7fa8-e854-4d0d-8a96-1100bb623c93" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_d01692f8-d5c0-4870-860e-049fd8fd8457" xlink:to="loc_us-gaap_PaymentsForRoyalties_bf1f7fa8-e854-4d0d-8a96-1100bb623c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_b6ef7026-fa77-43e0-ab47-714c67f0dd0b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_d01692f8-d5c0-4870-860e-049fd8fd8457" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_b6ef7026-fa77-43e0-ab47-714c67f0dd0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_ee125c8f-bbb0-4b81-8c62-89443b1db863" xlink:href="cpix-20190630.xsd#cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_d01692f8-d5c0-4870-860e-049fd8fd8457" xlink:to="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_ee125c8f-bbb0-4b81-8c62-89443b1db863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e8397a1f-f0fe-45c0-afd6-14acb01a4f1a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_d01692f8-d5c0-4870-860e-049fd8fd8457" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e8397a1f-f0fe-45c0-afd6-14acb01a4f1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsScheduleofPreliminaryPurchaseAllocationDetails" xlink:type="simple" xlink:href="cpix-20190630.xsd#RecentAdditionsandExpectedReturnofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsScheduleofPreliminaryPurchaseAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_3646fb05-52af-46dc-bb72-f5a063c5c412" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c91212f9-33fc-4358-ab90-87e644083132" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_3646fb05-52af-46dc-bb72-f5a063c5c412" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c91212f9-33fc-4358-ab90-87e644083132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8c1553c3-a310-40d9-b3c2-0e89a371f68b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c91212f9-33fc-4358-ab90-87e644083132" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8c1553c3-a310-40d9-b3c2-0e89a371f68b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6dc3bf30-4782-480e-a062-7438bf8da7b4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8c1553c3-a310-40d9-b3c2-0e89a371f68b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6dc3bf30-4782-480e-a062-7438bf8da7b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_a1c0268f-34cb-4460-b276-00e171b3f376" xlink:href="cpix-20190630.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6dc3bf30-4782-480e-a062-7438bf8da7b4" xlink:to="loc_cpix_VIBATIVMember_a1c0268f-34cb-4460-b276-00e171b3f376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_836f9c30-34cf-492d-b822-2d59c13d3685" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c91212f9-33fc-4358-ab90-87e644083132" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_836f9c30-34cf-492d-b822-2d59c13d3685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_1632fd96-61ad-48a1-88a8-33d06d819492" xlink:href="cpix-20190630.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_836f9c30-34cf-492d-b822-2d59c13d3685" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_1632fd96-61ad-48a1-88a8-33d06d819492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_ccf02570-2c75-4cf6-9c53-ed6b7ac4f81c" xlink:href="cpix-20190630.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_836f9c30-34cf-492d-b822-2d59c13d3685" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_ccf02570-2c75-4cf6-9c53-ed6b7ac4f81c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_6d8ca5fc-4187-4190-ba23-ed551b0f8e3a" xlink:href="cpix-20190630.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_836f9c30-34cf-492d-b822-2d59c13d3685" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_6d8ca5fc-4187-4190-ba23-ed551b0f8e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_4e52bd86-ba96-4286-a941-f978435bc2b0" xlink:href="cpix-20190630.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_836f9c30-34cf-492d-b822-2d59c13d3685" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_4e52bd86-ba96-4286-a941-f978435bc2b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_78d9b06a-8269-4487-8de8-6269fdd4c2a9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_836f9c30-34cf-492d-b822-2d59c13d3685" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_78d9b06a-8269-4487-8de8-6269fdd4c2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_2638f475-6a22-4a79-8f80-efa418491f3d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_836f9c30-34cf-492d-b822-2d59c13d3685" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_2638f475-6a22-4a79-8f80-efa418491f3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_aa64886e-bedb-47aa-9235-b39284379271" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_836f9c30-34cf-492d-b822-2d59c13d3685" xlink:to="loc_us-gaap_Goodwill_aa64886e-bedb-47aa-9235-b39284379271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_088abda2-a87e-4f28-8051-4ebdc16f100b" xlink:href="cpix-20190630.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_836f9c30-34cf-492d-b822-2d59c13d3685" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_088abda2-a87e-4f28-8051-4ebdc16f100b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_246c58e3-9ec4-46f0-b5cb-5779eb5aa7fb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_836f9c30-34cf-492d-b822-2d59c13d3685" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_246c58e3-9ec4-46f0-b5cb-5779eb5aa7fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>cpix-20190630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cpix="http://www.cumberlandpharma.com/20190630"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2018-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cpix-20190630.xsd" xlink:type="simple"/>
    <context id="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ie9d09c8c58d4466aa24ccf16fbf3dfe5_I20190809">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2019-08-09</instant>
        </period>
    </context>
    <context id="if478ab72402a4dbca17cebf84905f137_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i0d8f4802d39d424297c0f861bec1a0b2_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i6eecb6cf82d946f791b1e9b3d617a3ba_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="id5d60a75c7914cbf8204350654c33543_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="i0e1c5e9c7cbe4efc93a736d76e33fe31_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="icf52e3a90b564e61a9df4d3dd81a200b_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i9ec531ec35eb439399c9436b7345e202_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i8d3bd3dbf1ee431ca1035d16d2daf32b_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i4acfcd09578f42f994a9b89541ecf28c_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i12bdf0ab8f4c49578c9eb30f38190373_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i389b9f06784a4fa895bf9d85d0373d0a_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="ieeeb240a56f744c5976744da0dbe5ad7_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="ie2aef2419d2a434d882a0412b764c40a_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="i525c05bfba8a496bb3f3ad3dd759b4b6_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="ia885021b86044725a1fb10e4cc611b1f_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="if02d00db9a714fb7b9ff2e6a67ac03d2_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="iad96f105789947c999f7d544dd4620db_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i77e056bccd4543089353688903d60102_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="ifa6a17eccce2451499b89a8ee27e36af_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="i7ebb41ca72a9412d830adbbcce277c27_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="iefb8318507a84b1eab45ae17e36b7a7e_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="i86ad84a3cb90495fa0d9574cd4dfc3e8_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6695ed74ccf34594a009b751a9867ab5_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ib0658642e8184a7e8bcf52ddf1229693_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="idaa440b71edc463180ffe7cc20dc52c5_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i4b03a84c29d54b778087726fae7de356_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i73c240c1815a42e2ab3c71622ab5a7f7_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i9a0b25c5749f4e71aca5511d2c6057b6_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="iac307e50d1064fb993f7c13e652bf744_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="id01be75c70fd4c0390e4cb8f8a56f1f8_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i58d3402c22484d6bb6b255a3e69c04eb_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i4d6b70bf87e540e287238c2db49676b4_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i69067cc85b7d439ab6017dfcbfd70f2a_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="if5b7d8e3ae1349cea30af6ae38abd9fa_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i274cc8eea0aa47a382670b52aaf0929c_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ide4bf4cd636d4c2db7c36e6913c5b859_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ic39d78c819df43acb7f94d5a5d3f0944_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i8f374a018db6442e9076cb34a527615d_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ic019dd81917f4783874bd24e8143629b_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cpix:UsTreasuryNotesAndBondsSecuritiesMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i5397d60c4bf94ba38de2eefaf434ab55_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cpix:UsTreasuryNotesAndBondsSecuritiesMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="idd24a3ddd9ed4cff93e5196a8a035c10_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cpix:UsTreasuryNotesAndBondsSecuritiesMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ic7816c3023a04362a69740727a0dd6e9_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cpix:UsTreasuryNotesAndBondsSecuritiesMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i028152dc8c66421282a458a7c0e3da06_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cpix:UsTreasuryNotesAndBondsSecuritiesMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i8259efcffe104ccab3daeae3ae558f18_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cpix:UsTreasuryNotesAndBondsSecuritiesMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id6339bfa7be7414c90203e8b3decb32f_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i74755af90b0c4281990f79ae0cb80fab_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i766a4625499e44acb284ded61ea081ad_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i47855873ec2141deb6a6cffeea9a5bb5_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ic748d7f98c564aa2ba93b74292ce51c0_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie1ab8d666f804ee78d5b108e427da078_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i83a70ec3a6574e21aa0d9467d12afc51_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i43b135623a96479ea579b1956e4c6a0b_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i1494544e74bc4c1a9fcca142b7cf104f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i77a66b694d774bcf85ff772a27ee7736_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i07ba47fdb1fd4a0aa68832470d83b72c_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie26e2ca1b03b4f848952f34a6f12fe2d_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i666181952a8f4f1f9d14d2034e887833_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i8bd2419e0e6145b5b2690fdf708d4661_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i3d842da52c554dfe889a17eb09da349c_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ibf1ce67d14544c34852c969eba3ab613_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6dd35f38e91e4cad82cac63ffaf3bc06_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i44c95989d56940448855dceadabf3ab2_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i2ac200ae04284253b7355e519011ebb7_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="if9fe1490366c4bb1a705a3377e185ae5_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="icf31cf850409470eb07e4575e50d16c6_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i509cfd55792547fd9065aab962dd801a_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="id4235e45b96d4113803c1249687d3d50_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i77326b611af749e2afb25a76a3b386d1_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i4751466a08f94bcb8c0ebfec0b01ecfd_D20180101-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i491e5531cbfa47b496005caa8455badb_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i2c520713e19c495f82ed1f2dd92ef634_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i8396c0f613f441f58ba22039a93eb1c8_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ia32476d410f440b48f0c3b631a90632f_D20180101-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i781c10013fee46d6b029f560be240be7_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="idd51eac788ff4878870c597b6d74c24e_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i14a5b5dcc523443dab0df6907169ca3b_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="idcb718271f734482856f23f2d01609d5_D20180101-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i73375a6aee6f45c8b2af7cc1cfecddb0_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i7ad6dbad74074d38ac2d08ebcc3d3518_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i53374edc460d4ca6aba30ff2b618e21f_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i838404f0559b43babedeea791e195f2f_D20180101-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i30dca836f3804983b44dbc23d365d55e_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i70367091d6b44d47b966554d9af79237_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i588715008b8b450f8b15c09e4bcd9681_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="icc7ca2c1d2ac45b99b06dd4e5cff07df_D20180101-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i2ae15c900cfd4ad6a4de1687287609b2_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:EthyolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ic29f620b439f49eeaefd0f5c28509e1c_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:EthyolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="ie85bd361954b4f98bced4efeca36ce9f_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:EthyolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i231a37bb2fbf47f5b7eceed5c5e05224_D20180101-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:EthyolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i868db2e678dd4291af1d258118e04a77_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:TotectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ibccd184195764941825e341a41aa4fa5_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:TotectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i2f03cf3962ed4acf8caf27c28f2427d9_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:TotectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ibb51e348437d4dec85fd92befc0b9624_D20180101-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:TotectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="ic06c5fb3bfd44b16ab85550780690d5f_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="id7367fd73f204d1e8f84cd61df343493_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="ia9ea66098fd04256848a2d79539e4156_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i77b145b291264578bbd035e0bf21476c_D20180101-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="if954c9a78bb24172936c43e0061fedae_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="if66b9371f94f461f93cfcc16bb63966b_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i7677c5f4087746ed8da807d078e316b6_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i8da9ab9ca7a9436c81b40d1a21447d49_D20180101-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i40852bb795f343e3a355c9a4dac17887_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i3b6f56b360f242dba5580399c147efc2_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueRightsGrantedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i994113efc2f24ab7bbf0e24b5c88051c_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueRightsGrantedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i674a647fde3f44be85e9cae6e936a816_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i5332b0b2238e4d09b5c7a0b66e8b457a_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i24c5c7f1311c41b0adf7f2ad2954b3dc_I20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="i3c6be34147e74633b283a3faf26291a6_I20100513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2010-05-13</instant>
        </period>
    </context>
    <context id="ie34c3c9c4b6c4086a134e19d8fa48fdd_I20160131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2016-01-31</instant>
        </period>
    </context>
    <context id="idbb1a7efb54a4443b860e667b9d9f4ff_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i1fee3684442c4d5f9e424da6bdc3b780_D20180101-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="ide11bc6060924df19448d4e6a244010d_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i959855896ce142fbac309e421bbe56a9_D20171101-20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="i89a377e795d5407db1aaac39ada6ab01_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ia72329a5bc7744a280d614667782cdc8_D20180101-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i3a0c4a5e2fe642ca846722954640695b_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i94c12e61b0d14ff5a5b7a3c975510ecc_I20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:HongKongWinHealthPharmaGroupCoLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="ib97eaa219e974f16a39fa98e445d047a_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="i11a9395935dd46a587ef0b6c9587b057_I20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="id03a7800662a48cd8cf59f4d3cdb9811_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:GloriaPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="idf561525052b4733845421e5e0fffabf_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i265ae74e8bfa4726841ed00db8f8e437_I20181017">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:SecondAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-17</instant>
        </period>
    </context>
    <context id="ie283482fcb0a418f903f4565757a59f1_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i389446a0e5ad467cb0b7d185b5851168_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i4c66d110828e4d3290867f75611b26b4_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i5709e5c0528d4106ba0350257862d329_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="icca6e0f80b33475a8371b8499f5d8919_D20181101-20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="i1b571fa0594646398781261aceb478b2_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="i9d064a4268974d2eaa1aee9282ceb970_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ic8e3a8763ebf4e4299a795047276e3dd_I20181112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-12</instant>
        </period>
    </context>
    <context id="i62c36aedf5f84b7d8160f6870615925e_D20181113-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-13</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i385e5bd994794f80a9f4101d706edbbb_D20181112-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-12</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ibfc029c334714ab1b6a1fa6f662c915e_I20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-30</instant>
        </period>
    </context>
    <context id="i55ab197a5f614ea393244079e62f621c_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i89124f6164c440dea6f61c2e5b7f5ef8_D20191001-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>cpix:Segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:DocumentFiscalYearFocus
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180L2ZyYWc6NjQ3OWYzNGVkM2M5NDQ5NzkxNmI2NzY2OWY1YTViMDMvdGFibGU6MDJhYWUyODQ5YWEwNGM4ZTgyNDNmYzc0NzI3YTQzZmEvdGFibGVyYW5nZTowMmFhZTI4NDlhYTA0YzhlODI0M2ZjNzQ3MjdhNDNmYV83LTEtMS0xLTA_c47fa85f-932b-4cda-ac0a-0c43a6930ca9">2019</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180L2ZyYWc6NjQ3OWYzNGVkM2M5NDQ5NzkxNmI2NzY2OWY1YTViMDMvdGFibGU6MDJhYWUyODQ5YWEwNGM4ZTgyNDNmYzc0NzI3YTQzZmEvdGFibGVyYW5nZTowMmFhZTI4NDlhYTA0YzhlODI0M2ZjNzQ3MjdhNDNmYV84LTEtMS0xLTA_8c0bac0f-0677-41ed-81c6-72a216716055">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180L2ZyYWc6NjQ3OWYzNGVkM2M5NDQ5NzkxNmI2NzY2OWY1YTViMDMvdGFibGU6MDJhYWUyODQ5YWEwNGM4ZTgyNDNmYzc0NzI3YTQzZmEvdGFibGVyYW5nZTowMmFhZTI4NDlhYTA0YzhlODI0M2ZjNzQ3MjdhNDNmYV85LTEtMS0xLTA_41b3d616-32dd-4477-93ae-81685cef6136">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180L2ZyYWc6NjQ3OWYzNGVkM2M5NDQ5NzkxNmI2NzY2OWY1YTViMDMvdGV4dHJlZ2lvbjo2NDc5ZjM0ZWQzYzk0NDk3OTE2YjY3NjY5ZjVhNWIwM183OQ_a528c88a-7ec2-462e-8cbb-50577953b2d0">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180L2ZyYWc6NjQ3OWYzNGVkM2M5NDQ5NzkxNmI2NzY2OWY1YTViMDMvdGV4dHJlZ2lvbjo2NDc5ZjM0ZWQzYzk0NDk3OTE2YjY3NjY5ZjVhNWIwM184MA_14dbb1b9-a72a-4bc9-af79-436d92ea867a">0001087294</dei:EntityCentralIndexKey>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i3a0c4a5e2fe642ca846722954640695b_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181OC9mcmFnOmViNzI5MWIzYzY3NTRhM2ZiYmE0OWRkY2JmNzA3OGY0L3RleHRyZWdpb246ZWI3MjkxYjNjNjc1NGEzZmJiYTQ5ZGRjYmY3MDc4ZjRfMTg2MQ_7b6a6f88-b9bb-43f7-bebc-cb00283f1265">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xL2ZyYWc6ODg5OTZmNjBiZGFmNDAyYWFlNjcyYzM4MmY4NDkwNjcvdGV4dHJlZ2lvbjo4ODk5NmY2MGJkYWY0MDJhYWU2NzJjMzgyZjg0OTA2N18xOTQ1_5bef0efc-8a0c-4186-aad9-af06b51de814">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xL2ZyYWc6ODg5OTZmNjBiZGFmNDAyYWFlNjcyYzM4MmY4NDkwNjcvdGFibGU6ODhkNjBiZjA0ODRkNDYxMGIxOTVlN2MwNjJmYTQ4MzYvdGFibGVyYW5nZTo4OGQ2MGJmMDQ4NGQ0NjEwYjE5NWU3YzA2MmZhNDgzNl8wLTAtMS0xLTQwNTg_544fd539-b6dd-47fd-ab86-ac88d8489a5c">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xL2ZyYWc6ODg5OTZmNjBiZGFmNDAyYWFlNjcyYzM4MmY4NDkwNjcvdGV4dHJlZ2lvbjo4ODk5NmY2MGJkYWY0MDJhYWU2NzJjMzgyZjg0OTA2N185ODk1NjA0NjUyMDg2_2eecc618-50cc-428e-9622-94e35156892c">2019-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xL2ZyYWc6ODg5OTZmNjBiZGFmNDAyYWFlNjcyYzM4MmY4NDkwNjcvdGFibGU6YWQxZDVmYzI4NTBhNGUwYWJlNWZmZDRkNjZkYWYxYWUvdGFibGVyYW5nZTphZDFkNWZjMjg1MGE0ZTBhYmU1ZmZkNGQ2NmRhZjFhZV8wLTAtMS0xLTQwNjA_82f478b3-783c-4195-867f-351b89051dde">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xL2ZyYWc6ODg5OTZmNjBiZGFmNDAyYWFlNjcyYzM4MmY4NDkwNjcvdGV4dHJlZ2lvbjo4ODk5NmY2MGJkYWY0MDJhYWU2NzJjMzgyZjg0OTA2N182MDQ3MzEzOTU0Nzk2_10aea164-1a8c-4c60-89d7-6ecd72e0df5c">001-33637</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xL2ZyYWc6ODg5OTZmNjBiZGFmNDAyYWFlNjcyYzM4MmY4NDkwNjcvdGV4dHJlZ2lvbjo4ODk5NmY2MGJkYWY0MDJhYWU2NzJjMzgyZjg0OTA2N18xOTQ2_cb198088-9e54-498d-a4e2-487ba7de3e67">Cumberland Pharmaceuticals Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xL2ZyYWc6ODg5OTZmNjBiZGFmNDAyYWFlNjcyYzM4MmY4NDkwNjcvdGFibGU6OGUxOGU3OWJmZTQ1NGIzZjg5MjExYWFlNWNkZDYwOTAvdGFibGVyYW5nZTo4ZTE4ZTc5YmZlNDU0YjNmODkyMTFhYWU1Y2RkNjA5MF8wLTAtMS0xLTQwNDk_5d26c198-4d00-4375-8fd2-351ba0038f9b">TN</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xL2ZyYWc6ODg5OTZmNjBiZGFmNDAyYWFlNjcyYzM4MmY4NDkwNjcvdGFibGU6OGUxOGU3OWJmZTQ1NGIzZjg5MjExYWFlNWNkZDYwOTAvdGFibGVyYW5nZTo4ZTE4ZTc5YmZlNDU0YjNmODkyMTFhYWU1Y2RkNjA5MF8wLTItMS0xLTQwNTE_7bf2ef00-1bdc-4ca9-a841-5ebf2360e1eb">62-1765329</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xL2ZyYWc6ODg5OTZmNjBiZGFmNDAyYWFlNjcyYzM4MmY4NDkwNjcvdGFibGU6OGUxOGU3OWJmZTQ1NGIzZjg5MjExYWFlNWNkZDYwOTAvdGFibGVyYW5nZTo4ZTE4ZTc5YmZlNDU0YjNmODkyMTFhYWU1Y2RkNjA5MF8zLTAtMS0xLTQxMjUvdGV4dHJlZ2lvbjo2ZDhjMTIwYTNiZDc0N2FjODVmOTQxYjA4M2E5ZTAwNF84Nzk2MDkzMDIyMjg2_c6c2a4a1-70f2-4697-89fc-bbbccdd8aab8">2525 West End Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xL2ZyYWc6ODg5OTZmNjBiZGFmNDAyYWFlNjcyYzM4MmY4NDkwNjcvdGFibGU6OGUxOGU3OWJmZTQ1NGIzZjg5MjExYWFlNWNkZDYwOTAvdGFibGVyYW5nZTo4ZTE4ZTc5YmZlNDU0YjNmODkyMTFhYWU1Y2RkNjA5MF8zLTAtMS0xLTQxMjUvdGV4dHJlZ2lvbjo2ZDhjMTIwYTNiZDc0N2FjODVmOTQxYjA4M2E5ZTAwNF84Nzk2MDkzMDIyMzY5_80fe2264-35dd-4b19-ba75-26d6583a03b7">Suite 950</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xL2ZyYWc6ODg5OTZmNjBiZGFmNDAyYWFlNjcyYzM4MmY4NDkwNjcvdGFibGU6OGUxOGU3OWJmZTQ1NGIzZjg5MjExYWFlNWNkZDYwOTAvdGFibGVyYW5nZTo4ZTE4ZTc5YmZlNDU0YjNmODkyMTFhYWU1Y2RkNjA5MF8zLTAtMS0xLTQxMjUvdGV4dHJlZ2lvbjo2ZDhjMTIwYTNiZDc0N2FjODVmOTQxYjA4M2E5ZTAwNF84Nzk2MDkzMDIyMzgw_ab6dca6e-6df1-4266-a0ae-ed264134ae10">Nashville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xL2ZyYWc6ODg5OTZmNjBiZGFmNDAyYWFlNjcyYzM4MmY4NDkwNjcvdGFibGU6OGUxOGU3OWJmZTQ1NGIzZjg5MjExYWFlNWNkZDYwOTAvdGFibGVyYW5nZTo4ZTE4ZTc5YmZlNDU0YjNmODkyMTFhYWU1Y2RkNjA5MF8zLTAtMS0xLTQxMjUvdGV4dHJlZ2lvbjo2ZDhjMTIwYTNiZDc0N2FjODVmOTQxYjA4M2E5ZTAwNF84Nzk2MDkzMDIyMzkx_bf0bf2c6-2a8d-493f-afef-e8bc873c76c1">TN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xL2ZyYWc6ODg5OTZmNjBiZGFmNDAyYWFlNjcyYzM4MmY4NDkwNjcvdGFibGU6OGUxOGU3OWJmZTQ1NGIzZjg5MjExYWFlNWNkZDYwOTAvdGFibGVyYW5nZTo4ZTE4ZTc5YmZlNDU0YjNmODkyMTFhYWU1Y2RkNjA5MF8zLTItMS0xLTQwNTM_a542a111-2245-481a-b713-5374d2b328eb">37203</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xL2ZyYWc6ODg5OTZmNjBiZGFmNDAyYWFlNjcyYzM4MmY4NDkwNjcvdGV4dHJlZ2lvbjo4ODk5NmY2MGJkYWY0MDJhYWU2NzJjMzgyZjg0OTA2N182MDQ3MzEzOTU0Nzk0_89891fbe-96df-40e7-b9b9-e67cb33185ef">615</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xL2ZyYWc6ODg5OTZmNjBiZGFmNDAyYWFlNjcyYzM4MmY4NDkwNjcvdGV4dHJlZ2lvbjo4ODk5NmY2MGJkYWY0MDJhYWU2NzJjMzgyZjg0OTA2N182MDQ3MzEzOTU0Nzk1_be0b2698-cee8-4a6b-9923-c48602df1cc9">255-0068</dei:LocalPhoneNumber>
    <dei:EntityCurrentReportingStatus
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xL2ZyYWc6ODg5OTZmNjBiZGFmNDAyYWFlNjcyYzM4MmY4NDkwNjcvdGV4dHJlZ2lvbjo4ODk5NmY2MGJkYWY0MDJhYWU2NzJjMzgyZjg0OTA2N182MDQ3MzEzOTU0Nzky_3e6fea56-d65d-46a2-a3e5-56cb6daf3f19">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xL2ZyYWc6ODg5OTZmNjBiZGFmNDAyYWFlNjcyYzM4MmY4NDkwNjcvdGV4dHJlZ2lvbjo4ODk5NmY2MGJkYWY0MDJhYWU2NzJjMzgyZjg0OTA2N182MDQ3MzEzOTU0Nzkz_5de71190-c0a7-44d9-a53f-c8085c363ceb">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xL2ZyYWc6ODg5OTZmNjBiZGFmNDAyYWFlNjcyYzM4MmY4NDkwNjcvdGFibGU6ZjNkYTc2NzJjYzg0NGFmY2FjZmU4MWZjZDQ1NTdkMGQvdGFibGVyYW5nZTpmM2RhNzY3MmNjODQ0YWZjYWNmZTgxZmNkNDU1N2QwZF8xLTAtMS0xLTM5MjI_724a6440-8191-457b-85b0-472c04b8850a">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xL2ZyYWc6ODg5OTZmNjBiZGFmNDAyYWFlNjcyYzM4MmY4NDkwNjcvdGFibGU6ZjNkYTc2NzJjYzg0NGFmY2FjZmU4MWZjZDQ1NTdkMGQvdGFibGVyYW5nZTpmM2RhNzY3MmNjODQ0YWZjYWNmZTgxZmNkNDU1N2QwZF8xLTYtMS0xLTQwMjU_fdd45b0c-d7c9-4722-b739-94d5036bb454">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xL2ZyYWc6ODg5OTZmNjBiZGFmNDAyYWFlNjcyYzM4MmY4NDkwNjcvdGFibGU6ZjNkYTc2NzJjYzg0NGFmY2FjZmU4MWZjZDQ1NTdkMGQvdGFibGVyYW5nZTpmM2RhNzY3MmNjODQ0YWZjYWNmZTgxZmNkNDU1N2QwZF8yLTItMS0xLTQwNzM_862fb73e-531e-4905-aa18-042979db26eb">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xL2ZyYWc6ODg5OTZmNjBiZGFmNDAyYWFlNjcyYzM4MmY4NDkwNjcvdGV4dHJlZ2lvbjo4ODk5NmY2MGJkYWY0MDJhYWU2NzJjMzgyZjg0OTA2N182MDQ3MzEzOTU0Nzkx_cb864746-103a-4960-8ecb-64e64aaf5706">false</dei:EntityShellCompany>
    <dei:Security12bTitle
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xL2ZyYWc6ODg5OTZmNjBiZGFmNDAyYWFlNjcyYzM4MmY4NDkwNjcvdGFibGU6OGQ0ZDc0ZmI5MzZiNDg2Y2JkOTY0Yjk0MDcwMWM1YWIvdGFibGVyYW5nZTo4ZDRkNzRmYjkzNmI0ODZjYmQ5NjRiOTQwNzAxYzVhYl8xLTAtMS0xLTQwMzA_68faa833-afe8-4034-b7d8-883353a838ca">Common stock, no par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xL2ZyYWc6ODg5OTZmNjBiZGFmNDAyYWFlNjcyYzM4MmY4NDkwNjcvdGFibGU6OGQ0ZDc0ZmI5MzZiNDg2Y2JkOTY0Yjk0MDcwMWM1YWIvdGFibGVyYW5nZTo4ZDRkNzRmYjkzNmI0ODZjYmQ5NjRiOTQwNzAxYzVhYl8xLTItMS0xLTQwMzI_3711180e-0e74-41e4-bf37-4396d74446d1">CPIX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xL2ZyYWc6ODg5OTZmNjBiZGFmNDAyYWFlNjcyYzM4MmY4NDkwNjcvdGFibGU6OGQ0ZDc0ZmI5MzZiNDg2Y2JkOTY0Yjk0MDcwMWM1YWIvdGFibGVyYW5nZTo4ZDRkNzRmYjkzNmI0ODZjYmQ5NjRiOTQwNzAxYzVhYl8xLTQtMS0xLTQwMzQ_51e5451e-84af-4769-873f-35a85a5c361c">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ie9d09c8c58d4466aa24ccf16fbf3dfe5_I20190809"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xL2ZyYWc6ODg5OTZmNjBiZGFmNDAyYWFlNjcyYzM4MmY4NDkwNjcvdGFibGU6OGQ0ZDc0ZmI5MzZiNDg2Y2JkOTY0Yjk0MDcwMWM1YWIvdGFibGVyYW5nZTo4ZDRkNzRmYjkzNmI0ODZjYmQ5NjRiOTQwNzAxYzVhYl8xLTYtMS0xLTA_c38cd8a9-d0b7-42da-8772-d6b11f85897f"
      unitRef="shares">15373815</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMy0xLTEtMS0w_64ff01de-e5f8-4fa5-9571-16b3a82c0e0d"
      unitRef="usd">20951180</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMy0zLTEtMS0w_3f380190-3e9d-488d-8370-28ae35f07b93"
      unitRef="usd">27938960</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecurities
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfNC0xLTEtMS0w_f1cf7ab0-7168-4a2d-8bfc-23568647b904"
      unitRef="usd">9479686</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfNC0zLTEtMS0w_24f67d87-015d-43ca-a74f-0dcc8b2ae582"
      unitRef="usd">8290679</us-gaap:MarketableSecurities>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfNS0xLTEtMS0w_22b6386a-895b-4e09-a598-9400607c6200"
      unitRef="usd">8427278</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfNS0zLTEtMS0w_e119ce68-0c82-402b-8610-ed8cb342a875"
      unitRef="usd">7844249</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfNi0xLTEtMS0w_e8539f3c-5df8-46aa-a5e9-48d8e7be1cc1"
      unitRef="usd">10648859</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfNi0zLTEtMS0w_4e2061d1-326e-4d99-95d8-0e8fbf9121d3"
      unitRef="usd">12078343</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfNy0xLTEtMS0w_aa74f281-962e-4aae-ada0-38b167f08989"
      unitRef="usd">2425354</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfNy0zLTEtMS0w_2a2a3dbf-9285-4e43-a2bd-7ab942a8e445"
      unitRef="usd">2963806</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfOC0xLTEtMS0w_cbb14478-868f-47f5-ac53-01b396d3c99b"
      unitRef="usd">51932357</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfOC0zLTEtMS0w_f428eb97-89c2-4142-82e2-080162a4de1a"
      unitRef="usd">59116037</us-gaap:AssetsCurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfOS0xLTEtMS0w_029256be-cb24-43ab-b7bb-bbe737095e3e"
      unitRef="usd">15840962</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfOS0zLTEtMS0w_e36b531d-7a14-49a3-8007-ac7979b1fcf0"
      unitRef="usd">15749000</us-gaap:InventoryNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMTAtMS0xLTEtMA_d9d1c431-cfc8-45f3-8060-46c378db4263"
      unitRef="usd">737238</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMTAtMy0xLTEtMA_d2b16b0b-c69b-453c-a7e9-356b64e67773"
      unitRef="usd">771213</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMTEtMS0xLTEtMA_543744be-0803-4635-8440-11ab7d1cd7c3"
      unitRef="usd">32044234</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMTEtMy0xLTEtMA_7b05308c-2b29-4ae3-b514-e268caa3c286"
      unitRef="usd">33655099</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Goodwill
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMTItMS0xLTEtMA_89a23f38-0883-460a-a19c-7ac8d60fbfbe"
      unitRef="usd">882000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMTItMy0xLTEtMA_e33c4781-3d3a-4997-8831-1dd794ba337c"
      unitRef="usd">784000</us-gaap:Goodwill>
    <us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMTMtMS0xLTEtMA_3acb910d-90c7-4199-8390-9f0171849cca"
      unitRef="usd">43605</us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent>
    <us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent
      contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMTMtMy0xLTEtMA_430e8f10-6dfc-4ea3-b1ff-afbf53e6c5a4"
      unitRef="usd">87210</us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMTQtMS0xLTEtMA_5397b848-5bcb-4fa2-ba41-a015ff5b26c4"
      unitRef="usd">6065828</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMTQtMy0xLTEtMA_9177ba58-1468-4dc3-8e95-c0caa6100e40"
      unitRef="usd">2531309</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMTUtMS0xLTEtMA_fc96f856-abf3-4fc2-b339-2783a1a25005"
      unitRef="usd">107546224</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMTUtMy0xLTEtMA_148f6695-4ef5-4a65-8541-d80ca1dbed21"
      unitRef="usd">112693868</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMTgtMS0xLTEtMA_578d2940-c285-4dc4-b912-db0afbda6208"
      unitRef="usd">9539981</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMTgtMy0xLTEtMA_65568ab8-27b6-4cbe-91b8-bfd2be169c41"
      unitRef="usd">11093297</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMTktMS0xLTEtMA_0daf15a6-13b0-4a36-ac39-225cec7791fa"
      unitRef="usd">12777148</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMTktMy0xLTEtMA_15d030c5-7e5a-4a7c-ab66-33128ad0bd3b"
      unitRef="usd">16710927</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMjAtMS0xLTEtMA_4401a172-5c53-4dfe-a2e5-7c21522858e4"
      unitRef="usd">22317129</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMjAtMy0xLTEtMA_9d089725-b547-481c-b39c-06ac991d6ae2"
      unitRef="usd">27804224</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermLineOfCredit
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMjEtMS0xLTEtMA_e654cda4-04f1-4a43-8fe9-5fd8c7d40fd3"
      unitRef="usd">20000000</us-gaap:LongTermLineOfCredit>
    <us-gaap:LongTermLineOfCredit
      contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMjEtMy0xLTEtMA_7a900cf8-bb98-4c3b-971b-eafc19b081c8"
      unitRef="usd">20000000</us-gaap:LongTermLineOfCredit>
    <cpix:OtherLongTermObligationsExcludingCurrentPortion
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMjItMS0xLTEtMA_9bb9ce35-a710-401f-af42-928bcf0d6938"
      unitRef="usd">11540378</cpix:OtherLongTermObligationsExcludingCurrentPortion>
    <cpix:OtherLongTermObligationsExcludingCurrentPortion
      contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMjItMy0xLTEtMA_b8a50c7b-0a09-4375-94c1-6fccb5c9d864"
      unitRef="usd">9319143</cpix:OtherLongTermObligationsExcludingCurrentPortion>
    <us-gaap:Liabilities
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMjMtMS0xLTEtMA_ebcad7a0-7347-4ae7-b0b9-0c47ce4757c9"
      unitRef="usd">53857507</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMjMtMy0xLTEtMA_54ebadc5-8eaa-44b0-848c-0e947ca3d74d"
      unitRef="usd">57123367</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMjQtMS0xLTEtMA_7560ea79-9214-41fb-82d5-ae1fa8f4206a"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMjQtMy0xLTEtMA_6712adc9-dcfd-4c14-bfd1-9a63e563ad3d"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockNoParValue
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjViNDcyODZjODM0YjQzZmRiZGEzYTBkNGZkMDk4OWE0XzU0OTc1NTgxNDA2Mw_64672c3a-9461-4333-8f52-857fa2304eab"
      unitRef="usdPerShare">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockNoParValue
      contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjViNDcyODZjODM0YjQzZmRiZGEzYTBkNGZkMDk4OWE0XzU0OTc1NTgxNDA2Mw_8e90b6a6-09ca-42e1-aae8-36fb98997510"
      unitRef="usdPerShare">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjViNDcyODZjODM0YjQzZmRiZGEzYTBkNGZkMDk4OWE0XzU0OTc1NTgxNDA3Ng_13e34e6b-d976-45bc-9aaf-5878f33fa292"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjViNDcyODZjODM0YjQzZmRiZGEzYTBkNGZkMDk4OWE0XzU0OTc1NTgxNDA3Ng_270d4349-e74a-4909-8787-d041031d29f5"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjViNDcyODZjODM0YjQzZmRiZGEzYTBkNGZkMDk4OWE0XzU0OTc1NTgxNDA4OA_1315214b-cca7-45b5-bf5d-7fe1b94c1b5e"
      unitRef="shares">15471070</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjViNDcyODZjODM0YjQzZmRiZGEzYTBkNGZkMDk4OWE0XzU0OTc1NTgxNDA4OA_e963529f-b523-4320-8bdc-01b97dac63c2"
      unitRef="shares">15471070</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjViNDcyODZjODM0YjQzZmRiZGEzYTBkNGZkMDk4OWE0XzU0OTc1NTgxNDEwMA_02eb04d2-8252-4c90-8bde-a119168e77be"
      unitRef="shares">15481497</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjViNDcyODZjODM0YjQzZmRiZGEzYTBkNGZkMDk4OWE0XzU0OTc1NTgxNDEwMA_0d138625-da82-45ab-a263-910ce179efea"
      unitRef="shares">15481497</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMjctMS0xLTEtMA_c385ceed-0a8a-45b2-acf8-80bcea08d208"
      unitRef="usd">49938254</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMjctMy0xLTEtMA_84129ef0-f4d2-4815-8364-8ca781d22e58"
      unitRef="usd">51098613</us-gaap:CommonStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMjgtMS0xLTEtMA_145c63b7-8354-412c-a071-120a5cbd8834"
      unitRef="usd">4122769</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMjgtMy0xLTEtMA_f8a35567-2ff4-4ece-9bc9-5dcf1023c5aa"
      unitRef="usd">4746154</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMjktMS0xLTEtMA_ad08b794-9edc-4dfa-b174-fc165937cdf6"
      unitRef="usd">54061023</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMjktMy0xLTEtMA_a7b589b2-224d-4819-b6a4-ceb2e915ce72"
      unitRef="usd">55844767</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMzAtMS0xLTEtMA_111601e3-e765-4b65-b6c2-a815a7d7008d"
      unitRef="usd">-372306</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMzAtMy0xLTEtMA_f13c04ee-2ab6-46db-8366-ce55d2765223"
      unitRef="usd">-274266</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMzEtMS0xLTEtMA_1480bb0c-8fde-496a-b382-8225b41312b4"
      unitRef="usd">53688717</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMzEtMy0xLTEtMA_1d25acf8-7e37-4f56-a405-86eb1842a59a"
      unitRef="usd">55570501</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMzItMS0xLTEtMA_ae3c9cce-45de-43f7-b262-0cf99e713e49"
      unitRef="usd">107546224</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18xNi9mcmFnOmY2ZGM3YjM3Njg0MDRkNzI5YTUzM2FhNzdhM2ZiNGUxL3RhYmxlOjc2ZmFkZDE3MzMyMjQxODVhNTE1NGQxNDE1YzIyMTY5L3RhYmxlcmFuZ2U6NzZmYWRkMTczMzIyNDE4NWE1MTU0ZDE0MTVjMjIxNjlfMzItMy0xLTEtMA_510444a1-33c6-4548-94c1-744897b9954c"
      unitRef="usd">112693868</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMi0xLTEtMS0w_417c1621-036c-4f87-a446-68aa8cbf763e"
      unitRef="usd">11580600</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMi0zLTEtMS0w_9933222d-11ae-4edb-96ef-8fd6ab98d68a"
      unitRef="usd">10163724</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMi01LTEtMS0w_a5715e70-dcb2-4add-9a76-fc4d36389f09"
      unitRef="usd">23483347</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMi03LTEtMS0w_a5c78df2-7196-4d42-b9a1-2c9c67a1b707"
      unitRef="usd">18751329</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfNC0xLTEtMS0w_ea6d77cf-9316-45a6-8501-e858b4314579"
      unitRef="usd">2012196</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfNC0zLTEtMS0w_b03ae125-2dab-40ef-9761-0e6934794e87"
      unitRef="usd">1523319</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfNC01LTEtMS0w_5be4cac1-7301-4c8f-b2a1-fd0c7b74a85c"
      unitRef="usd">4011932</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfNC03LTEtMS0w_0370455d-e316-42b7-9e86-fb08c174a230"
      unitRef="usd">3051280</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfNS0xLTEtMS0w_db68069f-da67-4cf7-ae1d-b0715c8f05a0"
      unitRef="usd">5153129</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfNS0zLTEtMS0w_626e9b29-77c2-464a-b177-f6e53b415bee"
      unitRef="usd">5076250</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfNS01LTEtMS0w_57e30738-929a-4157-a85d-5e4c0f3d9427"
      unitRef="usd">10273634</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfNS03LTEtMS0w_53c624aa-24f1-4ec7-8fc7-e968e2b13bb4"
      unitRef="usd">9746761</us-gaap:SellingAndMarketingExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfNi0xLTEtMS0w_1a54158d-d322-4a3c-a666-fd21ea69498a"
      unitRef="usd">1458366</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfNi0zLTEtMS0w_8cbdf6a6-0c5c-429d-9238-8e93c4b9dc46"
      unitRef="usd">1450390</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfNi01LTEtMS0w_fc491f8c-0880-435d-9b3c-32f15184c6a9"
      unitRef="usd">2725967</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfNi03LTEtMS0w_7aecc0b7-154b-40c4-bc41-e1aa942ec321"
      unitRef="usd">3325329</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfNy0xLTEtMS0w_16d63399-0750-4784-b2bc-66dd89c3e685"
      unitRef="usd">2528916</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfNy0zLTEtMS0w_a3b25942-4a6a-41d3-8db6-88cae504f2c3"
      unitRef="usd">2334223</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfNy01LTEtMS0w_03fb1b71-1193-433d-9d8b-f3b473e2f664"
      unitRef="usd">5198972</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfNy03LTEtMS0w_dbb55a08-dd57-4120-a239-57edc65198c0"
      unitRef="usd">4664504</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfOC0xLTEtMS0w_aea76217-78e2-46ac-8df0-21a7386a7b15"
      unitRef="usd">1029708</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfOC0zLTEtMS0w_917fa066-f763-416a-8f76-9aa3e9a7a6c7"
      unitRef="usd">648520</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfOC01LTEtMS0w_baef68e8-fa8b-4f65-9f4e-d48d44945bc8"
      unitRef="usd">2051353</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfOC03LTEtMS0w_fdf3a310-e89e-4995-b7fd-b301d7c34e1a"
      unitRef="usd">1284655</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:CostsAndExpenses
      contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfOS0xLTEtMS0w_656fdada-0e77-4b21-a7b9-c1e0655fb50d"
      unitRef="usd">12182315</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfOS0zLTEtMS0w_2f23ba6f-ab5e-4ea6-bade-c0f7530a36f7"
      unitRef="usd">11032702</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfOS01LTEtMS0w_9bc3d1bf-a329-423e-9d3b-49dc00130619"
      unitRef="usd">24261858</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfOS03LTEtMS0w_a5a1f5c2-610b-4289-9feb-d18573551d79"
      unitRef="usd">22072529</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTAtMS0xLTEtMA_3e4ffe88-0aeb-4e58-8a4e-0b29693afd0f"
      unitRef="usd">-601715</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTAtMy0xLTEtMA_3b56503d-8cdf-4cf9-870b-0eaf8f98f738"
      unitRef="usd">-868978</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTAtNS0xLTEtMA_b0b88711-cc78-49c7-9f9e-60aa773f6e60"
      unitRef="usd">-778511</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTAtNy0xLTEtMA_f6cf5b0f-c899-4e7a-87a0-fa655c87b2be"
      unitRef="usd">-3321200</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTEtMS0xLTEtMA_290fb0b2-e67b-4def-a06d-dda76726a755"
      unitRef="usd">130565</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTEtMy0xLTEtMA_dc81906a-1404-4613-8e69-b02490530b5f"
      unitRef="usd">149706</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTEtNS0xLTEtMA_76577062-8395-4461-a381-3319980bb007"
      unitRef="usd">246426</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTEtNy0xLTEtMA_262204e7-876c-4095-823d-f876332ab489"
      unitRef="usd">232200</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTItMS0xLTEtMA_4936d22c-029b-4619-9ecc-9c77c9b9e4bd"
      unitRef="usd">91200</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTItMy0xLTEtMA_b96b2188-0893-486a-a33d-039b7582bfa5"
      unitRef="usd">22019</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTItNS0xLTEtMA_534923b4-3eea-4e01-ac8a-4fd138b5c81c"
      unitRef="usd">152111</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTItNy0xLTEtMA_4ca50792-e191-42aa-ae62-030260b85bb4"
      unitRef="usd">40321</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTMtMS0xLTEtMA_d7403299-e777-4209-8ad7-7a34a99c2171"
      unitRef="usd">-562350</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTMtMy0xLTEtMA_dc8e2363-da02-4641-b2bd-61f07d3307c1"
      unitRef="usd">-741291</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTMtNS0xLTEtMA_04d71cd5-66f9-40d9-994a-eb0802210fa4"
      unitRef="usd">-684196</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTMtNy0xLTEtMA_5672a11e-71c3-4580-897f-e3afb3c68a52"
      unitRef="usd">-3129321</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTQtMS0xLTEtMA_e0899da0-c324-4303-9695-7b32f539cfa7"
      unitRef="usd">4462</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTQtMy0xLTEtMA_7cee680c-f819-43c4-af9e-17605867200e"
      unitRef="usd">4159</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTQtNS0xLTEtMA_e30df282-f6a5-479e-91ff-936bc8e5b24f"
      unitRef="usd">-76966</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTQtNy0xLTEtMA_c390db93-557d-40be-ac22-5bb8cffa73d7"
      unitRef="usd">8318</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTUtMS0xLTEtMA_dec0831c-0e8f-4580-8dec-06302abed295"
      unitRef="usd">-566812</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTUtMy0xLTEtMA_06c947f1-0391-4c13-bbc8-6cad42d71f23"
      unitRef="usd">-745450</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTUtNS0xLTEtMA_05f039b4-c04b-4f6b-b9ae-a7afd2891e6d"
      unitRef="usd">-607230</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTUtNy0xLTEtMA_7cb21d88-5d9a-4824-b086-4dc7015a5371"
      unitRef="usd">-3137639</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTYtMS0xLTEtMA_0e7b7819-d604-4aed-b5a2-7fb7538b216b"
      unitRef="usd">-17305</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTYtMy0xLTEtMA_07fb3a9f-c106-4e47-a650-79b631936885"
      unitRef="usd">-24762</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTYtNS0xLTEtMA_132dc34e-de1e-43fa-8270-cf95b3c9466e"
      unitRef="usd">16155</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTYtNy0xLTEtMA_f0782fc4-9feb-4650-abd3-e046b3b73f38"
      unitRef="usd">-37712</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTctMS0xLTEtMA_add4c9d4-19fe-42c3-b3e0-8fb5897199ec"
      unitRef="usd">-549507</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTctMy0xLTEtMA_c8e813db-72ab-4215-9b40-2d664e7a66df"
      unitRef="usd">-720688</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTctNS0xLTEtMA_4a97237f-ebc4-49d9-9f6b-2181df84041a"
      unitRef="usd">-623385</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTctNy0xLTEtMA_ec10c811-3464-4156-bfca-a0c11e6df31d"
      unitRef="usd">-3099927</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTktMS0xLTEtMA_49b74102-cc2e-4dbe-8ed3-c9d0e715916b"
      unitRef="usdPerShare">-0.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTktMy0xLTEtMA_c9b19402-78d8-4c45-922c-4679216c3bf0"
      unitRef="usdPerShare">-0.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTktNS0xLTEtMA_b57f2e8c-80a4-4662-a394-be75c22d2908"
      unitRef="usdPerShare">-0.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMTktNy0xLTEtMA_28d5449c-2057-40d9-a244-e95963c74013"
      unitRef="usdPerShare">-0.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMjAtMS0xLTEtMA_d6b8ca60-0e85-492b-b292-2055e16407da"
      unitRef="usdPerShare">-0.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMjAtMy0xLTEtMA_2986163c-1d90-45bf-8a80-55c7b932cddf"
      unitRef="usdPerShare">-0.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMjAtNS0xLTEtMA_4934856b-6024-44f8-9488-9b03575d86ea"
      unitRef="usdPerShare">-0.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMjAtNy0xLTEtMA_8a8cd478-c482-4298-849e-30837eea9c92"
      unitRef="usdPerShare">-0.20</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMjItMS0xLTEtMA_d9b5111c-2bc0-4cbc-83fe-7896ce172251"
      unitRef="shares">15523628</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMjItMy0xLTEtMA_0fa9d9a4-68ad-4f79-8778-76e667214916"
      unitRef="shares">15674954</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMjItNS0xLTEtMA_9c8e3451-9ed6-4d22-9dc5-099938b01a48"
      unitRef="shares">15497989</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMjItNy0xLTEtMA_635a4480-003e-466b-bc7e-9be7fbb0e4e8"
      unitRef="shares">15682348</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMjMtMS0xLTEtMA_9b5d89ae-79ec-4590-be3a-bd33239874e7"
      unitRef="shares">15523628</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMjMtMy0xLTEtMA_d639cf17-4b62-4725-aacf-50b09be64284"
      unitRef="shares">15674954</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMjMtNS0xLTEtMA_5ab68aa6-f8a6-46df-8d37-a1e03abe2fab"
      unitRef="shares">15497989</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMjMtNy0xLTEtMA_6d7d3c2a-232d-4e3e-be5e-8a7fb56213dc"
      unitRef="shares">15682348</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMjUtMS0xLTEtMA_ffa47055-3dfa-48dc-851a-4810d97bb193"
      unitRef="usd">-549507</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMjUtMy0xLTEtMA_316e5b12-b2d4-48c1-81ac-12a72e4dad05"
      unitRef="usd">-720688</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMjUtNS0xLTEtMA_8e7802b4-add6-4d20-b518-b34a118af340"
      unitRef="usd">-623385</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMjUtNy0xLTEtMA_fa5e2cb5-ed40-4c22-bb88-13ea284effb5"
      unitRef="usd">-3099927</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMjYtMS0xLTEtMA_bb5ae260-e121-492f-b6e3-809f6afed0ce"
      unitRef="usd">17305</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMjYtMy0xLTEtMA_ddf5272a-9bdd-4c42-874a-0aea68e127b8"
      unitRef="usd">24762</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMjYtNS0xLTEtMA_205e05c7-306c-488c-8187-072fba1861bc"
      unitRef="usd">-16155</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMjYtNy0xLTEtMA_551329da-3241-441f-b8f9-9bac5ee3b7ba"
      unitRef="usd">37712</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMjctMS0xLTEtMA_4d8a651c-6621-439d-9e45-dc55928977ef"
      unitRef="usd">-566812</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMjctMy0xLTEtMA_aa615923-c674-4495-96dd-80ab85248b29"
      unitRef="usd">-745450</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMjctNS0xLTEtMA_8a916fd1-940f-494a-bc9d-f2f88d6370ea"
      unitRef="usd">-607230</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yMi9mcmFnOmM5MDBlNGRjNjQ4MDQ0MDE4NWQ4MWQ2YWQwMjlhNmIyL3RhYmxlOjQ4NjczMjYxNjFlZDRhMThhYjk2MDBjMmY0NGJmZTM5L3RhYmxlcmFuZ2U6NDg2NzMyNjE2MWVkNGExOGFiOTYwMGMyZjQ0YmZlMzlfMjctNy0xLTEtMA_8322a3e6-4f62-431d-a1da-58302255f109"
      unitRef="usd">-3137639</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMy0xLTEtMS0w_46bbc6e4-ffab-4b6e-b48e-a13a99bdfd8c"
      unitRef="usd">-607230</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMy0zLTEtMS0w_3f5fb8cb-2c96-4557-bf3b-182db3fcaa2e"
      unitRef="usd">-3137639</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfNS0xLTEtMS0w_6b8f7a28-009f-4e58-8831-c0471e69e661"
      unitRef="usd">2174397</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfNS0zLTEtMS0w_5e9f428b-6d4f-45e7-8341-4b0e5885dbce"
      unitRef="usd">1394728</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfNi0xLTEtMS0w_39c22164-6529-42ea-999c-6f4d77b94445"
      unitRef="usd">43605</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfNi0zLTEtMS0w_43dc85e9-d482-4f3f-a541-b1a3ef9fac85"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ShareBasedCompensation
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfNy0xLTEtMS0w_27b537f7-638f-4afa-8c26-35d4aac2af4a"
      unitRef="usd">760982</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfNy0zLTEtMS0w_fe250a23-628c-4b88-9352-cc9491664192"
      unitRef="usd">665309</us-gaap:ShareBasedCompensation>
    <us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfOC0xLTEtMS0w_4e280f49-0aeb-43a5-8d81-c851b1780477"
      unitRef="usd">321894</us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities>
    <us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfOC0zLTEtMS0w_f7ac5b25-4de7-43f5-b428-fd83f43e4b62"
      unitRef="usd">0</us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfOS0xLTEtMS0w_52c26fae-7df4-4149-b2cf-03400448fc1e"
      unitRef="usd">28111</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfOS0zLTEtMS0w_f72e17fc-942b-41cc-9072-5be3d6f94620"
      unitRef="usd">33730</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMTAtMS0xLTEtMA_a7673d44-95fa-457b-a9a5-74fc807589dd"
      unitRef="usd">125804</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMTAtMy0xLTEtMA_4a25a528-e955-4b9c-847c-acb278c54de2"
      unitRef="usd">118188</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMTItMS0xLTEtMA_0fc0b18c-8dc2-4fd3-984d-983c3e26721d"
      unitRef="usd">583029</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMTItMy0xLTEtMA_30b5ea76-f1de-448a-90c3-663a40c40e65"
      unitRef="usd">-2589017</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMTMtMS0xLTEtMA_cf124a29-4d7a-48c7-9ce7-18a90c211339"
      unitRef="usd">-1429484</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMTMtMy0xLTEtMA_c5b638b9-48b9-4cc0-aaa5-ed34f7362c32"
      unitRef="usd">607653</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMTQtMS0xLTEtMA_7e4839b2-ae42-4fcd-8c0e-7d4df9e6d23d"
      unitRef="usd">-141577</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMTQtMy0xLTEtMA_553b1164-d9ec-4d22-ac24-c521ecfc4a42"
      unitRef="usd">-804729</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <cpix:IncreaseDecreaseInCurrentOperatingLiabilities
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMTUtMS0xLTEtMA_7678d56c-7d6a-4be9-bcbd-36cf86deaa09"
      unitRef="usd">-1132333</cpix:IncreaseDecreaseInCurrentOperatingLiabilities>
    <cpix:IncreaseDecreaseInCurrentOperatingLiabilities
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMTUtMy0xLTEtMA_1524061f-a7fa-4463-aac9-33d2f1c22b4a"
      unitRef="usd">-730760</cpix:IncreaseDecreaseInCurrentOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMTYtMS0xLTEtMA_6d7946fc-bf1f-476a-953c-f762219460f6"
      unitRef="usd">-342940</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMTYtMy0xLTEtMA_91ae49bd-e81c-49a7-9382-cecfe94435fe"
      unitRef="usd">136402</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMTctMS0xLTEtMA_b1bc1906-1722-46a4-a3e8-80597af356eb"
      unitRef="usd">1464926</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMTctMy0xLTEtMA_6bad1374-480d-4387-974a-8912237c536e"
      unitRef="usd">1029675</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMTktMS0xLTEtMA_6b08ad9b-8500-4e9c-943c-a9032a540120"
      unitRef="usd">89070</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMTktMy0xLTEtMA_42bd5cd5-328e-4b78-ace2-710f17ed716d"
      unitRef="usd">131684</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMjAtMS0xLTEtMA_92c51b50-faa0-4e17-a1f6-3e3eb3c58529"
      unitRef="usd">9627191</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMjAtMy0xLTEtMA_8d551c8b-6ae8-452b-9d44-4b231d94ae8c"
      unitRef="usd">16916890</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMjEtMS0xLTEtMA_31e3e1c7-099f-4b5e-a823-57a0b9f628b7"
      unitRef="usd">8563988</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMjEtMy0xLTEtMA_03ee653b-ac9b-4be2-979e-87f77bbf6ca4"
      unitRef="usd">6904205</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMjItMS0xLTEtMA_318a10b5-7df2-47c8-9f4f-062efce3f55b"
      unitRef="usd">5000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMjItMy0xLTEtMA_e4a4b8cd-2f8f-4a7e-9329-1fe754ebd645"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMjMtMS0xLTEtMA_27885b2c-0147-4657-8fa2-860a9296440f"
      unitRef="usd">395005</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMjMtMy0xLTEtMA_b5bfd384-d107-4c93-ba04-c5df61ce8518"
      unitRef="usd">593121</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMjQtMS0xLTEtMA_3588df48-23ef-475c-a377-d904df9b0cdd"
      unitRef="usd">-6547278</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMjQtMy0xLTEtMA_0f97100e-9d35-4c96-b7e5-aca591e46ac9"
      unitRef="usd">-10737490</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromRepaymentsOfLinesOfCredit
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMjctMS0xLTEtMA_ebc4905e-3210-4d7c-a371-efb714b023a7"
      unitRef="usd">36000000</us-gaap:ProceedsFromRepaymentsOfLinesOfCredit>
    <us-gaap:ProceedsFromRepaymentsOfLinesOfCredit
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMjctMy0xLTEtMA_3f3dfac1-4f57-47e5-a38f-81aa06890957"
      unitRef="usd">24000000</us-gaap:ProceedsFromRepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMjgtMS0xLTEtMA_b62baa4f-ec20-4c01-9486-322dfa2e421a"
      unitRef="usd">36000000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMjgtMy0xLTEtMA_9741e0b0-a85c-4b9a-bc6b-a1897bd08448"
      unitRef="usd">21800000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMjktMS0xLTEtMA_979d9b0c-dd77-4177-bfed-4267979d2d63"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMjktMy0xLTEtMA_6ee77c58-24f6-49d2-bec9-bb06566b920c"
      unitRef="usd">200909</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMzAtMS0xLTEtMA_8e0e65fc-dfc5-4126-a843-949d4cb4d634"
      unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMzAtMy0xLTEtMA_acf8116a-fb37-4ab7-b5a3-3bccb4fbbaee"
      unitRef="usd">248108</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMzEtMS0xLTEtMA_22148dcc-4120-43bf-8de6-f72dbbc2fd2b"
      unitRef="usd">684738</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMzEtMy0xLTEtMA_f8d33617-6832-40b1-8219-70343f97973a"
      unitRef="usd">0</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMzUtMS0xLTEtMA_0d1f4493-b9a4-49f8-a536-434d4f48162f"
      unitRef="usd">1220690</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMzUtMy0xLTEtMA_cbb3067c-e019-4aea-931b-1a712759ae87"
      unitRef="usd">1951199</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMzYtMS0xLTEtMA_85bed606-f0b7-47d3-9291-eae94be3355a"
      unitRef="usd">-1905428</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMzYtMy0xLTEtMA_89692202-2bf3-479c-bc60-c470d6356386"
      unitRef="usd">201602</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMzctMS0xLTEtMA_252adae6-dca0-48b6-9acf-f132703d856d"
      unitRef="usd">-6987780</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMzctMy0xLTEtMA_4248ac45-42c2-459e-bdbe-809ae1d9dba1"
      unitRef="usd">-9506213</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMzgtMS0xLTEtMA_d71900bd-dda8-40fa-a5a9-513eabf1e510"
      unitRef="usd">27938960</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6eecb6cf82d946f791b1e9b3d617a3ba_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMzgtMy0xLTEtMA_36b634e6-e508-4fc8-8879-9ba9fad65537"
      unitRef="usd">45412868</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMzktMS0xLTEtMA_1b48b58e-5f8a-4559-ad2e-3245bce26694"
      unitRef="usd">20951180</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id5d60a75c7914cbf8204350654c33543_I20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfMzktMy0xLTEtMA_34b8a221-9b53-45a4-bc01-ccdc8555bec4"
      unitRef="usd">35906655</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfNDItMS0xLTEtMA_963d3767-69ea-4a4d-b56b-18440e2ae746"
      unitRef="usd">3629320</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfNDItMy0xLTEtMA_0da2f928-68c0-44f3-8d92-c361be99f848"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfNDQtMS0xLTEtMzY3OQ_b55b8e39-cc87-4312-bc23-bc9aca417346"
      unitRef="usd">-800000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfNDQtMy0xLTEtMzY4MQ_2b08f633-dc84-4fc5-a691-95357029332b"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfNDUtMS0xLTEtMzY4Mw_62eeffdb-d2a4-42c9-aa92-acec8fdadba7"
      unitRef="usd">148000</us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yNS9mcmFnOmViMWVhYzIzMWI1ZTRjZTg5Y2I2ZThkODY5MjllN2ExL3RhYmxlOjBmZTIzODMwNGJiMjRiYmZiYjFjZGEzMmQ5YzkyNjUxL3RhYmxlcmFuZ2U6MGZlMjM4MzA0YmIyNGJiZmJiMWNkYTMyZDljOTI2NTFfNDUtMy0xLTEtMzY4NQ_7517b55c-f120-483d-9f2d-4d00e4dab118"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0e1c5e9c7cbe4efc93a736d76e33fe31_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjIzYzg4ZTU5ZTNmMDQ0Zjk4MDEwMWZiZjRmNzBjZjE2L3RhYmxlcmFuZ2U6MjNjODhlNTllM2YwNDRmOTgwMTAxZmJmNGY3MGNmMTZfMi0xLTEtMS0zNzEx_d37d03bb-843c-405b-b7b3-4b4041b32a90"
      unitRef="shares">15723075</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0e1c5e9c7cbe4efc93a736d76e33fe31_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjIzYzg4ZTU5ZTNmMDQ0Zjk4MDEwMWZiZjRmNzBjZjE2L3RhYmxlcmFuZ2U6MjNjODhlNTllM2YwNDRmOTgwMTAxZmJmNGY3MGNmMTZfMi0zLTEtMS0zNzEz_dcf1be5f-0022-4765-af5a-d30ab34d6b36"
      unitRef="usd">52410941</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icf52e3a90b564e61a9df4d3dd81a200b_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjIzYzg4ZTU5ZTNmMDQ0Zjk4MDEwMWZiZjRmNzBjZjE2L3RhYmxlcmFuZ2U6MjNjODhlNTllM2YwNDRmOTgwMTAxZmJmNGY3MGNmMTZfMi01LTEtMS0zNzE1_22f7b1b4-6f88-4f90-b972-b245f28b10ea"
      unitRef="usd">11709222</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9ec531ec35eb439399c9436b7345e202_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjIzYzg4ZTU5ZTNmMDQ0Zjk4MDEwMWZiZjRmNzBjZjE2L3RhYmxlcmFuZ2U6MjNjODhlNTllM2YwNDRmOTgwMTAxZmJmNGY3MGNmMTZfMi03LTEtMS0zNzE3_73fc10a8-1d9f-4101-b7b9-3fbcde6ebb43"
      unitRef="usd">-198562</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6eecb6cf82d946f791b1e9b3d617a3ba_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjIzYzg4ZTU5ZTNmMDQ0Zjk4MDEwMWZiZjRmNzBjZjE2L3RhYmxlcmFuZ2U6MjNjODhlNTllM2YwNDRmOTgwMTAxZmJmNGY3MGNmMTZfMi05LTEtMS0zNzE5_59cd7bce-f53b-4f50-bd48-16a307fa0edd"
      unitRef="usd">63921601</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i8d3bd3dbf1ee431ca1035d16d2daf32b_D20180101-20180331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjIzYzg4ZTU5ZTNmMDQ0Zjk4MDEwMWZiZjRmNzBjZjE2L3RhYmxlcmFuZ2U6MjNjODhlNTllM2YwNDRmOTgwMTAxZmJmNGY3MGNmMTZfMy0xLTEtMS0zNzQ3_2cfc4fac-b5dd-44ee-8643-d135a220f1a3"
      unitRef="shares">30704</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i8d3bd3dbf1ee431ca1035d16d2daf32b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjIzYzg4ZTU5ZTNmMDQ0Zjk4MDEwMWZiZjRmNzBjZjE2L3RhYmxlcmFuZ2U6MjNjODhlNTllM2YwNDRmOTgwMTAxZmJmNGY3MGNmMTZfMy0zLTEtMS0zNzQ1_6dfa8e44-981d-4d15-b42c-85abe07ff688"
      unitRef="usd">200909</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i4acfcd09578f42f994a9b89541ecf28c_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjIzYzg4ZTU5ZTNmMDQ0Zjk4MDEwMWZiZjRmNzBjZjE2L3RhYmxlcmFuZ2U6MjNjODhlNTllM2YwNDRmOTgwMTAxZmJmNGY3MGNmMTZfMy05LTEtMS0zNzIx_175c6d7a-b47c-430e-bd24-fee0a1aebb57"
      unitRef="usd">200909</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i8d3bd3dbf1ee431ca1035d16d2daf32b_D20180101-20180331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjIzYzg4ZTU5ZTNmMDQ0Zjk4MDEwMWZiZjRmNzBjZjE2L3RhYmxlcmFuZ2U6MjNjODhlNTllM2YwNDRmOTgwMTAxZmJmNGY3MGNmMTZfNC0xLTEtMS0zNzQ5_b2863dbd-5662-4337-962a-de1a4f704cb1"
      unitRef="shares">145550</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i8d3bd3dbf1ee431ca1035d16d2daf32b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjIzYzg4ZTU5ZTNmMDQ0Zjk4MDEwMWZiZjRmNzBjZjE2L3RhYmxlcmFuZ2U6MjNjODhlNTllM2YwNDRmOTgwMTAxZmJmNGY3MGNmMTZfNC0zLTEtMS0zNzQz_96a9608b-4dad-427b-8a97-164f637a2a59"
      unitRef="usd">339209</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i4acfcd09578f42f994a9b89541ecf28c_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjIzYzg4ZTU5ZTNmMDQ0Zjk4MDEwMWZiZjRmNzBjZjE2L3RhYmxlcmFuZ2U6MjNjODhlNTllM2YwNDRmOTgwMTAxZmJmNGY3MGNmMTZfNC05LTEtMS0zNzIz_fcc77199-f759-40c3-a4c5-bec413dc7207"
      unitRef="usd">339209</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i8d3bd3dbf1ee431ca1035d16d2daf32b_D20180101-20180331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjIzYzg4ZTU5ZTNmMDQ0Zjk4MDEwMWZiZjRmNzBjZjE2L3RhYmxlcmFuZ2U6MjNjODhlNTllM2YwNDRmOTgwMTAxZmJmNGY3MGNmMTZfNS0xLTEtMS0zNzUx_44260695-082d-4d4b-b2f5-729846b40060"
      unitRef="shares">172079</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i8d3bd3dbf1ee431ca1035d16d2daf32b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjIzYzg4ZTU5ZTNmMDQ0Zjk4MDEwMWZiZjRmNzBjZjE2L3RhYmxlcmFuZ2U6MjNjODhlNTllM2YwNDRmOTgwMTAxZmJmNGY3MGNmMTZfNS0zLTEtMS0zNzQx_0140f06b-7c26-49d3-af15-8395683edb3f"
      unitRef="usd">1195225</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i4acfcd09578f42f994a9b89541ecf28c_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjIzYzg4ZTU5ZTNmMDQ0Zjk4MDEwMWZiZjRmNzBjZjE2L3RhYmxlcmFuZ2U6MjNjODhlNTllM2YwNDRmOTgwMTAxZmJmNGY3MGNmMTZfNS05LTEtMS0zNzI1_59fa61a9-dbd8-4f3f-b58a-9fa92b41484b"
      unitRef="usd">1195225</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:ProfitLoss
      contextRef="i12bdf0ab8f4c49578c9eb30f38190373_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjIzYzg4ZTU5ZTNmMDQ0Zjk4MDEwMWZiZjRmNzBjZjE2L3RhYmxlcmFuZ2U6MjNjODhlNTllM2YwNDRmOTgwMTAxZmJmNGY3MGNmMTZfNi01LTEtMS0zNzM1_cdb83a72-c7eb-4a17-ba8b-0a81104b3ebe"
      unitRef="usd">-2379239</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i389b9f06784a4fa895bf9d85d0373d0a_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjIzYzg4ZTU5ZTNmMDQ0Zjk4MDEwMWZiZjRmNzBjZjE2L3RhYmxlcmFuZ2U6MjNjODhlNTllM2YwNDRmOTgwMTAxZmJmNGY3MGNmMTZfNi03LTEtMS0zNzMz_4a8dd21c-2edb-40f5-8a75-dd99a1f5cb4f"
      unitRef="usd">-12950</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4acfcd09578f42f994a9b89541ecf28c_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjIzYzg4ZTU5ZTNmMDQ0Zjk4MDEwMWZiZjRmNzBjZjE2L3RhYmxlcmFuZ2U6MjNjODhlNTllM2YwNDRmOTgwMTAxZmJmNGY3MGNmMTZfNi05LTEtMS0zNzI3_73913fcf-8316-477a-b66c-c51a2d5f53b9"
      unitRef="usd">-2392189</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ieeeb240a56f744c5976744da0dbe5ad7_I20180331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjIzYzg4ZTU5ZTNmMDQ0Zjk4MDEwMWZiZjRmNzBjZjE2L3RhYmxlcmFuZ2U6MjNjODhlNTllM2YwNDRmOTgwMTAxZmJmNGY3MGNmMTZfNy0xLTEtMS0zNzUz_29bd2abe-dd45-4469-b2d1-f342e8f0a84b"
      unitRef="shares">15727250</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ieeeb240a56f744c5976744da0dbe5ad7_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjIzYzg4ZTU5ZTNmMDQ0Zjk4MDEwMWZiZjRmNzBjZjE2L3RhYmxlcmFuZ2U6MjNjODhlNTllM2YwNDRmOTgwMTAxZmJmNGY3MGNmMTZfNy0zLTEtMS0zNzM5_0ca0cd52-7a4d-499e-98f1-929924572ce4"
      unitRef="usd">51755834</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie2aef2419d2a434d882a0412b764c40a_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjIzYzg4ZTU5ZTNmMDQ0Zjk4MDEwMWZiZjRmNzBjZjE2L3RhYmxlcmFuZ2U6MjNjODhlNTllM2YwNDRmOTgwMTAxZmJmNGY3MGNmMTZfNy01LTEtMS0zNzM3_86c12e7f-cd47-4e5a-a733-d1c81de346b5"
      unitRef="usd">9329983</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i525c05bfba8a496bb3f3ad3dd759b4b6_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjIzYzg4ZTU5ZTNmMDQ0Zjk4MDEwMWZiZjRmNzBjZjE2L3RhYmxlcmFuZ2U6MjNjODhlNTllM2YwNDRmOTgwMTAxZmJmNGY3MGNmMTZfNy03LTEtMS0zNzMx_50ecc596-ecfe-4c3b-b677-a45aa493eb70"
      unitRef="usd">-211512</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia885021b86044725a1fb10e4cc611b1f_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjIzYzg4ZTU5ZTNmMDQ0Zjk4MDEwMWZiZjRmNzBjZjE2L3RhYmxlcmFuZ2U6MjNjODhlNTllM2YwNDRmOTgwMTAxZmJmNGY3MGNmMTZfNy05LTEtMS0zNzI5_735188a7-d38a-40c5-8c61-e6ee7a060b70"
      unitRef="usd">60874305</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ieeeb240a56f744c5976744da0dbe5ad7_I20180331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjMyY2IyMjdjMzJjMjRmM2E4ZDY3OWFhNjgwYzc2NjIyL3RhYmxlcmFuZ2U6MzJjYjIyN2MzMmMyNGYzYThkNjc5YWE2ODBjNzY2MjJfMi0xLTEtMS0w_7ff7bde5-d294-4b6c-bf74-5aba6bdce258"
      unitRef="shares">15727250</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ieeeb240a56f744c5976744da0dbe5ad7_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjMyY2IyMjdjMzJjMjRmM2E4ZDY3OWFhNjgwYzc2NjIyL3RhYmxlcmFuZ2U6MzJjYjIyN2MzMmMyNGYzYThkNjc5YWE2ODBjNzY2MjJfMi0zLTEtMS0w_b43b50ba-f3b7-4045-87bd-234be4bffed8"
      unitRef="usd">51755834</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie2aef2419d2a434d882a0412b764c40a_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjMyY2IyMjdjMzJjMjRmM2E4ZDY3OWFhNjgwYzc2NjIyL3RhYmxlcmFuZ2U6MzJjYjIyN2MzMmMyNGYzYThkNjc5YWE2ODBjNzY2MjJfMi01LTEtMS0w_a63ba878-d1b0-4a16-9b8c-fdd67f1a845d"
      unitRef="usd">9329983</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i525c05bfba8a496bb3f3ad3dd759b4b6_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjMyY2IyMjdjMzJjMjRmM2E4ZDY3OWFhNjgwYzc2NjIyL3RhYmxlcmFuZ2U6MzJjYjIyN2MzMmMyNGYzYThkNjc5YWE2ODBjNzY2MjJfMi03LTEtMS0w_c15ff446-b606-4635-8240-9ea0089e5eaf"
      unitRef="usd">-211512</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia885021b86044725a1fb10e4cc611b1f_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjMyY2IyMjdjMzJjMjRmM2E4ZDY3OWFhNjgwYzc2NjIyL3RhYmxlcmFuZ2U6MzJjYjIyN2MzMmMyNGYzYThkNjc5YWE2ODBjNzY2MjJfMi05LTEtMS0w_2f1a8fef-5970-4890-9f5d-f2b1cde4c9e8"
      unitRef="usd">60874305</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="if02d00db9a714fb7b9ff2e6a67ac03d2_D20180401-20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjMyY2IyMjdjMzJjMjRmM2E4ZDY3OWFhNjgwYzc2NjIyL3RhYmxlcmFuZ2U6MzJjYjIyN2MzMmMyNGYzYThkNjc5YWE2ODBjNzY2MjJfMy0xLTEtMS0w_3c223fc0-87a9-40f9-bb6b-38d66f570a0e"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="if02d00db9a714fb7b9ff2e6a67ac03d2_D20180401-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjMyY2IyMjdjMzJjMjRmM2E4ZDY3OWFhNjgwYzc2NjIyL3RhYmxlcmFuZ2U6MzJjYjIyN2MzMmMyNGYzYThkNjc5YWE2ODBjNzY2MjJfMy0zLTEtMS0w_5bd3ac35-59a0-48a5-a3f2-ac60cfcfc4b7"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjMyY2IyMjdjMzJjMjRmM2E4ZDY3OWFhNjgwYzc2NjIyL3RhYmxlcmFuZ2U6MzJjYjIyN2MzMmMyNGYzYThkNjc5YWE2ODBjNzY2MjJfMy05LTEtMS0w_6e559078-99dd-4508-bfea-8f528d9ac56e"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="if02d00db9a714fb7b9ff2e6a67ac03d2_D20180401-20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjMyY2IyMjdjMzJjMjRmM2E4ZDY3OWFhNjgwYzc2NjIyL3RhYmxlcmFuZ2U6MzJjYjIyN2MzMmMyNGYzYThkNjc5YWE2ODBjNzY2MjJfNC0xLTEtMS0w_c0d28fca-d100-4f45-8da8-6fe9c68aed8a"
      unitRef="shares">4750</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if02d00db9a714fb7b9ff2e6a67ac03d2_D20180401-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjMyY2IyMjdjMzJjMjRmM2E4ZDY3OWFhNjgwYzc2NjIyL3RhYmxlcmFuZ2U6MzJjYjIyN2MzMmMyNGYzYThkNjc5YWE2ODBjNzY2MjJfNC0zLTEtMS0w_6ad5a682-e00e-4948-93ea-b0d3e63bdda8"
      unitRef="usd">326100</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjMyY2IyMjdjMzJjMjRmM2E4ZDY3OWFhNjgwYzc2NjIyL3RhYmxlcmFuZ2U6MzJjYjIyN2MzMmMyNGYzYThkNjc5YWE2ODBjNzY2MjJfNC05LTEtMS0w_e47012ca-67d3-4bbd-a65d-094c8822f9a4"
      unitRef="usd">326100</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="if02d00db9a714fb7b9ff2e6a67ac03d2_D20180401-20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjMyY2IyMjdjMzJjMjRmM2E4ZDY3OWFhNjgwYzc2NjIyL3RhYmxlcmFuZ2U6MzJjYjIyN2MzMmMyNGYzYThkNjc5YWE2ODBjNzY2MjJfNS0xLTEtMS0w_073dfcb4-114b-4cfd-a418-78ed4a71cf83"
      unitRef="shares">127291</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="if02d00db9a714fb7b9ff2e6a67ac03d2_D20180401-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjMyY2IyMjdjMzJjMjRmM2E4ZDY3OWFhNjgwYzc2NjIyL3RhYmxlcmFuZ2U6MzJjYjIyN2MzMmMyNGYzYThkNjc5YWE2ODBjNzY2MjJfNS0zLTEtMS0w_85853ba4-9294-45c0-a157-b09e1f7a371e"
      unitRef="usd">784505</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjMyY2IyMjdjMzJjMjRmM2E4ZDY3OWFhNjgwYzc2NjIyL3RhYmxlcmFuZ2U6MzJjYjIyN2MzMmMyNGYzYThkNjc5YWE2ODBjNzY2MjJfNS05LTEtMS0w_a15cd438-208e-41d8-aef4-fa4ac842eeee"
      unitRef="usd">784505</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:ProfitLoss
      contextRef="iad96f105789947c999f7d544dd4620db_D20180401-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjMyY2IyMjdjMzJjMjRmM2E4ZDY3OWFhNjgwYzc2NjIyL3RhYmxlcmFuZ2U6MzJjYjIyN2MzMmMyNGYzYThkNjc5YWE2ODBjNzY2MjJfNi01LTEtMS0w_791cbc43-978b-4eba-8b12-bd0a7bfac6e5"
      unitRef="usd">-720688</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i77e056bccd4543089353688903d60102_D20180401-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjMyY2IyMjdjMzJjMjRmM2E4ZDY3OWFhNjgwYzc2NjIyL3RhYmxlcmFuZ2U6MzJjYjIyN2MzMmMyNGYzYThkNjc5YWE2ODBjNzY2MjJfNi03LTEtMS0w_f5bbb9e1-e026-4e2e-9224-3e0fd32a003c"
      unitRef="usd">-24762</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjMyY2IyMjdjMzJjMjRmM2E4ZDY3OWFhNjgwYzc2NjIyL3RhYmxlcmFuZ2U6MzJjYjIyN2MzMmMyNGYzYThkNjc5YWE2ODBjNzY2MjJfNi05LTEtMS0w_47fd0524-b404-4c01-bd6a-bef97cd514a9"
      unitRef="usd">-745450</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ifa6a17eccce2451499b89a8ee27e36af_I20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjMyY2IyMjdjMzJjMjRmM2E4ZDY3OWFhNjgwYzc2NjIyL3RhYmxlcmFuZ2U6MzJjYjIyN2MzMmMyNGYzYThkNjc5YWE2ODBjNzY2MjJfNy0xLTEtMS0w_4f7db7b3-bd6f-4ee6-9072-63677fe6d46f"
      unitRef="shares">15604709</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifa6a17eccce2451499b89a8ee27e36af_I20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjMyY2IyMjdjMzJjMjRmM2E4ZDY3OWFhNjgwYzc2NjIyL3RhYmxlcmFuZ2U6MzJjYjIyN2MzMmMyNGYzYThkNjc5YWE2ODBjNzY2MjJfNy0zLTEtMS0w_c5199d73-953c-470a-a966-764be11e65a4"
      unitRef="usd">51297429</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7ebb41ca72a9412d830adbbcce277c27_I20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjMyY2IyMjdjMzJjMjRmM2E4ZDY3OWFhNjgwYzc2NjIyL3RhYmxlcmFuZ2U6MzJjYjIyN2MzMmMyNGYzYThkNjc5YWE2ODBjNzY2MjJfNy01LTEtMS0w_08d97631-d5c5-4608-98b8-6fe0f345e2ac"
      unitRef="usd">8609295</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iefb8318507a84b1eab45ae17e36b7a7e_I20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjMyY2IyMjdjMzJjMjRmM2E4ZDY3OWFhNjgwYzc2NjIyL3RhYmxlcmFuZ2U6MzJjYjIyN2MzMmMyNGYzYThkNjc5YWE2ODBjNzY2MjJfNy03LTEtMS0w_6e725005-a0c4-4e20-a6ed-9bf6fe0ad8a0"
      unitRef="usd">-236274</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id5d60a75c7914cbf8204350654c33543_I20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjMyY2IyMjdjMzJjMjRmM2E4ZDY3OWFhNjgwYzc2NjIyL3RhYmxlcmFuZ2U6MzJjYjIyN2MzMmMyNGYzYThkNjc5YWE2ODBjNzY2MjJfNy05LTEtMS0w_0d7559a1-a5af-4124-80cd-7dcafcd27721"
      unitRef="usd">59670450</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i86ad84a3cb90495fa0d9574cd4dfc3e8_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjNjA2N2VkNTgwZjRmMDVhNWY5MmY1YTY2YjhiNDRkL3RhYmxlcmFuZ2U6MmM2MDY3ZWQ1ODBmNGYwNWE1ZjkyZjVhNjZiOGI0NGRfMi0xLTEtMS0zODIz_257d4b8e-3c66-4914-9d30-ad6afb5d3e57"
      unitRef="shares">15481497</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i86ad84a3cb90495fa0d9574cd4dfc3e8_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjNjA2N2VkNTgwZjRmMDVhNWY5MmY1YTY2YjhiNDRkL3RhYmxlcmFuZ2U6MmM2MDY3ZWQ1ODBmNGYwNWE1ZjkyZjVhNjZiOGI0NGRfMi0zLTEtMS0zODI1_b2d6ff87-4e13-4559-ad9c-d4b7f8509dd1"
      unitRef="usd">51098613</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6695ed74ccf34594a009b751a9867ab5_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjNjA2N2VkNTgwZjRmMDVhNWY5MmY1YTY2YjhiNDRkL3RhYmxlcmFuZ2U6MmM2MDY3ZWQ1ODBmNGYwNWE1ZjkyZjVhNjZiOGI0NGRfMi01LTEtMS0zODI3_ccab0403-988a-4752-969c-dc7073c8005d"
      unitRef="usd">4746154</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib0658642e8184a7e8bcf52ddf1229693_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjNjA2N2VkNTgwZjRmMDVhNWY5MmY1YTY2YjhiNDRkL3RhYmxlcmFuZ2U6MmM2MDY3ZWQ1ODBmNGYwNWE1ZjkyZjVhNjZiOGI0NGRfMi03LTEtMS0zODI5_10e8327b-f5ad-46c8-b52e-39e0e4d4dc08"
      unitRef="usd">-274266</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjNjA2N2VkNTgwZjRmMDVhNWY5MmY1YTY2YjhiNDRkL3RhYmxlcmFuZ2U6MmM2MDY3ZWQ1ODBmNGYwNWE1ZjkyZjVhNjZiOGI0NGRfMi05LTEtMS0zODM0_aaaf6ce4-badd-47b6-af0e-bd5b4a9fde72"
      unitRef="usd">55570501</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="idaa440b71edc463180ffe7cc20dc52c5_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjNjA2N2VkNTgwZjRmMDVhNWY5MmY1YTY2YjhiNDRkL3RhYmxlcmFuZ2U6MmM2MDY3ZWQ1ODBmNGYwNWE1ZjkyZjVhNjZiOGI0NGRfMy0xLTEtMS0zODQx_a9c6d755-cc7e-4c2f-b9f4-0b0ba855cc49"
      unitRef="shares">187486</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="idaa440b71edc463180ffe7cc20dc52c5_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjNjA2N2VkNTgwZjRmMDVhNWY5MmY1YTY2YjhiNDRkL3RhYmxlcmFuZ2U6MmM2MDY3ZWQ1ODBmNGYwNWE1ZjkyZjVhNjZiOGI0NGRfMy0zLTEtMS0zODM4_09db7e5b-c792-4c9a-8753-0289dfb011a7"
      unitRef="usd">364434</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i4b03a84c29d54b778087726fae7de356_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjNjA2N2VkNTgwZjRmMDVhNWY5MmY1YTY2YjhiNDRkL3RhYmxlcmFuZ2U6MmM2MDY3ZWQ1ODBmNGYwNWE1ZjkyZjVhNjZiOGI0NGRfMy05LTEtMS0zODM2_b1d70942-7b99-4d6e-b750-dc9f71b4533b"
      unitRef="usd">364434</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="idaa440b71edc463180ffe7cc20dc52c5_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjNjA2N2VkNTgwZjRmMDVhNWY5MmY1YTY2YjhiNDRkL3RhYmxlcmFuZ2U6MmM2MDY3ZWQ1ODBmNGYwNWE1ZjkyZjVhNjZiOGI0NGRfNC0xLTEtMS0zODQz_5a7b5605-8bd0-4562-967a-d6a6e4046d31"
      unitRef="shares">121466</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="idaa440b71edc463180ffe7cc20dc52c5_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjNjA2N2VkNTgwZjRmMDVhNWY5MmY1YTY2YjhiNDRkL3RhYmxlcmFuZ2U6MmM2MDY3ZWQ1ODBmNGYwNWE1ZjkyZjVhNjZiOGI0NGRfNC0zLTEtMS0zODQ1_d86d81f6-8a38-463f-bff4-968960bddb6b"
      unitRef="usd">703790</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i4b03a84c29d54b778087726fae7de356_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjNjA2N2VkNTgwZjRmMDVhNWY5MmY1YTY2YjhiNDRkL3RhYmxlcmFuZ2U6MmM2MDY3ZWQ1ODBmNGYwNWE1ZjkyZjVhNjZiOGI0NGRfNC05LTEtMS0zODQ3_9d1672a3-6dc9-4734-85e5-82644920152a"
      unitRef="usd">703790</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:ProfitLoss
      contextRef="i73c240c1815a42e2ab3c71622ab5a7f7_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjNjA2N2VkNTgwZjRmMDVhNWY5MmY1YTY2YjhiNDRkL3RhYmxlcmFuZ2U6MmM2MDY3ZWQ1ODBmNGYwNWE1ZjkyZjVhNjZiOGI0NGRfNS01LTEtMS0zODUz_38f90e01-4034-420d-be70-295794de26f6"
      unitRef="usd">-73878</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i9a0b25c5749f4e71aca5511d2c6057b6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjNjA2N2VkNTgwZjRmMDVhNWY5MmY1YTY2YjhiNDRkL3RhYmxlcmFuZ2U6MmM2MDY3ZWQ1ODBmNGYwNWE1ZjkyZjVhNjZiOGI0NGRfNS03LTEtMS0zODUw_6bf8fbe0-ba44-484d-b296-3d928068db6b"
      unitRef="usd">33460</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4b03a84c29d54b778087726fae7de356_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjNjA2N2VkNTgwZjRmMDVhNWY5MmY1YTY2YjhiNDRkL3RhYmxlcmFuZ2U6MmM2MDY3ZWQ1ODBmNGYwNWE1ZjkyZjVhNjZiOGI0NGRfNS05LTEtMS0zODQ5_ee2aead6-efdb-4fc8-9557-07e9e5bea3ba"
      unitRef="usd">-40418</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iac307e50d1064fb993f7c13e652bf744_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjNjA2N2VkNTgwZjRmMDVhNWY5MmY1YTY2YjhiNDRkL3RhYmxlcmFuZ2U6MmM2MDY3ZWQ1ODBmNGYwNWE1ZjkyZjVhNjZiOGI0NGRfNi0xLTEtMS0zODU1_66a293c5-65b0-4bf5-a5f0-e74546cbb3cd"
      unitRef="shares">15547517</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iac307e50d1064fb993f7c13e652bf744_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjNjA2N2VkNTgwZjRmMDVhNWY5MmY1YTY2YjhiNDRkL3RhYmxlcmFuZ2U6MmM2MDY3ZWQ1ODBmNGYwNWE1ZjkyZjVhNjZiOGI0NGRfNi0zLTEtMS0zODU3_4ea2dfc8-a4ce-438f-9558-73dd6103588f"
      unitRef="usd">50759257</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id01be75c70fd4c0390e4cb8f8a56f1f8_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjNjA2N2VkNTgwZjRmMDVhNWY5MmY1YTY2YjhiNDRkL3RhYmxlcmFuZ2U6MmM2MDY3ZWQ1ODBmNGYwNWE1ZjkyZjVhNjZiOGI0NGRfNi01LTEtMS0zODU5_0487dff2-5db2-40f1-8d86-6a7ceb948954"
      unitRef="usd">4672276</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i58d3402c22484d6bb6b255a3e69c04eb_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjNjA2N2VkNTgwZjRmMDVhNWY5MmY1YTY2YjhiNDRkL3RhYmxlcmFuZ2U6MmM2MDY3ZWQ1ODBmNGYwNWE1ZjkyZjVhNjZiOGI0NGRfNi03LTEtMS0zODYx_655445bb-e4b9-4aec-bac0-57b1d78cf839"
      unitRef="usd">-240806</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4d6b70bf87e540e287238c2db49676b4_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjNjA2N2VkNTgwZjRmMDVhNWY5MmY1YTY2YjhiNDRkL3RhYmxlcmFuZ2U6MmM2MDY3ZWQ1ODBmNGYwNWE1ZjkyZjVhNjZiOGI0NGRfNi05LTEtMS0zODYz_4b399ed4-941b-4bf6-926c-03bc2fa334fb"
      unitRef="usd">55190727</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iac307e50d1064fb993f7c13e652bf744_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjZDRiNGFhNjQ1MTQxMTI5OTIwNGRkYWE4ZTlhNzYxL3RhYmxlcmFuZ2U6MmNkNGI0YWE2NDUxNDExMjk5MjA0ZGRhYThlOWE3NjFfMy0xLTEtMS0w_95bf0d13-09cc-4f46-9c6b-c13e2590e845"
      unitRef="shares">15547517</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iac307e50d1064fb993f7c13e652bf744_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjZDRiNGFhNjQ1MTQxMTI5OTIwNGRkYWE4ZTlhNzYxL3RhYmxlcmFuZ2U6MmNkNGI0YWE2NDUxNDExMjk5MjA0ZGRhYThlOWE3NjFfMy0zLTEtMS0w_84d15c4f-0c4e-4c2b-8c4f-8ca4e1af4aee"
      unitRef="usd">50759257</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id01be75c70fd4c0390e4cb8f8a56f1f8_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjZDRiNGFhNjQ1MTQxMTI5OTIwNGRkYWE4ZTlhNzYxL3RhYmxlcmFuZ2U6MmNkNGI0YWE2NDUxNDExMjk5MjA0ZGRhYThlOWE3NjFfMy01LTEtMS0w_17bc52e1-d833-458a-b80a-88930c9779e1"
      unitRef="usd">4672276</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i58d3402c22484d6bb6b255a3e69c04eb_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjZDRiNGFhNjQ1MTQxMTI5OTIwNGRkYWE4ZTlhNzYxL3RhYmxlcmFuZ2U6MmNkNGI0YWE2NDUxNDExMjk5MjA0ZGRhYThlOWE3NjFfMy03LTEtMS0w_0859a064-aaad-47b2-ae46-5157eb19de27"
      unitRef="usd">-240806</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4d6b70bf87e540e287238c2db49676b4_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjZDRiNGFhNjQ1MTQxMTI5OTIwNGRkYWE4ZTlhNzYxL3RhYmxlcmFuZ2U6MmNkNGI0YWE2NDUxNDExMjk5MjA0ZGRhYThlOWE3NjFfMy05LTEtMS0w_a53d7a5e-5c75-40d0-8667-8bce29ac3d9e"
      unitRef="usd">55190727</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i69067cc85b7d439ab6017dfcbfd70f2a_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjZDRiNGFhNjQ1MTQxMTI5OTIwNGRkYWE4ZTlhNzYxL3RhYmxlcmFuZ2U6MmNkNGI0YWE2NDUxNDExMjk5MjA0ZGRhYThlOWE3NjFfNi0xLTEtMS0w_d2752fae-534a-4505-8e61-7e1a6a522276"
      unitRef="shares">8000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i69067cc85b7d439ab6017dfcbfd70f2a_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjZDRiNGFhNjQ1MTQxMTI5OTIwNGRkYWE4ZTlhNzYxL3RhYmxlcmFuZ2U6MmNkNGI0YWE2NDUxNDExMjk5MjA0ZGRhYThlOWE3NjFfNi0zLTEtMS0w_ef84a84a-1c98-4a41-bb19-41f694648633"
      unitRef="usd">396548</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjZDRiNGFhNjQ1MTQxMTI5OTIwNGRkYWE4ZTlhNzYxL3RhYmxlcmFuZ2U6MmNkNGI0YWE2NDUxNDExMjk5MjA0ZGRhYThlOWE3NjFfNi05LTEtMS0w_9d1e2e7e-7612-4e45-b701-09639cbd3951"
      unitRef="usd">396548</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i69067cc85b7d439ab6017dfcbfd70f2a_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjZDRiNGFhNjQ1MTQxMTI5OTIwNGRkYWE4ZTlhNzYxL3RhYmxlcmFuZ2U6MmNkNGI0YWE2NDUxNDExMjk5MjA0ZGRhYThlOWE3NjFfNi0zLTEtMS0xNTYx_3ea8f8bd-5928-4b85-a0b4-be9ea976b13d"
      unitRef="usd">685805</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="if5b7d8e3ae1349cea30af6ae38abd9fa_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjZDRiNGFhNjQ1MTQxMTI5OTIwNGRkYWE4ZTlhNzYxL3RhYmxlcmFuZ2U6MmNkNGI0YWE2NDUxNDExMjk5MjA0ZGRhYThlOWE3NjFfMy03LTEtMS0zODgy_4afd3067-d3f2-4991-89d2-ee74a077b911"
      unitRef="usd">114195</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjZDRiNGFhNjQ1MTQxMTI5OTIwNGRkYWE4ZTlhNzYxL3RhYmxlcmFuZ2U6MmNkNGI0YWE2NDUxNDExMjk5MjA0ZGRhYThlOWE3NjFfNi05LTEtMS0xNTY4_b436ee7e-7997-4c72-b18f-8b4cde5b69c9"
      unitRef="usd">800000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i69067cc85b7d439ab6017dfcbfd70f2a_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjZDRiNGFhNjQ1MTQxMTI5OTIwNGRkYWE4ZTlhNzYxL3RhYmxlcmFuZ2U6MmNkNGI0YWE2NDUxNDExMjk5MjA0ZGRhYThlOWE3NjFfOS0xLTEtMS0w_5fcd391c-68d4-4475-a015-0d95814f6158"
      unitRef="shares">84447</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i69067cc85b7d439ab6017dfcbfd70f2a_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjZDRiNGFhNjQ1MTQxMTI5OTIwNGRkYWE4ZTlhNzYxL3RhYmxlcmFuZ2U6MmNkNGI0YWE2NDUxNDExMjk5MjA0ZGRhYThlOWE3NjFfOS0zLTEtMS0w_a79a32c2-6e05-4b04-93b4-3d340ea6ea8e"
      unitRef="usd">531746</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjZDRiNGFhNjQ1MTQxMTI5OTIwNGRkYWE4ZTlhNzYxL3RhYmxlcmFuZ2U6MmNkNGI0YWE2NDUxNDExMjk5MjA0ZGRhYThlOWE3NjFfOS05LTEtMS0w_6ca82cca-71bd-413f-ae8a-f6ae3cdb8f5c"
      unitRef="usd">531746</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:ProfitLoss
      contextRef="i274cc8eea0aa47a382670b52aaf0929c_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjZDRiNGFhNjQ1MTQxMTI5OTIwNGRkYWE4ZTlhNzYxL3RhYmxlcmFuZ2U6MmNkNGI0YWE2NDUxNDExMjk5MjA0ZGRhYThlOWE3NjFfMTAtNS0xLTEtMA_d19acb10-2c82-43c5-a51f-1dc24c9e1c7b"
      unitRef="usd">-549507</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="if5b7d8e3ae1349cea30af6ae38abd9fa_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjZDRiNGFhNjQ1MTQxMTI5OTIwNGRkYWE4ZTlhNzYxL3RhYmxlcmFuZ2U6MmNkNGI0YWE2NDUxNDExMjk5MjA0ZGRhYThlOWE3NjFfMTAtNy0xLTEtMA_ad387e97-2185-49e4-baa1-3cd8f88c028d"
      unitRef="usd">-17305</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjZDRiNGFhNjQ1MTQxMTI5OTIwNGRkYWE4ZTlhNzYxL3RhYmxlcmFuZ2U6MmNkNGI0YWE2NDUxNDExMjk5MjA0ZGRhYThlOWE3NjFfMTAtOS0xLTEtMA_4a712ff5-b7d3-422e-a3e5-8e6662bc6bfa"
      unitRef="usd">-566812</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ide4bf4cd636d4c2db7c36e6913c5b859_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjZDRiNGFhNjQ1MTQxMTI5OTIwNGRkYWE4ZTlhNzYxL3RhYmxlcmFuZ2U6MmNkNGI0YWE2NDUxNDExMjk5MjA0ZGRhYThlOWE3NjFfMTEtMS0xLTEtMA_0e14e1e0-fdd8-487f-895f-dc2fe859ce7b"
      unitRef="shares">15471070</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ide4bf4cd636d4c2db7c36e6913c5b859_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjZDRiNGFhNjQ1MTQxMTI5OTIwNGRkYWE4ZTlhNzYxL3RhYmxlcmFuZ2U6MmNkNGI0YWE2NDUxNDExMjk5MjA0ZGRhYThlOWE3NjFfMTEtMy0xLTEtMA_c7e073ff-e6e4-4906-b67d-939b6ef0916c"
      unitRef="usd">49938254</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic39d78c819df43acb7f94d5a5d3f0944_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjZDRiNGFhNjQ1MTQxMTI5OTIwNGRkYWE4ZTlhNzYxL3RhYmxlcmFuZ2U6MmNkNGI0YWE2NDUxNDExMjk5MjA0ZGRhYThlOWE3NjFfMTEtNS0xLTEtMA_11528a9e-e416-4ff9-8fff-35260a9416e7"
      unitRef="usd">4122769</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8f374a018db6442e9076cb34a527615d_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjZDRiNGFhNjQ1MTQxMTI5OTIwNGRkYWE4ZTlhNzYxL3RhYmxlcmFuZ2U6MmNkNGI0YWE2NDUxNDExMjk5MjA0ZGRhYThlOWE3NjFfMTEtNy0xLTEtMA_ae3333b3-9394-4d48-a5af-53b72575729e"
      unitRef="usd">-372306</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18yOC9mcmFnOjNhNmFkYzBkYWVmZTQ5NTFiYjhkNjU2OTAxYzYzYzUwL3RhYmxlOjJjZDRiNGFhNjQ1MTQxMTI5OTIwNGRkYWE4ZTlhNzYxL3RhYmxlcmFuZ2U6MmNkNGI0YWE2NDUxNDExMjk5MjA0ZGRhYThlOWE3NjFfMTEtOS0xLTEtMA_2624d009-ba43-4ade-8734-6a16496388fc"
      unitRef="usd">53688717</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNC9mcmFnOjEwNzJiODA1MTI3ZjQzMzdiZmMzYmM2NjFiOTVjN2M4L3RleHRyZWdpb246MTA3MmI4MDUxMjdmNDMzN2JmYzNiYzY2MWI5NWM3YzhfODMzNw_637df4a1-6a92-4c50-8683-d13ad09ad584">ORGANIZATION AND BASIS OF PRESENTATION&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Cumberland Pharmaceuticals Inc. (&#x201c;Cumberland,&#x201d; the &#x201c;Company,&#x201d; or as used in the context of &#x201c;we,&#x201d; &#x201c;us,&#x201d; or &#x201c;our&#x201d;) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products.  The Company's primary target markets are hospital acute care, gastroenterology, and oncology supportive care. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company&#x2019;s products are manufactured by third parties, which are overseen by Cumberland&#x2019;s quality control and manufacturing professionals. The Company works closely with its third-party distribution partners to make its products available in the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In the opinion of management, the accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a basis consistent with the December 31, 2018 audited consolidated financial statements, with the exception of the impacts of adopting accounting pronouncements during 2019, and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly present the information set forth herein. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements have been prepared in accordance with the regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;), and certain information and disclosures have been condensed or omitted as permitted by the SEC for interim period presentation. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2018 (the &#x201c;2018 Annual Report on Form 10-K&#x201d;). The results of operations for the three and six months ended June 30, 2019 are not necessarily indicative of the results to be expected for the entire fiscal year or any future period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Total comprehensive income (loss) consisted solely of net income (loss) for the three and six months ended June 30, 2019 and 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recent Accounting Guidance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Recent Adopted Accounting Pronouncement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:7pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In February 2016, the Financial Accounting Standards Board ("FASB") issued guidance in the form of a FASB Accounting Standards Update ("ASU") No. 2016-02, &#x201c;Leases.&#x201d; The new standard establishes a right-of-use (&#x201c;ROU&#x201d;) model that requires a lessee to record an ROU asset and a lease liability on the balance sheet for all leases with terms longer than twelve months. Leases will be classified as either finance (formerly "capital leases") or operating, with classification affecting the pattern of expense recognition in the income statement. The standard provides for a modified retrospective transition approach for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain optional practical expedients.  In July 2018, the FASB issued ASU 2018-11, "Leases: Targeted Improvements", allowing for an alternative transition method (the effective date approach). It allows an entity to initially apply the new lease guidance at the adoption date (rather than at the beginning of the earliest period presented). Cumberland adopted the lease guidance effective January 1, 2019 using the package of transition practical expedients.  This allowed the Company to retain the lease classification for any leases existing prior to adoption, in addition to other benefits. See additional discussion of the impact of adopting the lease accounting guidance in Note 6.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Recent Accounting Pronouncements - Not Yet Adopted &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &#x201c;Financial Instruments-Credit Losses,&#x201d; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#x201c;expected loss&#x201d; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose significantly more information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#x2019;s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is adopted. This standard is effective for the Company on January 1, 2020 with early adoption permitted. The Company is in the initial stage of evaluating the impact of this new standard on its trade and other receivables.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In November 2018, the FASB issued ASU No. 2018-18, &#x201c;Collaboration Arrangements: Clarifying the Interaction between Topic 808 and Topic 606&#x201d; (ASU 2018-18). The issuance of ASU 2014-09 raised questions about the interaction between the guidance on collaborative arrangements and revenue recognition. ASU 2018-18 addresses this uncertainty by (1) clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASU 2014-09 when the collaboration arrangement participant is a customer, (2) adding unit of account guidance to assess whether the collaboration arrangement or a part of the arrangement is with a customer and (3) precluding a company from presenting transactions with collaboration arrangement participants that are not directly related to sales to third parties together with revenue from contracts with customers. The new standard will be effective for the Company on January 1, 2020 with early adoption permitted. The Company is in the initial stage of evaluating the impact of this new standard on its condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;In May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably elect the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met, the election must be applied on an instrument-by-instrument basis, and the election is not available for either available-for-sale or held-to-maturity debt securities. As Cumberland has not yet adopted ASU 2016-13, the effective dates are the same as those in ASU 2016-13, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;January 1, 2020. The Company is in the initial stage of evaluating the impact of this new standard on its condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In January 2017, the FASB issued ASU No. 2017-04, &#x201c;Simplifying the Test for Goodwill Impairment&#x201d; (ASU 2017-04). The guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation.  As a result of the revised guidance, a goodwill impairment will be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The new standard will be effective for the Company on January 1, 2020 and will be applied prospectively. The Company is in the initial stage of evaluating the impact of this new standard on its condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Accounting Policies:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:7pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns (2) the allowances for obsolescent or unmarketable inventory (3) assumptions used in estimating acquisition date fair value of assets acquired in business combinations and (4) valuation of contingent consideration liability associated with business combinations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Operating Segments&lt;/span&gt;&lt;/div&gt;The Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#x2019;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNC9mcmFnOjEwNzJiODA1MTI3ZjQzMzdiZmMzYmM2NjFiOTVjN2M4L3RleHRyZWdpb246MTA3MmI4MDUxMjdmNDMzN2JmYzNiYzY2MWI5NWM3YzhfODM0MA_156e0cbe-cbe1-41de-a91d-c6b50f76d9a4">&lt;div style="margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recent Accounting Guidance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Recent Adopted Accounting Pronouncement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:7pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In February 2016, the Financial Accounting Standards Board ("FASB") issued guidance in the form of a FASB Accounting Standards Update ("ASU") No. 2016-02, &#x201c;Leases.&#x201d; The new standard establishes a right-of-use (&#x201c;ROU&#x201d;) model that requires a lessee to record an ROU asset and a lease liability on the balance sheet for all leases with terms longer than twelve months. Leases will be classified as either finance (formerly "capital leases") or operating, with classification affecting the pattern of expense recognition in the income statement. The standard provides for a modified retrospective transition approach for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain optional practical expedients.  In July 2018, the FASB issued ASU 2018-11, "Leases: Targeted Improvements", allowing for an alternative transition method (the effective date approach). It allows an entity to initially apply the new lease guidance at the adoption date (rather than at the beginning of the earliest period presented). Cumberland adopted the lease guidance effective January 1, 2019 using the package of transition practical expedients.  This allowed the Company to retain the lease classification for any leases existing prior to adoption, in addition to other benefits. See additional discussion of the impact of adopting the lease accounting guidance in Note 6.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Recent Accounting Pronouncements - Not Yet Adopted &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &#x201c;Financial Instruments-Credit Losses,&#x201d; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#x201c;expected loss&#x201d; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose significantly more information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#x2019;s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is adopted. This standard is effective for the Company on January 1, 2020 with early adoption permitted. The Company is in the initial stage of evaluating the impact of this new standard on its trade and other receivables.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In November 2018, the FASB issued ASU No. 2018-18, &#x201c;Collaboration Arrangements: Clarifying the Interaction between Topic 808 and Topic 606&#x201d; (ASU 2018-18). The issuance of ASU 2014-09 raised questions about the interaction between the guidance on collaborative arrangements and revenue recognition. ASU 2018-18 addresses this uncertainty by (1) clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASU 2014-09 when the collaboration arrangement participant is a customer, (2) adding unit of account guidance to assess whether the collaboration arrangement or a part of the arrangement is with a customer and (3) precluding a company from presenting transactions with collaboration arrangement participants that are not directly related to sales to third parties together with revenue from contracts with customers. The new standard will be effective for the Company on January 1, 2020 with early adoption permitted. The Company is in the initial stage of evaluating the impact of this new standard on its condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;In May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably elect the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met, the election must be applied on an instrument-by-instrument basis, and the election is not available for either available-for-sale or held-to-maturity debt securities. As Cumberland has not yet adopted ASU 2016-13, the effective dates are the same as those in ASU 2016-13, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;January 1, 2020. The Company is in the initial stage of evaluating the impact of this new standard on its condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In January 2017, the FASB issued ASU No. 2017-04, &#x201c;Simplifying the Test for Goodwill Impairment&#x201d; (ASU 2017-04). The guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation.  As a result of the revised guidance, a goodwill impairment will be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The new standard will be effective for the Company on January 1, 2020 and will be applied prospectively. The Company is in the initial stage of evaluating the impact of this new standard on its condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNC9mcmFnOjEwNzJiODA1MTI3ZjQzMzdiZmMzYmM2NjFiOTVjN2M4L3RleHRyZWdpb246MTA3MmI4MDUxMjdmNDMzN2JmYzNiYzY2MWI5NWM3YzhfODMzMw_04d5100b-e5cb-40ef-9641-32df150a1c95">&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:7pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns (2) the allowances for obsolescent or unmarketable inventory (3) assumptions used in estimating acquisition date fair value of assets acquired in business combinations and (4) valuation of contingent consideration liability associated with business combinations.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNC9mcmFnOjEwNzJiODA1MTI3ZjQzMzdiZmMzYmM2NjFiOTVjN2M4L3RleHRyZWdpb246MTA3MmI4MDUxMjdmNDMzN2JmYzNiYzY2MWI5NWM3YzhfODMzNQ_19082bea-29a2-4b20-adf1-d642e2041013">Operating SegmentsThe Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#x2019;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNC9mcmFnOjEwNzJiODA1MTI3ZjQzMzdiZmMzYmM2NjFiOTVjN2M4L3RleHRyZWdpb246MTA3MmI4MDUxMjdmNDMzN2JmYzNiYzY2MWI5NWM3YzhfNzUzMA_0d9804b3-9c19-43e9-b805-319738051748"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RleHRyZWdpb246Mzk5Mjk5Mjc5NDYyNGU3YzlhNDFiNmJhN2Q5NWRiNjFfMzM4Nw_a0e5e37d-7f86-4ce4-8cef-ce1748818a68">MARKETABLE SECURITIES&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company invests in marketable debt securities in order to maximize its return on cash. Marketable securities consist of short-term cash investments, U.S. Treasury notes and bonds,  corporate bonds and commercial paper.  At the time of purchase, the Company classifies marketable securities as either trading securities or available-for-sale securities, depending on the intent at that time.  As of June 30, 2019 and December&#160;31, 2018, marketable securities were comprised solely of trading securities.  Trading securities are carried at fair value with unrealized gains and losses recognized as a component of interest income in the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company's fair value measurements follow the appropriate rules as well as the fair value hierarchy that prioritizes the information used to develop the measurements.  It applies whenever other guidance requires (or permits) assets or liabilities to be measured at fair value and gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;A summary of the fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels is described below:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-45pt;padding-left:81pt;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 1 -   Quoted prices for identical instruments in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-45pt;padding-left:81pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 2 -   Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-45pt;padding-left:81pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 3 -   Significant inputs to the valuation model are unobservable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company's fair values of marketable securities are determined based on valuations provided by a third-party pricing service, as derived from such service's pricing models, and are considered either Level 1 or Level 2 measurements, depending on the nature of the investment.  The Company has no marketable securities in which the fair value is determined based on Level 3 measurements.  The level of management judgment required in evaluating fair value for Level 1 investments is minimal.  Similarly, there is little subjectivity or judgment required for Level 2 investments valued using valuation models that are standard across the industry and whose parameter inputs are quoted in active markets.  Inputs to the models may include, but are not limited to, reported trades, executable bid and ask prices, broker/dealer quotations, prices or yields of securities with similar characteristics, benchmark curves or information pertaining to the issuer, as well as industry and economic events. Based on the information available, the Company believes that the valuations provided by the third-party pricing service, as derived from such service's pricing models, are representative of prices that would be received to sell the assets at the measurement date (exit prices).  There were no transfers of assets between levels within the fair value hierarchy.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:11pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the fair value of our marketable securities, by level within the fair value hierarchy, as of each period end:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:27.368576%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160059%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160059%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160059%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160059%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160059%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160059%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. Treasury notes and bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,155,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,155,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,034,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,034,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,504,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,504,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,265,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,265,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Short-term cash investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,058,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,058,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;751,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;751,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total fair value of marketable  securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,155,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,323,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,479,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,034,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,255,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,290,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RleHRyZWdpb246Mzk5Mjk5Mjc5NDYyNGU3YzlhNDFiNmJhN2Q5NWRiNjFfMzM4NQ_2a792503-6eb2-477e-96bf-c07090d87eaa">&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the fair value of our marketable securities, by level within the fair value hierarchy, as of each period end:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:27.368576%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160059%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160059%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160059%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160059%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160059%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160059%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. Treasury notes and bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,155,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,155,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,034,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,034,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,504,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,504,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,265,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,265,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Short-term cash investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,058,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,058,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;751,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;751,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total fair value of marketable  securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,155,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,323,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,479,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,034,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,255,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,290,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:TradingSecurities
      contextRef="ic019dd81917f4783874bd24e8143629b_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfMi0xLTEtMS0w_260d9c5a-9c4b-4c37-b5cf-502f73d07683"
      unitRef="usd">5155696</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i5397d60c4bf94ba38de2eefaf434ab55_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfMi0zLTEtMS0w_bd88111b-5edc-4437-bd2c-b60fa3eeab3f"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="idd24a3ddd9ed4cff93e5196a8a035c10_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfMi01LTEtMS0w_b624775d-a78d-4fdf-aa4a-5ea372da186b"
      unitRef="usd">5155696</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="ic7816c3023a04362a69740727a0dd6e9_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfMi03LTEtMS0w_c56f31fd-5d68-4418-ae72-79cf809253a6"
      unitRef="usd">5034955</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i028152dc8c66421282a458a7c0e3da06_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfMi05LTEtMS0w_1fc60e1e-6f41-4a99-bb07-a0be34f3145e"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i8259efcffe104ccab3daeae3ae558f18_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfMi0xMS0xLTEtMA_b89c2348-77b4-434b-86ea-c3e9553fd3a5"
      unitRef="usd">5034955</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="id6339bfa7be7414c90203e8b3decb32f_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfMy0xLTEtMS0w_63354b1d-479e-4558-9614-9c68143ac640"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i74755af90b0c4281990f79ae0cb80fab_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfMy0zLTEtMS0w_3d5a2a6c-431a-42de-af6f-38f289ae1f09"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i766a4625499e44acb284ded61ea081ad_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfMy01LTEtMS0w_1110b0cf-775b-4ab1-811e-57614f531f0c"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i47855873ec2141deb6a6cffeea9a5bb5_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfMy03LTEtMS0w_ccf2c687-6db9-4236-8f0d-42b8713c0718"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="ic748d7f98c564aa2ba93b74292ce51c0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfMy05LTEtMS0w_87fbd62c-dda3-4ae4-bee6-67c2d59e24b0"
      unitRef="usd">2504551</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="ie1ab8d666f804ee78d5b108e427da078_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfMy0xMS0xLTEtMA_b72ee745-2201-41ec-863c-f6856b94f09f"
      unitRef="usd">2504551</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i83a70ec3a6574e21aa0d9467d12afc51_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfNC0zLTEtMS0w_c5935278-ea91-4979-9786-eaf71573cb26"
      unitRef="usd">2265824</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i43b135623a96479ea579b1956e4c6a0b_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfNC01LTEtMS0w_8747ffc1-1b14-4525-92cf-ba52d5a03184"
      unitRef="usd">2265824</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i1494544e74bc4c1a9fcca142b7cf104f_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfNC03LTEtMS0w_4da7f795-10b9-4be7-bd3b-25900721a1ee"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i77a66b694d774bcf85ff772a27ee7736_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfNC05LTEtMS0w_4414f542-3e4e-48d7-9b6b-6b6e0ea66928"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i07ba47fdb1fd4a0aa68832470d83b72c_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfNC0xMS0xLTEtMA_7cd259ac-cff5-4735-bb57-99425d14268f"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="ie26e2ca1b03b4f848952f34a6f12fe2d_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfNS0xLTEtMS0w_abe1412e-64bc-4214-b2de-537db28219c3"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i666181952a8f4f1f9d14d2034e887833_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfNS0zLTEtMS0w_9a44295e-967d-4b21-8a02-bab11d2f3e15"
      unitRef="usd">2058166</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i8bd2419e0e6145b5b2690fdf708d4661_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfNS01LTEtMS0w_4d7ab56b-725c-457f-9a69-a1a7d100ef92"
      unitRef="usd">2058166</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i3d842da52c554dfe889a17eb09da349c_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfNS03LTEtMS0w_7d8bced4-7b98-4682-93fb-f6ce7f9808bb"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="ibf1ce67d14544c34852c969eba3ab613_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfNS05LTEtMS0w_2b635e76-dd65-4500-b365-fc408da3acb5"
      unitRef="usd">751173</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i6dd35f38e91e4cad82cac63ffaf3bc06_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfNS0xMS0xLTEtMA_7752e5c8-ddd3-4d24-baae-485ba79676b8"
      unitRef="usd">751173</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i44c95989d56940448855dceadabf3ab2_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfNi0xLTEtMS0w_0872d7c2-2e24-4cbf-9d21-f3e6b7356561"
      unitRef="usd">5155696</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i2ac200ae04284253b7355e519011ebb7_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfNi0zLTEtMS0w_2ff84cb4-fc2f-4a5f-9f00-e6b130f9a2b5"
      unitRef="usd">4323990</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfNi01LTEtMS0w_46b65590-1b76-4462-9cab-e58009762283"
      unitRef="usd">9479686</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="if9fe1490366c4bb1a705a3377e185ae5_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfNi03LTEtMS0w_85d8d416-d140-4a8e-b686-842774fb0557"
      unitRef="usd">5034955</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="icf31cf850409470eb07e4575e50d16c6_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfNi05LTEtMS0w_fc7de41b-c9ab-4531-beec-17342798011e"
      unitRef="usd">3255724</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N18zNy9mcmFnOjM5OTI5OTI3OTQ2MjRlN2M5YTQxYjZiYTdkOTVkYjYxL3RhYmxlOjdjN2Q0NmE5YjRhNDRhMDc4ZDU2MDE0ZDlmOGVlYzc3L3RhYmxlcmFuZ2U6N2M3ZDQ2YTliNGE0NGEwNzhkNTYwMTRkOWY4ZWVjNzdfNi0xMS0xLTEtMA_e8f17900-037a-4644-9661-4aff1978268d"
      unitRef="usd">8290679</us-gaap:TradingSecurities>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180MC9mcmFnOjRjYjg3MTk1ZTMwODQ3MDE4MzliNGM0MGY1YmQyYTQ2L3RleHRyZWdpb246NGNiODcxOTVlMzA4NDcwMTgzOWI0YzQwZjViZDJhNDZfNDI3_295b4d52-0fc9-4d29-9f74-1bb359cc537e">EARNINGS (LOSS) PER SHARE&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three and six months ended June 30, 2019 and 2018:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.122807%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:58.029499%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.616519%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.537463%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.616519%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net income (loss) attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(549,507)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(720,688)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-average shares outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,523,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,674,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Dilutive effect of other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-average shares outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,523,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,674,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:11pt;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:57.210526%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.883041%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.823392%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.883041%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net income (loss) attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(623,385)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,099,927)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-average shares outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,497,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,682,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Dilutive effect of other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-average shares outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,497,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,682,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:11pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;As of June 30, 2019 and 2018, restricted stock awards and options to purchase 13,500 and 231,905 shares of common stock, respectively, were outstanding but were not included in the computation of diluted earnings per share because the effect would be antidilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180MC9mcmFnOjRjYjg3MTk1ZTMwODQ3MDE4MzliNGM0MGY1YmQyYTQ2L3RleHRyZWdpb246NGNiODcxOTVlMzA4NDcwMTgzOWI0YzQwZjViZDJhNDZfNjA0NzMxMzk1MzIxMg_5a2f6bf0-b05b-48b8-920d-27877de5448c">&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three and six months ended June 30, 2019 and 2018:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.122807%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:58.029499%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.616519%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.537463%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.616519%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net income (loss) attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(549,507)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(720,688)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-average shares outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,523,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,674,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Dilutive effect of other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-average shares outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,523,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,674,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:57.210526%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.883041%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.823392%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.883041%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net income (loss) attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(623,385)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,099,927)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-average shares outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,497,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,682,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Dilutive effect of other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-average shares outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,497,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,682,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180MC9mcmFnOjRjYjg3MTk1ZTMwODQ3MDE4MzliNGM0MGY1YmQyYTQ2L3RhYmxlOmRiNGIyNTZkOWE0NjQyYTJhZTA4MGRkM2E0YzE3MjY5L3RhYmxlcmFuZ2U6ZGI0YjI1NmQ5YTQ2NDJhMmFlMDgwZGQzYTRjMTcyNjlfMy0xLTEtMS0w_add4c9d4-19fe-42c3-b3e0-8fb5897199ec"
      unitRef="usd">-549507</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180MC9mcmFnOjRjYjg3MTk1ZTMwODQ3MDE4MzliNGM0MGY1YmQyYTQ2L3RhYmxlOmRiNGIyNTZkOWE0NjQyYTJhZTA4MGRkM2E0YzE3MjY5L3RhYmxlcmFuZ2U6ZGI0YjI1NmQ5YTQ2NDJhMmFlMDgwZGQzYTRjMTcyNjlfMy0zLTEtMS0w_c8e813db-72ab-4215-9b40-2d664e7a66df"
      unitRef="usd">-720688</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180MC9mcmFnOjRjYjg3MTk1ZTMwODQ3MDE4MzliNGM0MGY1YmQyYTQ2L3RhYmxlOmRiNGIyNTZkOWE0NjQyYTJhZTA4MGRkM2E0YzE3MjY5L3RhYmxlcmFuZ2U6ZGI0YjI1NmQ5YTQ2NDJhMmFlMDgwZGQzYTRjMTcyNjlfNS0xLTEtMS0w_d9b5111c-2bc0-4cbc-83fe-7896ce172251"
      unitRef="shares">15523628</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180MC9mcmFnOjRjYjg3MTk1ZTMwODQ3MDE4MzliNGM0MGY1YmQyYTQ2L3RhYmxlOmRiNGIyNTZkOWE0NjQyYTJhZTA4MGRkM2E0YzE3MjY5L3RhYmxlcmFuZ2U6ZGI0YjI1NmQ5YTQ2NDJhMmFlMDgwZGQzYTRjMTcyNjlfNS0zLTEtMS0w_0fa9d9a4-68ad-4f79-8778-76e667214916"
      unitRef="shares">15674954</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180MC9mcmFnOjRjYjg3MTk1ZTMwODQ3MDE4MzliNGM0MGY1YmQyYTQ2L3RhYmxlOmRiNGIyNTZkOWE0NjQyYTJhZTA4MGRkM2E0YzE3MjY5L3RhYmxlcmFuZ2U6ZGI0YjI1NmQ5YTQ2NDJhMmFlMDgwZGQzYTRjMTcyNjlfNi0xLTEtMS0w_f9ffb428-f991-4927-b231-6349a668236f"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180MC9mcmFnOjRjYjg3MTk1ZTMwODQ3MDE4MzliNGM0MGY1YmQyYTQ2L3RhYmxlOmRiNGIyNTZkOWE0NjQyYTJhZTA4MGRkM2E0YzE3MjY5L3RhYmxlcmFuZ2U6ZGI0YjI1NmQ5YTQ2NDJhMmFlMDgwZGQzYTRjMTcyNjlfNi0zLTEtMS0w_1561ba71-2573-4c80-b652-cdea4430555b"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180MC9mcmFnOjRjYjg3MTk1ZTMwODQ3MDE4MzliNGM0MGY1YmQyYTQ2L3RhYmxlOmRiNGIyNTZkOWE0NjQyYTJhZTA4MGRkM2E0YzE3MjY5L3RhYmxlcmFuZ2U6ZGI0YjI1NmQ5YTQ2NDJhMmFlMDgwZGQzYTRjMTcyNjlfNy0xLTEtMS0w_9b5d89ae-79ec-4590-be3a-bd33239874e7"
      unitRef="shares">15523628</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180MC9mcmFnOjRjYjg3MTk1ZTMwODQ3MDE4MzliNGM0MGY1YmQyYTQ2L3RhYmxlOmRiNGIyNTZkOWE0NjQyYTJhZTA4MGRkM2E0YzE3MjY5L3RhYmxlcmFuZ2U6ZGI0YjI1NmQ5YTQ2NDJhMmFlMDgwZGQzYTRjMTcyNjlfNy0zLTEtMS0w_d639cf17-4b62-4725-aacf-50b09be64284"
      unitRef="shares">15674954</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180MC9mcmFnOjRjYjg3MTk1ZTMwODQ3MDE4MzliNGM0MGY1YmQyYTQ2L3RhYmxlOjYxOThhZGMzZDdkNjQzYzJhMWNjNGQzOTFjZTg0N2NiL3RhYmxlcmFuZ2U6NjE5OGFkYzNkN2Q2NDNjMmExY2M0ZDM5MWNlODQ3Y2JfMy0xLTEtMS0xNzY5_4a97237f-ebc4-49d9-9f6b-2181df84041a"
      unitRef="usd">-623385</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180MC9mcmFnOjRjYjg3MTk1ZTMwODQ3MDE4MzliNGM0MGY1YmQyYTQ2L3RhYmxlOjYxOThhZGMzZDdkNjQzYzJhMWNjNGQzOTFjZTg0N2NiL3RhYmxlcmFuZ2U6NjE5OGFkYzNkN2Q2NDNjMmExY2M0ZDM5MWNlODQ3Y2JfMy0zLTEtMS0xNzcx_ec10c811-3464-4156-bfca-a0c11e6df31d"
      unitRef="usd">-3099927</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180MC9mcmFnOjRjYjg3MTk1ZTMwODQ3MDE4MzliNGM0MGY1YmQyYTQ2L3RhYmxlOjYxOThhZGMzZDdkNjQzYzJhMWNjNGQzOTFjZTg0N2NiL3RhYmxlcmFuZ2U6NjE5OGFkYzNkN2Q2NDNjMmExY2M0ZDM5MWNlODQ3Y2JfNS0xLTEtMS0xODcx_9c8e3451-9ed6-4d22-9dc5-099938b01a48"
      unitRef="shares">15497989</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180MC9mcmFnOjRjYjg3MTk1ZTMwODQ3MDE4MzliNGM0MGY1YmQyYTQ2L3RhYmxlOjYxOThhZGMzZDdkNjQzYzJhMWNjNGQzOTFjZTg0N2NiL3RhYmxlcmFuZ2U6NjE5OGFkYzNkN2Q2NDNjMmExY2M0ZDM5MWNlODQ3Y2JfNS0zLTEtMS0xODc1_635a4480-003e-466b-bc7e-9be7fbb0e4e8"
      unitRef="shares">15682348</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180MC9mcmFnOjRjYjg3MTk1ZTMwODQ3MDE4MzliNGM0MGY1YmQyYTQ2L3RhYmxlOjYxOThhZGMzZDdkNjQzYzJhMWNjNGQzOTFjZTg0N2NiL3RhYmxlcmFuZ2U6NjE5OGFkYzNkN2Q2NDNjMmExY2M0ZDM5MWNlODQ3Y2JfNy0xLTEtMS0xODcz_5ab68aa6-f8a6-46df-8d37-a1e03abe2fab"
      unitRef="shares">15497989</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180MC9mcmFnOjRjYjg3MTk1ZTMwODQ3MDE4MzliNGM0MGY1YmQyYTQ2L3RhYmxlOjYxOThhZGMzZDdkNjQzYzJhMWNjNGQzOTFjZTg0N2NiL3RhYmxlcmFuZ2U6NjE5OGFkYzNkN2Q2NDNjMmExY2M0ZDM5MWNlODQ3Y2JfNy0zLTEtMS0xODc3_6d7d3c2a-232d-4e3e-be5e-8a7fb56213dc"
      unitRef="shares">15682348</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180MC9mcmFnOjRjYjg3MTk1ZTMwODQ3MDE4MzliNGM0MGY1YmQyYTQ2L3RleHRyZWdpb246NGNiODcxOTVlMzA4NDcwMTgzOWI0YzQwZjViZDJhNDZfMjUw_f736066e-ecb3-4817-8ce5-2e0ef64bbd86"
      unitRef="shares">13500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180MC9mcmFnOjRjYjg3MTk1ZTMwODQ3MDE4MzliNGM0MGY1YmQyYTQ2L3RleHRyZWdpb246NGNiODcxOTVlMzA4NDcwMTgzOWI0YzQwZjViZDJhNDZfMjU3_1709cf7f-b8c6-42b0-86ae-a30143205615"
      unitRef="shares">231905</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RleHRyZWdpb246ZGMwOGNjMmI1YzM5NGU1N2FhMGIwM2VkNTlhMzY2OGFfMTY5NQ_78dc5c2c-c2e0-4a1f-a66e-f5975618c76c">REVENUES&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company accounts for revenues from contracts with customers under ASC 606, which became effective January 1, 2018. As part of the adoption of ASC 606, the Company applied the new standard on a modified retrospective basis analyzing open contracts as of January 1, 2018. Results for reporting periods beginning after January 1, 2018 are presented under ASC 606. As discussed in Note 10, during November 2018 Cumberland entered into an agreement to acquire the global responsibility for Vibativ.  The product began contributing to Cumberland's net revenue during 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s net revenues consisted of the following for the three and six months ended June 30, 2019 and 2018:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:27.824561%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.444444%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.823392%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.298246%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.058480%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.888889%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Products:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Acetadote&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;983,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;841,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,832,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,115,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Omeclamox-Pak&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;478,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;89,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;678,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;231,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Kristalose&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,476,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,203,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,785,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,473,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vaprisol&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;212,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,685,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;499,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,779,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Caldolor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,054,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,101,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,372,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,140,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Ethyol&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,008,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,809,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,099,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,065,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Totect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;154,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;269,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;235,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;681,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vibativ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,599,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,659,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;612,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;162,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,320,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;262,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total net revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,580,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,163,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23,483,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,751,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Other Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;During the three months ended June 30, 2019, Cumberland executed a License and Distribution agreement with HongKong WinHealth Pharma Group Co. Limited (&#x201c;WinHealth&#x201d;) for our Caldolor and Acetadote&lt;/span&gt;&lt;sup style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"&gt; &lt;/sup&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;brands in China and Hong Kong.  In conjunction with these new arrangements, the Company terminated a previous License and Distribution agreement with Gloria Pharmaceuticals Co ("Gloria Pharmaceuticals") for the two brands.  In addition, we also signed a new License and Distribution agreement with DB Pharm Korea Co., Ltd. (&#x201c;DB Pharm&#x201d;) for Vibativ in South Korea. As a result of these agreements, Cumberland recognized approximately $0.3&#160;million of non-refundable up-front payments as other revenue in the consolidated statement of operations during the three months ended June 30, 2019.  Cumberland's performance obligation was satisfied upon entering into the agreements to license each of the products intellectual property. &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;CET grant revenue for the three and six months ended June 30, 2019 included in other revenue was $0.2&#160;million  and $0.8&#160;million, respectively. &lt;/span&gt;&lt;/div&gt;The Company has agreements with international partners for commercialization of the Company's products. The international agreements provide that each of the partners are responsible for seeking regulatory approvals for the products, and following approvals, each partner will handle ongoing distribution and sales in the respective international territories. The Company maintains responsibility for the intellectual property and product formulations. Under the international agreements, the Company is typically entitled to receive a non-refundable, up-front payment at the time each agreement is entered into as a result of providing the distinct intellectual property rights for the respective international territory. These agreements also provide for additional payments upon the partners' achievement of defined regulatory approvals, sales milestones or both. The Company may also be entitled to receive royalties on future sales of the products under the agreements and a transfer price on supplies.  The contractual payments associated with the partners achievement of regulatory approvals, sales milestones and royalties on future sales are recognized as revenue upon occurrence, or at such time that the Company has a high degree of confidence that the revenue would not be reversed in a subsequent period.</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RleHRyZWdpb246ZGMwOGNjMmI1YzM5NGU1N2FhMGIwM2VkNTlhMzY2OGFfMTY5Nw_67b4181c-a337-4dfd-bb7a-75dfbd95a8bc">&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s net revenues consisted of the following for the three and six months ended June 30, 2019 and 2018:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:27.824561%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.444444%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.823392%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.298246%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.058480%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.888889%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Products:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Acetadote&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;983,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;841,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,832,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,115,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Omeclamox-Pak&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;478,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;89,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;678,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;231,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Kristalose&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,476,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,203,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,785,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,473,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vaprisol&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;212,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,685,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;499,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,779,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Caldolor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,054,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,101,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,372,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,140,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Ethyol&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,008,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,809,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,099,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,065,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Totect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;154,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;269,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;235,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;681,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vibativ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,599,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,659,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;612,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;162,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,320,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;262,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total net revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,580,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,163,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23,483,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,751,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i509cfd55792547fd9065aab962dd801a_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfMy0xLTEtMS0w_a408ac8d-f023-4305-ae54-8ad8a56bc374"
      unitRef="usd">983473</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id4235e45b96d4113803c1249687d3d50_D20180401-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfMy0zLTEtMS0w_eb2cd48f-20ff-43f7-9697-c48041f86f20"
      unitRef="usd">841431</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i77326b611af749e2afb25a76a3b386d1_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfMy01LTEtMS0w_7139bade-0cc9-4e0d-a28b-0afa169907ea"
      unitRef="usd">1832976</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4751466a08f94bcb8c0ebfec0b01ecfd_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfMy03LTEtMS0w_bc94b556-a674-4211-a998-5b1c2fee785b"
      unitRef="usd">2115741</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i491e5531cbfa47b496005caa8455badb_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfNC0xLTEtMS0w_b5fbbddb-fa23-4ccd-b5c0-83365e932cd3"
      unitRef="usd">478604</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2c520713e19c495f82ed1f2dd92ef634_D20180401-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfNC0zLTEtMS0w_aa68a909-b0ce-4f69-8259-7553a02e9621"
      unitRef="usd">89952</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8396c0f613f441f58ba22039a93eb1c8_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfNC01LTEtMS0w_d3322c21-6139-4282-9022-0b1e1bb70cab"
      unitRef="usd">678141</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia32476d410f440b48f0c3b631a90632f_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfNC03LTEtMS0w_b564c1ab-907f-40a7-be44-2f64425c235e"
      unitRef="usd">231344</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i781c10013fee46d6b029f560be240be7_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfNS0xLTEtMS0w_2bfa6e3c-b12c-433c-81e4-be1508e91d6b"
      unitRef="usd">3476807</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idd51eac788ff4878870c597b6d74c24e_D20180401-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfNS0zLTEtMS0w_50693c57-20ae-424a-bd12-d4ae7ccbcab2"
      unitRef="usd">3203743</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i14a5b5dcc523443dab0df6907169ca3b_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfNS01LTEtMS0w_22d13cc4-291c-482a-bbe3-9dea55dddc6d"
      unitRef="usd">6785050</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idcb718271f734482856f23f2d01609d5_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfNS03LTEtMS0w_93857472-6e0f-410d-a3b0-aab79c0769cc"
      unitRef="usd">6473097</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i73375a6aee6f45c8b2af7cc1cfecddb0_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfNi0xLTEtMS0w_31502195-b3f6-4fe6-970f-abef0dbff244"
      unitRef="usd">212526</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7ad6dbad74074d38ac2d08ebcc3d3518_D20180401-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfNi0zLTEtMS0w_3352e62b-0568-4b95-84b2-eeef9b42c4a7"
      unitRef="usd">1685900</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i53374edc460d4ca6aba30ff2b618e21f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfNi01LTEtMS0w_024566b7-7def-4d4b-8bfc-21ef3ee2fb49"
      unitRef="usd">499202</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i838404f0559b43babedeea791e195f2f_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfNi03LTEtMS0w_a9553978-4f76-40f7-9eca-8ad43131bf9b"
      unitRef="usd">1779790</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i30dca836f3804983b44dbc23d365d55e_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfNy0xLTEtMS0w_3384b760-9cb2-437d-8ce9-f83f995445bc"
      unitRef="usd">1054718</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i70367091d6b44d47b966554d9af79237_D20180401-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfNy0zLTEtMS0w_4f4219c4-b95f-4d86-9740-075166022f47"
      unitRef="usd">1101023</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i588715008b8b450f8b15c09e4bcd9681_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfNy01LTEtMS0w_d93416dd-84f2-4f05-9f13-b2d8d5dd1f14"
      unitRef="usd">2372599</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icc7ca2c1d2ac45b99b06dd4e5cff07df_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfNy03LTEtMS0w_16fd7e42-cfbe-41da-ac70-8d15f56cdb34"
      unitRef="usd">2140771</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2ae15c900cfd4ad6a4de1687287609b2_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfOC0xLTEtMS0w_c6fb3d9c-4bd6-4afe-a194-529a906fff11"
      unitRef="usd">2008247</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic29f620b439f49eeaefd0f5c28509e1c_D20180401-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfOC0zLTEtMS0w_3327a096-90ea-4028-91fa-be2d0b74b311"
      unitRef="usd">2809691</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie85bd361954b4f98bced4efeca36ce9f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfOC01LTEtMS0w_2d61d66b-d10e-4cc9-b83c-2a86ebec8344"
      unitRef="usd">5099429</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i231a37bb2fbf47f5b7eceed5c5e05224_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfOC03LTEtMS0w_e35510f6-24b0-4a9c-81c8-d3ffd24c0754"
      unitRef="usd">5065764</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i868db2e678dd4291af1d258118e04a77_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfOS0xLTEtMS0w_654a8730-3de2-4dba-bee3-11ef2615461d"
      unitRef="usd">154910</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibccd184195764941825e341a41aa4fa5_D20180401-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfOS0zLTEtMS0w_2da864c5-523f-48c0-8a6b-a6f61f895ea5"
      unitRef="usd">269190</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2f03cf3962ed4acf8caf27c28f2427d9_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfOS01LTEtMS0w_3c23d1fe-28e1-43ec-b378-b99046f24c15"
      unitRef="usd">235805</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibb51e348437d4dec85fd92befc0b9624_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfOS03LTEtMS0w_c919cc94-7686-4c1b-b87d-5067e2a8443d"
      unitRef="usd">681964</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic06c5fb3bfd44b16ab85550780690d5f_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfMTAtMS0xLTEtMA_54a6e9f3-24ab-4462-992a-5c60b37fd317"
      unitRef="usd">2599280</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id7367fd73f204d1e8f84cd61df343493_D20180401-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfMTAtMy0xLTEtMA_e7b6d017-9450-4acb-a823-e0ae81bbba8a"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia9ea66098fd04256848a2d79539e4156_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfMTAtNS0xLTEtOTc3_2aceb591-f936-4558-9de6-f1c822ba4e64"
      unitRef="usd">4659471</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i77b145b291264578bbd035e0bf21476c_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfMTAtNy0xLTEtMzkxNg_430d72c6-8cb4-478c-8634-dc63d45a03c2"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if954c9a78bb24172936c43e0061fedae_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfMTEtMS0xLTEtMA_9a79dbd8-c897-439e-9848-04a262cef3af"
      unitRef="usd">612035</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if66b9371f94f461f93cfcc16bb63966b_D20180401-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfMTEtMy0xLTEtMA_86e621a1-c3bc-4e8c-8d9c-d07a0d964656"
      unitRef="usd">162794</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7677c5f4087746ed8da807d078e316b6_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfMTEtNS0xLTEtMA_8dd6a9cf-92c6-42be-9202-568cb7722573"
      unitRef="usd">1320674</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8da9ab9ca7a9436c81b40d1a21447d49_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfMTEtNy0xLTEtMA_a6d5672f-eb2c-4f22-9d76-a053f632a726"
      unitRef="usd">262858</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfMTItMS0xLTEtMA_0e0bc066-ae8e-4f49-abbc-a6ece491154f"
      unitRef="usd">11580600</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i522b6e6bf79f4780984d17ca2d7b0962_D20180401-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfMTItMy0xLTEtMA_94199575-2475-439c-9951-75ae6d6dacae"
      unitRef="usd">10163724</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfMTItNS0xLTEtMA_f5a3fff4-ccc4-4fd1-81d0-dbe695f64d49"
      unitRef="usd">23483347</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RhYmxlOmRiN2Q5MDgxMGMzNDQ5NzhiNjUwZGFhNGY1NWYzZmJkL3RhYmxlcmFuZ2U6ZGI3ZDkwODEwYzM0NDk3OGI2NTBkYWE0ZjU1ZjNmYmRfMTItNy0xLTEtMA_77d29cc4-9750-4453-bab8-f9910fc0d2ef"
      unitRef="usd">18751329</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i40852bb795f343e3a355c9a4dac17887_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RleHRyZWdpb246ZGMwOGNjMmI1YzM5NGU1N2FhMGIwM2VkNTlhMzY2OGFfNzY5NjU4MTQwMDg4Nw_d57e80b4-026a-4f0d-bbd5-b1bfde2b015b"
      unitRef="usd">300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b6f56b360f242dba5580399c147efc2_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RleHRyZWdpb246ZGMwOGNjMmI1YzM5NGU1N2FhMGIwM2VkNTlhMzY2OGFfNzY5NjU4MTQwMDkwMQ_20fc04b4-16fc-46c5-8b96-6cc67ea2e113"
      unitRef="usd">200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i994113efc2f24ab7bbf0e24b5c88051c_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180My9mcmFnOmRjMDhjYzJiNWMzOTRlNTdhYTBiMDNlZDU5YTM2NjhhL3RleHRyZWdpb246ZGMwOGNjMmI1YzM5NGU1N2FhMGIwM2VkNTlhMzY2OGFfNzY5NjU4MTQwMDkxNQ_3cc7ea37-580b-43fc-95a1-bd668ca70fa1"
      unitRef="usd">800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180Ni9mcmFnOmJhZGI2MmVmYTE1YjQ4MWE4ZmY0YWVlY2E4NzRhODhiL3RleHRyZWdpb246YmFkYjYyZWZhMTViNDgxYThmZjRhZWVjYTg3NGE4OGJfMTg5NA_397f0f57-2b6c-4b6b-af3f-74310a47a121">INVENTORIES&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company works closely with third parties to manufacture and package finished goods for sale.  Based on the relationship with the manufacturer or packager, the Company will either take title to the finished goods at the time of shipment or at the time of arrival from the manufacturer.  The Company then warehouses such goods until distribution and sale. Inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company continually evaluates inventory for potential losses due to excess, obsolete or slow-moving inventory by comparing sales history and sales projections to the inventory on hand. When evidence indicates that the carrying value may not be recoverable, a charge is taken to reduce the inventory to its current net realizable value.  At June 30, 2019 and December 31, 2018, the Company has recognized and maintained cumulative charges for potential obsolescence and discontinuance losses of approximately $0.1 million and $0.3 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In connection with the acquisition of certain product rights related to the Kristalose brand, the Company is responsible for the purchase of the active pharmaceutical ingredient (&#x201c;API&#x201d;) for Kristalose and maintains the inventory at the third-party manufacturer. As the API is consumed in production, the value of the API is transferred from raw materials to finished goods. API for the Company's Vaprisol brand is also included in the raw materials inventory total.  Consigned inventory represents Authorized Generic inventory stored until shipment.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;As part of the Vibativ acquisition, Cumberland acquired API and work in process inventories of $14.9 million that are classified as non-current inventories at June 30, 2019 and December 31, 2018. Non-current inventories also include $0.6 million and $0.8 million in Vibativ finished goods at June 30, 2019 and December&#160;31, 2018, respectively.  During 2019, Cumberland also obtained $0.3&#160;million in non-current inventory for API related to its ifetroban clinical initiatives.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company's net inventories consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:7pt;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:56.737151%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.121586%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.530103%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.681057%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.530103%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Raw materials and work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,076,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,378,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Consigned inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;774,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;937,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finished goods, net of reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,639,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,511,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:13pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26,489,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27,827,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:13pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;less non-current inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(15,840,962)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(15,749,000)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total inventories classified as current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,648,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,078,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:InventoryValuationReserves
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180Ni9mcmFnOmJhZGI2MmVmYTE1YjQ4MWE4ZmY0YWVlY2E4NzRhODhiL3RleHRyZWdpb246YmFkYjYyZWZhMTViNDgxYThmZjRhZWVjYTg3NGE4OGJfOTky_a6bf1991-bc51-4e32-84a4-c898806c2294"
      unitRef="usd">100000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180Ni9mcmFnOmJhZGI2MmVmYTE1YjQ4MWE4ZmY0YWVlY2E4NzRhODhiL3RleHRyZWdpb246YmFkYjYyZWZhMTViNDgxYThmZjRhZWVjYTg3NGE4OGJfMTAwMA_c1381d16-fcfa-4376-b16d-a7292a196162"
      unitRef="usd">300000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i674a647fde3f44be85e9cae6e936a816_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180Ni9mcmFnOmJhZGI2MmVmYTE1YjQ4MWE4ZmY0YWVlY2E4NzRhODhiL3RleHRyZWdpb246YmFkYjYyZWZhMTViNDgxYThmZjRhZWVjYTg3NGE4OGJfMTY2Ng_0e75540c-42d9-4054-834a-52ceb81f4b04"
      unitRef="usd">14900000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i5332b0b2238e4d09b5c7a0b66e8b457a_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180Ni9mcmFnOmJhZGI2MmVmYTE1YjQ4MWE4ZmY0YWVlY2E4NzRhODhiL3RleHRyZWdpb246YmFkYjYyZWZhMTViNDgxYThmZjRhZWVjYTg3NGE4OGJfMTY2Ng_b1dcccf4-3a9f-4216-b1c2-e1c9ec9d5e0d"
      unitRef="usd">14900000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i5332b0b2238e4d09b5c7a0b66e8b457a_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180Ni9mcmFnOmJhZGI2MmVmYTE1YjQ4MWE4ZmY0YWVlY2E4NzRhODhiL3RleHRyZWdpb246YmFkYjYyZWZhMTViNDgxYThmZjRhZWVjYTg3NGE4OGJfMTc2Nw_3c89045d-ec42-4fa9-ae0d-e3d439d8a6ea"
      unitRef="usd">600000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i674a647fde3f44be85e9cae6e936a816_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180Ni9mcmFnOmJhZGI2MmVmYTE1YjQ4MWE4ZmY0YWVlY2E4NzRhODhiL3RleHRyZWdpb246YmFkYjYyZWZhMTViNDgxYThmZjRhZWVjYTg3NGE4OGJfMTc3NA_3a763226-c581-4bdb-813e-b7fc0b7b1f3e"
      unitRef="usd">800000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="i5332b0b2238e4d09b5c7a0b66e8b457a_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180Ni9mcmFnOmJhZGI2MmVmYTE1YjQ4MWE4ZmY0YWVlY2E4NzRhODhiL3RleHRyZWdpb246YmFkYjYyZWZhMTViNDgxYThmZjRhZWVjYTg3NGE4OGJfODI0NjMzNzIxMDQ3OA_6f9bfa2c-cb32-49d2-aa04-d5546c62bc10"
      unitRef="usd">300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180Ni9mcmFnOmJhZGI2MmVmYTE1YjQ4MWE4ZmY0YWVlY2E4NzRhODhiL3RleHRyZWdpb246YmFkYjYyZWZhMTViNDgxYThmZjRhZWVjYTg3NGE4OGJfMTg5Mw_967f9516-dd5d-43e0-a5cc-635cdf28ce8d">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company's net inventories consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:7pt;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:56.737151%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.121586%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.530103%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.681057%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.530103%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Raw materials and work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,076,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,378,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Consigned inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;774,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;937,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finished goods, net of reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,639,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,511,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:13pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26,489,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27,827,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:13pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;less non-current inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(15,840,962)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(15,749,000)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total inventories classified as current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,648,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,078,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180Ni9mcmFnOmJhZGI2MmVmYTE1YjQ4MWE4ZmY0YWVlY2E4NzRhODhiL3RhYmxlOjc2MWUyNGZlMzA2YjQ3ZjFhODg0YzhkM2Q2OTJhNmRlL3RhYmxlcmFuZ2U6NzYxZTI0ZmUzMDZiNDdmMWE4ODRjOGQzZDY5MmE2ZGVfMi0yLTEtMS0w_970fbddb-d0dc-4977-b0d9-f0033e859a9f"
      unitRef="usd">19076378</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180Ni9mcmFnOmJhZGI2MmVmYTE1YjQ4MWE4ZmY0YWVlY2E4NzRhODhiL3RhYmxlOjc2MWUyNGZlMzA2YjQ3ZjFhODg0YzhkM2Q2OTJhNmRlL3RhYmxlcmFuZ2U6NzYxZTI0ZmUzMDZiNDdmMWE4ODRjOGQzZDY5MmE2ZGVfMi00LTEtMS0w_73b4066b-db9e-447d-8ad2-e2bc1473dc7a"
      unitRef="usd">18378450</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180Ni9mcmFnOmJhZGI2MmVmYTE1YjQ4MWE4ZmY0YWVlY2E4NzRhODhiL3RhYmxlOjc2MWUyNGZlMzA2YjQ3ZjFhODg0YzhkM2Q2OTJhNmRlL3RhYmxlcmFuZ2U6NzYxZTI0ZmUzMDZiNDdmMWE4ODRjOGQzZDY5MmE2ZGVfMy0yLTEtMS0w_47d4b109-b85d-4b67-9d9e-6a787e4f791c"
      unitRef="usd">774225</us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment>
    <us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
      contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180Ni9mcmFnOmJhZGI2MmVmYTE1YjQ4MWE4ZmY0YWVlY2E4NzRhODhiL3RhYmxlOjc2MWUyNGZlMzA2YjQ3ZjFhODg0YzhkM2Q2OTJhNmRlL3RhYmxlcmFuZ2U6NzYxZTI0ZmUzMDZiNDdmMWE4ODRjOGQzZDY5MmE2ZGVfMy00LTEtMS0w_0e9a0672-5e2b-4e78-a3c3-198ebb09b241"
      unitRef="usd">937006</us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180Ni9mcmFnOmJhZGI2MmVmYTE1YjQ4MWE4ZmY0YWVlY2E4NzRhODhiL3RhYmxlOjc2MWUyNGZlMzA2YjQ3ZjFhODg0YzhkM2Q2OTJhNmRlL3RhYmxlcmFuZ2U6NzYxZTI0ZmUzMDZiNDdmMWE4ODRjOGQzZDY5MmE2ZGVfNC0yLTEtMS0w_9ec1ed49-1a26-41f7-a7fe-fd7932678ccd"
      unitRef="usd">6639218</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180Ni9mcmFnOmJhZGI2MmVmYTE1YjQ4MWE4ZmY0YWVlY2E4NzRhODhiL3RhYmxlOjc2MWUyNGZlMzA2YjQ3ZjFhODg0YzhkM2Q2OTJhNmRlL3RhYmxlcmFuZ2U6NzYxZTI0ZmUzMDZiNDdmMWE4ODRjOGQzZDY5MmE2ZGVfNC00LTEtMS0w_d15f52e3-ccd9-4578-a94b-538717d92983"
      unitRef="usd">8511887</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryGross
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180Ni9mcmFnOmJhZGI2MmVmYTE1YjQ4MWE4ZmY0YWVlY2E4NzRhODhiL3RhYmxlOjc2MWUyNGZlMzA2YjQ3ZjFhODg0YzhkM2Q2OTJhNmRlL3RhYmxlcmFuZ2U6NzYxZTI0ZmUzMDZiNDdmMWE4ODRjOGQzZDY5MmE2ZGVfNS0yLTEtMS0w_c705a2a1-ca55-4f21-ba38-bb1f36668dc9"
      unitRef="usd">26489821</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180Ni9mcmFnOmJhZGI2MmVmYTE1YjQ4MWE4ZmY0YWVlY2E4NzRhODhiL3RhYmxlOjc2MWUyNGZlMzA2YjQ3ZjFhODg0YzhkM2Q2OTJhNmRlL3RhYmxlcmFuZ2U6NzYxZTI0ZmUzMDZiNDdmMWE4ODRjOGQzZDY5MmE2ZGVfNS00LTEtMS0w_56b0af4a-75ba-4a35-874c-93436fb6c6b6"
      unitRef="usd">27827343</us-gaap:InventoryGross>
    <us-gaap:InventoryNoncurrent
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180Ni9mcmFnOmJhZGI2MmVmYTE1YjQ4MWE4ZmY0YWVlY2E4NzRhODhiL3RhYmxlOjc2MWUyNGZlMzA2YjQ3ZjFhODg0YzhkM2Q2OTJhNmRlL3RhYmxlcmFuZ2U6NzYxZTI0ZmUzMDZiNDdmMWE4ODRjOGQzZDY5MmE2ZGVfNi0yLTEtMS0w_1f0f421d-6475-4c70-b463-69ef32df6b23"
      unitRef="usd">15840962</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180Ni9mcmFnOmJhZGI2MmVmYTE1YjQ4MWE4ZmY0YWVlY2E4NzRhODhiL3RhYmxlOjc2MWUyNGZlMzA2YjQ3ZjFhODg0YzhkM2Q2OTJhNmRlL3RhYmxlcmFuZ2U6NzYxZTI0ZmUzMDZiNDdmMWE4ODRjOGQzZDY5MmE2ZGVfNi00LTEtMS0w_22e59bd1-bc11-470f-96a3-f4f71768b36c"
      unitRef="usd">15749000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNet
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180Ni9mcmFnOmJhZGI2MmVmYTE1YjQ4MWE4ZmY0YWVlY2E4NzRhODhiL3RhYmxlOjc2MWUyNGZlMzA2YjQ3ZjFhODg0YzhkM2Q2OTJhNmRlL3RhYmxlcmFuZ2U6NzYxZTI0ZmUzMDZiNDdmMWE4ODRjOGQzZDY5MmE2ZGVfNy0yLTEtMS0w_7d377025-9bf9-426a-b2c6-1fa26ed6c625"
      unitRef="usd">10648859</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i0d8f4802d39d424297c0f861bec1a0b2_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N180Ni9mcmFnOmJhZGI2MmVmYTE1YjQ4MWE4ZmY0YWVlY2E4NzRhODhiL3RhYmxlOjc2MWUyNGZlMzA2YjQ3ZjFhODg0YzhkM2Q2OTJhNmRlL3RhYmxlcmFuZ2U6NzYxZTI0ZmUzMDZiNDdmMWE4ODRjOGQzZDY5MmE2ZGVfNy00LTEtMS0w_41814051-7890-4e85-83cf-4bdf8d33a9b4"
      unitRef="usd">12078343</us-gaap:InventoryNet>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181Mi9mcmFnOmQ0NDRlYTE0ZTk3OTRlNTI5NDIzZTZjNDBkNmExNDQ1L3RleHRyZWdpb246ZDQ0NGVhMTRlOTc5NGU1Mjk0MjNlNmM0MGQ2YTE0NDVfMzA5NA_ce4f1edc-7417-4df6-9d1d-5f24f896f432">LEASESIn March 2016, the FASB issued ASU 2016-02. ASU 2016-02&#x2019;s core principle is to increase transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information. The Company adopted ASU 2016-02 under the alternative transition method (the effective date approach). It allowed the Company to initially apply the new lease guidance at the adoption date (rather than at the beginning of the earliest period presented). Prior periods have not been adjusted.   &lt;div style="text-align:justify;margin-top:7pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The primary effect of adopting ASU 2016-02 to the Company was to record right-of-use assets and obligations for the leases currently classified as operating leases.  The Company&#x2019;s significant operating leases include the lease of approximately 25,500 square feet of office space in Nashville, Tennessee for its corporate headquarters.  This lease currently expires in October 2022.  The operating leases also include the lease of approximately 14,200 square feet of wet laboratory and office space in Nashville, Tennessee by Cumberland Emerging Technologies (&#x201c;CET&#x201d;), our majority-owned subsidiary, where it operates the CET Life Sciences Center.  This lease currently expires in April 2023. The Company did not have any leases classified as finance leases at January 1, 2019 or June 30, 2019.  The new lease accounting standard did not have a significant impact on the Company's Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) for any period presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company elected the package of practical expedients offered in the transition guidance which allows management not to reassess lease identification, lease classification and initial direct costs at the adoption date. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:7pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;These operating leases resulted in initial ROU assets of $3.6 million and lease liabilities of $3.8 million as of January 1, 2019 for non-cancelable operating leases with original lease terms in excess of one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Operating lease liabilities were recorded as the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for lease incentives and initial direct costs. As the Company&#x2019;s leases do not contain implicit borrowing rates, the incremental borrowing rates were calculated based on information available at January 1, 2019. Incremental borrowing rates reflect the Company&#x2019;s estimated interest rates for collateralized borrowings over similar lease terms. The weighted-average remaining lease term is 3.5 years and the weighted-average incremental borrowing rate used to discount the present value of the remaining lease payments is 7.42%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Lease Position&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;At June 30, 2019, the Company recorded the following on the Condensed Consolidated Balance Sheet: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.368421%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:34.036036%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.751952%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:38.090090%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.751952%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.969970%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Right-of-Use Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,260,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:7pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,260,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.368421%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:34.036036%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.751952%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:38.090090%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.751952%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.969970%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:7pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other current liabilities&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;899,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Noncurrent:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:7pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,502,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,402,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.368421%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:76.078078%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.751952%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.969970%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Maturity of Leases Liabilities at June 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;532,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,120,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,144,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,019,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;92,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;After 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,909,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(507,098)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,402,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i24c5c7f1311c41b0adf7f2ad2954b3dc_I20190101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181Mi9mcmFnOmQ0NDRlYTE0ZTk3OTRlNTI5NDIzZTZjNDBkNmExNDQ1L3RleHRyZWdpb246ZDQ0NGVhMTRlOTc5NGU1Mjk0MjNlNmM0MGQ2YTE0NDVfMTgxMw_22760e33-7604-4112-88d9-e1cc08f16397"
      unitRef="usd">3600000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="i24c5c7f1311c41b0adf7f2ad2954b3dc_I20190101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181Mi9mcmFnOmQ0NDRlYTE0ZTk3OTRlNTI5NDIzZTZjNDBkNmExNDQ1L3RleHRyZWdpb246ZDQ0NGVhMTRlOTc5NGU1Mjk0MjNlNmM0MGQ2YTE0NDVfMTg0OQ_b7e1cbf9-6437-49b1-acbc-69691305a07b"
      unitRef="usd">3800000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181Mi9mcmFnOmQ0NDRlYTE0ZTk3OTRlNTI5NDIzZTZjNDBkNmExNDQ1L3RleHRyZWdpb246ZDQ0NGVhMTRlOTc5NGU1Mjk0MjNlNmM0MGQ2YTE0NDVfMjYzNg_ab04f4bf-94e0-41c2-b456-97559a2b4c17">P3Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181Mi9mcmFnOmQ0NDRlYTE0ZTk3OTRlNTI5NDIzZTZjNDBkNmExNDQ1L3RleHRyZWdpb246ZDQ0NGVhMTRlOTc5NGU1Mjk0MjNlNmM0MGQ2YTE0NDVfMjc2Nw_126d9e1c-1942-40e8-a1b9-7030fd3cab90"
      unitRef="number">0.0742</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <cpix:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181Mi9mcmFnOmQ0NDRlYTE0ZTk3OTRlNTI5NDIzZTZjNDBkNmExNDQ1L3RleHRyZWdpb246ZDQ0NGVhMTRlOTc5NGU1Mjk0MjNlNmM0MGQ2YTE0NDVfMzA5NQ_8ea1b418-ab89-4f8e-b118-759448a26702">&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;At June 30, 2019, the Company recorded the following on the Condensed Consolidated Balance Sheet: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.368421%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:34.036036%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.751952%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:38.090090%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.751952%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.969970%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Right-of-Use Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,260,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:7pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,260,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.368421%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:34.036036%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.751952%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:38.090090%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.751952%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.969970%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:7pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other current liabilities&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;899,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Noncurrent:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:7pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,502,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,402,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</cpix:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181Mi9mcmFnOmQ0NDRlYTE0ZTk3OTRlNTI5NDIzZTZjNDBkNmExNDQ1L3RhYmxlOjYxZDU4NzIyYzI2MzRmMDJhMzcwYzlhNWJjZjlmMmNhL3RhYmxlcmFuZ2U6NjFkNTg3MjJjMjYzNGYwMmEzNzBjOWE1YmNmOWYyY2FfMS00LTEtMS0w_2ff43882-a1d9-4c5a-b66d-44b4049fe444"
      unitRef="usd">3260767</us-gaap:OperatingLeaseRightOfUseAsset>
    <cpix:LeaseAsset
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181Mi9mcmFnOmQ0NDRlYTE0ZTk3OTRlNTI5NDIzZTZjNDBkNmExNDQ1L3RhYmxlOjYxZDU4NzIyYzI2MzRmMDJhMzcwYzlhNWJjZjlmMmNhL3RhYmxlcmFuZ2U6NjFkNTg3MjJjMjYzNGYwMmEzNzBjOWE1YmNmOWYyY2FfMi00LTEtMS0w_55eb81c8-9ae1-45ca-93ea-41719aae9cb7"
      unitRef="usd">3260767</cpix:LeaseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181Mi9mcmFnOmQ0NDRlYTE0ZTk3OTRlNTI5NDIzZTZjNDBkNmExNDQ1L3RhYmxlOmI4MmQzMTM5MGI2ZTQ2ZWJiMzNkZDMxYzdiNzFiMDMyL3RhYmxlcmFuZ2U6YjgyZDMxMzkwYjZlNDZlYmIzM2RkMzFjN2I3MWIwMzJfMi00LTEtMS0w_5a8a475b-c45c-4925-8879-ce0f8037c947"
      unitRef="usd">899262</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181Mi9mcmFnOmQ0NDRlYTE0ZTk3OTRlNTI5NDIzZTZjNDBkNmExNDQ1L3RhYmxlOmI4MmQzMTM5MGI2ZTQ2ZWJiMzNkZDMxYzdiNzFiMDMyL3RhYmxlcmFuZ2U6YjgyZDMxMzkwYjZlNDZlYmIzM2RkMzFjN2I3MWIwMzJfNC00LTEtMS0w_589de204-4864-4e68-87e7-3b37c518ee83"
      unitRef="usd">2502850</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <cpix:LeaseLiability
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181Mi9mcmFnOmQ0NDRlYTE0ZTk3OTRlNTI5NDIzZTZjNDBkNmExNDQ1L3RhYmxlOmI4MmQzMTM5MGI2ZTQ2ZWJiMzNkZDMxYzdiNzFiMDMyL3RhYmxlcmFuZ2U6YjgyZDMxMzkwYjZlNDZlYmIzM2RkMzFjN2I3MWIwMzJfNS00LTEtMS0w_b87bef02-2940-4e0c-902a-53d5cb19f558"
      unitRef="usd">3402112</cpix:LeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181Mi9mcmFnOmQ0NDRlYTE0ZTk3OTRlNTI5NDIzZTZjNDBkNmExNDQ1L3RleHRyZWdpb246ZDQ0NGVhMTRlOTc5NGU1Mjk0MjNlNmM0MGQ2YTE0NDVfMzA5Ng_614fbd22-73c7-4384-8c50-c91b35d3625a">&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.368421%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:76.078078%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.751952%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.969970%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Maturity of Leases Liabilities at June 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;532,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,120,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,144,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,019,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;92,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;After 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,909,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(507,098)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,402,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181Mi9mcmFnOmQ0NDRlYTE0ZTk3OTRlNTI5NDIzZTZjNDBkNmExNDQ1L3RhYmxlOmI0NmI3OGFhZTVmNDRhN2Q4MmRmZmJhNTg0NGVkOGU0L3RhYmxlcmFuZ2U6YjQ2Yjc4YWFlNWY0NGE3ZDgyZGZmYmE1ODQ0ZWQ4ZTRfMS0yLTEtMS0w_24ba8293-65b6-4a62-a076-df09b00df923"
      unitRef="usd">532465</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181Mi9mcmFnOmQ0NDRlYTE0ZTk3OTRlNTI5NDIzZTZjNDBkNmExNDQ1L3RhYmxlOmI0NmI3OGFhZTVmNDRhN2Q4MmRmZmJhNTg0NGVkOGU0L3RhYmxlcmFuZ2U6YjQ2Yjc4YWFlNWY0NGE3ZDgyZGZmYmE1ODQ0ZWQ4ZTRfMi0yLTEtMS0w_579dd10d-eedd-4e2a-905c-db6951d41f09"
      unitRef="usd">1120066</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181Mi9mcmFnOmQ0NDRlYTE0ZTk3OTRlNTI5NDIzZTZjNDBkNmExNDQ1L3RhYmxlOmI0NmI3OGFhZTVmNDRhN2Q4MmRmZmJhNTg0NGVkOGU0L3RhYmxlcmFuZ2U6YjQ2Yjc4YWFlNWY0NGE3ZDgyZGZmYmE1ODQ0ZWQ4ZTRfMy0yLTEtMS0w_ba9a73fb-2dbb-443f-8201-9aa2d048fdd3"
      unitRef="usd">1144889</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181Mi9mcmFnOmQ0NDRlYTE0ZTk3OTRlNTI5NDIzZTZjNDBkNmExNDQ1L3RhYmxlOmI0NmI3OGFhZTVmNDRhN2Q4MmRmZmJhNTg0NGVkOGU0L3RhYmxlcmFuZ2U6YjQ2Yjc4YWFlNWY0NGE3ZDgyZGZmYmE1ODQ0ZWQ4ZTRfNC0yLTEtMS0w_8970ce79-445b-4153-802a-48c32c7d3316"
      unitRef="usd">1019313</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181Mi9mcmFnOmQ0NDRlYTE0ZTk3OTRlNTI5NDIzZTZjNDBkNmExNDQ1L3RhYmxlOmI0NmI3OGFhZTVmNDRhN2Q4MmRmZmJhNTg0NGVkOGU0L3RhYmxlcmFuZ2U6YjQ2Yjc4YWFlNWY0NGE3ZDgyZGZmYmE1ODQ0ZWQ4ZTRfNS0yLTEtMS0w_84dd757a-2563-43a0-85f3-8491962391ea"
      unitRef="usd">92477</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181Mi9mcmFnOmQ0NDRlYTE0ZTk3OTRlNTI5NDIzZTZjNDBkNmExNDQ1L3RhYmxlOmI0NmI3OGFhZTVmNDRhN2Q4MmRmZmJhNTg0NGVkOGU0L3RhYmxlcmFuZ2U6YjQ2Yjc4YWFlNWY0NGE3ZDgyZGZmYmE1ODQ0ZWQ4ZTRfNi0yLTEtMS0w_90b60545-3b25-44af-9ae5-1ada26d48f80"
      unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181Mi9mcmFnOmQ0NDRlYTE0ZTk3OTRlNTI5NDIzZTZjNDBkNmExNDQ1L3RhYmxlOmI0NmI3OGFhZTVmNDRhN2Q4MmRmZmJhNTg0NGVkOGU0L3RhYmxlcmFuZ2U6YjQ2Yjc4YWFlNWY0NGE3ZDgyZGZmYmE1ODQ0ZWQ4ZTRfNy0yLTEtMS0w_d5c68c01-84a5-4fa3-a9bb-08944711796d"
      unitRef="usd">3909210</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181Mi9mcmFnOmQ0NDRlYTE0ZTk3OTRlNTI5NDIzZTZjNDBkNmExNDQ1L3RhYmxlOmI0NmI3OGFhZTVmNDRhN2Q4MmRmZmJhNTg0NGVkOGU0L3RhYmxlcmFuZ2U6YjQ2Yjc4YWFlNWY0NGE3ZDgyZGZmYmE1ODQ0ZWQ4ZTRfOC0yLTEtMS0w_207e4108-eb00-4660-aee3-9770d7cb6c2c"
      unitRef="usd">507098</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="if478ab72402a4dbca17cebf84905f137_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181Mi9mcmFnOmQ0NDRlYTE0ZTk3OTRlNTI5NDIzZTZjNDBkNmExNDQ1L3RhYmxlOmI0NmI3OGFhZTVmNDRhN2Q4MmRmZmJhNTg0NGVkOGU0L3RhYmxlcmFuZ2U6YjQ2Yjc4YWFlNWY0NGE3ZDgyZGZmYmE1ODQ0ZWQ4ZTRfOS0yLTEtMS0w_1a34a410-08b9-415c-a2ed-b64b87d5c90a"
      unitRef="usd">3402112</us-gaap:OperatingLeaseLiability>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181OC9mcmFnOmViNzI5MWIzYzY3NTRhM2ZiYmE0OWRkY2JmNzA3OGY0L3RleHRyZWdpb246ZWI3MjkxYjNjNjc1NGEzZmJiYTQ5ZGRjYmY3MDc4ZjRfNDYxMw_639bd782-c880-4a8f-b923-e29f693bcf53">SHAREHOLDERS&#x2019; EQUITY AND DEBT&lt;div style="margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Share repurchases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company currently has a share repurchase program to repurchase up to $10 million of its common stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. In January 2019, the Company's Board of Directors established the current $10 million repurchase program to replace the prior authorizations.  During the six months ended June 30, 2019 and June 30, 2018, the Company repurchased 205,913 shares and 299,370 shares, respectively, of common stock for approximately $1.2 million and $2.0 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Share purchases and sales&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;During the Company's March 2019 trading window, several members of Cumberland's Board of Directors entered into share purchase agreements of the Company's stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. These purchases are designed to increase ownership in the Company by the members of the Board.  During the March 2019 trading window, one member of the Board of Directors entered into a share sale agreement, as required by a policy change by his employer, which prohibits his ownership in a pharmaceutical company.  The policy change did not impact his ability to serve on the Company's Board of Directors.  This Board member sold 47,969 Cumberland shares during the second quarter 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Share Sale&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In November 2017, the Company filed a Shelf Registration on Form S-3 with the SEC associated with the sale of up to $100 million in corporate securities. The Shelf Registration was declared effective in January 2018. During the six months ended June 30, 2018, the Company issued 30,704 shares of common stock for gross proceeds of $0.2 million as part of its At-The-Market (&#x201c;ATM&#x201d;) sales agreement with B. Riley FBR. The Company did not issue any shares under the ATM during the six months ended June 30, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Restricted Share Grants &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;During the six months ended June 30, 2019, and June 30, 2018, the Company issued 222,469 shares and 233,330 shares of restricted stock to employees and directors, respectively. Restricted stock issued to employees generally cliff-vests on the fourth anniversary of the date of grant and for directors on the &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181OC9mcmFnOmViNzI5MWIzYzY3NTRhM2ZiYmE0OWRkY2JmNzA3OGY0L3RleHRyZWdpb246ZWI3MjkxYjNjNjc1NGEzZmJiYTQ5ZGRjYmY3MDc4ZjRfMTg2MQ_7b6a6f88-b9bb-43f7-bebc-cb00283f1265"&gt;one&lt;/span&gt;-year anniversary of the date of grant.  Stock compensation expense is presented as a component of general and administrative expense in the condensed consolidated statements of operations and comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Cumberland Emerging Technologies&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In April 2019, Cumberland Emerging Technologies ("CET"), our majority-owned subsidiary, entered into &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;an agreement with WinHealth whereby WinHealth will make a $1&#160;million investment through the purchase of shares of CET stock. As part of the agreement, WinHealth obtained a Board position at CET and the first opportunity to license CET products for the Chinese market. In connection with WinHealth's investment in CET, Cumberland also made an additional $1&#160;million investment in CET.  Cumberland purchased additional CET shares through contribution of $0.3&#160;million in cash and a conversion of $0.7&#160;million in intercompany loans payable.  Upon completion of the additional investment by WinHealth and Cumberland, Gloria Pharmaceuticals agreed to return it's shares in CET in exchange for a payment of $0.8&#160;million.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Debt Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;On May 10, 2019, the Company entered into a third amendment ("Third Amendment") to the Revolving Credit Loan Agreement, dated July 28, 2017, with Pinnacle Bank (&#x201c;Pinnacle Agreement&#x201d;). The Third Amendment extended the term of the Pinnacle Agreement through July 31, 2021 as well as modified certain definitions and terms of the existing financial covenants.  The initial revolving line of credit under the Pinnacle Agreement was for up to an aggregate principal amount of $12.0 million with the ability to increase the principal amount available for borrowing up to $20.0 million, upon the satisfaction of certain conditions.   On October 17, 2018, the Company entered into a second amendment (&#x201c;Second Amendment&#x201d;) which increased the maximum aggregate principal available for borrowing under the Pinnacle Agreement to $20.0 million.  Cumberland increased the maximum aggregate principal available for borrowing to support potential future acquisitions and general corporate purposes.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. There is no LIBOR minimum and the LIBOR pricing provides for an interest rate spread of 1.75% to 2.75% (representing an interest rate of 5.15% at June 30, 2019).  In addition, a fee of 0.25% per year is charged on the unused line of credit.  Interest and the unused line fee are payable quarterly.  Borrowings under the line of credit are collateralized by substantially all of our assets. &lt;/span&gt;&lt;/div&gt;Under the Pinnacle Agreement, Cumberland was initially subject to one financial covenant, the maintenance of a Funded Debt Ratio, as such term is defined in the agreement and determined on a quarterly basis.  On August 14, 2018, the Company amended the Pinnacle Agreement ("First Amendment") to replace the single financial covenant with the maintenance of either the Funded Debt Ratio or a Tangible Capital Ratio, as defined in the First Amendment.  The Third Amendment modified the definition of the Funded Debt Ratio and the compliance target of the Tangible Capital Ratio. Both Third Amendment modifications were related to the Vibativ transaction.  The Company was in compliance with the Tangible Capital Ratio financial covenant as of June 30, 2019.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i3c6be34147e74633b283a3faf26291a6_I20100513"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181OC9mcmFnOmViNzI5MWIzYzY3NTRhM2ZiYmE0OWRkY2JmNzA3OGY0L3RleHRyZWdpb246ZWI3MjkxYjNjNjc1NGEzZmJiYTQ5ZGRjYmY3MDc4ZjRfMTMw_e266faa1-5b9a-4da0-b63b-8ab1c913fd05"
      unitRef="usd">10000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="ie34c3c9c4b6c4086a134e19d8fa48fdd_I20160131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181OC9mcmFnOmViNzI5MWIzYzY3NTRhM2ZiYmE0OWRkY2JmNzA3OGY0L3RleHRyZWdpb246ZWI3MjkxYjNjNjc1NGEzZmJiYTQ5ZGRjYmY3MDc4ZjRfMjkx_3d79d3ee-2558-49a1-b87a-4abea9794bbd"
      unitRef="usd">10000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="idbb1a7efb54a4443b860e667b9d9f4ff_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181OC9mcmFnOmViNzI5MWIzYzY3NTRhM2ZiYmE0OWRkY2JmNzA3OGY0L3RleHRyZWdpb246ZWI3MjkxYjNjNjc1NGEzZmJiYTQ5ZGRjYmY3MDc4ZjRfMzk3_cdda5d58-5861-42d9-a2ba-ecdb3c28eb23"
      unitRef="shares">205913</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i1fee3684442c4d5f9e424da6bdc3b780_D20180101-20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181OC9mcmFnOmViNzI5MWIzYzY3NTRhM2ZiYmE0OWRkY2JmNzA3OGY0L3RleHRyZWdpb246ZWI3MjkxYjNjNjc1NGEzZmJiYTQ5ZGRjYmY3MDc4ZjRfNDEx_f30a6891-55e8-4448-a1a2-81fd57656b95"
      unitRef="shares">299370</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="idbb1a7efb54a4443b860e667b9d9f4ff_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181OC9mcmFnOmViNzI5MWIzYzY3NTRhM2ZiYmE0OWRkY2JmNzA3OGY0L3RleHRyZWdpb246ZWI3MjkxYjNjNjc1NGEzZmJiYTQ5ZGRjYmY3MDc4ZjRfNDcw_32c745ee-7058-4929-af75-1a6febb147c2"
      unitRef="usd">1200000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i1fee3684442c4d5f9e424da6bdc3b780_D20180101-20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181OC9mcmFnOmViNzI5MWIzYzY3NTRhM2ZiYmE0OWRkY2JmNzA3OGY0L3RleHRyZWdpb246ZWI3MjkxYjNjNjc1NGEzZmJiYTQ5ZGRjYmY3MDc4ZjRfNDg1_15648305-dc20-4b8e-b8b8-8edb0a7c7d92"
      unitRef="usd">2000000.0</us-gaap:StockRepurchasedDuringPeriodValue>
    <cpix:SaleOfStockNumberOfSharesSold
      contextRef="ide11bc6060924df19448d4e6a244010d_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181OC9mcmFnOmViNzI5MWIzYzY3NTRhM2ZiYmE0OWRkY2JmNzA3OGY0L3RleHRyZWdpb246ZWI3MjkxYjNjNjc1NGEzZmJiYTQ5ZGRjYmY3MDc4ZjRfMTA5OTUxMTYzMjY1Ng_3583b5d4-493e-426a-8428-bc9b9e6b45f7"
      unitRef="shares">47969</cpix:SaleOfStockNumberOfSharesSold>
    <cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities
      contextRef="i959855896ce142fbac309e421bbe56a9_D20171101-20171130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181OC9mcmFnOmViNzI5MWIzYzY3NTRhM2ZiYmE0OWRkY2JmNzA3OGY0L3RleHRyZWdpb246ZWI3MjkxYjNjNjc1NGEzZmJiYTQ5ZGRjYmY3MDc4ZjRfMTI1NA_b8d49751-5140-42a6-bc44-b0816abe7dad"
      unitRef="usd">100000000</cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities>
    <cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding
      contextRef="i1fee3684442c4d5f9e424da6bdc3b780_D20180101-20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181OC9mcmFnOmViNzI5MWIzYzY3NTRhM2ZiYmE0OWRkY2JmNzA3OGY0L3RleHRyZWdpb246ZWI3MjkxYjNjNjc1NGEzZmJiYTQ5ZGRjYmY3MDc4ZjRfMTM3OQ_5d93bdd1-1016-4c43-9e39-39d77e8881b6"
      unitRef="shares">30704</cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i4c5d89cebdad42e6a0f2f469b8137b7b_D20180101-20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181OC9mcmFnOmViNzI5MWIzYzY3NTRhM2ZiYmE0OWRkY2JmNzA3OGY0L3RleHRyZWdpb246ZWI3MjkxYjNjNjc1NGEzZmJiYTQ5ZGRjYmY3MDc4ZjRfMTQyNw_8f6722e4-433a-47dd-88ab-b3804891c170"
      unitRef="usd">200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i89a377e795d5407db1aaac39ada6ab01_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181OC9mcmFnOmViNzI5MWIzYzY3NTRhM2ZiYmE0OWRkY2JmNzA3OGY0L3RleHRyZWdpb246ZWI3MjkxYjNjNjc1NGEzZmJiYTQ5ZGRjYmY3MDc4ZjRfMTY0NA_2e327579-d059-497a-8e3b-36c13a87fb4f"
      unitRef="shares">222469</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ia72329a5bc7744a280d614667782cdc8_D20180101-20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181OC9mcmFnOmViNzI5MWIzYzY3NTRhM2ZiYmE0OWRkY2JmNzA3OGY0L3RleHRyZWdpb246ZWI3MjkxYjNjNjc1NGEzZmJiYTQ5ZGRjYmY3MDc4ZjRfMTY1OA_3cc501c6-712c-4aa3-afd4-ff3e0503b18f"
      unitRef="shares">233330</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <cpix:SubsidiaryInvestmentPurchaseOfShares
      contextRef="i94c12e61b0d14ff5a5b7a3c975510ecc_I20190430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181OC9mcmFnOmViNzI5MWIzYzY3NTRhM2ZiYmE0OWRkY2JmNzA3OGY0L3RleHRyZWdpb246ZWI3MjkxYjNjNjc1NGEzZmJiYTQ5ZGRjYmY3MDc4ZjRfODI0NjMzNzIxODQ0OA_33ccfd92-61e9-4602-a263-0e2e42cb9a58"
      unitRef="usd">1000000</cpix:SubsidiaryInvestmentPurchaseOfShares>
    <cpix:SubsidiaryInvestmentPurchaseOfShares
      contextRef="i94c12e61b0d14ff5a5b7a3c975510ecc_I20190430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181OC9mcmFnOmViNzI5MWIzYzY3NTRhM2ZiYmE0OWRkY2JmNzA3OGY0L3RleHRyZWdpb246ZWI3MjkxYjNjNjc1NGEzZmJiYTQ5ZGRjYmY3MDc4ZjRfODI0NjMzNzIxODQ2MA_e941bab7-b14e-4d22-85b8-c2a9e1e12427"
      unitRef="usd">1000000</cpix:SubsidiaryInvestmentPurchaseOfShares>
    <cpix:SubsidiaryInvestmentCashContribution
      contextRef="ib97eaa219e974f16a39fa98e445d047a_D20190401-20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181OC9mcmFnOmViNzI5MWIzYzY3NTRhM2ZiYmE0OWRkY2JmNzA3OGY0L3RleHRyZWdpb246ZWI3MjkxYjNjNjc1NGEzZmJiYTQ5ZGRjYmY3MDc4ZjRfODI0NjMzNzIxODQ3NA_59f58b5d-09c1-4d73-8faf-216978b249e8"
      unitRef="usd">300000</cpix:SubsidiaryInvestmentCashContribution>
    <cpix:SubsidiaryInvestmentConversionOfIntercompanyLoansPayable
      contextRef="i11a9395935dd46a587ef0b6c9587b057_I20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181OC9mcmFnOmViNzI5MWIzYzY3NTRhM2ZiYmE0OWRkY2JmNzA3OGY0L3RleHRyZWdpb246ZWI3MjkxYjNjNjc1NGEzZmJiYTQ5ZGRjYmY3MDc4ZjRfODI0NjMzNzIxODUxNg_ec706ac3-7b94-44b9-a5e2-3173d6beb05a"
      unitRef="usd">700000</cpix:SubsidiaryInvestmentConversionOfIntercompanyLoansPayable>
    <cpix:SubsidiaryInvestmentPaymentsForReturnOfCapital
      contextRef="id03a7800662a48cd8cf59f4d3cdb9811_D20190401-20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181OC9mcmFnOmViNzI5MWIzYzY3NTRhM2ZiYmE0OWRkY2JmNzA3OGY0L3RleHRyZWdpb246ZWI3MjkxYjNjNjc1NGEzZmJiYTQ5ZGRjYmY3MDc4ZjRfODI0NjMzNzIxODUzMA_5d9b83a9-8803-4e85-bb94-e9e3ec12e701"
      unitRef="usd">800000</cpix:SubsidiaryInvestmentPaymentsForReturnOfCapital>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="idf561525052b4733845421e5e0fffabf_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181OC9mcmFnOmViNzI5MWIzYzY3NTRhM2ZiYmE0OWRkY2JmNzA3OGY0L3RleHRyZWdpb246ZWI3MjkxYjNjNjc1NGEzZmJiYTQ5ZGRjYmY3MDc4ZjRfMjkxNw_51826786-335a-42bf-b69f-fb7191aa56b2"
      unitRef="usd">12000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <cpix:LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions
      contextRef="idf561525052b4733845421e5e0fffabf_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181OC9mcmFnOmViNzI5MWIzYzY3NTRhM2ZiYmE0OWRkY2JmNzA3OGY0L3RleHRyZWdpb246ZWI3MjkxYjNjNjc1NGEzZmJiYTQ5ZGRjYmY3MDc4ZjRfMzAwMA_de04b950-8291-427b-9e85-09b2f5ecad48"
      unitRef="usd">20000000.0</cpix:LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i265ae74e8bfa4726841ed00db8f8e437_I20181017"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181OC9mcmFnOmViNzI5MWIzYzY3NTRhM2ZiYmE0OWRkY2JmNzA3OGY0L3RleHRyZWdpb246ZWI3MjkxYjNjNjc1NGEzZmJiYTQ5ZGRjYmY3MDc4ZjRfMTA5OTUxMTYzNjg1Ng_7cd30365-40c9-4026-a68d-902988354d4c"
      unitRef="usd">20000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie283482fcb0a418f903f4565757a59f1_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181OC9mcmFnOmViNzI5MWIzYzY3NTRhM2ZiYmE0OWRkY2JmNzA3OGY0L3RleHRyZWdpb246ZWI3MjkxYjNjNjc1NGEzZmJiYTQ5ZGRjYmY3MDc4ZjRfMzU1Mw_fa6637da-bcf6-4a0a-adf7-2dfde501a5ac"
      unitRef="number">0.0175</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i389446a0e5ad467cb0b7d185b5851168_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181OC9mcmFnOmViNzI5MWIzYzY3NTRhM2ZiYmE0OWRkY2JmNzA3OGY0L3RleHRyZWdpb246ZWI3MjkxYjNjNjc1NGEzZmJiYTQ5ZGRjYmY3MDc4ZjRfMzU1OQ_eab5ed07-a7d0-49ea-81b5-ce1018683905"
      unitRef="number">0.0275</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idf561525052b4733845421e5e0fffabf_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181OC9mcmFnOmViNzI5MWIzYzY3NTRhM2ZiYmE0OWRkY2JmNzA3OGY0L3RleHRyZWdpb246ZWI3MjkxYjNjNjc1NGEzZmJiYTQ5ZGRjYmY3MDc4ZjRfMzU5Ng_30013126-f88d-4692-9ed8-bb6dca5a5372"
      unitRef="number">0.0515</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="i4c66d110828e4d3290867f75611b26b4_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181OC9mcmFnOmViNzI5MWIzYzY3NTRhM2ZiYmE0OWRkY2JmNzA3OGY0L3RleHRyZWdpb246ZWI3MjkxYjNjNjc1NGEzZmJiYTQ5ZGRjYmY3MDc4ZjRfMzYzMA_94be63da-f599-44a6-9a7b-8bb5a45e98a2"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N182NC9mcmFnOmEwOTE0MzFmNWEyYjQyN2NiYTM0ZGFlMjcwOGFlNGNhL3RleHRyZWdpb246YTA5MTQzMWY1YTJiNDI3Y2JhMzRkYWUyNzA4YWU0Y2FfMTU0NA_ff3ef8c7-0db7-42b6-b9ef-e3595da7621f">INCOME TAXES&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (&#x201c;the Tax Act&#x201d;).  The Tax Act makes broad and complex changes to the U.S. tax code, including, but not limited to, (1) reducing the U.S. federal corporate tax rate to 21%; (2) eliminating the corporate alternative minimum tax (&#x201c;AMT&#x201d;) and changing how AMT credits can be realized; (3) capital expensing; and (4) creating new limitations on deductible interest expense and executive compensation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The SEC staff issued Staff Accounting Bulletin (&#x201c;SAB&#x201d;) 118, providing guidance on applying the Tax Act.  SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740.  In accordance with SAB 118, a company reflects the income tax effects of the Tax Act for which the accounting under ASC 740 is complete.  To the extent that a company&#x2019;s accounting for certain income tax effects of the Tax Act is incomplete but a reasonable estimate is available, it must record the estimate in the financial statements.  If a company cannot determine an estimate, it should continue to apply ASC 740 on the basis of the tax laws that were in effect immediately prior to enactment of the Tax Act.  The Company expects it will continue to pay minimal taxes in future periods through the continued utilization of net operating loss carryforwards, as it is able to achieve taxable income through its operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N182Ny9mcmFnOjZhYWI5ZGM5NWVkMDRmOTU4ZjE3MDFiZGM2NGFhYTk1L3RleHRyZWdpb246NmFhYjlkYzk1ZWQwNGY5NThmMTcwMWJkYzY0YWFhOTVfOTgw_a9974540-8075-410b-9ee4-861102f4cfd9">COLLABORATIVE AGREEMENTS&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Cumberland is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The Company has determined that these collaborative agreements do not meet the criteria for accounting under ASC Topic 808, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Collaborative Agreements&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;. The agreements do not specifically designate each party&#x2019;s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from grants are recorded as net revenues in the condensed consolidated statements of operations and comprehensive income (loss).&lt;/span&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RleHRyZWdpb246ZDQ4OWI1YThlY2E3NDBiOTkxNDMyY2E5ZTFkYjgwZjFfNjA0NzMxMzk1ODI5Ng_c6d89799-0ec5-4c70-8f46-8f095cc0f4d6">RECENT ADDITIONS AND EXPECTED RETURN OF PRODUCT RIGHTS&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Omeclamox-Pak&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:7pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In December 2018, Cumberland completed an agreement with Gasto-enterlogics Inc. ("GEL") to acquire the remaining product rights associated with Omeclamox-Pak, including the product&#x2019;s FDA-approved New Drug Application and the domestic and international trademarks. As part of the transaction, which was accounted for as an asset acquisition, Cumberland paid $2.3 million during 2018 and ended Cumberland&#x2019;s payments of royalties and manufacturing fees to GEL.  The Company has now assumed responsibility for the maintenance of the product&#x2019;s FDA approval and for the oversight of the product&#x2019;s manufacturing and packaging.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:7pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Vibativ&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;During November 2018, the Company closed on an agreement with Theravance Biopharma ("Theravance") to acquire the global responsibility for Vibativ including the marketing, distribution, manufacturing and regulatory activities associated with the brand.  Vibativ is a patented, FDA approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.  Cumberland acquired Vibativ to further add to its product offerings, increase its net revenue and positively contribute to the Company's operating results.  While Cumberland is still evaluating the tax deductibility of the goodwill acquired in the acquisition, it expects those amounts to be deductible for tax purposes.    &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company made an upfront payment of $20.0 million at the closing of the transaction and a $5.0 million milestone payment in early April 2019. In addition, Cumberland has agreed to pay a royalty of up to 20% on future net sales of the product.  The future royalty payments are required to be recognized at their acquisition-date fair value as part of the contingent consideration transferred in the business combination. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the initial payments and consideration for the business combination:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:75.631579%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:20.368421%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Consideration:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash paid at closing&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash payment during early 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair value of contingent consideration - net sales royalty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,182,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total consideration &lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,182,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The contingent consideration liability represents the future net sales royalty payments discussed above.  Cumberland prepared the valuations of the contingent consideration liability and the intangible assets utilizing significant unobservable inputs.  As a result, the valuations are classified as Level 3 fair value measurements.  The Company will continue to evaluate the assets acquired and liabilities assumed during the measurement period. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table presents the changes in the Company's Level 3 contingent consideration liability that is measured at fair value on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to the seller quarterly.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:75.923977%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:20.076023%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at November 12, 2018&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,034,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in fair value of contingent consideration included in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(40,000)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration earned and accrued in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;508,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,502,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Adjustment to initial fair value of the contingent consideration liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;148,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash payment of royalty during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(684,738)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in fair value of contingent consideration included in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(321,894)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration earned and accrued in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;423,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at June 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,066,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the final allocation of the fair values of the assets acquired as part of the acquisition of Vibativ:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:75.923977%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:20.076023%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finished goods inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,624,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Work in process - unlabeled vials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,970,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Work in process - validation vials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,827,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,129,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:13pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,550,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Intellectual property amortizable intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;882,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:13pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total intangibles and goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,632,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,182,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company's contingent consideration liability is a Level 3 fair value measurement that is updated on a recurring basis at each reporting period using a valuation model.  Consistent with Level 3 fair value measurements, there are significant inputs to the valuation model that are unobservable. The current portion of the contingent consideration liability is $2.1 million and the non-current portion is $7.0 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Ethyol and Totect &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;During May 2019, Cumberland entered into a Dissolution Agreement with Clinigen Healthcare Limited ("Agreement") in which the Company will return the exclusive rights to commercialize Ethyol and Totect in the United States to Clinigen. The Agreement results in a transition from the Company's current arrangement with Clinigen effective September 30, 2019.  Under the terms of the agreement, Cumberland will no longer be involved directly or indirectly with the distribution, marketing and promotion of either Ethyol or Totect or any competing products.  In exchange for the return of these product license rights and not competing with either product, Cumberland will receive $5&#160;million in financial consideration paid over the two-years following September 30, 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <cpix:PaymentsForAssetAcquisitions
      contextRef="i5709e5c0528d4106ba0350257862d329_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RleHRyZWdpb246ZDQ4OWI1YThlY2E3NDBiOTkxNDMyY2E5ZTFkYjgwZjFfNDA2_0ecc3f34-e666-4044-8018-3d8b80c2abe1"
      unitRef="usd">2300000</cpix:PaymentsForAssetAcquisitions>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="icca6e0f80b33475a8371b8499f5d8919_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RleHRyZWdpb246ZDQ4OWI1YThlY2E3NDBiOTkxNDMyY2E5ZTFkYjgwZjFfMTg2OQ_0fea43eb-a727-4a38-99c9-32be260841af"
      unitRef="usd">20000000.0</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:OtherPaymentsToAcquireBusinesses
      contextRef="i1b571fa0594646398781261aceb478b2_D20190401-20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RleHRyZWdpb246ZDQ4OWI1YThlY2E3NDBiOTkxNDMyY2E5ZTFkYjgwZjFfMTg3OQ_ce49fd95-2244-47f6-b0b8-415b770bb5e0"
      unitRef="usd">5000000.0</us-gaap:OtherPaymentsToAcquireBusinesses>
    <cpix:TieredRoyaltyPaymentsPercentage
      contextRef="icca6e0f80b33475a8371b8499f5d8919_D20181101-20181130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RleHRyZWdpb246ZDQ4OWI1YThlY2E3NDBiOTkxNDMyY2E5ZTFkYjgwZjFfMTk5NQ_4a4b0536-6314-4df8-8cda-3fa726ffa6ae"
      unitRef="number">0.20</cpix:TieredRoyaltyPaymentsPercentage>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RleHRyZWdpb246ZDQ4OWI1YThlY2E3NDBiOTkxNDMyY2E5ZTFkYjgwZjFfMzU4Mw_abe831c2-77bc-49ac-b63f-4ba7ec24c344">&lt;div style="margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the initial payments and consideration for the business combination:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:75.631579%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:20.368421%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Consideration:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash paid at closing&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash payment during early 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair value of contingent consideration - net sales royalty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,182,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total consideration &lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,182,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i9d064a4268974d2eaa1aee9282ceb970_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RhYmxlOjNjMDNhODg0YThhZDRlMjViNjE4NWE2YzQ3NzNhZWU1L3RhYmxlcmFuZ2U6M2MwM2E4ODRhOGFkNGUyNWI2MTg1YTZjNDc3M2FlZTVfMi0xLTEtMS0w_040b9ef1-574f-4416-9f5d-88d603e31a78"
      unitRef="usd">20000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:OtherPaymentsToAcquireBusinesses
      contextRef="i9d064a4268974d2eaa1aee9282ceb970_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RhYmxlOjNjMDNhODg0YThhZDRlMjViNjE4NWE2YzQ3NzNhZWU1L3RhYmxlcmFuZ2U6M2MwM2E4ODRhOGFkNGUyNWI2MTg1YTZjNDc3M2FlZTVfMy0xLTEtMS0w_19c97551-0081-4636-a5ef-fd78afaeaf9e"
      unitRef="usd">5000000</us-gaap:OtherPaymentsToAcquireBusinesses>
    <cpix:PaymentsForContingentConsideration
      contextRef="i9d064a4268974d2eaa1aee9282ceb970_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RhYmxlOjNjMDNhODg0YThhZDRlMjViNjE4NWE2YzQ3NzNhZWU1L3RhYmxlcmFuZ2U6M2MwM2E4ODRhOGFkNGUyNWI2MTg1YTZjNDc3M2FlZTVfNC0xLTEtMS0w_7f8654cd-3a1c-42c3-8441-31c680bb45ac"
      unitRef="usd">9182000</cpix:PaymentsForContingentConsideration>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i9d064a4268974d2eaa1aee9282ceb970_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RhYmxlOjNjMDNhODg0YThhZDRlMjViNjE4NWE2YzQ3NzNhZWU1L3RhYmxlcmFuZ2U6M2MwM2E4ODRhOGFkNGUyNWI2MTg1YTZjNDc3M2FlZTVfNS0xLTEtMS0w_5d6c97fb-68c9-4706-94c9-43bce4f8d769"
      unitRef="usd">34182000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RleHRyZWdpb246ZDQ4OWI1YThlY2E3NDBiOTkxNDMyY2E5ZTFkYjgwZjFfMzU4NA_ebaed603-fae9-4057-a4b6-823fb561fb97">&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table presents the changes in the Company's Level 3 contingent consideration liability that is measured at fair value on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to the seller quarterly.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:75.923977%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:20.076023%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at November 12, 2018&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,034,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in fair value of contingent consideration included in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(40,000)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration earned and accrued in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;508,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,502,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Adjustment to initial fair value of the contingent consideration liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;148,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash payment of royalty during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(684,738)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in fair value of contingent consideration included in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(321,894)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration earned and accrued in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;423,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at June 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,066,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ic8e3a8763ebf4e4299a795047276e3dd_I20181112"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RhYmxlOjc1ZDBlODQ3MTFhYjQ3MGU4OWE0NTc5MjhiNTRjMDg3L3RhYmxlcmFuZ2U6NzVkMGU4NDcxMWFiNDcwZTg5YTQ1NzkyOGI1NGMwODdfMS0xLTEtMS0w_3e8d7973-3879-4b14-b368-bb7e45f92300"
      unitRef="usd">9034000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i62c36aedf5f84b7d8160f6870615925e_D20181113-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RhYmxlOjc1ZDBlODQ3MTFhYjQ3MGU4OWE0NTc5MjhiNTRjMDg3L3RhYmxlcmFuZ2U6NzVkMGU4NDcxMWFiNDcwZTg5YTQ1NzkyOGI1NGMwODdfMi0xLTEtMS0w_eb91546d-81c5-476c-ac5f-c89e7f40ca25"
      unitRef="usd">-40000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses
      contextRef="i385e5bd994794f80a9f4101d706edbbb_D20181112-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RhYmxlOjc1ZDBlODQ3MTFhYjQ3MGU4OWE0NTc5MjhiNTRjMDg3L3RhYmxlcmFuZ2U6NzVkMGU4NDcxMWFiNDcwZTg5YTQ1NzkyOGI1NGMwODdfMy0xLTEtMS0w_da5d481b-e92a-4cde-bd45-718f997a9c9f"
      unitRef="usd">508000</cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i674a647fde3f44be85e9cae6e936a816_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RhYmxlOjc1ZDBlODQ3MTFhYjQ3MGU4OWE0NTc5MjhiNTRjMDg3L3RhYmxlcmFuZ2U6NzVkMGU4NDcxMWFiNDcwZTg5YTQ1NzkyOGI1NGMwODdfNC0xLTEtMS0w_d45676dc-511d-4f0d-b3a1-3eb73840503c"
      unitRef="usd">9502000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <cpix:BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment
      contextRef="i9d064a4268974d2eaa1aee9282ceb970_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RhYmxlOjc1ZDBlODQ3MTFhYjQ3MGU4OWE0NTc5MjhiNTRjMDg3L3RhYmxlcmFuZ2U6NzVkMGU4NDcxMWFiNDcwZTg5YTQ1NzkyOGI1NGMwODdfNS0xLTEtMS0w_1be39357-a608-42ae-b16b-371de25be7da"
      unitRef="usd">148000</cpix:BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment>
    <us-gaap:PaymentsForRoyalties
      contextRef="i9d064a4268974d2eaa1aee9282ceb970_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RhYmxlOjc1ZDBlODQ3MTFhYjQ3MGU4OWE0NTc5MjhiNTRjMDg3L3RhYmxlcmFuZ2U6NzVkMGU4NDcxMWFiNDcwZTg5YTQ1NzkyOGI1NGMwODdfNi0xLTEtMS0w_d84f8453-1737-4bba-8301-186dc1db75a9"
      unitRef="usd">684738</us-gaap:PaymentsForRoyalties>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i9d064a4268974d2eaa1aee9282ceb970_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RhYmxlOjc1ZDBlODQ3MTFhYjQ3MGU4OWE0NTc5MjhiNTRjMDg3L3RhYmxlcmFuZ2U6NzVkMGU4NDcxMWFiNDcwZTg5YTQ1NzkyOGI1NGMwODdfNy0xLTEtMS0w_bd23186a-07ad-4425-b1b3-d340fd391412"
      unitRef="usd">-321894</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses
      contextRef="i9d064a4268974d2eaa1aee9282ceb970_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RhYmxlOjc1ZDBlODQ3MTFhYjQ3MGU4OWE0NTc5MjhiNTRjMDg3L3RhYmxlcmFuZ2U6NzVkMGU4NDcxMWFiNDcwZTg5YTQ1NzkyOGI1NGMwODdfOC0xLTEtMS0w_f1861305-a9b9-4afe-82ad-64f514170fac"
      unitRef="usd">423041</cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i5332b0b2238e4d09b5c7a0b66e8b457a_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RhYmxlOjc1ZDBlODQ3MTFhYjQ3MGU4OWE0NTc5MjhiNTRjMDg3L3RhYmxlcmFuZ2U6NzVkMGU4NDcxMWFiNDcwZTg5YTQ1NzkyOGI1NGMwODdfOS0xLTEtMS0w_1d72aa37-7525-4a5b-a5b4-108baa5c4d22"
      unitRef="usd">9066409</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RleHRyZWdpb246ZDQ4OWI1YThlY2E3NDBiOTkxNDMyY2E5ZTFkYjgwZjFfMzU4NQ_913428ec-9663-49b6-9593-e6ff3dce85d0">&lt;div style="margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the final allocation of the fair values of the assets acquired as part of the acquisition of Vibativ:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:75.923977%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:20.076023%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finished goods inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,624,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Work in process - unlabeled vials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,970,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Work in process - validation vials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,827,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,129,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:13pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,550,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Intellectual property amortizable intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;882,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:13pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total intangibles and goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,632,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,182,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory
      contextRef="ibfc029c334714ab1b6a1fa6f662c915e_I20181130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RhYmxlOmMxODMzZTViMTQ4YjQ5ZmRiMmViNGQ2Mjk3ZGQxYmM1L3RhYmxlcmFuZ2U6YzE4MzNlNWIxNDhiNDlmZGIyZWI0ZDYyOTdkZDFiYzVfMC0xLTEtMS0w_7afa74f9-03d5-4364-a317-ac06057fa489"
      unitRef="usd">6624000</cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory>
    <cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials
      contextRef="ibfc029c334714ab1b6a1fa6f662c915e_I20181130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RhYmxlOmMxODMzZTViMTQ4YjQ5ZmRiMmViNGQ2Mjk3ZGQxYmM1L3RhYmxlcmFuZ2U6YzE4MzNlNWIxNDhiNDlmZGIyZWI0ZDYyOTdkZDFiYzVfMS0xLTEtMS0w_cfb437b2-988d-4e51-be8a-3f8e2b7a6e36"
      unitRef="usd">3970000</cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials>
    <cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials
      contextRef="ibfc029c334714ab1b6a1fa6f662c915e_I20181130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RhYmxlOmMxODMzZTViMTQ4YjQ5ZmRiMmViNGQ2Mjk3ZGQxYmM1L3RhYmxlcmFuZ2U6YzE4MzNlNWIxNDhiNDlmZGIyZWI0ZDYyOTdkZDFiYzVfMi0xLTEtMS0w_a73500ac-8475-4dff-9cfe-ebff3233d5bf"
      unitRef="usd">1827000</cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials>
    <cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory
      contextRef="ibfc029c334714ab1b6a1fa6f662c915e_I20181130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RhYmxlOmMxODMzZTViMTQ4YjQ5ZmRiMmViNGQ2Mjk3ZGQxYmM1L3RhYmxlcmFuZ2U6YzE4MzNlNWIxNDhiNDlmZGIyZWI0ZDYyOTdkZDFiYzVfMy0xLTEtMS0w_15722482-ab44-4a3f-adcc-01d618edafa4"
      unitRef="usd">9129000</cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="ibfc029c334714ab1b6a1fa6f662c915e_I20181130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RhYmxlOmMxODMzZTViMTQ4YjQ5ZmRiMmViNGQ2Mjk3ZGQxYmM1L3RhYmxlcmFuZ2U6YzE4MzNlNWIxNDhiNDlmZGIyZWI0ZDYyOTdkZDFiYzVfNC0xLTEtMS0w_6c7f7f86-ca05-4960-bd87-dad5ee15f13a"
      unitRef="usd">21550000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="ibfc029c334714ab1b6a1fa6f662c915e_I20181130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RhYmxlOmMxODMzZTViMTQ4YjQ5ZmRiMmViNGQ2Mjk3ZGQxYmM1L3RhYmxlcmFuZ2U6YzE4MzNlNWIxNDhiNDlmZGIyZWI0ZDYyOTdkZDFiYzVfNi0xLTEtMS0w_9d32e30b-5a9c-45f4-bbb6-592795b7920f"
      unitRef="usd">11750000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:Goodwill
      contextRef="ibfc029c334714ab1b6a1fa6f662c915e_I20181130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RhYmxlOmMxODMzZTViMTQ4YjQ5ZmRiMmViNGQ2Mjk3ZGQxYmM1L3RhYmxlcmFuZ2U6YzE4MzNlNWIxNDhiNDlmZGIyZWI0ZDYyOTdkZDFiYzVfNy0xLTEtMS0w_d8d230c0-1ad5-49aa-a6e0-02d1df365ebf"
      unitRef="usd">882000</us-gaap:Goodwill>
    <cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill
      contextRef="ibfc029c334714ab1b6a1fa6f662c915e_I20181130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RhYmxlOmMxODMzZTViMTQ4YjQ5ZmRiMmViNGQ2Mjk3ZGQxYmM1L3RhYmxlcmFuZ2U6YzE4MzNlNWIxNDhiNDlmZGIyZWI0ZDYyOTdkZDFiYzVfOC0xLTEtMS0w_98bb5af0-06c5-4bd2-9e79-24fcb27b379d"
      unitRef="usd">12632000</cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="ibfc029c334714ab1b6a1fa6f662c915e_I20181130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RhYmxlOmMxODMzZTViMTQ4YjQ5ZmRiMmViNGQ2Mjk3ZGQxYmM1L3RhYmxlcmFuZ2U6YzE4MzNlNWIxNDhiNDlmZGIyZWI0ZDYyOTdkZDFiYzVfOS0xLTEtMS0w_56998aa3-58ac-46b2-9110-8fd7fbb53a94"
      unitRef="usd">34182000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i55ab197a5f614ea393244079e62f621c_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RleHRyZWdpb246ZDQ4OWI1YThlY2E3NDBiOTkxNDMyY2E5ZTFkYjgwZjFfMzUyNg_f857078f-fded-48da-ad0e-6e5977e57004"
      unitRef="usd">2100000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i55ab197a5f614ea393244079e62f621c_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RleHRyZWdpb246ZDQ4OWI1YThlY2E3NDBiOTkxNDMyY2E5ZTFkYjgwZjFfMzU2OA_49bbf964-f68f-479b-8f56-3a353125ef39"
      unitRef="usd">7000000.0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="i89124f6164c440dea6f61c2e5b7f5ef8_D20191001-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N183MC9mcmFnOmQ0ODliNWE4ZWNhNzQwYjk5MTQzMmNhOWUxZGI4MGYxL3RleHRyZWdpb246ZDQ4OWI1YThlY2E3NDBiOTkxNDMyY2E5ZTFkYjgwZjFfNjA0NzMxMzk1ODMwOA_7673d6d7-42e3-404b-b163-8f0276fc477c"
      unitRef="usd">5000000</us-gaap:ProceedsFromSaleOfIntangibleAssets>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6758984160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Aug. 09, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover page.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Cumberland Pharmaceuticals Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001087294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">TN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">62-1765329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2525 West End Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Nashville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">37203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">255-0068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, no par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CPIX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,373,815<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6759597488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 20,951,180<span></span>
</td>
<td class="nump">$ 27,938,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">9,479,686<span></span>
</td>
<td class="nump">8,290,679<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">8,427,278<span></span>
</td>
<td class="nump">7,844,249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">10,648,859<span></span>
</td>
<td class="nump">12,078,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">2,425,354<span></span>
</td>
<td class="nump">2,963,806<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">51,932,357<span></span>
</td>
<td class="nump">59,116,037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="nump">15,840,962<span></span>
</td>
<td class="nump">15,749,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">737,238<span></span>
</td>
<td class="nump">771,213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">32,044,234<span></span>
</td>
<td class="nump">33,655,099<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">882,000<span></span>
</td>
<td class="nump">784,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent', window );">Deferred tax assets, net</a></td>
<td class="nump">43,605<span></span>
</td>
<td class="nump">87,210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">6,065,828<span></span>
</td>
<td class="nump">2,531,309<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">107,546,224<span></span>
</td>
<td class="nump">112,693,868<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">9,539,981<span></span>
</td>
<td class="nump">11,093,297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">12,777,148<span></span>
</td>
<td class="nump">16,710,927<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">22,317,129<span></span>
</td>
<td class="nump">27,804,224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Revolving line of credit</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_OtherLongTermObligationsExcludingCurrentPortion', window );">Other long-term liabilities</a></td>
<td class="nump">11,540,378<span></span>
</td>
<td class="nump">9,319,143<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">53,857,507<span></span>
</td>
<td class="nump">57,123,367<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock&#8212;no par value; 100,000,000 shares authorized; 15,555,865 and 15,723,075 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively</a></td>
<td class="nump">49,938,254<span></span>
</td>
<td class="nump">51,098,613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">4,122,769<span></span>
</td>
<td class="nump">4,746,154<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">54,061,023<span></span>
</td>
<td class="nump">55,844,767<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="num">(372,306)<span></span>
</td>
<td class="num">(274,266)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">53,688,717<span></span>
</td>
<td class="nump">55,570,501<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 107,546,224<span></span>
</td>
<td class="nump">$ 112,693,868<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_OtherLongTermObligationsExcludingCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Long Term Obligations, Excluding Current Portion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_OtherLongTermObligationsExcludingCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting and classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31917-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31931-109318<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1336-112600<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1314-112600<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6614679952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">15,471,070<span></span>
</td>
<td class="nump">15,481,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">15,471,070<span></span>
</td>
<td class="nump">15,481,497<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6758897744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Income (loss) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">$ 11,580,600<span></span>
</td>
<td class="nump">$ 10,163,724<span></span>
</td>
<td class="nump">$ 23,483,347<span></span>
</td>
<td class="nump">$ 18,751,329<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold</a></td>
<td class="nump">2,012,196<span></span>
</td>
<td class="nump">1,523,319<span></span>
</td>
<td class="nump">4,011,932<span></span>
</td>
<td class="nump">3,051,280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling and marketing</a></td>
<td class="nump">5,153,129<span></span>
</td>
<td class="nump">5,076,250<span></span>
</td>
<td class="nump">10,273,634<span></span>
</td>
<td class="nump">9,746,761<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,458,366<span></span>
</td>
<td class="nump">1,450,390<span></span>
</td>
<td class="nump">2,725,967<span></span>
</td>
<td class="nump">3,325,329<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,528,916<span></span>
</td>
<td class="nump">2,334,223<span></span>
</td>
<td class="nump">5,198,972<span></span>
</td>
<td class="nump">4,664,504<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="nump">1,029,708<span></span>
</td>
<td class="nump">648,520<span></span>
</td>
<td class="nump">2,051,353<span></span>
</td>
<td class="nump">1,284,655<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">12,182,315<span></span>
</td>
<td class="nump">11,032,702<span></span>
</td>
<td class="nump">24,261,858<span></span>
</td>
<td class="nump">22,072,529<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="num">(601,715)<span></span>
</td>
<td class="num">(868,978)<span></span>
</td>
<td class="num">(778,511)<span></span>
</td>
<td class="num">(3,321,200)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">130,565<span></span>
</td>
<td class="nump">149,706<span></span>
</td>
<td class="nump">246,426<span></span>
</td>
<td class="nump">232,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(91,200)<span></span>
</td>
<td class="num">(22,019)<span></span>
</td>
<td class="num">(152,111)<span></span>
</td>
<td class="num">(40,321)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income (loss) before income taxes</a></td>
<td class="num">(562,350)<span></span>
</td>
<td class="num">(741,291)<span></span>
</td>
<td class="num">(684,196)<span></span>
</td>
<td class="num">(3,129,321)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (expense) benefit</a></td>
<td class="num">(4,462)<span></span>
</td>
<td class="num">(4,159)<span></span>
</td>
<td class="nump">76,966<span></span>
</td>
<td class="num">(8,318)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(566,812)<span></span>
</td>
<td class="num">(745,450)<span></span>
</td>
<td class="num">(607,230)<span></span>
</td>
<td class="num">(3,137,639)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net (income) loss at subsidiary attributable to noncontrolling interests</a></td>
<td class="nump">17,305<span></span>
</td>
<td class="nump">24,762<span></span>
</td>
<td class="num">(16,155)<span></span>
</td>
<td class="nump">37,712<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to common shareholders</a></td>
<td class="num">$ (549,507)<span></span>
</td>
<td class="num">$ (720,688)<span></span>
</td>
<td class="num">$ (623,385)<span></span>
</td>
<td class="num">$ (3,099,927)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings (loss) per share attributable to common shareholders</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">- basic (in dollars per share)</a></td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.20)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">- diluted (in dollars per share)</a></td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.20)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">- basic (in shares)</a></td>
<td class="nump">15,523,628<span></span>
</td>
<td class="nump">15,674,954<span></span>
</td>
<td class="nump">15,497,989<span></span>
</td>
<td class="nump">15,682,348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">- diluted (in shares)</a></td>
<td class="nump">15,523,628<span></span>
</td>
<td class="nump">15,674,954<span></span>
</td>
<td class="nump">15,497,989<span></span>
</td>
<td class="nump">15,682,348<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income (loss) attributable to common shareholders</a></td>
<td class="num">$ (549,507)<span></span>
</td>
<td class="num">$ (720,688)<span></span>
</td>
<td class="num">$ (623,385)<span></span>
</td>
<td class="num">$ (3,099,927)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Net (income) loss at subsidiary attributable to noncontrolling interests</a></td>
<td class="nump">17,305<span></span>
</td>
<td class="nump">24,762<span></span>
</td>
<td class="num">(16,155)<span></span>
</td>
<td class="nump">37,712<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive income (loss)</a></td>
<td class="num">$ (566,812)<span></span>
</td>
<td class="num">$ (745,450)<span></span>
</td>
<td class="num">$ (607,230)<span></span>
</td>
<td class="num">$ (3,137,639)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4613674-111683<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=109256448&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=109256448&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6758634080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">$ (607,230)<span></span>
</td>
<td class="num">$ (3,137,639)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">2,174,397<span></span>
</td>
<td class="nump">1,394,728<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax expense</a></td>
<td class="nump">43,605<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">760,982<span></span>
</td>
<td class="nump">665,309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities', window );">(Decrease) increase in non-cash contingent consideration</a></td>
<td class="num">(321,894)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Noncash interest expense</a></td>
<td class="nump">28,111<span></span>
</td>
<td class="nump">33,730<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Noncash investment gains</a></td>
<td class="num">(125,804)<span></span>
</td>
<td class="num">(118,188)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Net changes in assets and liabilities affecting operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(583,029)<span></span>
</td>
<td class="nump">2,589,017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="nump">1,429,484<span></span>
</td>
<td class="num">(607,653)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other current assets and other assets</a></td>
<td class="nump">141,577<span></span>
</td>
<td class="nump">804,729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_IncreaseDecreaseInCurrentOperatingLiabilities', window );">Accounts payable and other current liabilities</a></td>
<td class="num">(1,132,333)<span></span>
</td>
<td class="num">(730,760)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="num">(342,940)<span></span>
</td>
<td class="nump">136,402<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">1,464,926<span></span>
</td>
<td class="nump">1,029,675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Additions to property and equipment</a></td>
<td class="num">(89,070)<span></span>
</td>
<td class="num">(131,684)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(9,627,191)<span></span>
</td>
<td class="num">(16,916,890)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sale of marketable securities</a></td>
<td class="nump">8,563,988<span></span>
</td>
<td class="nump">6,904,205<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid for acquisitions</a></td>
<td class="num">(5,000,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Additions to intangible assets</a></td>
<td class="num">(395,005)<span></span>
</td>
<td class="num">(593,121)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(6,547,278)<span></span>
</td>
<td class="num">(10,737,490)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit', window );">Borrowings on line of credit</a></td>
<td class="nump">36,000,000<span></span>
</td>
<td class="nump">24,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments on line of credit</a></td>
<td class="num">(36,000,000)<span></span>
</td>
<td class="num">(21,800,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sales of common stock, net of offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">200,909<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of deferred offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(248,108)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Cash payment of contingent consideration</a></td>
<td class="num">(684,738)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common shares</a></td>
<td class="num">(1,220,690)<span></span>
</td>
<td class="num">(1,951,199)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(1,905,428)<span></span>
</td>
<td class="nump">201,602<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(6,987,780)<span></span>
</td>
<td class="num">(9,506,213)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">27,938,960<span></span>
</td>
<td class="nump">45,412,868<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">20,951,180<span></span>
</td>
<td class="nump">35,906,655<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental non-cash operating, investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Recognition of operating lease assets and liabilities through adoption of ASC 842</a></td>
<td class="nump">3,629,320<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Repurchase of subsidiary shares from noncontrolling interests</a></td>
<td class="num">(800,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1', window );">Additions to intangible assets from final purchase price allocation</a></td>
<td class="nump">$ 148,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_IncreaseDecreaseInCurrentOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_IncreaseDecreaseInCurrentOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11374-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569655-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4616395-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6759703888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Retained earnings</div></th>
<th class="th"><div>Noncontrolling interests</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Beginning of Period at Dec. 31, 2017</a></td>
<td class="nump">$ 63,921,601<span></span>
</td>
<td class="nump">$ 52,410,941<span></span>
</td>
<td class="nump">$ 11,709,222<span></span>
</td>
<td class="num">$ (198,562)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning of Period (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,723,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from sales of common stock, net of offering costs</a></td>
<td class="nump">200,909<span></span>
</td>
<td class="nump">$ 200,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from the sale of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">339,209<span></span>
</td>
<td class="nump">$ 339,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="num">(1,195,225)<span></span>
</td>
<td class="num">$ (1,195,225)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(172,079)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(2,392,189)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,379,239)<span></span>
</td>
<td class="num">(12,950)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, End of Period at Mar. 31, 2018</a></td>
<td class="nump">60,874,305<span></span>
</td>
<td class="nump">$ 51,755,834<span></span>
</td>
<td class="nump">9,329,983<span></span>
</td>
<td class="num">(211,512)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, End of Period (in shares) at Mar. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,727,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Beginning of Period at Dec. 31, 2017</a></td>
<td class="nump">63,921,601<span></span>
</td>
<td class="nump">$ 52,410,941<span></span>
</td>
<td class="nump">11,709,222<span></span>
</td>
<td class="num">(198,562)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning of Period (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,723,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Repurchase of subsidiary shares from noncontrolling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,000,000.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(299,370)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(3,137,639)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, End of Period at Jun. 30, 2018</a></td>
<td class="nump">59,670,450<span></span>
</td>
<td class="nump">$ 51,297,429<span></span>
</td>
<td class="nump">8,609,295<span></span>
</td>
<td class="num">(236,274)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, End of Period (in shares) at Jun. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,604,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Beginning of Period at Mar. 31, 2018</a></td>
<td class="nump">60,874,305<span></span>
</td>
<td class="nump">$ 51,755,834<span></span>
</td>
<td class="nump">9,329,983<span></span>
</td>
<td class="num">(211,512)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning of Period (in shares) at Mar. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,727,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from sales of common stock, net of offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from the sale of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">326,100<span></span>
</td>
<td class="nump">$ 326,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="num">(784,505)<span></span>
</td>
<td class="num">$ (784,505)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(127,291)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(745,450)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(720,688)<span></span>
</td>
<td class="num">(24,762)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, End of Period at Jun. 30, 2018</a></td>
<td class="nump">59,670,450<span></span>
</td>
<td class="nump">$ 51,297,429<span></span>
</td>
<td class="nump">8,609,295<span></span>
</td>
<td class="num">(236,274)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, End of Period (in shares) at Jun. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,604,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Beginning of Period at Dec. 31, 2018</a></td>
<td class="nump">$ 55,570,501<span></span>
</td>
<td class="nump">$ 51,098,613<span></span>
</td>
<td class="nump">4,746,154<span></span>
</td>
<td class="num">(274,266)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning of Period (in shares) at Dec. 31, 2018</a></td>
<td class="nump">15,481,497<span></span>
</td>
<td class="nump">15,481,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">$ 364,434<span></span>
</td>
<td class="nump">$ 364,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="num">(703,790)<span></span>
</td>
<td class="num">$ (703,790)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(121,466)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(40,418)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(73,878)<span></span>
</td>
<td class="nump">33,460<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, End of Period at Mar. 31, 2019</a></td>
<td class="nump">55,190,727<span></span>
</td>
<td class="nump">$ 50,759,257<span></span>
</td>
<td class="nump">4,672,276<span></span>
</td>
<td class="num">(240,806)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, End of Period (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,547,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Beginning of Period at Dec. 31, 2018</a></td>
<td class="nump">$ 55,570,501<span></span>
</td>
<td class="nump">$ 51,098,613<span></span>
</td>
<td class="nump">4,746,154<span></span>
</td>
<td class="num">(274,266)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning of Period (in shares) at Dec. 31, 2018</a></td>
<td class="nump">15,481,497<span></span>
</td>
<td class="nump">15,481,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Repurchase of subsidiary shares from noncontrolling interest</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(205,913)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(607,230)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, End of Period at Jun. 30, 2019</a></td>
<td class="nump">$ 53,688,717<span></span>
</td>
<td class="nump">$ 49,938,254<span></span>
</td>
<td class="nump">4,122,769<span></span>
</td>
<td class="num">(372,306)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, End of Period (in shares) at Jun. 30, 2019</a></td>
<td class="nump">15,471,070<span></span>
</td>
<td class="nump">15,471,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Beginning of Period at Mar. 31, 2019</a></td>
<td class="nump">$ 55,190,727<span></span>
</td>
<td class="nump">$ 50,759,257<span></span>
</td>
<td class="nump">4,672,276<span></span>
</td>
<td class="num">(240,806)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning of Period (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,547,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">396,548<span></span>
</td>
<td class="nump">$ 396,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Repurchase of subsidiary shares from noncontrolling interest</a></td>
<td class="num">(800,000)<span></span>
</td>
<td class="num">$ (685,805)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(114,195)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="num">(531,746)<span></span>
</td>
<td class="num">$ (531,746)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(84,447)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(566,812)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(549,507)<span></span>
</td>
<td class="num">(17,305)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, End of Period at Jun. 30, 2019</a></td>
<td class="nump">$ 53,688,717<span></span>
</td>
<td class="nump">$ 49,938,254<span></span>
</td>
<td class="nump">$ 4,122,769<span></span>
</td>
<td class="num">$ (372,306)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, End of Period (in shares) at Jun. 30, 2019</a></td>
<td class="nump">15,471,070<span></span>
</td>
<td class="nump">15,471,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569655-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4616395-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6607744256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION AND BASIS OF PRESENTATION</a></td>
<td class="text">ORGANIZATION AND BASIS OF PRESENTATION<div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Cumberland Pharmaceuticals Inc. (&#8220;Cumberland,&#8221; the &#8220;Company,&#8221; or as used in the context of &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products.  The Company's primary target markets are hospital acute care, gastroenterology, and oncology supportive care. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company&#8217;s products are manufactured by third parties, which are overseen by Cumberland&#8217;s quality control and manufacturing professionals. The Company works closely with its third-party distribution partners to make its products available in the United States.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In the opinion of management, the accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a basis consistent with the December 31, 2018 audited consolidated financial statements, with the exception of the impacts of adopting accounting pronouncements during 2019, and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly present the information set forth herein. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements have been prepared in accordance with the regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;), and certain information and disclosures have been condensed or omitted as permitted by the SEC for interim period presentation. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2018 (the &#8220;2018 Annual Report on Form 10-K&#8221;). The results of operations for the three and six months ended June 30, 2019 are not necessarily indicative of the results to be expected for the entire fiscal year or any future period.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Total comprehensive income (loss) consisted solely of net income (loss) for the three and six months ended June 30, 2019 and 2018.</span></div><div style="margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Guidance</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Recent Adopted Accounting Pronouncement</span></div><div style="text-align:justify;margin-top:7pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In February 2016, the Financial Accounting Standards Board ("FASB") issued guidance in the form of a FASB Accounting Standards Update ("ASU") No. 2016-02, &#8220;Leases.&#8221; The new standard establishes a right-of-use (&#8220;ROU&#8221;) model that requires a lessee to record an ROU asset and a lease liability on the balance sheet for all leases with terms longer than twelve months. Leases will be classified as either finance (formerly "capital leases") or operating, with classification affecting the pattern of expense recognition in the income statement. The standard provides for a modified retrospective transition approach for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain optional practical expedients.  In July 2018, the FASB issued ASU 2018-11, "Leases: Targeted Improvements", allowing for an alternative transition method (the effective date approach). It allows an entity to initially apply the new lease guidance at the adoption date (rather than at the beginning of the earliest period presented). Cumberland adopted the lease guidance effective January 1, 2019 using the package of transition practical expedients.  This allowed the Company to retain the lease classification for any leases existing prior to adoption, in addition to other benefits. See additional discussion of the impact of adopting the lease accounting guidance in Note 6.</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Recent Accounting Pronouncements - Not Yet Adopted </span></div><div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the FASB issued ASU No. 2016-13, &#8220;Financial Instruments-Credit Losses,&#8221; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#8220;expected loss&#8221; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose significantly more information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#8217;s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is adopted. This standard is effective for the Company on January 1, 2020 with early adoption permitted. The Company is in the initial stage of evaluating the impact of this new standard on its trade and other receivables.</span></div><div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In November 2018, the FASB issued ASU No. 2018-18, &#8220;Collaboration Arrangements: Clarifying the Interaction between Topic 808 and Topic 606&#8221; (ASU 2018-18). The issuance of ASU 2014-09 raised questions about the interaction between the guidance on collaborative arrangements and revenue recognition. ASU 2018-18 addresses this uncertainty by (1) clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASU 2014-09 when the collaboration arrangement participant is a customer, (2) adding unit of account guidance to assess whether the collaboration arrangement or a part of the arrangement is with a customer and (3) precluding a company from presenting transactions with collaboration arrangement participants that are not directly related to sales to third parties together with revenue from contracts with customers. The new standard will be effective for the Company on January 1, 2020 with early adoption permitted. The Company is in the initial stage of evaluating the impact of this new standard on its condensed consolidated financial statements and related disclosures.</span></div><div style="text-align:justify;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">In May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably elect the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met, the election must be applied on an instrument-by-instrument basis, and the election is not available for either available-for-sale or held-to-maturity debt securities. As Cumberland has not yet adopted ASU 2016-13, the effective dates are the same as those in ASU 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">January 1, 2020. The Company is in the initial stage of evaluating the impact of this new standard on its condensed consolidated financial statements and related disclosures.</span></div><div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In January 2017, the FASB issued ASU No. 2017-04, &#8220;Simplifying the Test for Goodwill Impairment&#8221; (ASU 2017-04). The guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation.  As a result of the revised guidance, a goodwill impairment will be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The new standard will be effective for the Company on January 1, 2020 and will be applied prospectively. The Company is in the initial stage of evaluating the impact of this new standard on its condensed consolidated financial statements and related disclosures.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accounting Policies:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Use of Estimates</span></div><div style="text-align:justify;margin-top:7pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns (2) the allowances for obsolescent or unmarketable inventory (3) assumptions used in estimating acquisition date fair value of assets acquired in business combinations and (4) valuation of contingent consideration liability associated with business combinations.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Operating Segments</span></div>The Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#8217;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6744838144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">MARKETABLE SECURITIES</a></td>
<td class="text">MARKETABLE SECURITIES<div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company invests in marketable debt securities in order to maximize its return on cash. Marketable securities consist of short-term cash investments, U.S. Treasury notes and bonds,  corporate bonds and commercial paper.  At the time of purchase, the Company classifies marketable securities as either trading securities or available-for-sale securities, depending on the intent at that time.  As of June 30, 2019 and December&#160;31, 2018, marketable securities were comprised solely of trading securities.  Trading securities are carried at fair value with unrealized gains and losses recognized as a component of interest income in the consolidated statements of operations.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company's fair value measurements follow the appropriate rules as well as the fair value hierarchy that prioritizes the information used to develop the measurements.  It applies whenever other guidance requires (or permits) assets or liabilities to be measured at fair value and gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">A summary of the fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels is described below:</span></div><div style="text-indent:-45pt;padding-left:81pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Level 1 -   Quoted prices for identical instruments in active markets.</span></div><div style="text-indent:-45pt;padding-left:81pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Level 2 -   Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.</span></div><div style="text-indent:-45pt;padding-left:81pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Level 3 -   Significant inputs to the valuation model are unobservable.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company's fair values of marketable securities are determined based on valuations provided by a third-party pricing service, as derived from such service's pricing models, and are considered either Level 1 or Level 2 measurements, depending on the nature of the investment.  The Company has no marketable securities in which the fair value is determined based on Level 3 measurements.  The level of management judgment required in evaluating fair value for Level 1 investments is minimal.  Similarly, there is little subjectivity or judgment required for Level 2 investments valued using valuation models that are standard across the industry and whose parameter inputs are quoted in active markets.  Inputs to the models may include, but are not limited to, reported trades, executable bid and ask prices, broker/dealer quotations, prices or yields of securities with similar characteristics, benchmark curves or information pertaining to the issuer, as well as industry and economic events. Based on the information available, the Company believes that the valuations provided by the third-party pricing service, as derived from such service's pricing models, are representative of prices that would be received to sell the assets at the measurement date (exit prices).  There were no transfers of assets between levels within the fair value hierarchy.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:11pt;font-weight:400;line-height:120%;"> </span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the fair value of our marketable securities, by level within the fair value hierarchy, as of each period end:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:27.368576%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.160059%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160059%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160059%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160059%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160059%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160059%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasury notes and bonds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,155,696&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,155,696&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,034,955&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,034,955&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate bonds</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,504,551&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,504,551&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,265,824&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,265,824&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term cash investments</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,058,166&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,058,166&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">751,173&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">751,173&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total fair value of marketable  securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,155,696&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4,323,990&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">9,479,686&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,034,955&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,255,724&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">8,290,679&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6640829968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS (LOSS) PER SHARE</a></td>
<td class="text">EARNINGS (LOSS) PER SHARE<div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three and six months ended June 30, 2019 and 2018:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.122807%;"><tr><td style="width:1.0%;"/><td style="width:58.029499%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.616519%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.537463%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.616519%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) attributable to common shareholders</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(549,507)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(720,688)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">15,523,628&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">15,674,954&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Dilutive effect of other securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">15,523,628&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">15,674,954&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="text-align:justify;margin-top:11pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:57.210526%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.883041%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823392%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.883041%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) attributable to common shareholders</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(623,385)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(3,099,927)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">15,497,989&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">15,682,348&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Dilutive effect of other securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">15,497,989&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">15,682,348&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div style="text-align:justify;margin-top:11pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">As of June 30, 2019 and 2018, restricted stock awards and options to purchase 13,500 and 231,905 shares of common stock, respectively, were outstanding but were not included in the computation of diluted earnings per share because the effect would be antidilutive.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6744942320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">REVENUES</a></td>
<td class="text">REVENUES<div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Product Revenues</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for revenues from contracts with customers under ASC 606, which became effective January 1, 2018. As part of the adoption of ASC 606, the Company applied the new standard on a modified retrospective basis analyzing open contracts as of January 1, 2018. Results for reporting periods beginning after January 1, 2018 are presented under ASC 606. As discussed in Note 10, during November 2018 Cumberland entered into an agreement to acquire the global responsibility for Vibativ.  The product began contributing to Cumberland's net revenue during 2018.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s net revenues consisted of the following for the three and six months ended June 30, 2019 and 2018:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:27.824561%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.444444%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823392%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.298246%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.058480%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.888889%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Products:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Acetadote</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">983,473&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">841,431&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,832,976&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,115,741&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Omeclamox-Pak</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">478,604&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">89,952&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">678,141&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">231,344&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Kristalose</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,476,807&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,203,743&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6,785,050&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6,473,097&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Vaprisol</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">212,526&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,685,900&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">499,202&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,779,790&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Caldolor</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,054,718&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,101,023&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,372,599&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,140,771&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Ethyol</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,008,247&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,809,691&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,099,429&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,065,764&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Totect</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">154,910&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">269,190&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">235,805&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">681,964&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Vibativ</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,599,280&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4,659,471&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">612,035&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">162,794&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,320,674&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">262,858&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total net revenues</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11,580,600&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">10,163,724&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">23,483,347&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">18,751,329&#160;</span></td></tr></table></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Other Revenues</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">During the three months ended June 30, 2019, Cumberland executed a License and Distribution agreement with HongKong WinHealth Pharma Group Co. Limited (&#8220;WinHealth&#8221;) for our Caldolor and Acetadote</span><sup style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"> </sup><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">brands in China and Hong Kong.  In conjunction with these new arrangements, the Company terminated a previous License and Distribution agreement with Gloria Pharmaceuticals Co ("Gloria Pharmaceuticals") for the two brands.  In addition, we also signed a new License and Distribution agreement with DB Pharm Korea Co., Ltd. (&#8220;DB Pharm&#8221;) for Vibativ in South Korea. As a result of these agreements, Cumberland recognized approximately $0.3&#160;million of non-refundable up-front payments as other revenue in the consolidated statement of operations during the three months ended June 30, 2019.  Cumberland's performance obligation was satisfied upon entering into the agreements to license each of the products intellectual property. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">CET grant revenue for the three and six months ended June 30, 2019 included in other revenue was $0.2&#160;million  and $0.8&#160;million, respectively. </span></div>The Company has agreements with international partners for commercialization of the Company's products. The international agreements provide that each of the partners are responsible for seeking regulatory approvals for the products, and following approvals, each partner will handle ongoing distribution and sales in the respective international territories. The Company maintains responsibility for the intellectual property and product formulations. Under the international agreements, the Company is typically entitled to receive a non-refundable, up-front payment at the time each agreement is entered into as a result of providing the distinct intellectual property rights for the respective international territory. These agreements also provide for additional payments upon the partners' achievement of defined regulatory approvals, sales milestones or both. The Company may also be entitled to receive royalties on future sales of the products under the agreements and a transfer price on supplies.  The contractual payments associated with the partners achievement of regulatory approvals, sales milestones and royalties on future sales are recognized as revenue upon occurrence, or at such time that the Company has a high degree of confidence that the revenue would not be reversed in a subsequent period.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6630750352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text">INVENTORIES<div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company works closely with third parties to manufacture and package finished goods for sale.  Based on the relationship with the manufacturer or packager, the Company will either take title to the finished goods at the time of shipment or at the time of arrival from the manufacturer.  The Company then warehouses such goods until distribution and sale. Inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company continually evaluates inventory for potential losses due to excess, obsolete or slow-moving inventory by comparing sales history and sales projections to the inventory on hand. When evidence indicates that the carrying value may not be recoverable, a charge is taken to reduce the inventory to its current net realizable value.  At June 30, 2019 and December 31, 2018, the Company has recognized and maintained cumulative charges for potential obsolescence and discontinuance losses of approximately $0.1 million and $0.3 million, respectively. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In connection with the acquisition of certain product rights related to the Kristalose brand, the Company is responsible for the purchase of the active pharmaceutical ingredient (&#8220;API&#8221;) for Kristalose and maintains the inventory at the third-party manufacturer. As the API is consumed in production, the value of the API is transferred from raw materials to finished goods. API for the Company's Vaprisol brand is also included in the raw materials inventory total.  Consigned inventory represents Authorized Generic inventory stored until shipment.  </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">As part of the Vibativ acquisition, Cumberland acquired API and work in process inventories of $14.9 million that are classified as non-current inventories at June 30, 2019 and December 31, 2018. Non-current inventories also include $0.6 million and $0.8 million in Vibativ finished goods at June 30, 2019 and December&#160;31, 2018, respectively.  During 2019, Cumberland also obtained $0.3&#160;million in non-current inventory for API related to its ifetroban clinical initiatives.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company's net inventories consisted of the following:</span></div><div style="text-align:center;margin-top:7pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:56.737151%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.121586%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.530103%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.681057%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.530103%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials and work in process</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">19,076,378&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">18,378,450&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Consigned inventory</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">774,225&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">937,006&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods, net of reserves</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6,639,218&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">8,511,887&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:13pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">26,489,821&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">27,827,343&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:13pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">less non-current inventories</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(15,840,962)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(15,749,000)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventories classified as current</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">10,648,859&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">12,078,343&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6627134368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASESIn March 2016, the FASB issued ASU 2016-02. ASU 2016-02&#8217;s core principle is to increase transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information. The Company adopted ASU 2016-02 under the alternative transition method (the effective date approach). It allowed the Company to initially apply the new lease guidance at the adoption date (rather than at the beginning of the earliest period presented). Prior periods have not been adjusted.   <div style="text-align:justify;margin-top:7pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The primary effect of adopting ASU 2016-02 to the Company was to record right-of-use assets and obligations for the leases currently classified as operating leases.  The Company&#8217;s significant operating leases include the lease of approximately 25,500 square feet of office space in Nashville, Tennessee for its corporate headquarters.  This lease currently expires in October 2022.  The operating leases also include the lease of approximately 14,200 square feet of wet laboratory and office space in Nashville, Tennessee by Cumberland Emerging Technologies (&#8220;CET&#8221;), our majority-owned subsidiary, where it operates the CET Life Sciences Center.  This lease currently expires in April 2023. The Company did not have any leases classified as finance leases at January 1, 2019 or June 30, 2019.  The new lease accounting standard did not have a significant impact on the Company's Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) for any period presented. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company elected the package of practical expedients offered in the transition guidance which allows management not to reassess lease identification, lease classification and initial direct costs at the adoption date. </span></div><div style="text-align:justify;margin-top:7pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">These operating leases resulted in initial ROU assets of $3.6 million and lease liabilities of $3.8 million as of January 1, 2019 for non-cancelable operating leases with original lease terms in excess of one year.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Operating lease liabilities were recorded as the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for lease incentives and initial direct costs. As the Company&#8217;s leases do not contain implicit borrowing rates, the incremental borrowing rates were calculated based on information available at January 1, 2019. Incremental borrowing rates reflect the Company&#8217;s estimated interest rates for collateralized borrowings over similar lease terms. The weighted-average remaining lease term is 3.5 years and the weighted-average incremental borrowing rate used to discount the present value of the remaining lease payments is 7.42%.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Lease Position</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">At June 30, 2019, the Company recorded the following on the Condensed Consolidated Balance Sheet: </span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.368421%;"><tr><td style="width:1.0%;"/><td style="width:34.036036%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.751952%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:38.090090%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.751952%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.969970%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Right-of-Use Assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance Sheet Classification</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other non-current assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,260,767&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:7pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,260,767&#160;</span></td></tr></table></div><div style="margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.368421%;"><tr><td style="width:1.0%;"/><td style="width:34.036036%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.751952%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:38.090090%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.751952%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.969970%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Lease Liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance Sheet Classification</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Current:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:7pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other current liabilities&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">899,262&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Noncurrent:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:7pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other long-term liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,502,850&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,402,112&#160;</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.368421%;"><tr><td style="width:1.0%;"/><td style="width:76.078078%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.751952%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.969970%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Maturity of Leases Liabilities at June 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Operating Leases</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">532,465&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,120,066&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,144,889&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,019,313&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">92,477&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">After 2023</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">0&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,909,210&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Interest</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(507,098)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,402,112&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6744925104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity and Debt<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_EquityAndDebtAbstract', window );"><strong>Equity and Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHAREHOLDERS' EQUITY AND DEBT</a></td>
<td class="text">SHAREHOLDERS&#8217; EQUITY AND DEBT<div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Share repurchases</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company currently has a share repurchase program to repurchase up to $10 million of its common stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. In January 2019, the Company's Board of Directors established the current $10 million repurchase program to replace the prior authorizations.  During the six months ended June 30, 2019 and June 30, 2018, the Company repurchased 205,913 shares and 299,370 shares, respectively, of common stock for approximately $1.2 million and $2.0 million, respectively. </span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Share purchases and sales</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">During the Company's March 2019 trading window, several members of Cumberland's Board of Directors entered into share purchase agreements of the Company's stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. These purchases are designed to increase ownership in the Company by the members of the Board.  During the March 2019 trading window, one member of the Board of Directors entered into a share sale agreement, as required by a policy change by his employer, which prohibits his ownership in a pharmaceutical company.  The policy change did not impact his ability to serve on the Company's Board of Directors.  This Board member sold 47,969 Cumberland shares during the second quarter 2019.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Share Sale</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In November 2017, the Company filed a Shelf Registration on Form S-3 with the SEC associated with the sale of up to $100 million in corporate securities. The Shelf Registration was declared effective in January 2018. During the six months ended June 30, 2018, the Company issued 30,704 shares of common stock for gross proceeds of $0.2 million as part of its At-The-Market (&#8220;ATM&#8221;) sales agreement with B. Riley FBR. The Company did not issue any shares under the ATM during the six months ended June 30, 2019.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Restricted Share Grants </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">During the six months ended June 30, 2019, and June 30, 2018, the Company issued 222,469 shares and 233,330 shares of restricted stock to employees and directors, respectively. Restricted stock issued to employees generally cliff-vests on the fourth anniversary of the date of grant and for directors on the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmY3MGIwYzUzM2Y5ODQ4OWE4Y2UzMTUwZTI0MTdiNzU3L3NlYzpmNzBiMGM1MzNmOTg0ODlhOGNlMzE1MGUyNDE3Yjc1N181OC9mcmFnOmViNzI5MWIzYzY3NTRhM2ZiYmE0OWRkY2JmNzA3OGY0L3RleHRyZWdpb246ZWI3MjkxYjNjNjc1NGEzZmJiYTQ5ZGRjYmY3MDc4ZjRfMTg2MQ_7b6a6f88-b9bb-43f7-bebc-cb00283f1265">one</span>-year anniversary of the date of grant.  Stock compensation expense is presented as a component of general and administrative expense in the condensed consolidated statements of operations and comprehensive income (loss).</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Cumberland Emerging Technologies</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In April 2019, Cumberland Emerging Technologies ("CET"), our majority-owned subsidiary, entered into </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">an agreement with WinHealth whereby WinHealth will make a $1&#160;million investment through the purchase of shares of CET stock. As part of the agreement, WinHealth obtained a Board position at CET and the first opportunity to license CET products for the Chinese market. In connection with WinHealth's investment in CET, Cumberland also made an additional $1&#160;million investment in CET.  Cumberland purchased additional CET shares through contribution of $0.3&#160;million in cash and a conversion of $0.7&#160;million in intercompany loans payable.  Upon completion of the additional investment by WinHealth and Cumberland, Gloria Pharmaceuticals agreed to return it's shares in CET in exchange for a payment of $0.8&#160;million.  </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Debt Agreement</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On May 10, 2019, the Company entered into a third amendment ("Third Amendment") to the Revolving Credit Loan Agreement, dated July 28, 2017, with Pinnacle Bank (&#8220;Pinnacle Agreement&#8221;). The Third Amendment extended the term of the Pinnacle Agreement through July 31, 2021 as well as modified certain definitions and terms of the existing financial covenants.  The initial revolving line of credit under the Pinnacle Agreement was for up to an aggregate principal amount of $12.0 million with the ability to increase the principal amount available for borrowing up to $20.0 million, upon the satisfaction of certain conditions.   On October 17, 2018, the Company entered into a second amendment (&#8220;Second Amendment&#8221;) which increased the maximum aggregate principal available for borrowing under the Pinnacle Agreement to $20.0 million.  Cumberland increased the maximum aggregate principal available for borrowing to support potential future acquisitions and general corporate purposes.  </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. There is no LIBOR minimum and the LIBOR pricing provides for an interest rate spread of 1.75% to 2.75% (representing an interest rate of 5.15% at June 30, 2019).  In addition, a fee of 0.25% per year is charged on the unused line of credit.  Interest and the unused line fee are payable quarterly.  Borrowings under the line of credit are collateralized by substantially all of our assets. </span></div>Under the Pinnacle Agreement, Cumberland was initially subject to one financial covenant, the maintenance of a Funded Debt Ratio, as such term is defined in the agreement and determined on a quarterly basis.  On August 14, 2018, the Company amended the Pinnacle Agreement ("First Amendment") to replace the single financial covenant with the maintenance of either the Funded Debt Ratio or a Tangible Capital Ratio, as defined in the First Amendment.  The Third Amendment modified the definition of the Funded Debt Ratio and the compliance target of the Tangible Capital Ratio. Both Third Amendment modifications were related to the Vibativ transaction.  The Company was in compliance with the Tangible Capital Ratio financial covenant as of June 30, 2019.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_EquityAndDebtAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity and Debt [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_EquityAndDebtAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6744941632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXES<div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (&#8220;the Tax Act&#8221;).  The Tax Act makes broad and complex changes to the U.S. tax code, including, but not limited to, (1) reducing the U.S. federal corporate tax rate to 21%; (2) eliminating the corporate alternative minimum tax (&#8220;AMT&#8221;) and changing how AMT credits can be realized; (3) capital expensing; and (4) creating new limitations on deductible interest expense and executive compensation.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The SEC staff issued Staff Accounting Bulletin (&#8220;SAB&#8221;) 118, providing guidance on applying the Tax Act.  SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740.  In accordance with SAB 118, a company reflects the income tax effects of the Tax Act for which the accounting under ASC 740 is complete.  To the extent that a company&#8217;s accounting for certain income tax effects of the Tax Act is incomplete but a reasonable estimate is available, it must record the estimate in the financial statements.  If a company cannot determine an estimate, it should continue to apply ASC 740 on the basis of the tax laws that were in effect immediately prior to enactment of the Tax Act.  The Company expects it will continue to pay minimal taxes in future periods through the continued utilization of net operating loss carryforwards, as it is able to achieve taxable income through its operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6635760800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">COLLABORATIVE AGREEMENTS</a></td>
<td class="text">COLLABORATIVE AGREEMENTS<span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Cumberland is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The Company has determined that these collaborative agreements do not meet the criteria for accounting under ASC Topic 808, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaborative Agreements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">. The agreements do not specifically designate each party&#8217;s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from grants are recorded as net revenues in the condensed consolidated statements of operations and comprehensive income (loss).</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6632666896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Additions and Expected Return of Product Rights<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">RECENT ADDITIONS AND EXPECTED RETURN OF PRODUCT RIGHTS</a></td>
<td class="text">RECENT ADDITIONS AND EXPECTED RETURN OF PRODUCT RIGHTS<div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Omeclamox-Pak</span></div><div style="text-align:justify;margin-top:7pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In December 2018, Cumberland completed an agreement with Gasto-enterlogics Inc. ("GEL") to acquire the remaining product rights associated with Omeclamox-Pak, including the product&#8217;s FDA-approved New Drug Application and the domestic and international trademarks. As part of the transaction, which was accounted for as an asset acquisition, Cumberland paid $2.3 million during 2018 and ended Cumberland&#8217;s payments of royalties and manufacturing fees to GEL.  The Company has now assumed responsibility for the maintenance of the product&#8217;s FDA approval and for the oversight of the product&#8217;s manufacturing and packaging.</span></div><div style="text-align:justify;margin-top:7pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Vibativ</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">During November 2018, the Company closed on an agreement with Theravance Biopharma ("Theravance") to acquire the global responsibility for Vibativ including the marketing, distribution, manufacturing and regulatory activities associated with the brand.  Vibativ is a patented, FDA approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.  Cumberland acquired Vibativ to further add to its product offerings, increase its net revenue and positively contribute to the Company's operating results.  While Cumberland is still evaluating the tax deductibility of the goodwill acquired in the acquisition, it expects those amounts to be deductible for tax purposes.    </span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company made an upfront payment of $20.0 million at the closing of the transaction and a $5.0 million milestone payment in early April 2019. In addition, Cumberland has agreed to pay a royalty of up to 20% on future net sales of the product.  The future royalty payments are required to be recognized at their acquisition-date fair value as part of the contingent consideration transferred in the business combination. </span></div><div style="margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the initial payments and consideration for the business combination:</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:75.631579%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:20.368421%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Consideration:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid at closing</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">20,000,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash payment during early 2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,000,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of contingent consideration - net sales royalty</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">9,182,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total consideration </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">34,182,000&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:6pt;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The contingent consideration liability represents the future net sales royalty payments discussed above.  Cumberland prepared the valuations of the contingent consideration liability and the intangible assets utilizing significant unobservable inputs.  As a result, the valuations are classified as Level 3 fair value measurements.  The Company will continue to evaluate the assets acquired and liabilities assumed during the measurement period. </span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table presents the changes in the Company's Level 3 contingent consideration liability that is measured at fair value on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to the seller quarterly.</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:75.923977%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:20.076023%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration liability</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at November 12, 2018</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">9,034,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(40,000)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">508,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">9,502,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustment to initial fair value of the contingent consideration liability</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">148,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash payment of royalty during the period</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(684,738)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(321,894)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">423,041&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at June 30, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">9,066,409&#160;</span></td></tr></table></div><div style="margin-top:8pt;"><span><br/></span></div><div style="margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the final allocation of the fair values of the assets acquired as part of the acquisition of Vibativ:</span></div><div style="text-align:justify;margin-top:8pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:75.923977%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:20.076023%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods inventory</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6,624,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Work in process - unlabeled vials</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,970,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Work in process - validation vials</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,827,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">9,129,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:13pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventory</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">21,550,000&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Intellectual property amortizable intangible assets</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11,750,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">882,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:13pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total intangibles and goodwill</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">12,632,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets acquired</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">34,182,000&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company's contingent consideration liability is a Level 3 fair value measurement that is updated on a recurring basis at each reporting period using a valuation model.  Consistent with Level 3 fair value measurements, there are significant inputs to the valuation model that are unobservable. The current portion of the contingent consideration liability is $2.1 million and the non-current portion is $7.0 million. </span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Ethyol and Totect </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">During May 2019, Cumberland entered into a Dissolution Agreement with Clinigen Healthcare Limited ("Agreement") in which the Company will return the exclusive rights to commercialize Ethyol and Totect in the United States to Clinigen. The Agreement results in a transition from the Company's current arrangement with Clinigen effective September 30, 2019.  Under the terms of the agreement, Cumberland will no longer be involved directly or indirectly with the distribution, marketing and promotion of either Ethyol or Totect or any competing products.  In exchange for the return of these product license rights and not competing with either product, Cumberland will receive $5&#160;million in financial consideration paid over the two-years following September 30, 2019.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6635545024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Guidance</a></td>
<td class="text"><div style="margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Guidance</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Recent Adopted Accounting Pronouncement</span></div><div style="text-align:justify;margin-top:7pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In February 2016, the Financial Accounting Standards Board ("FASB") issued guidance in the form of a FASB Accounting Standards Update ("ASU") No. 2016-02, &#8220;Leases.&#8221; The new standard establishes a right-of-use (&#8220;ROU&#8221;) model that requires a lessee to record an ROU asset and a lease liability on the balance sheet for all leases with terms longer than twelve months. Leases will be classified as either finance (formerly "capital leases") or operating, with classification affecting the pattern of expense recognition in the income statement. The standard provides for a modified retrospective transition approach for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain optional practical expedients.  In July 2018, the FASB issued ASU 2018-11, "Leases: Targeted Improvements", allowing for an alternative transition method (the effective date approach). It allows an entity to initially apply the new lease guidance at the adoption date (rather than at the beginning of the earliest period presented). Cumberland adopted the lease guidance effective January 1, 2019 using the package of transition practical expedients.  This allowed the Company to retain the lease classification for any leases existing prior to adoption, in addition to other benefits. See additional discussion of the impact of adopting the lease accounting guidance in Note 6.</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Recent Accounting Pronouncements - Not Yet Adopted </span></div><div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the FASB issued ASU No. 2016-13, &#8220;Financial Instruments-Credit Losses,&#8221; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#8220;expected loss&#8221; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose significantly more information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#8217;s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is adopted. This standard is effective for the Company on January 1, 2020 with early adoption permitted. The Company is in the initial stage of evaluating the impact of this new standard on its trade and other receivables.</span></div><div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In November 2018, the FASB issued ASU No. 2018-18, &#8220;Collaboration Arrangements: Clarifying the Interaction between Topic 808 and Topic 606&#8221; (ASU 2018-18). The issuance of ASU 2014-09 raised questions about the interaction between the guidance on collaborative arrangements and revenue recognition. ASU 2018-18 addresses this uncertainty by (1) clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASU 2014-09 when the collaboration arrangement participant is a customer, (2) adding unit of account guidance to assess whether the collaboration arrangement or a part of the arrangement is with a customer and (3) precluding a company from presenting transactions with collaboration arrangement participants that are not directly related to sales to third parties together with revenue from contracts with customers. The new standard will be effective for the Company on January 1, 2020 with early adoption permitted. The Company is in the initial stage of evaluating the impact of this new standard on its condensed consolidated financial statements and related disclosures.</span></div><div style="text-align:justify;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">In May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably elect the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met, the election must be applied on an instrument-by-instrument basis, and the election is not available for either available-for-sale or held-to-maturity debt securities. As Cumberland has not yet adopted ASU 2016-13, the effective dates are the same as those in ASU 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">January 1, 2020. The Company is in the initial stage of evaluating the impact of this new standard on its condensed consolidated financial statements and related disclosures.</span></div><div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In January 2017, the FASB issued ASU No. 2017-04, &#8220;Simplifying the Test for Goodwill Impairment&#8221; (ASU 2017-04). The guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation.  As a result of the revised guidance, a goodwill impairment will be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The new standard will be effective for the Company on January 1, 2020 and will be applied prospectively. The Company is in the initial stage of evaluating the impact of this new standard on its condensed consolidated financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Use of Estimates</span></div><div style="text-align:justify;margin-top:7pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns (2) the allowances for obsolescent or unmarketable inventory (3) assumptions used in estimating acquisition date fair value of assets acquired in business combinations and (4) valuation of contingent consideration liability associated with business combinations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Operating Segments</a></td>
<td class="text">Operating SegmentsThe Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#8217;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6744937232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Fair value of marketable securities, by type</a></td>
<td class="text"><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the fair value of our marketable securities, by level within the fair value hierarchy, as of each period end:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:27.368576%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.160059%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160059%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160059%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160059%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160059%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160059%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasury notes and bonds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,155,696&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,155,696&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,034,955&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,034,955&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate bonds</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,504,551&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,504,551&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,265,824&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,265,824&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term cash investments</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,058,166&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,058,166&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">751,173&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">751,173&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total fair value of marketable  securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,155,696&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4,323,990&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">9,479,686&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,034,955&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,255,724&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">8,290,679&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6614611648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Reconciliation of numerator and denominator</a></td>
<td class="text"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three and six months ended June 30, 2019 and 2018:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.122807%;"><tr><td style="width:1.0%;"/><td style="width:58.029499%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.616519%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.537463%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.616519%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) attributable to common shareholders</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(549,507)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(720,688)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">15,523,628&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">15,674,954&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Dilutive effect of other securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">15,523,628&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">15,674,954&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:57.210526%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.883041%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823392%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.883041%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) attributable to common shareholders</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(623,385)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(3,099,927)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">15,497,989&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">15,682,348&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Dilutive effect of other securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">15,497,989&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">15,682,348&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6744937232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Summary of net revenue</a></td>
<td class="text"><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s net revenues consisted of the following for the three and six months ended June 30, 2019 and 2018:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:27.824561%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.444444%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823392%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.298246%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.058480%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.888889%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Products:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Acetadote</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">983,473&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">841,431&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,832,976&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,115,741&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Omeclamox-Pak</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">478,604&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">89,952&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">678,141&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">231,344&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Kristalose</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,476,807&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,203,743&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6,785,050&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6,473,097&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Vaprisol</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">212,526&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,685,900&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">499,202&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,779,790&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Caldolor</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,054,718&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,101,023&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,372,599&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,140,771&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Ethyol</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,008,247&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,809,691&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,099,429&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,065,764&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Totect</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">154,910&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">269,190&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">235,805&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">681,964&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Vibativ</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,599,280&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4,659,471&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">612,035&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">162,794&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,320,674&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">262,858&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total net revenues</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11,580,600&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">10,163,724&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">23,483,347&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">18,751,329&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6636193312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventory</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company's net inventories consisted of the following:</span></div><div style="text-align:center;margin-top:7pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:56.737151%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.121586%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.530103%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.681057%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.530103%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials and work in process</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">19,076,378&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">18,378,450&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Consigned inventory</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">774,225&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">937,006&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods, net of reserves</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6,639,218&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">8,511,887&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:13pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">26,489,821&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">27,827,343&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:13pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">less non-current inventories</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(15,840,962)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(15,749,000)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventories classified as current</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">10,648,859&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">12,078,343&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6636009696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Lease Position</a></td>
<td class="text"><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">At June 30, 2019, the Company recorded the following on the Condensed Consolidated Balance Sheet: </span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.368421%;"><tr><td style="width:1.0%;"/><td style="width:34.036036%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.751952%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:38.090090%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.751952%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.969970%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Right-of-Use Assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance Sheet Classification</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other non-current assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,260,767&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:7pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,260,767&#160;</span></td></tr></table></div><div style="margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.368421%;"><tr><td style="width:1.0%;"/><td style="width:34.036036%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.751952%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:38.090090%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.751952%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.969970%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Lease Liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance Sheet Classification</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Current:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:7pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other current liabilities&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">899,262&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Noncurrent:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:7pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other long-term liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,502,850&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,402,112&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturity of Lease Liabilities</a></td>
<td class="text"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.368421%;"><tr><td style="width:1.0%;"/><td style="width:76.078078%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.751952%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.969970%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Maturity of Leases Liabilities at June 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Operating Leases</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">532,465&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,120,066&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,144,889&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,019,313&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">92,477&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">After 2023</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">0&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,909,210&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Interest</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(507,098)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,402,112&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets and Liabilities, Lessee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6614379728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Additions and Expected Return of Product Rights (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of Business Acquisitions, by Acquisition</a></td>
<td class="text"><div style="margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the initial payments and consideration for the business combination:</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:75.631579%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:20.368421%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Consideration:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid at closing</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">20,000,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash payment during early 2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,000,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of contingent consideration - net sales royalty</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">9,182,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total consideration </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">34,182,000&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock', window );">Schedule of Business Acquisitions by Acquisition, Contingent Consideration</a></td>
<td class="text"><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table presents the changes in the Company's Level 3 contingent consideration liability that is measured at fair value on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to the seller quarterly.</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:75.923977%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:20.076023%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration liability</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at November 12, 2018</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">9,034,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(40,000)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">508,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">9,502,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustment to initial fair value of the contingent consideration liability</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">148,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash payment of royalty during the period</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(684,738)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(321,894)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">423,041&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at June 30, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">9,066,409&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><div style="margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the final allocation of the fair values of the assets acquired as part of the acquisition of Vibativ:</span></div><div style="text-align:justify;margin-top:8pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:75.923977%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:20.076023%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods inventory</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6,624,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Work in process - unlabeled vials</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3,970,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Work in process - validation vials</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,827,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">9,129,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:13pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventory</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">21,550,000&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Intellectual property amortizable intangible assets</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11,750,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">882,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:13pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total intangibles and goodwill</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">12,632,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets acquired</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">34,182,000&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1486-128463<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6610656944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation Organization (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2019 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6760969440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 9,479,686<span></span>
</td>
<td class="nump">$ 8,290,679<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=cpix_UsTreasuryNotesAndBondsSecuritiesMemberMember', window );">U.S. Treasury notes and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">5,155,696<span></span>
</td>
<td class="nump">5,034,955<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,504,551<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">2,265,824<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Short-term cash investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">2,058,166<span></span>
</td>
<td class="nump">751,173<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">5,155,696<span></span>
</td>
<td class="nump">5,034,955<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | U.S. Treasury notes and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">5,155,696<span></span>
</td>
<td class="nump">5,034,955<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Short-term cash investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">4,323,990<span></span>
</td>
<td class="nump">3,255,724<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. Treasury notes and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,504,551<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">2,265,824<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Short-term cash investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 2,058,166<span></span>
</td>
<td class="nump">$ 751,173<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradingSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradingSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=cpix_UsTreasuryNotesAndBondsSecuritiesMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=cpix_UsTreasuryNotesAndBondsSecuritiesMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6918664016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_NumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to common shareholders</a></td>
<td class="num">$ (549,507)<span></span>
</td>
<td class="num">$ (720,688)<span></span>
</td>
<td class="num">$ (623,385)<span></span>
</td>
<td class="num">$ (3,099,927)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding &#8211; basic (in shares)</a></td>
<td class="nump">15,523,628<span></span>
</td>
<td class="nump">15,674,954<span></span>
</td>
<td class="nump">15,497,989<span></span>
</td>
<td class="nump">15,682,348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive effect of other securities (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding &#8211; diluted (in shares)</a></td>
<td class="nump">15,523,628<span></span>
</td>
<td class="nump">15,674,954<span></span>
</td>
<td class="nump">15,497,989<span></span>
</td>
<td class="nump">15,682,348<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DenominatorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Denominator.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DenominatorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_NumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Numerator.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_NumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6636984016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share (Details Textual) - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock available for purchase through restricted stock awards and options (in shares)</a></td>
<td class="nump">13,500<span></span>
</td>
<td class="nump">231,905<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6759426912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">$ 11,580,600<span></span>
</td>
<td class="nump">$ 10,163,724<span></span>
</td>
<td class="nump">$ 23,483,347<span></span>
</td>
<td class="nump">$ 18,751,329<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueRightsGrantedMember', window );">CET Grant Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember', window );">WinHealth and DB Pharm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_AcetadoteMember', window );">Acetadote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">983,473<span></span>
</td>
<td class="nump">841,431<span></span>
</td>
<td class="nump">1,832,976<span></span>
</td>
<td class="nump">2,115,741<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_OmeclamoxPakMember', window );">Omeclamox-Pak</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">478,604<span></span>
</td>
<td class="nump">89,952<span></span>
</td>
<td class="nump">678,141<span></span>
</td>
<td class="nump">231,344<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_KristaloseMember', window );">Kristalose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">3,476,807<span></span>
</td>
<td class="nump">3,203,743<span></span>
</td>
<td class="nump">6,785,050<span></span>
</td>
<td class="nump">6,473,097<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_VaprisolMember', window );">Vaprisol</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">212,526<span></span>
</td>
<td class="nump">1,685,900<span></span>
</td>
<td class="nump">499,202<span></span>
</td>
<td class="nump">1,779,790<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_CaldolorMember', window );">Caldolor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">1,054,718<span></span>
</td>
<td class="nump">1,101,023<span></span>
</td>
<td class="nump">2,372,599<span></span>
</td>
<td class="nump">2,140,771<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_EthyolMember', window );">Ethyol</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">2,008,247<span></span>
</td>
<td class="nump">2,809,691<span></span>
</td>
<td class="nump">5,099,429<span></span>
</td>
<td class="nump">5,065,764<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_TotectMember', window );">Totect</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">154,910<span></span>
</td>
<td class="nump">269,190<span></span>
</td>
<td class="nump">235,805<span></span>
</td>
<td class="nump">681,964<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_VIBATIVMember', window );">Vibativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">2,599,280<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,659,471<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_OtherProductsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">$ 612,035<span></span>
</td>
<td class="nump">$ 162,794<span></span>
</td>
<td class="nump">$ 1,320,674<span></span>
</td>
<td class="nump">$ 262,858<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ProductsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Products.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ProductsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueRightsGrantedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueRightsGrantedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_AcetadoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_AcetadoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_OmeclamoxPakMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_OmeclamoxPakMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_KristaloseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_KristaloseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_VaprisolMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_VaprisolMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_CaldolorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_CaldolorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_EthyolMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_EthyolMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_TotectMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_TotectMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_OtherProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_OtherProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6913166192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Nov. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Reserve for potential obsolescence of products</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials and work in process</a></td>
<td class="nump">19,076,378<span></span>
</td>
<td class="nump">18,378,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods, net of reserves</a></td>
<td class="nump">6,639,218<span></span>
</td>
<td class="nump">8,511,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember', window );">Vibativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials and work in process</a></td>
<td class="nump">14,900,000<span></span>
</td>
<td class="nump">14,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods, net of reserves</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Non-current inventory</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,550,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=108330185&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6642888256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Schedule of Inventories) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials and work in process</a></td>
<td class="nump">$ 19,076,378<span></span>
</td>
<td class="nump">$ 18,378,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment', window );">Consigned inventory</a></td>
<td class="nump">774,225<span></span>
</td>
<td class="nump">937,006<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods, net of reserves</a></td>
<td class="nump">6,639,218<span></span>
</td>
<td class="nump">8,511,887<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Inventory, Gross, Total</a></td>
<td class="nump">26,489,821<span></span>
</td>
<td class="nump">27,827,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory, Noncurrent</a></td>
<td class="num">(15,840,962)<span></span>
</td>
<td class="num">(15,749,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories classified as current</a></td>
<td class="nump">$ 10,648,859<span></span>
</td>
<td class="nump">$ 12,078,343<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of inventory owned by the entity but in the hands of a customer, typically a reseller.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6614331584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 3,260,767<span></span>
</td>
<td class="nump">$ 3,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 3,402,112<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Present value of remaining lease payments, percent</a></td>
<td class="nump">7.42%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6647075936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Lease Position) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 3,260,767<span></span>
</td>
<td class="nump">$ 3,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_LeaseAsset', window );">Total</a></td>
<td class="nump">3,260,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">899,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">2,502,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_LeaseLiability', window );">Total</a></td>
<td class="nump">$ 3,402,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LeaseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease, Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LeaseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6903031136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Maturity of Leases Liabilities at June 30, 2019</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2019</a></td>
<td class="nump">$ 532,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2020</a></td>
<td class="nump">1,120,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2021</a></td>
<td class="nump">1,144,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2022</a></td>
<td class="nump">1,019,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2023</a></td>
<td class="nump">92,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">After 2023</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">3,909,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="num">(507,098)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 3,402,112<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6759801328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity and Debt (Shareholders' Equity) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Nov. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jan. 31, 2016</div></th>
<th class="th"><div>May 13, 2010</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Repurchase outstanding common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (531,746)<span></span>
</td>
<td class="num">$ (703,790)<span></span>
</td>
<td class="num">$ (784,505)<span></span>
</td>
<td class="num">$ (1,195,225)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities', window );">Shelf Registration, sale of corporate securities (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sales of common stock, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 200,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_SubsidiaryInvestmentCashContribution', window );">Contribution of cash</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable', window );">Conversion of intercompany loans payable</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_HongKongWinHealthPharmaGroupCoLimitedMember', window );">WinHealth</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_SubsidiaryInvestmentPurchaseOfShares', window );">Investment through purchase of shares of CET Stock</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_GloriaPharmaceuticalsMember', window );">Gloria Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital', window );">Cash payments for return of shares</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted in period, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,469<span></span>
</td>
<td class="nump">233,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember', window );">Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_SaleOfStockNumberOfSharesSold', window );">Number of shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember', window );">Director | Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Restricted stock awards, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,447<span></span>
</td>
<td class="nump">121,466<span></span>
</td>
<td class="nump">127,291<span></span>
</td>
<td class="nump">172,079<span></span>
</td>
<td class="nump">205,913<span></span>
</td>
<td class="nump">299,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (531,746)<span></span>
</td>
<td class="num">$ (703,790)<span></span>
</td>
<td class="num">$ (784,505)<span></span>
</td>
<td class="num">$ (1,195,225)<span></span>
</td>
<td class="num">$ (1,200,000)<span></span>
</td>
<td class="num">$ (2,000,000.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding', window );">Common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from the sale of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">30,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_SaleOfStockNumberOfSharesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Number Of Shares Sold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_SaleOfStockNumberOfSharesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Net of Shares for Tax Withholding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ShareholdersEquityTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shareholders Equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ShareholdersEquityTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_SubsidiaryInvestmentCashContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subsidiary Investment, Cash Contribution</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_SubsidiaryInvestmentCashContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subsidiary Investment, Conversion Of Intercompany Loans Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subsidiary Investment, Payments For Return Of Capital</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_SubsidiaryInvestmentPurchaseOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subsidiary Investment, Purchase Of Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_SubsidiaryInvestmentPurchaseOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_HongKongWinHealthPharmaGroupCoLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_HongKongWinHealthPharmaGroupCoLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_GloriaPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_GloriaPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6901913552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity and Debt (Debt) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Oct. 17, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Revolving line of credit</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember', window );">Pinnacle Bank | Second Amendment | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember', window );">Pinnacle Bank | Line of Credit | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit, maximum borrowing capacity</a></td>
<td class="nump">12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions', window );">Line of credit, maximum borrowing capacity upon satisfaction of certain conditions</a></td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate spread</a></td>
<td class="nump">5.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Line of credit, unused capacity, commitment fee percentage</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember', window );">Pinnacle Bank | Line of Credit | Revolving Credit Facility | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate spread</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember', window );">Pinnacle Bank | Line of Credit | Revolving Credit Facility | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate spread</a></td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Maximum Borrowing Capacity Upon Satisfaction Of Certain Conditions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1336-112600<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1314-112600<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cpix_SecondAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cpix_SecondAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6607899824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details Textual) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent', window );">Deferred tax assets, net</a></td>
<td class="nump">$ 43,605<span></span>
</td>
<td class="nump">$ 87,210<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting and classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31917-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31931-109318<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6635817648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Additions and Expected Return of Product Rights - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">24 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_PaymentsForAssetAcquisitions', window );">Payments for asset acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payment to acquire business upon closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_ClinigenHealthcareLimitedMember', window );">Agreement | Scenario, Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfIntangibleAssets', window );">Financial consideration received in exchange for product license rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of the contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Noncurrent portion of the contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember', window );">Vibativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payment to acquire business upon closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPaymentsToAcquireBusinesses', window );">Cash payment during early 2019</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_TieredRoyaltyPaymentsPercentage', window );">Percentage of tiered royalty payments (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_PaymentsForAssetAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for Asset Acquisitions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_PaymentsForAssetAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_TieredRoyaltyPaymentsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tiered Royalty Payments, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_TieredRoyaltyPaymentsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPaymentsToAcquireBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPaymentsToAcquireBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_ClinigenHealthcareLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_ClinigenHealthcareLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6904410608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Additions and Expected Return of Product Rights - Schedule of Initial Payments and Consideration (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payment to acquire business upon closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember', window );">Vibativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payment to acquire business upon closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPaymentsToAcquireBusinesses', window );">Cash payment during early 2019</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_PaymentsForContingentConsideration', window );">Fair value of contingent consideration - net sales royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,182,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,182,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_PaymentsForContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_PaymentsForContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109124213&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109124213&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPaymentsToAcquireBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPaymentsToAcquireBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6744762864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Additions and Expected Return of Product Rights - Change in Consideration (Details) - Vibativ - USD ($)<br></strong></div></th>
<th class="th" colspan="2">2 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualRollForward', window );"><strong>Loss Contingency Accrual [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Beginning balance</a></td>
<td class="nump">$ 9,034,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,502,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment', window );">Adjustment to initial fair value of the contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Cash payment of royalty during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(684,738)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration included in operating expenses</a></td>
<td class="num">(40,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(321,894)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses', window );">Contingent consideration earned and accrued in operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 508,000<span></span>
</td>
<td class="nump">423,041<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Ending balance</a></td>
<td class="nump">$ 9,502,000<span></span>
</td>
<td class="nump">$ 9,502,000<span></span>
</td>
<td class="nump">$ 9,066,409<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration Arrangements, Contingent Consideration, Liability, Initial Fair Value Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6912787152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Recent Additions and Expected Return of Product Rights - Schedule of Preliminary Purchase Allocation (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Nov. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 882,000<span></span>
</td>
<td class="nump">$ 784,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember', window );">Vibativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory', window );">Finished goods inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,624,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials', window );">Work in process - unlabeled vials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,970,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials', window );">Work in process - validation vials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,827,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory', window );">Raw materials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,129,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Total inventory</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,550,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intellectual property amortizable intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,750,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">882,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill', window );">Total intangibles and goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,632,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,182,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finished Goods Inventory</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles and Goodwill</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Raw Materials Inventory</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Unlabeled Vials</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Validation Vials</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=108330185&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=108330185&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>51
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+""
MWTG] E!+ P04    " "(BPY/?L<EI?     K @  $0   &1O8U!R;W!S+V-O
M<F4N>&ULS9)-:L,P$$:O4K2WQW+2/^%XT]!5"X4&6KH3TB01M2PA3;%S^\IJ
MXE#: P2TT<RG-V] C?)"N8 OP7D,9#!>C;;KHU!^Q?9$7@!$M4<K8YD2?6IN
M7;"2TC7LP$OU*7<(=57=@$626I*$"5CXF<C:1BNA DIRX8C7:L;[K]!EF%:
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M"^C<!T$\@I]VA GD76#["LDC^)E'F$#J!7:YX"8F/_D $[*)P%87W,DT\54
M9AI0P7X7W,XT\U4 9AY0P9X7W-&2O1H )O!R$-CV@IM:DJ\",($WA,#.%]S7
M,O-5 ";'*H2]3]S7TL\^P(2R3]C[Q'TM_0J#,($*0]C[Q'TM_0H#,%G +X2]
M3]S7F5]A$"9080A[G[BO,[_"($R@PA#V/G%?9WZ%09B0"O8^<5]G[(P!3.B,
M8>\3]W7F5QB "55+PMXG[NN,G3'PT@^I8.\3]W7NUS& ":E(['W)?9W[)QEA
M B=98N]+[NO</\D($SAC$GM?<E_G_DE&F,"7D@Q\MG-?YUX=6P^8W&&:X9--
M3N5,^)4YN>EW:M7N76O811M]:EQ?>C,[MI\/KL%*_L*OO>O7HMV731>]:&.[
M+M<;[;0VRBXHO;-+.=AV>1Q4:F?ZVZF];Z\]XW5@]''HAY.Q*5_] 5!+ P04
M    " "(BPY/4C2\#D@$  #&$@  &    'AL+W=O<FMS:&5E=',O<VAE970R
M+GAM;(V8VV[C-A"&7\7P?5><X3EP#*R]*%J@!8(MVEXK-AT;*UFNI,3;MR\E
M*X;"&2YZ8QW\#_E3''X<:75MVF_=,81^\;VNSMWC\MCWEX>BZ';'4)?=I^82
MSO&?0]/691\OVY>BN[2AW(]!=56@$*:HR]-YN5Z-]Y[:]:IY[:O3.3RUB^ZU
MKLOVWTVHFNOC$I;O-[Z>7H[]<*-8KR[E2_@C]']>GMIX5=Q;V9_J<.Y.S7G1
MAL/C\C,\;*48 D;%7Z=P[6;GBV$HSTWS;;CX=?^X%(.C4(5=/S11QL-;V(:J
M&EJ*/OZ9&EW>^QP"Y^?OK?\\#CX.YKGLPK:I_C[M^^/CTBT7^W H7ZO^:W/]
M)4P#TLO%-/K?PENHHGQP$OO8-54W_BYVKUW?U%,KT4I=?K\=3^?Q>)W:?P_C
M W *P'L J!\&R"E )@'%S=DXU"]E7ZY7;7-=M+?9NI1#4L"#C ]S-]P<G]WX
M7QQM%^^^K;5;%6]#.Y-D<Y/@3((?%5NJT/XN*6+_=Q/(FL Q7L[BC>#C)1LO
MQW@UCX=D$#>)&27GVR"$UP!.)&-AA-9+YW..%.M(44?)0]O<)'K6D5?6&V<2
M0U3GT MC,T]8LWXT]2,3/YKVH]"B3=)A2W76*84JX\>P?@SUHQ(_AO0#PBCG
M9JEU,\0(45@GE>0=6=:1I8YTXLB2CE"AECIQOF5TWD@G#._'L7X<]9-DQL:1
M?C1XB5+;Q! C] !&2,L[\JPC3QTE'6T\G0KME/!I\F\YH55>B,PJ \'32U!/
M!%^")JRT*-.\YG06$#)9!!F> G7D4T= >I(HXAJ2:29Q2FFT%CZSVH '+"!Q
M947J"BD ',YG9/)$=1$ ^9GCD0V4V39E]J29]Z2D$3HU1&7.(N3\\, &2FR;
M$ALHBHTPVB%))2J,G  I<K/&0QLHM6U*;: X!F&U,H@DF1@IH(F;VVS-?/3%
MPQL,V:^MRK3 PQ8H;6U*6Z 8]5IZ[R =%Q4"B A"G\$;\,0%BER;(A<H2@%M
MY(0B.< HC8V^,.>*IRY0[-H4NT!QBB@ATBO=*SFE=4+-L^5CP<:#%REXTT)A
M@Q2H TX$1<K_47YTQ<,7*7QM"E^D2 70*NZ%Z0PR2B_!0ZZNP$QQ2]F;%IT;
MI$S5TFFK1;J5<\HXSW%7R*05\OQ%RM]T86TX3;J1_UCST0E/7E2$)B[WA'E.
M(N6D2ZM)I/!3/J(/2?7&*'5<ML[D*@'D*8FTQG4IXY#6K@H0;5HR;#FA509T
M;MGRW$7*W?1]8X,4IW%Y&! H4U.,,I9[RF9SD0<O4O"Z%'%(<?K34,6)]'6)
M$Z)5:#+5-_+818I=1P!'8:JE<<X"6;6,4FLKM #>E>2Q*REV70JX23-_@\U5
M!)PT4Q$4LP\*PQ>>W\OVY73N%L]-WS?U^ 7AT#1]B,V*3W&<QU#N[Q=5./3#
MJ8WG[>W+RNVB;R[35Z/B_NEJ_1]02P,$%     @ B(L.3^]^O[GP 0  @04
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M9!4^^M$NM1,E5J)D2Q2OB)+/$EF%-B*T^!G4X?03LTO;<^=,A?RO]-=?4RI
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M078^&]7_'E_B-N%]3U(;=_6V'?[.[I[;KMZ-65)7=M77X^=F/WR^COF_A>$
M'@/X%)#:?BM CP'Z>X!Y,\", >9G6[!C@!4M+([:A\%<55UU>]W4K[/FN!X.
M5;_LZ,JFZ;KK;PZS,_POC6>;[K[<%NYZ\=+G&9'E$>%SQ%\BJQRA$[%([9\Z
MP:@32\["^;*!,B>*(/KPPR3K-Y-<=%/#L=)#O#Z/+W"\@?%FB#?GHZ24&.PC
MXP9F?V3(!N4D6 )0D=.>C1B7'&1M@M9&3.(:9 S>DN8)D1:*M-D@I7[A! XF
M<&"4Q$PNCXP]UZ2(22[=,N?(LM94B#'*.:.("BU74,YI98F#P@(]%.B!0"T$
M^JPA2U83BXZ7@%/>L16K995S:5"]=EJLEG4.%MXX[R:F,$"% 2@4#2U#WB-C
M@W9R"B&G="$5YAQ[MH63JSSGM&8[N<@+*+   JT06.0=LAP*D@(!EQY.9K$D
M5CEGJ0B%EVLTYXQS:<@,%D@*UP4%)&:50:%E57@E]N82@,X$RW(2 <?I =-6
M#,8:M<S!.&LG5$Y4/P(JO51)H"T*K,E*F8!,SS9[N8&M ,F&'04;I%) LDI+
M>VK%$JRQ'XB!U""E<M;8.Z?(YTH!&%Q:C;(J(]#[8(FD3@"F)Y-836RNA(LT
M::"SD#IU/E%I)W>93,"9M+Z=5)ES;%R:4"D2<)JG)6(?0<!(D#02(W0QGL7%
M:(X2 9=ZE)5(Q*5B2OE$ M"DAV"B@A"V$62!1I(:;=Z4=:QE^2L1Z$TJIR15
M M %DSF+-0+[^CRM$[L= G:'I-VAW'>\,\9)DPPQLME,YIAWA2R\:Y0M:)IP
MS(2]#@&S0]+L4&XZTC2Z(,>A1* WUF1V!X$N;9I:29$ U*2]TU.[*W8\!"P/
M2<M#P,MX+8U#"3 V7L[V"F#OR)&U4B)P/-Z?C>VE/FQX"#@>6126(^0NYM$4
M5E;4$H&>E0M9]0!@>KYUR$0"4*NB*-ACG8QM#ZO\]>7,L5VFP)Z"@:<@Z2E&
MR)_W5[V7)KF<P(3ZU<]E6V-L8B$PMA$,; 1)&S%"/U2'L4S=3V5;8VQ*'38/
MG+_B$TWL!(R+,X/B+'WNDO,:F1Y<UHZE<X:D\^FIDN_YD$QF);TCR)&".4-_
M+# A%==H!C6:98WFO%!.244DEHI(+!7F?$LJ+M,,RC3+,CU"/][_$ CW/P3"
M_0^!;^]_N%XSJM>RCC$X30!U#&"HC@$,UC' O5''&-=I!G5:OFDO1^AR'I$?
M02#T(PB$?@2!V(\LSDYX=[%Y'([;V]E=_;SO^AWL[.[I2/\#]R?$XOZ2KDH"
M]U=TM3X>V']/?_S]X(^J>=SLV]GGNNOJW7!Z_%#774P"U/LT/T^QNC]=;.-#
MUW_UZ7MS/+<_7G3U8?Q-8G'Z8>3V?U!+ P04    " "(BPY/CSBT10$%  "%
M%P  &    'AL+W=O<FMS:&5E=',O<VAE970U+GAM;'V8W6[C-A"%7\7PO=?D
M#'_$(#$0NRA:H 6"+;:]5A(F-M:V7$E)MF]?2G:\SO PN8@M^7!XAB(_CGC]
MUK3?NW6,_>3';KOO;J;KOC]<S>?=PSKNZNY+<XC[],M3T^[J/EVVS_/NT,;Z
M<6RTV\Y)*3??U9O]='$]WKMK%]?-2[_=[.-=.^E>=KNZ_6\9M\W;S51/WV]\
MW3RO^^'&?'%]J)_C7['_=KAKT]7\'.5QLXO[;M/L)VU\NIG>ZJN544.#4?'W
M)KYU%]\G0RKW3?-]N/C]\6:J!D=Q&Q_Z(42=/E[C*FZW0Z3DX]]3T.FYSZ'A
MY??WZ+^.R:=D[NLNKIKM/YO'?GTSK::3Q_A4OVS[K\W;;_&4D)U.3MG_$5_C
M-LD')ZF/AV;;C?\G#R]=W^Q.49*57?WC^+G9CY]OI_COS7 #.C6@<X/4]V<-
M^-2 ?S8P8_)'9V.JO]1]O;ANF[=)>WQ:AWJ8%/J*TV ^##?'L1M_2]EVZ>[K
M0I.YGK\.@4Z:Y5%#EYJS8IZBG[L@U,62LN;TL8-5K@@5[H%A$CRVYP])6!S
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MP10&H;; E).F+#"EK9<@ [HT2SP5%JS&:-6 K2S9JG-HIKG&Q,S2%%"F=9*
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MRHX"4Y98+BPM88Q;!KBU$K<,#@4JM L 8<&.P;PU@+=RDBU/HLMSK[1WY6Z
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M9JG0#5W")+6(I+)HMIJD%'*GQ6&,.H!1534[@-$0$]?4;5^A$XD0#IW"N'4
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MEXW];Q =>"G)C1^ASG^PQ9#0N'#\Z,]F&K/)<-C//X@MW[C\"U!+ P04
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M4]MNW" 0_17$!P0OWJ31RK:4356E4BNM4K5Y9NVQC0(>%_ Z_?L"=EPG<5^
M&<XY<V'(1C3/M@5PY$6KSN:T=:X_,&;+%K2P5]A#YV]J-%HX;YJ&V=Z J"))
M*\:3Y(9I(3M:9-%W,D6&@U.R@Y,A=M!:F#]'4#CF=$=?'8^R:5UPL"+K10,_
MP/WL3\9;;%&II(;.2NR(@3JG=[O#<1_P$?!+PFA79Q(J.2,^!^-KE=,D) 0*
M2A<4A-\N< ]*!2&?QN]9DRXA W%]?E7_$FOWM9R%A7M43[)R;4YO*:F@%H-R
MCS@^P%S/-25S\=_@ LK#0R8^1HG*QI64@W6H9Q6?BA8OTRZ[N(_33<IGVC:!
MSP2^$&YC'#8%BIE_%DX4F<&1F*GWO0A/O#MPWYLR.&,KXIU/WGKOI=BEUQF[
M!*$9<YPP?(U9$,RK+R'X5H@C_T#GV_1T,\,TTM,U/?E/_/VFP#X*[-\(\'<E
M;F'2=T'8JJ<:3!.GR9(2ARY.\LJ[#.Q=?$3V#SY-^W=A&ME9<D;G7S;VOT9T
MX%-)KOP(M?Z#+8:"VH7C)W\VTYA-AL-^_D%L^<;%7U!+ P04    " "(BPY/
MB>I@Z[8!  #2 P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6QM4]MN
MW" 0_17$!P0OZR2KE6TIFZIJI59:I6K[S-IC&X6+"WB=_GT!$\=)_0+,,.?,
MF6$H)FV>;0_@T(L4RI:X=VXX$F+K'B2S-WH Y6]:;21SWC0=L8,!UD20%(1F
MV1V1C"M<%=%W-E6A1R>X@K-!=I22F;\G$'HJ\0Z_.IYXU[O@(%4QL Y^@/LY
MG(VWR,+2< G*<JV0@;;$#[OC*0_Q,> 7A\FNSBA4<M'Z.1A?FQ)G01 (J%U@
M8'Z[PB,($8B\C#^)$R\I W!]?F7_'&OWM5R8A4<M?O/&]24^8-1 RT;AGO3T
M!5(]MQBEXK_!%80/#TI\CEH+&U=4C]9IF5B\%,E>YIVKN$_IYI!@VP": '0!
M'&(>,B>*RC\QQZK"Z F9N?<#"T^\.U+?FSHX8ROBG1=OO?=:T2POR#40I9C3
M'$-7,;LE@GCV)07=2G&B_\'I-GR_J7 ?X?MW"F^W"?)-@CP2Y.\([CZ4N!5S
M_R$)6?54@NGB-%E4ZU'%25YYEX%]H/%-WL+G:?_.3,>511?M_,O&_K=:._!2
MLAL_0KW_8(LAH'7A>._/9AZSV7!Z2#^(+-^X^@=02P,$%     @ B(L.3T$1
M\&2U 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL;5-ACYP@
M$/TKA!]P*+MMMQLUN;W+I4W:9'--V\^LCDH.Q *NUW_? 5UKKWX!9ICWYLTP
M9*.Q+ZX%\.15J\[EM/6^/S+FRA:T<'>FAPYO:F.U\&C:AKG>@J@B2"O&D^0]
MTT)VM,BB[VR+S Q>R0[.EKA!:V%_GT"9,:<IO3F>9=/ZX&!%UHL&OH'_WI\M
M6FQAJ:2&SDG3$0MU3N_3XVD?XF/ #PFC6YU)J.1BS$LP/E<Y38(@4%#ZP"!P
MN\(#*!6(4,:OF9,N*0-P?;ZQ/\7:L9:+</!@U$]9^3:G!THJJ,6@_+,9/\%<
MSSM*YN*_P!44A@<EF*,TRL65E(/S1L\L*$6+UVF77=S'Z69W@VT#^ S@"^ 0
M 6Q*%)4_"B^*S)J1V*GWO0A/G!XY]J8,SMB*>(?B'7JO!4\.&;L&HCGF-,7P
M54RZ1#!D7U+PK10G_A^<;\-WFPIW$;[[1^'';8+])L$^$NS7!&GRIL2MF+=%
MLE5/-=@F3I,CI1FZ.,DK[S*P]SR^R=_P:=J_"MO(SI&+\?BRL?^U,1Y02G*'
M(]3B!UL,!;4/QP]XMM.8388W_?R#V/*-BS]02P,$%     @ B(L.3Z[;T(:V
M 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H965T,30N>&UL;5-A;]P@#/TK
MB!]0+B3=JE,2J==IVJ1-.G7:]IE+G 050@;DTOW[&9*F:9<O@(W?\[,Q^63L
MD^L /'G6JG<%[;P?CHRYJ@,MW(T9H,>;QE@M/)JV96ZP(.H(THKQP^$#TT+V
MM,RC[VS+W(Q>R1[.EKA1:V'_GD"9J: )?7$\RK;SP<'*?! M_ #_<SA;M-C*
M4DL-O9.F)Q::@MXGQU,6XF/ +PF3VYQ)J.1BS%,POM8%/01!H*#R@4'@=H4'
M4"H0H8P_"R==4P;@]OS"_CG6CK5<A(,'HW[+VG<%O:.DAD:,RC^:Z0LL]=Q2
MLA3_#:Z@,#PHP1R542ZNI!J=-WIA02E:/,^[[.,^S3=INL#V 7P!\!5P%_.P
M.5%4_DEX4>;63,3.O1]$>.+DR+$W57#&5L0[%._0>RUYPG-V#41+S&F.X9N8
M9(U@R+ZFX'LI3OP_.-^'I[L*TPA/WRA,]PFR78(L$F1O"+)W)>[%W+Y+PC8]
MU6#;.$V.5&;LXR1OO.O WO/X)J_A\[1_%[:5O2,7X_%E8_\;8SR@E,,-CE"'
M'VPU%#0^'#_BV<YC-AO>#,L/8NLW+O\!4$L#!!0    ( (B+#D]AP^Y#LP$
M -(#   9    >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;&U3VXZ;,!#]%<L?
ML Y.FHTB0-IL5;52*T5;M7UV8 !K;4QM$[9_W[$A+$UYP3/#.6<N'J>#L:^N
M ?#D3:O69;3QOCLRYHH&M' /IH,6_U3&:N'1M35SG0511I)6C&\V>Z:%;&F>
MQMC9YJGIO9(MG"UQO=;"_CF!,D-&$WH+O,BZ\2' \K03-7P'_Z,[6_38K%)*
M#:V3IB46JHP^)<?3+N CX*>$P2UL$CJY&/,:G"]E1C>A(%!0^* @\+C",R@5
MA+",WY,FG5,&XM*^J7^*O6,O%^'@V:A?LO1-1@^4E%")7OD7,WR&J9\/E$S-
M?X4K*(2'2C!'892+7U+TSAL]J6 I6KR-IVSC.4SZ-]HZ@4\$?D=@8Z)8^4?A
M19Y:,Q [SKX3X8J3(\?9%"$81Q'_8?$.H]><)_N478/0A#F-&+[ )#."H?J<
M@J^E./'_Z'R=OEVM<!OIVV7VPWY=8+<JL(L"NW]:?+QK<0USN$O"%C/58.NX
M38X4IF_C)B^B\\(^\7@G[_!QV[\)6\O6D8OQ>+-Q_I4Q'K"4S0.N4(,/;'84
M5#Z8CVC;<<U&QYMN>D%L?L;Y7U!+ P04    " "(BPY/;TA/4[8!  #2 P
M&0   'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6QM4V%OW" ,_2N('U 2[F[K
M3DFD7JMJDS;IU&G=9RYQ$E0(&9!+]^]G2)IE7;X -G[/S\9DH[$OK@7PY%6K
MSN6T];X_,N;*%K1P-Z:'#F]J8[7P:-J&N=Z"J")(*\:3Y /30G:TR*+O;(O,
M#%[)#LZ6N$%K87^?0)DQIRE]<SS)IO7!P8JL%PU\!_^C/UNTV,)220V=DZ8C
M%NJ<WJ7'TS[$QX!G":-;G4FHY&+,2S"^5#E-@B!04/K ('"[PCTH%8A0QJ^9
MDRXI W!]?F-_C+5C+1?AX-ZHG[+R;4YO*:F@%H/R3V;\#',]!TKFXK_"%12&
M!R68HS3*Q964@_-&SRPH18O7:9==W,?IYG"88=L /@/X KB->=B4*"I_$%X4
MF34CL5/O>Q&>.#UR[$T9G+$5\0[%._1>"YY^RM@U$,TQIRF&KV+2)8(A^Y*"
M;Z4X\?_@?!N^VU2XB_#=&LZ3;8+])L$^$NS_(4C?E;@5\UXE6_54@VWB-#E2
MFJ&+D[SR+@-[Q^.;_ V?IOV;L(WL'+D8CR\;^U\;XP&E)#<X0BU^L,504/MP
M_(AG.XW99'C3SS^(+=^X^ -02P,$%     @ B(L.3YK>4(G. 0  G 0  !D
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M=7<TW*1**0NNE,V#:[AQ3\4<"*BLWSZZO1X'9@RLZJ:W@,P/4OX'4$L#!!0
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M^+*Q_[4Q'E!*<H4CU.('6PP%M0_'3WBVTYA-AC?]_(/8\HV+OU!+ P04
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M_S6BAY#*YB:,4!L^V&PHJ'T\WH6S'<=L-#QVTP]B\S<N_@!02P,$%     @
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M]KJZD[HX]?MX\74S<?4?4$L#!!0    ( (B+#D]'>&JH1P(  (D'   9
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MQ;%!X"Q4-95U-CP.0T/0SCQ\:'Q]RW]02P,$%     @ B(L.3_6J8 !( @
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M5_I7L >VYER!YB,/6G6CK[ E8% K,TWU7$P_\A0H/LQW%%XNRN(?4$L#!!0
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MBL-@JOX;N[%&RTTFFG'DC;3/X'B5BK>3BTZEI6]C6W>V'2;_>Y@_ $\!> Y
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M:AXT[*Q,-]5],1[9XT#Q?KJ.P'PGEO\ 4$L#!!0    ( (B+#D\,F4M&#@0
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MF&6ED%FY7V0^9Q$=VH=8',OJELO[O#FJ:1[*[*J.H9SV+&S^/U!+ P04
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M- .4 IA@#A+,'_>*;+A4[/^[7;4@OV<7.??LHHFZ1(!8.!1#3^XM BMTB1Q
M;/AR@Z#YA Y<@\@=4P3V4 <"37QP$%RJ:%RK;C#QM4!P;2'_B?<%KBX4/+*K
M "B8TH&+$ %5&$Q\!Q!<76CVA%NXOM#\$;< */ '.E;O["H(.^J^@!L)/96Z
M*>FM=KW'TM%GWQ7>-"X_,#MF)3=V5,@35)]S!TH%D;G8+_()I[)7ZB8Y.0@U
M#.68-0U#,Q&T:ILAJ^O(XG]02P,$%     @ B(L.3R4(N(FW 0  TP,  !D
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M<7,]W;.IL&J(3XC,[[CZ!U!+ P04    " "(BPY/LY (1]("   &"P  &0
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M@4PVULB0(AJGV,PQ* DG-@R8,>)ICDABLU/?V#!?\_VAT^B#4@.C0* %@I&
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MO&=$2@-\KWFDCUO$5!AJ-O\(([W+SVD5G6X_5)CT!BT@Y;F28Q%?4!XH98P
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MM5KOM[E*]FD/K2),B)1.H:V@#R0=J,4 3C;.K(BN2-S(U."RB^?+DA61\_V
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M+F,#(AF.<HYS2Y9B\F512P7D4=@#%0=:&K6LMIK3-[COH.?L^4QS4'3!> L
M'@&41UC"=E?I40;N*(#[ ? (BA54%LRCSLB: !?2-*,Z-F7^M@8FAR,[ZQ=%
M'@$RX^)*#LWCB$"T/\'6G@=J]YW@]PXP7=!9C@8?S.<R2+]Q$&5\/SC$3[6C
M=&=O'T4=M&/VX:%_XA@V=&!T@*;#+RO#0A&164\D6%* G($PS,>/;8F$0;O"
M@8KZ%PH" X# W EKHN'I-&*+@;-;!<>P3[:=)+3GQ]$@JQ@Y#1G1.>$!IK"V
M:N<Z14Y4'D*;:67QD)"&A1C"L.)<L!TH4?*4XU[I?5J_& F(N(H(@E9\9B<*
MK?)"(X=],QI81Q95(@@S@5(,TU5YV$;0 @O'#6#?A[(11$U7EF>C^^)&%@9_
MW:U(/#)>-13WC)IES7>7&P!8G!_7@>4!-A$HC'-&Z'1/'+N@10)%PJI,Y6[Q
MUY@3KZC4ES_SG056>P*:?B4^YQJZ69=$JW[1LL#L>@;X"FAJP0F;C/VHGVT0
M;O8UD7O:0 2N'627.3?17DGP(4B@YI)B_!Z;9$.CI9"_HT2/'!PJ'^]"JA-%
MY2<A#B$2M4]Q\>,*N#8L#E?$F!XJ\@'@V2=QNJ)[4_<H*E)BPJA!9E_BL'&V
M7.-V,+?V@8>Q&>66;7"D)O$FR1I3.#'!#APQ[SO?),L 52Z$T8O("E)WXOR4
MH.4*<#H^6SLG6^XUAV=]PYM=D/*H8P0Y.$W 2XMY-$%_Z)02ZSI"@605T6ZJ
MNC@A81GQYZ22X=CF!/.1F)?E;,R]0RIKU"3E8Q%.A@>IXF$:&"K?8A:=Z+B8
M4A GUC*0JXYA=&$C50D1O$P0GI@U%,]EC)%#XID$&O>\)OKZ48F*5J@KS7%[
MS;\>5!Z"9\%%V+NX"$?3$?PM59!JOUZ$W<$PG%Y<U-Y0OU[6] _U3MM_^^%%
M=QA>7/2LORYK^@H\ZH\NPDE_:/W5-N"\77FR)NU>3,+>:&3]I9Z-+WIA;SS0
M_V7 N<?=S$!<0 W#07\03J==^'L:#L?3<#2I W 0]B^P4-00_IZ$_6DW'(VG
M7A4K4S/D#054?@"(4()BZXOZC0,*\]7LYMWUN]=S&/7]? ZC7MT$\]_,;JZ.
M?K'QFNAJ%7Q-,I"V !OR0NK@($'+Z-]* @41;8DN_E@7!HE;:Z1\=2CI<U@K
M?G+@5;I+[]1RGP=?5>X%SO'T8C@%3!Z?X=_C/ASI9'(&UU;O_'EP1&451L?>
M3U)0!:N+ 3:-^A/\<S1&!!H&+Q%@2%PE- ()$<E/%E+6K\>7S*T.I'GV^6'0
M?S-XCF#JP>2"X#D(N]-I..V/OP5$A]-Q.)U,:4^3?C@83OYO0K1A]C93!ULW
MT%8 +(_- OGR4Q ]4H@Q1Y.:VAG*3=(; !JR5Z /S&+:U:7HO/QHN[)<R)S4
M7CU*7L)>*R>HGNT5&Y#<M&G1N\3F]B[B941Q1=H19\0 T'>2E0#?*XQ\TU+0
M2TR.5L76=G)W<_6'JW<?CS0)JI<QJ)"LOFH%CC:A,TW85BQO'/3ZZ]B,2XQY
M41XO!,RF/0QT0D8P)UBB5O^ QK(E/^7^48YAVUW3&L+,Z4B@LZ3[OTE9F\S:
MB50JK"_M1@S\# 0WM*JT8K HA+G^.4F*)DC9@0[M6J)&&=TH^+,'-T/<#4X
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M__+CY6UP<_WZ-SYQ^KI1:MG(U[9435JR1=H4)UTU6"A?1V65=TB-1M/G4O5
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ML\2?Q MQNI+@IZQ]NL6W]$'G2''58CPIEKL-\L E"ES!O"E!W<(DDS@JE[-
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MHB\\S9A072*O\&Z+N(*5J+O>%?KJJ^#JP^S(^F![FQVGZ3'WY>L=P\WB_?*
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M]+\38M;) EO'706^CQPRAYVI*/=&$":=++!T\ F1.]/(,.EDP:6#879=3,Q
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M8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " "(BPY/?L<EI?     K @  $0
M            @ &9 0  9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " "(
MBPY/F5R<(Q &  "<)P  $P              @ &X @  >&PO=&AE;64O=&AE
M;64Q+GAM;%!+ 0(4 Q0    ( (B+#D^G;W$!1P,  * /   8
M  "  ?D(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " "(
MBPY/4C2\#D@$  #&$@  &               @ %V#   >&PO=V]R:W-H965T
M<R]S:&5E=#(N>&UL4$L! A0#%     @ B(L.3^]^O[GP 0  @04  !@
M         ( !]!   'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0
M   ( (B+#D\BI"U--04  "09   8              "  1H3  !X;"]W;W)K
M<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " "(BPY/CSBT10$%  "%%P
M&               @ &%&   >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L!
M A0#%     @ B(L.3\SOVOK,!@  RR8  !@              ( !O!T  'AL
M+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( (B+#D\%73D\LP$
M -(#   8              "  ;XD  !X;"]W;W)K<VAE971S+W-H965T-RYX
M;6Q02P$"% ,4    " "(BPY/]2Y&R+8!  #2 P  &               @ &G
M)@  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ B(L.3X'/
M#L^V 0  T@,  !@              ( !DR@  'AL+W=O<FMS:&5E=',O<VAE
M970Y+GAM;%!+ 0(4 Q0    ( (B+#D\?B"O[N $  -(#   9
M  "  7\J  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @
MB(L.3_V74B"U 0  T@,  !D              ( !;BP  'AL+W=O<FMS:&5E
M=',O<VAE970Q,2YX;6Q02P$"% ,4    " "(BPY/B>I@Z[8!  #2 P  &0
M            @ %:+@  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4
M Q0    ( (B+#D]!$?!DM0$  -(#   9              "  4<P  !X;"]W
M;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ B(L.3Z[;T(:V 0
MT@,  !D              ( !,S(  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX
M;6Q02P$"% ,4    " "(BPY/8</N0[,!  #2 P  &0              @ $@
M-   >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( (B+#D]O
M2$]3M@$  -(#   9              "  0HV  !X;"]W;W)K<VAE971S+W-H
M965T,38N>&UL4$L! A0#%     @ B(L.3YK>4(G. 0  G 0  !D
M     ( !]S<  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
M" "(BPY/W(;:\[8!  #2 P  &0              @ '\.0  >&PO=V]R:W-H
M965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( (B+#D]N*_I5MP$  -(#   9
M              "  >D[  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L!
M A0#%     @ B(L.3V0LN_^W 0  T@,  !D              ( !UST  'AL
M+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " "(BPY/<A]'M[8!
M  #2 P  &0              @ '%/P  >&PO=V]R:W-H965T<R]S:&5E=#(Q
M+GAM;%!+ 0(4 Q0    ( (B+#D\B5A;LPP$  #<$   9              "
M ;)!  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ B(L.
M3^5OOWG5 0  G 0  !D              ( !K$,  'AL+W=O<FMS:&5E=',O
M<VAE970R,RYX;6Q02P$"% ,4    " "(BPY/T^JF+[@!  #2 P  &0
M        @ &X10  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0
M   ( (B+#D]96H9;D@,  ,<2   9              "  :='  !X;"]W;W)K
M<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ B(L.3]0M?DY_ @  +0@
M !D              ( !<$L  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q0
M2P$"% ,4    " "(BPY/0.SH=> !  !G!   &0              @ $F3@
M>&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( (B+#D\LJ"-X
M500  %@4   9              "  3U0  !X;"]W;W)K<VAE971S+W-H965T
M,C@N>&UL4$L! A0#%     @ B(L.3T=X:JA' @  B0<  !D
M ( !R50  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " "(
MBPY/]:I@ $@"  "U!@  &0              @ %'5P  >&PO=V]R:W-H965T
M<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( (B+#D\T*W 1[ $  #0%   9
M          "  <99  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#
M%     @ B(L.3[9E7:_] 0  ? 4  !D              ( !Z5L  'AL+W=O
M<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " "(BPY/2>WV6T4"   ?
M!P  &0              @ $=7@  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM
M;%!+ 0(4 Q0    ( (B+#D\,F4M&#@0  !<3   9              "  9E@
M  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ B(L.3_Z#
MP;2% @  G0D  !D              ( !WF0  'AL+W=O<FMS:&5E=',O<VAE
M970S-2YX;6Q02P$"% ,4    " "(BPY/)0BXB;<!  #3 P  &0
M    @ &:9P  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    (
M (B+#D^SD A'T@(   8+   9              "  8AI  !X;"]W;W)K<VAE
M971S+W-H965T,S<N>&UL4$L! A0#%     @ B(L.3PKI20)B @  QP<  !D
M             ( !D6P  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"
M% ,4    " "(BPY/J&LS=F4"  "+!P  &0              @ $J;P  >&PO
M=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( (B+#D]AXV)A>@(
M )<(   9              "  <9Q  !X;"]W;W)K<VAE971S+W-H965T-# N
M>&UL4$L! A0#%     @ B(L.3_<B!HS400  _0(! !0              ( !
M=W0  'AL+W-H87)E9%-T<FEN9W,N>&UL4$L! A0#%     @ B(L.3]\C18XL
M @  V0@   T              ( !?;8  'AL+W-T>6QE<RYX;6Q02P$"% ,4
M    " "(BPY/]]B_T(D#  #=&@  #P              @ '4N   >&PO=V]R
M:V)O;VLN>&UL4$L! A0#%     @ B(L.3_[W3D.D 0  W1@  !H
M     ( !BKP  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%
M  @ B(L.3W'*SM&H 0  +AD  !,              ( !9KX  %M#;VYT96YT
A7U1Y<&5S72YX;6Q02P4&     #$ ,0!)#0  /\

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>140</ContextCount>
  <ElementCount>266</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>34</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="cpix-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cpix-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cpix-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cpix-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Income (loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cpix-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cpix-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statement of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity</Role>
      <ShortName>Condensed Consolidated Statement of Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cpix-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cpix-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/MarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cpix-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2107103 - Disclosure - Earnings (Loss) Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShare</Role>
      <ShortName>Earnings (Loss) Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cpix-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2111104 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cpix-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2114105 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cpix-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2118106 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cpix-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2123107 - Disclosure - Shareholders' Equity and Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt</Role>
      <ShortName>Shareholders' Equity and Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cpix-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2126108 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cpix-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2128109 - Disclosure - Collaborative Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CollaborativeAgreements</Role>
      <ShortName>Collaborative Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cpix-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2129110 - Disclosure - Recent Additions and Expected Return of Product Rights</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRights</Role>
      <ShortName>Recent Additions and Expected Return of Product Rights</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cpix-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Organization and Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies</Role>
      <ShortName>Organization and Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cpix-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/MarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/MarketableSecurities</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="cpix-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2308302 - Disclosure - Earnings (Loss) Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShareTables</Role>
      <ShortName>Earnings (Loss) Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/EarningsLossPerShare</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="cpix-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2312303 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/Revenues</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="cpix-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2315304 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/Inventories</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="cpix-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2319305 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/Leases</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="cpix-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2330306 - Disclosure - Recent Additions and Expected Return of Product Rights (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsTables</Role>
      <ShortName>Recent Additions and Expected Return of Product Rights (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRights</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="cpix-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Organization and Basis of Presentation Organization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails</Role>
      <ShortName>Organization and Basis of Presentation Organization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="cpix-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/MarketableSecuritiesTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cpix-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Earnings (Loss) Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails</Role>
      <ShortName>Earnings (Loss) Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/EarningsLossPerShareTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cpix-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Earnings (Loss) Per Share (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual</Role>
      <ShortName>Earnings (Loss) Per Share (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/EarningsLossPerShareTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cpix-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2413405 - Disclosure - Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RevenuesDetails</Role>
      <ShortName>Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/RevenuesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cpix-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2416406 - Disclosure - Inventories (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails</Role>
      <ShortName>Inventories (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/InventoriesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cpix-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2417407 - Disclosure - Inventories (Schedule of Inventories) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails</Role>
      <ShortName>Inventories (Schedule of Inventories) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/InventoriesTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="cpix-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2420408 - Disclosure - Leases (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/LeasesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="cpix-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2421409 - Disclosure - Leases (Lease Position) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails</Role>
      <ShortName>Leases (Lease Position) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/LeasesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="cpix-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2422410 - Disclosure - Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails</Role>
      <ShortName>Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/LeasesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cpix-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2424411 - Disclosure - Shareholders' Equity and Debt (Shareholders' Equity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails</Role>
      <ShortName>Shareholders' Equity and Debt (Shareholders' Equity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="cpix-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2425412 - Disclosure - Shareholders' Equity and Debt (Debt) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails</Role>
      <ShortName>Shareholders' Equity and Debt (Debt) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="cpix-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2427413 - Disclosure - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual</Role>
      <ShortName>Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/IncomeTaxes</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="cpix-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2431414 - Disclosure - Recent Additions and Expected Return of Product Rights - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsNarrativeDetails</Role>
      <ShortName>Recent Additions and Expected Return of Product Rights - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="cpix-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2432415 - Disclosure - Recent Additions and Expected Return of Product Rights - Schedule of Initial Payments and Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsScheduleofInitialPaymentsandConsiderationDetails</Role>
      <ShortName>Recent Additions and Expected Return of Product Rights - Schedule of Initial Payments and Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="cpix-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2433416 - Disclosure - Recent Additions and Expected Return of Product Rights - Change in Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsChangeinConsiderationDetails</Role>
      <ShortName>Recent Additions and Expected Return of Product Rights - Change in Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="cpix-20190630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2434417 - Disclosure - Recent Additions and Expected Return of Product Rights - Schedule of Preliminary Purchase Allocation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsScheduleofPreliminaryPurchaseAllocationDetails</Role>
      <ShortName>Recent Additions and Expected Return of Product Rights - Schedule of Preliminary Purchase Allocation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="cpix-20190630.htm">cpix-20190630.htm</File>
    <File>a2019q2-exhibit311.htm</File>
    <File>a2019q2-exhibit312.htm</File>
    <File>a2019q2-exhibit321.htm</File>
    <File>cpix-20190630.xsd</File>
    <File>cpix-20190630_cal.xml</File>
    <File>cpix-20190630_def.xml</File>
    <File>cpix-20190630_lab.xml</File>
    <File>cpix-20190630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2018-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>57
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cpix-20190630.htm": {
   "axisCustom": 0,
   "axisStandard": 14,
   "contextCount": 140,
   "dts": {
    "calculationLink": {
     "local": [
      "cpix-20190630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cpix-20190630_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-eedm-def-2018-01-31.xml",
      "http://xbrl.fasb.org/srt/2018/elts/srt-eedm1-def-2018-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "cpix-20190630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cpix-20190630_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-doc-2018-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cpix-20190630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-ref-2018-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "cpix-20190630.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2018/elts/srt-types-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd",
      "http://xbrl.fasb.org/srt/2018/elts/srt-roles-2018-01-31.xsd",
      "http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-parts-codification-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 312,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2018-01-31": 1,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 6
   },
   "keyCustom": 23,
   "keyStandard": 243,
   "memberCustom": 16,
   "memberStandard": 17,
   "nsprefix": "cpix",
   "nsuri": "http://www.cumberlandpharma.com/20190630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.cumberlandpharma.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111104 - Disclosure - Revenues",
     "role": "http://www.cumberlandpharma.com/role/Revenues",
     "shortName": "Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114105 - Disclosure - Inventories",
     "role": "http://www.cumberlandpharma.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118106 - Disclosure - Leases",
     "role": "http://www.cumberlandpharma.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123107 - Disclosure - Shareholders' Equity and Debt",
     "role": "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt",
     "shortName": "Shareholders' Equity and Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126108 - Disclosure - Income Taxes",
     "role": "http://www.cumberlandpharma.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128109 - Disclosure - Collaborative Agreements",
     "role": "http://www.cumberlandpharma.com/role/CollaborativeAgreements",
     "shortName": "Collaborative Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129110 - Disclosure - Recent Additions and Expected Return of Product Rights",
     "role": "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRights",
     "shortName": "Recent Additions and Expected Return of Product Rights",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Organization and Basis of Presentation (Policies)",
     "role": "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies",
     "shortName": "Organization and Basis of Presentation (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Marketable Securities (Tables)",
     "role": "http://www.cumberlandpharma.com/role/MarketableSecuritiesTables",
     "shortName": "Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308302 - Disclosure - Earnings (Loss) Per Share (Tables)",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShareTables",
     "shortName": "Earnings (Loss) Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "if478ab72402a4dbca17cebf84905f137_I20190630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "if478ab72402a4dbca17cebf84905f137_I20190630",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:MarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312303 - Disclosure - Revenues (Tables)",
     "role": "http://www.cumberlandpharma.com/role/RevenuesTables",
     "shortName": "Revenues (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315304 - Disclosure - Inventories (Tables)",
     "role": "http://www.cumberlandpharma.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319305 - Disclosure - Leases (Tables)",
     "role": "http://www.cumberlandpharma.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330306 - Disclosure - Recent Additions and Expected Return of Product Rights (Tables)",
     "role": "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsTables",
     "shortName": "Recent Additions and Expected Return of Product Rights (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - Organization and Basis of Presentation Organization (Details)",
     "role": "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails",
     "shortName": "Organization and Basis of Presentation Organization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "if478ab72402a4dbca17cebf84905f137_I20190630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:TradingSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Marketable Securities (Details)",
     "role": "http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails",
     "shortName": "Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "if478ab72402a4dbca17cebf84905f137_I20190630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:TradingSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409403 - Disclosure - Earnings (Loss) Per Share (Details)",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails",
     "shortName": "Earnings (Loss) Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Earnings (Loss) Per Share (Details Textual)",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual",
     "shortName": "Earnings (Loss) Per Share (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413405 - Disclosure - Revenues (Details)",
     "role": "http://www.cumberlandpharma.com/role/RevenuesDetails",
     "shortName": "Revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "i3b6f56b360f242dba5580399c147efc2_D20190401-20190630",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "if478ab72402a4dbca17cebf84905f137_I20190630",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryValuationReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416406 - Disclosure - Inventories (Narrative) (Details)",
     "role": "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
     "shortName": "Inventories (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "if478ab72402a4dbca17cebf84905f137_I20190630",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryValuationReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "if478ab72402a4dbca17cebf84905f137_I20190630",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockNoParValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "if478ab72402a4dbca17cebf84905f137_I20190630",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockNoParValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "if478ab72402a4dbca17cebf84905f137_I20190630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417407 - Disclosure - Inventories (Schedule of Inventories) (Details)",
     "role": "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails",
     "shortName": "Inventories (Schedule of Inventories) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "if478ab72402a4dbca17cebf84905f137_I20190630",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cpix:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "if478ab72402a4dbca17cebf84905f137_I20190630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420408 - Disclosure - Leases (Narrative) (Details)",
     "role": "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails",
     "shortName": "Leases (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "if478ab72402a4dbca17cebf84905f137_I20190630",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cpix:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "if478ab72402a4dbca17cebf84905f137_I20190630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421409 - Disclosure - Leases (Lease Position) (Details)",
     "role": "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails",
     "shortName": "Leases (Lease Position) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cpix:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "if478ab72402a4dbca17cebf84905f137_I20190630",
      "decimals": "0",
      "lang": null,
      "name": "cpix:LeaseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "if478ab72402a4dbca17cebf84905f137_I20190630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422410 - Disclosure - Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)",
     "role": "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails",
     "shortName": "Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "if478ab72402a4dbca17cebf84905f137_I20190630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "ie34c3c9c4b6c4086a134e19d8fa48fdd_I20160131",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424411 - Disclosure - Shareholders' Equity and Debt (Shareholders' Equity) (Details)",
     "role": "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails",
     "shortName": "Shareholders' Equity and Debt (Shareholders' Equity) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "ie34c3c9c4b6c4086a134e19d8fa48fdd_I20160131",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "if478ab72402a4dbca17cebf84905f137_I20190630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermLineOfCredit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425412 - Disclosure - Shareholders' Equity and Debt (Debt) (Details)",
     "role": "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails",
     "shortName": "Shareholders' Equity and Debt (Debt) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "i265ae74e8bfa4726841ed00db8f8e437_I20181017",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "if478ab72402a4dbca17cebf84905f137_I20190630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427413 - Disclosure - Income Taxes (Details Textual)",
     "role": "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual",
     "shortName": "Income Taxes (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "i5709e5c0528d4106ba0350257862d329_D20180101-20181231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "cpix:PaymentsForAssetAcquisitions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431414 - Disclosure - Recent Additions and Expected Return of Product Rights - Narrative (Details)",
     "role": "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsNarrativeDetails",
     "shortName": "Recent Additions and Expected Return of Product Rights - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "i5709e5c0528d4106ba0350257862d329_D20180101-20181231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "cpix:PaymentsForAssetAcquisitions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432415 - Disclosure - Recent Additions and Expected Return of Product Rights - Schedule of Initial Payments and Consideration (Details)",
     "role": "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsScheduleofInitialPaymentsandConsiderationDetails",
     "shortName": "Recent Additions and Expected Return of Product Rights - Schedule of Initial Payments and Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "i9d064a4268974d2eaa1aee9282ceb970_D20190101-20190630",
      "decimals": "0",
      "lang": null,
      "name": "cpix:PaymentsForContingentConsideration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "ic8e3a8763ebf4e4299a795047276e3dd_I20181112",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433416 - Disclosure - Recent Additions and Expected Return of Product Rights - Change in Consideration (Details)",
     "role": "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsChangeinConsiderationDetails",
     "shortName": "Recent Additions and Expected Return of Product Rights - Change in Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "ic8e3a8763ebf4e4299a795047276e3dd_I20181112",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (loss)",
     "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Income (loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "i7ebb93630dfe44cbba795040f7cda407_D20190401-20190630",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "if478ab72402a4dbca17cebf84905f137_I20190630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434417 - Disclosure - Recent Additions and Expected Return of Product Rights - Schedule of Preliminary Purchase Allocation (Details)",
     "role": "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsScheduleofPreliminaryPurchaseAllocationDetails",
     "shortName": "Recent Additions and Expected Return of Product Rights - Schedule of Preliminary Purchase Allocation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "ibfc029c334714ab1b6a1fa6f662c915e_I20181130",
      "decimals": "0",
      "lang": null,
      "name": "cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "i6eecb6cf82d946f791b1e9b3d617a3ba_I20171231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statement of Equity",
     "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
     "shortName": "Condensed Consolidated Statement of Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "i4acfcd09578f42f994a9b89541ecf28c_D20180101-20180331",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Basis of Presentation",
     "role": "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation",
     "shortName": "Organization and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - Marketable Securities",
     "role": "http://www.cumberlandpharma.com/role/MarketableSecurities",
     "shortName": "Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107103 - Disclosure - Earnings (Loss) Per Share",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShare",
     "shortName": "Earnings (Loss) Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190630.htm",
      "contextRef": "ie4c899d2244a468ba5f90d07e7b3826f_D20190101-20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 34,
   "tag": {
    "cpix_AcetadoteMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Acetadote",
        "label": "Acetadote [Member]",
        "terseLabel": "Acetadote"
       }
      }
     },
     "localname": "AcetadoteMember",
     "nsuri": "http://www.cumberlandpharma.com/20190630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Assets and Liabilities, Lessee",
        "label": "Assets and Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Lease Position"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.cumberlandpharma.com/20190630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration Arrangements, Contingent Consideration, Liability, Initial Fair Value Adjustment",
        "label": "Business Combination, Contingent Consideration Arrangements, Contingent Consideration, Liability, Initial Fair Value Adjustment",
        "terseLabel": "Adjustment to initial fair value of the contingent consideration liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment",
     "nsuri": "http://www.cumberlandpharma.com/20190630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsChangeinConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses",
        "label": "Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses",
        "terseLabel": "Contingent consideration earned and accrued in operating expenses"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses",
     "nsuri": "http://www.cumberlandpharma.com/20190630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsChangeinConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finished Goods Inventory",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finished Goods Inventory",
        "terseLabel": "Finished goods inventory"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory",
     "nsuri": "http://www.cumberlandpharma.com/20190630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles and Goodwill",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles and Goodwill",
        "terseLabel": "Total intangibles and goodwill"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill",
     "nsuri": "http://www.cumberlandpharma.com/20190630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Raw Materials Inventory",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Raw Materials Inventory",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory",
     "nsuri": "http://www.cumberlandpharma.com/20190630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Unlabeled Vials",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Unlabeled Vials",
        "terseLabel": "Work in process - unlabeled vials"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials",
     "nsuri": "http://www.cumberlandpharma.com/20190630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Validation Vials",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Validation Vials",
        "terseLabel": "Work in process - validation vials"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials",
     "nsuri": "http://www.cumberlandpharma.com/20190630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_CaldolorMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Caldolor",
        "label": "Caldolor [Member]",
        "terseLabel": "Caldolor"
       }
      }
     },
     "localname": "CaldolorMember",
     "nsuri": "http://www.cumberlandpharma.com/20190630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ClinigenHealthcareLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Clinigen Healthcare Limited",
        "label": "Clinigen Healthcare Limited [Member]",
        "terseLabel": "Agreement"
       }
      }
     },
     "localname": "ClinigenHealthcareLimitedMember",
     "nsuri": "http://www.cumberlandpharma.com/20190630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_DenominatorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Denominator.",
        "label": "Denominator [Abstract]",
        "verboseLabel": "Denominator:"
       }
      }
     },
     "localname": "DenominatorAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20190630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_EquityAndDebtAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity and Debt [Abstract]",
        "label": "Equity and Debt [Abstract]"
       }
      }
     },
     "localname": "EquityAndDebtAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20190630",
     "xbrltype": "stringItemType"
    },
    "cpix_EthyolMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ethyol",
        "label": "Ethyol [Member]",
        "terseLabel": "Ethyol"
       }
      }
     },
     "localname": "EthyolMember",
     "nsuri": "http://www.cumberlandpharma.com/20190630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_GloriaPharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gloria Pharmaceuticals",
        "label": "Gloria Pharmaceuticals [Member]",
        "terseLabel": "Gloria Pharmaceuticals"
       }
      }
     },
     "localname": "GloriaPharmaceuticalsMember",
     "nsuri": "http://www.cumberlandpharma.com/20190630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "HongKong WinHealth Pharma Group Co. Limited And DB Pharm Korea Co., Ltd.",
        "label": "HongKong WinHealth Pharma Group Co. Limited And DB Pharm Korea Co., Ltd. [Member]",
        "terseLabel": "WinHealth and DB Pharm"
       }
      }
     },
     "localname": "HongKongWinHealthPharmaGroupCoLimitedAndDBPharmKoreaCoLtdMember",
     "nsuri": "http://www.cumberlandpharma.com/20190630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_HongKongWinHealthPharmaGroupCoLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "HongKong WinHealth Pharma Group Co. Limited",
        "label": "HongKong WinHealth Pharma Group Co. Limited [Member]",
        "terseLabel": "WinHealth"
       }
      }
     },
     "localname": "HongKongWinHealthPharmaGroupCoLimitedMember",
     "nsuri": "http://www.cumberlandpharma.com/20190630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_IncreaseDecreaseInCurrentOperatingLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "IncreaseDecreaseInCurrentOperatingLiabilities",
        "verboseLabel": "Accounts payable and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInCurrentOperatingLiabilities",
     "nsuri": "http://www.cumberlandpharma.com/20190630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_KristaloseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Kristalose",
        "label": "Kristalose [Member]",
        "terseLabel": "Kristalose"
       }
      }
     },
     "localname": "KristaloseMember",
     "nsuri": "http://www.cumberlandpharma.com/20190630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_LeaseAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lease, Asset",
        "label": "Lease, Asset",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "LeaseAsset",
     "nsuri": "http://www.cumberlandpharma.com/20190630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_LeaseLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lease, Liability",
        "label": "Lease, Liability",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "LeaseLiability",
     "nsuri": "http://www.cumberlandpharma.com/20190630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line Of Credit Facility, Maximum Borrowing Capacity Upon Satisfaction Of Certain Conditions",
        "label": "Line Of Credit Facility, Maximum Borrowing Capacity Upon Satisfaction Of Certain Conditions",
        "terseLabel": "Line of credit, maximum borrowing capacity upon satisfaction of certain conditions"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions",
     "nsuri": "http://www.cumberlandpharma.com/20190630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_NumeratorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Numerator.",
        "label": "Numerator [Abstract]",
        "verboseLabel": "Numerator:"
       }
      }
     },
     "localname": "NumeratorAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20190630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_OmeclamoxPakMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Omeclamox-Pak",
        "label": "Omeclamox-Pak [Member]",
        "terseLabel": "Omeclamox-Pak"
       }
      }
     },
     "localname": "OmeclamoxPakMember",
     "nsuri": "http://www.cumberlandpharma.com/20190630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_OtherLongTermObligationsExcludingCurrentPortion": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Long Term Obligations, Excluding Current Portion",
        "label": "Other Long Term Obligations, Excluding Current Portion",
        "verboseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLongTermObligationsExcludingCurrentPortion",
     "nsuri": "http://www.cumberlandpharma.com/20190630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_OtherProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Products",
        "label": "Other Products [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherProductsMember",
     "nsuri": "http://www.cumberlandpharma.com/20190630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_PaymentsForAssetAcquisitions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments for Asset Acquisitions",
        "label": "Payments for Asset Acquisitions",
        "terseLabel": "Payments for asset acquisitions"
       }
      }
     },
     "localname": "PaymentsForAssetAcquisitions",
     "nsuri": "http://www.cumberlandpharma.com/20190630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_PaymentsForContingentConsideration": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsScheduleofInitialPaymentsandConsiderationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments for Contingent Consideration",
        "label": "Payments for Contingent Consideration",
        "terseLabel": "Fair value of contingent consideration - net sales royalty"
       }
      }
     },
     "localname": "PaymentsForContingentConsideration",
     "nsuri": "http://www.cumberlandpharma.com/20190630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsScheduleofInitialPaymentsandConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_PinnacleBankMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pinnacle Bank",
        "label": "Pinnacle Bank [Member]",
        "terseLabel": "Pinnacle Bank"
       }
      }
     },
     "localname": "PinnacleBankMember",
     "nsuri": "http://www.cumberlandpharma.com/20190630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ProductsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Products.",
        "label": "Products [Abstract]",
        "verboseLabel": "Products:"
       }
      }
     },
     "localname": "ProductsAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20190630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_SaleOfStockNumberOfSharesSold": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale Of Stock, Number Of Shares Sold",
        "label": "Sale Of Stock, Number Of Shares Sold",
        "terseLabel": "Number of shares sold (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesSold",
     "nsuri": "http://www.cumberlandpharma.com/20190630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cpix_SecondAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Second Amendment",
        "label": "Second Amendment [Member]",
        "terseLabel": "Second Amendment"
       }
      }
     },
     "localname": "SecondAmendmentMember",
     "nsuri": "http://www.cumberlandpharma.com/20190630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Net of Shares for Tax Withholding",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Net of Shares for Tax Withholding",
        "terseLabel": "Common stock issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding",
     "nsuri": "http://www.cumberlandpharma.com/20190630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cpix_ShareholdersEquityTextualAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shareholders Equity.",
        "label": "Shareholders Equity (Textual) [Abstract]",
        "verboseLabel": "Shareholders' Equity (Textual) [Abstract]"
       }
      }
     },
     "localname": "ShareholdersEquityTextualAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20190630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities",
        "terseLabel": "Shelf Registration, sale of corporate securities (up to)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities",
     "nsuri": "http://www.cumberlandpharma.com/20190630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_SubsidiaryInvestmentCashContribution": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Subsidiary Investment, Cash Contribution",
        "label": "Subsidiary Investment, Cash Contribution",
        "terseLabel": "Contribution of cash"
       }
      }
     },
     "localname": "SubsidiaryInvestmentCashContribution",
     "nsuri": "http://www.cumberlandpharma.com/20190630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Subsidiary Investment, Conversion Of Intercompany Loans Payable",
        "label": "Subsidiary Investment, Conversion Of Intercompany Loans Payable",
        "terseLabel": "Conversion of intercompany loans payable"
       }
      }
     },
     "localname": "SubsidiaryInvestmentConversionOfIntercompanyLoansPayable",
     "nsuri": "http://www.cumberlandpharma.com/20190630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Subsidiary Investment, Payments For Return Of Capital",
        "label": "Subsidiary Investment, Payments For Return Of Capital",
        "terseLabel": "Cash payments for return of shares"
       }
      }
     },
     "localname": "SubsidiaryInvestmentPaymentsForReturnOfCapital",
     "nsuri": "http://www.cumberlandpharma.com/20190630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_SubsidiaryInvestmentPurchaseOfShares": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Subsidiary Investment, Purchase Of Shares",
        "label": "Subsidiary Investment, Purchase Of Shares",
        "terseLabel": "Investment through purchase of shares of CET Stock"
       }
      }
     },
     "localname": "SubsidiaryInvestmentPurchaseOfShares",
     "nsuri": "http://www.cumberlandpharma.com/20190630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_TieredRoyaltyPaymentsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tiered Royalty Payments, Percentage",
        "label": "Tiered Royalty Payments, Percentage",
        "terseLabel": "Percentage of tiered royalty payments (up to)"
       }
      }
     },
     "localname": "TieredRoyaltyPaymentsPercentage",
     "nsuri": "http://www.cumberlandpharma.com/20190630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cpix_TotectMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Totect",
        "label": "Totect [Member]",
        "terseLabel": "Totect"
       }
      }
     },
     "localname": "TotectMember",
     "nsuri": "http://www.cumberlandpharma.com/20190630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_UsTreasuryNotesAndBondsSecuritiesMemberMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Us Treasury Notes And Bonds Securities Member",
        "label": "Us Treasury Notes And Bonds Securities Member [Member]",
        "terseLabel": "U.S. Treasury notes and bonds"
       }
      }
     },
     "localname": "UsTreasuryNotesAndBondsSecuritiesMemberMember",
     "nsuri": "http://www.cumberlandpharma.com/20190630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_VIBATIVMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "VIBATIV",
        "label": "VIBATIV [Member]",
        "terseLabel": "Vibativ"
       }
      }
     },
     "localname": "VIBATIVMember",
     "nsuri": "http://www.cumberlandpharma.com/20190630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsChangeinConsiderationDetails",
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsScheduleofInitialPaymentsandConsiderationDetails",
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsScheduleofPreliminaryPurchaseAllocationDetails",
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_VaprisolMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Vaprisol",
        "label": "Vaprisol [Member]",
        "terseLabel": "Vaprisol"
       }
      }
     },
     "localname": "VaprisolMember",
     "nsuri": "http://www.cumberlandpharma.com/20190630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r41",
      "r76"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RevenuesDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r107",
      "r137",
      "r139",
      "r234"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RevenuesDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r15",
      "r138"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.",
        "label": "Accounts Receivable, Net, Current",
        "verboseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net income (loss) to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r50",
      "r68",
      "r196"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "verboseLabel": "Noncash interest expense"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r68",
      "r124",
      "r126"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "verboseLabel": "Amortization"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Common stock available for purchase through restricted stock awards and options (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r105",
      "r212",
      "r226"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r40"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r145",
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by award type pertaining to equity-based compensation.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsChangeinConsiderationDetails",
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsScheduleofInitialPaymentsandConsiderationDetails",
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r160",
      "r161"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsChangeinConsiderationDetails",
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsScheduleofInitialPaymentsandConsiderationDetails",
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "verboseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsChangeinConsiderationDetails",
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsScheduleofInitialPaymentsandConsiderationDetails",
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r166",
      "r167",
      "r170"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsScheduleofInitialPaymentsandConsiderationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "totalLabel": "Total consideration"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsScheduleofInitialPaymentsandConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r67",
      "r173"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Change in fair value of contingent consideration included in operating expenses"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsChangeinConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r165",
      "r168",
      "r172"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsChangeinConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r165",
      "r169"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Current portion of the contingent consideration liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r165",
      "r169"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Noncurrent portion of the contingent consideration liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "RECENT ADDITIONS AND EXPECTED RETURN OF PRODUCT RIGHTS"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRights"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "auth_ref": [
      "r163"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "terseLabel": "Total assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r162",
      "r163"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "terseLabel": "Intellectual property amortizable intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "auth_ref": [
      "r162",
      "r163"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of inventory recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
        "terseLabel": "Total inventory",
        "verboseLabel": "Non-current inventory"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r25",
      "r70"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.",
        "label": "Cash and Cash Equivalents, Period Increase (Decrease)",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "COLLABORATIVE AGREEMENTS"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CollaborativeAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r34",
      "r128",
      "r217",
      "r231"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "verboseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNoParValue": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount per share of no-par value common stock.",
        "label": "Common Stock, No Par Value",
        "verboseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockNoParValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r14",
      "r132"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balance, End of Period (in shares)",
        "periodStartLabel": "Balance, Beginning of Period (in shares)",
        "verboseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock\u2014no par value; 100,000,000 shares authorized; 15,555,865 and 15,723,075 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r43",
      "r45",
      "r46"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r43",
      "r45",
      "r179",
      "r180",
      "r188"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Net (income) loss at subsidiary attributable to noncontrolling interests"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r43",
      "r45",
      "r178",
      "r188"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Comprehensive income (loss) attributable to common shareholders"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r96",
      "r97",
      "r193",
      "r194"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r96",
      "r97",
      "r193",
      "r194",
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "verboseLabel": "Cost of products sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "verboseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r213",
      "r214",
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate spread"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r68",
      "r75",
      "r156",
      "r157"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred tax expense"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent": {
     "auth_ref": [
      "r153",
      "r154",
      "r155"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting and classified as noncurrent.",
        "label": "Deferred Tax Assets, Net, Noncurrent",
        "terseLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNetNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r68",
      "r103"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DirectorMember": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Person serving on the board of directors (who collectively have responsibility for governing the entity).",
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "verboseLabel": "Earnings (loss) per share attributable to common shareholders"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r49",
      "r81",
      "r84",
      "r85",
      "r86",
      "r87",
      "r90",
      "r220",
      "r233"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "- basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r49",
      "r81",
      "r84",
      "r85",
      "r86",
      "r87",
      "r90",
      "r220",
      "r233"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "- diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "EARNINGS (LOSS) PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue from External Customer [Line Items]",
        "terseLabel": "Revenue from External Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities": {
     "auth_ref": [
      "r151"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.",
        "label": "Excess Tax Benefit from Share-based Compensation, Operating Activities",
        "negatedLabel": "(Decrease) increase in non-cash contingent consideration"
       }
      }
     },
     "localname": "ExcessTaxBenefitFromShareBasedCompensationOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r190",
      "r191",
      "r192"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.",
        "label": "Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]",
        "terseLabel": "Fair value of marketable securities, by type"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r140",
      "r141",
      "r142",
      "r192",
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails",
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r140",
      "r141",
      "r142",
      "r192",
      "r207"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r140",
      "r141",
      "r142",
      "r192",
      "r208"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r140",
      "r141",
      "r142",
      "r192",
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails",
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r122",
      "r123"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income (loss) before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r75",
      "r104",
      "r158"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax (expense) benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Net changes in assets and liabilities affecting operating activities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other current assets and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r47",
      "r102",
      "r195",
      "r196",
      "r221"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryCurrentTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Current [Table]",
        "terseLabel": "Inventory, Current [Table]"
       }
      }
     },
     "localname": "InventoryCurrentTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r20",
      "r120"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "verboseLabel": "Finished goods, net of reserves"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Inventory, Gross, Total"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r2",
      "r37",
      "r118"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "totalLabel": "Total inventories classified as current",
        "verboseLabel": "Inventories, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory, Net, Items Net of Reserve Alternative [Abstract]",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNetItemsNetOfReserveAlternativeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNoncurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
        "label": "Inventory, Noncurrent",
        "negatedLabel": "Inventory, Noncurrent",
        "terseLabel": "Non-current inventories"
       }
      }
     },
     "localname": "InventoryNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r21",
      "r120"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "verboseLabel": "Raw materials and work in process"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r37",
      "r80",
      "r118",
      "r119"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory Valuation Reserves",
        "verboseLabel": "Reserve for potential obsolescence of products"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r54",
      "r101"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "verboseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r117",
      "r211",
      "r224",
      "r236"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "MARKETABLE SECURITIES"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Maturity of Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r202"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r202"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five",
        "terseLabel": "After 2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r202"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months",
        "terseLabel": "2019"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r202"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r202"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r202"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r202"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r202"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r19",
      "r216",
      "r229"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r28",
      "r77"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]",
        "terseLabel": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r28"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Line of credit, maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r28",
      "r77"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.",
        "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage",
        "terseLabel": "Line of credit, unused capacity, commitment fee percentage"
       }
      }
     },
     "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermLineOfCredit": {
     "auth_ref": [
      "r33",
      "r130",
      "r131"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit, Noncurrent",
        "verboseLabel": "Revolving line of credit"
       }
      }
     },
     "localname": "LongTermLineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyAccrualRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Loss Contingency Accrual [Roll Forward]",
        "terseLabel": "Loss Contingency Accrual [Roll Forward]"
       }
      }
     },
     "localname": "LossContingencyAccrualRollForward",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsChangeinConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecurities": {
     "auth_ref": [
      "r218"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in marketable security.",
        "label": "Marketable Securities",
        "verboseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r36",
      "r215",
      "r228"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromRedemptions": {
     "auth_ref": [
      "r133",
      "r181",
      "r182"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).",
        "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests",
        "negatedLabel": "Repurchase of subsidiary shares from noncontrolling interest",
        "terseLabel": "Repurchase of subsidiary shares from noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromRedemptions",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MunicipalBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.",
        "label": "Municipal Bonds [Member]",
        "terseLabel": "Short-term cash investments"
       }
      }
     },
     "localname": "MunicipalBondsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r64",
      "r66",
      "r69"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r42",
      "r44",
      "r48",
      "r69",
      "r89",
      "r219",
      "r232"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income (loss) attributable to common shareholders",
        "totalLabel": "Net income (loss) attributable to common shareholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r42",
      "r44",
      "r184",
      "r187"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedLabel": "Net (income) loss at subsidiary attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Guidance"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r71",
      "r72",
      "r73"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Intangible Assets Acquired",
        "terseLabel": "Additions to intangible assets from final purchase price allocation"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "verboseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating income (loss)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Lease Liabilities, Payments Due [Abstract]",
        "terseLabel": "Maturity of Leases Liabilities at June 30, 2019"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r198"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r198"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r198"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r197"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails",
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r201",
      "r203"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Present value of remaining lease payments, percent"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r200",
      "r203"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r189"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "ORGANIZATION AND BASIS OF PRESENTATION"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "verboseLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross amount of inventory owned by the entity but in the hands of a customer, typically a reseller.",
        "label": "Other Inventory, Materials, Supplies and Merchandise under Consignment, Gross",
        "terseLabel": "Consigned inventory"
       }
      }
     },
     "localname": "OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r30"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "verboseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPaymentsToAcquireBusinesses": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsScheduleofInitialPaymentsandConsiderationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.",
        "label": "Other Payments to Acquire Businesses",
        "terseLabel": "Cash payment during early 2019"
       }
      }
     },
     "localname": "OtherPaymentsToAcquireBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsScheduleofInitialPaymentsandConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "negatedLabel": "Cash payment of contingent consideration"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchase of common shares"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRoyalties": {
     "auth_ref": [
      "r65"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash paid for royalties during the current period.",
        "label": "Payments for Royalties",
        "negatedLabel": "Cash payment of royalty during the period"
       }
      }
     },
     "localname": "PaymentsForRoyalties",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsChangeinConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedTerseLabel": "Payments of deferred offering costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r56",
      "r171"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      },
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsScheduleofInitialPaymentsandConsiderationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "negatedLabel": "Cash paid for acquisitions",
        "terseLabel": "Payment to acquire business upon closing",
        "verboseLabel": "Payment to acquire business upon closing"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsScheduleofInitialPaymentsandConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Additions to intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Additions to property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from sales of common stock, net of offering costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfLinesOfCredit": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).",
        "label": "Proceeds from (Repayments of) Lines of Credit",
        "terseLabel": "Borrowings on line of credit"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from sale of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfIntangibleAssets": {
     "auth_ref": [
      "r55"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Proceeds from Sale of Intangible Assets",
        "terseLabel": "Financial consideration received in exchange for product license rights"
       }
      }
     },
     "localname": "ProceedsFromSaleOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r42",
      "r44",
      "r63",
      "r105",
      "r106",
      "r178",
      "r183",
      "r185",
      "r187",
      "r188"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss)",
        "totalLabel": "Net income (loss)",
        "verboseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r8",
      "r9",
      "r127",
      "r230"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "verboseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "negatedTerseLabel": "Repayments on line of credit"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r152",
      "r237"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r16",
      "r133",
      "r227"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "verboseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r135",
      "r136",
      "r137"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Net revenues",
        "verboseLabel": "Net revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss",
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRightsGrantedMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue during the period derived from licenses, patents, trademarks and other rights granted to other parties, when it serves as a benchmark in a concentration of risk calculation.",
        "label": "Revenue, Rights Granted [Member]",
        "terseLabel": "CET Grant Revenue"
       }
      }
     },
     "localname": "RevenueRightsGrantedMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenues [Abstract]",
        "verboseLabel": "Net Revenues"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r199",
      "r203"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Recognition of operating lease assets and liabilities through adoption of ASC 842"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScenarioForecastMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The reporting scenario used to indicate financial results forecast for a future period.",
        "label": "Scenario, Forecast [Member]",
        "terseLabel": "Scenario, Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScenarioUnspecifiedDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Any scenario, that is, the particular reporting scenario is left unspecified. Scenarios distinguish among different kinds of business reporting facts, as for example actual versus budgeted figures.",
        "label": "Scenario, Unspecified [Domain]",
        "terseLabel": "Scenario, Unspecified [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r114",
      "r115",
      "r116",
      "r222",
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r160",
      "r161"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsChangeinConsiderationDetails",
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsScheduleofInitialPaymentsandConsiderationDetails",
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "auth_ref": [
      "r160",
      "r161"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Reconciliation of numerator and denominator"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table]",
        "terseLabel": "Revenue from External Customers by Products and Services [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Summary of net revenue"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r7",
      "r22",
      "r23",
      "r24"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r145",
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of an equity-based arrangement under which compensation is awarded to employees, typically comprised of compensation expense; changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan; and cash flow effects resulting from the equity-based payment arrangement. Component disclosures are by type of award and plan name.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "REVENUES"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/Revenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "verboseLabel": "Operating Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingAndMarketingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.",
        "label": "Selling and Marketing Expense",
        "verboseLabel": "Selling and marketing"
       }
      }
     },
     "localname": "SellingAndMarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.",
        "label": "Share-based Compensation",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Restricted stock awards, vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted stock granted in period, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r143",
      "r147"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity-based compensation award.",
        "label": "Equity Award [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r35",
      "r132"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementScenarioAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by scenario to be reported. Scenarios distinguish among different kinds of business reporting facts, as for example actual versus budgeted figures.",
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentAdditionsandExpectedReturnofProductRightsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r132",
      "r133"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Proceeds from the sale of common stock, net of offering costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r13",
      "r14",
      "r132",
      "r133"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.",
        "label": "Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures",
        "terseLabel": "Share-based compensation (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r132",
      "r133"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Proceeds from sales of common stock, net of offering costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r13",
      "r14",
      "r133",
      "r144",
      "r149"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.",
        "label": "Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "verboseLabel": "Repurchase outstanding common shares"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r13",
      "r14",
      "r132",
      "r133"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedLabel": "Repurchase of shares (in shares)",
        "terseLabel": "Repurchase of shares (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r13",
      "r14",
      "r132",
      "r133"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "negatedLabel": "Repurchase of common shares",
        "negatedTerseLabel": "Repurchase of shares, value"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r14",
      "r17",
      "r18",
      "r109"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Shareholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r176",
      "r177",
      "r186"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance, End of Period",
        "periodStartLabel": "Balance, Beginning of Period",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "verboseLabel": "Equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "SHAREHOLDERS' EQUITY AND DEBT"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental non-cash operating, investing and financing activities:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TitleOfIndividualAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of individual, or nature of relationship to individual or group of individuals.",
        "label": "Relationship to Entity [Domain]",
        "terseLabel": "Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradingSecurities": {
     "auth_ref": [
      "r218"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Debt Securities, Trading, and Equity Securities, FV-NI",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "TradingSecurities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.",
        "label": "Unrealized Gain (Loss) on Investments",
        "negatedLabel": "Noncash investment gains"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r92",
      "r93",
      "r94",
      "r95",
      "r98",
      "r99",
      "r100"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Dilutive effect of other securities (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r83",
      "r87"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Weighted-average shares outstanding \u2013 diluted (in shares)",
        "verboseLabel": "- diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "verboseLabel": "Weighted-average shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r82",
      "r87"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares outstanding \u2013 basic (in shares)",
        "verboseLabel": "- basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26853-111562"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27198-111563"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27290-111563"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27337-111563"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27340-111563"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27357-111563"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1314-112600"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1336-112600"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=112275985&loc=d3e4179-114921"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11374-113907"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e31917-109318"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e31931-109318"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=108330185&loc=d3e2207-128464"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=84161108&loc=d3e4845-128472"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=84161108&loc=d3e4845-128472"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=109124213&loc=d3e6578-128477"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=109124213&loc=d3e6613-128477"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613674-111683"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569655-111683"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4616395-111683"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4590271-111686"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4591551-111686"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4591552-111686"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19190-110258"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13531-108611"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13537-108611"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=68078379&loc=d3e122625-111746"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.4)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62557-112803"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99384497&loc=SL65671331-158438"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r238": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r239": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r241": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r242": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r243": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(d))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e557-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6904-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6911-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3000-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1448-109256"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1505-109256"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>58
<FILENAME>0001628280-19-010781-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-19-010781-xbrl.zip
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M+0)1B\(6KV$O!T+J%-JAW%6P8K9.HF3 0KBMR3%P7LB 1!VQ=>Z#$8V'C+1
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MN,78."6(-3E=UXEG0YH9 ]RTZ..P%%IR&C4!"5)1N[PH&T(BE!IIV+.ASY,
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M:%Q>;J25#JAT0*4#9BEU:E('\,5L\ _[P"0%_K_K]WP,&?(K@)\C I:7U2J
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M#Y%F54#S/J Y$W_DUBC*<I$)YSGB)I>WR>E6E&@2DN:8$[NQ*2FKF%Y0 +*
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M/O:@U3L9#H:VFP?<[-VA,IHRFC*:!8ZF;(G</>-Z>?/UB,NJC2S.PS6?GIC
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M_=<+\4^'M0W&(2TP1CR:7(>(>60-9M0*CDFN/I2/#*FU:PI>(*"9>[D% AH
M 3.%/Z@+P@>!&-41<:<TLCY2I A.1,6@B,Q)JXQ4\HHS-XW=PFTNFWEWTO>'
M=@#WZJ76D>U_C<,Z;VT0_4F_[.0^4OJR<[[0>^?K7&!K'MCZ<J$8F:%>$"<P
M")3-S(4H9$F2B$46'?-""VHV-DTEJ:J(N5PQM>S=/E(E?TB"4I1\$4H^Y28Z
M"$%\;N]KHT9<4(=,+D#('64D& ZO>N FLC+P/VT>(,/LL8=>@'(#GH1Q7'(
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M MSK"=QD!KC) :5).>(XDDGG1@X&(V<418YRD:AV!,?<<IA4"IN*TEOU&RW
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M( -T/6/@ ,,C@91UCV#:\[N]7A_&E_^:S%8WQO"C8_AS)6ZXCHYD>]!JPR3
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M'9R6/:[JL7'A\.[\\8O/;E=+.I@>JBJ$.Q^KNE4NROKDV8813+.(P,0?#X[
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MVYL[__MJ=_/W/U_EDZ5_[;S=+46C[EU*Y?;G+H_3:F&BPS1Y \(&K\*8E#&
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MPF7XO\4-^)99_G_>QYC2;5("MWS86>./-6LWYJE?U*K'G[AO$L<5F,;_N!:
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M8HJ<=80$@.5(1([M8:';1#YDX9!&RY^UENM<!Y(8<#PEX<()1Z7!*22%=>"
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MLMYG"SG*%AD@O7K?5@*[6@0A0]VH==H;=UL>7G  <C8">@#LOK7YX64+> =
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M2VWF>\<!6&T>\LS@>Y#0L_R<2@XR 9M9?3\ NU_Q6]OR75BM6+@QJ,=QQ<J
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M76K,RNX>[1Q\PE$)P;%'G :#.!8<@=MND:! Y#1)W&%^OZ-SC%$'9( R'7G
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M[D+U--.JKI[67]2OK4<^&OQA//"?NX,^F,K1J_^;E%(OX[@%/DA_,)H,5^9
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M4C'L1<XB<@M)0WN!P??\V5O*9IJ+672[JY7 -\>+]MQZ4N?VS5-,@J=?+@!
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MU>C#]V=YU7DN+5FN0MYT$0BP/8XP746\^(%AVB!:7#L"L1)S= $8D<F=T$N
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M5G$4:$_+#:IRR37ATTME:WQA:%*/Y+J[%VVF;M(C)=N-9VYMT*D@P2$D E"
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M)J%/VN_]S8"L'<<R"L>(7:38\:DVY67I4F?+!+T#X $C93LI4LSL0<"2;T(
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MF%6P@!.,9L O!6J:R%4X,)F95"9*@#S<"TIKU?K#6T)1\A!P0YP'^>H7H;$
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MNR':KZK*'O3%Z\S9\DQ'#=PUC<,-J+O,2K, =6L;3QI0=\G\4AQN9[GFBPU
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M6%,[]SYI-?LVX%P\0I^?%R):3)6!D<7705\")]J$F'X>,2>C&W8+]CM+B!V
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M.]"$)Y;>]G)M+O.-P)]\?JFL4PJ-)7=79&%B1[8CG)6X^QHU<76HCK<_FX4
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ML.451NZ<*/+$:@5RT;<JG2_E?)S RIBNT*$-G_%=9$]B<FQ!-9GXU+L!NQ4
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M'$KS^2=MJ/8C[HUA+IR.&\J=.,H1[VCTGF/*0M5A5R\)+6VZ[2&Y'N!=0M[
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M"K$LXS?<,C;U(<(]O6RZ:?P>.9MPW+?A;T4<82"5B*A3=5SM^&R+<RP1"5X
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MW179[4L+ V_3K@\V^%2+]Q%$%VMW(YY8,#7Y/>D2, !9^>N4*7\(5+EE&_=
M3-E$^$/O,?VSF[[_;_KO7^/I/Q$FBZ/7?3#</V;=R8?GW:OQ\7B!F>;4'Y_U
M'_QW-T.@OR_RV=J9A#;12$/&*2?I9&YKJ#QA=Z9$94O@>KV(F1V![-<P::3;
M[D"*:9(%.4U8(T#ZE7L\_^/9EV<X34?',/NC?ZP,%Y"]T;7G:.TN%X%!?>N
M5NLH=09L$B%Q%[ _C9\F*AQPQ^YF?.?HSIZ]=?"UK&]Q%\##U*P85JUW<F8
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MD.P_5'< #5VKN[J+>!L$W+X;+^IR^7*:QQ_'N7H2E=9@,Y!)9EA6FH:8,+#
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MW7L(>VX0=0R8R[=9C\AU0'[K_7HW4N1675BWT<+!^O6B Y\TCRPJ4:LO*<W
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MJ/4 E2)@I0G(9V"E"U#%'*RU 94Z8*W/R:DI^([@4V,<%?-]4 ON$]0=7JH
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MJJH<-BJ?T2EXUD,^FH_U\SSG^H+IM'%0N#%*YQFT(YXAYJ5G?FJDUNL"&"7
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M(FRT+1!@AAF,E! 0\2B#5"099"GE(<,RH4HX50WH0<BQ4<[-?R]-\$ E<,=
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MW3;2V"ABG;AA.L-5Q>D W1+7P7IIQ=?",/2%6L^TL0-8)>AV"U%O@#G8=KZ
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M5WMT/-=B.S?JT!79+%$X4I?-]DY?1:E7C5=,+BR3,:=9ED :I2E$<<8@HXF
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MR8OE;/%9FX"?I)[0V6*2QE$6RS"#*4TB;:;Q#!(E)914!H' F4G8Z!ZZ?5Z
ML9'304SW7#YI*]IXL>OH[N>UY_JYUN"2&&^+";+;2?8)>\_<>'!,L)(>-.*#
ME?S *' %/IW!_<*8<7OP^@LFMY#A%:/,[1%J#S]W>$[7$)"OLJYU6IK.@DWK
MT,7+O>3+>16GX!Q68/O $2VP+:&O0-71<M7:=O$"-I+W%%7@"IC?J +KT0>.
M*G!%Y3"JP/D)'0V*Q:.<KX*R7G[12W.>TVEYOWQ^GII19GH+-#?10B(OY:^F
MS7J5N/\PJVJ7$Y&)($IB2&-%](Y&FQB41!A*3D,I$:(1=>JE>Y$T8S,U&M&J
M&/)&(T=;XJ*YL30LAD*\;RO#Z+&.^GRY FM5KL!*F;HXW48=L#3Z@"V%KL#/
M\Z+T&#'J!5ZO=LA% @UKE/C [L!"\?+0KFET!?_]MBR74KS3+#Y[T%907HBJ
M;/M'^4?UFW*B8G-6%V.HB&G'A44,B8@Y#*(X$HHP%6 K+Y'3J&/CSMU<D9).
M]>K5FS5>/#T5,U#6Q21F<F'^L5!*&KWT;TO73!R[*;&C4N] ]TR9E;R@%AC4
M$H-:Y*M5&U0M=GV!1TIT@LEO^I_-P -G!3I@<9@LZ'*S&V4)F4_>-1[#_[VD
M<[WFIR^?Y7,Q7TP0PC$3@8 )50PBADQ=@(3"., XDIPCQ4(;@FH98VQTM!(3
MK.4$M:!V;-.&9CNW>,*H9R9QA\>:-2P V'!$N2*)4O(?'XJO/^F[#3\0\Y?*
M5;Q%"VU/'H0$+%1;+7F;2[O9)&_U%S6O-YK:]EF79^-58U#%J**80Y0F(411
M;"R12,!4Q4(DL0KCU"G/OV6LL2WX+5&K70/?%M;-Q&A#V,ZP\(1;SR2P#]E;
M*\B<S0<+,'P:#6W##6HJ6.B];R#8W-)W=^&U U8PG"F<"!A12B&* PD)EPJF
M#)-$1,S\KUMDHKL0+JMEF$C%JB&NFA9_-#L=#[EV'>;&CH;ZQ;MG=NK0?;@7
MAWEW$%^G(?'K.-"[H]2]0;$GA_JZA$M3CO&QF.J;R]I][[CBK)XUHD6VJ0Y4
M-!4_&XG_974<U<>2<D*IEWI"K0._3IDA&RQ.5A^RNMG=H?"VT!]5RR5P</V(
M7O-*+O!,'^2/?C:X1Q6]8%N[^[S!-K-'U=C>PAZ_X/+J5GHGW$3MW*D/)@_G
M3KV=2Y$O)HA%%&%.(5=$[V-Q%$+"HABFH6)8AAA'2G8M<'5RU+%M9M\4\WGQ
M1Y724753GU6!3[R2M7OAJM.@VWW<O$/9\ZK?/9+X?B.R!O,'4$EM8'W;#NM%
M1:S.PM17':O3 []:*:NS6+15LSI_<]<,O5+JFQ[U=ON=_"JGQ;,99-7N37%"
M.4TU6ZLTABA0(:0I%3 D- XEK?C(-3FO9;SQ[797XE;^(;$1V#4]KPUD._+Q
M!ES/I+.#V):D_COK62'B-Q&O;<"!<_ L=#],O[.YJ7M@8Q6@4(6C3+A4L501
MA5+A5!,')1#'80#U3R1-%>6$$)=J^[N/=S)7!BBTOQ7$4\EW!1PR2DX@:,<*
MW7'IF0;V(?$;P'FHLN\@S:T1!@_$/-3N6+#ED:LZ)'NMR@"\+9Y8/JM2;3Y+
M7CS,\K]+<2OT*+G*Z;I\9E4?0-L=FD(^;$JOZ=\MGZ3X6S'__79662UEN1;Q
MKW2:B^K!?S5Q2Q,<\8RH((&!P %$88),.ED(LX1BCHBD";<ZHWL=\<>V4S)"
MFY)LS[78 )H\D49@\-5([)#=-?S+T,YRXY_BGEET78]E2_DKL%$?;.O?5",&
M*P0J"VP+ ]" < 56+TT#Q'80Z@8+\-?1OST.*8BC?HL&RG0<\=ODEE_Y:I/9
MFL8YO%3#98N^&N([2:FO)T67YHZFF]G.@83I&;G<*ARK H1DEF3:_DPSJ$T?
M#(EQ^JJ()'H%AX3;>E?L!AR?>V5;Y/6)V_>-V#_8G+UUP=W"Z/"*9=]GF%NR
M#H:A2P-(GU@.U03R$%,/)V=N<+0W?CS[E &;/]IJM-L TOJNCM6'-Y0_$:G>
M9J:1WNF3Q'2-X2FD(B,PC%(2814&@CHU?]QZ]MA\497GJ7O'MVW4[%Q0';'H
MF10_6 #@7L'W4%6OM7FW'C]LU=U#O0[JZ1ZYI-NZ/&+$F3S[:5$NYW+=5GL2
M4H3#D%,8(Y)"1&,!:485#).(1%1P*3.KG VW8<?FWOE\\_;FXQ=P_>[=[9?;
MNX_WX/KC.W#SGY]NWGZY>0<^WWSY]?-'</<>?/I\]^[7MU_ Y]N?__+EWFW)
M6TZ('1OXA_D57"Q@(S+XS0@-*JD]1H"YP>239"Q''I1_W-#8IR;'NWOH9?"K
MR;VM*H5(<?/-;"BOG\Q/$Q;P!%&B24R$5)-8FD!"4ZEW>#)""59*<.36$*J3
M'%;+;=!&44:-/YE.:E(_U?$TO=M46!HSO<$[GDX'VVJ 6@]0*S)0KX-S. [6
M[^"D(./I>7 .*Z>^!V<?UC& W)0BJ,)PZ=2$KK^?%G_<SE0Q?ZK(>.TSH 15
M 8PP"0B&B,D8$L9#J"DR3;E,.0V<0ALMQQV;3;<M-I@5,\A-EL<ZC^:J*KY2
MUBDU,P%4W>_SD@0;VPFRX\@>8._;0[:->)538V0&6T+W$^;O!I370'_+H8<-
M]7?#XR#8W_%V]W#_+W,J]$*[?WEBQ7022Q1D<< @YUQ E' )<4A";<%%,8FX
M_HVT*A5U\.2Q$5(C'*BELR\0L M7.WE<!$+/]&"IOU."Q%%=+TB0V'W>8 D2
M1]783I X?D$W.V+5%N"3G%?.X3>TS/E$$D*26'(HTT1"A%$$,0TH)$313/$X
M04*ZQ2 ?'6=\AV,0,",8^#Z? 5%,IW1>F@JOH#0RG^YJX0"MW??^8KAZ7K[K
M[A]:0%!)> 4J&?U]R5LA\/G=/C[0H%_I5EWWO\GM%W>C@;TBK!^7IJ#]G:J>
M7]XM%^7"U#J;/33T0&F21IC",$L01"K6],!% /66 A'%<10BY48/3N./FS8J
MJB@=N<(-?\H4"7F*(5/,]&]*":0)3B".DBC$/*+4KJM*[^@/$HW9" ]I4RBZ
MG@!0;.0&_^.?]3L9_GG86;)C^MZP[_D+<%"?NY:\RNFN)V!+>.\?ATZH^?QH
MN DPZ,>D$S;['YEN#^E<7>IY+A_EK,R_RML9+Y[D1[FX4U_HM^O%8IZSY<($
MF'TI/FH BME"@Z&?]K#R9$\2E60904SO%U$(D509I)B&4&4\PX(@)6GL6('J
M$GG&1I"FJ(FF/*/&#V!:E"6@"U N69F+G,Y?]$\;G<"B,.ZQ+:U WJCE7M#J
MHDFU8\\!IZIG/MW1!-2J@.\_Z.GZP538K(IE:*VNP/7>=.UJ=OY\ITLM+1\8
M>ZZW=9%(0]?D\H'?D;I=7A[;C;/?Y[-\(3_HH85^HGZ1\W4(\$?3J(CIF1,I
M@J&V12$B$8>4<0(3(CG2#\Q82MUV".T#CF]+L!$2T$K*JA*Q&X>> =F.(OT!
MUS,#UH+"2E*P!=]U ]]''[VBW%#QR5EG1AR4DNRTWV<<R[NZUQ"N2Q/?S,0[
MNI"3 (=Q' L)]9^!MNUP $DL*!21:8+'.0F0]5G T1'&9JBM"^364H(;D\VO
MY70O'[P+Y/E3@HOAZ9D:G)'I5#GXJ/8>Z@;O/G?PJL%'U3I6,_CXA1W2<#[-
M"['DBTWIR#@*0QFEL?[^TPBB.$.0!+'>IG'&(Y:1E*;"(>MF__GC^_JO)+0,
M&CB.6ONZO1B)GM?L2K1NV3 '8#@DOUP"RD"Y+BL1?26XG%*Y-9_EX*;ATE=.
MR;N3K7+RHJYNIIGI)C>O<QCS\O<W<L8?G^C\]W>%Z>XXH3SF(E)ZOR*,'RD6
M"<0XHS"(>( %X4*FD9L?J7W L=D?._("(S!82PQ^JV6V7,/6F-NZ>?PAV;L?
MYQ(0.SAG[)#QZWTY,^; [A4[! [])Y;W=2W.Q.<F$/2=K/][.ZN:2AEGS'(^
MUP-O9WW1B"1(JA"F)DT.F6X*-!(Q1%)B(646!=0I2M-E\+&Q4-VC;5K,'J >
M[JE[6IW3#-CQ4%^X]LQ)*['!]RO!?S#%(VJD-\*#7A+XNF#FM[*4P_@#UYUR
M1^:P*E6'9_20CO.IJ93Y;BG_2]+Y>_WN3D(4HB2BB9D9!A&*,HAE%$(9QI(%
M62"YG0.GJP!C8[8HB"*/:3?'(+>CL3Z![)G*;))M/JV;LVL=@%$"&"T&RK1I
MP6^P))MC,HPGOZ8%(:?4FK;G=/!:O9.SXLDD,Q:;\O,T49E,$FV3R4!36( "
M2*0((0D55UF:DCBQ#(0]-<3X?%=;0KJXKX[!9^'!NA"2OAW/&^FZ^;&.H>+@
MRKH0G8&\65M2^G)HM2C>ZM,Z=M]P;JT6J7<\6VW7>>VU]7Z5R':DGQ.3%*$T
M$E"B*M<&9Y"B,(%!%A*&"4]5Q+WTVFH18GSLM]]KRT,J8(>YL;/C^L6[9VH]
MTVMKK<0K]=JR '& 7EMM4HRAUY8%2I:]MFR>U(T:KY^*^2+_>_4-O%/K<=Z:
M/N 3ID20$I+!S!2Z00&AD&4DA#RE@5)9S#.1N)%@VW#CHSOC*#"+<!7E">29
ME@'N$-MQF2_8>F:M;3%-2.8[R195\W,MK@1O6WO+.U.3#28^2:AUO$'IQD;S
M?6*QNJ=[IX6RZI%:!UJNHY1YFO$ 40P12;AIUA)#' 42)ESBB*94\BATHX]3
M0XV/.E:2@3JVW+WSPE%$;1WQEZ/4N]-])6(3S7W50VSV.1Q\MV@X.M;@S1K:
M-#[6MJ'U^@Z>HK_2YWE>%M-?I,F*F2B"0YR&&90T2#43I!AB$:4P3GD2*LR0
MQ-RZN\+NL\?FPEY)Y^ !V0/+PB74'8*>E_1*,/!;+9J+(V@/!@<?4'<X!G+_
MG'TIW%P_Q_5M]?KLW3*<P^>XK#N^GA.7=*"=:RX75!0+N>*=2 2"XQ!&*3-)
M%IDV/F*6:7P2F5(2<JRH->_L/7QLQ+,6SV')[>-E03T7H-#WQF,E61?RV4?"
M@7TN0&0@^CG_:KCQSPF-6PEH_Y[A&.B$M#L4=.J:;INA+W,Z*Y5>\]<S<2_G
M7W.SRUION.CT=E8NYM7$EU_T".7Q7S7Q?[&*LBS#%*H@T[93B"6D::PI3<DX
M14D0(DE<8@1\"C<V#EQ+"K9$[1B8Z742[?9LKS4U/1-SQUEQWNKU 9_/[:%7
M^0;=4O:![/XVM)<QNO%W%2"VBIWX4C0=>U85G4TT:BJ42L(04B081%$00\(9
MA2)$3+%4,,*L[$K; <?&L]6I5-/Z&8CEW!Q"23J?O@#SX7?CV;-@VW&G3PA[
MYL,ZJG0EJZE0T$@+-N+Z8T5;8'PRW=DQ!V4O6P3V&<GZOJY-SK\6TZ_&_UZU
M3']/>16SU6Q $E*E[X90_V$H)HT@#40 DXAG*2*4JRQSH9C6T<;&+VMA02TM
M6(GKVN&\#6$[7O&&6\^D<A*R\[OA#CW.+3#QV^.\;<"!>YQ;Z'[8X]SFI@X.
MKYJBFBS YKT.4180%3%(%$80F:QK0E1J-HS:.$DB2;+4VNEU9("QD44EHH.K
MYQAF%HZO"Y$8QJ989Q2[>\".P>+@!;L0GH$\8;LP>7*'M:C>ZA([=M]P;K$6
MJ7=<8VW7]9LF\U%^6WSY0TZ_RE^*V>*QG"")<19GF:E;QXP[/X(LP1*&L:0!
MIHP0;G6,>*D@8V- ]TU7YRFP,YJ& +9G0G5/HS'*@%H;4*LS?#[-*4!?(Z_F
M0)91YM><0JQKGLW)YW6N_/E4S.X7!?_]KW2ZE)-0B"R),PXIQ0HB9&K$I!Q!
M)BC. BI)HASCJ?:'<%F$ T6<5Q*"THA8%2J._CPKP#.=@Z]&X#^#, BN@OK_
M5\6-Z7+Q6,Q-"V[]Z^0J29(KG"95[QK]8Q;%5T&6K"[.RW+9-)/?+HI,2Q/
M^+^6,PGBX,KXMG!US3O)J^\@B,/J7[,KH)_R+$U<KIPZ;E(/9MB.8B^9M9ZI
MLYFN2K8K4$EW546 2N&UYN91_3T7T=P=8^BJF$<U/%+F\OAU'9W?QRENDR\]
MB6@8FDHP$"-,((H#4TT841@P&G":A2EE3EG+9T<<F[VUL0FF5=& S@48SF-M
MZ?SVB6#?.]46@VHCL$?_MRTV7AW@9P<=U@-NB\&!"]SZQHZ9)U5MS$T5/$E3
M)F,,.4FU<<,-LZ0!@FF:T4A@O<43J6.NR<X XS-MKN_O;UQ;(^^!9D<1W8'H
MF0]JP7I)7#NNL]=\D-T1ALT .:K=0<['\:N\=4G_+'GQ,#-V]JW0?)"KG*YK
MWC8G9N)Z)K:*K.C?+9^V"^26$Q/*%%#.8<I-)0$D"&0X22!'BL59$J9AQBYL
MJ^Y#SK'9(292?SK5VXXEG8+GN6G6N7@!M,GR,96A\_T:VQ<W8?<RWW:4-8)9
M[)G[CK5YOP(;)<&VEDV9[U6P0+U=W=(4-*I>@1-UPCWZHWJ>FIY;RWL1];5[
MT?O$VZ)YO=?A.NY,YP]TUJ0OOBUF93'-1=UD=28^Z66Y.C[:B@R[U_]2-6=U
M-9>\C#4BIMG6YPKL:%3QR+9.QNFUB=G<J-6+C>85:*];."^"#;O-\XGEP5;0
MZ\.[,8#))=\$>W[4[WL37QTF$:6<*ACBB.N-(XDA"0-LFJNP *N0)K%3D/RI
M@<9F =;)]6M!KX 1M6/ ^TEP[1C3!V0]DV!'M)PY[1P4/FGJY%B#,L\YC??)
MY.SU;OQ0SA>3SWJFY?6WO)PD/ H52@4TY9L@DJF"A$@"DR1@+)&1PM3*/[WS
MU+&M_$HP_476HEFN\UV0VA=U9]5[7L%66ENOUZ-:MBQ.??W6PM0_[2_*W0<.
ML@*/ZK!:;L=_V?$DFI:/^E-O_G.CS?VO=%I]V!=OZ7S^DL\>ZL-+C!4+0YQ
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MZ35PA<NK%\%Z\&&]"JZ8''@9G!_0N2::G"VWVGQQFI"("0X%I@%$::P@2;F
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M\)N6?W2D@9/SV[0]3-%OO;KK;N!:"/V6E)^*<D&G_R=_?EL(:>J!(9:R .)
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M,5-AC)"$2A$*$641Q#*6,(O#3,81%T& 74[M^Q)T;$?[OUQ__H^;+]=O/MR
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MC3;>%B_70N@WM:P*WMS-/\V+K[E6=\(C%+-(9# 1D2E_*A#4KV9D\J$R18)
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M'PI/X6C>-SUUE"E^0:7=;+YT6=>)^]:NCHISJ3.=<I) S(" 2@&<IPE@,49
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MH"PW'QXJ.* QS$&L<$IL3Q&>.6T)-3Q_:DN.HSS)=;0#V25I],!@NW4:@)?
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M5^^AC$:E8B0JFM'%<[X,P],D*# $7##,<9^EK.=8/Z1GV-VO$H;ZD'T3(-K
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M,S'X00GO4M#2JE"KM_UQJ@8?:#P,VO;52Z,P^[@XA=G-;K$:$,?1VV6>>V+
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M"7YK/V)U^]\#_M;CO)B-'J1.!!*5I2;0$I^Y( QRZ4"FQM J]9H[43DL&&O
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ME^S;Z+?YU]ER<[G\T"V6QSVONVF:WUB!U2:PW@J2$$ISI4@(#K<"NVQ+BI$
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M&G+IWHR.Z!1PQ\U6$Z]PQU4)UUB.@G-;YZ:>_>AMU%KM@J;'O>QZFGN)MNR
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M+FAT;5!+ 0(4 Q0    ( (B+#D^3NH04WP@  -$_   6              "
M 14)  !A,C Q.7$R+65X:&EB:70S,3(N:'1M4$L! A0#%     @ B(L.3XK4
M5^9[!0  5B,  !8              ( !*!(  &$R,#$Y<3(M97AH:6)I=#,R
M,2YH=&U02P$"% ,4    " "(BPY//$*OEVYK 0 -^Q  $0
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M+3(P,3DP-C,P7VQA8BYX;6Q02P$"% ,4    " ")BPY/]V)(CL]5  !)N ,
M%0              @ &_:0( 8W!I>"TR,#$Y,#8S,%]P<F4N>&UL4$L%!@
0   )  D 5@(  ,&_ @    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
